company,drug,streak,start,end,reasons,color,type,info,,,,,,,,,,,,,
APP,acetylcysteine,1,7/24/13,7/24/13,demand increase,orange,pediatric;pulmonary;,200 mg/mL- 30 mL (NDC 63323-690-30) Backordered.  Next delivery expected late July.  Check wholesalers for inventory.;NULL Backordered.  Next delivery expected late July.  Check wholesalers for inventory.,,,,,,,,,,,,,
APP,acetylcysteine,2,8/7/13,11/8/13,demand increase,orange,pediatric;pulmonary;,200 mg/mL- 30 mL (NDC 63323-690-30) Backordered.  Next delivery expected late July.  Check wholesalers for inventory.;NULL Backordered.  Next delivery expected late July.  Check wholesalers for inventory.;200 mg/mL- 30 mL (NDC 63323-690-30) Backordered.  Next delivery expected September 2013.  Check wholesalers for inventory.;NULL Backordered.  Next delivery expected September 2013.  Check wholesalers for inventory.;200 mg/mL- 30 mL (NDC 63323-690-30) Backordered.  Next delivery expected mid September 2013.  Check wholesalers for inventory.;NULL Backordered.  Next delivery expected mid September 2013.  Check wholesalers for inventory.,,,,,,,,,,,,,
Fresenius,acetylcysteine,1,12/28/13,2/14/14,demand increase,orange,pediatric;pulmonary;,200 mg/mL- 30 mL (NDC 63323-690-30) Available.  Check wholesalers for inventory.;NULL Available.  Check wholesalers for inventory.;200 mg/mL- 30 mL (NDC 63323-690-30) Available Check wholesalers for inventory.;200mg/ml-4ml (NDC 63323-694-04) Available Check wholesalers for inventory.;200mg/ml -10 mL (NDC:63323-692-10)   Available  Check wholesalers for inventory.;NULL NULL Check wholesalers for inventory.,,,,,,,,,,,,,
Hospira,acetylcysteine,1,4/28/11,5/12/11,demand increase,orange,pediatric;pulmonary;,,,,,,,,,,,,,,
AmericanRegent,acetylcysteine,1,4/28/11,5/12/11,manufacturing delays,blue,pediatric;pulmonary;,,,,,,,,,,,,,,
Hospira,acetylcysteine,2,4/29/12,2/14/14,manufacturing delays; demand increase; available,blue,pediatric;pulmonary;,";100 mg/mL; 30 mL vial (NDC 0409-3307-03) Next delivery November Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial (NDC 0409-3308-03) Next delivery November  Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial (NDC 0409-3308-03) Available  Please check with your wholesaler for available inventory.;100 mg/mL; 30 mL vial (NDC 0409-3307-03) Next delivery December Estimated recovery: 1Q 2013 Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial (NDC 0409-3308-03) Next delivery December Estimated recovery: 1Q 2013 Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial 
 (NDC 0409-3308-03) Next delivery December
 Estimated recovery: 1Q 2013 Please check with your wholesaler for available inventory.;100 mg/mL; 30 mL vial 
 (NDC 0409-3307-03) Next delivery December
 Estimated recovery: 1Q 2013 Please check with your wholesaler for available inventory.;100 mg/mL; 30 mL vial (NDC 0409-3307-03) Next delivery end December Estimated recovery: 1Q 2013 Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial (NDC 0409-3308-03) Next delivery end December 2012 Estimated recovery: 1Q 2013 Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial (NDC 0409-3308-03) Next delivery January. Estimated recovery: 1Q 2013 Please check with your wholesaler for available inventory.;100 mg/mL; 30 mL vial (NDC 0409-3307-03) Next delivery January Estimated recovery: 1Q 2013 Please check with your wholesaler for available inventory.;100 mg/mL; 30 mL vial (NDC 0409-3307-03) Next delivery March Estimated recovery: 2Q 2013 Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial (NDC 0409-3308-03) Next delivery March 2013. Estimated recovery: 2Q 2013 Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial (NDC 0409-3308-03) Next delivery April 2013. Estimated recovery: 2Q 2013 Please check with your wholesaler for available inventory.;100 mg/mL; 30 mL vial (NDC 0409-3307-03) Next delivery April Estimated recovery: 2Q 2013 Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial (NDC 0409-3308-03) Next delivery May 2013. Estimated recovery: 2Q 2013 Please check with your wholesaler for available inventory.;100 mg/mL; 30 mL vial (NDC 0409-3307-03) Next delivery May Estimated recovery: 2Q 2013 Please check with your wholesaler for available inventory.;100 mg/mL; 30 mL vial (NDC 0409-3307-03) Next delivery early June Estimated recovery: 3Q 2013 Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial (NDC 0409-3308-03) Next delivery early June 2013. Estimated recovery: 3Q 2013 Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial (NDC 0409-3308-03) Next delivery early July 2013 Estimated recovery: 3Q 2013 Please check with your wholesaler for available inventory.;100 mg/mL; 30 mL vial (NDC 0409-3307-03) Next delivery early July 2013 Estimated recovery: 3Q 2013 Please check with your wholesaler for available inventory.;100 mg/mL; 30 mL vial (NDC 0409-3307-03) Recently released in early July.  Next delivery late July 2013. Estimated recovery: 3Q 2013 Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial (NDC 0409-3308-03) Recently released in early July.  Next delivery late July 2013. Estimated recovery: 3Q 2013   Please check with your wholesaler for available inventory.;100 mg/mL; 30 mL vial (NDC 0409-3307-03) Next delivery August 2013. Estimated recovery: 4Q 2013 Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial (NDC 0409-3308-03) Next delivery August 2013. Estimated recovery: 4Q 2013   Please check with your wholesaler for available inventory.;100 mg/mL; 30 mL vial (NDC 0409-3307-03) Next delivery late September. Estimated recovery: 4Q 2013 Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial (NDC 0409-3308-03) Next delivery late September. Estimated recovery: 4Q 2013   Please check with your wholesaler for available inventory.;100 mg/mL; 30 mL vial (NDC 0409-3307-03) Next delivery December Estimated recovery: 1Q 2014 Please check with your wholesaler for available inventory.;200 mg/mL; 30 mL vial (NDC 0409-3308-03) Available  Please check with your wholesaler for available inventory. Shortage per Manufacturer: Available;100 mg/mL; 30 mL vial (NDC 0409-3307-03) Available Please check with your wholesaler for available inventory. Shortage per Manufacturer: Available",,,,,,,,,,,,,
AmericanRegent,acetylcysteine,2,4/29/12,2/14/14,manufacturing delays; not releasing,blue,pediatric;pulmonary;,;100 mg/mL- 4 mL (NDC 00517-7504-25) Unavailable American Regent is currently not releasing Acetylcysteine inhalation solution. Shortage per Manufacturer: Unavailable;100 mg/mL- 10 mL (NDC 00517-7510-03) Unavailable American Regent is currently not releasing Acetylcysteine inhalation solution. Shortage per Manufacturer: Unavailable;200 mg/mL- 10 mL (NDC 00517-7610-03) Unavailable American Regent is currently not releasing Acetylcysteine inhalation solution. Shortage per Manufacturer: Unavailable;200 mg/mL- 4 mL (NDC 00517-7604-25) Unavailable American Regent is currently not releasing Acetylcysteine inhalation solution. Shortage per Manufacturer: Unavailable;200 mg/mL- 30 mL (NDC 00517-7630-03) Unavailable American Regent is currently not releasing Acetylcysteine inhalation solution. Shortage per Manufacturer: Unavailable;100 mg/mL- 10 mL (NDC 00517-7510-03) Unavailable American Regent is currently not releasing Acetylcysteine inhalation solution.;100 mg/mL- 4 mL (NDC 00517-7504-25) Unavailable American Regent is currently not releasing Acetylcysteine inhalation solution.;200 mg/mL- 10 mL (NDC 00517-7610-03) Unavailable American Regent is currently not releasing Acetylcysteine inhalation solution.;200 mg/mL- 4 mL (NDC 00517-7604-25) Unavailable American Regent is currently not releasing Acetylcysteine inhalation solution.;200 mg/mL- 30 mL (NDC 00517-7630-03) Unavailable American Regent is currently not releasing Acetylcysteine inhalation solution.;200 mg/mL- 10 mL (NDC 00517-7610-03) Unavailable - No product available for release. No plan to manufacture. American Regent is currently not releasing Acetylcysteine inhalation solution.;100 mg/mL- 4 mL (NDC 00517-7504-25) Unavailable - No product available for release. No plan to manufacture. American Regent is currently not releasing Acetylcysteine inhalation solution.;100 mg/mL- 10 mL (NDC 00517-7510-03) Unavailable - No product available for release. No plan to manufacture. American Regent is currently not releasing Acetylcysteine inhalation solution.;200 mg/mL- 4 mL (NDC 00517-7604-25) Unavailable - No product available for release. No plan to manufacture. American Regent is currently not releasing Acetylcysteine inhalation solution.;200 mg/mL- 30 mL (NDC 00517-7630-03) Unavailable - No product available for release. No plan to manufacture. American Regent is currently not releasing Acetylcysteine inhalation solution.,,,,,,,,,,,,,
Bedford,acyclovir,1,8/19/13,11/8/13,capacity constraints,blue,pediatric;antiviral;,500mg Inj SDV 10mL (NDC 5539061210) Unavailable  Shortage per Manufacturer: Capacity constraint Availability of products is updated on the Bedford Laboratories website.;1g Inj SDV 20 mL (NDC 5539061320) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.,,,,,,,,,,,,,
APP,acyclovir,1,11/13/12,11/8/13,demand increase; manufacturing delays,blue,pediatric;antiviral;,500mg- 10mL (NDC # 63323-325-10)   Next delivery expected mid December 2012   All presentations currently on allocation with manufacturer.  Shortage per manufacturer: Manufacturing delay;1g- 20mL (NDC # 63323-325-20) Next delivery expected mid December 2012   All presentations currently on allocation with manufacturer.  Shortage per manufacturer: Manufacturing delay;500mg- 10mL (NDC # 63323-325-10)   Next delivery expected mid January 2013   All presentations currently on allocation with manufacturer.  Shortage per manufacturer: Manufacturing delay;1g- 20mL (NDC # 63323-325-20) Next delivery expected mid January 2013   All presentations currently on allocation with manufacturer.  Shortage per manufacturer: Manufacturing delay;500mg- 10mL (NDC # 63323-325-10)   Next delivery expected early March 2013   All presentations currently on allocation with manufacturer.  Shortage per manufacturer: Manufacturing delay;1g- 20mL (NDC # 63323-325-20) Next delivery expected early March 2013   All presentations currently on allocation with manufacturer.  Shortage per manufacturer: Manufacturing delay;1g- 20mL (NDC # 63323-325-20) Next delivery expected May 2013. Check wholesaler inventory.   All presentations currently on allocation with manufacturer.  Shortage per manufacturer: Manufacturing delay;500mg- 10mL (NDC # 63323-325-10)   Next delivery expected May 2013. Check wholesaler inventory.   All presentations currently on allocation with manufacturer.  Shortage per manufacturer: Manufacturing delay;500mg- 10mL (NDC # 63323-325-10)   Next delivery expected June 2013. Check wholesaler inventory.   All presentations currently on allocation with manufacturer.  Shortage per manufacturer: Manufacturing delay;1g- 20mL (NDC # 63323-325-20) Next delivery expected June 2013. Check wholesaler inventory.   All presentations currently on allocation with manufacturer.  Shortage per manufacturer: Manufacturing delay;1g- 20mL (NDC # 63323-325-20) Next delivery expected July 2013. Check wholesaler inventory.   All presentations currently on allocation with manufacturer.  Shortage per manufacturer: Manufacturing delay;500mg- 10mL (NDC # 63323-325-10)   Next delivery expected July 2013. Check wholesaler inventory.   All presentations currently on allocation with manufacturer.  Shortage per manufacturer: Manufacturing delay;500mg- 10mL (NDC # 63323-325-10)   Available.   Check wholesaler inventory.   All presentations currently on allocation with manufacturer.  Shortage per manufacturer: Manufacturing delay;1g- 20mL (NDC # 63323-325-20) Currently on allocation.  Check wholesalers for inventory. All presentations currently on allocation with manufacturer.  Shortage per manufacturer: Manufacturing delay,,,,,,,,,,,,,
Carlsbad,acyclovir,1,4/8/10,7/3/10,manufacturing delays; demand increase,blue,pediatric;antiviral;,Manufacturing Delays         Increased Demand         Pending site transfer                         Increased Demand;Manufacturing Delays     Increased Demand             Pending site transfer                                           Increased Demand;Manufacturing Delays     Increased Demand           Pending site transfer                                   Increased Demand,,,,,,,,,,,,,
GlaxoSmithKline,acyclovir,1,1/17/10,7/3/10,manufacturing delays; demand increase,blue,pediatric;antiviral;,Manufacturing Delays     Increased Demand;Manufacturing Delays     Increased Demand               Pending site transfer;Manufacturing Delays                   Increased Demand               Pending site transfer;Manufacturing Delays                   Increased Demand                 Pending site transfer;Manufacturing Delays               Increased Demand             Pending site transfer;Manufacturing Delays           Increased Demand           Pending site transfer;Manufacturing Delays         Increased Demand         Pending site transfer                         Increased Demand;Manufacturing Delays     Increased Demand             Pending site transfer                                           Increased Demand;Manufacturing Delays     Increased Demand           Pending site transfer                                   Increased Demand,,,,,,,,,,,,,
Mylan,acyclovir,1,1/25/10,7/3/10,manufacturing delays; demand increase,blue,pediatric;antiviral;,Manufacturing Delays     Increased Demand               Pending site transfer;Manufacturing Delays                   Increased Demand               Pending site transfer;Manufacturing Delays                   Increased Demand                 Pending site transfer;Manufacturing Delays               Increased Demand             Pending site transfer;Manufacturing Delays           Increased Demand           Pending site transfer;Manufacturing Delays         Increased Demand         Pending site transfer                         Increased Demand;Manufacturing Delays     Increased Demand             Pending site transfer                                           Increased Demand;Manufacturing Delays     Increased Demand           Pending site transfer                                   Increased Demand,,,,,,,,,,,,,
Teva,acyclovir,1,1/17/10,7/3/10,manufacturing delays; demand increase,blue,pediatric;antiviral;,Manufacturing Delays     Increased Demand;Manufacturing Delays     Increased Demand               Pending site transfer;Manufacturing Delays                   Increased Demand               Pending site transfer;Manufacturing Delays                   Increased Demand                 Pending site transfer;Manufacturing Delays               Increased Demand             Pending site transfer;Manufacturing Delays           Increased Demand           Pending site transfer;Manufacturing Delays         Increased Demand         Pending site transfer                         Increased Demand;Manufacturing Delays     Increased Demand             Pending site transfer                                           Increased Demand;Manufacturing Delays     Increased Demand           Pending site transfer                                   Increased Demand,,,,,,,,,,,,,
Bedford,adriamycin,1,10/19/10,11/12/10,demand increase,orange,,Increased demand  ,,,,,,,,,,,,,
Akorn,alcohol,1,12/16/11,3/1/12,available,,,Akorn has Alcohol Dehydrated (Ethanol > 98%) available in a 5 mL vials.,,,,,,,,,,,,,
AmericanRegent,alcohol,1,8/5/11,3/1/12,manufacturing delays; available,blue,,American Regent anticipates releases of the 1 mL and 5mL ampoules at the end of July and August.;1 ml ampoules adn 5 ml ampoules are now being released.;1 ml ampules and 5 ml ampules are now being released.;1ml ampules being released.;American Regent has 1 mL ampules (NDC 00517-8571-10) and 5 mL ampules (NDC 00517-8575-10) available.,,,,,,,,,,,,,
Akorn,alfentanil,2,8/1/13,8/1/13,available,,;analgesia;,0.5 mg/ml; 2ml ampule (NDC 17478-0067-02) Readily available N/A;0.5 mg/ml; 5ml ampule (NDC 17478-0067-05) Readily available N/A,,,,,,,,,,,,,
Hospira,alfentanil,2,8/1/13,8/1/13,available,,;analgesia;,500 mcg/mL; 2 mL amp (NDC 0409-2266-02) Available Please check your wholesaler for all available inventory.;500 mcg/mL; 5 mL amp (NDC 0409-2266-05) Available Please check your wholesaler for all available inventory.,,,,,,,,,,,,,
Akorn,alfentanil,1,2/2/12,7/7/13,demand increase; available; quota request filled,orange,;analgesia;,"Limited emergency supply of Alfenta 2 mL and 5 mL ampules. 2 mL ampules are available- 2012. 5 mL ampules have a production scheduled for late 1Q 2012.;Limited emergency supply of Alfenta 2 mL and 5 mL ampules.
 
 2 mL ampules are available- 2012.
 
 
 5 mL ampules have a production scheduled for late 1Q 2012.;Limited emergency supply of Alfenta 2 mL and 5 mL ampules. 2 mL (NDC 17478-0067-02) due to release in April. 5 mL (NDC 17478-0067-05) due to release in April.;Increased demand Limited emergency supply of Alfenta 2 mL and 5 mL ampules. 2 mL (NDC 17478-0067-02) due to release in April. 5 mL (NDC 17478-0067-05) due to release in April.;;0.5 mg/ml; 2ml ampule (NDC 17478-0067-02) Readily available Quota request filed. (Per manufacturer)  Shortage per Manufacturer: Delayed DEA response (Per manufacturer);0.5 mg/ml; 5ml ampule (NDC 17478-0067-05) On backorder pending DEA quota authorization. (Per manufacturer) Quota request filed. (Per manufacturer)  Shortage per Manufacturer: Delayed DEA response (Per manufacturer);0.5 mg/ml; 5ml ampule (NDC 17478-0067-05) On backorder due to release late October Quota request filed. (Per manufacturer)  Shortage per Manufacturer: Delayed DEA response (Per manufacturer);0.5 mg/ml; 2ml ampule (NDC 17478-0067-02) Readily available Shortage per Manufacturer: Quota request filed Partial DEA authorization;0.5 mg/ml; 5ml ampule (NDC 17478-0067-05) On backorder due to release late October Shortage per Manufacturer: Quota request filed Partial DEA authorization;0.5 mg/ml; 5ml ampule (NDC 17478-0067-05) On backorder due to release late October Shortage per Manufacturer: 
 Quota request filed 
 Partial DEA authorization;0.5 mg/ml; 2ml ampule (NDC 17478-0067-02) Readily available Shortage per Manufacturer: 
 Quota request filed 
 Partial DEA authorization;0.5 mg/ml; 2ml ampule (NDC 17478-0067-02) Readily available NA;0.5 mg/ml; 5ml ampule (NDC 17478-0067-05) Readily available NA;0.5 mg/ml; 2ml ampule (NDC 17478-0067-02) Readily available N/A;0.5 mg/ml; 5ml ampule (NDC 17478-0067-05) Readily available N/A",,,,,,,,,,,,,
Hospira,alfentanil,1,2/2/12,7/7/13,material shortage; demand increase; available,green,;analgesia;,"Product 500 mcg/mL- 2 mL amp (NDC 0409-2266-02): next delivery May. Product 500 mcg/mL; 5 mL amp (NDC 0409-2266-05): next delivery May. Please check your wholesaler for all available inventory.;Product 500 mcg/mL- 2 mL amp (NDC 0409-2266-02): next delivery May.
 
 
 Product 500 mcg/mL; 5 mL amp (NDC 0409-2266-05): next delivery May.
 
 
 Please check your wholesaler for all available inventory.;Material shortage (API). Product 500 mcg/mL- 2 mL amp (NDC 0409-2266-02): next delivery May. Product 500 mcg/mL; 5 mL amp (NDC 0409-2266-05): next delivery May. Please check your wholesaler for all available inventory.;;500 mcg/mL; 5 mL amp (NDC 0409-2266-05) Available Please check your wholesaler for all available inventory.   Due to increased demand- could see intermittent supply issues over the next couple months- until stable inventory position is attained.;500 mcg/mL; 2 mL amp (NDC 0409-2266-02) Available Please check your wholesaler for all available inventory.   Due to increased demand- could see intermittent supply issues over the next couple months- until stable inventory position is attained.;500 mcg/mL; 2 mL amp (NDC 0409-2266-02) Available Please check your wholesaler for all available inventory.
  
 Due to increased demand- could see intermittent supply issues over the next couple months- until stable inventory position is attained.;500 mcg/mL; 5 mL amp (NDC 0409-2266-05) Available Please check your wholesaler for all available inventory.
  
 Due to increased demand- could see intermittent supply issues over the next couple months- until stable inventory position is attained.;500 mcg/mL; 2 mL amp (NDC 0409-2266-02) Available Please check your wholesaler for all available inventory.;500 mcg/mL; 5 mL amp (NDC 0409-2266-05) Available Please check your wholesaler for all available inventory.",,,,,,,,,,,,,
Genentech,alteplase,1,3/6/13,11/8/13,manufacturing issues; available,blue,pediatric;cardiovascular;,lteplase (Activase) 100 mg vial (50242-085-27)     Shortage per manufacturer: Manufacturing issues. Contact your authorized Genentech distributor regarding product availability.;lteplase (Activase)- 50 mg vial (NDC 50242-044-13) Available.   Shortage per manufacturer: Manufacturing issues. Contact your authorized Genentech distributor regarding product availability.;Alteplase (Cathflo Activase)- 2 mg vial  (NDC 50242-0041-64) Potential limited availability projected to continue into Q2 2013.    Shortage per manufacturer: Manufacturing issues. Contact your authorized Genentech distributor regarding product availability.;Alteplase (Activase) 100 mg vial (50242-085-27)   Available;Alteplase (Activase)- 50 mg vial (NDC 50242-044-13) Available;Alteplase (Cathflo Activase)- 2 mg vial  (NDC 50242-0041-64) Potential limited availability of Cathflo Activase 2mg vial is projected to continue into Q2 2013  Shortage per Manufacturer: Manufacturing Issues Contact your authorized Genentech distributor regarding product availability   Some vials of Cathflo Activase have been found to contain rubber stopper particulates after reconstitution. Studies have indicated that filtration through a 5 micron filter needle is sufficient to remove these particles. Cathflo Activase vials should be carefully inspected after reconstitution for foreign matter or discoloration. Do not administer Cathflo Activase if particulate matter is discovered. There is a potential risk that particulate matter may cause embolic events if introduced into the bloodstream.   Please see the Dear Pharmacist Letter (PDF - 352KB) for additional information.;Alteplase (Cathflo Activase)- 2 mg vial  (NDC 50242-0041-64) Potential limited availability of Cathflo Activase 2mg vial is projected to continue into Q3 2013  Shortage per Manufacturer: Manufacturing Issues Contact your authorized Genentech distributor regarding product availability   Some vials of Cathflo Activase have been found to contain rubber stopper particulates after reconstitution. Studies have indicated that filtration through a 5 micron filter needle is sufficient to remove these particles. Cathflo Activase vials should be carefully inspected after reconstitution for foreign matter or discoloration. Do not administer Cathflo Activase if particulate matter is discovered. There is a potential risk that particulate matter may cause embolic events if introduced into the bloodstream.   Please see the Dear Pharmacist Letter (PDF - 352KB) for additional information.,,,,,,,,,,,,,
Heritage,amikacin,1,2/14/14,3/25/14,available,,pediatric;anti-infective;,250 mg/mL: 2 mL vials- package of 10 (NDC 23155-290-41)   Available from March 2014    Expected new launch;250 mg/mL: 4 mL vials- package of 10 (NDC 23155-290-42)   Available from March 2014    Expected new launch,,,,,,,,,,,,,
Bedford,amikacin,1,7/9/10,10/9/10,manufacturing delays,blue,pediatric;anti-infective;,Manufacturing delays reported by both manufacturers. ;Manufacturing delays reported by both manufacturers.  ,,,,,,,,,,,,,
Teva,amikacin,1,7/9/10,10/9/10,manufacturing delays,blue,pediatric;anti-infective;,Manufacturing delays reported by both manufacturers. ;Manufacturing delays reported by both manufacturers.  ,,,,,,,,,,,,,
Bedford,amikacin,1,12/18/10,3/25/14,manufacturing delays; capacity constraints; pending manufacturing change; available,blue,pediatric;anti-infective;,"Bedford has all presentations of amikacin on a back order and the company cannot estimate a release date.;Bedford anticipates release of the 500mg and 1g presentations in late May.  The 100mg presentation has been discontinued.;Bedford anticipates release of the 500mg and 1g presentations in late May.  The 100mg presentation has been discontinued. 250 mg/mL- 2 mL vials- package of 10 (NDC 55390-0226-02) ? Available in 10 pack presentation 250 mg/mL- 4 mL vials- package of 10 (NDC 55390-0226-04) ? Available in 10 pack presentation;250 mg/mL- 2 mL vials- package of 10 (NDC 55390-0226-02) ? Available in 10 pack presentation 250 mg/mL- 4 mL vials- package of 10 (NDC 55390-0226-04) ? Available in 10 pack presentation;Amikacin 250 mg/mL- 2 mL vials- package of 10 (NDC 55390-0226-02) are available. The 250 mg/mL- 4 mL vials- package of 10 (NDC 55390-0226-04) are on backorder with no estimated date of release. Emergency supplies are available.;Bedford has amikacin 250 mg/mL 2 mL on intermittent backorder with product available as it is released. The 4 mL presentation does not have estimated estimate release timing.;Bedford has limited allocated quantities of amikacin 250 mg/mL 2 mL (NDC 55390-0226-02)  available for drop shipment- contact your local Bedford  Account Executives. The 1 g/4 mL (NDC 55390-0226-04) are available on short supply with next estimate release late September.;Bedford has limited allocated quantities of amikacin 250 mg/mL 2 mL (NDC 55390-0226-02)  available for drop shipment- contact your local Bedford  Account Executives. The 1 g/4 mL (NDC 55390-0226-04) are available on short supply with next estimate release Mid October.;Bedford has limited allocated quantities of amikacin 250 mg/mL 2 mL (NDC 55390-0226-02) and 1 g/4 mL (NDC 55390-0226-04)  available for drop shipment- contact your local Bedford  Account Executives.;Bedford has all amikacin presentations on back order and the company cannot estimate a release date.;Bedford Laboratories has 500mg/2ml and 1gm/4ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.;Manufacturing delays Bedford Laboratories has 500mg/2ml and 1gm/4ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.;;250 mg/mL- 2 mL vials (NDC 55390-0226-02) Unavailable Bedford Laboratories has 500mg/2ml and 1gm/4ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;250 mg/mL- 4 mL vials (NDC 55390-0226-04) Unavailable Bedford Laboratories has 500mg/2ml and 1gm/4ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;250 mg/mL- 2 mL vials (NDC 55390-0226-02) Unavailable Bedford Laboratories has 500mg/2ml and 1gm/4ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;250 mg/mL- 4 mL vials (NDC 55390-0226-04) Unavailable Bedford Laboratories has 500mg/2ml and 1gm/4ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;250 mg/mL- 4 mL vials (NDC 55390-0226-04) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;250 mg/mL- 2 mL vials (NDC 55390-0226-02) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;250 mg/mL- 2 mL vials (NDC 55390-0226-02) Available Check Wholesaler for inventory.;250 mg/mL- 4 mL vials (NDC 55390-0226-04) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.;250 mg/mL- 4 mL vials (NDC 55390-0226-04) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products is updated on the Bedford Laboratories website.",,,,,,,,,,,,,
Teva,amikacin,1,12/18/10,3/25/14,manufacturing delays; demand increase; available,blue,pediatric;anti-infective;,Teva has amikacin 250 mg/mL 2 mL (NDC 00703-9032-03) and 4 mL (NDC 00703-9040-03) vials on allocation. If a pharmacy cannot obtain product from their wholesaler- please have the wholesaler contact Teva directly to place an emergency order.;Teva has amikacin 250 mg/mL 4 mL vials available for drop shipment (NDC 00703-9040-03).;Teva has released batches of amikacin 250 mg/mL 4 mL vials on 3/30/2012.  The product is available for drop shipment and Teva is shipping to wholesalers on allocation.;Available Teva has released batches of amikacin 250 mg/mL 4 mL vials on 3/30/2012.  The product is available for drop shipment and Teva is shipping to wholesalers on allocation.;;250 mg/mL 4 mL vials   (NDC 00703-9040-03) Teva expects additional inventory to be available by the beginning of August. Shortage per Manufacturer: Manufacturing delays;250 mg/mL 4 mL vials   (NDC 00703-9040-03) Teva has 4mL vials available for drop shipment only through the month of September.;250 mg/mL 4 mL vials   (NDC 00703-9040-03) Teva has 4mL vials available for drop shipment only through the month of September. Teva expects to continue to allocate the product for the remainder of 2012.;250 mg/mL 4 mL vials   (NDC 00703-9040-03) Teva has 4mL vials available on allocation. Teva expects to continue to allocate the product for the remainder of 2012.;250 mg/mL 4 mL vials   (NDC 00703-9040-03) Teva has 4mL vials available on allocation. Teva expects to continue to allocate the product through January 2013.;250 mg/mL 4 mL vials   (NDC 00703-9040-03) Teva has 4mL vials available on allocation. Teva expects to continue to allocate the product through at least the end of March 2013.;250 mg/mL 4 mL vials   (NDC 00703-9040-03) Teva has 4mL vials available on allocation. Teva expects  additional supply in  April- and will be shipping to wholesalers.  Product is currently available for dropship.;250 mg/mL 2 mL vials (NDC 00703-9032-03) Teva has 2 mL and 4mL vials available on allocation with limited supply through the end of 2013. Teva has shipped product to wholesalers as supply allows.  Product is currently available for drop shipment.;250 mg/mL 4 mL vials (NDC 00703-9040-03) Teva has 2 mL and 4mL vials available on allocation with limited supply through the end of 2013. Teva has shipped product to wholesalers as supply allows.  Product is currently available for drop shipment.;250 mg/mL 4 mL vials (NDC 00703-9040-03) Available Teva has shipped product to wholesalers as supply allows.  Product is currently available for drop shipment.;250 mg/mL 2 mL vials (NDC 00703-9032-03) Available Teva has shipped product to wholesalers as supply allows.  Product is currently available for drop shipment.,,,,,,,,,,,,,
Bbraun,amino,2,2/16/12,7/7/13,available,,;gastroenterology;,All B. Braun Amino Acids are available. BBraun may start allocation if demand starts to exceed their increased production plans.;Available All B. Braun Amino Acids are available. BBraun may start allocation if demand starts to exceed their increased production plans.;;15% Amino Acids Injection 1-000 mL (NDC 0264-3200-55) All B. Braun Amino Acids are available. BBraun may start allocation if demand starts to exceed their increased production plans. Shortage per Manufacturer: Available;FreAmine III 10%- 1000 mL (NDC 00264-9010-55) All B. Braun Amino Acids are available. BBraun may start allocation if demand starts to exceed their increased production plans. Shortage per Manufacturer: Available;TrophAmine 6%- 500 mL (NDC 00264-9361-55) All B. Braun Amino Acids are available. BBraun may start allocation if demand starts to exceed their increased production plans. Shortage per Manufacturer: Available;Specialty Amino Acid Solutions FreAmine HBC 6.9%- 750 mL (NDC 00264-9350-55) All B. Braun Amino Acids are available. BBraun may start allocation if demand starts to exceed their increased production plans. Shortage per Manufacturer: Available;HepatAmine 8%- 500 mL (NDC 00264-9371-55) All B. Braun Amino Acids are available. BBraun may start allocation if demand starts to exceed their increased production plans. Shortage per Manufacturer: Available;TrophAmine 10%- 500 mL (NDC 00264-9361-55) All B. Braun Amino Acids are available. BBraun may start allocation if demand starts to exceed their increased production plans. Shortage per Manufacturer: Available;NephrAmine 5.4%- 250 mL (NDC 00264-1909-55) All B. Braun Amino Acids are available. BBraun may start allocation if demand starts to exceed their increased production plans. Shortage per Manufacturer: Available;NephrAmine 5.4%- 250 mL (NDC 00264-1909-55) All presentations available;Specialty Amino Acid Solutions FreAmine HBC 6.9%- 750 mL (NDC 00264-9350-55) All presentations available;HepatAmine 8%- 500 mL (NDC 00264-9371-55) All presentations available;TrophAmine 6%- 500 mL (NDC 00264-9361-55) All presentations available;FreAmine III 10%- 1000 mL (NDC 00264-9010-55) All presentations available;15% Amino Acids Injection 1-000 mL (NDC 0264-3200-55) All presentations available;TrophAmine 10%- 500 mL (NDC 00264-9361-55) All presentations available,,,,,,,,,,,,,
Bbraun,amino,3,8/1/13,8/1/13,available,,;gastroenterology;,Specialty Amino Acid Solutions FreAmine HBC 6.9%- 750 mL (NDC 00264-9350-55) All presentations available;HepatAmine 8%- 500 mL (NDC 00264-9371-55) All presentations available;TrophAmine 10%- 500 mL (NDC 00264-9361-55) All presentations available;15% Amino Acids Injection 1-000 mL (NDC 0264-3200-55) All presentations available;NephrAmine 5.4%- 250 mL (NDC 00264-1909-55) All presentations available;FreAmine III 10%- 1000 mL (NDC 00264-9010-55) All presentations available;TrophAmine 6%- 500 mL (NDC 00264-9361-55) All presentations available,,,,,,,,,,,,,
Baxter,amino,3,8/1/13,8/1/13,demand increase,orange,;gastroenterology;,CLINIMIX sulfite-free (2.75%- 4.25%- 5.0% Amino Acid in Dextrose) Injections in 1000 mL and 2000 mL Containers Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 500 mL- sulfite-free (NDC 00338-0502-03) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 2000 mL- sulfite-free (NDC 00338-0502-06) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 1000 mL (NDC 00338-0644-04) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX E sulfite-free (2.75%- 4.25%- 5.0% Amino Acid with Electrolytes in Dextrose with Calcium) Injections in 1000 mL and 2000 mL Containers Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 2000 mL- sulfite-free (NDC 00338-1130-06) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 1000 mL- sulfite-free (NDC 00338-1130-04) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 500 mL- sulfite-free (NDC 00338-1130-03) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 500 mL (NDC 00338-0644-03) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 2000 mL (NDC 00338-0644-06) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Prosol 20%- 2000 mL- sulfite-free (NDC 00338-0499-06) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 6%- 500 mL- sulfite-free (NDC 00338-1131-03) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Hepatosol 8%- 500 mL (NDC 00338-0504-03) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.,,,,,,,,,,,,,
BBraun,amino,1,10/19/10,4/22/11,demand increase,orange,;gastroenterology;,Commodity shortage Increase in demand Increase in demand  ;Commodity shortage Increase in demand Increase in demand;Commodity shortage Increase in demand Increase in demand,,,,,,,,,,,,,
Bbraun,amino,1,4/28/11,9/15/11,demand increase,orange,;gastroenterology;,"All FreAmine 10% (S9010-SS & S9011-SS)- TrophAmine 10% (S9341-SS) - and TrophAmine 6%( S9361-SS) products are off allocation and currently available to all customers via direct or indirect distribution- as inventory is very healthy to support new customers. Feel free to contact your local B. Braun sales representative or place orders via Customer Service at 800-227-2862.;All FreAmine 10% (S9010-SS & S9011-SS)- TrophAmine 10% (S9341-SS) - and TrophAmine 6%( S9361-SS) products are off allocation and currently available to all customers via direct or indirect distribution- as inventory is very healthy to support new customers.
 Feel free to contact your local B. Braun sales representative or place orders via Customer Service at 800-227-2862.",,,,,,,,,,,,,
Baxter,amino,2,2/23/12,7/7/13,demand increase,orange,;gastroenterology;,"Travasol products available Premasol products available Hepatosol product available Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol and Clinisol due to unforeseen demand. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol products available 
 
 Premasol products available 
 
 Hepatosol product available 
 
 Clinimix and Clinimix E products are available 
 
 Baxter is currently experiencing a backorder situation on all presentations of Prosol and Clinisol due to unforeseen demand. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Increase in product demand due to market supply issues. Travasol products available Premasol products available Hepatosol product available Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol and Clinisol due to unforeseen demand. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;;Premasol 10%- 500 mL- sulfite-free (NDC 00338-1130-03) Travasol products available Premasol products available Hepatosol product available   Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through Nov. 2012. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 2000 mL- sulfite-free (NDC 00338-1130-06) Travasol products available Premasol products available Hepatosol product available   Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through Nov. 2012. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 6%- 500 mL- sulfite-free (NDC 00338-1131-03) Travasol products available Premasol products available Hepatosol product available   Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through Nov. 2012. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX E sulfite-free (2.75%- 4.25%- 5.0% Amino Acid with Electrolytes in Dextrose with Calcium) Injections in 1000 mL and 2000 mL Containers Travasol products available Premasol products available Hepatosol product available   Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through Nov. 2012. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX sulfite-free (2.75%- 4.25%- 5.0% Amino Acid in Dextrose) Injections in 1000 mL and 2000 mL Containers Travasol products available Premasol products available Hepatosol product available   Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through Nov. 2012. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Prosol 20%- 2000 mL- sulfite-free (NDC 00338-0499-06) Travasol products available Premasol products available Hepatosol product available   Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through Nov. 2012. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 2000 mL (NDC 00338-0644-06) Travasol products available Premasol products available Hepatosol product available   Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through Nov. 2012. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 2000 mL- sulfite-free (NDC 00338-0502-06) Travasol products available Premasol products available Hepatosol product available   Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through Nov. 2012. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Hepatosol 8%- 500 mL (NDC 00338-0504-03) Travasol products available Premasol products available Hepatosol product available   Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through Nov. 2012. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 1000 mL (NDC 00338-0644-04) Travasol products available Premasol products available Hepatosol product available   Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through Nov. 2012. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 500 mL (NDC 00338-0644-03) Travasol products available Premasol products available Hepatosol product available   Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through Nov. 2012. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 1000 mL- sulfite-free (NDC 00338-1130-04) Travasol products available Premasol products available Hepatosol product available   Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through Nov. 2012. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 500 mL- sulfite-free (NDC 00338-0502-03) Travasol products available Premasol products available Hepatosol product available   Clinimix and Clinimix E products are available Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through Nov. 2012. Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX E sulfite-free (2.75%- 4.25%- 5.0% Amino Acid with Electrolytes in Dextrose with Calcium) Injections in 1000 mL and 2000 mL Containers Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 2000 mL (NDC 00338-0644-06) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 1000 mL- sulfite-free (NDC 00338-1130-04) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 2000 mL- sulfite-free (NDC 00338-0502-06) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Prosol 20%- 2000 mL- sulfite-free (NDC 00338-0499-06) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 1000 mL (NDC 00338-0644-04) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Hepatosol 8%- 500 mL (NDC 00338-0504-03) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 500 mL (NDC 00338-0644-03) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX sulfite-free (2.75%- 4.25%- 5.0% Amino Acid in Dextrose) Injections in 1000 mL and 2000 mL Containers Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 500 mL- sulfite-free (NDC 00338-0502-03) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 2000 mL- sulfite-free (NDC 00338-1130-06) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 6%- 500 mL- sulfite-free (NDC 00338-1131-03) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 500 mL- sulfite-free (NDC 00338-1130-03) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Hepatosol 8%- 500 mL (NDC 00338-0504-03) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.
  
 Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 6%- 500 mL- sulfite-free (NDC 00338-1131-03) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.
  
 Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX sulfite-free (2.75%- 4.25%- 5.0% Amino Acid in Dextrose) Injections in 1000 mL and 2000 mL Containers Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.
  
 Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX E sulfite-free (2.75%- 4.25%- 5.0% Amino Acid with Electrolytes in Dextrose with Calcium) Injections in 1000 mL and 2000 mL Containers Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.
  
 Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 500 mL- sulfite-free (NDC 00338-1130-03) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.
  
 Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 500 mL (NDC 00338-0644-03) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.
  
 Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 500 mL- sulfite-free (NDC 00338-0502-03) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.
  
 Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 2000 mL- sulfite-free (NDC 00338-1130-06) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.
  
 Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 2000 mL- sulfite-free (NDC 00338-0502-06) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.
  
 Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 1000 mL- sulfite-free (NDC 00338-1130-04) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.
  
 Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 1000 mL (NDC 00338-0644-04) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.
  
 Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Prosol 20%- 2000 mL- sulfite-free (NDC 00338-0499-06) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.
  
 Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 2000 mL (NDC 00338-0644-06) Baxter is currently experiencing a backorder situation on all presentations of Prosol- Premasol and Clinisol due to unforeseen demand. Allocated availability continued through November 2012.
  
 Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX sulfite-free (2.75%- 4.25%- 5.0% Amino Acid in Dextrose) Injections in 1000 mL and 2000 mL Containers Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through December 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 1000 mL- sulfite-free (NDC 00338-1130-04) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through December 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 500 mL- sulfite-free (NDC 00338-0502-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through December 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 6%- 500 mL- sulfite-free (NDC 00338-1131-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through December 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 1000 mL (NDC 00338-0644-04) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through December 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 2000 mL (NDC 00338-0644-06) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through December 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX E sulfite-free (2.75%- 4.25%- 5.0% Amino Acid with Electrolytes in Dextrose with Calcium) Injections in 1000 mL and 2000 mL Containers Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through December 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Prosol 20%- 2000 mL- sulfite-free (NDC 00338-0499-06) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through December 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 2000 mL- sulfite-free (NDC 00338-1130-06) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through December 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Hepatosol 8%- 500 mL (NDC 00338-0504-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through December 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 2000 mL- sulfite-free (NDC 00338-0502-06) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through December 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 500 mL- sulfite-free (NDC 00338-1130-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through December 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 500 mL (NDC 00338-0644-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through December 2012.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 6%- 500 mL- sulfite-free (NDC 00338-1131-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through March 2013.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX E sulfite-free (2.75%- 4.25%- 5.0% Amino Acid with Electrolytes in Dextrose with Calcium) Injections in 1000 mL and 2000 mL Containers Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through March 2013.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 1000 mL- sulfite-free (NDC 00338-1130-04) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through March 2013.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 2000 mL- sulfite-free (NDC 00338-1130-06) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through March 2013.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 2000 mL (NDC 00338-0644-06) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through March 2013.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 500 mL- sulfite-free (NDC 00338-0502-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through March 2013.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 500 mL- sulfite-free (NDC 00338-1130-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through March 2013.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 1000 mL (NDC 00338-0644-04) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through March 2013.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX sulfite-free (2.75%- 4.25%- 5.0% Amino Acid in Dextrose) Injections in 1000 mL and 2000 mL Containers Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through March 2013.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Hepatosol 8%- 500 mL (NDC 00338-0504-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through March 2013.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 2000 mL- sulfite-free (NDC 00338-0502-06) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through March 2013.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 500 mL (NDC 00338-0644-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through March 2013.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Prosol 20%- 2000 mL- sulfite-free (NDC 00338-0499-06) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand. Allocated availability continued through March 2013.   Clinimix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 2000 mL- sulfite-free (NDC 00338-0502-06) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand.   Allocated availability continued through May 2013.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 500 mL- sulfite-free (NDC 00338-1130-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand.   Allocated availability continued through May 2013.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 1000 mL- sulfite-free (NDC 00338-1130-04) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand.   Allocated availability continued through May 2013.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 6%- 500 mL- sulfite-free (NDC 00338-1131-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand.   Allocated availability continued through May 2013.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX sulfite-free (2.75%- 4.25%- 5.0% Amino Acid in Dextrose) Injections in 1000 mL and 2000 mL Containers Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand.   Allocated availability continued through May 2013.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 500 mL- sulfite-free (NDC 00338-0502-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand.   Allocated availability continued through May 2013.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Hepatosol 8%- 500 mL (NDC 00338-0504-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand.   Allocated availability continued through May 2013.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Prosol 20%- 2000 mL- sulfite-free (NDC 00338-0499-06) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand.   Allocated availability continued through May 2013.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 1000 mL (NDC 00338-0644-04) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand.   Allocated availability continued through May 2013.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 500 mL (NDC 00338-0644-03) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand.   Allocated availability continued through May 2013.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX E sulfite-free (2.75%- 4.25%- 5.0% Amino Acid with Electrolytes in Dextrose with Calcium) Injections in 1000 mL and 2000 mL Containers Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand.   Allocated availability continued through May 2013.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 2000 mL- sulfite-free (NDC 00338-1130-06) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand.   Allocated availability continued through May 2013.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 2000 mL (NDC 00338-0644-06) Baxter is currently experiencing a backorder situation on presentation of Premasol due to unforeseen demand.   Allocated availability continued through May 2013.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 6%- 500 mL- sulfite-free (NDC 00338-1131-03) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 500 mL- sulfite-free (NDC 00338-1130-03) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 500 mL (NDC 00338-0644-03) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX sulfite-free (2.75%- 4.25%- 5.0% Amino Acid in Dextrose) Injections in 1000 mL and 2000 mL Containers Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX E sulfite-free (2.75%- 4.25%- 5.0% Amino Acid with Electrolytes in Dextrose with Calcium) Injections in 1000 mL and 2000 mL Containers Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 2000 mL (NDC 00338-0644-06) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Prosol 20%- 2000 mL- sulfite-free (NDC 00338-0499-06) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Travasol 10%- 1000 mL (NDC 00338-0644-04) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Hepatosol 8%- 500 mL (NDC 00338-0504-03) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 500 mL- sulfite-free (NDC 00338-0502-03) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 2000 mL- sulfite-free (NDC 00338-1130-06) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Premasol 10%- 1000 mL- sulfite-free (NDC 00338-1130-04) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;Clinisol 15%- 2000 mL- sulfite-free (NDC 00338-0502-06) Baxter is currently experiencing a backorder situation on presentations of Prosol and Clinimix E due to unforeseen demand.   Climinix is a viable source of Amino Acids for most patients requiring parenteral nutrition.;CLINIMIX E sulfite-free (2.75%- 4.25%- 5.0% Amino Acid with Electrolytes in Dextrose with Calcium) Injections in 1000 mL and 2000 mL Containers Available   Climinix is a viable source of Amino Acids for most patients requiring pa",,,,,,,,,,,,,
Baxter,amino,1,10/19/10,9/15/11,demand increase; available,orange,;gastroenterology;,"Baxter has the following bulk pharmacy Amino Acid Injections for compounding on allocation  and is working to increase production to meet US market demand. Clinisol- Baxter Clinisol 15%- 500 mL (NDC 00338-0502-03) Clinisol 15%- 2000 mL (NDC 00338-0502-06) Prosol- Baxter Prosol 20%- 2000 mL (NDC 00338-0499-06) Travasol- Baxter Travasol 10%- 500 mL (NDC 00338-0644-03) Travasol 10%- 1000 mL (NDC 00338-0644-04) Travasol 10%- 2000 mL (NDC 00338-0644-06);Baxter has the following bulk pharmacy Amino Acid Injections for compounding on allocation  and is working to increase production to meet US market demand.
 Clinisol- Baxter 
 Clinisol 15%- 500 mL (NDC 00338-0502-03) 
 Clinisol 15%- 2000 mL (NDC 00338-0502-06)
 Prosol- Baxter Prosol 20%- 2000 mL (NDC 00338-0499-06)
 Travasol- Baxter 
 Travasol 10%- 500 mL (NDC 00338-0644-03) 
 Travasol 10%- 1000 mL (NDC 00338-0644-04) Travasol 10%- 2000 mL (NDC 00338-0644-06);Baxter has the following bulk pharmacy Amino Acid Injections available through normal distribution.  Clinisol- Baxter Clinisol 15%- 500 mL (NDC 00338-0502-03) Clinisol 15%- 2000 mL (NDC 00338-0502-06) Prosol- Baxter Prosol 20%- 2000 mL (NDC 00338-0499-06) Travasol- Baxter Travasol 10%- 500 mL (NDC 00338-0644-03) Travasol 10%- 1000 mL (NDC 00338-0644-04) Travasol 10%- 2000 mL (NDC 00338-0644-06)",,,,,,,,,,,,,
Hospira,amino,1,10/19/10,9/15/11,demand increase; material shortage; available,green,;gastroenterology;,Hospira Information (PDF - 15KB);The next release of this product is expected in July which will achieve target inventory levels to support demand.  Potential short term alternative is NDC 0409-4164-03 (Aminosyn II 10% 500mL) which has inventory available.   All other Aminosyn products are available with ample levels of inventory to support recent demand.;All Aminosyn products are available with ample levels of inventory to support recent demand.,,,,,,,,,,,,,
Hospira,amino,3,8/1/13,8/1/13,manufacturing delays,blue,;gastroenterology;,Aminosyn 10%- Sulfite-free; 500 mL bag (NDC 0409-4191-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn HBC 7%- 500 mL- Sulfite-free (NDC 0409-4168-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn 3.5%- sulfite-free- 1 L (NDC 0409-4196-05) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn II 10%- Sulfite-free; 2 L bag (NDC 0409-7172-17) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn-PF 7%- sulfite-free- 500 mL (NDC 0409-4178-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn RF 5.2%- 500 mL- sulfite-free (NDC 0409-4166-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn 8.5%- Sulfite-free; 500 mL bag (NDC 0409-4187-03) Available  Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn II 8.5%- sulfite-free- 500 mL (NDC 0409-4162-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn II 15%- Sulfite-free; 2 L bag (NDC 0409-7171-17) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn II 10%; 2 L bag (NDC 0409-7121-07) Product being replaced by (NDC 0409-7172-17) Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn II 10%- Sulfite-free; 1 L bag (NDC 0409-4164-05) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn-PF 10%- 1000 mL- sulfite-free (NDC 0409-4179-05) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn II 10%- 500 mL- Sulfite-free (NDC 0409-4164-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn 8.5%- Sulfite-free; 500 mL bag (NDC 0409-4187-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn II 8.5% with electrolytes- sulfite-free- 500 mL (NDC 0409-4171-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn 10%- Sulfite-free- 1 L (NDC 0409-4191-05) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay,,,,,,,,,,,,,
Hospira,amino,2,2/16/12,7/7/13,manufacturing delays; discontinued; manufacturing practices requirements; available,yellow,;gastroenterology;,"Product Aminosyn II 10%- Sulfite-free; 1 L bag (NDC 0409-4164-05): next delivery February. Product Aminosyn 10%- Sulfite-free; 500 mL bag (NDC 0409-4191-03): next delivery May. Product Aminosyn 8.5%- Sulfite-free; 500 mL bag (NDC 0409-4187-03): next delivery March. Product Aminosyn II 10%; 2 L bag (NDC 0409-7121-07): next delivery TBD. Product Aminosyn II 15%- Sulfite-free; 2 L bag (NDC 0409-7171-17): next delivery TBD. Product Aminosyn 10%- Sulfite-free- 1L (NDC 0409-4191-05): next delivery March. Product Aminosyn II 10%- 500 mL- Sulfite-free (NDC 0409-4164-03): next delivery March. Product Aminosyn HBC 7%- 500 mL- Sulfite-free (NDC 0409-4168-03): next delivery TBD. Please check with your wholesaler for available inventory. Other presentations available. Please see the Dear Customer Letter (PDF - 31KB);Product Aminosyn II 10%- Sulfite-free; 1 L bag (NDC 0409-4164-05): next delivery March. 
 
 Product Aminosyn 10%- Sulfite-free; 500 mL bag (NDC 0409-4191-03): ample supply available. 
 
 Product Aminosyn 8.5%- Sulfite-free; 500 mL bag (NDC 0409-4187-03): next delivery March. 
 Product Aminosyn 8.5%- Sulfite-free with Electrolytes- 500 mL (NDC 0409-4203-03): next delivery March. 
 
 Product Aminosyn II 10%; 2 L bag (NDC 0409-7121-07): next delivery TBD. 
 
 Product Aminosyn II 15%- Sulfite-free; 2 L bag (NDC 0409-7171-17): next delivery July. 
 
 Product Aminosyn 10%- Sulfite-free- 1L (NDC 0409-4191-05): next delivery March. 
 
 Product Aminosyn II 10%- 500 mL- Sulfite-free (NDC 0409-4164-03): next delivery March. 
 
 Product Aminosyn HBC 7%- 500 mL- Sulfite-free (NDC 0409-4168-03): next delivery TBD. 
 
 Please check with your wholesaler for available inventory. 
 
 Other presentations available. 
 
 Please see the Dear Customer Letter (PDF - 31KB);Product Aminosyn II 10%- Sulfite-free; 1 L bag (NDC 0409-4164-05): ample supply available. Product Aminosyn 10%- Sulfite-free; 500 mL bag (NDC 0409-4191-03): ample supply available. Product Aminosyn 8.5%- Sulfite-free; 500 mL bag (NDC 0409-4187-03): ample supply available. Product Aminosyn 8.5%- Sulfite-free with Electrolytes- 500 mL (NDC 0409-4203-03): ample supply available. Product Aminosyn II 10%; 2 L bag (NDC 0409-7121-07): ample supply available. Product Aminosyn II 15%- Sulfite-free; 2 L bag (NDC 0409-7171-17): next delivery July. Product Aminosyn 10%- Sulfite-free- 1L (NDC 0409-4191-05): ample supply available. Product Aminosyn II 10%- 500 mL- Sulfite-free (NDC 0409-4164-03): next delivery May. Product Aminosyn HBC 7%- 500 mL- Sulfite-free (NDC 0409-4168-03): next delivery TBD. Please check with your wholesaler for available inventory. Other presentations available. Please see the Dear Customer Letter (PDF - 31KB);Manufacturing delay; Higher than anticipated market demand. Product Aminosyn II 10%- Sulfite-free; 1 L bag (NDC 0409-4164-05): ample supply available. Product Aminosyn 10%- Sulfite-free; 500 mL bag (NDC 0409-4191-03): ample supply available. Product Aminosyn 8.5%- Sulfite-free; 500 mL bag (NDC 0409-4187-03): ample supply available. Product Aminosyn 8.5%- Sulfite-free with Electrolytes- 500 mL (NDC 0409-4203-03): ample supply available. Product Aminosyn II 10%; 2 L bag (NDC 0409-7121-07): ample supply available. Product Aminosyn II 15%- Sulfite-free; 2 L bag (NDC 0409-7171-17): next delivery July. Product Aminosyn 10%- Sulfite-free- 1L (NDC 0409-4191-05): ample supply available. Product Aminosyn II 10%- 500 mL- Sulfite-free (NDC 0409-4164-03): next delivery May. Product Aminosyn HBC 7%- 500 mL- Sulfite-free (NDC 0409-4168-03): next delivery TBD. Please check with your wholesaler for available inventory. Other presentations available. Please see the Dear Customer Letter (PDF - 31KB);;Aminosyn 10%- Sulfite-free- 1 L (NDC 0409-4191-05) Available    Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn II 15%- Sulfite-free; 2 L bag (NDC 0409-7171-17) Available    Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn HBC 7%- 500 mL- Sulfite-free (NDC 0409-4168-03) Available    Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn RF 5.2%- 500 mL- sulfite-free (NDC 0409-4166-03) Available    Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn 10%- Sulfite-free; 500 mL bag (NDC 0409-4191-03) Available    Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn II 8.5%- sulfite-free- 500 mL (NDC 0409-4162-03) Available    Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn II 10%- 500 mL- Sulfite-free (NDC 0409-4164-03) Available    Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn 8.5%- Sulfite-free; 500 mL bag (NDC 0409-4187-03) Available    Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn 3.5%- sulfite-free- 1 L (NDC 0409-4196-05) Available    Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn II 8.5% with electrolytes- sulfite-free- 500 mL (NDC 0409-4171-03) Available    Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn II 10%- Sulfite-free; 1 L bag (NDC 0409-4164-05) Available    Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn-PF 7%- sulfite-free- 500 mL (NDC 0409-4178-03) Available    Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn 8.5%- sulfite-free- 500 mL (NDC 0409-4187-03) Available    Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn II 10%; 2 L bag (NDC 0409-7121-07) Product being replaced by (NDC 0409-7172-17) Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn-PF 10%- 1000 mL- sulfite-free (NDC 0409-4179-05) Available    Please check with your wholesaler for available inventory. Please see the Dear Customer Letter (PDF - 31KB) Shortage per Manufacturer: Available;Aminosyn 8.5%- Sulfite-free; 500 mL bag (NDC 0409-4187-03) Temporarily suspended Please check with your wholesaler for available inventory.;Aminosyn HBC 7%- 500 mL- Sulfite-free (NDC 0409-4168-03) Temporarily suspended Please check with your wholesaler for available inventory.;Aminosyn-PF 10%- 1000 mL- sulfite-free (NDC 0409-4179-05) Available Please check with your wholesaler for available inventory.;Aminosyn II 8.5% with electrolytes- sulfite-free- 500 mL (NDC 0409-4171-03) Available Please check with your wholesaler for available inventory.;Aminosyn II 10%- Sulfite-free; 1 L bag (NDC 0409-4164-05) Available    Please check with your wholesaler for available inventory.;Aminosyn II 10%; 2 L bag (NDC 0409-7121-07) Product being replaced by (NDC 0409-7172-17) Please check with your wholesaler for available inventory.;Aminosyn-PF 7%- sulfite-free- 500 mL (NDC 0409-4178-03) Available Please check with your wholesaler for available inventory.;Aminosyn 10%- Sulfite-free- 1 L (NDC 0409-4191-05) Temporarily suspended Please check with your wholesaler for available inventory.;Aminosyn 3.5%- sulfite-free- 1 L (NDC 0409-4196-05) Available Please check with your wholesaler for available inventory.;Aminosyn RF 5.2%- 500 mL- sulfite-free (NDC 0409-4166-03) Available Please check with your wholesaler for available inventory.;Aminosyn 8.5%- Sulfite-free; 500 mL bag (NDC 0409-4187-03) Available Please check with your wholesaler for available inventory.;Aminosyn II 10%- Sulfite-free; 2 L bag (NDC 0409-7172-17) Available Please check with your wholesaler for available inventory.;Aminosyn 10%- Sulfite-free; 500 mL bag (NDC 0409-4191-03) Available Please check with your wholesaler for available inventory.;Aminosyn II 15%- Sulfite-free; 2 L bag (NDC 0409-7171-17) Temporarily suspended Please check with your wholesaler for available inventory.;Aminosyn II 10%- 500 mL- Sulfite-free (NDC 0409-4164-03) Available Please check with your wholesaler for available inventory.;Aminosyn II 8.5%- sulfite-free- 500 mL (NDC 0409-4162-03) Available Please check with your wholesaler for available inventory.;Aminosyn II 10%- Sulfite-free; 1 L bag (NDC 0409-4164-05) Temporarily suspended   Please check with your wholesaler for available inventory.;Aminosyn RF 5.2%- 500 mL- sulfite-free (NDC 0409-4166-03) Temporarily suspended Please check with your wholesaler for available inventory.;Aminosyn II 10%- Sulfite-free; 1 L bag (NDC 0409-4164-05) Temporarily suspended
   Please check with your wholesaler for available inventory.;Aminosyn II 10%- 500 mL- Sulfite-free (NDC 0409-4164-03) Temporarily suspended Please check with your wholesaler for available inventory.;Aminosyn II 10%- Sulfite-free; 2 L bag (NDC 0409-7172-17) Temporarily suspended Please check with your wholesaler for available inventory.;Aminosyn II 10%- 500 mL- Sulfite-free (NDC 0409-4164-03) Next delivery 2Q 2013  Estimated Recovery 2Q 2013 Please check with your wholesaler for available inventory.;Aminosyn II 10%- Sulfite-free; 2 L bag (NDC 0409-7172-17) Next delivery 2Q 2013  Estimated Recovery 2Q 2013 Please check with your wholesaler for available inventory.;Aminosyn 10%- Sulfite-free- 1 L (NDC 0409-4191-05) Next delivery 2Q 2013  Estimated Recovery 2Q 2013 Please check with your wholesaler for available inventory.;Aminosyn HBC 7%- 500 mL- Sulfite-free (NDC 0409-4168-03) Next delivery 2Q 2013  Estimated Recovery 2Q 2013 Please check with your wholesaler for available inventory.;Aminosyn II 10%- Sulfite-free; 1 L bag (NDC 0409-4164-05) Next delivery 2Q 2013  Estimated Recovery 2Q 2013 Please check with your wholesaler for available inventory.;Aminosyn II 15%- Sulfite-free; 2 L bag (NDC 0409-7171-17) Next delivery 2Q 2013  Estimated Recovery 2Q 2013 Please check with your wholesaler for available inventory.;Aminosyn 8.5%- Sulfite-free; 500 mL bag (NDC 0409-4187-03) Next delivery 2Q 2013  Estimated Recovery 2Q 2013 Please check with your wholesaler for available inventory.;Aminosyn RF 5.2%- 500 mL- sulfite-free (NDC 0409-4166-03) Next delivery 2Q 2013  Estimated Recovery 2Q 2013 Please check with your wholesaler for available inventory.;Aminosyn 8.5%- Sulfite-free; 500 mL bag (NDC 0409-4187-03) Next delivery mid March. Estimated Recovery mid March Please check with your wholesaler for available inventory.;Aminosyn 10%- Sulfite-free; 500 mL bag (NDC 0409-4191-03) Next delivery mid March. Estimated Recovery mid March Please check with your wholesaler for available inventory.;Aminosyn 8.5%- Sulfite-free; 500 mL bag (NDC 0409-4187-03) Next delivery mid March. Estimated Recovery mid March  Please check with your wholesaler for available inventory.;Aminosyn II 10%- Sulfite-free; 2 L bag (NDC 0409-7172-17) Next delivery mid March. Estimated Recovery mid March Please check with your wholesaler for available inventory.;Aminosyn RF 5.2%- 500 mL- sulfite-free (NDC 0409-4166-03) Next delivery mid March. Estimated Recovery mid March Please check with your wholesaler for available inventory.;Aminosyn II 10%- 500 mL- Sulfite-free (NDC 0409-4164-03) Next delivery mid March. Estimated Recovery mid March Please check with your wholesaler for available inventory.;Aminosyn 10%- Sulfite-free- 1 L (NDC 0409-4191-05) Next delivery mid March. Estimated Recovery mid March Please check with your wholesaler for available inventory.;Aminosyn II 10%- Sulfite-free; 1 L bag (NDC 0409-4164-05) Next delivery mid March. Estimated Recovery mid March Please check with your wholesaler for available inventory.;Aminosyn II 15%- Sulfite-free; 2 L bag (NDC 0409-7171-17) Next delivery mid March. Estimated Recovery mid March Please check with your wholesaler for available inventory.;Aminosyn-PF 10%- 1000 mL- sulfite-free (NDC 0409-4179-05) Next delivery and estimated recovery: mid April Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn II 8.5%- sulfite-free- 500 mL (NDC 0409-4162-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn 8.5%- Sulfite-free; 500 mL bag (NDC 0409-4187-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn 10%- Sulfite-free- 1 L (NDC 0409-4191-05) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn II 8.5% with electrolytes- sulfite-free- 500 mL (NDC 0409-4171-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn II 10%; 2 L bag (NDC 0409-7121-07) Product being replaced by (NDC 0409-7172-17) Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn 10%- Sulfite-free; 500 mL bag (NDC 0409-4191-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn II 10%- Sulfite-free; 1 L bag (NDC 0409-4164-05) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn HBC 7%- 500 mL- Sulfite-free (NDC 0409-4168-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn 3.5%- sulfite-free- 1 L (NDC 0409-4196-05) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn II 10%- 500 mL- Sulfite-free (NDC 0409-4164-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn II 15%- Sulfite-free; 2 L bag (NDC 0409-7171-17) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn 8.5%- Sulfite-free; 500 mL bag (NDC 0409-4187-03) Available  Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn-PF 7%- sulfite-free- 500 mL (NDC 0409-4178-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn II 10%- Sulfite-free; 2 L bag (NDC 0409-7172-17) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn RF 5.2%- 500 mL- sulfite-free (NDC 0409-4166-03) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay;Aminosyn-PF 10%- 1000 mL- sulfite-free (NDC 0409-4179-05) Available Please check with your wholesaler for available inventory.   Shortage per manufacturer: Manufacturing delay",,,,,,,,,,,,,
Hospira,aminocaproic,2,4/11/13,1/8/14,capacity constraints; manufacturing delays,blue,;hematology;,250 mg/mL; 20 mL vial(NDC 0409-4346-73) Next delivery May Estimated recovery: 2Q 2013   Shortage per Manufacturer:  Capacity constraints.;250 mg/mL; 20 mL vial(NDC 0409-4346-73) Next delivery early June Estimated recovery: 4Q 2013   Shortage per Manufacturer:  Capacity constraints.;250 mg/mL; 20 mL vial(NDC 0409-4346-73) Next delivery early July Estimated recovery: 4Q 2013   Shortage per Manufacturer:  Capacity constraints.;250 mg/mL; 20 mL vial(NDC 0409-4346-73) Next delivery August Estimated recovery: 1Q 2014   Shortage per Manufacturer:  Manufacturing delay.;250 mg/mL; 20 mL vial(NDC 0409-4346-73) Available  Shortage per Manufacturer:  Manufacturing delay.;250 mg/mL; 20 mL vial(NDC 0409-4346-73) Next delivery December Estimated recovery: 1Q 2013   Shortage per Manufacturer:  Manufacturing delay.,,,,,,,,,,,,,
AmericanRegent,aminocaproic,1,8/14/11,3/1/12,manufacturing delays; available,blue,;hematology;,Lutipold estimates product being available mid-September- 2011.;Aminocaproic Acid Injection- USP 250 mg/mL- 20 mL vial (NDC 00517-9120-25) has been released as of October 4- 2011.;American Regent/Luitpold has 250 mg/mL- 20 mL vial (NDC 00517-9120-25) available.,,,,,,,,,,,,,
Hospira,aminocaproic,1,8/14/11,3/1/12,other manufacturer shortage,orange,;hematology;,"Product availability is unknown at this time. Please check with your wholesaler for available inventory.;One lot delivered week of 8/15/11; second lot expected to deliver week of 8/22. Please check with your wholesaler for available inventory.;Product 250 mg/mL; 20 mL vial (NDC 0409-4345-73):  next delivery December. Please check with your wholesaler for available inventory.;Product 250 mg/mL; 20 mL vial (NDC 0409-4345-73):  next delivery December. 
 
 Please check with your wholesaler for available inventory.;Product 250 mg/mL; 20 mL vial (NDC 0409-4345-73):  October delivery rec?d; next delivery December. Please check with your wholesaler for available inventory.;Product 250 mg/mL; 20 mL vial (NDC 0409-4346-73):  next delivery November. Please check with your wholesaler for available inventory.;Product 250 mg/mL; 20 mL vial (NDC 0409-4346-73):  next delivery November. 
 
 Please check with your wholesaler for available inventory.;Product 250 mg/mL; 20 mL vial (NDC 0409-4346-73):  next delivery December. Please check with your wholesaler for available inventory.;Product 250 mg/mL; 20 mL vial (NDC 0409-4346-73):  next delivery January- 2012. Please check with your wholesaler for available inventory.;Product 250 mg/mL; 20 mL vial (NDC 0409-4346-73):  next delivery January- 2012. 
 
 Please check with your wholesaler for available inventory.;Product 250 mg/mL; 20 mL vial (NDC 0409-4346-73):  next delivery February. Please check with your wholesaler for available inventory.;Product 250 mg/mL; 20 mL vial (NDC 0409-4346-73): ample supply available. Please check with your wholesaler for available inventory.",,,,,,,,,,,,,
Hospira,aminophylline,1,12/24/12,1/8/14,material shortage; manufacturing delays; available,green,pediatric;pulmonary;,500mg/20mL(NDC 0409-5922-01)  Next delivery February Estimated recovery: 1Q 2013;250mg/20mL(NDC 0409-5921-01) Next delivery February Estimated recovery: 1Q 2013;500mg/20mL(NDC 0409-5922-01)  Next delivery February. Estimated recovery: 2Q 2013;250mg/20mL(NDC 0409-5921-01) Next delivery February. Estimated recovery: 2Q 2013;500mg/20mL(NDC 0409-5922-01)  Next delivery March. Estimated recovery: 1Q 2013;250mg/20mL(NDC 0409-5921-01) Next delivery March Estimated recovery: 2Q 2013;500mg/20mL(NDC 0409-5922-01)  Next delivery April     Estimated recovery: 2Q2013;250mg/20mL(NDC 0409-5921-01) Next delivery April Estimated recovery: 2Q 2013;500mg/20mL(NDC 0409-5922-01)  Next delivery May     Estimated recovery: 3Q2013;250mg/20mL(NDC 0409-5921-01) Next delivery May Estimated recovery: 3Q 2013;500mg/20mL (NDC 0409-5922-01)  Available Available;250mg/20mL (NDC 0409-5921-01) Next delivery early June Estimated recovery: 3Q 2013 Shortage per Manufacturer:  Manufacturing delay;250mg/20mL (NDC 0409-5921-01) Next delivery early July Estimated recovery: 4Q 2013 Shortage per Manufacturer:  Manufacturing delay;250mg/20mL (NDC 0409-5921-01) Next delivery July Estimated recovery: 3Q 2013 Shortage per Manufacturer:  Manufacturing delay;250mg/20mL (NDC 0409-5921-01) Next delivery August Estimated recovery: 3Q 2013 Shortage per Manufacturer:  Manufacturing delay;250mg/20mL (NDC 0409-5921-01) Next delivery late September Estimated recovery: 3Q 2013 Shortage per Manufacturer:  Manufacturing delay;500mg/20mL (NDC 0409-5922-01) Available Available;250mg/20mL (NDC 0409-5921-01) Next delivery 1Q 2024 Estimated recovery: 1Q 2014 Shortage per Manufacturer:  Manufacturing delay,,,,,,,,,,,,,
Hospira,aminophylline,1,10/9/10,1/26/11,supply interruption,green,pediatric;pulmonary;,Supplier of one excipient can no longer supply; currently arranging for new supplier.  ,,,,,,,,,,,,,
Hospira,ammonium,1,2/2/11,3/25/14,material issues; other manufacturer shortage; manufacturing delays,green,;endocrinology;,"Hospira has ammonium chloride 5 mEq/mL 20 mL vials on back order and the company estimates a release date of 2nd quarter- 2011.;Product 5 mEq/mL; 20 mL vial:  company estimates a release date of 3rd quarter- 2011.   Please check with your wholesaler for available inventory.;Product 5 mEq/mL; 20 mL vial:  company estimates a release date of 4th quarter- 2011.   Please check with your wholesaler for available inventory.;Product 5 mEq/mL; 20 mL vial:  company estimates a release date of 4th quarter- 2011.
  
 Please check with your wholesaler for available inventory.;Product 5 mEq/mL; 20 mL vial:  company estimates a release date of 1st quarter- 2012.   Please check with your wholesaler for available inventory.;Product 5 mEq/mL; 20 mL vial (NDC 0409-6043-01):  company estimates a release date by June 2012. Please check with your wholesaler for available inventory.;Product 5 mEq/mL; 20 mL vial (NDC 0409-6043-01):  company estimates a release date by June 2012. 
 
 Please check with your wholesaler for available inventory.;Other manufacturer shortages/market withdrawal. Product 5 mEq/mL; 20 mL vial (NDC 0409-6043-01):  company estimates a release date by June 2012. Please check with your wholesaler for available inventory.;;5 mEq/mL; 20 mL vial (NDC 0409-6043-01)  Company estimates a release date by 1Q 2013 Please check with your wholesaler for available inventory.;5 mEq/mL; 20 mL vial (NDC 0409-6043-01)  Company estimates a release date by 1Q 2013 Estimated recovery: 2Q 2013 Please check with your wholesaler for available inventory. Shortage per Manufacturer: Manufacturing delay;5 mEq/mL; 20 mL vial
 (NDC 0409-6043-01)
   Company estimates a release date by 1Q 2013
 Estimated recovery: 2Q 2013 Please check with your wholesaler for available inventory.
 Shortage per Manufacturer: Manufacturing delay;5 mEq/mL; 20 mL vial (NDC 0409-6043-01)  Company estimates a release date by 2Q 2013 Estimated recovery: 2Q 2013 Please check with your wholesaler for available inventory. Shortage per Manufacturer: Manufacturing delay;5 mEq/mL; 20 mL vial (NDC 0409-6043-01)  Next delivery 3Q 2013 Estimated recovery: 3Q 2013 Please check with your wholesaler for available inventory. Shortage per Manufacturer: Manufacturing delay;5 mEq/mL; 20 mL vial (NDC 0409-6043-01)  Next delivery 4Q 2013 Estimated recovery: 4Q 2013 Please check with your wholesaler for available inventory. Shortage per Manufacturer: Manufacturing delay;5 mEq/mL; 20 mL vial (NDC 0409-6043-01)  Next delivery 2Q 2014 Estimated recovery: 2Q 2014 Please check with your wholesaler for available inventory. Shortage per Manufacturer: Manufacturing delay",,,,,,,,,,,,,
AmericanRegent,ammoniummoly,1,5/25/11,3/1/12,manufacturing delays; available,blue,,American Regent has ammonium molybdate injection on back order and the company cannot estimate a release date.;American Regent has ammonium molybdate injection available.,,,,,,,,,,,,,
Ucyclyd,ammonul,1,6/6/09,11/2/12,,,,See information in Related Information section. ;See information in Related Information section.  ;See information in Related Information section.,,,,,,,,,,,,,
Global,amphetamine,1,4/14/11,11/20/12,demand increase; material availability; available,green,,"API limitations due to DEA quota and uneven product distribution patterns. All product strengths other than 25 mg are currently available on an allocated basis.;All finished product strengths are currently available on an allocated basis.;Inadequate finished product supply to support current market demand All finished product strengths are currently available on an allocated basis.;;20 mg- 100 count (NDC 00115-1331-01) All finished product strengths are currently available on an allocated basis. Shortage per Manufacturer: Inadequate finished product supply to support current market demand;25 mg- 100 count (NDC 00115-1332-01) All finished product strengths are currently available on an allocated basis. Shortage per Manufacturer: Inadequate finished product supply to support current market demand;30 mg- 100 count (NDC 00115-1333-01) All finished product strengths are currently available on an allocated basis. Shortage per Manufacturer: Inadequate finished product supply to support current market demand;15 mg- 100 count (NDC 00115-1330-01) All finished product strengths are currently available on an allocated basis. Shortage per Manufacturer: Inadequate finished product supply to support current market demand;10 mg -100 count (NDC 00115-1329-01) All finished product strengths are currently available on an allocated basis. Shortage per Manufacturer: Inadequate finished product supply to support current market demand;10 mg -100 count (NDC 00115-1329-01) All finished product strengths are currently available on an allocated basis. Shortage per Manufacturer: 
 Inadequate finished product supply to support current market demand;25 mg- 100 count (NDC 00115-1332-01) All finished product strengths are currently available on an allocated basis. Shortage per Manufacturer: 
 Inadequate finished product supply to support current market demand;30 mg- 100 count (NDC 00115-1333-01) All finished product strengths are currently available on an allocated basis. Shortage per Manufacturer: 
 Inadequate finished product supply to support current market demand;20 mg- 100 count (NDC 00115-1331-01) All finished product strengths are currently available on an allocated basis. Shortage per Manufacturer: 
 Inadequate finished product supply to support current market demand;15 mg- 100 count (NDC 00115-1330-01) All finished product strengths are currently available on an allocated basis. Shortage per Manufacturer: 
 Inadequate finished product supply to support current market demand",,,,,,,,,,,,,
Shire,amphetamine,1,4/14/11,11/20/12,material availability; material shortage; demand increase; available,green,,"API limitations due to DEA quota and uneven product distribution patterns. This product is subject to DEA quota limitations. Waiting on additional information.;API limitations due to DEA quota and uneven product distribution patterns. This product is subject to DEA quota limitations. Waiting on additional information.; Expect increased product availability in May 2011. Shire Customer Service Number: 1-800-828-2088 Shire Pharmacy Locator Number: 1-800-828-2088 select ?Option 5? for assistance in locating a pharmacy in your area with product availability.;Product availability has improved for all dosage strengths. Shire Customer Service Number: 1-800-828-2088 Shire Pharmacy Locator Number: 1-800-828-2088 select ?Option 5? for assistance in locating a pharmacy in your area with product availability.;Product availability for all dosage strengths is adequate.;API supply issues and uneven product distribution patterns. Product availability for all dosage strengths is adequate.;;25 mg - 100 count (NDC 54092-0389-01) Product availability for all dosage strengths is adequate. Shortage per Manufacturer: API supply issues and uneven product distribution patterns.;20 mg - 100 count (NDC 54092-0387-01) Product availability for all dosage strengths is adequate. Shortage per Manufacturer: API supply issues and uneven product distribution patterns.;15 mg - 100 count (NDC 54092-0385-01) Product availability for all dosage strengths is adequate. Shortage per Manufacturer: API supply issues and uneven product distribution patterns.;30 mg - 100 count (NDC 54092-0391-01) Product availability for all dosage strengths is adequate. Shortage per Manufacturer: API supply issues and uneven product distribution patterns.;5 mg - 100 count (NDC 54092-0381-01) Product availability for all dosage strengths is adequate. Shortage per Manufacturer: API supply issues and uneven product distribution patterns.;10 mg - 100 count (NDC 54092-0383-01) Product availability for all dosage strengths is adequate. Shortage per Manufacturer: API supply issues and uneven product distribution patterns.;25 mg - 100 count (NDC 54092-0389-01) Product availability for all dosage strengths is adequate. Shortage per Manufacturer: 
 API supply issues and uneven product distribution patterns.;30 mg - 100 count (NDC 54092-0391-01) Product availability for all dosage strengths is adequate. Shortage per Manufacturer: 
 API supply issues and uneven product distribution patterns.;10 mg - 100 count (NDC 54092-0383-01) Product availability for all dosage strengths is adequate. Shortage per Manufacturer: 
 API supply issues and uneven product distribution patterns.;15 mg - 100 count (NDC 54092-0385-01) Product availability for all dosage strengths is adequate. Shortage per Manufacturer: 
 API supply issues and uneven product distribution patterns.;20 mg - 100 count (NDC 54092-0387-01) Product availability for all dosage strengths is adequate. Shortage per Manufacturer: 
 API supply issues and uneven product distribution patterns.;5 mg - 100 count (NDC 54092-0381-01) Product availability for all dosage strengths is adequate. Shortage per Manufacturer: 
 API supply issues and uneven product distribution patterns.",,,,,,,,,,,,,
Teva,amphetamine,1,4/14/11,11/20/12,material shortage; demand increase,green,,API limitations due to DEA quota and uneven product distribution patterns. This product is subject to DEA quota limitations. Waiting on additional information.;API limitations due to DEA quota and uneven product distribution patterns. This product is subject to DEA quota limitations. Waiting on additional information.; 20 mg and 30 mg market availability: approx 4/14/11. All other strengths market availability: approx 4/29/11.;Teva continue to release product as it becomes available.;API supply issues Teva continue to release product as it becomes available.;;25 mg - 100 count (NDC 00555-0792-02) Teva continues to release product as it becomes available. Shortage per Manufacturer: API supply issues;20 mg - 100 count (NDC 00555-0788-02) Teva continues to release product as it becomes available. Shortage per Manufacturer: API supply issues;10 mg - 100 count (NDC 00555-0787-02) Teva continues to release product as it becomes available. Shortage per Manufacturer: API supply issues;30 mg - 100 count (NDC 00555-0789-02) Teva continues to release product as it becomes available. Shortage per Manufacturer: API supply issues;15 mg - 100 count (NDC 00555-0791-02) Teva continues to release product as it becomes available. Shortage per Manufacturer: API supply issues;5 mg - 100 count (NDC 00555-0790-02) Teva continues to release product as it becomes available. Shortage per Manufacturer: API supply issues;30 mg - 100 count (NDC 00555-0789-02) Teva continues to release product as it becomes available.;25 mg - 100 count (NDC 00555-0792-02) Teva continues to release product as it becomes available.;15 mg - 100 count (NDC 00555-0791-02) Teva continues to release product as it becomes available.;5 mg - 100 count (NDC 00555-0790-02) Teva continues to release product as it becomes available.;10 mg - 100 count (NDC 00555-0787-02) Teva continues to release product as it becomes available.;20 mg - 100 count (NDC 00555-0788-02) Teva continues to release product as it becomes available.,,,,,,,,,,,,,
CorePharma,amphetaminet,1,11/3/11,11/20/12,manufacturing delays; demand increase,blue,,"CorePharma has all amphetamine mixed salt immediate-release tablets on allocation.;CorePharma is releasing product as it becomes available.;Increase in demand CorePharma is releasing product as it becomes available.;;10 mg tablets- 100 count (NDC 64720-0132-10) CorePharma is releasing product as it becomes available. Shortage per Manufacturer: Increase in demand;5 mg tablets- 100 count (NDC 64720-0130-10) CorePharma is releasing product as it becomes available. Shortage per Manufacturer: Increase in demand;20 mg tablets- 100 count (NDC 64720-0135-10) CorePharma is releasing product as it becomes available. Shortage per Manufacturer: Increase in demand;30 mg tablets- 100 count (NDC 64720-0136-10) CorePharma is releasing product as it becomes available. Shortage per Manufacturer: Increase in demand;10 mg tablets- 100 count (NDC 64720-0132-10) CorePharma is releasing product as it becomes available. Shortage per Manufacturer: 
 Increase in demand;30 mg tablets- 100 count (NDC 64720-0136-10) CorePharma is releasing product as it becomes available. Shortage per Manufacturer: 
 Increase in demand;5 mg tablets- 100 count (NDC 64720-0130-10) CorePharma is releasing product as it becomes available. Shortage per Manufacturer: 
 Increase in demand;20 mg tablets- 100 count (NDC 64720-0135-10) CorePharma is releasing product as it becomes available. Shortage per Manufacturer: 
 Increase in demand",,,,,,,,,,,,,
Teva,amphetaminet,1,11/3/11,11/20/12,material availability; material shortage; ,green,,Teva continue to release product as it becomes available.;API supply issues Teva continue to release product as it becomes available.;;12.5 mg tablets- 100 count (NDC 00555-0776-02) Teva supply is adequate to meet demand. Shortage per Manufacturer: API supply issues;15 mg tablets- 100 count (NDC 00555-0777-02) Teva supply is adequate to meet demand. Shortage per Manufacturer: API supply issues;20 mg tablets- 100 count (NDC 00555-0973-02) Low inventory- possible backorders through September   Shortage per Manufacturer: API supply issues;Adderall- 10 mg tablets- 100 count (NDC 00555-0764-02) Teva supply is adequate to meet demand. Shortage per Manufacturer: API supply issues;Adderall- 12.5 mg tablets- 100 count (NDC 00555-0765-02) Teva supply is adequate to meet demand. Shortage per Manufacturer: API supply issues;Adderall- 15 mg tablets- 100 count (NDC 00555-0766-02) Teva supply is adequate to meet demand. Shortage per Manufacturer: API supply issues;5 mg tablets- 100 count (NDC 00555-0971-02) Low inventory- possible backorders through September Shortage per Manufacturer: API supply issues;Adderall- 20 mg tablets- 100 count (NDC 00555-0767-02) Teva supply is adequate to meet demand. Shortage per Manufacturer: API supply issues;7.5 mg tablets- 100 count (NDC 00555-0775-02) Backorder through August Shortage per Manufacturer: API supply issues;Adderall- 30 mg tablets- 100 count (NDC 00555-0768-02) Teva supply is adequate to meet demand. Shortage per Manufacturer: API supply issues;10 mg tablets- 100 count (NDC 00555-0972-02) Low inventory- possible backorders through September   Shortage per Manufacturer: API supply issues;Adderall- 7.5 mg tablets- 100 count (NDC 00555-0763-02) Teva supply is adequate to meet demand. Shortage per Manufacturer: API supply issues;30 mg tablets- 100 count (NDC 00555-0974-02) Low inventory- possible backorders through October Shortage per Manufacturer: API supply issues;Adderall- 5 mg tablets- 100 count (NDC 00555-0762-02) Teva supply is adequate to meet demand. Shortage per Manufacturer: API supply issues;10 mg tablets- 100 count (NDC 00555-0972-02) Low inventory- possible backorders through October;5 mg tablets- 100 count (NDC 00555-0971-02) Teva supply is adequate to meet demand.;Adderall- 10 mg tablets- 100 count (NDC 00555-0764-02) Teva supply is adequate to meet demand.;Adderall- 7.5 mg tablets- 100 count (NDC 00555-0763-02) Teva supply is adequate to meet demand.;Adderall- 20 mg tablets- 100 count (NDC 00555-0767-02) Teva supply is adequate to meet demand.;7.5 mg tablets- 100 count (NDC 00555-0775-02) Teva supply is adequate to meet demand.;20 mg tablets- 100 count (NDC 00555-0973-02) Low inventory- possible backorders through October;Adderall- 12.5 mg tablets- 100 count (NDC 00555-0765-02) Teva supply is adequate to meet demand.;Adderall- 30 mg tablets- 100 count (NDC 00555-0768-02) Teva supply is adequate to meet demand.;12.5 mg tablets- 100 count (NDC 00555-0776-02) Teva supply is adequate to meet demand.;15 mg tablets- 100 count (NDC 00555-0777-02) Teva supply is adequate to meet demand.;Adderall- 5 mg tablets- 100 count (NDC 00555-0762-02) Teva supply is adequate to meet demand.;30 mg tablets- 100 count (NDC 00555-0974-02) Low inventory- possible backorders through October;Adderall- 15 mg tablets- 100 count (NDC 00555-0766-02) Teva supply is adequate to meet demand.;10 mg tablets- 100 count (NDC 00555-0972-02) Low inventory- possible backorders through November;30 mg tablets- 100 count (NDC 00555-0974-02) Low inventory- possible backorders through November;20 mg tablets- 100 count (NDC 00555-0973-02) Low inventory- possible backorders through November,,,,,,,,,,,,,
Hospira,aquasol,1,12/9/10,11/2/12,manufacturing site change; manufacturing delays,blue,,Change in manufacturing sites. ;Change in manufacturing sites.; Hospira anticipates releasing product sometime in 2011.;Hospira anticipates next delivery in 1Q 2012.;Hospira anticipates next delivery in 2Q 2012.;Hospira anticipates next delivery in July- 2012.;Hospira anticipates next delivery in December- 2012.;Change in manufacturing sites. Hospira anticipates next delivery in December- 2012.;;50-000 units/mL- 2 mL ampule (NDC 61703-418-07) Next delivery TBD Shortage per Manufacturer: Change in manufacturing site;NULL NULL Shortage per Manufacturer: Change in manufacturing site,,,,,,,,,,,,,
Pfizer,arginine,1,11/12/10,4/22/11,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
Schering,asmanex,1,5/5/12,5/15/12,manufacturing delays,blue,,,,,,,,,,,,,,,
Hospira,atracurium,1,3/6/13,1/8/14,demand increase; available,orange,pediatric;anesthesia;neurology;,10 mg/mL; 5 mL vial (NDC 0409-1109-01)  10 mg/mL; 10 mL vial (NDC 0409-1105-02) Available   New product launch in February 2013.;10 mg/mL; 5 mL vial (NDC 0409-1109-01)  10 mg/mL; 10 mL vial (NDC 0409-1105-02) Yet to be Launched; expected in March. New product launch in February 2013.;10 mg/mL; 5 mL vial (NDC 0409-1109-01)  10 mg/mL; 10 mL vial (NDC 0409-1105-02) Available;10 mg/mL; 5 mL vial (NDC 0409-1109-01)  10 mg/mL; 10 mL vial (NDC 0409-1105-02) Yet to be Launched; expected in May Expected launch in May;10 mg/mL; 10 mL vial (NDC 0409-1105-02) Available   New product launch.;10 mg/mL; 5 mL vial (NDC 0409-1109-01)  Available   New product launch.;10 mg/mL; 10 mL vial (NDC 0409-1105-02) Available,,,,,,,,,,,,,
AmericanRegent,atracurium,1,1/12/12,2/23/12,manufacturing delays,blue,pediatric;anesthesia;neurology;,Atracurium besylate is on back order with no estimated date of availability.,,,,,,,,,,,,,
Bedford,atracurium,1,4/30/10,12/9/10,manufacturing delays,blue,pediatric;anesthesia;neurology;,Manufacturing delays,,,,,,,,,,,,,
Bedford,atracurium,1,3/1/12,1/8/14,manufacturing delays; capacity constraints; pending manufacturing change,blue,pediatric;anesthesia;neurology;,"Atracurium besylate is on back order with no estimated date of availability.;Bedford Laboratories has 50mg Inj SDV 5ml and 100mg Inj MDV 10ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.;Manufacturing delays Bedford Laboratories has 50mg Inj SDV 5ml and 100mg Inj MDV 10ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.;;10 mg/mL- 5 mL vial- single dose vial (NDC 55390-0102-05)   Bedford Laboratories has 50mg Inj SDV 5ml and 100mg Inj MDV 10ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;5 mL Novaplus vial- single dose vial (NDC 55390-0180-05)   Bedford Laboratories has 50mg Inj SDV 5ml and 100mg Inj MDV 10ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;10 mL Novaplus vial- multi-dose vial (NDC 55390-0179-10)   Bedford Laboratories has 50mg Inj SDV 5ml and 100mg Inj MDV 10ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;10 mL vial- multi-dose vial (NDC 55390-0103-10)   Bedford Laboratories has 50mg Inj SDV 5ml and 100mg Inj MDV 10ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;10 mL vial- multi-dose vial (NDC 55390-0103-10)   Bedford Laboratories has 50mg Inj SDV 5ml and 100mg Inj MDV 10ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;10 mL Novaplus vial- multi-dose vial (NDC 55390-0179-10)   Bedford Laboratories has 50mg Inj SDV 5ml and 100mg Inj MDV 10ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;10 mg/mL- 5 mL vial- single dose vial (NDC 55390-0102-05)   Bedford Laboratories has 50mg Inj SDV 5ml and 100mg Inj MDV 10ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;5 mL Novaplus vial- single dose vial (NDC 55390-0180-05)   Bedford Laboratories has 50mg Inj SDV 5ml and 100mg Inj MDV 10ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;10 mg/mL- 5 mL vial- single dose vial (NDC 55390-0102-05)  Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;10 mL vial- multi-dose vial (NDC 55390-0103-10)  Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;10 mL vial- multi-dose vial (NDC 55390-0103-10)  Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.;10 mg/mL- 5 mL vial- single dose vial (NDC 55390-0102-05)  Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.",,,,,,,,,,,,,
WestWard,atropine,1,12/15/11,3/25/14,demand increase,orange,pediatric;anesthesia;neurology;,"N/A;West-Ward is currently experiencing a backorder situation on the 0.4 mg/mL- 20 mL vial.   West-Ward has accelerated production on this product and is projecting to have several lots available by the end of December 2011.   Product will be made available as it is released;West-Ward is currently experiencing a backorder situation on the 0.4 mg/mL- 20 mL vial.
  
 West-Ward has accelerated production on this product and is projecting to have several lots available by the end of December 2011.
  
 Product will be made available as it is released;West-Ward is currently experiencing a backorder situation on the 0.4 mg/mL- 20 mL vial. West-Ward has accelerated production on this product and is projecting to have additional inventory available by middle of March 2012. Product will be made available as it is release.;West-Ward is currently experiencing a backorder situation on the 0.4 mg/mL- 20 mL vial.
 
 West-Ward has accelerated production on this product and is projecting to have additional inventory available by middle of March 2012.
 
 Product will be made available as it is release.;West-Ward is currently experiencing a backorder situation on the 0.4 mg/mL- 20 mL vial. West-Ward has accelerated production on this product and is projecting to have additional inventory available by end of April 2012.  Additional lots will also be manufactured in May 2012.   Product will be made available as it is released.;Increase in product demand. West-Ward is currently experiencing a backorder situation on the 0.4 mg/mL- 20 mL vial. West-Ward has accelerated production on this product and is projecting to have additional inventory available by end of April 2012.  Additional lots will also be manufactured in May 2012.   Product will be made available as it is released.;;0.4 mg/mL- 20 mL vial (NDC 0641-6006-10) West-Ward currently has limited quantities available.   Additional lots will also be manufactured and available in August 2012.   Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand.;0.4 mg/mL- 20 mL vial 
 (NDC 0641-6006-10) West-Ward currently has limited quantities available.
  
 Additional lots will also be manufactured and available in August 2012.  
 Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand.;0.4 mg/mL- 20 mL vial (NDC 0641-6006-10) West-Ward currently experiencing a backorder sitation. West-Ward has accelerated production to meet increased demand.   Several lots are scheduled for production and anticipated to be available by the end of January 2013.   Product will be made available as it is released.;0.4 mg/mL- 20 mL vial (NDC 0641-6006-10) West-Ward currently experiencing a backorder sitation. West-Ward has accelerated production to meet increased demand.   Several lots are scheduled for production and anticipated to be available by the end of February 2013.   Product will be made available as it is released.;0.4 mg/mL- 20 mL vial (NDC 0641-6006-10) West-Ward currently has limited quantities available on this product. West-Ward has accelerated production to meet increased demand.   Additional lots are anticipated to be available in the July-August 2013 timeframe.   Product will be made available as it is released.;0.4 mg/mL- 20 mL vial (NDC 0641-6006-10) West-Ward currently has limited quantities available on this product. West-Ward has accelerated production to meet increased demand.   Additional lots are anticipated to be available in the August-September 2013 timeframe.   Product will be made available as it is released.;0.4 mg/mL- 20 mL vial (NDC 0641-6006-10) West-Ward currently has inventory available for this product. West-Ward has accelerated production to meet increased demand.   Additional lots are anticipated to be available in November 2013.   Product will be made available as it is released.;0.4 mg/mL- 20 mL vial (NDC 0641-6006-10) West-Ward currently has inventory available for this product. West-Ward has accelerated production to meet increased demand.   Additional lots are anticipated to be manufactured and available in the January - February 2014 timeframe.   Product will be made available as it is released.;0.4 mg/mL- 20 mL vial (NDC 0641-6006-10)   West-Ward currently has inventory available for this product. West-Ward has accelerated production to meet increased demand.   Additional lots are anticipated to be manufactured and available in the January - February 2014 timeframe.   Product will be made available as it is released.",,,,,,,,,,,,,
Amphastar,atropine,1,12/15/11,3/25/14,demand increase; available,orange,pediatric;anesthesia;neurology;,"N/A;No current shortage N/A;;0.1 mg/mL- 10 mL- Luer-Jet Prefilled Syringe   NDC 76329-3339-1 (old NDC 00548-3339-00)  Available;0.1 mg/mL- 10 mL- Luer-Jet Prefilled Syringe   NDC 76329-3339-1 (old NDC 00548-3339-00)  Amphastar will regularly release products. Shortage per Manufacturer: Increase in product demand caused by market supply issues.;0.1 mg/mL- 10 mL- Luer-Jet Prefilled Syringe
  
 NDC 76329-3339-1
 (old NDC 00548-3339-00)  Amphastar will regularly release products. Shortage per Manufacturer: Increase in product demand caused by market supply issues.;0.1 mg/mL- 10 mL- Luer-Jet Prefilled Syringe   NDC 76329-3339-1 (old NDC 00548-3339-00)  Amphastar will regularly release products. Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues.",,,,,,,,,,,,,
Hospira,atropine,1,12/15/11,3/25/14,manufacturing delays; material shortage; manufacturing delays; available,green,pediatric;anesthesia;neurology;,"Product 0.1 mg/mL; 10 mL Ansyr syringe (NDC 0409-1630-10): ample levels of inventory to support market demand.   Product 0.05 mg/mL; 5 mL Ansyr syringe (NDC 0409-9630-05): next delivery February 2012.   Product 0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34): currently product is available.   Product 0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34): currently product is available. Please check with your wholesaler for available inventory.;Product 0.1 mg/mL; 10 mL Ansyr syringe (NDC 0409-1630-10): ample levels of inventory to support market demand.
  
 Product 0.05 mg/mL; 5 mL Ansyr syringe (NDC 0409-9630-05): next delivery February 2012.
  
 Product 0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34): currently product is available.
  
 Product 0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34): currently product is available. Please check with your wholesaler for available inventory.;Product 0.1 mg/mL; 10 mL Ansyr syringe (NDC 0409-1630-10): ample levels of inventory to support market demand.   Product 0.05 mg/mL; 5 mL Ansyr syringe (NDC 0409-9630-05): next delivery March.   Product 0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34): currently product is available.   Product 0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34): currently product is available. Please check with your wholesaler for available inventory.;Product 0.1 mg/mL; 10 mL Ansyr syringe (NDC 0409-1630-10): ample levels of inventory to support market demand. Product 0.05 mg/mL; 5 mL Ansyr syringe (NDC 0409-9630-05): next delivery April. Product 0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34): currently product is available. Product 0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34): currently product is available. Please check with your wholesaler for available inventory.;Product 0.1 mg/mL; 10 mL Ansyr syringe (NDC 0409-1630-10): ample levels of inventory to support market demand. 
 
 Product 0.05 mg/mL; 5 mL Ansyr syringe (NDC 0409-9630-05): next delivery April. 
 
 Product 0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34): currently product is available. 
 
 Product 0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34): currently product is available. Please check with your wholesaler for available inventory.;Product 0.1 mg/mL; 10 mL Ansyr syringe (NDC 0409-1630-10): ample levels of inventory to support market demand. Product 0.05 mg/mL; 5 mL Ansyr syringe (NDC 0409-9630-05): next delivery June. Product 0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34): currently product is available. Product 0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34): currently product is available. Please check with your wholesaler for available inventory.;Manufacturing delay Product 0.1 mg/mL; 10 mL Ansyr syringe (NDC 0409-1630-10): ample levels of inventory to support market demand. Product 0.05 mg/mL; 5 mL Ansyr syringe (NDC 0409-9630-05): next delivery June. Product 0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34): currently product is available. Product 0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34): currently product is available. Please check with your wholesaler for available inventory.;;0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34) Next delivery 1Q 2013 Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay;0.1 mg/mL; 10 mL Ansyr syringe (NDC 0409-1630-10) Available Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay;0.05 mg/mL; 5 mL Ansyr syringe (NDC 0409-9630-05) Next delivery 1Q 2013 Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay;0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34) Next delivery 1Q 2013 Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay;0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34) Next delivery and estimated recovery 1Q 2013 Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay;0.05 mg/mL; 5 mL Ansyr syringe (NDC 0409-9630-05) Next delivery and estimated recovery 1Q 2013 Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay;0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34) Next delivery and estimated recovery 1Q 2013 Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay;0.1 mg/mL; 10 mL Ansyr syringe 
 (NDC 0409-1630-10) Available Please check with your wholesaler for available inventory. 
 Shortage per Manufacturer: 
 Manufacturing delay;0.05 mg/mL; 5 mL Ansyr syringe 
 (NDC 0409-9630-05) Next delivery and estimated recovery 1Q 2013 Please check with your wholesaler for available inventory. 
 Shortage per Manufacturer: 
 Manufacturing delay;0.1 mg/mL; 10 mL Lifeshield syringe 
 (NDC 0409-4911-34) Next delivery and estimated recovery 1Q 2013 Please check with your wholesaler for available inventory. 
 Shortage per Manufacturer: 
 Manufacturing delay;0.1 mg/mL; 5 mL Lifeshield syringe 
 (NDC 0409-4910-34) Next delivery and estimated recovery 1Q 2013 Please check with your wholesaler for available inventory. 
 Shortage per Manufacturer: 
 Manufacturing delay;0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34) Next delivery and estimated recovery TBD Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay;0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34) Next delivery and estimated recovery TBD Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay;0.05 mg/mL; 5 mL Ansyr syringe (NDC 0409-9630-05) Next delivery and estimated recovery TBD Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay;0.1 mg/mL; 10 mL Ansyr syringe (NDC 0409-1630-10) Next delivery and estimated recovery TBD Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay;0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34) Company estimates a release date by 2Q 2013 Estimated recovery: 2Q 2013 Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay; Material shortage;0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34) Next delivery 2Q 2013 Estimated recovery: 2Q 2013  Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay; Material shortage;0.1 mg/mL; 10 mL Ansyr syringe (NDC 0409-1630-10) Next delivery and estimated recovery TBD Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay; Material shortage;0.05 mg/mL; 5 mL Ansyr syringe (NDC 0409-9630-05) Next delivery and estimated recovery TBD Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay; Material shortage;0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34) Next delivery mid May Estimated recovery: 2Q 2013  Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay; Material shortage;0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34) Company estimates a release date by early May. Estimated recovery: 2Q 2013 Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay; Material shortage;0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34) Next delivery late May   Estimated recovery 2Q 2013  Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay; Material shortage;0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34) Company estimates a release date by late May.   Estimated recovery: 2Q 2013 Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay; Material shortage;0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34) Next delivery mid June Estimated recovery 3Q 2013  Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay; Material shortage;0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34) Next delivery early July Estimated recovery 3Q 2013  Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay; Material shortage;0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34) Next delivery mid July Estimated recovery July Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay; Material shortage;0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34) Next delivery mid July Estimated recovery 3Q 2013  Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay; Material shortage;0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34) Next delivery mid August Estimated recovery 4Q 2013 Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay; Material shortage;0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34) Next delivery late July Estimated recovery 3Q 2013  Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay; Material shortage;0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34) Next delivery late September Estimated recovery 4Q 2013 Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay;0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34) Next delivery late September Estimated recovery 3Q 2013  Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay;0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34) Next delivery October Estimated recovery 4Q 2013  Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay;0.05 mg/mL; 5 mL Ansyr syringe (NDC 0409-9630-05) Next delivery and estimated recovery TBD Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay/Available;0.1 mg/mL; 10 mL Ansyr syringe (NDC 0409-1630-10) Next delivery TBD Estimated recovery TBD Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay/Available;0.1 mg/mL; 10 mL Lifeshield syringe (NDC 0409-4911-34) Available Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay/Available;0.1 mg/mL; 5 mL Lifeshield syringe (NDC 0409-4910-34) Available Please check with your wholesaler for available inventory.  Shortage per Manufacturer: Manufacturing delay/Available",,,,,,,,,,,,,
AmericanRegent,atropine,1,12/15/11,3/25/14,production suspended; discontinued; available; not releasing; shipping delay; demand increase,black,pediatric;anesthesia;neurology;,"No stock available. Anticipate to have lots available March 2012.;Discontinued ampoules. American Regent anticipates to have lots available end of Mid-May 2012.;No stock available Discontinued ampoules. American Regent anticipates to have lots available end of Mid-May 2012.;;0.4 mg/mL- 0.5 mL ampule- package of 25 (NDC 00517-0805-25) Unavailable Shortage per Manufacturer: American Regent/Luitpold has discontinued manufacturing the ampoules;0.4 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-0401-25) Unavailable Shortage per Manufacturer: American Regent is currently not releasing Atropine Sulfate Injection 0.4 mg/mL- 1 mL single-dose vial;1 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-1010-25) Available Please check with your wholesaler for available inventory.;1 mg/mL- 1 mL ampule- package of 25 (NDC 00517-0101-25) Unavailable Shortage per Manufacturer: American Regent/Luitpold has discontinued manufacturing the ampoules;1 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-1010-25) Unavailable Please check with your wholesaler for available inventory.;0.4 mg/mL- 0.5 mL ampule- package of 25 
 (NDC 00517-0805-25) Unavailable Shortage per Manufacturer: 
 American Regent/Luitpold has discontinued manufacturing the ampoules;1 mg/mL- 1 mL single-dose vial- package of 25 
 (NDC 00517-1010-25) Unavailable Please check with your wholesaler for available inventory.;1 mg/mL- 1 mL ampule- package of 25 (NDC 00517-0101-25) Unavailable Shortage per Manufacturer: 
 American Regent/Luitpold has discontinued manufacturing the ampoules;0.4 mg/mL- 1 mL single-dose vial- package of 25 
 (NDC 00517-0401-25) Unavailable Shortage per Manufacturer: 
 American Regent is currently not releasing Atropine Sulfate Injection 0.4 mg/mL- 1 mL single-dose vial;0.4 mg/mL- 0.5 mL ampule- package of 25 (NDC 00517-0805-25) Unavailable Shortage per Manufacturer: American Regent/Luitpold has discontinued manufacturing the ampules;1 mg/mL- 1 mL ampule- package of 25 (NDC 00517-0101-25) Unavailable Shortage per Manufacturer: American Regent/Luitpold has discontinued manufacturing the ampules;1 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-1010-25) Available American Regent is currently releasing Atropine Sulfate Injection  1 mg/mL- 1 mL single-dose vial;0.4 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-0401-25) Available American Regent is currently releasing Atropine Sulfate Injection  0.4 mg/mL- 1 mL single-dose vial;0.4 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-0401-25) Available;1 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-1010-25) Unavailable;1 mg/mL- 1 mL ampule- package of 25 (NDC 00517-0101-25) Available;0.4 mg/mL- 0.5 mL ampule- package of 25 (NDC 00517-0805-25) Unavailable American Regent/Luitpold has discontinued manufacturing the ampoules;0.4 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-0401-25) Unavailable American Regent is currently not releasing Atropine Sulfate Injection 0.4 mg/mL- 1 mL single-dose vial;1 mg/mL- 1 mL ampule- package of 25 (NDC 00517-0101-25) Available American Regent is currently releasing Atropine Sulfate Injection 1 mg/mL- 1 mL single-dose vial;0.4 mg/mL- 0.5 mL ampule- package of 25 (NDC 00517-0805-25)   1 mg/mL- 1 mL ampule- package of 25 (NDC 00517-0101-25) Unavailable American Regent/Luitpold has discontinued manufacturing the ampoules;#NAME?;1 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-1010-25) Temporarily unavailable. Next release August 2013.;1 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-1010-25) Available American Regent is currently releasing Atropine Sulfate Injection 1mg/mL- 1 mL single-dose vial;1 mg/mL- 1 mL ampule- package of 25 (NDC 00517-0101-25) Unavailable American Regent/Luitpold has discontinued manufacturing the ampoules;1 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-1010-25) Unavailable American Regent is currently not releasing Atropine Sulfate Injection 1mg/mL- 1 mL single-dose vial;0.4 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-0401-25) Unavailable - Product on backorder and will be made available as it is released. American Regent is currently not releasing Atropine Sulfate Injection 0.4 mg/mL- 1 mL single-dose vial;1 mg/mL- 1 mL ampule- package of 25 (NDC 00517-0101-25) Unavailable - No product available for release. No plan to manufacure American Regent/Luitpold has discontinued manufacturing the ampules;1 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-1010-25) Unavailable - Product on backorder and will be made available as it is released. American Regent is currently releasing Atropine Sulfate Injection 1mg/mL- 1 mL single-dose vial;0.4 mg/mL- 0.5 mL ampule- package of 25 (NDC 00517-0805-25) Unavailable - No product available for release. No plan to manufacure American Regent/Luitpold has discontinued manufacturing the ampules;1 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-1010-25) Unavailable - Product on backorder and will be made available as it is released. American Regent/Luitpold has discontinued manufacturing the ampules.                                   American Regent is currently not releasing Atropine Sulfate Injection 0.4 mg/mL- 1 mL single-dose vial or 1mg/mL- 1 mL single-dose vial.;0.4 mg/mL- 1 mL single-dose vial- package of 25 (NDC 00517-0401-25) Unavailable - Product on backorder and will be made available as it is released. American Regent/Luitpold has discontinued manufacturing the ampules.                                   American Regent is currently not releasing Atropine Sulfate Injection 0.4 mg/mL- 1 mL single-dose vial or 1mg/mL- 1 mL single-dose vial.;0.4 mg/mL- 0.5 mL ampule- package of 25 (NDC 00517-0805-25) Unavailable - No product available for release. No plan to manufacture                           American Regent/Luitpold has discontinued manufacturing the ampules.                                   American Regent is currently not releasing Atropine Sulfate Injection 0.4 mg/mL- 1 mL single-dose vial or 1mg/mL- 1 mL single-dose vial.;1 mg/mL- 1 mL ampule- package of 25 (NDC 00517-0101-25) Unavailable - No product available for release. No plan to manufacture                           American Regent/Luitpold has discontinued manufacturing the ampules.                                   American Regent is currently not releasing Atropine Sulfate Injection 0.4 mg/mL- 1 mL single-dose vial or 1mg/mL- 1 mL single-dose vial.",,,,,,,,,,,,,
Bristol,avalide,1,4/28/11,3/1/12,manufacturing delays,blue,,Please see the following link for updated information: Bristol-Myers Squib,,,,,,,,,,,,,
BristolMyersSquibb,avalide,1,1/6/11,4/22/11,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
Baxter,azactam,1,6/6/09,6/25/10,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
BMS,azactam,1,3/26/10,6/25/10,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
Elan,azactam,1,6/6/09,3/20/10,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
APP,bacteriostatic,1,9/1/12,8/15/13,demand increase,orange,pediatric;,"30 mL MD Vial Glass (NDC # 63323-259-30)  Unavailable   Shortage per Manufacturer: Increased demand;10mL MD Vial Plastic (NDC # 63323-924-10)  Next delivery for October 2012   Shortage per Manufacturer: Increased demand;30 mL MD Vial Plastic (NDC # 63323-924-30)  Next delivery for October 2012   Shortage per Manufacturer: Increased demand;30 mL MD Vial Glass (NDC # 63323-259-30)  Next delivery for October 2012  Shortage per Manufacturer: Increased demand;30 mL MD Vial Plastic 
 (NDC # 63323-924-30)  Available 
 Check wholesaler inventory  Shortage per Manufacturer: 
 Increased demand;30 mL MD Vial Glass 
 (NDC # 63323-259-30)  Next delivery for October 2012  Shortage per Manufacturer: 
 Increased demand;10mL MD Vial Plastic 
 (NDC # 63323-924-10)  Next delivery for October 2012 
   Shortage per Manufacturer: 
 Increased demand;30 mL MD Vial Plastic (NDC # 63323-924-30)  Next delivery for December 2012  Shortage per Manufacturer: Increased demand;30 mL MD Vial Glass (NDC # 63323-259-30)  Next delivery anticipated December 2012  Shortage per Manufacturer: Increased demand;10mL MD Vial Plastic (NDC # 63323-924-10)  Available Check wholesalers inventory.   Shortage per Manufacturer: Increased demand;30 mL MD Vial Plastic (NDC # 63323-924-30)  Available Check wholesalers inventory.  Shortage per Manufacturer: Increased demand;30 mL MD Vial Glass (NDC # 63323-259-30)  Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand;30 mL MD Vial Plastic (NDC # 63323-924-30)  Back-ordered.  No estimated delivery at this time.  Shortage per Manufacturer: Increased demand;30 mL MD Vial Plastic (NDC # 63323-924-30)  Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand",,,,,,,,,,,,,
Hospira,bacteriostatic,1,9/1/12,8/15/13,manufacturing delays,blue,pediatric;,"30 mL vial (NDC 0409-1966-07)   Next delivery September   Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;20 mL vial (NDC 0409-1966-05)   Next delivery December   Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;10 mL vial (NDC 0409-1966-12)   Next delivery October   Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;20 mL vial (NDC 0409-1966-05)   Next delivery 2013 Estimated recovery: 2013   Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;10 mL vial (NDC 0409-1966-12)   Next delivery October Estimated recovery: 2Q 2013   Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;30 mL vial (NDC 0409-1966-07)   Next delivery September Estimated recovery: 2013   Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;10 mL vial (NDC 0409-1966-12)   Next delivery December Estimated recovery: 4Q 2013   Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;30 mL vial (NDC 0409-1966-07)   Next delivery October Estimated recovery: 1Q 2013   Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;20 mL vial (NDC 0409-1966-05)   Next delivery December Estimated recovery: December   Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;20 mL vial 
 (NDC 0409-1966-05) 
   Next delivery December Estimated recovery: December 
   Please check with your wholesaler for available inventory. 
 Shortage per Manufacturer: manufacturing delay;10 mL vial 
 (NDC 0409-1966-12) 
   Next delivery December Estimated recovery: 4Q 2013 
   Please check with your wholesaler for available inventory. 
 Shortage per Manufacturer: manufacturing delay;30 mL vial 
 (NDC 0409-1966-07) 
   Next delivery October Estimated recovery: 1Q 2013 
   Please check with your wholesaler for available inventory. 
 Shortage per Manufacturer: manufacturing delay;20 mL vial (NDC 0409-1966-05)   Next delivery November Estimated recovery: 1Q 2013  Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;10 mL vial (NDC 0409-1966-12)   Next delivery December  Estimated recovery: 4Q 2012   Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;20 mL vial (NDC 0409-1966-05)   Next delivery December Estimated recovery: 1Q 2013  Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;30 mL vial (NDC 0409-1966-07)   Next delivery November Estimated recovery: 1Q 2013   Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;10 mL vial (NDC 0409-1966-12)   Available  Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;30 mL vial (NDC 0409-1966-07)   Next delivery January  Estimated recovery: 1Q 2013   Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;30 mL vial (NDC 0409-1966-07)   Available  Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;20 mL vial (NDC 0409-1966-05)   Next delivery January Estimated recovery: 1Q 2013  Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay;20 mL vial (NDC 0409-1966-05)   Available Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay",,,,,,,,,,,,,
Bracco,barium,1,3/6/13,3/25/14,demand increase; material shortage,green,;medical;,LIQUID POLIBAR PLUS BARIUM SULFATE SUSPENSION (105% w/v- 58% w/w)- (NDC 32909-168-02);LIQUID E-Z-PAQUE BARIUM SULFATE SUSPENSION (60% w/v- 41% w/w)-(NDC 32909-186-01);E-Z-CAT DRY BARIUM SULFATE FOR SUSPENSION (2% w/w After Mixing)- (NDC 32909-727-01);E-Z-HD BARIUM SULFATE FOR SUSPENSION (98% w/w)-(NDC 32909-764-01);LIQUID E-Z-PAQUE BARIUM SULFATE SUSPENSION (60% w/v- 41% w/w)-(NDC 32909-186-02);POLIBAR ACB BARIUM SULFATE (96% w/w)-  (NDC 32909-804-01);DIGIBAR 190 BARIUM SULFATE FOR SUSPENSION- (190% w/v when constituted 232 g)- (NDC 32909-270-19 );E-Z-DISK BARIUM SULFATE TABLETS (NDC 10361-778-31);POLIBAR ACB BARIUM SULFATE (96% w/w)- NDC 32909-804-02;MAXIBAR BARIUM SULFATE SUSPENSION (210% w/v- 80% w/w)-(NDC 32909-150-08);DIGIBAR 190 BARIUM SULFATE FOR SUSPENSION- (190% w/v when constituted 232 g)- (NDC 32909-270-19 )   Not yet available. Duration uncertain.;ENTERO-H BARIUM SULFATE SUSPENSION (80% w/v- 49% w/w) (NDC 32909-147-01) Not yet available. Duration uncertain.;MAXIBAR BARIUM SULFATE SUSPENSION (210% w/v- 80% w/w)-(NDC 32909-150-08) Not yet available. Duration uncertain.;LIQUID POLIBAR BARIUM SULFATE SUSPENSION (100% w/v- 56% w/w) (NDC 32909-164-01)   Not yet available. Duration uncertain.;LIQUID E-Z-PAQUE BARIUM SULFATE SUSPENSION (60% w/v- 41% w/w)-(NDC 32909-186-01) This product is still on shortage.;Sensatrast BARIUM SULFATE USP- Ph. Eur 100% (NDC 32909-788-61) Not yet available. Duration uncertain.;E-Z-DISK BARIUM SULFATE TABLETS (NDC 10361-778-31) This product is still on shortage but should be available sometime in August 2013.;DIGIBAR 190 BARIUM SULFATE FOR SUSPENSION- (190% w/v when constituted 232 g)- (NDC 32909-270-19 )   To be discontinued;Sensatrast BARIUM SULFATE USP- Ph. Eur 100% (NDC 32909-788-61) To be discontinued;E-Z-DISK BARIUM SULFATE TABLETS (NDC 10361-778-31) This product is still on shortage but should be available sometime in 4Q 2013.;MAXIBAR BARIUM SULFATE SUSPENSION (210% w/v- 80% w/w)-(NDC 32909-150-08) To be discontinued;E-Z-DOSE WITH LIQUID POLIBAR PLUS BARIUM SULFATE SUSPENSION (105% w/v- 58% w/w) (NDC 32909-652-02) Not yet available. Duration uncertain.;E-Z-DISK BARIUM SULFATE TABLETS (NDC 10361-778-31) Available;LIQUID E-Z-PAQUE BARIUM SULFATE SUSPENSION (60% w/v- 41% w/w)-(NDC 32909-186-01) This product is still on shortage;NULL NULL;E-Z-DISK BARIUM SULFATE TABLETS (NDC 10361-778-31) Available mid-March 2014,,,,,,,,,,,,,
EZEM,barium,1,10/14/12,3/1/13,demand increase; material shortage,green,;medical;,DIGIBAR 190 BARIUM SULFATE FOR SUSPENSION- (190% w/v when constituted 232 g)- (NDC 32909-270-19 );POLIBAR ACB BARIUM SULFATE (96% w/w)- NDC 32909-804-02;LIQUID POLIBAR PLUS BARIUM SULFATE SUSPENSION (105% w/v- 58% w/w)- (NDC 32909-168-02);MAXIBAR BARIUM SULFATE SUSPENSION (210% w/v- 80% w/w)-(NDC 32909-150-08);LIQUID E-Z-PAQUE BARIUM SULFATE SUSPENSION (60% w/v- 41% w/w)-(NDC 32909-186-02);E-Z-DISK BARIUM SULFATE TABLETS (NDC 10361-778-31);E-Z-HD BARIUM SULFATE FOR SUSPENSION (98% w/w)-(NDC 32909-764-01);LIQUID E-Z-PAQUE BARIUM SULFATE SUSPENSION (60% w/v- 41% w/w)-(NDC 32909-186-01);E-Z-CAT DRY BARIUM SULFATE FOR SUSPENSION (2% w/w After Mixing)- (NDC 32909-727-01);POLIBAR ACB BARIUM SULFATE (96% w/w)-  (NDC 32909-804-01),,,,,,,,,,,,,
Schering,betamethasone,1,3/16/12,5/15/12,product recall,yellow,,Voluntary product recall conducted Jan 23- 2012. Product will be unavailable for an undetermined period of time.;Technical Issue Voluntary product recall conducted Jan 23- 2012. Product will be unavailable for an undetermined period of time.;,,,,,,,,,,,,,
Bristol,bicnu,1,5/11/11,5/18/11,manufacturing delays,blue,,Bristol-Myers Squibb has BICNU injection on back order and the company estimates a release date of late-May 2011.,,,,,,,,,,,,,
BristolMyersSquibb,bicnu,1,1/13/11,3/2/11,manufacturing delays,blue,,Manufacturing delays at contract manufacturer.,,,,,,,,,,,,,
APP,bleomycin,1,12/18/10,3/1/12,demand increase; manufacturing delays,blue,,Manufacturing delays      ;Increased demand Manufacturing delays   Manufacturing delays   Manufacturing delays   ;Increased demand Manufacturing delays   Manufacturing delays   Manufacturing delays   ;APP is currently back-ordered on all presentations of Bleomycin for Injection at this time. APP is anticipating batch releases to resume in the first quarter of 2011.;APP has Bleomycin 15 units and 30 units presentations on back order.   The 15 unit is estimated to release mid-July and 30 unit is estimated to release early-August.;APP has Bleomycin 15 units and 30 units presentations on back order. Releases on both presentations are expected in early January 2012.;APP has Bleomycin 15 units and 30 units presentations on back order.   Releases on both presentations are expected in early January 2012.,,,,,,,,,,,,,
Teva,bleomycin,1,12/18/10,3/1/12,demand increase; manufacturing delays,blue,,Increased demand   Manufacturing delays; 15 unit vials (NDC 00703-3154-01) and 30 unit vials (NDC 00703-3155-01) are now available and the company is reviewing orders prior to shipping.;Teva has bleomycin 15 unit and 30 unit vials on back order and anticipates release by end of August 2011.;Teva-Sicor has available bleomycin 15 unit (NDC 00703-3154-01) vials. They are reviewing orders prior to release.;Teva has available bleomycin 15 unit (NDC 00703-3154-01) and 30 unit vial (NDC 00703-3155-01).,,,,,,,,,,,,,
Bedford,bleomycin,1,12/18/10,3/1/12,demand increase; manufacturing delays; discontinued,blue,,Increased demand   Manufacturing delays   Manufacturing delays   Manufacturing delays      ;Increased demand Manufacturing delays   Manufacturing delays   Manufacturing delays   ;Increased demand Manufacturing delays   Manufacturing delays   Manufacturing delays   ; Bedford has bleomycin 15 and 30 unit vials on long term back order with no release date.;Bedford currently has all presentations discontinued.,,,,,,,,,,,,,
Hospira,bleomycin,1,12/18/10,3/1/12,manufacturing delays; demand increase; other manufacturer shortage,blue,,"Increased demand   Manufacturing delays; Backordered until 1Q 2011.;NDC 61703-332-18 is expected to be available in June; NDC 61703-323-22 is expected to be available in May.;Products 15 unit vial (NDC 61703-332-18) and 30 unit vial (NDC 61703-323-22):  next release in June.   Please check with your wholesaler for available inventory.;Product 15 unit vial (NDC 61703-332-18):  releases received weeks of June 6 and June 13- however- supply is tight and being managed through allocation from Hospira direct.  Next delivery expected in August. Product 30 unit vial (NDC 61703-323-22):  releases received weeks of June 6 and June 13- however- supply is tight and being managed through allocation from Hospira direct.  Next delivery expected in July.;Product 15 unit vial (NDC 61703-332-18):  releases received weeks of June 6 and June 13- however- supply is tight and being managed through allocation from Hospira direct.  Next delivery expected in July. Product 30 unit vial (NDC 61703-323-22):  releases received weeks of June 6 and June 13- however- supply is tight and being managed through allocation from Hospira direct.  Next delivery expected in August.;Product 15 unit vial (NDC 61703-332-18):  July delivery received; next release September. Product 30 unit vial (NDC 61703-323-22):  releases received weeks of June 6 and June 13- however- supply is tight and being managed through allocation from Hospira direct.  Next delivery expected in August.;Product 15 unit vial (NDC 61703-332-18):  July delivery received; next release in September. Product 30 unit vial (NDC 61703-323-22):  releases received weeks of June 6 and June 13- however- supply is tight and being managed through allocation from Hospira direct.  Next delivery expected in September.;Product 15 unit vial (NDC 61703-332-18):  July delivery received; next delivery in September. Product 30 unit vial (NDC 61703-323-22):  delivery received in August- however- supply is tight and being managed through allocation from Hospira direct.  Next delivery expected in September.;Product 15 unit vial (NDC 61703-332-18): next delivery October. Product 30 unit vial (NDC 61703-323-22):  delivery received in September; next delivery December.;Product 15 unit vial (NDC 61703-332-18): October deliver in transit; next delivery December. Product 30 unit vial (NDC 61703-323-22):  next delivery December.;Product 15 unit vial (NDC 61703-332-18): October deliver in transit; next delivery December. 
 
 Product 30 unit vial (NDC 61703-323-22):  next delivery December.;Product 15 unit vial (NDC 61703-332-18): October delivery rec?d; next delivery December. Product 30 unit vial (NDC 61703-323-22):  October delivery rec?d; next delivery December. Please check with your wholesaler for available inventory.;Product 15 unit vial (NDC 61703-332-18):  next delivery January. Product 30 unit vial (NDC 61703-323-22):  next delivery January. Please check with your wholesaler for available inventory.;Product 15 unit vial (NDC 61703-332-18):  next delivery February.
 
 Product 30 unit vial (NDC 61703-323-22):  next delivery February.
 
 Please check with your wholesaler for available inventory.;Product 15 unit vial (NDC 61703-332-18):  next delivery February. Product 30 unit vial (NDC 61703-323-22):  next delivery February. Please check with your wholesaler for available inventory.;Product 15 unit vial (NDC 61703-332-18):  next delivery January 2012. Product 30 unit vial (NDC 61703-323-22):  next delivery January 2012. Please check with your wholesaler for available inventory.;Product 15 unit vial (NDC 61703-332-18):  next delivery February.   Product 30 unit vial (NDC 61703-323-22):  next delivery January. Please check with your wholesaler for available inventory.;Product 15 unit vial (NDC 61703-332-18):  next delivery February.
  
 Product 30 unit vial (NDC 61703-323-22):  next delivery January.
 
 Please check with your wholesaler for available inventory.;Product 15 unit vial (NDC 61703-332-18):  next delivery February.   Product 30 unit vial (NDC 61703-323-22):  next delivery February. Please check with your wholesaler for available inventory.;Product 15 unit vial (NDC 61703-332-18): ample supply available. Product 30 unit vial (NDC 61703-323-22): next delivery February. Please check with your wholesaler for available inventory.",,,,,,,,,,,,,
Genentech,boniva,1,6/13/12,8/4/12,,,,,,,,,,,,,,,,,
WestWard,bumetanide,1,6/23/12,3/25/14,demand increase,orange,;cardiovascular;renal;,";0.25mg/mL- 4mL vial (NDC 00641-6008-10) West-Ward has very limited quantities available for both presentations. Additional lots of each code are scheduled for production and units are expected to be available in the beginning of August 2012. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;Bumetanide Injection- USP (formerly a Baxter product) 0.25 mg/mL- 10 mL vial (NDC 0641-6007-10) West-Ward has very limited quantities available for both presentations. Additional lots of each code are scheduled for production and units are expected to be available in the beginning of August 2012. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;0.25mg/mL- 4mL vial 
 (NDC 00641-6008-10) West-Ward has very limited quantities available for both presentations. 
 
 Additional lots of each code are scheduled for production and units are expected to be available in the beginning of August 2012. 
 
 Product will be made available as it is released. Shortage per Manufacturer: 
 Increase in product demand due to market supply issues.;Bumetanide Injection- USP 
 (formerly a Baxter product) 
 
 0.25 mg/mL- 10 mL vial 
 (NDC 0641-6007-10) West-Ward has very limited quantities available for both presentations. 
 
 Additional lots of each code are scheduled for production and units are expected to be available in the beginning of August 2012. 
 
 Product will be made available as it is released. Shortage per Manufacturer: 
 Increase in product demand due to market supply issues.;Bumetanide Injection- USP   0.25 mg/mL- 10 mL vial (NDC 0641-6007-10) West-Ward is currently experiencing a backorder situation on the 4 mL vial.   Quantities of the 10 mL vial are available.    West-Ward has accelerated production on this product   West-Ward is anticipating having product available by the middle of February 2013.   Product will be made available as it is released.;0.25mg/mL- 4mL vial (NDC 00641-6008-10) West-Ward is currently experiencing a backorder situation on the 4 mL vial.   Quantities of the 10 mL vial are available.    West-Ward has accelerated production on this product   West-Ward is anticipating having product available by the middle of February 2013.   Product will be made available as it is released.;0.25mg/mL- 4mL vial (NDC 00641-6008-10) West-Ward is currently experiencing a backorder situation on the 4 mL vial.   Quantities of the 10 mL vial are available.    West-Ward has accelerated production on this product   West-Ward is anticipating having product available by the end of July 2013.   Product will be made available as it is released.;0.25 mg/mL- 10 mL vial (NDC 0641-6007-10) West-Ward is currently experiencing a backorder situation on the 4 mL vial.   Quantities of the 10 mL vial are available.    West-Ward has accelerated production on this product   West-Ward is anticipating having product available by the end of July 2013.   Product will be made available as it is released.;0.25 mg/mL- 10 mL vial (NDC 0641-6007-10) West-Ward currently has inventory available for both presentations.   Quantities of the 10 mL vial are available.    West-Ward has accelerated production on this product   West-Ward is anticipating having product available by the end of September 2013.   Product will be made available as it is released.;0.25mg/mL- 4mL vial (NDC 00641-6008-10) West-Ward currently has inventory available for both presentations.   Quantities of the 10 mL vial are available.    West-Ward has accelerated production on this product   West-Ward is anticipating having product available by the end of September 2013.   Product will be made available as it is released.;0.25mg/mL- 4mL vial (NDC 00641-6008-10) West-Ward currently has quantities available for both presentations.   West-Ward has accelerated production on this product   West-Ward has accelerated production on this product     West-Ward is anticipating having additional product available by the end of November 2013.   Product will be made available as it is released.;0.25 mg/mL- 10 mL vial (NDC 0641-6007-10) West-Ward currently has quantities available for both presentations.   West-Ward has accelerated production on this product   West-Ward has accelerated production on this product     West-Ward is anticipating having additional product available by the end of November 2013.   Product will be made available as it is released.;0.25 mg/mL- 10 mL vial (NDC 0641-6007-10) West-Ward currently has inventory available for both presentations.   West-Ward has accelerated production on this product   West-Ward is anticipating having additional product available for both presentations by the end of February 2014.   Product will be made available as it is released.;0.25mg/mL- 4mL vial (NDC 00641-6008-10) West-Ward currently has inventory available for both presentations.   West-Ward has accelerated production on this product   West-Ward is anticipating having additional product available for both presentations by the end of February 2014.   Product will be made available as it is released.",,,,,,,,,,,,,
Baxter,bumetanide,1,10/9/10,5/11/11,demand increase; manufacturing delays,blue,;cardiovascular;renal;,Baxter has all bumetanide 0.25 mg/mL injections on back order.,,,,,,,,,,,,,
Bedford,bumetanide,1,10/19/10,5/11/11,demand increase; manufacturing delays,blue,;cardiovascular;renal;,Bedford has 0.25 mg/mL 4 mL vials (NDC 55390-0500-05) available and plans the 10 mL vials and 2 mL vials to be released by end of March 2011.;Bedford will have all presentations anticipated for release within the next 3-months.,,,,,,,,,,,,,
Hospira,bumetanide,1,10/9/10,5/11/11,demand increase; manufacturing delays,blue,;cardiovascular;renal;,Hospira is continuing to release the 0.25 mg/mL; 4 mL vial NDC 0409-1412-04; 0.25 mg/.mL; 4 mL Novaplus vial NDC 0409-1412-49- the 0.25 mg/mL; 10 mL vial NDC 0409-1412-10; 0.25 mg.mL; and the 10 mL Novaplus vial NDC 0409-1412-50 as they become available. Hospira is continuing to produce and release product as it becomes available.,,,,,,,,,,,,,
Hospira,bumetanide,2,6/23/12,3/25/14,demand increase; manufacturing delays; available,blue,;cardiovascular;renal;,";0.25mg/mL; 4mL (NDC 00409-1412-04) Next delivery October Drug product allocated to direct orders;0.25mg/mL; 10mL vial (NDC 00074-1412-10) Next delivery September Drug product allocated to direct orders;0.25mg/mL; 4mL (NDC 00409-1412-04) Available Drug product allocated to direct orders;0.25mg/mL; 10mL vial (NDC 00074-1412-10) Next delivery September Estimated recovery: December Drug product allocated to direct orders;0.25mg/mL; 10mL vial (NDC 00074-1412-10) Next delivery October Estimated recovery: December Drug product allocated to direct orders;0.25mg/mL; 10mL vial 
 (NDC 00074-1412-10) Next delivery October Estimated recovery: December Drug product allocated to direct orders;0.25mg/mL; 4mL 
 (NDC 00409-1412-04) Available Drug product allocated to direct orders;0.25mg/mL; 10mL vial (NDC 00074-1412-10) Next delivery November Estimated recovery: December Drug product allocated to direct orders;0.25mg/mL; 10mL vial (NDC 00074-1412-10) Available Drug product allocated to direct orders;0.25mg/mL; 4mL (NDC 00409-1412-04) Next delivery January  Estimated recovery: 2Q 2013. Drug product allocated to direct orders;0.25mg/mL; 4mL (NDC 00409-1412-04) Next delivery February  Estimated recovery: 2Q 2013. Drug product allocated to direct orders;0.25mg/mL; 10mL vial (NDC 00074-1412-10) Next delivery February Estimated recovery: 2Q 2013 Drug product allocated to direct orders;0.25mg/mL; 10mL vial (NDC 00074-1412-10) Next delivery April Estimated recovery: 2Q 2013 Drug product allocated to direct orders;0.25mg/mL; 4mL (NDC 00409-1412-04) Next delivery May Estimated recovery: 2Q 2013 Drug product allocated to direct orders;0.25mg/mL; 10mL vial (NDC 00074-1412-10) Next delivery May Estimated recovery: 2Q 2013 Drug product allocated to direct orders;0.25mg/mL; 10mL vial (NDC 00074-1412-10) Next delivery early July Estimated recovery: 3Q 2013 Drug product allocated to direct orders  Shortage per manufacturer: Manufacturing delay.;0.25mg/mL; 4mL (NDC 00409-1412-04) Next delivery July Estimated recovery: 3Q 2013 Drug product allocated to direct orders  Shortage per manufacturer: Manufacturing delay.;0.25mg/mL; 10mL vial (NDC 00074-1412-10) Available Drug product allocated to direct orders  Shortage per manufacturer: Manufacturing delay.;0.25mg/mL; 10mL vial (NDC 00074-1412-10) Available Drug product allocated to direct orders  Shortage per manufacturer: Manufacturing delay / Available;0.25mg/mL; 4mL (NDC 00409-1412-04) Next delivery September Estimated recovery: 4Q 2013 Drug product allocated to direct orders  Shortage per manufacturer: Manufacturing delay / Available;0.25mg/mL; 4mL (NDC 00409-1412-04) Next delivery late September Estimated recovery: 4Q 2013 Drug product allocated to direct orders  Shortage per manufacturer: Manufacturing delay / Available;0.25mg/mL; 10mL vial (NDC 00409-1412-10) Available Drug product allocated to direct orders  Shortage per manufacturer: Manufacturing delay / Available;0.25mg/mL; 4mL (NDC 00409-1412-04) Available Drug product allocated to direct orders  Shortage per manufacturer: Manufacturing delay / Available;0.25mg/mL; 10mL vial (NDC 00409-1412-10) Next delivery February 2014 Estimated Recovery 2Q 2014   Drug product allocated to direct orders  Shortage per manufacturer: Manufacturing delay;0.25mg/mL; 4mL (NDC 00409-1412-04) Next delivery March 2014 Estimated Recovery 2Q 2014 Drug product allocated to direct orders  Shortage per manufacturer: Manufacturing delay;0.25mg/mL; 10mL vial (NDC 0409-1412-10) Next delivery April 2014 Estimated Recovery 2Q 2014   Drug product allocated to direct orders  Shortage per manufacturer: Manufacturing delay;0.25mg/mL; 4mL (NDC 0409-1412-04) Next delivery April 2014 Estimated Recovery 2Q 2014 Drug product allocated to direct orders  Shortage per manufacturer: Manufacturing delay",,,,,,,,,,,,,
Bedford,bumetanide,2,6/23/12,3/25/14,manufacturing delays; capacity constraints,blue,;cardiovascular;renal;,";0.25mg/mL- 10 mL vial (NDC 55390-0500-10) Not available Shortage per Manufacturer: Manufacturing delay;0.25mg/mL- 2 mL vial (NDC 55390-0500-02) Not available Shortage per Manufacturer: Manufacturing delay;0.25mg/mL- 4 mL vial (NDC 55390-0500-05) Not available Shortage per Manufacturer: Manufacturing delay;0.25mg/mL- 10 mL vial (NDC 55390-0500-10) Not available Shortage per Manufacturer: 
 Manufacturing delay;0.25mg/mL- 2 mL vial (NDC 55390-0500-02) Not available Shortage per Manufacturer: 
 Manufacturing delay;0.25mg/mL- 4 mL vial (NDC 55390-0500-05) Not available Shortage per Manufacturer: 
 Manufacturing delay;0.25mg/mL- 10 mL vial (NDC 55390-0500-10) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;0.25mg/mL- 4 mL vial (NDC 55390-0500-05) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;0.25mg/mL- 2 mL vial (NDC 55390-0500-02) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;0.25mg/mL- 10 mL vial (NDC 55390-0500-10) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.;0.25mg/mL- 2 mL vial (NDC 55390-0500-02) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.;0.25mg/mL- 4 mL vial (NDC 55390-0500-05) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.",,,,,,,,,,,,,
AuroMedics,bupivacaine,1,2/14/14,3/25/14,available,,pediatric;anesthesia;,0.25%- 10 mL SDV (NDC 55150-167-10)   Available All presentations are available;0.25%- 30 mL SDV (NDC 55150-168-30)   Available All presentations are available;0.5%- 10 mL SDV (NDC 55150-169-10)   Available All presentations are available;0.5%- 30 mL SDV (NDC 55150-170-30) Available All presentations are available;0.75%- 10 mL SDV (NDC 55150-171-10)   Available All presentations are available;0.75%- 30 mL SDV (NDC 55150-172-30) Available All presentations are available;0.25%- 10 mL SDV (NDC 55150-167-10)   Available All presentations are are available;0.25%- 30 mL SDV (NDC 55150-168-30)   Available All presentations are are available;0.5%- 10 mL SDV (NDC 55150-169-10)   Available All presentations are are available;0.5%- 30 mL SDV (NDC 55150-170-30) Available All presentations are are available;0.75%- 10 mL SDV (NDC 55150-171-10)   Available All presentations are are available;0.75%- 30 mL SDV (NDC 55150-172-30) Available All presentations are are available,,,,,,,,,,,,,
Fresenius,bupivacaine,1,12/28/13,3/25/14,demand increase,orange,pediatric;anesthesia;,0.25%; 10 mL- SDV- MPF (NDC# 63323-464-17) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5%; 30 mL- SDV- MPF (NDC# 63323-466-37) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.25%; 30 mL- SDV- MPF (NDC# 63323-464-37) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.75%; 30 mL- SDV- MPF (NDC# 63323-472-37)   Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.75% w/EPI; 30 mL- SDV- MPF (NDC# 63323-460-37)  Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5% w/EPI; 50 mL- MDV (NDC# 63323-463-57)   Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.75%; 10 mL- SDV- MPF (NDC# 63323-472-17) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5% w/EPI; 30 mL- SDV- MPF (NDC# 63323-462-37)  Backordered.  Next release anticipated December 2013. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5%; 10 mL- SDV- MPF (NDC# 63323-466-17) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.25% w/EPI; 10 mL- SDV- MPF (NDC# 63323-468-17)   Backordered.  Next release anticipated December 2013. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.25%  w/EPI; 50 mL- MDV (NDC# 63323-461-57)  Backordered.  Next release anticipated January 2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5%;  50 mL- MDV (NDC# 63323-467-57) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.25%; 30 mL- SDV- Steripak- MPF (NDC# 63323-464-31)  Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5%; 30 mL- SDV- Steripak- MPF (NDC# 63323-466-31) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.25%; 50 mL- MDV (NDC# 63323-465-57) Backordered.  Next release anticipated January 2014.  Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5% w/EPI; 30 mL- SDV- Steripak- MPF (NDC# 63323-462-31)  Backordered.  Next release anticipated January 2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5% w/EPI; 10 mL- SDV- MPF (NDC# 63323-462-17)  Backordered.  Next release anticipated January 2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.25% w/EPI; 30mL- SDV MPF (NDC# 63323-468-37)  Backordered.  Next release anticipated January 2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.25%  w/EPI; 50 mL- MDV (NDC# 63323-461-57)  Backordered.  Next release anticipated February 2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.25%; 50 mL- MDV (NDC# 63323-465-57) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5% w/EPI; 50 mL- MDV (NDC# 63323-463-57)   Backordered.  Next release anticipated March 2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5% w/EPI; 30 mL- SDV- Steripak- MPF (NDC# 63323-462-31)  Backordered.  Next release anticipated April 2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5% w/EPI; 10 mL- SDV- MPF (NDC# 63323-462-17)  Backordered.  No release available at this time. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5% w/EPI; 30 mL- SDV- MPF (NDC# 63323-462-37)  Backordered.  Next release anticipated February  2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.25% w/EPI; 10 mL- SDV- MPF (NDC# 63323-468-17)   Backordered.  No release available at this time. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.25% w/EPI; 30mL- SDV MPF (NDC# 63323-468-37)  Backordered.  Next release anticipated March 2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5% w/EPI; 30 mL- SDV- MPF (NDC# 63323-462-37)  Backordered.  Next release anticipated March 2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5% w/EPI; 30 mL- SDV- Steripak- MPF (NDC# 63323-462-31)  Backordered.  Next release anticipated March 2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.25%  w/EPI; 50 mL- MDV (NDC# 63323-461-57)  Backordered.  Next release anticipated March 2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5%; 30 mL- SDV- MPF (NDC# 63323-466-37) Backordered. Next release anticipated early March. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.25% w/EPI; 10 mL- SDV- MPF (NDC# 63323-468-17)   Backordered.  Next release anticipated April 2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5% w/EPI; 50 mL- MDV (NDC# 63323-463-57)   Backordered.  Next release anticipated April 2014. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5% w/EPI; 30 mL- SDV- Steripak- MPF (NDC# 63323-462-31)  Backordered.  Next release anticipated April 2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5%; 30 mL- SDV- MPF (NDC# 63323-466-37) Backordered. Next release anticipated mid March. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.5% w/EPI; 10 mL- SDV- MPF (NDC# 63323-462-17)  Backordered.  Next release anticipated April 2014. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers;0.25%  w/EPI; 50 mL- MDV (NDC# 63323-461-57)  Backordered. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand    Fresenius Kabi has increased manufacturing in response to the increased demand and is releasing product as it becomes becomes available. Please continue to check wholesalers,,,,,,,,,,,,,
APP,bupivacaine,1,11/10/11,11/8/13,demand increase,orange,pediatric;anesthesia;,"APP has Sensorcaine (with & without Epinephrine) on intermittent back-order and the company is releasing product as it becomes available.;Increased demand APP has Sensorcaine (with & without Epinephrine) on intermittent back-order and the company is releasing product as it becomes available.;APP has Sensorcaine (with & without Epinephrine) on intermittent back-order and the company is releasing product as it becomes available. Check Wholesaler Inventory.;;APP has Sensorcaine (with & without Epinephrine) on intermittent back-order and the company is releasing product as it becomes available. Check Wholesaler Inventory.  Shortage per Manufacturer: Increased demand;APP has Sensorcaine (with & without Epinephrine) on intermittent back-order and the company is releasing product as it becomes available. Check Wholesaler Inventory.  Shortage per Manufacturer: 
 Increased demand",,,,,,,,,,,,,
Hospira,bupivacaine,1,11/10/11,3/25/14,manufacturing delays; production suspended; available,blue,pediatric;anesthesia;,"Product 0.25%; 30 mL amp (NDC 0409-1158-01): next delivery December. Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery November. Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery November. Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery December. Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery December. Product 0.5%; 30 mL vial (NDC 0409-1162-02): next delivery December. Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery December. Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery January. Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): next delivery November. Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery March. Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery March. Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery November. Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery November. Please check with your wholesaler for available inventory.;Product 0.25%; 30 mL amp (NDC 0409-1158-01): next delivery December.
 
 Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery November.
 
 Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery November.
 
 Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery December.
 
 Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery December.
 
 Product 0.5%; 30 mL vial (NDC 0409-1162-02): next delivery December.
  
 Product 0.5%; 50 mL vial (NDC 0409-1163-01):  next delivery November.
  
 Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery December.
 
 Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery January.
 
 Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): next delivery November.
 
 Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery January.
  
  
 Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery January.
 
 Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery November.
 
 Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery January.
 
 Please check with your wholesaler for available inventory.;Product 0.25%; 30 mL amp (NDC 0409-1158-01): next delivery December. Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery December. Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery December. Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery December. Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery December. Product 0.5%; 30 mL vial (NDC 0409-1162-02): next delivery December.   Product 0.5%; 50 mL vial (NDC 0409-1163-01):  next delivery December.   Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery December. Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery April 2012. Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): next delivery December. Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery March 2012.     Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery April 2012. Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery December. Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery January. Please check with your wholesaler for available inventory.;Product 0.25%; 30 mL amp (NDC 0409-1158-01): next delivery December. Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery December. Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery December. Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery January 2012. Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery December. Product 0.5%; 30 mL vial (NDC 0409-1162-02): next delivery December.   Product 0.5%; 50 mL vial (NDC 0409-1163-01):  next delivery December.   Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery December. Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery April 2012. Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): next delivery December. Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery March 2012.   Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery April 2012. Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery December. Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery January.   Please check with your wholesaler for available inventory.;Product 0.25%; 30 mL amp (NDC 0409-1158-01): next delivery January 2012. Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery December. Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery December. Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery January 2012. Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery December. Product 0.5%; 30 mL vial (NDC 0409-1162-02): next delivery December.   Product 0.5%; 50 mL vial (NDC 0409-1163-01):  next delivery December.   Product 0.75%; 10 mL vial (NDC 0409-1165-01): next delivery January 2012.   Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery December. Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery April 2012. Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): next delivery December. Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery December.   Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery April 2012. Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery December. Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery January 2012.   Product 50 mg/20 mL Sterile pack amp (NDC 0409-4272-01)  next delivery December.    Please check with your wholesaler for available inventory.;Product 0.25%; 30 mL amp (NDC 0409-1158-01): next delivery January 2012. Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery January 2012. Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery January 2012. Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery January 2012. Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery January 2012. Product 0.5%; 30 mL vial (NDC 0409-1162-02): next delivery December.   Product 0.5%; 50 mL vial (NDC 0409-1163-01):  next delivery January 2012.   Product 0.75%; 10 mL vial (NDC 0409-1165-01): next delivery January 2012.   Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery January 2012. Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery April 2012. Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): next delivery January 2012. Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery January 2012.   Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery April 2012. Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery January 2012. Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery January 2012.   Product 50 mg/20 mL Sterile pack amp (NDC 0409-4272-01)  next delivery January 2012.    Please check with your wholesaler for available inventory.;Product 0.25%; 30 mL amp (NDC 0409-1158-01): next delivery January 2012. Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery January 2012. Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery January 2012. Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery January 2012. Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery January 2012. Product 0.5%; 30 mL vial (NDC 0409-1162-02):  Product available.   Product 0.5%; 50 mL vial (NDC 0409-1163-01):  next delivery January 2012.   Product 0.75%; 10 mL vial (NDC 0409-1165-01): next delivery January 2012.   Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery January 2012. Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery April 2012. Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): next delivery January 2012. Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery January 2012.   Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery April 2012. Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery January 2012. Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery January 2012.   Product 50 mg/20 mL Sterile pack amp (NDC 0409-4272-01)  next delivery January 2012.    Please check with your wholesaler for available inventory.;Product 0.25%; 30 mL amp (NDC 0409-1158-01): next delivery January 2012.
 
 Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery January 2012.
 
 Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery January 2012.
 
 Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery January 2012.
 
 Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery January 2012.
 
 Product 0.5%; 30 mL vial (NDC 0409-1162-02):  Product available.
  
 Product 0.5%; 50 mL vial (NDC 0409-1163-01):  next delivery January 2012.
  
 Product 0.75%; 10 mL vial (NDC 0409-1165-01): next delivery January 2012.
  
 Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery January 2012.
 
 Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery April 2012.
 
 Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): next delivery January 2012.
 
 Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery January 2012.
  
 Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery April 2012.
 
 Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery January 2012.
 
 Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery January 2012.
  
 Product 50 mg/20 mL Sterile pack amp (NDC 0409-4272-01)  next delivery January 2012.
   
 Please check with your wholesaler for available inventory.;Product 0.25%; 30 mL amp (NDC 0409-1158-01): next delivery April. Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery January. Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery January. Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery January. Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery January. Product 0.5%; 30 mL vial (NDC 0409-1162-02):  next delivery January.   Product 0.5%; 50 mL vial (NDC 0409-1163-01):  next delivery January.   Product 0.75%; 10 mL vial (NDC 0409-1165-01): next delivery January.   Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery January. Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery April. Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): ample levels of inventory to support market demand. Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery January.   Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery April. Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery January. Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery January.   Product 50 mg/20 mL Sterile pack amp (NDC 0409-4272-01)  next delivery March.   Product 0.25%; 20 mL amp (NDC 0409-5622-01):  next delivery February.   Product 0.5%; 20 mL Sterile pack amp (NDC 0409-4273-01):  next delivery March.    Please check with your wholesaler for available inventory.;Product 0.25%; 30 mL amp (NDC 0409-1158-01): next delivery April. Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery January. Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery January. Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery January. Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery January. Product 0.5%; 30 mL vial (NDC 0409-1162-02):  next delivery January.   Product 0.5%; 50 mL vial (NDC 0409-1163-01):  next delivery January.   Product 0.75%; 10 mL vial (NDC 0409-1165-01): next delivery January.   Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery January. Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery April. Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): ample levels of inventory to support market demand. Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery February.   Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery April. Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery January. Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery February.   Product 50 mg/20 mL Sterile pack amp (NDC 0409-4272-01)  next delivery March.   Product 0.25%; 20 mL amp (NDC 0409-5622-01):  next delivery February.   Product 0.5%; 20 mL Sterile pack amp (NDC 0409-4273-01):  next delivery March.   Please check with your wholesaler for available inventory.;Product 0.25%; 30 mL amp (NDC 0409-1158-01): next delivery April. Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery February. Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery February. Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery February. Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery February. Product 0.5%; 30 mL vial (NDC 0409-1162-02):  next delivery February.   Product 0.5%; 50 mL vial (NDC 0409-1163-01):  next delivery February.   Product 0.75%; 10 mL vial (NDC 0409-1165-01): next delivery February.   Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery February. Products 0.75% w/ dextrose 8.25%; 2 mL ampule (NDC 0409-3613-01): next delivery March. Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery April. Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): next delivery February. Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery February.   Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery April. Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery February.. Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery February.   Product 50 mg/20 mL Sterile pack amp (NDC 0409-4272-01) next delivery March.   Product 0.25%; 20 mL amp (NDC 0409-5622-01):  next delivery February.   Product 0.5%; 20 mL Sterile pack amp (NDC 0409-4273-01):  next delivery March.   Please check with your wholesaler for available inventory.;Product 0.25%; 30 mL amp (NDC 0409-1158-01): next delivery April. Product 0.5%; 30 mL amp (NDC 0409-1161-01): next delivery May. Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery February. Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery February. Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery February. Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery February. Product 0.5%; 30 mL vial (NDC 0409-1162-02): next delivery February. Product 0.5%; 50 mL vial (NDC 0409-1163-01): next delivery February. Product 0.75%; 10 mL vial (NDC 0409-1165-01): next delivery February. Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery February. Products 0.75% w/ dextrose 8.25%; 2 mL ampule (NDC 0409-3613-01): next delivery March. Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery April. Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): next delivery February. Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery February. Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery April. Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery February.. Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery February. Product 50 mg/20 mL Sterile pack amp (NDC 0409-4272-01) next delivery March. Product 0.25%; 20 mL amp (NDC 0409-5622-01): next delivery February. Product 0.5%; 20 mL Sterile pack amp (NDC 0409-4273-01): next delivery March. Please check with your wholesaler for available inventory.;Product 0.25%; 30 mL amp (NDC 0409-1158-01): next delivery April. 
 Product 0.5%; 30 mL amp 
 (NDC 0409-1161-01): next delivery May. 
 
 Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery March. 
 
 Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery March. 
 
 Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery March. 
 
 Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery March. 
 
 Product 0.5%; 30 mL vial (NDC 0409-1162-02): next delivery March. 
 
 Product 0.5%; 50 mL vial (NDC 0409-1163-01): next delivery March. 
 
 Product 0.75%; 10 mL vial (NDC 0409-1165-01): next delivery March. 
 
 Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery March. 
 
 Products 0.75% w/ dextrose 8.25%; 2 mL ampule (NDC 0409-3613-01): next delivery March. 
 
 Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery May. 
 
 Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): next delivery March. 
 
 Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery March. 
 
 Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery April. 
 
 Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery February.. 
 
 Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery March. 
 
 Product 50 mg/20 mL Sterile pack amp (NDC 0409-4272-01) next delivery March. 
 
 Product 0.25%; 20 mL amp (NDC 0409-5622-01): next delivery March. 
 
 Product 0.5%; 20 mL Sterile pack amp (NDC 0409-4273-01): next delivery March. 
 
 Please check with your wholesaler for available inventory.;Manufacturing delays Product 0.25%; 30 mL amp (NDC 0409-1158-01): ample supplies available. Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery April. Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery April. Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery April. Product 0.5%; 30mL amp (NDC 0409-1161-01): next delivery May. Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery April. Product 0.5%; 30 mL vial (NDC 0409-1162-02): next delivery April. Product 0.5%; 50 mL vial (NDC 0409-1163-01): next delivery April. Product 0.75%; 10 mL vial (NDC 0409-1165-01): next delivery April. Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery March. Products 0.75% w/ dextrose 8.25%; 2 mL ampule (NDC 0409-3613-01): next delivery April. Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery May. Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): next delivery April. Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery April. Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery April. Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery April. Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery April. Product 50 mg/20 mL Sterile pack amp (NDC 0409-4272-01) next delivery June. Product 0.25%; 20 mL amp (NDC 0409-5622-01): next delivery April. Product 0.5%; 20 mL Sterile pack amp (NDC 0409-4273-01): next delivery April. Please check with your wholesaler for available inventory.;Product 0.25%; 30 mL amp (NDC 0409-1158-01): ample supplies available. Product 0.25%; 10 mL vial (NDC 0409-1159-01): next delivery April. Product 0.25%; 30 mL vial (NDC 0409-1159-02): next delivery April. Product 0.25%; 50 mL vial (NDC 0409-1160-01): next delivery April. Product 0.5%; 30mL amp (NDC 0409-1161-01): next delivery May. Product 0.5%; 10 mL vial (NDC 0409-1162-01): next delivery April. Product 0.5%; 30 mL vial (NDC 0409-1162-02): next delivery April. Product 0.5%; 50 mL vial (NDC 0409-1163-01): next delivery April. Product 0.75%; 10 mL vial (NDC 0409-1165-01): next delivery April. Product 0.75%; 30 mL vial (NDC 0409-1165-02): next delivery March. Products 0.75% w/ dextrose 8.25%; 2 mL ampule (NDC 0409-3613-01): next delivery April. Product 0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01): next delivery May. Product 0.25% w/epi 1:200-000; 30 mL vial (NDC 0409-9042-17): next delivery April. Product 0.25% w/epi 1:200-000; 50 mL vial (NDC 0409-9043-01): next delivery April. Product 0.5% w/epi 1:200-000; 10 mL vial (NDC 0409-9045-01): next delivery April. Product 0.5% w/epi 1:200-000; 30 mL vial (NDC 0409-9045-17): next delivery April. Product 0.5% w/epi 1:200-000; 50 mL vial (NDC 0409-9046-01): next delivery April. Product 50 mg/20 mL Sterile pack amp (NDC 0409-4272-01) next delivery June. Product 0.25%; 20 mL amp (NDC 0409-5622-01): next delivery April. Product 0.5%; 20 mL Sterile pack amp (NDC 0409-4273-01): next delivery April. Please check with your wholesaler for available inventory.;;0.25%; 10 mL vial (NDC 0409-1159-01) Next delivery October Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25%; 30 mL vial (NDC 0409-1159-02) Next delivery August Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.75%; 10 mL vial (NDC 0409-1165-01) Next delivery October Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;100mg/20mL Sterile pack amp (NDC 0409-4273-01) Next delivery August Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01) Next delivery October Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25%; 50 mL vial (NDC 0409-1160-01) Available Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5%; 30 mL vial (NDC 0409-1162-02) Next delivery October Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25% w/epi 1:200-000; 30 mL vial(NDC 0409-9042-17)   Available  Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;50 mg/20 mL Sterile pack amp (NDC 0409-4272-01) Next delivery September Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5% w/epi 1:200-000; Carpujects (NDC 0409-7600-01) Company estimates a release date by 2013 Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.75%; 30 mL vial (NDC 0409-1165-02) Next delivery October Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5% w/epi 1:200-000; 50 mL (NDC 0409-9046-01) Available   Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25% w/epi 1:200-000; 50 mL (NDC 0409-9043-01) Next delivery September Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5% w/epi 1:200-000; 30 mL (NDC 0409-9045-17) Available   Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25%; 30 mL amp (NDC 0409-1158-01)  Next delivery September Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5%; 50 mL vial (NDC 0409-1163-01) Next delivery August Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5%; 10 mL vial (NDC 0409-1162-01) Next delivery August Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.75% in Dex 8.25%; 2mL amp (NDC 0409 3613-01) Next delivery September Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;100mg/20mL Sterile pack amp (NDC 0409-4273-01) Next delivery and estimated recovery: November Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5%; 10 mL vial (NDC 0409-1162-01) Next delivery September Estimated recovery 1Q 2013 Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25%; 30 mL vial (NDC 0409-1159-02) Next delivery September Estimated recovery 1Q 2013 Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25%; 10 mL vial (NDC 0409-1159-01) Available Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25%; 30 mL amp (NDC 0409-1158-01)  Next delivery and estimated recovery September Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01) Next delivery October Estimated recovery: 1Q 2013   Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25% w/epi 1:200-000; 50 mL (NDC 0409-9043-01) Next delivery September Estimated recovery: December   Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.75%; 30 mL vial (NDC 0409-1165-02) Next delivery November Estimated recovery: 1Q 2013 Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.75% in Dex 8.25%; 2mL amp (NDC 0409 3613-01) Next delivery September Estimated recovery: 1Q 2013 Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5%; 50 mL vial (NDC 0409-1163-01) Available Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.75%; 10 mL vial (NDC 0409-1165-01) Next delivery October Estimated recovery: 1Q 2013 Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;50 mg/20 mL Sterile pack amp (NDC 0409-4272-01) Next delivery September Estimated recovery: 1Q 2013   Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5%; 30 mL vial (NDC 0409-1162-02) Next delivery November Estimated recovery: 3Q 2013   Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25%; 30 mL amp (NDC 0409-1158-01)  Available Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25%; 30 mL vial (NDC 0409-1159-02) Next delivery November Estimated recovery: December Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5% w/epi 1:200-000; Carpujects (NDC 0409-7600-01) Next delivery and estimated recovery 1Q 2013 Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25% w/epi 1:200-000; 50 mL (NDC 0409-9043-01) Next delivery November Estimated recovery: 1Q 2013   Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.75% in Dex 8.25%; 2mL amp (NDC 0409 3613-01) Next delivery December Estimated recovery: 1Q 2013   Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5% w/epi 1:200-000; 30 mL (NDC 0409-9045-17)   Available   Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5% w/epi 1:200-000; 10 mL (NDC 0409-9045-17) Next delivery October Estimated recovery: October  Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5%; 10 mL vial (NDC 0409-1162-01) Available Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;50 mg/20 mL Sterile pack amp (NDC 0409-4272-01) Next delivery and recovery December  Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5%; 30 mL vial (NDC 0409-1161-02) Next delivery October Estimated recovery: 4Q 2012  Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;100mg/20mL Sterile pack amp (NDC 0409-4273-01) Next delivery November Estimated recovery 4Q 2012 Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5% w/epi 1:200-000; 50 mL (NDC 0409-9046-01)   Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25%; 10 mL vial (NDC 0409-1159-01) Next delivery October Estimated recovery: 4Q 2012 Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.75%; 30 mL vial (NDC 0409-1165-02) Next delivery November Estimated recovery: 2Q 2013 Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.25% w/epi 1:200-000; 10 mL vial (NDC 0409-9042-01) Next delivery October  Estimated recovery: 1Q 2013 Please check with your wholesaler for available inventory.      Shortage per Manufacturer: manufacturing delay;0.5% w/epi 1:200-000; 10 mL (NDC 0409-9045-01) Next delivery October 
  
 Estimated recovery: October  Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.25% w/epi 1:200-000; 10 mL vial 
 (NDC 0409-9042-01) Next delivery October  Estimated recovery: 1Q 2013 Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.5%; 30 mL vial 
 (NDC 0409-1162-02) Next delivery November 
 Estimated recovery: 2Q 2013 
   Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.75%; 30 mL vial 
 (NDC 0409-1165-02) Next delivery November 
 Estimated recovery: 2Q 2013 Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.25% w/epi 1:200-000; 50 mL (NDC 0409-9043-01) Next delivery October
 Estimated recovery: 1Q 2013 
   Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.5% w/epi 1:200-000; 50 mL (NDC 0409-9046-01)  Available Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.25%; 30 mL amp 
 (NDC 0409-1158-01)  Available Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.25%; 50 mL vial 
 (NDC 0409-1160-01) Available Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.5%; 50 mL vial 
 (NDC 0409-1163-01) Available Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.5%; 30 mL vial 
 (NDC 0409-1161-02) Next delivery October
 Estimated recovery: 4Q 2012  Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.25% w/epi 1:200-000; 30 mL vial(NDC 0409-9042-17) 
   Available  Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.5%; 30 mL amp 
 (NDC 0409-1161-01) Next delivery October 
 Estimated recovery 4Q 2012 
   Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.5% w/epi 1:200-000; 30 mL (NDC 0409-9045-17) 
   Available 
   Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.5% w/epi 1:200-000; Carpujects (NDC 0409-7600-01) Next delivery and estimated recovery 1Q 2013 Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.25%; 30 mL vial 
 (NDC 0409-1159-02) Next delivery November Estimated recovery: December Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.75% in Dex 8.25%; 2mL amp (NDC 0409 3613-01) Next delivery December 
 Estimated recovery: 1Q 2013 
   Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;100mg/20mL Sterile pack amp (NDC 0409-4273-01) Next delivery November Estimated recovery 4Q 2012 Please check with your wholesaler for available inventory.  
  
  
 Shortage per Manufacturer: manufacturing delay;0.25%; 10 mL vial 
 (NDC 0409-1159-0",,,,,,,,,,,,,
Bedford,buprenorphine,1,8/5/11,3/2/14,delays; capacity constraints,blue,,"Bedford has buprenorphine injection on back order and the company estimates a release date of 3rd quarter- 2011.;Bedford has buprenorphine injection on back order and the company cannot estimate a release date.;Delays Bedford has buprenorphine injection on back order and the company cannot estimate a release date.;;1 mL vial (NDC 55390-0010-10)   Bedford has buprenorphine injection on back order and the company cannot estimate a release date. Shortage per Manufacturer: Delays;1 mL vial (NDC 55390-0010-10)   Bedford has buprenorphine injection on back order and the company cannot estimate a release date.
 Shortage per Manufacturer: 
 Delays;1 mL vial (NDC 55390-0100-10)  Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;1 mL vial (NDC 55390-0100-10)  Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.",,,,,,,,,,,,,
AmericanRegent,buprenorphine,1,8/5/11,3/2/14,delays; not releasing,,,"American Regent has buprenorphine injection 0.3 mg/mL 1 mL vials on long term back order and the company cannot estimate a release date.;American Regent has buprenorphine injection 0.3 mg/mL 1 mL vials on back order and the company cannot estimate a release date.;Delays American Regent has buprenorphine injection 0.3 mg/mL 1 mL vials on back order and the company cannot estimate a release date.;;1 mL vial (NDC 00517-0725-05) Unavailable Shortage per Manufacturer: Currently not releasing.;1 mL vial (NDC 00517-0725-05) Unavailable Shortage per Manufacturer: 
 Currently not releasing.;0.3 mg (base/mL) 1 mL vial (NDC 00517-0725-05) Unavailable Shortage per Manufacturer: American Regent is currently not releasing Buprenorphine Injection;0.3 mg (base/mL) 1 mL vial (NDC 00517-0725-05) Unavailable - No product available for release. No plan to manufacture American Regent is currently not releasing Buprenorphine Injection",,,,,,,,,,,,,
Bedford,butorphanol,1,1/26/12,3/1/13,manufacturing delays; ,blue,,"Bedford has all butorphanol presentations on back order and the company cannot estimate a release date.;Manufacturing delays Bedford has all butorphanol presentations on back order and the company cannot estimate a release date.;;1 mg/mL 1 mL vial (NDC 55390-0183-01) Bedford has all butorphanol presentations on back order and the company cannot estimate a release date.   Shortage per Manufacturer: Manufacturing delays;2 mg/mL 2 mL vial (NDC 55390-0184-02) Bedford has all butorphanol presentations on back order and the company cannot estimate a release date.   Shortage per Manufacturer: Manufacturing delays;1 mg/mL 1 mL Novaplus vial (NDC 55390-0341-10) Bedford has all butorphanol presentations on back order and the company cannot estimate a release date.   Shortage per Manufacturer: Manufacturing delays;2 mg/mL 1 mL Novaplus vial (NDC 55390-0342-10) Bedford has all butorphanol presentations on back order and the company cannot estimate a release date.   Shortage per Manufacturer: Manufacturing delays;2 mg/mL 10 mL vial (NDC 55390-0185-10) Bedford has all butorphanol presentations on back order and the company cannot estimate a release date.   Shortage per Manufacturer: Manufacturing delays;2 mg/mL 1 mL vial (NDC 55390-0184-01) Bedford has all butorphanol presentations on back order and the company cannot estimate a release date.   Shortage per Manufacturer: Manufacturing delays;1 mg/mL 1 mL vial (NDC 55390-0183-01) Bedford has all butorphanol presentations on back order and the company cannot estimate a release date. 
   Shortage per Manufacturer: 
 Manufacturing delays;2 mg/mL 1 mL Novaplus vial (NDC 55390-0342-10) Bedford has all butorphanol presentations on back order and the company cannot estimate a release date. 
   Shortage per Manufacturer: 
 Manufacturing delays;2 mg/mL 1 mL vial (NDC 55390-0184-01) Bedford has all butorphanol presentations on back order and the company cannot estimate a release date. 
   Shortage per Manufacturer: 
 Manufacturing delays;2 mg/mL 10 mL vial (NDC 55390-0185-10) Bedford has all butorphanol presentations on back order and the company cannot estimate a release date. 
   Shortage per Manufacturer: 
 Manufacturing delays;2 mg/mL 2 mL vial (NDC 55390-0184-02) Bedford has all butorphanol presentations on back order and the company cannot estimate a release date. 
   Shortage per Manufacturer: 
 Manufacturing delays;1 mg/mL 1 mL Novaplus vial (NDC 55390-0341-10) Bedford has all butorphanol presentations on back order and the company cannot estimate a release date. 
   Shortage per Manufacturer: 
 Manufacturing delays",,,,,,,,,,,,,
AmericanRegent,caffeine,1,11/24/11,3/25/14,manufacturing delays; not releasing,blue,,American Regent has caffeine and sodium benzoate injection on back order and the company cannot estimate a release date.;Manufacturing delays American Regent has caffeine and sodium benzoate injection on back order and the company cannot estimate a release date.;;2 mL single-dose vial- package of 10 (NDC 00517-2502-10) Unavailable Currently not releasing.;2 mL single-dose vial- package of 10 (NDC 00517-2502-10) Unavailable Shortage per Manufacturer: American Regent is currently not releasing Caffeine and Sodium Benzoate Injection.;2 mL single-dose vial- package of 10 (NDC 00517-2502-10) Unavailable American Regent is currently not releasing Caffeine and Sodium Benzoate Injection;2 mL single-dose vial- package of 10 (NDC 00517-2502-10) Unavailable - No product available for release. No plan to manufacture American Regent is currently not releasing Caffeine and Sodium Benzoate Injection,,,,,,,,,,,,,
Akorn,calcitriol,1,11/17/11,7/12/12,available,,,Akorn has calcitriol 1 mcg/mL 1 mL ampules in 10-packs available to order.;Wholesalers have product. Product releases scheduled for March and April to support market demand.;n/a Wholesalers have product. Product releases scheduled for March and April to support market demand.;,,,,,,,,,,,,,
AmericanRegent,calcitriol,1,5/18/11,7/12/12,demand increase; available,orange,,American Regent has calcitriol injection on back order and the company cannot estimate a release date.;American Regent- Inc. is currently releasing Calcitriol Injection 1 mcg/mL in a 1 mL ampoule as they become available.;Available American Regent- Inc. is currently releasing Calcitriol Injection 1 mcg/mL in a 1 mL ampoule as they become available.;,,,,,,,,,,,,,
APP,calcitriol,1,5/18/11,7/12/12,demand increase; available,orange,,APP has calcitriol injection on intermittent back order with multiple releases estimated by Late-May.;APP has calcitriol injection on back order and plans releases in early November.;APP has Calcitriol injection on back order and plans releases in early December.;APP has Calcitriol injection available.;APP has Calcitriol available. Please check wholesalers for inventory.;Available APP has Calcitriol available. Please check wholesalers for inventory.;,,,,,,,,,,,,,
Abbott,calcitriol,1,5/18/11,1/6/12,manufacturing delays,blue,,Abbott has Calcijex 1 mcg/mL injection on back order with an estimated release date of early June 2011.;Abbott has Calcijex 1 mcg/mL injection on back order with an estimated release date of early August 2011.;Abbott has Calcijex 1 mcg/mL injection on back order with an estimated release date in October 2011.,,,,,,,,,,,,,
WestWard,calcitriol,1,5/18/11,5/15/12,manufacturing issues,blue,,West-Ward has calcitriol injection on back order and the company cannot estimate a release date.;Contract manufacturer cannot meet USP requirements West-Ward has calcitriol injection on back order and the company cannot estimate a release date.;,,,,,,,,,,,,,
Amphastar,calcium,1,8/7/10,7/12/12,; demand increase; available,orange,,Amphastar (IMS) in cooperation with FDA will re-introduce its emergency syringes including Dextrose 50%- Epinephrine 0.1mg/mL- Calcium Chloride 100mg/mL- Sodium Bicarbonate 8.4%- Atropine Sulfate 0.1mg/mL- Lidocaine 2%- and Morphine 1mg/mL. Calcium Chloride 100mg/ml syringes (NDC 0548-3304-00/product code 3304) were released by Amphastar/IMS on 9/7/10 and are now available.;,,,,,,,,,,,,,
AmnealAgila,calcium,1,8/19/13,3/25/14,[temporary import],brown,,10% w/v (100mg/mL-10mL) (NDC 53150-697-01)  Amneal-Agila LLC will regularly release products.  No supply issue anticipated. Amneal-Agila LLC in conjunction with FDA has initiate temporary importation of CaCl injection into the US market to address this shortage.  Please see the Dear Healthcare Professional Letter (PDF - 28KB) and Comparison Package (PDF - 49KB) for information about supplies that are now available.,,,,,,,,,,,,,
Graceway,calcium,1,7/13/09,10/24/09,demand increase,orange,,Increase in demand,,,,,,,,,,,,,
Hospira,calcium,1,7/16/10,8/15/10,demand increase,orange,,Unanticipated Increased Demand,,,,,,,,,,,,,
Hospira,calcium,2,9/14/10,4/22/11,demand increase,orange,,Unanticipated Increased Demand,,,,,,,,,,,,,
Amphastar,calcium,2,12/24/12,3/25/14,demand increase; available,orange,,10%- 10mL Luer-Jet Prefilled Syringe- NDC 0548-3304-00 Amphastar will regularly release products. Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues;10%- 10mL Luer-Jet Prefilled Syringe   NDC 76329-3304-1 (old NDC 0548-3304-00)   Amphastar will regularly release products. Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues;10%- 10mL Luer-Jet Prefilled Syringe   NDC 76329-3304-1 (old NDC 0548-3304-00)   Available N/A;10%- 10mL Luer-Jet Prefilled Syringe   NDC 76329-3304-1 (old NDC 0548-3304-00)   Amphastar will regularly release products  Amphastar is  experiencing a product shortage due to an increase in product demand caused by market supply issues;10%- 10mL Luer-Jet Prefilled Syringe   NDC 76329-3304-1 (old NDC 0548-3304-00)   Available,,,,,,,,,,,,,
AmericanRegent,calcium,1,7/16/10,7/12/12,demand increase; not releasing; available,orange,,American Regent- Inc. currently has Calcium Chloride Injection- USP 100 mg/mL in a 10 mL vial available. Due to increases in demand- American Regent- Inc. may not be able to fill all orders. Contact your wholesaler regarding product availability.;American Regent- Inc. is not currently releasing Calcium Chloride Injection- USP 100 mg/mL in a 10 mL vial. Information on releases will be posted once available.;American Regent- Inc. is currently releasing Calcium Chloride Injection- USP 100 mg/mL in a 10 mL vial.;Unavailable American Regent- Inc. is not currently releasing Calcium Chloride Injection- USP 100 mg/mL in a 10 mL vial.  Information on releases will be posted once available.;American Regent- Inc. is not currently releasing Calcium Chloride Injection- USP 100 mg/mL in a 10 mL vial.  Information on releases will be posted once available.;American Regent anticipates to have lots available end of April 2012.;,,,,,,,,,,,,,
AmericanRegent,calcium,2,12/24/12,3/25/14,not releasing,,,10 mL single-dose vial- package of 25 (NDC 00517-2710-25)   Unavailable American Regent is currently not releasing Calcium Chloride Injection;10 mL single-dose vial- package of 25 (NDC 00517-2710-25)   Temporarily unavailable. Temporarily unavailable. Next delivery end of April 2013.;10 mL single-dose vial- package of 25 (NDC 00517-2710-25)   Temporarily unavailable. Next delivery mid May 2013.;10 mL single-dose vial- package of 25 (NDC 00517-2710-25)   Temporarily unavailable. Next delivery end of June.;10 mL single-dose vial- package of 25 (NDC 00517-2710-25)   Temporarily unavailable. Next delivery end of July.;10 mL single-dose vial- package of 25 (NDC 00517-2710-25)   Temporarily unavailable. Next release end of July.;10 mL single-dose vial- package of 25 (NDC 00517-2710-25)   Temporarily unavailable. Next release August 2013.;10 mL single-dose vial- package of 25 (NDC 00517-2710-25)   Unavailable American Regent is currently not releasing Calcium Chloride Injection.;10 mL single-dose vial- package of 25 (NDC 00517-2710-25)   Unavailable - No product available for release. No plan to manufacture. American Regent is currently not releasing Calcium Chloride Injection.,,,,,,,,,,,,,
AmericanRegent,calciumg,2,3/6/13,3/25/14,; not releasing; manufacturing delays; shipping delay; demand increase,blue,,10% 100 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3900-25)   Temporarily unavailable. Next delivery end of April 2013.;10% 50 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3950-25) Temporarily unavailable. Next delivery end of April 2013.;10% 100 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3900-25)     American Regent is currently releasing Calcium Gluconate 100mL Pharmacy Bulk Package;10% 50 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3950-25) Product being released intermittently.  See Dear Healthcare Provider Letter (PDF - 582KB).    American Regent is currently releasing Calcium Gluconate 100mL Pharmacy Bulk Package;10% 50 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3950-25) Temporarily unavailable    American Regent is currently releasing Calcium Gluconate 100mL Pharmacy Bulk Package;10% 100 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3900-25)    Unavailable American Regent is currently not releasing Calcium Gluconate 100mL Pharmacy Bulk Package;10% 50 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3950-25) Temporarily unavailable    American Regent is currently not releasing Calcium Gluconate 100mL Pharmacy Bulk Package;10% 50 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3950-25) Temporarily unavailable  Next release mid-October 2013  American Regent is currently not releasing Calcium Gluconate 50 mL vial     American Regent is currently not releasing Calcium Gluconate 100mL Pharmacy Bulk Package;10% 100 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3900-25)    Unavailable American Regent is currently not releasing Calcium Gluconate 50 mL vial     American Regent is currently not releasing Calcium Gluconate 100mL Pharmacy Bulk Package;10% 50 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3950-25) Estimate release end December 2013  Shortage per Manufacturer: Manufacturing delay;10% 100 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3900-25)   Unavailable American Regent is currently not releasing Calcium Gluconate 100mL Pharmacy Bulk Package;10% 100 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3900-25)   Unavailable - Product on backorder and will be made available as it is released. Shortage per Manufacturer: Manufacturing delay;10% 50 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3950-25) Unavailable - No product available for release. No plan to manufacture. American Regent is currently not releasing Calcium Gluconate 50 mL vials;USP 10% 50 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3950-25) Unavailable - No product available for release. No plan to manufacture. American Regent is currently not releasing Calcium Gluconate 50 mL vials.     Shortage per Manufacturer: Manufacturing delay.;USP 10% 100 mL vial Calcium (0.465 mEq/mL)- Preservative Free (NDC 0517-3900-25)   Unavailable - Product on backorder and will be made available as it is released. American Regent is currently not releasing Calcium Gluconate 50 mL vials.     Shortage per Manufacturer: Manufacturing delay.,,,,,,,,,,,,,
APP,calciumg,1,3/11/11,4/22/11,demand increase,orange,,Increase in demand Increase in demand  ;Increase in demand Increase in demand;Increase in demand Increase in demand,,,,,,,,,,,,,
APP,calciumg,1,4/28/11,3/16/12,demand increase,orange,,"APP has all calcium gluconate products on intermittent back-order- due to increased demand- and the company has regular releases and distributes inventory directly to the wholesale channel. Please check with your wholesaler for all available inventory. APP has the 10mL vials (63323-311-10) and 100mL vials (63323-311-61) on back-order with estimated releases mid-March- 2011. APP has the 50mL vials (63323-311-50) also on backorder with estimated release early-April- 2011. The 200mL vials have been discontinued.;APP has all calcium gluconate products on intermittent back-order- due to increased demand- and the company has regular releases and distributes inventory directly to the wholesale channel. 
 
 Please check with your wholesaler for all available inventory. APP has the 10mL vials (63323-311-10) and 100mL vials (63323-311-61) on back-order with estimated releases mid-March- 2011. APP has the 50mL vials (63323-311-50) also on backorder with estimated release early-April- 2011. The 200mL vials have been discontinued.;APP has calcium gluconate 100 mg/mL - 100 mL (63323-311-61) & 100mg/mL- 50 mL (63323-311-50) vials on intermittent back order due to increased demand and the company is releasing the product as it becomes available. The 100 mg/mL- 10mL (63323-311-10) vials are being allocated.  The 200 mL vials have been discontinued.;APP has available calcium gluconate 100 mg/mL vials- 10 mL vials (NDC 63323-0311-10)50 mL vials (NDC 63323-0311-50)  100 mg/mL - 100 mL (63323-311-61).  The 200 mL vials have been discontinued.",,,,,,,,,,,,,
APP,calciumg,2,3/6/13,11/8/13,demand increase,orange,,10% 100 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 10 g/ 100 mL- PBP (NDC 63323-311-61)   Back-ordered. Next delivery anticipated April 2013.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)   Backordered.  Next delivery anticipated April 2013.;10% 10 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 1 g/ 10 mL- SDV (NDC 63323-311-10) Backordered.  Next delivery anticipated late March 2013.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)   Back-ordered. Next delivery anticipated April 2013.;10% 100 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 10 g/ 100 mL- PBP (NDC 63323-311-61)   Back-ordered. Next delivery anticipated May 2013.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)   Back-ordered. Next delivery anticipated May 2013.;10% 10 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 1 g/ 10 mL- SDV (NDC 63323-311-10) Backordered.  Next delivery anticipated late May 2013.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)   Backordered.  Next delivery anticipated late May 2013.;10% 10 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 1 g/ 10 mL- SDV (NDC 63323-311-10) Manufacturer is currently allocating.;10% 100 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 10 g/ 100 mL- PBP (NDC 63323-311-61)   Back-ordered. Next delivery anticipated June 2013.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)   Backordered.  Next delivery anticipated late June 2013.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)   Back-ordered. Next delivery anticipated June 2013.;10% 100 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 10 g/ 100 mL- PBP (NDC 63323-311-61)   Back-ordered. Next delivery anticipated August 2013.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)   Backordered.  Next delivery anticipated late July 2013.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)   Back-ordered. Next delivery anticipated August 2013.;10% 10 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 1 g/ 10 mL- SDV (NDC 63323-311-10) Backordered. Next delivery anticipated August 2013.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)   Backordered.  Next delivery anticipated late August 2013.;10% 100 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 10 g/ 100 mL- PBP (NDC 63323-311-61)   Back-ordered. Next delivery anticipated September 2013.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)   Backordered.  Next delivery anticipated late September 2013.;10% 10 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 1 g/ 10 mL- SDV (NDC 63323-311-10) Currently on allocation.  Next delivery anticipated October 2013.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)   Back-ordered. Next delivery anticipated September 2013.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)   Currently on allocation.   Next delivery anticipated October 2013.,,,,,,,,,,,,,
Fresenius,calciumg,1,12/28/13,3/25/14,demand increase,orange,,10% 100 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 10 g/ 100 mL- PBP (NDC 63323-311-61)  Currently on allocation Next delivery anticipated December 2013.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)  Currently back-ordered.   Next delivery anticipated January 2014;10% 10 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 1 g/ 10 mL- SDV (NDC 63323-311-10) Currently on allocation. Next delivery anticipated January 2014. Check wholesalers for inventory.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)  Currently on allocation Next delivery anticipated December 2013.;10% 10 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 1 g/ 10 mL- SDV (NDC 63323-311-10) Currently on allocation. Next delivery anticipated February 2014. Check wholesalers for inventory.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)  Currently on allocation. Next delivery anticipated March 2014. Check wholesalers for inventory.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)  Currently on allocation. Next delivery anticipated March 2014. Check wholesalers for inventory..;10% 100 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 10 g/ 100 mL- PBP (NDC 63323-311-61)  Currently on allocation. Next delivery anticipated March 2014. Check wholesalers for inventory..;10% 10 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 1 g/ 10 mL- SDV (NDC 63323-311-10) Available. Check wholesalers for inventory.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)  Backordered Next delivery anticipated March 2014. Check wholesalers for inventory.;10% 50 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 5 g/ 50 mL- SDV (NDC 63323-311-50)  Backordered Next delivery anticipated April 2014. Check wholesalers for inventory..;10% 100 mL vial   Calcium (0.465 mEq/mL)- Preservative Free 10 g/ 100 mL- PBP (NDC 63323-311-61)  Backordered Next delivery anticipated April 2014. Check wholesalers for inventory..,,,,,,,,,,,,,
Luitpold,calciumg,1,3/11/11,4/22/11,demand increase,orange,,Increase in demand Increase in demand  ;Increase in demand Increase in demand;Increase in demand Increase in demand,,,,,,,,,,,,,
AmericanRegent,calciumg,1,4/28/11,3/16/12,demand increase,orange,,American Regent has calcium gluconate 100 mg/mL 50 mL and 100 mL vials on back order. The 10 mL vials have been discontinued.;American Regent- Inc. is currently releasing Calcium Gluconate 100 mg/mL 50 mL and 100 mL vials. The 10 mL vial has been discontinued.,,,,,,,,,,,,,
Akorn,capastat,1,3/1/12,3/16/12,available,,,Akorn has Capastat available to supply US market needs- and is allocating non-domestic worldwide supply.,,,,,,,,,,,,,
Genzyme,cerezyme,1,9/22/11,3/16/12,manufacturing delays,blue,,Please see the Dear U.S. Healthcare Provider Letter (PDF - 112KB).,,,,,,,,,,,,,
Genzyme,cerezyme,1,8/14/09,1/6/11,manufacturing delays,blue,,Manufacturing delays  ;Manufacturing delays  ,,,,,,,,,,,,,
EMDSerono,cetrorelix,1,9/28/12,3/13/13,demand increase,orange,,0.25 mg  (NDC 44087-1225-1) Product is currently available on an allocated basis.,,,,,,,,,,,,,
Fresenius,chloramphenicol,1,12/28/13,3/25/14,material shortage,green,,EQ 1GM base/vial (NDC 63323-0011-15) Estimated recovery: TBD Shortage per Manufacturer:  Long term supplier interruption due to API,,,,,,,,,,,,,
APP,chloroprocaine,1,4/18/12,10/7/12,demand increase; available,orange,,All strengths on backorder with an estimated release date of late April/Early May- 2012.;Increased Demand All strengths on backorder with an estimated release date of late April/Early May- 2012.;;10 mg/mL with preservative- 30 mL vial- 25 count (NDC 63323-0475-37) Available Shortage per Manufacturer: Increased Demand;20 mg/mL with preservative- 30 mL vial- 25 count (NDC 63323-0476-37) Currently back-ordered Shortage per Manufacturer: Increased Demand;30 mg/mL preservative-free- 20 mL vials- 25 count (NDC 63323-0478-27) Currently back-ordered Shortage per Manufacturer: Increased Demand,,,,,,,,,,,,,
Bedford,chloroprocaine,1,4/18/12,10/7/12,manufacturing delays,blue,,Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford Laboratories website.;Manufacturing delays Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford Laboratories website.;;20 mg/mL preservative-free- 20 mL vials (NDC 55390-0403-20) Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford Laboratories website . Shortage per Manufacturer: Manufacturing delays;30 mg/mL preservative-free- 20 mL vials (NDC 55390-0404-20) Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford Laboratories website . Shortage per Manufacturer: Manufacturing delays,,,,,,,,,,,,,
APP,chromic,1,10/14/12,3/1/13,demand increase,orange,,"20 mg/mL with preservative- 30 mL vial- 25 count (NDC 63323-0476-37) Next delivery for November 2012 Shortage per Manufacturer: Increased Demand;20mg/mL with preservative- 20 mL vial- 25 count (NDC 63323-0477-27) Next delivery for November 2012 Shortage per Manufacturer: Increased Demand;30 mg/mL preservative-free- 20 mL vials- 25 count (NDC 63323-0478-27) Next delivery for November 2012 Shortage per Manufacturer: Increased Demand;10 mg/mL with preservative- 30 mL vial- 25 count (NDC 63323-0475-37) Available Shortage per Manufacturer: Increased Demand;10 mg/mL with preservative- 30 mL vial- 25 count (NDC 63323-0475-37) Available Shortage per Manufacturer: 
 Increased Demand;20 mg/mL with preservative- 30 mL vial- 25 count (NDC 63323-0476-37) Available Shortage per Manufacturer: 
 Increased Demand;30 mg/mL preservative-free- 20 mL vials- 25 count (NDC 63323-0478-27) Next delivery for November 2012 Shortage per Manufacturer: 
 Increased Demand;20mg/mL with preservative- 20 mL vial- 25 count (NDC 63323-0477-27) Next delivery for November 2012 Shortage per Manufacturer: 
 Increased Demand;10 mg/mL with preservative- 30 mL vial- 25 count (NDC 63323-0475-37) Available Shortage per Manufacturer: Increased Demand Check wholesalers for inventory;20 mg/mL with preservative- 30 mL vial- 25 count (NDC 63323-0476-37) Available Shortage per Manufacturer: Increased Demand Check wholesalers for inventory;30 mg/mL preservative-free- 20 mL vials- 25 count (NDC 63323-0478-27) Available Shortage per Manufacturer: Increased Demand Check wholesalers for inventory;20mg/mL with preservative- 20 mL vial- 25 count (NDC 63323-0477-27) Available Shortage per Manufacturer: Increased Demand Check wholesalers for inventory",,,,,,,,,,,,,
Bedford,chromic,1,10/14/12,3/1/13,manufacturing delays,blue,,"20 mg/mL preservative-free- 20 mL vials (NDC 55390-0403-20) Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford Laboratories website . Shortage per Manufacturer: Manufacturing delays;30 mg/mL preservative-free- 20 mL vials (NDC 55390-0404-20) Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford Laboratories website . Shortage per Manufacturer: Manufacturing delays;20 mg/mL preservative-free- 20 mL vials (NDC 55390-0403-20) Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford Laboratories website .
 Shortage per Manufacturer: 
 Manufacturing delays;30 mg/mL preservative-free- 20 mL vials (NDC 55390-0404-20) Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford Laboratories website .
 Shortage per Manufacturer: 
 Manufacturing delays",,,,,,,,,,,,,
AmericanRegent,chromic,1,11/30/11,3/25/14,manufacturing delays; not releasing,blue,,American Regent product is on back order with no estimated date of availability.;Manufacturing delays American Regent product is on back order with no estimated date of availability.;;SOL 4 mcg/ml INTRAVENOUS 10 ml 25s (NDC 00517-6310-25) Unavailable Currently not releasing;4 mcg/mL; 10 mL vial- 25s (NDC 00517-6310-25) Unavailable Currently not releasing;4 mcg/mL; 10 mL vial- 25s (NDC 00517-6310-25) Unavailable American Regent is currently not releasing Chromic Chloride Injection;4 mcg/mL; 10 mL vial- 25s (NDC 00517-6310-25) Unavailable - No product available for release. No plan to manufacture. American Regent is currently not releasing Chromic Chloride Injection,,,,,,,,,,,,,
Gilead,cidofovir,1,7/24/13,7/24/13,product recall,yellow,,VISTIDE (cidofovir injection) 75 mg/mL for intravenous infusion- is supplied as a non-preserved solution in single-use clear glass vials as follows: 375 mg in a 5 mL vial in a single-unit carton (NDC 61958-0101-1)   Currently unavailable. Shortage duration unknown at this time- but further updates anticipated   Gilead Sciences- Inc. issued a recall for Vistide (cidofovir injection) on February 7- 2013 (NDC 61958-0101-1; Lot # B120217A).  Information concerning this recall can be found at: Dear Customer Letter,,,,,,,,,,,,,
Gilead,cidofovir,2,8/7/13,3/25/14,product recall,yellow,,VISTIDE (cidofovir injection) 75 mg/mL for intravenous infusion- is supplied as a non-preserved solution in single-use clear glass vials as follows: 375 mg in a 5 mL vial in a single-unit carton (NDC 61958-0101-1)   Currently unavailable. Shortage duration unknown at this time- but further updates anticipated   Gilead Sciences- Inc. issued a recall for Vistide (cidofovir injection) on February 7- 2013 (NDC 61958-0101-1; Lot # B120217A).  Information concerning this recall can be found at: Dear Customer Letter,,,,,,,,,,,,,
Heritage,cidofovir,1,3/6/13,3/25/14,product recall; available,yellow,,375 mg/5 mL vial (NDC 2315-5216-31)   Available Gilead Sciences- Inc. issued a recall for Vistide (cidofovir injection) on February 7- 2013 (NDC 61958-0101-1; Lot # B120217A).  Information concerning this recall can be found at: http://www.gilead.com/pdf/Vistide-Recall-Pharmalert.pdf  Heritage Pharmaceuticals and Mylan Institutional have product available.;375 mg/5 mL vial (NDC 2315-5216-31)   Available,,,,,,,,,,,,,
APP,cisplatin,1,6/6/09,6/6/09,available,,,Available,,,,,,,,,,,,,
Bedford,cisplatin,1,6/6/09,6/6/09,available,,,Available,,,,,,,,,,,,,
Teva,cisplatin,1,6/6/09,6/6/09,available,,,Available,,,,,,,,,,,,,
APP,cisplatin,1,4/28/11,7/12/12,demand increase; available,orange,,APP is continuing to allocate as releases occur: 50 mL vial (NDC 63323-0103-51)- 100 mL vial (NDC 63323-0103-65) and 200 mL vial (NDC 63323-0103-64).;APP is continuing to allocate as releases occur.;APP is allocating 1 mg/ml; 50 mL vial (NDC 63323-0103-51)- 1 mg/ml; 100 mL vial (NDC 63323-0103-65)- & 1 mg/ml; 200 mL vial (NDC 63323-0103-64) ? check wholesalers for inventory.;APP has all Cisplatin presentations available. Please check wholesalers for inventory.;Increased Demand APP has all Cisplatin presentations available. Please check wholesalers for inventory.;,,,,,,,,,,,,,
APP,cisplatin,2,10/30/10,4/22/11,demand increase; manufacturing delays,blue,,Increased demand. Manufacturing delays Manufacturing delays  ;Increased demand. Manufacturing delays Manufacturing delays  ;Increased demand. Manufacturing delays Manufacturing delays  ,,,,,,,,,,,,,
Bedford,cisplatin,2,8/20/10,4/14/11,demand increase; manufacturing delays,blue,,Increased demand. Manufacturing delays Manufacturing delays ;Increased demand. Manufacturing delays Manufacturing delays  ;Increased demand. Manufacturing delays Manufacturing delays  ,,,,,,,,,,,,,
Teva,cisplatin,2,8/20/10,4/22/11,demand increase; manufacturing delays,blue,,Increased demand. Manufacturing delays Manufacturing delays ;Increased demand. Manufacturing delays Manufacturing delays  ;Increased demand. Manufacturing delays Manufacturing delays  ;Increased demand. Manufacturing delays Manufacturing delays  ,,,,,,,,,,,,,
Teva,cisplatin,1,4/28/11,7/12/12,manufacturing delays; demand increase; available,blue,,Teva continues to release cisplatin injection 1 mg/mL solution. 50 mL vial (NDC 00703-5747-11) and 100 mL vial (NDC 00703-5748-11) as it becomes available.;Teva has ample inventory of both presentations.;Increased Demand Teva has ample inventory of both presentations.;,,,,,,,,,,,,,
Bedford,cisplatin,1,4/28/11,7/12/12,manufacturing delays; discontinued,black,,Cisplatin injection 1 mg/mL solution from Bedford are all on back order with no estimated release date.;Bedford currently has all presentations discontinued.;Product discontinued Bedford currently has all presentations discontinued.;,,,,,,,,,,,,,
UnitedGuardian,citric,1,9/1/12,3/2/14,manufacturing delays; manufacturing issues,blue,,"Renacidin® Irrigation 6.602GM/100ML;198MG/100ML;3.177GM/100ML     (NDC: 00327-00011-05) Limited Availability Shortage per Manufacturer: Manufacturing Delay;Renacidin® Irrigation 
 
 6.602GM/100ML;198MG/100ML;3.177GM/100ML  
    
 (NDC: 00327-00011-05) Limited Availability Shortage per Manufacturer: 
 Manufacturing Delay;Renacidin® Irrigation 6.602GM/100ML;198MG/100ML;3.177GM/100ML     (NDC: 00327-00011-05) Availability is not expected before May 2013 Shortage per Manufacturer: Manufacturing Delay;Renacidin Irrigation 6.602GM/100ML;198MG/100ML;3.177GM/100ML     (NDC: 00327-00011-05) Availability is not expected before Sept/Oct 2013 Shortage per Manufacturer: Manufacturing Delay;Renacidin Irrigation 6.602GM/100ML;198MG/100ML;3.177GM/100ML     (NDC: 00327-0011-05) Availability approximately mid-Oct 2013 Shortage per Manufacturer: Manufacturing Delay;Renacidin Irrigation 6.602GM/100ML;198MG/100ML;3.177GM/100ML     (NDC: 00327-0011-05) Shipments to drug wholesalers will commence October 31- 2013. National availability at the retail level expected by 11/15/2013. Shortage per Manufacturer: Manufacturing Delay- multiple manufacturing issues over a 15-18 month period",,,,,,,,,,,,,
United,citric,1,7/12/12,8/4/12,,,,,,,,,,,,,,,,,
MedicinesCompany,cleviprex,1,3/26/10,4/22/11,,,,See Related Information Section,,,,,,,,,,,,,
Akorn,clindamycin,1,12/28/13,3/25/14,available,,,300 mg / 50 mL Pre-mix VialNDC 17478-0120-50 Readily Available N/A;600 mg / 50 mL Pre-mix VialNDC 17478-0121-50 Readily Available N/A;900 mg / 50 mL Pre-mix VialNDC 17478-0122-50 Readily Available N/A,,,,,,,,,,,,,
Fresenius,clindamycin,1,12/28/13,3/25/14,demand increase,orange,,300 mg per 2 mL- single dose vial (NDC 63323-282-02) Available.  Check wholesalers for inventory. Shortage per Manufacturer:   Increased demand for the product.;900 mg per 6 mL- single dose vial (NDC 63323-282-06) Currently back-ordered. Next release anticipated January 2014. Shortage per Manufacturer:   Increased demand for the product.;9 g per 60 mL- PBP (NDC 63323-282-60) Available.  Check wholesalers for inventory. Shortage per Manufacturer:   Increased demand for the product.;600 mg per 4 mL- single dose vial (NDC 63323-282-04) Currently back-ordered. Next release anticipated January 2014. Shortage per Manufacturer:   Increased demand for the product.;900 mg per 6 mL- single dose vial (NDC 63323-282-06) Currently back-ordered. Next release anticipated March 2014. Shortage per Manufacturer:   Increased demand for the product.;600 mg per 4 mL- single dose vial (NDC 63323-282-04) Currently back-ordered. Next release anticipated March 2014. Shortage per Manufacturer:   Increased demand for the product.;900 mg per 6 mL- single dose vial (NDC 63323-282-06) Available.  Check wholesalers for inventory. Shortage per Manufacturer:   Increased demand for the product.,,,,,,,,,,,,,
AmericanRegent,copper,1,4/11/13,3/25/14,not releasing; shipping delay; demand increase,orange,,Cupric Sulfate Injection 0.4 mg/mL 10 mL vial- package of  25 (NDC 00517-6210-25   Cannot provide an estimated date of availability   American Regent is currently not releasing Cupric Sulfate Injection;Cupric Sulfate Injection 0.4 mg/mL 10 mL vial- package of  25 (NDC 00517-6310-25   Unavailable  American Regent is currently not releasing Cupric Sulfate Injection;Cupric Sulfate Injection 0.4 mg/mL 10 mL vial- package of  25 (NDC 00517-6310-25   Unavailable - Product on backorder and will be made available as it is released Shortage per Manufacturer: Manufacturing delay;Cupric Sulfate Injection 0.4 mg/mL 10 mL vial- package of  25 (NDC 00517-6210-25)   Unavailable - Product on backorder and will be made available as it is released Shortage per Manufacturer: Manufacturing delay,,,,,,,,,,,,,
Ferring,corticorelin,1,2/16/12,3/1/13,manufacturing issues; manufacturing delays; compliance issues,yellow,,"No stock available.;Manufacturing No stock available.;;EQ 0.1 MG Base/Vial (NDC 55566-0302-1) No stock available Shortage per Manufacturer: Manufacturing delay;EQ 0.1 MG Base/Vial (NDC 55566-0302-1) No stock available Shortage per Manufacturer: Product availability pending resolution of compliance issues at manufacturing site;EQ 0.1 MG Base/Vial (NDC 55566-0302-1) No stock available Shortage per Manufacturer: 
 Product availability pending resolution of compliance issues at manufacturing site",,,,,,,,,,,,,
AmericanRegent,cyanocobalamin,2,3/6/13,3/25/14,; not releasing; manufacturing delays; available; shipping delay; demand increase,blue,,1000 mcg/mL- 1 mL vial (NDC 00517-0031-25)   Temporarily unavailable. Next delivery mid February 2013.;1000 mcg/mL- 10 mL vial (NDC 00517-0032-25) Temporarily unavailable. Next delivery mid February 2013.;1000 mcg/mL- 30 mL vial (NDC 00517-0130-05) Temporarily unavailable. Next delivery mid February 2013.;1000 mcg/mL- 30 mL vial (NDC 00517-0130-05)   American Regent is currently releasing 1 mL single-dose vial   American Regent is currently not releasing 10 mL or the 30mL vial;1000 mcg/mL- 10 mL vial (NDC 00517-0032-25) Unavailable American Regent is currently releasing 1 mL single-dose vial   American Regent is currently not releasing 10 mL or the 30mL vial;1000 mcg/mL- 1 mL vial (NDC 00517-0031-25)   Available American Regent is currently releasing 1 mL single-dose vial   American Regent is currently not releasing 10 mL or the 30mL vial;1000 mcg/mL- 1 mL vial (NDC 00517-0031-25)   Available American Regent is currently releasing the 1 mL- 10 mL and 30 mL vials.;1000 mcg/mL- 10 mL vial (NDC 00517-0032-25) Available American Regent is currently releasing the 1 mL- 10 mL and 30 mL vials.;1000 mcg/mL- 30 mL vial (NDC 00517-0130-05) Available  American Regent is currently releasing the 1 mL- 10 mL and 30 mL vials.;1000 mcg/mL- 30 mL vial (NDC 00517-0130-05) Available  American Regent is currently not releasing the 1 mL vials.   American Regent is currently releasing the 10 mL and 30 mL vials.;1000 mcg/mL- 1 mL vial (NDC 00517-0031-25)   Unavailable American Regent is currently not releasing the 1 mL vials.   American Regent is currently releasing the 10 mL and 30 mL vials.;1000 mcg/mL- 10 mL vial (NDC 00517-0032-25) Available American Regent is currently not releasing the 1 mL vials.   American Regent is currently releasing the 10 mL and 30 mL vials.;1000 mcg/mL- 30 mL vial (NDC 00517-0130-05) Estimated release date for the 30 mL vials is end of August 2013 American Regent is currently not releasing the 1 mL vials.   American Regent is currently releasing the 10 mL vials.   Shortage per Manufacturer: Manufacturing delay.;1000 mcg/mL- 1 mL vial (NDC 00517-0031-25)   Unavailable American Regent is currently not releasing the 1 mL vials.   American Regent is currently releasing the 10 mL vials.   Shortage per Manufacturer: Manufacturing delay.;1000 mcg/mL- 10 mL vial (NDC 00517-0032-25) Available American Regent is currently not releasing the 1 mL vials.   American Regent is currently releasing the 10 mL vials.   Shortage per Manufacturer: Manufacturing delay.;1000 mcg/mL- 30 mL vial (NDC 00517-0130-05) Unavailable Estimated release date for the 1 mL and 30 mL vials is mid-September 2013 American Regent is currently not releasing the 1 mL or the 30 mL vials.;1000 mcg/mL- 1 mL vial (NDC 00517-0031-25)   Unavailable American Regent is currently not releasing the 1 mL or the 30 mL vials.;1000 mcg/mL- 10 mL vial (NDC 00517-0032-25) Available American Regent is currently not releasing the 1 mL or the 30 mL vials.;1000 mcg/mL- 10 mL vial (NDC 00517-0032-25) Unavailable Estimated release end-December 2013.   Shortage per Manufacturer: Manufacturing delay;1000 mcg/mL- 1 mL vial (NDC 00517-0031-25)   Unavailable Estimated release end-December 2013.   Shortage per Manufacturer: Manufacturing delay;1000 mcg/mL- 30 mL vial (NDC 00517-0130-05) Unavailable Estimated release end-December 2013.   Shortage per Manufacturer: Manufacturing delay;1000 mcg/mL- 10 mL vial (NDC 00517-0032-25) Unavailable - Product on backorder and will be made available as it is released   Shortage per Manufacturer: Manufacturing delay;1000 mcg/mL- 1 mL vial (NDC 00517-0031-25)   Unavailable - Product on backorder and will be made available as it is released   Shortage per Manufacturer: Manufacturing delay;1000 mcg/mL- 30 mL vial (NDC 00517-0130-05) Unavailable - Product on backorder and will be made available as it is released   Shortage per Manufacturer: Manufacturing delay,,,,,,,,,,,,,
APP,cyanocobalamin,2,3/6/13,11/8/13,demand increase,orange,,1000 mcg/mL- 1 mL vial (NDC 63323-0044-01)  Currently back-ordered. Check wholesalers for inventory.  Next release anticipated late February 2013.  Check wholesalers for inventory;1000 mcg/mL- 1 mL vial (NDC 63323-0044-01)  Available. Check wholesalers for inventory.  Next release anticipated  May 2013. Check wholesalers for inventory;1000 mcg/mL- 1 mL vial (NDC 63323-0044-01)  Currently back-ordered - next release anticipated late May. Check wholesalers for inventory.  Next release anticipated  May 2013. Check wholesalers for inventory;1000 mcg/mL- 1 mL vial (NDC 63323-0044-01)  Currently back-ordered - next release anticipated late June 2013. Check wholesalers for inventory. Check wholesalers for inventory;1000 mcg/mL- 1 mL vial (NDC 63323-0044-01)  Currently back-ordered - next release anticipated July 2013. Check wholesalers for inventory. Check wholesalers for inventory;1000 mcg/mL- 1 mL vial (NDC 63323-0044-01)  Currently back-ordered - next release anticipated late July 2013. Check wholesalers for inventory. Check wholesalers for inventory;1000 mcg/mL- 1 mL vial (NDC 63323-0044-01)  Currently back-ordered.  Next release anticipated early September. Check wholesalers for inventory;1000 mcg/mL- 1 mL vial (NDC 63323-0044-01)  Currently back-ordered.  Next release anticipated mid September. Check wholesalers for inventory,,,,,,,,,,,,,
Fresenius,cyanocobalamin,1,12/28/13,3/25/14,demand increase,orange,,1000 mcg/mL- 1 mL vial (NDC 63323-0044-01)  Currently back-ordered.  Next release anticipated December 2013. Check wholesalers for inventory;1000 mcg/mL- 1 mL vial (NDC 63323-0044-01)  Currently back-ordered.  Next release anticipated late February 2014. Check wholesalers for inventory;1000 mcg/mL- 1 mL vial (NDC 63323-0044-01)  Currently back-ordered.  Next release anticipated March 2014. Check wholesalers for inventory,,,,,,,,,,,,,
APP,cyanocobalamin,1,6/30/11,3/1/12,demand increase; available,orange,,APP has cyanocobalamin injection on intermittent back order and the company is releasing product as it becomes available.;APP has cyanocobalamin injection available.,,,,,,,,,,,,,
AmericanRegent,cyanocobalamin,1,6/30/11,3/1/12,manufacturing delays; available,blue,,American Regent has cyanocobalamin injection 1 mL and 10 mL vial sizes available. The 30 mL vial size is on backorder.;American Regent has 1ml and 10 ml vials being released the week of September 26th.;American Regent has all presentations available.,,,,,,,,,,,,,
AmericanRegent,cyanocobalamin_00517,1,6/22/11,6/22/11,manufacturing delays,blue,,American Regent has cyanocobalamin injection 1 mL and 10 mL vial sizes available.  The 30 mL vial size is on backorder.,,,,,,,,,,,,,
APP,cyanocobalamin_63323,1,6/22/11,6/22/11,demand increase,orange,,APP has cyanocobalamin injection on intermittent back order and the company is releasing product as it becomes available,,,,,,,,,,,,,
APP,cytarabine,1,12/18/10,4/22/11,manufacturing delays,blue,,Manufacturing delays   Manufacturing delays   Raw material issues;Manufacturing delays   Manufacturing delays   API shortage/manufacturing delay  ;Manufacturing delays Manufacturing delays   API shortage/manufacturing delay;Manufacturing delays Manufacturing delays   Increased demand,,,,,,,,,,,,,
APP,cytarabine,1,4/28/11,10/18/11,manufacturing delays,blue,,Limited supplies available - please see attached Dear Healthcare Professional Letter (PDF - 43KB) for important information. APP has been able to increase production to help address the shortage and estimates additional supplies to be released by end of April.;APP has 2 gram vials available on allocation. Please see attached Dear Healthcare Professional Letter (PDF - 43KB) for important information. APP has been able to increase production to help address the shortage.,,,,,,,,,,,,,
Bedford,cytarabine,1,12/18/10,4/22/11,manufacturing delays,blue,,Manufacturing delays   Manufacturing delays   Raw material issues;Manufacturing delays   Manufacturing delays   API shortage/manufacturing delay  ;Manufacturing delays Manufacturing delays   API shortage/manufacturing delay;Manufacturing delays Manufacturing delays   Increased demand,,,,,,,,,,,,,
Bedford,cytarabine,1,4/28/11,10/18/11,manufacturing delays,blue,,Bedford has all cytarabine presentations on back order.;Release of Bedford?s 1g presentation is anticipated in early May; the 100 mg presentation in the next 3-months; the 500 mg presentation in the next 6-months.  The 2g presentation has been discontinued.;Bedford has cytarabine 1 gram vials on intermittent back order and the company is releasing product as it becomes available. All other cytarabine presentations are on back order and the company cannot estimate a release date.;Bedford has available cytarabine lyophilized powder for injection 1 gram (NDC 55390-0133-01). Cytarabine 500 mg (NDC 555390-0132-10) is on backorder with an anticipated release Early October.  Cytarabine 100 mg (55390-0131-10) is on back order and the company cannot estimate a release date.,,,,,,,,,,,,,
Hospira,cytarabine,1,12/18/10,4/22/11,manufacturing delays,blue,,Manufacturing delays   Manufacturing delays   Raw material issues;Manufacturing delays   Manufacturing delays   API shortage/manufacturing delay  ;Manufacturing delays Manufacturing delays   API shortage/manufacturing delay;Manufacturing delays Manufacturing delays   Increased demand,,,,,,,,,,,,,
Bedford,daunorubicin,1,4/28/11,3/25/14,demand increase; manufacturing delays; capacity constraints; pending manufacturing change,blue,,"Bedford has Cerubidine 20 mg lyophilized powder for injection on back order and the company cannot estimate a release date. Bedford has all daunorubicin solution for injection presentations on back order and the company cannot estimate a release date.;Bedford will release 20 mg lyophilized powder for injection in early May. Bedford will release daunorubicin solution for injection- 20 mg and 50 mg- in the next 3-months.;Bedford Laboratories has limited emergency quantities of 5mg/ml solution. Cerubidine lyophilized powder for injection 20 mg is on backorder and there is not an estimate release date.;Bedford has short supplies of daunorubicin injection 20 mg/4 mL (NDC 55390-0108-10) and 50 mg/10 mL (NDC 55390-0108-01). Bedford Laboratories also has short supplies of Cerubidine (daunorubicin for injection) 20 mg (NDC 55390-0281-10).;Bedford has short supplies of daunorubicin injection 20 mg/4 mL (NDC 55390-0108-10) and 50 mg/10 mL (NDC 55390-0108-01) contact your local Bedford Account Executive. Bedford Laboratories also has short supplies of Cerubidine (daunorubicin for injection) 20 mg (NDC 55390-0281-10)contact your local Bedford Account Executive.;Bedford has all daunorbucin presentations on back order and the company cannot estimate a release date.;Bedford Laboratories has limited quantities available of daunorubicin 5 mg/mL in 4 mL and 10 mL single-dose vials (NDC 55390-0108-10- and NDC 55390-0108-01)- and 20 mg cerubidine lyophilized powder for injection (NDC 55390-0281-10)   The company cannot estimate a future release date for more product.;Bedford Laboratories has limited quantities available of daunorubicin 5 mg/mL in 4 mL and 10 mL single-dose vials (NDC 55390-0108-10- and NDC 55390-0108-01)- and 20 mg cerubidine lyophilized powder for injection (NDC 55390-0281-10)
  
 The company cannot estimate a future release date for more product.;Manufacturing delays Bedford Laboratories has 5 mg/mL in 4 mL and 10 mL single-dose vials  and 20 mg cerubidine lyophilized powder for injection available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website;Bedford Laboratories has 5 mg/mL in 4 mL and 10 mL single-dose vials  and 20 mg cerubidine lyophilized powder for injection available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website;;10 mL single-dose vial (NDC 55390-0108-01) Available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Manufacturing delays;5 mg/mL- 4 mL single-dose vial (NDC 55390-0108-10) Available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Manufacturing delays;Cerubidine lyophilized powder for injection- 20mg single-dose vial- package of 10 (NDC 55390-0281-10) Available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Manufacturing delays;Cerubidine lyophilized powder for injection- 20mg single-dose vial- package of 10 (NDC 55390-0281-10) Available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website
 Shortage per Manufacturer: 
 Manufacturing delays;5 mg/mL- 4 mL single-dose vial (NDC 55390-0108-10) Available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website
 Shortage per Manufacturer: 
 Manufacturing delays;10 mL single-dose vial (NDC 55390-0108-01) Available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website
 Shortage per Manufacturer: 
 Manufacturing delays;10 mL single-dose vial (NDC 55390-0108-01) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;Cerubidine lyophilized powder for injection- 20mg single-dose vial- package of 10 (NDC 55390-0281-10) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;5 mg/mL- 4 mL single-dose vial (NDC 55390-0108-10) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;5 mg/mL- 4 mL single-dose vial (NDC 55390-0108-10) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.;10 mL single-dose vial (NDC 55390-0108-01) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.;Cerubidine lyophilized powder for injection- 20mg single-dose vial- package of 10 (NDC 55390-0281-10) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.",,,,,,,,,,,,,
Teva,daunorubicin,1,4/28/11,3/25/14,manufacturing issues; demand increase; available; manufacturing practices requirements,yellow,,Teva has daunorubicin solution for injection on back order and estimates a release date of August- 2011.;Teva has daunorubicin 5 mg/ml 4ml vials (NDC 00703-5233-13) available but the company is reviewing orders prior to release and the product is available through drop shipment only.;Teva has daunorubicin available but the company is reviewing orders prior to release.;Increased Demand Teva has daunorubicin available but the company is reviewing orders prior to release.;;5 mg/mL- 4 mL single-dose vial (NDC 00703-5233-13) Teva has daunorubicin available but the company is reviewing orders prior to release. Shortage per Manufacturer: Increased Demand;5 mg/mL- 4 mL single-dose vial (NDC 00703-5233-13) Teva has ample supply available;5 mg/mL- 4 mL single-dose vial (NDC 00703-5233-13) Teva has Daunorubicin on back order and the company cannot estimate a release date.;5 mg/mL- 4 mL single-dose vial (NDC 00703-5233-13) Teva has placed the product on allocation while in the process of executing a supply recovery plan.  Limited supply is expected through 1Q14. Product  is  currently available for dropship.  Teva asks for your cooperation during this time by ordering only needed quantities.             Customers can order directly from Teva by contacting Customer Service at 1-800-545-8800 between the hours of 8 am and 5 pm EST   Teva will make reasonable attempts to fill orders although the product has been placed on short-term allocation in an effort to help manage the supply.;5 mg/mL- 4 mL single-dose vial (NDC 00703-5233-13) Teva has placed the product on allocation while in the process of executing a supply recovery plan.  Limited supply is expected through 2Q14. Product  is currently available for dropship.  Teva asks for your cooperation during this time by ordering only needed quantities.             Customers can order directly from Teva by contacting Customer Service at 1-800-545-8800 between the hours of 8 am and 5 pm EST   Teva will make reasonable attempts to fill orders although the product has been placed on short-term allocation in an effort to help manage the supply.,,,,,,,,,,,,,
SanofiAventis,ddavp,1,7/16/10,8/28/10,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
Eisai,denileukin,1,11/13/12,1/8/14,material shortage,green,,150 mcg/mL- Eisai 2 mL vial (NDC 62856-0603-01) Eisai is working to have product available again. For information on Patient Access Program- please visit: http://www.ontak.com/ Shortage per Manufacturer: Manufacturing issue,,,,,,,,,,,,,
Ferring,desmopressin,2,8/19/13,3/2/14,available,,,4 mcg/mL- 1mL ampule (NDC 55566-5030-01 Product is currently available  No supply issue anticipated in the next 6 months;4MCG/ML 1X10ML (NDC00703-5054-01) Product is currently available  No supply issue anticipated in the next 6 months;4 mcg/mL- 1mL vials (NDC 55566-5030-01)   Product is currently available  No supply issue anticipated in the next 6 months;4 mcg/mL; 10 mL multiple-dose vials (NDC 55566-5040-01) Product is currently available  No supply issue anticipated in the next 6 months,,,,,,,,,,,,,
SanofiAventis,desmopressin,2,6/5/13,3/2/14,available,,,4 mcg/mL- 10 mL vial (NDC 0075-2451-53) Product is currently available No supply issue anticipated;4 mcg/mL- 1mL ampule (NDC 0075-2451-01) Product is currently available No supply issue anticipated;4 mcg/mL- 10 mL vial (NDC 0075-2451-53) Product is currently available No supply issue anticipated in the next 6 months;4 mcg/mL- 1mL ampule (NDC 0075-2451-01) Product is currently available No supply issue anticipated in the next 6 months,,,,,,,,,,,,,
SanofiAventis,desmopressin,1,4/28/11,3/1/13,demand increase; available,orange,,"Sanofi is continuing to release product as soon as it becomes available.;Desmopressin 4 mcg/mL- 1 mL (NDC 00075245101) ampule is available.   Desmopressin 4 mcg/mL-10 mL (NDC00075245153) vials will be available in Mid December.;Desmopressin 4 mcg/mL- 1 mL (NDC 00075245101) ampule is available.
  
 Desmopressin 4 mcg/mL-10 mL (NDC00075245153) vials will be available in Mid December.;Sanofi-Aventis desmopressin has both presentations available.;Available Sanofi-Aventis desmopressin has both presentations available.;;4 mcg/mL; 10 mL vial (NDC 00075-2451-53) Both presentations available. Shortage per Manufacturer: Available;(DDAVP) 4 mcg/mL;  1 mL  ampule (NDC 00075-2451-01)  Both presentations available. Shortage per Manufacturer: Available;4 mcg/mL; 10 mL vial (NDC 00075-2451-53) Both presentations available. Shortage per Manufacturer: 
 Available;(DDAVP) 4 mcg/mL;  1 mL  ampule (NDC 00075-2451-01)  Both presentations available. Shortage per Manufacturer: 
 Available",,,,,,,,,,,,,
Ferring,desmopressin,1,11/12/10,4/22/11,demand increase; manufacturing delays,blue,,n/a Increased demand/manufacturing delays Unanticipated increased demand   Manufacturing delays      ;n/a Increased demand / manufacturing delays Unanticipated increased demand     Manufacturing delays ;n/a Increased demand / manufacturing delays Unanticipated increased demand     Manufacturing delays ,,,,,,,,,,,,,
Hospira,desmopressin,1,9/23/10,4/22/11,demand increase; manufacturing delays,blue,,Increased demand/manufacturing delays Unanticipated increased demand   Manufacturing delays      ;n/a Increased demand/manufacturing delays Unanticipated increased demand   Manufacturing delays      ;n/a Increased demand / manufacturing delays Unanticipated increased demand     Manufacturing delays ;n/a Increased demand / manufacturing delays Unanticipated increased demand     Manufacturing delays ,,,,,,,,,,,,,
SanofiAventis,desmopressin,1,9/23/10,4/22/11,demand increase; manufacturing delays,blue,,Increased demand/manufacturing delays Unanticipated increased demand   Manufacturing delays      ;n/a Increased demand/manufacturing delays Unanticipated increased demand   Manufacturing delays      ;n/a Increased demand / manufacturing delays Unanticipated increased demand     Manufacturing delays ;n/a Increased demand / manufacturing delays Unanticipated increased demand     Manufacturing delays ,,,,,,,,,,,,,
Teva,desmopressin,1,9/23/10,4/22/11,demand increase; manufacturing delays,blue,,Increased demand/manufacturing delays Unanticipated increased demand   Manufacturing delays      ;n/a Increased demand/manufacturing delays Unanticipated increased demand   Manufacturing delays      ;n/a Increased demand / manufacturing delays Unanticipated increased demand     Manufacturing delays ;n/a Increased demand / manufacturing delays Unanticipated increased demand     Manufacturing delays ,,,,,,,,,,,,,
Ferring,desmopressin,1,4/28/11,3/1/13,manufacturing delays; available,blue,,"Ferring is continuing to release product as soon as it becomes available.;Product 4 mcg/mL; 1 mL amp (NDC 0409-2265-01):  next delivery March. Please check with your wholesaler for available inventory.;Limited inventory of the 10 mL vial available (NDC 55566-5040-01) Ferring currently has no inventory of the 1 ml ampules (NDC 0409-2265-01) The firm anticipates additional limited inventory of the ampules and vials in March 2012.;Limited inventory of the 10 mL vial available (NDC 55566-5040-01) 
 Ferring currently has no inventory of the 1 ml ampules (NDC 0409-2265-01) 
 
 The firm anticipates additional limited inventory of the ampules and vials in March 2012.;Ferring currently has no inventory of the 10 mL vial available (NDC 55566-5040-01) Ferring currently has no inventory of the 1 mL ampoules (NDC 0409-2265-01) The firm anticipates additional limited inventory of the ampoules in March 2012.  The firm anticipates additional limited inventory of the 10 mL vials in May 2012.;Manufacturing delay Ferring currently has no inventory of the 10 mL vial available (NDC 55566-5040-01) Ferring currently has no inventory of the 1 mL ampoules (NDC 0409-2265-01) The firm anticipates additional limited inventory of the ampoules in March 2012.  The firm anticipates additional limited inventory of the 10 mL vials in May 2012.;;4 mcg/mL 1ml vials (NDC 55566-5030-01) Available Shortage per Manufacturer:  Available;4mcg/mL 10ml (NDC 55566-5040-01) Available Shortage per Manufacturer:  Available;4 mcg/mL 1ml vials (NDC 55566-5030-01) Available Shortage per Manufacturer:  
 Available;4mcg/mL 10ml (NDC 55566-5040-01) Available Shortage per Manufacturer:  
 Available",,,,,,,,,,,,,
Teva,desmopressin,1,4/28/11,3/1/13,manufacturing delays; available; material shortage; manufacturing practices requirements,yellow,,Teva has available desmopressin 4 mcg/mL 1 mL (NDC 00703-5051-03) and 10 mL (NDC 00703-5054-01) vials and is reviewing orders prior to release.;Teva has all Desmopressin Injection on back order.  The company estimates availability of product again in Q412.;Manufacturing delays Teva has all Desmopressin Injection on back order.  The company estimates availability of product again in Q412.;Teva has all presentation on back order and the company cannot estimate a release date.;;4mcg/mL- 4mcg (NDC 00703-5051-03)   All presentation on back order and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delays;4mcg/mL- 40 mcg (NDC 00703-5054-01) All presentation on back order and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delays;4mcg/mL- 4mcg (NDC 00703-5051-03)   All presentation on back order and the company cannot estimate a release date.;4mcg/mL- 40 mcg (NDC 00703-5054-01) All presentation on back order and the company cannot estimate a release date.,,,,,,,,,,,,,
Teva,desmopressin,2,6/5/13,3/2/14,method remediation; method remediation delays; ,yellow,,4MCG/ML 1X10ML (NDC00703-5054-01) Next delivery 2016;4MCG/ML 10X1ML (NDC00703-5051-03) Next delivery 2016;4mcg/mL;  1x10mL (NDC 00703-5054-01) Next delivery 2016   Method remediation and transfer;4 mcg/mL;  10x1mL (NDC 00703-5051-03) Next delivery 2016   Method remediation and transfer,,,,,,,,,,,,,
SanofiAventis,desmopressini,1,5/11/12,7/12/12,manufacturing issues; available,blue,,,,,,,,,,,,,,,
APP,dexamethasone,2,3/6/13,11/8/13,demand increase,orange,,10 mg/mL- single dose vial (NDC 63323-0506-01) 10 mg/mL- single dose vial (NDC 63323-0506-01) 10 mg/ml single dose vial Back-ordered.  Next release anticipated February 2013.;20 mg/5 mL single dose vial (NDC 63323-0165-05) 20 mg/5 mL single dose vial (NDC 63323-0165-05) Available.  Check wholesaler inventory;100 mg/10 mL multiple-dose vial (NDC 63323-0516-10)   100 mg/10 mL multiple-dose vial (NDC 63323-0516-10)   100 mg/10 mL multiple-dose vial Backordered.  Next release expected mid-late April 2013;4 mg/mL- 1 mL single dose vial (NDC 63323-0165-01)   4 mg/mL- 1 mL single dose vial (NDC 63323-0165-01)   Available.  Check wholesaler inventory;10 mg/mL- single dose vial (NDC 63323-0506-01) 10 mg/mL- single dose vial (NDC 63323-0506-01) 100 mg/10 mL multiple-dose vial Backordered.  Next release expected mid-late April 2013;120 mg/30 mL multiple dose vial (NDC 63323-0165-30) 120 mg/30 mL multiple dose vial (NDC 63323-0165-30) Back-ordered.  Next release anticipated March 2013. Check wholesalers for inventory.;10 mg/mL- single dose vial (NDC 63323-0506-01) 10 mg/mL- single dose vial (NDC 63323-0506-01) 10 mg/ml single dose vial back-ordered.  Next release anticipated May 2013.;100 mg/10 mL multiple-dose vial (NDC 63323-0516-10)   100 mg/10 mL multiple-dose vial (NDC 63323-0516-10)   100 mg/10 mL multiple-dose vial Backordered.  Next release expected May 2013;120 mg/30 mL multiple dose vial (NDC 63323-0165-30) 120 mg/30 mL multiple dose vial (NDC 63323-0165-30) Back-ordered.  Next release anticipated May 2013. Check wholesalers for inventory.;10 mg/mL- single dose vial (NDC 63323-0506-01) 10 mg/mL- single dose vial (NDC 63323-0506-01) 100 mg/10 mL multiple-dose vial Backordered.  Next release expected May 2013;10 mg/mL- single dose vial (NDC 63323-0506-01) 10 mg/mL- single dose vial (NDC 63323-0506-01) 100 mg/10 mL multiple-dose vial Backordered.  Next release expected June 2013;10 mg/mL- single dose vial (NDC 63323-0506-01) 10 mg/mL- single dose vial (NDC 63323-0506-01) 10 mg/ml single dose vial back-ordered.  Next release anticipated June 2013.;100 mg/10 mL multiple-dose vial (NDC 63323-0516-10)   100 mg/10 mL multiple-dose vial (NDC 63323-0516-10)   100 mg/10 mL multiple-dose vial Backordered.  Next release expected June 2013;120 mg/30 mL multiple dose vial (NDC 63323-0165-30) 120 mg/30 mL multiple dose vial (NDC 63323-0165-30) Available.  Check wholesaler inventory;100 mg/10 mL multiple-dose vial (NDC 63323-0516-10)   100 mg/10 mL multiple-dose vial (NDC 63323-0516-10)   100 mg/10 mL multiple-dose vial Backordered.  Next release expected July 2013;10 mg/mL- single dose vial (NDC 63323-0506-01) 10 mg/mL- single dose vial (NDC 63323-0506-01) 100 mg/10 mL multiple-dose vial Backordered.  Next release expected July 2013;10 mg/mL- single dose vial (NDC 63323-0506-01) 10 mg/mL- single dose vial (NDC 63323-0506-01) 10 mg/ml single dose vial back-ordered.  Next release anticipated July 2013.;10 mg/mL- single dose vial (NDC 63323-0506-01) 10 mg/mL- single dose vial (NDC 63323-0506-01) Available.  Check wholesalers for inventory.;100 mg/10 mL multiple-dose vial (NDC 63323-0516-10)   100 mg/10 mL multiple-dose vial (NDC 63323-0516-10)   Available.  Check wholesalers for inventory.,,,,,,,,,,,,,
Fresenius,dexamethasone,1,12/28/13,3/25/14,demand increase,orange,,10 mg/mL- single dose vial (NDC 63323-0506-01)  10 mg/mL- single dose vial (NDC 63323-0506-01)  Available.  Check wholesalers for inventory.;100 mg/10 mL multiple-dose vial (NDC 63323-0516-10)  100 mg/10 mL multiple-dose vial (NDC 63323-0516-10)  Available.  Check wholesalers for inventory.;4 mg/mL- 1 mL single dose vial (NDC 63323-0165-01)   4 mg/mL- 1 mL single dose vial (NDC 63323-0165-01)   Currently allocated for direct orders. Next release anticipated December 2013.;20 mg/5 mL single dose vial (NDC 63323-0165-05) 20 mg/5 mL single dose vial (NDC 63323-0165-05) Backordered.  Next release anticipated December 2013.;120 mg/30 mL multiple dose vial (NDC 63323-0165-30) 120 mg/30 mL multiple dose vial (NDC 63323-0165-30) Backordered.  Next release anticipated January 2014.;20 mg/5 mL single dose vial (NDC 63323-0165-05) 20 mg/5 mL single dose vial (NDC 63323-0165-05) Currently allocated for direct orders. Next release anticipated February 2014.;10 mg/mL- single dose vial (NDC 63323-0506-01)  10 mg/mL- single dose vial (NDC 63323-0506-01)  Currently backordered. Next release anticipated February 2014.;4 mg/mL- 1 mL single dose vial (NDC 63323-0165-01)   4 mg/mL- 1 mL single dose vial (NDC 63323-0165-01)   Currently allocated for direct orders. Next release anticipated February 2014.;120 mg/30 mL multiple dose vial (NDC 63323-0165-30) 120 mg/30 mL multiple dose vial (NDC 63323-0165-30) Backordered.  Next release anticipated February 2014.;10 mg/mL- single dose vial (NDC 63323-0506-01)  10 mg/mL- single dose vial (NDC 63323-0506-01)  Currently backordered. Next release anticipated March 2014.;4 mg/mL- 1 mL single dose vial (NDC 63323-0165-01)   4 mg/mL- 1 mL single dose vial (NDC 63323-0165-01)   Currently allocated for direct orders. Next release anticipated March 2014.;120 mg/30 mL multiple dose vial (NDC 63323-0165-30) 120 mg/30 mL multiple dose vial (NDC 63323-0165-30) Backordered.  Next release anticipated March 2014.;20 mg/5 mL single dose vial (NDC 63323-0165-05) 20 mg/5 mL single dose vial (NDC 63323-0165-05) Currently allocated for direct orders. Next release anticipated March 2014.;10 mg/mL- single dose vial (NDC 63323-0506-01)  10 mg/mL- single dose vial (NDC 63323-0506-01)  Currently backordered. Next release anticipated April 2014.;100 mg/10 mL multiple-dose vial (NDC 63323-0516-10)  100 mg/10 mL multiple-dose vial (NDC 63323-0516-10)  Currently backordered. Next release anticipated April 2014.,,,,,,,,,,,,,
WestWard,dexamethasone,1,7/16/11,3/16/12,demand increase,orange,,West-Ward is currently experiencing a backorder situation on the 10 mg/mL- 1 mL vial  (NDC 0641-0367-25). West-Ward has accelerated production and will have product available by the middle of July.  Additional lots are scheduled to be released by the end of August.;West-Ward is currently experiencing a backorder situation on the 1 mL vial (NDC 0641-0367-25).  West-Ward has accelerated production and will have product available in the middle to end of February 2012.;West-Ward has accelerated production on this code and has inventory available.,,,,,,,,,,,,,
WestWard,dexamethasone,2,3/6/13,3/25/14,demand increase,orange,,Dexamethasone Sodium Phosphate Injection- USP 1 mL vial- 10 mg/mL (NDC 0641-0367-25)   Dexamethasone Sodium Phosphate Injection- USP 1 mL vial- 10 mg/mL (NDC 0641-0367-25)   West-Ward currently has limited quantities available. West-Ward has continued to accelerate production on this product.;Dexamethasone Sodium Phosphate Injection- USP 1 mL vial- 10 mg/mL (NDC 0641-0367-25)   Dexamethasone Sodium Phosphate Injection- USP 1 mL vial- 10 mg/mL (NDC 0641-0367-25)   West-Ward currently has limited quantities available.   West-Ward has continued to accelerate production on this product.;Dexamethasone Sodium Phosphate Injection- USP 1 mL vial- 10 mg/mL (NDC 0641-0367-25)   Dexamethasone Sodium Phosphate Injection- USP 1 mL vial- 10 mg/mL (NDC 0641-0367-25)   West-Ward currently has quantities available.   West-Ward has continued to accelerate production on this product.;1 mL vial- 10 mg/mL (NDC 0641-0367-25)   1 mL vial- 10 mg/mL (NDC 0641-0367-25)   West-Ward currently has sufficient quantities available.,,,,,,,,,,,,,
APP,dexamethasone,1,4/28/11,3/16/12,demand increase,orange,,"All 4mg/mL Dexamethasone codes are currently on allocation due to increase demand: 4mg/mL-1mL (NDC 63323-165-01)- 4mg/mL-5mL (NDC 63323-165-05)- 4mg/mL-30mL (NDC 63323-165-30). The 10mg/mL-1mL ( NDC 63323-506-01) and 10mg/mL-10mL (NDC 63323-516-10) presentations are currently available. APP is continuing to release the product as it becomes available.;All 4mg/mL Dexamethasone codes are currently on allocation due to increase demand: 
 4mg/mL-1mL (NDC 63323-165-01)- 4mg/mL-5mL (NDC 63323-165-05)- 4mg/mL-30mL (NDC 63323-165-30). 
 
 The 10mg/mL-1mL ( NDC 63323-506-01) and 10mg/mL-10mL (NDC 63323-516-10) presentations are currently available. 
 
 APP is continuing to release the product as it becomes available.;APP has all presentations on intermittent back-order and is releasing product as it becomes available. The next estimated release date for all presentations is late-May 2011.;APP has all dexamethasone 4mg/mL and 10mg/mL presentations on intermittent back order and the company is releasing the product as it becomes available.  APP will have releases throughout June- July- and August to respond to the increased demand..;APP has Dexamethasone Sodium Phosphate Injection- 4 mg/mL- 1 mL SDV (NDC 63323-165-01)- 4 mg/mL- 5 mL SDV (NDC 63323-165-05)- 4 mg/mL- 30 mL MDV (NDC 63323-165-30)- 10 mg/mL- 1 mL SDV (NDC 63323-506-01)-  10 mg/mL- 10 mL MDV (NDC 63323-516-10) presentations available.",,,,,,,,,,,,,
AmericanRegent,dexamethasone,1,3/31/11,4/22/11,manufacturing delays,blue,,Manufacturing issues Increase in demand  ;Manufacturing issues Increase in demand;Manufacturing issues Increase in demand,,,,,,,,,,,,,
APP,dexamethasone,1,3/31/11,4/22/11,manufacturing delays,blue,,Manufacturing issues Increase in demand  ;Manufacturing issues Increase in demand;Manufacturing issues Increase in demand,,,,,,,,,,,,,
AmericanRegent,dexamethasone,2,3/6/13,3/25/14,not manufacturing,,,30 mL multiple dose vial (NDC 00517-4930-25)  30 mL multiple dose vial (NDC 00517-4930-25)  Unavailable;5 mL multiple dose vial (NDC 00517-4905-25)   5 mL multiple dose vial (NDC 00517-4905-25)   Unavailable;Dexamethasone Sodium Phosphate Injection- USP Dexamethasone Sodium Phosphate Injection- USP Unavailable;4 mg/mL 1 mL single dose vial (NDC 00517-4901-25)   4 mg/mL 1 mL single dose vial (NDC 00517-4901-25)   Unavailable;4 mg/mL -1 mL single dose vial (NDC 00517-4901-25)   4 mg/mL -1 mL single dose vial (NDC 00517-4901-25)   Unavailable;4 mg/mL -30 mL multiple dose vial (NDC 00517-4930-25)  4 mg/mL -30 mL multiple dose vial (NDC 00517-4930-25)  Unavailable;4 mg/mL -5 mL multiple dose vial (NDC 00517-4905-25)   4 mg/mL -5 mL multiple dose vial (NDC 00517-4905-25)   Unavailable;4 mg/mL -30 mL multiple dose vial (NDC 00517-4930-25)  4 mg/mL -30 mL multiple dose vial (NDC 00517-4930-25)  Unavailable  - No product available for release. No plan to manufacture.;4 mg/mL -1 mL single dose vial (NDC 00517-4901-25)   4 mg/mL -1 mL single dose vial (NDC 00517-4901-25)   Unavailable  - No product available for release. No plan to manufacture.;4 mg/mL -5 mL multiple dose vial (NDC 00517-4905-25)   4 mg/mL -5 mL multiple dose vial (NDC 00517-4905-25)   Unavailable  - No product available for release. No plan to manufacture.,,,,,,,,,,,,,
AmericanRegent,dexamethasone,1,4/28/11,3/16/12,product recall,yellow,,American Regent has recalled a number of their dexamethasone 4 mg/mL presentations due to the presence of particulate matter. The firm has placed their product on hold with no estimated release date.,,,,,,,,,,,,,
Teva,dexmethylphenidate,1,2/14/14,3/25/14,material shortage,green,,10mg Tablet; 100 count bottle (NDC 0093-5277-01)     Product is currently on backorder and will last through end of Q2 2014;5mg Tablet; 100 count bottle (NDC 0093-5276-01)    Product is currently on backorder with intermittent supply expected.  Backorder will last through Q4 2014;2.5mg Tablet; 100 count bottle (NDC 0093-5275-01)   Product is currently on backorder with intermittent supply expected.  Backorder will last through end of Q2 2014;40 mg ER Capsule; 100 count bottle (NDC 00093-5562-01)  Capsules are currently on backorder and supply is expected in March 2014.,,,,,,,,,,,,,
Bedford,dexrazoxane,1,8/19/13,11/8/13,capacity constraints,blue,,250mg Inj Lyo w/Dil SDV 30 mL (NDC 5539001402)  Unavailable  Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;500mg Inj Lyo w/Dil SDV 50 mL (NDC 5539006002) Unavailable  Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.,,,,,,,,,,,,,
BenVenue,dexrazoxane,1,6/6/09,10/24/09,manufacturing delays,blue,,Manufacturing delays;Manufacturing delays     Zinecard now available from Pfizer,,,,,,,,,,,,,
Biocodex,dexrazoxane,1,8/19/13,11/8/13,manufacturing delays,blue,,Totect 500 mg (dexrazoxane) for injection (NDC 38423-110-01)   Biocodex- new owner of Totect Kits- is working with the US Food and Drug Administration (FDA) to increase the availability of Totect Kits.  Effective February 12- 2013- the FDA has approved the extension of the expiration date to 36 months for Totect Kits (formally owned by Apricus/Topotarget USA) with following batch number: Batch 2262383/W005755/013 expiration date extended from July 2013 to July 2014  (Dear Healthcare Customer Letter 013 PDF ? 1MB) The company cannot estimate a release for additional Totect Kits at this time. Shortage per Manufacturer: Manufacturing Delays,,,,,,,,,,,,,
PfizerZinecard,dexrazoxane,1,6/6/09,10/24/09,manufacturing delays,blue,,Manufacturing delays;Manufacturing delays     Zinecard now available from Pfizer,,,,,,,,,,,,,
Topotarget,dexrazoxane,1,2/2/12,8/15/13,manufacturing delays,blue,,"Limited supplies available at Cardinal- McKesson Specialty and Morris & Dickson each have 2 kits a piece (total 6 kits). Please check with these wholesalers directly for available inventory. Out of stock at ICS- ASD Healthcare- Oncology Supply and US Oncology. Topotarget USA- Inc. has product on back order and the company cannot estimate a release;Limited supplies available at Cardinal- McKesson Specialty and Morris & Dickson each have 2 kits a piece (total 6 kits). Please check with these wholesalers directly for available inventory. Out of stock at ICS- ASD Healthcare- Oncology Supply and US Oncology.
 
 
 Topotarget USA- Inc. has product on back order and the company cannot estimate a release;Manufacturing Delays Limited supplies available at Cardinal- McKesson Specialty and Morris & Dickson each have 2 kits a piece (total 6 kits). Please check with these wholesalers directly for available inventory. Out of stock at ICS- ASD Healthcare- Oncology Supply and US Oncology. Topotarget USA- Inc. has product on back order and the company cannot estimate a release;Topotarget USA has worked with the US Food and Drug Administration (FDA) to increase the availability of Totect Kits.  Effective February 6- 2012- the FDA has approved the extension of the expiration date to 36 months for Totect Kits with following batch numbers: Batch 1914008/W005755/008 expired Nov 2011  (Dear Healthcare Customer Letter 008 PDF - 78KB) Batch 1925943/W005755/009 expired Dec 2011  (Dear Healthcare Customer Letter 009 PDF - 75KB)  Batch 1979183/W005755/010 expired Mar 2012   (Dear Healthcare Customer Letter 010 PDF - 75KB) Batch 1985218/W005755/011 expired Mar 2012   (Dear Healthcare Customer Letter 011 PDF - 75KB)  Topotarget USA- Inc. has recently released additional 129 kits to help fill the back order for this product. The company cannot estimate a release for additional Totect Kits at this time.;;Totect 500 mg (dexrazoxane) for injection (NDC 38423-110-01)   Topotarget USA has worked with the US Food and Drug Administration (FDA) to increase the availability of Totect Kits.  Effective February 6- 2012- the FDA has approved the extension of the expiration date to 36 months for Totect Kits with following batch numbers: Batch 1914008/W005755/008 expired Nov 2011  (Dear Healthcare Customer Letter 008 PDF - 78KB) Batch 1925943/W005755/009 expired Dec 2011  (Dear Healthcare Customer Letter 009 PDF - 75KB)  Batch 1979183/W005755/010 expired Mar 2012   (Dear Healthcare Customer Letter 010 PDF - 75KB) Batch 1985218/W005755/011 expired Mar 2012   (Dear Healthcare Customer Letter 011 PDF - 75KB)  Topotarget USA- Inc. has recently released additional 129 kits to help fill the back order for this product. The company cannot estimate a release for additional Totect Kits at this time. Shortage per Manufacturer: Manufacturing Delays;Totect 500 mg (dexrazoxane) for injection 
 (NDC 38423-110-01)   Topotarget USA has worked with the US Food and Drug Administration (FDA) to increase the availability of Totect Kits.  Effective February 6- 2012- the FDA has approved the extension of the expiration date to 36 months for Totect Kits with following batch numbers:
 Batch 1914008/W005755/008 expired Nov 2011  (Dear Healthcare Customer Letter 008 PDF - 78KB)
 Batch 1925943/W005755/009 expired Dec 2011  (Dear Healthcare Customer Letter 009 PDF - 75KB) 
 Batch 1979183/W005755/010 expired Mar 2012   (Dear Healthcare Customer Letter 010 PDF - 75KB)
 Batch 1985218/W005755/011 expired Mar 2012   (Dear Healthcare Customer Letter 011 PDF - 75KB)  
 Topotarget USA- Inc. has recently released additional 129 kits to help fill the back order for this product. The company cannot estimate a release for additional Totect Kits at this time.
 Shortage per Manufacturer: 
 Manufacturing Delays",,,,,,,,,,,,,
Teva,dextroamphetamine,1,1/12/12,3/1/13,manufacturing delays; shipping delays,blue,,Teva has dextroamphetamine 5 mg and 10 mg- 100 count tablets- will be on intermittent back order through mid-2012. Product will be released as it becomes available.;Manufacturing delays Teva has dextroamphetamine 5 mg and 10 mg- 100 count tablets- will be on intermittent back order through mid-2012. Product will be released as it becomes available.;;5 mg tablets- 100 count (NDC 00555-0952-02) Available. As of August 17- low inventory levels- however- no backorder or future projections of backorder. Improved inventory position expected by Q412.   Shortage per Manufacturer: Manufacturing delays;10 mg tablets- 100 count (NDC 00555-0953-02) Available. Inventory will remain low until 4Q12. As of August 17- low inventory levels- however- no backorder or future projections of backorder. Improved inventory position expected by Q412.   Shortage per Manufacturer: Manufacturing delays;10 mg tablets- 100 count (NDC 00555-0953-02) Low inventory- possible backorders through October.;5 mg tablets- 100 count (NDC 00555-0952-02) Teva supply is adequate to meet demand.;10 mg tablets- 100 count (NDC 00555-0953-02) Low inventory- possible backorders through November.;10 mg tablets- 100 count (NDC 00555-0953-02) Teva supply is adequate to meet demand.,,,,,,,,,,,,,
Amphastar,dextrose,1,8/7/10,8/15/10,demand increase,orange,,Unanticipated Increased Demand,,,,,,,,,,,,,
Amphastar,dextrose,2,9/14/10,12/19/10,demand increase,orange,,Unanticipated Increased Demand,,,,,,,,,,,,,
Hospira,dextrose,1,7/9/10,8/15/10,demand increase,orange,,Unanticipated Increased Demand,,,,,,,,,,,,,
Hospira,dextrose,2,9/14/10,12/19/10,demand increase,orange,,Unanticipated Increased Demand,,,,,,,,,,,,,
Amphastar,dextrose,1,6/13/12,3/25/14,demand increase; available,orange,,";50%- 50mL Luer-Jet Prefilled Syringe   NDC 76329-3301-1(old NDC 0548-3301-00) Amphastar will regularly release products Amphastar is  experiencing a product shortage due to an increase in product demand caused by market supply issues.   Shortage per Manufacturer: Increased Demand;50%- 50mL Luer-Jet Prefilled Syringe
  
 NDC 76329-3301-1
 (old NDC 0548-3301-00) Amphastar will regularly release products Amphastar is  experiencing a product shortage due to an increase in product demand caused by market supply issues.
  
 Shortage per Manufacturer: 
 Increased Demand;50%- 50mL Luer-Jet Prefilled Syringe   NDC 76329-3301-1(old NDC 0548-3301-00) Amphastar will regularly release products Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues.;50%- 50mL Luer-Jet Prefilled Syringe   NDC 76329-3301-1(old NDC 0548-3301-00) Available",,,,,,,,,,,,,
Covis,digoxin,2,9/1/12,10/20/12,available,,,Lanoxin Injection- USP 250 mcg/mL- 2 mL (10s - NDC 00173-0260-10) Available No longer on limited supply. Shortage per Manufacturer: Available;Lanoxin Injection- USP 250 mcg/mL- 2 mL (50s - NDC 00173-0260-35) Covis Pharma S.à.r.l has discontinued manufacturing Lanoxin Injection- USP 250 mcg/mL- 2 mL (50s - NDC 00173-0260-35). No longer on limited supply. Shortage per Manufacturer: Available,,,,,,,,,,,,,
Baxter,digoxin,1,4/28/11,6/22/11,demand increase,orange,,Baxter is currently experiencing a back order situation on the 2 mL ampuls (NDC 0641-1410-35). Baxter has accelerated production and will have product available by the end of April.,,,,,,,,,,,,,
WestWard,digoxin,1,6/30/11,10/20/12,demand increase; available; ,orange,,"West-Ward is currently experiencing a back order situation on the 2 mL ampuls (NDC 0641-1410-35) due to unforeseen demand driven by competitors' supply issues.  West-Ward has accelerated production and will have product available by the end of July ? beginning of August.;West-Ward currently has limited availability of the 2 mL ampul. Production has been accelerated and additional units are expected to be released by the end of February 2012. Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on the 2 mL ampul.
  
 Production has been accelerated and several additional lots are scheduled to be released by the end of March 2012.
  
 Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on the 2 mL ampul.   Production has been accelerated and several additional lots are scheduled to be released by the end of March 2012.   Product will be made available as it is released.;Increase in product demand West-Ward is currently experiencing a backorder situation on the 2 mL ampul.   Production has been accelerated and several additional lots are scheduled to be released by the end of March 2012.   Product will be made available as it is released.;;250 mcg/mL- 2 mL ampuls (NDC 0641-1410-35) West-Ward currently has available inventory. Production has been accelerated and additional lots are scheduled to be released in August 2012. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand",,,,,,,,,,,,,
GlaxoSmithKline,digoxin,1,4/28/11,3/1/12,discontinued; manufacturing delays,blue,,"Pediatric presentation 100 mcg/mL- 1 mL (10s - NDC 00173-0262-10) and 250 mcg/mL- 2 mL (10s - NDC 00173-0260-10) are available.;GSK has discontinued the manufacturing Lanoxin Injection- USP 250 mcg/mL- 2 mL (50s - NDC 00173-0260-35) 250 mcg/mL- 2 mL (10s - NDC 00173-0260-10) is currently on back-order and should be available January 2012.;GSK has discontinued the manufacturing Lanoxin Injection- USP 250 mcg/mL- 2 mL (50s - NDC 00173-0260-35) 
 
 250 mcg/mL- 2 mL (10s - NDC 00173-0260-10) is currently on back-order and should be available January 2012.",,,,,,,,,,,,,
Covis,digoxin,1,3/16/12,4/26/12,manufacturing delays,blue,,"Lanoxin Injection 250 mcg/mL- 2 mL (10s - NDC 00173-0260-10) is currently available in limited quantities through March 2012 with full availability expected in April 2012.
  
 Covis Pharma S.à.r.l has discontinued manufacturing Lanoxin Injection- USP 250 mcg/mL- 2 mL (50s - NDC 00173-0260-35).;Manufacturing delays Lanoxin Injection 250 mcg/mL- 2 mL (10s - NDC 00173-0260-10) is currently available in limited quantities through March 2012 with full availability expected in April 2012.   Covis Pharma S.à.r.l has discontinued manufacturing Lanoxin Injection- USP 250 mcg/mL- 2 mL (50s - NDC 00173-0260-35).;Lanoxin Injection 250 mcg/mL- 2 mL (10s - NDC 00173-0260-10) is currently available in limited quantities through March 2012 with full availability expected in April 2012.   Covis Pharma S.à.r.l has discontinued manufacturing Lanoxin Injection- USP 250 mcg/mL- 2 mL (50s - NDC 00173-0260-35).",,,,,,,,,,,,,
CorePharma,digoxin,1,4/29/12,8/4/12,manufacturing delays; discontinued; available,black,,,,,,,,,,,,,,,
Akorn,diltiazem,1,12/8/11,7/12/12,available,,,Akorn has product available.;N/A All SKUs available by end of month. Increased production available- contingent on market demand.;All SKUs available by end of month. Increased production available- contingent on market demand.;,,,,,,,,,,,,,
Baxter,diltiazem,1,4/22/11,4/22/11,demand increase,orange,,Demand increase,,,,,,,,,,,,,
Baxter,diltiazem,1,4/28/11,12/16/11,demand increase,orange,,"Baxter is experiencing a back order situation on all codes and estimates the following product availability: 5 mL vial (NDC 10019-510-01) Additional product releases expected later this month and at the end of May. 10 mL vial (NDC 10019-510-02) - Product will be available end of May 25 mL vial (NDC 10019-510-04) - Product releases expected by mid April and end of May. Product will be made available as it is released.;Baxter is experiencing a back order situation on all codes and estimates the following product availability: 
 
 5 mL vial (NDC 10019-510-01) Additional product releases expected later this month and at the end of May. 
 
 10 mL vial (NDC 10019-510-02) - Product will be available end of May 
 
 25 mL vial (NDC 10019-510-04) - Product releases expected by mid April and end of May. 
 
 Product will be made available as it is released.",,,,,,,,,,,,,
Hospira,diltiazem,1,4/22/11,4/22/11,demand increase,orange,,Demand increase,,,,,,,,,,,,,
WestWard,diltiazem,1,12/22/11,7/12/12,demand increase,orange,,"West-Ward is experiencing a back order situation on all codes and estimates the following product availability: 5 mL vial (NDC 10019-510-01) Additional product releases expected later this month and at the end of May. 10 mL vial (NDC 10019-510-02) - Product will be available end of May 25 mL vial (NDC 10019-510-04) - Product releases expected by mid April and end of May. Product will be made available as it is released.;West-Ward is experiencing a back order situation on all codes and estimates the following product availability: 
 
 5 mL vial (NDC 10019-510-01) Additional product releases expected later this month and at the end of May. 
 
 10 mL vial (NDC 10019-510-02) - Product will be available end of May 
 
 25 mL vial (NDC 10019-510-04) - Product releases expected by mid April and end of May. 
 
 Product will be made available as it is released.;Increase in product demand West-Ward is experiencing a back order situation on all codes and estimates the following product availability: 5 mL vial (NDC 10019-510-01) Additional product releases expected later this month and at the end of May. 10 mL vial (NDC 10019-510-02) - Product will be available end of May 25 mL vial (NDC 10019-510-04) - Product releases expected by mid April and end of May. Product will be made available as it is released.;",,,,,,,,,,,,,
Bedford,diltiazem,1,4/28/11,7/12/12,manufacturing delays,blue,,Bedford has all diltiazem injection on back order and the company estimates a release date early-April- 2011.;Bedford anticipates release of all presentations in the next 3 months.;Bedford has available 50 mg/10 mL (NDC 55390-0565-10). Limited allocated quanties of 125 mg/25 mL (NDC 55390-0565-30)- contact your local Bedford Account Executives.  All other 5 mg/mL injectable products are on back order and the company cannot estimate a release date.;Bedford has available 50 mg/10 mL (NDC 55390-0565-10). Short supply available of 125 mg/25 mL (NDC 55390-0565-30) contact your local Bedford Account Executive.  All other 5 mg/mL injectable products are on back order and the company cannot estimate a release date.;Bedford has all diltiazem presentations  on back order and the company cannot estimate a release date.;Bedford Laboratories has 50mg Inj 10ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown.  The 25mg Inj 5ml vials  are out of stock and the 125mg Inj 25ml vial is pending release with  release date yet to be determined.  Availability of products is updated on the Bedford  Laboratories website.;Manufacturing delays Bedford Laboratories has 50mg Inj 10ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown.  The 25mg Inj 5ml vials  are out of stock and the 125mg Inj 25ml vial is pending release with  release date yet to be determined.  Availability of products is updated on the Bedford  Laboratories website.;,,,,,,,,,,,,,
APP,diphenhydramine,1,11/30/11,7/12/12,demand increase,orange,,APP has increased production in an effort to meet market demand by January.;APP is releasing product as it becomes available. Please check wholesalers for inventory.;APP 50 mg/ml- 1 ml (NDC 63323-0664-01) is available.  Please check wholesalers for inventory.;APP has Diphenhydramine available. Please check wholesalers for inventory.;Increased in demand APP has Diphenhydramine available. Please check wholesalers for inventory.;,,,,,,,,,,,,,
WestWard,diphenhydramine,1,11/30/11,7/12/12,demand increase; available,orange,,"West-Ward is currently experiencing a backorder situation on the 50 mg/mL- 1 mL vial. West-Ward has accelerated production on this product and is projecting to have several lots available by the middle of December 2011. Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on the 50 mg/mL- 1 mL vial.
 West-Ward has accelerated production on this product and is projecting to have several lots available by the middle of December 2011.
 Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on the 50 mg/mL- 1 mL vial. West-Ward has accelerated production on this product and is projecting availability in the middle to end of February 2012. Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on the 50 mg/mL- 1 mL vial. 
 West-Ward has accelerated production on this product and is projecting availability in the middle to end of February 2012. 
 Product will be made available as it is released.;West-Ward currently has inventory available for the 50 mg/mL- 1 mL vial. West-Ward has accelerated production on this product.  Additional units will also be available in the May ? June 2012 timeframe.   Product will be made available as it is released.;Increased demand West-Ward currently has inventory available for the 50 mg/mL- 1 mL vial. West-Ward has accelerated production on this product.  Additional units will also be available in the May ? June 2012 timeframe.   Product will be made available as it is released.;",,,,,,,,,,,,,
WestWard,dipyridamole,1,8/4/12,2/14/14,; demand increase,orange,,";Dipyridamole Injection- USP (Formerly a Baxter Product) 5 mg/mL; 10 mL vial (NDC 0641-2569-44) West-Ward is currently experiencing a backorder situation. West-Ward has increased production and is anticipating having product available in the middle of August 2012. Additional lots are projected to be available by the end of September 2012. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;Dipyridamole Injection- USP 
 (Formerly a Baxter Product)
 5 mg/mL; 10 mL vial 
 (NDC 0641-2569-44) West-Ward is currently experiencing a backorder situation. 
 West-Ward has increased production and is anticipating having product available in the middle of August 2012. 
 Additional lots are projected to be available by the end of September 2012. 
 Product will be made available as it is released. Shortage per Manufacturer: 
 Increase in product demand due to market supply issues.;Dipyridamole Injection- USP (Formerly a Baxter Product) 5 mg/mL; 10 mL vial (NDC 0641-2569-44) West-Ward is currently experiencing a backorder situation.   West-Ward has increased production and is anticipating having product available by the end of January 2013. Additional lots are projected to be available in February 2013.   Product will be made available as it is released.   Shortage per Manufacturer: Increase in product demand due to market supply issues. West-Ward has accelerated production on this product.;Dipyridamole Injection- USP   5 mg/mL; 10 mL vial (NDC 0641-2569-44) West-Ward has limited quantities available.    West-Ward has accelerated production on this product.   West-Ward has increased production and is anticipating having product available by the end of August 2013.   Product will be made available as it is released.;Dipyridamole Injection- USP   5 mg/mL; 10 mL vial (NDC 0641-2569-44) West-Ward currently has inventory available.    West-Ward has accelerated production on this product.   West-Ward has increased production.   Product will be made available as it is released.;5 mg/mL; 10 mL vial (NDC 0641-2569-44) West-Ward currently has sufficient inventory available.     West-Ward has accelerated production on this product.  West-Ward has accelerated production on this product.    Additional lots are scheduled to be manufactured in November 2013.   Product will be made available as it is released.;5 mg/mL; 10 mL vial (NDC 0641-2569-44) West-Ward currently has sufficient inventory available.   West-Ward has accelerated production on this product.    Additional lots are scheduled to be manufactured in February 2014.   Product will be made available as it is released.",,,,,,,,,,,,,
Bedford,dobutamine,1,8/19/13,3/25/14,capacity constraints,blue,,12.5 mg base/mL; 20 mL vial (NDC 55390-0560-90) Unavailable Shortage per Manufacturer: Capacity constraint Availability of products is updated on the Bedford Laboratories website.;12.5 mg base/mL; 20 mL vial (NDC 55390-0560-90) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website,,,,,,,,,,,,,
Baxter,dobutamine,1,4/11/13,3/25/14,demand increase,orange,,Dobutamine Hydrochloride in 5% Dextrose Injection 500 mg/ 250 mL  (NDC 00338107502) Baxter continues to release product and anticipates supplies to recovery by June/July 2013.;Dobutamine Hydrochloride in 5% Dextrose Injection 1000 mg/250 mL (NDC 00338107702)   Baxter continues to release product and anticipates supplies to recovery by June/July 2013.;Dobutamine Hydrochloride in 5% Dextrose Injection 250 mg/250 mL (NDC 00338107302)   Baxter continues to release product and anticipates supplies to recovery by June/July 2013.;Dobutamine Hydrochloride in 5% Dextrose Injection 1000 mg/250 mL (NDC 00338107702)   Baxter continues to release product and anticipates supplies to recovery by September 2013.;Dobutamine Hydrochloride in 5% Dextrose Injection 500 mg/ 250 mL  (NDC 00338107502) Baxter continues to release product and anticipates supplies to recovery by September 2013.;Dobutamine Hydrochloride in 5% Dextrose Injection 250 mg/250 mL (NDC 00338107302)   Baxter continues to release product and anticipates supplies to recovery by September 2013.;Dobutamine Hydrochloride in 5% Dextrose Injection 500 mg/ 250 mL  (NDC 00338-1075-02) Available;Dobutamine Hydrochloride in 5% Dextrose Injection 1000 mg/250 mL (NDC 00338-1077-02)   Baxter continues to release product and anticipates supplies to recovery by September 2013.;Dobutamine Hydrochloride in 5% Dextrose Injection 250 mg/250 mL (NDC 00338-1073-02)   Available;Dobutamine Hydrochloride in 5% Dextrose Injection 1000 mg/250 mL (NDC 00338-1077-02)   Available;Dobutamine Hydrochloride in 5% Dextrose Injection 500 mg/ 250 mL  (NDC 00338-1075-02) Baxter is experiencing intermittent interruptions in supply.;Dobutamine Hydrochloride in 5% Dextrose Injection 500 mg/ 250 mL  (NDC 00338-1075-02) Baxter is experiencing intermittent interruptions in supply. Anticipates supplies to recover by April 2014.,,,,,,,,,,,,,
Bedford,doxorubicin,1,11/18/10,4/22/11,demand increase,orange,,Increased demand,,,,,,,,,,,,,
Bedford,doxorubicin,1,4/28/11,3/25/14,demand increase; manufacturing delays; capacity constraints; pending manufacturing change,blue,,"Bedford has available doxorubicin and lyophilized powder 10 mg vials (NDC 553900231-10) and is working to release the other presentations.;Bedford anticipates release of all presentations in the next 6-months.;Bedford has limited allocated quantities available of 10 mg (NDC 55390-0231-10)- 20 mg (NDC 55390-0232-10) and 50mg (NDC 55390-0233-01)- contact your local Bedford Account Executives.;Bedford has 10 mg (NDC 55390-0231-10)- 20 mg (NDC 55390-0232-10) and 50mg (NDC 55390-0233-01) on back order and the company cannot estimate a release date.;Bedford has limited allocated quantities available of 50 mg injection (NDC 55390-0237-01)and short supplies of 200 mg/100 mL (NDC 55390-0238-01) contact your local Bedford Account Executive.  All other presentations are on backorder and the company cannot estimate a release date.;Bedford has all doxorubicin lyophilized presentations on back order and the company cannot estimate a release date.;Bedford Laboratories has  10 mg available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Other presentations are pending release with release date yet to be determined. Availability of products is updated on the Bedford  Laboratories website.;Manufacturing delays Bedford Laboratories has  10 mg available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Other presentations are pending release with release date yet to be determined. Availability of products is updated on the Bedford  Laboratories website.;;10 mg vials (NDC 55390-0231-01) Bedford Laboratories has 10 mg available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are pending release with release date yet to be determined. Availability of products is updated on the Bedford Laboratories website. Shortage per Manufacturer: Manufacturing delays;20 mg vials (NDC 55390-0232-10) Bedford Laboratories has 10 mg available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are pending release with release date yet to be determined. Availability of products is updated on the Bedford Laboratories website. Shortage per Manufacturer: Manufacturing delays;50 mg vials (NDC 55390-0233-01) Bedford Laboratories has 10 mg available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are pending release with release date yet to be determined. Availability of products is updated on the Bedford Laboratories website. Shortage per Manufacturer: Manufacturing delays;20 mg vials (NDC 55390-0232-10) Bedford Laboratories has 10 mg available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are pending release with release date yet to be determined. Availability of products is updated on the Bedford Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;10 mg vials (NDC 55390-0231-01) Bedford Laboratories has 10 mg available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are pending release with release date yet to be determined. Availability of products is updated on the Bedford Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;50 mg vials (NDC 55390-0233-01) Bedford Laboratories has 10 mg available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are pending release with release date yet to be determined. Availability of products is updated on the Bedford Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;10 mg vials (NDC 55390-0231-01) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;50 mg vials (NDC 55390-0233-01) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;20 mg vials (NDC 55390-0232-10) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;10 mg vials (NDC 55390-0231-01) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.;50 mg vials (NDC 55390-0233-01) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.;20 mg vials (NDC 55390-0232-10) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.",,,,,,,,,,,,,
Sun,doxorubicinl,1,2/23/12,6/17/13,[temporary import]; available,brown,,"Sun Pharma Global FZE- and its authorized distributor- Caraco Pharmaceutical Laboratories Ltd- in conjunction with the FDA- are initiating a temporary importation of Lipodox (doxorubicin HCL liposomal for injection)- into the United States market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 65KB) for information about supplies that are now available to help address the current shortage;Sun Pharma Global FZE- and its authorized distributor- Caraco Pharmaceutical Laboratories Ltd- in conjunction with the FDA- are initiating a temporary importation of Lipodox (doxorubicin HCL liposomal for injection)- into the United States market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 65KB) for information about supplies that are now available to help address the current shortage.
  
 Frequently Asked Questions (FAQs) about Sun's Lipodox (doxorubicin HCL liposomal injection) (PDF - 20KB);Sun Pharma Global FZE- and its authorized distributor- Caraco Pharmaceutical Laboratories Ltd- in conjunction with the FDA- are initiating a temporary importation of Lipodox (doxorubicin HCL liposomal for injection)- into the United States market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 65KB) for information about supplies that are now available to help address the current shortage.   Frequently Asked Questions (FAQs) about Sun's Lipodox (doxorubicin HCL liposomal injection) (PDF - 20KB);;Lipodox (10 ml): NDC 47335-082-50 Available Sun Pharma Global FZE- and its authorized distributor- Caraco Pharmaceutical Laboratories Ltd- in conjunction with the FDA- are initiating a temporary importation of Lipodox (doxorubicin HCL liposomal for injection)- into the United States market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 65KB) for information about supplies that are now available to help address the current shortage.   Frequently Asked Questions (FAQs) about Sun's Lipodox (doxorubicin HCL liposomal injection) (PDF - 20KB);Lipodox 50 (25 ml): NDC 47335-083-50 Available Sun Pharma Global FZE- and its authorized distributor- Caraco Pharmaceutical Laboratories Ltd- in conjunction with the FDA- are initiating a temporary importation of Lipodox (doxorubicin HCL liposomal for injection)- into the United States market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 65KB) for information about supplies that are now available to help address the current shortage.   Frequently Asked Questions (FAQs) about Sun's Lipodox (doxorubicin HCL liposomal injection) (PDF - 20KB);Lipodox (10 ml): NDC 47335-082-50 Available Sun Pharma Global FZE- and its authorized distributor- Caraco Pharmaceutical Laboratories Ltd- in conjunction with the FDA- are initiating a temporary importation of Lipodox (doxorubicin HCL liposomal for injection)- into the United States market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 65KB) for information about supplies that are now available to help address the current shortage.
  
 Frequently Asked Questions (FAQs) about Sun's Lipodox (doxorubicin HCL liposomal injection) (PDF - 20KB);Lipodox 50 (25 ml): NDC 47335-083-50 Available Sun Pharma Global FZE- and its authorized distributor- Caraco Pharmaceutical Laboratories Ltd- in conjunction with the FDA- are initiating a temporary importation of Lipodox (doxorubicin HCL liposomal for injection)- into the United States market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 65KB) for information about supplies that are now available to help address the current shortage.
  
 Frequently Asked Questions (FAQs) about Sun's Lipodox (doxorubicin HCL liposomal injection) (PDF - 20KB);2 mg/ml; 25 mL vial (NDC 47335-050-40) Expected availability; first week of March;Lipodox (10 ml): NDC 47335-082-50     Available   Sun Pharma Global FZE- and its authorized distributor- Caraco Pharmaceutical Laboratories Ltd- in conjunction with the FDA- are initiating a temporary importation of Lipodox (doxorubicin HCL liposomal for injection)- into the United States market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 65KB) for information about supplies that are now available to help address the current shortage.   Frequently Asked Questions (FAQs) about Sun's Lipodox (doxorubicin HCL liposomal injection) (PDF - 20KB);2 mg/mL; 10 mL  vial (NDC 47335-049-40)   Expected availability; first week of March;2 mg/ml; 25 mL vial (NDC 47335-050-40) Available;2 mg/mL; 10 mL  vial (NDC 47335-049-40)   Available",,,,,,,,,,,,,
APP,doxorubicins,1,4/14/11,4/22/11,demand increase,orange,,Increased demand Manufacturing delays   Increased demand;Increased demand Manufacturing delays   Increased demand,,,,,,,,,,,,,
APP,doxorubicins,1,4/28/11,7/12/12,demand increase,orange,,APP is releasing the 2mg/ml 100 ml vials (NDC 63323-0101-61)- the 2mg/ml 25 ml vials (NDC 63323-0883-30)- and the 2mg/ml 5 ml vials (NDC 63323-0883-05) as it becomes available.;APP has available the 2 mg/mL 5 mL vials (NDC 63323-883-05)- the 2 mg/mL 10 mL vials (NDC 63323-883-10)- the 2 mg/mL 25 mL vials (NDC 63323-0883-30)- and the 2 mg/mL 100 mL vials (NDC 63323-0101-61).;Increased demand APP has available the 2 mg/mL 5 mL vials (NDC 63323-883-05)- the 2 mg/mL 10 mL vials (NDC 63323-883-10)- the 2 mg/mL 25 mL vials (NDC 63323-0883-30)- and the 2 mg/mL 100 mL vials (NDC 63323-0101-61).;,,,,,,,,,,,,,
Bedford,doxorubicins,1,11/18/10,4/22/11,demand increase; manufacturing delays,blue,,Increased demand Manufacturing delays   Increased demand ;Increased demand Manufacturing delays   Increased demand ;Increased demand Manufacturing delays   Increased demand;Increased demand Manufacturing delays   Increased demand,,,,,,,,,,,,,
Bedford,doxorubicins,1,4/28/11,7/12/12,demand increase; manufacturing delays,blue,,"Bedford is releasing the following products as they become available: Adriamycin solution for injection- 2 mg/mL- 5 mL vial (NDC 55390-0235-10) ; 10 mL vial (NDC 55390-0236-10) 25 mL vial (NDC 55390-0237-01) 100 mL vial (NDC 55390-0238-01) Doxorubicin solution for injection- 2 mg/mL- Novaplus 25 mL multi-dose vial (NDC 55390-0247-01) Novaplus 100 mL multi-dose vial (NDC 55390-0248-01).;Bedford is releasing the following products as they become available: 
 Adriamycin solution for injection- 2 mg/mL- 5 mL vial (NDC 55390-0235-10) ; 10 mL vial (NDC 55390-0236-10) 25 mL vial (NDC 55390-0237-01) 100 mL vial (NDC 55390-0238-01) 
 
 Doxorubicin solution for injection- 2 mg/mL- Novaplus 25 mL multi-dose vial (NDC 55390-0247-01) Novaplus 100 mL multi-dose vial (NDC 55390-0248-01).;Bedford anticipates release of the 50mg presentation in the next 3months and release of the 10 mg- 25 mg- and 100 mg solutions in the next 6-months.;Bedford has limited allocated quantities available of 50 mg injection (NDC 55390-0237-01)- contact your local Bedford Account Executives. All other presentations are on backorder and the company cannot estimate a release date.;Bedford has limited allocated quantities available of 50 mg injection (NDC 55390-0237-01)- contact your local Bedford Account Executives. Bedford has short supplies of 200 mg/100 mL (NDC 55390-0238-01).  All other presentations are on backorder and the company cannot estimate a release date.;Bedford has limited allocated quantities available of 50 mg/25 mL injection (NDC 55390-0237-01)and short supplies of 200 mg/100 mL (NDC 55390-0238-01)- 10 mg/5 mL (NDC 55390-235-10 and 20 mg/10 mL (NDC 55390-236-10). Contact your local Bedford Account Executive.  All other presentations are on backorder and the company cannot estimate a release date.;Bedford has  all doxorubicin solution presentations on backorder and the company cannot estimate a release date.;Manufacturing delays Bedford has  all doxorubicin solution presentations on backorder and the company cannot estimate a release date.;",,,,,,,,,,,,,
Teva,doxorubicins,1,11/18/10,4/22/11,demand increase; manufacturing delays,blue,,Increased demand Manufacturing delays   Increased demand ;Increased demand Manufacturing delays   Increased demand ;Increased demand Manufacturing delays   Increased demand;Increased demand Manufacturing delays   Increased demand,,,,,,,,,,,,,
Teva,doxorubicins,1,4/28/11,7/12/12,manufacturing delays; available,blue,,Teva is releasing all strengths on allocation: Doxorubicin solution for injection- 2 mg/mL 5 mL vial (NDC 00703-5043-03) 25 mL vial (NDC 00703-5046-01) 100 mL vial (NDC 00703-5040-01).;Teva plans to have doxorubicin solution for injection- 2 mg/mL 5 mL vial (NDC 00703-5043-03) 25 mL vial (NDC 00703-5046-01) 100 mL vial (NDC 00703-5040-01) available again in early 2012.;Teva has all doxorubicin injection on back order and the company estimates a release date of May 2012.;Manufacturing delays Teva has all doxorubicin injection on back order and the company estimates a release date of May 2012.;,,,,,,,,,,,,,
Watson,doxycycline,1,3/6/13,11/8/13,demand increase,orange,,100 mg capsules- 50 count (NDC 00591-5440-50) Limited supplies available. Watson is currently supporting supply for current contracted customers only.;100 mg capsules- 500 count (NDC 00591-5440-05) Limited supplies available. Watson is currently supporting supply for current contracted customers only.;50 mg capsules- 50 count (NDC 00591-5535-50) Limited supplies available. Watson is currently supporting supply for current contracted customers only.;100 mg capsules- 500 count (NDC 00591-5440-05) Limited supplies available. Normal supply to be restored 09/2013 Watson is currently supporting supply for current contracted customers only.;50 mg capsules- 50 count (NDC 00591-5535-50) Limited supplies available. Normal supply to be restored 09/2013 Watson is currently supporting supply for current contracted customers only.;100 mg capsules- 50 count (NDC 00591-5440-50) Limited supplies available. Normal supply to be restored 09/2013 Watson is currently supporting supply for current contracted customers only.,,,,,,,,,,,,,
WestWard,doxycycline,1,3/6/13,11/8/13,manufacturing delays; available,blue,,100 mg capsules- 50 count (NDC 00143-3142-50)   End of February/ Early March Manufacturing delays.  Estimated availability is Mid-February- 2013;100 mg tablets- 50 count (NDC 00143-2112-50) End of February/ Early March Manufacturing delays.  Estimated availability is Mid-February- 2013;100 mg capsules- 50 count (NDC 0143-9803-50) Available Manufacturing delays.  Estimated availability is Mid-February- 2013;100 mg tablets- 500 count (NDC 00143-2112-05)   Manufacturing delays.  Estimated availability is Mid-February- 2013;100 mg capsules- 500 count (NDC 00143-3142-05)     Manufacturing delays.  Estimated availability is Mid-February- 2013;50 mg capsules- 50 count (NDC 00143-3141-50)   No date as to when will be available Manufacturing delays.  Estimated availability is Mid-February- 2013;50 mg capsules- 50 count (NDC 00143-3141-50)   End of February/ Early March Manufacturing delays.  Estimated availability is Mid-February- 2013;100 mg capsules- 20 count (NDC 00143-3142-20)   End of February/Early March Manufacturing delays.  Estimated availability is Mid-February- 2013;100 mg capsules- 500 count (NDC 0143-9803-05) Available Manufacturing delays.  Estimated availability is Mid-February- 2013;100 mg capsules- 50 count (NDC 00143-3142-50)   Available;100 mg capsules- 500 count (NDC 0143-9803-05) Available;100 mg capsules- 500 count (NDC 00143-3142-05)   Available;100 mg tablets- 500 count (NDC 00143-2112-05) Available;100 mg capsules- 20 count (NDC 00143-3142-20)   Not currently packaging in this container size;50 mg capsules- 50 count (NDC 00143-3141-50)   Available;100 mg tablets- 50 count (NDC 00143-2112-50) Available;100 mg capsules- 50 count (NDC 0143-9803-50) Available;100 mg tablets- 50 count (NDC 00143-2112-50) Available  Product is available;100 mg capsules- 20 count (NDC 00143-3142-20)   Not currently packaging in this container size  Product is available;100 mg capsules- 500 count (NDC 00143-3142-05)   Available    Product is available;100 mg capsules- 50 count (NDC 00143-3142-50)   Available  Product is available;50 mg capsules- 50 count (NDC 00143-3141-50)   Available  Product is available;100 mg tablets- 500 count (NDC 00143-2112-05) Available   Product is available;100 mg capsules- 50 count (NDC 0143-9803-50) Available  Product is available;100 mg capsules- 500 count (NDC 0143-9803-05) Available  Product is available,,,,,,,,,,,,,
Graceway,edetate,1,6/6/09,7/5/09,demand increase,orange,,Increase in demand,,,,,,,,,,,,,
Lundbeck,elspar,1,4/15/10,6/20/10,manufacturing delays,blue,,Manufacturing delays.,,,,,,,,,,,,,
Akorn,ephedrine,1,2/26/10,8/28/10,manufacturing delays,blue,,Manufacturing delays           Increase in demand.      ;Manufacturing delays           Increase in demand.      ;Manufacturing delays.           Increase in demand.      ;Manufacturing delays.                 Increase in demand.      ;Manufacturing delays.               Increase in demand.      ,,,,,,,,,,,,,
Hospira,ephedrine,1,2/26/10,8/28/10,manufacturing delays,blue,,Manufacturing delays           Increase in demand.      ;Manufacturing delays           Increase in demand.      ;Manufacturing delays.           Increase in demand.      ;Manufacturing delays.                 Increase in demand.      ;Manufacturing delays.               Increase in demand.      ,,,,,,,,,,,,,
Sandoz,ephedrine,1,2/26/10,8/28/10,manufacturing delays,blue,,Manufacturing delays           Increase in demand.      ;Manufacturing delays           Increase in demand.      ;Manufacturing delays.           Increase in demand.      ;Manufacturing delays.                 Increase in demand.      ;Manufacturing delays.               Increase in demand.      ,,,,,,,,,,,,,
AmericanRegent,epinephrine,1,8/20/10,8/28/10,demand increase,orange,,Unanticipated Increased Demand,,,,,,,,,,,,,
Amphastar,epinephrine,1,8/7/10,8/15/10,demand increase,orange,,Unanticipated increased demand,,,,,,,,,,,,,
Amphastar,epinephrine,2,9/14/10,12/19/10,demand increase,orange,,Unanticipated increased demand,,,,,,,,,,,,,
Amphastar,epinephrine,1,5/11/12,10/19/12,demand increase,orange,,;1:10-000- 10mL Luer-Jet Prefilled Syringe   NDC 76329-3316-1(old NDC 0548-3316-00) Amphastar will regularly release products. Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues. Shortage by Manufacturer: Increased Demand,,,,,,,,,,,,,
Amphastar(IMS),epinephrine,1,8/20/10,8/28/10,demand increase,orange,,Unanticipated Increased Demand,,,,,,,,,,,,,
Hospira,epinephrine,1,6/11/10,12/19/10,demand increase,orange,,Unanticipated increased demand;Unanticipated Increased Demand,,,,,,,,,,,,,
Amphastar,epinephrine,2,11/2/12,3/25/14,demand increase; available,orange,,1:10-000- 10mL Luer-Jet Prefilled Syringe   NDC 76329-3316-1(old NDC 0548-3316-00) Amphastar will regularly release products. Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues. Shortage by Manufacturer: Increased Demand;1:10-000- 10mL Luer-Jet Prefilled Syringe   NDC 76329-3316-1(old NDC 0548-3316-00) Available;1:10-000- 10mL Luer-Jet Prefilled Syringe   NDC 76329-3316-1(old NDC 0548-3316-00) Amphastart will regularly release products  Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues;Epinephrine Inj. USP- 1mg/mL- 30mL vial- NDC 76329-9061-00 Available;1:10-000- 10mL Luer-Jet Prefilled Syringe   NDC 76329-3316-1(old NDC 0548-3316-00) Available  Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues,,,,,,,,,,,,,
AmericanRegent,epinephrine,1,10/6/13,3/25/14,manufacturing delays; not releasing,blue,,Preservative Free- Sulfite Free- 1 mL ampoule- package of 25 (NDC 00517-1071-25) Estimate release end-October 2013   Estimate release end-October 2013 American Regent is currently not releasing the preserved 30 mL vial. Shortage per Manufacturer: Manufacturing delay;30 mL vial- package of 5 (NDC 00517-1130-05) Unavailable American Regent is currently not releasing the preserved 30 mL vial. Shortage per Manufacturer: Manufacturing delay;NULL NULL American Regent is currently not releasing the preserved 30 mL vial.;30 mL vial- package of 5 (NDC 00517-1130-05) Unavailable Estimate release end-December 2013. American Regent is currently not releasing the preserved 30 mL vial.,,,,,,,,,,,,,
AmericanRegent,epinephrinep,1,6/23/12,10/19/12,; not releasing,,,;1 mg/mL- 1 mL ampule- (sulfite-free) package of 25 (NDC 00517-1071-25) Unavailable American Regent is currently not releasing Epinephrine Injection.;30 mL vial- package of 5 (NDC 00517-1130-05) Unavailable American Regent is currently not releasing Epinephrine Injection.,,,,,,,,,,,,,
AmericanRegent,epinephrinep,2,11/2/12,3/25/14,not releasing; manufacturing issues; recall; manufacturing delays; available; shipping delay; demand increase,yellow,,30 mL vial- package of 5 (NDC 00517-1130-05) Unavailable American Regent is currently not releasing Epinephrine Injection.;1 mg/mL- 1 mL ampule- (sulfite-free) package of 25 (NDC 00517-1071-25) Unavailable American Regent is currently not releasing Epinephrine Injection.;30 mL vial- package of 5 (NDC 00517-1130-05) Unavailable Shortage per Manufacturer: American Regent is currently not releasing Epinephrine Injection.;1 mg/mL- 1 mL ampule- preservative free- sulfite-free -package of 25 (NDC 00517-1071-25) Unavailable Shortage per Manufacturer: American Regent is currently not releasing Epinephrine Injection.;1 mg/mL- 1 mL ampule- preservative free- sulfite-free -package of 25 (NDC 00517-1071-25) Intermittent releases throughout February 2013. See the Dear Healthcare Provider Letter (PDF - 63KB) regarding release of lots with potential discoloration and precipitate.;30 mL vial- package of 5 (NDC 00517-1130-05) Unavailable See the Dear Healthcare Provider Letter (PDF - 63KB) regarding release of lots with potential discoloration and precipitate.;1 mg/mL- 1 mL ampule- preservative free- sulfite-free -package of 25 (NDC 00517-1071-25) Available American Regent is currently not releasing the preserved 30 mL vial   American Regent is currently releasing preservative free- sulfite free- 1 mL ampoule;30 mL vial- package of 5 (NDC 00517-1130-05) Unavailable American Regent is currently not releasing the preserved 30 mL vial   American Regent is currently releasing preservative free- sulfite free- 1 mL ampoule;30 mL vial- package of 5 (NDC 00517-1130-05) Unavailable American Regent is currently not releasing the preserved 30 mL vial Shortage per Manufacturer: Manufacturing delay;1 mg/mL- 1 mL ampule- preservative free- sulfite-free -package of 25 (NDC 00517-1071-25) Company estimates a manufacturing date of 2Q 2013 American Regent is currently not releasing the preserved 30 mL vial Shortage per Manufacturer: Manufacturing delay;1 mg/mL- 1 mL ampule- preservative free- sulfite-free -package of 25 (NDC 00517-1071-25) Estimate release end of July 2013 American Regent is currently not releasing the preserved 30 mL vial Shortage per Manufacturer: Manufacturing delay;1 mg/mL- 1 mL ampule- preservative free- sulfite-free -package of 25 (NDC 00517-1071-25) Estimate release August 2013 American Regent is currently not releasing the preserved 30 mL vial Shortage per Manufacturer: Manufacturing delay;1 mg/mL- 1 mL ampule- preservative free- sulfite-free -package of 25 (NDC 00517-1071-25) Estimate release September 2013 American Regent is currently not releasing the preserved 30 mL vial Shortage per Manufacturer: Manufacturing delay;1 mg/mL- 1 mL ampule- preservative free- sulfite-free -package of 25 (NDC 00517-1071-25) Unavailable Estimate release end December 2013. Shortage per Manufacturer: Manufacturing delay;1 mg/mL- 1 mL ampule- preservative free- sulfite-free -package of 25 (NDC 00517-1071-25) Unavailable  - Product on backorder and will be made available as it is released.   Shortage per Manufacturer: Manufacturing delay,,,,,,,,,,,,,
Epogen(Amgen),epoetin,1,10/9/10,12/19/10,available,,,Centocor Ortho Biotech reports that short-term availability of the 24,,000 unit and the 40,000 unit PROCRIT vials may be limited. Amgen does not anticipate a disruption in the availability of EPOGEN for patients.   For additional information see Related Information section.  ,,,,,,,,,,
Procrit(Centocor),epoetin,1,10/9/10,12/19/10,available,,,Centocor Ortho Biotech reports that short-term availability of the 2000 unit and the 40000 unit PROCRIT vials may be limited. Amgen does not anticipate a disruption in the availability of EPOGEN for patients.   For additional information see Related Information section.  ,,,,,,,,,,,,,
BauschLomb,erythromycin,1,8/14/09,2/20/10,demand increase,orange,,Increase in demand.;Increase in demand.                                 Product delays;Increase in demand.                                 Production delays;Increase in demand.                                               Production delays;Increase in demand.                                               Fera Pharmaceuticals has begun shipping Erythromycin Ophthalmic Ointment,,,,,,,,,,,,,
Fera,erythromycin,1,8/30/09,2/20/10,demand increase,orange,,Increase in demand.                                 Product delays;Increase in demand.                                 Production delays;Increase in demand.                                               Production delays;Increase in demand.                                               Fera Pharmaceuticals has begun shipping Erythromycin Ophthalmic Ointment,,,,,,,,,,,,,
Hospira,erythromycin,1,10/26/10,4/22/11,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
AstraZeneca,esomeprazole,2,11/2/12,11/2/12,manufacturing delays,blue,,20 mg packets- unit: dose packages of 30 (NDC 0186-4020-01)   Limited availability through September Order management will remain in effect through September. Shortage per Manufacturer: Manufacturing delays,,,,,,,,,,,,,
AstraZeneca,esomeprazole,1,4/18/12,10/19/12,manufacturing delays,blue,,Manufacturing delays NEXIUM (esomeprazole) For Delayed-Release Oral Suspension- 10mg-  is Out of Stock.  Product will be available in early May 2012.;NEXIUM (esomeprazole) For Delayed-Release Oral Suspension- 10mg-  is Out of Stock.  Product will be available in early May 2012.;;20 mg packets- unit: dose packages of 30 (NDC 0186-4020-01)   Limited availability through July. Order management will remain in effect through July. Shortage per Manufacturer: Manufacturing delays;40 mg packets- unit: dose packages of 30 (NDC 0186-4040-01) Limited availability through July. Order management will remain in effect through July. Shortage per Manufacturer: Manufacturing delays;10 mg packets- unit: dose packages of 30 (NDC 0186-4010-01) Limited availability through July. Order management will remain in effect through July. Shortage per Manufacturer: Manufacturing delays;20 mg packets- unit: dose packages of 30 (NDC 0186-4020-01)   Limited availability through September Order management will remain in effect through September. Shortage per Manufacturer: Manufacturing delays,,,,,,,,,,,,,
Guerbet,ethiodol,1,5/15/10,4/22/11,discontinued,black,,Product has been discontinued by Nycomed US Inc.,,,,,,,,,,,,,
Nycomed,ethiodol,1,3/19/10,5/8/10,discontinued,black,,Product has been discontinued.,,,,,,,,,,,,,
Guerbet,ethiodol,1,4/28/11,10/19/12,production suspended; [temporary import],brown,,"Guerbet has acquired the Ethiodol NDA from Nycomed US Inc. effective May 7- 2010 and is working with FDA to resume manufacturing of Ethiodol in the near future to ensure continued availability for the US patients. During this interim period- Guerbet- in conjunction with the FDA- is initiating a temporary importation of LIPIODOL ULTRA-FLUIDE- ethyl esters of iodized fatty acids of poppy seed oil- to the United States market. See Dear Healthcare Professional Letter (PDF - 588KB) for additional information. (Letter updated 12/10/2010);Guerbet has acquired the Ethiodol NDA from Nycomed US Inc. effective May 7- 2010 and is working with FDA to resume manufacturing of Ethiodol in the near future to ensure continued availability for the US patients. During this interim period- Guerbet- in conjunction with the FDA- is initiating a temporary importation of LIPIODOL ULTRA-FLUIDE- ethyl esters of iodized fatty acids of poppy seed oil- to the United States market. 
 
 See Dear Healthcare Professional Letter (PDF - 588KB) for additional information. 
 (Letter updated 12/10/2010);Guerbet has acquired the Ethiodol NDA from Nycomed US Inc. effective May 7- 2010 and is working with FDA to resume manufacturing of Ethiodol in the near future to ensure continued availability for the US patients. During this interim period- Guerbet- in conjunction with the FDA- is initiating a temporary importation of LIPIODOL ULTRA-FLUIDE- ethyl esters of iodized fatty acids of poppy seed oil- to the United States market. See Dear Healthcare Professional Letter (PDF - 483KB) for additional information. (Letter updated 3/20/2012);Product has been discontinued by Nycomed US Inc. Guerbet has acquired the Ethiodol NDA from Nycomed US Inc. effective May 7- 2010 and is working with FDA to resume manufacturing of Ethiodol in the near future to ensure continued availability for the US patients. During this interim period- Guerbet- in conjunction with the FDA- is initiating a temporary importation of LIPIODOL ULTRA-FLUIDE- ethyl esters of iodized fatty acids of poppy seed oil- to the United States market. See Dear Healthcare Professional Letter (PDF - 483KB) for additional information. (Letter updated 3/20/2012);;Guerbet has acquired the Ethiodol NDA from Nycomed US Inc. effective May 7- 2010 and is working with FDA to resume manufacturing of Ethiodol in the near future to ensure continued availability for the US patients. During this interim period- Guerbet- in conjunction with the FDA- is initiating a temporary importation of LIPIODOL ULTRA-FLUIDE- ethyl esters of iodized fatty acids of poppy seed oil- to the United States market. See Dear Healthcare Professional Letter (PDF - 483KB) for additional information. (Letter updated 3/20/2012) Shortage per Manufacturer: Product has been discontinued by Nycomed US Inc.",,,,,,,,,,,,,
Guerbet,ethiodol,2,11/2/12,3/25/14,production suspended; [temporary import],brown,,Guerbet has acquired the Ethiodol NDA from Nycomed US Inc. effective May 7- 2010 and is working with FDA to resume manufacturing of Ethiodol in the near future to ensure continued availability for the US patients. During this interim period- Guerbet- in conjunction with the FDA- is initiating a temporary importation of LIPIODOL ULTRA-FLUIDE- ethyl esters of iodized fatty acids of poppy seed oil- to the United States market. See Dear Healthcare Professional Letter (PDF - 483KB) for additional information. (Letter updated 3/20/2012) Shortage per Manufacturer: Product has been discontinued by Nycomed US Inc.;LIPIODOL ULTRA-FLUIDE- 48% Iodine w/vol (i.e. 480 mg Iodine/mL) (ethyl esters of iodized fatty acids of poppy seed oil) injection- 10 mL  (NDC 67684-1901-0)  Guerbet has acquired the Ethiodol NDA from Nycomed US Inc. effective May 7- 2010 and is working with FDA to resume manufacturing of Ethiodol in the near future to ensure continued availability for the US patients. During this interim period- Guerbet- in conjunction with the FDA- is initiating a temporary importation of LIPIODOL ULTRA-FLUIDE- ethyl esters of iodized fatty acids of poppy seed oil- to the United States market. See Dear Healthcare Professional Letter (PDF - 789KB) for additional information. (Letter updated 7/1/2013)   Shortage per Manufacturer: Product has been discontinued by Nycomed US Inc.,,,,,,,,,,,,,
AmericanRegent,etomidate,1,2/16/12,10/19/12,demand increase; not releasing; available,orange,,"Two lots of the 10 mL vial size will be released mid-February 2012 Two lots of the 20 mL vial size will be released end-March 2012;Two lots of the 10 mL vial size will be released end-March 2012 
 
 Two lots of the 20 mL vial size will be released end-March 2012.;American Regent anticipates to have the 10 mL vial product available end of May 2012.;Increase demand American Regent anticipates to have the 10 mL vial product available end of May 2012.;;2 mg/mL vial 10 mL vial (NDC 00517-0780-10) Available   Please check with your wholesaler for available inventory;20 mL vial (NDC 00517-0781-10) Unavailable   Please check with your wholesaler for available inventory;2 mg/mL vial 10 mL vial (NDC 00517-0780-10) Unavailable   Please check with your wholesaler for available inventory.   Shortage per manufacturer: American Regent is currently not releasing the 20 mL vial size of Etomidate Injection.;20 mL vial (NDC 00517-0781-10) Unavailable   Please check with your wholesaler for available inventory.   Shortage per manufacturer: American Regent is currently not releasing the 20 mL vial size of Etomidate Injection.",,,,,,,,,,,,,
Bedford,etomidate,1,3/1/12,10/19/12,manufacturing delays,blue,,Etomidate injection is on back order with no estimated date of availability.;Manufacturing Delay Etomidate injection is on back order with no estimated date of availability.;;20 mL (NDC 55390-0763-20) Etomidate injection is on back order with no estimated date of availability. Shortage per Manufacturer: Manufacturing Delay;2 mg/mL injection 10 mL vial (NDC 55390-0762-10) Etomidate injection is on back order with no estimated date of availability. Shortage per Manufacturer: Manufacturing Delay,,,,,,,,,,,,,
Bedford,etomidate,2,11/2/12,3/2/14,manufacturing delays; capacity constraints; manufacturing change; pending manufacturing change,blue,,20 mL (NDC 55390-0763-20) Etomidate injection is on back order with no estimated date of availability. Shortage per Manufacturer: Manufacturing Delay;2 mg/mL injection 10 mL vial (NDC 55390-0762-10) Etomidate injection is on back order with no estimated date of availability. Shortage per Manufacturer: Manufacturing Delay;2 mg/mL injection 10 mL vial (NDC 55390-0762-10) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;20 mL (NDC 55390-0763-20) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;2 mg/mL injection 10 mL vial (NDC 55390-0762-10) Unavailable Shortage per Manufacturer: Pending manufacturing change or addition. Availability of products is updated on the Bedford Laboratories website.;20 mL (NDC 55390-0763-20) Unavailable Shortage per Manufacturer: Pending manufacturing change or addition. Availability of products is updated on the Bedford Laboratories website.,,,,,,,,,,,,,
AmericanRegent,etomidate,2,11/2/12,3/2/14,not releasing,,,2 mg/mL vial 10 mL vial (NDC 00517-0780-10) Unavailable   Please check with your wholesaler for available inventory.   Shortage per manufacturer: American Regent is currently not releasing the 20 mL vial size of Etomidate Injection.;20 mL vial (NDC 00517-0781-10) Unavailable   Please check with your wholesaler for available inventory.   Shortage per manufacturer: American Regent is currently not releasing the 20 mL vial size of Etomidate Injection.;2 mg/mL vial 10 mL vial (NDC 00517-0780-10) Unavailable   Shortage per manufacturer: American Regent is currently not releasing the 10 mL or the 20 mL vial sizes of Etomidate Injection.;20 mL vial (NDC 00517-0781-10) Unavailable   Shortage per manufacturer: American Regent is currently not releasing the 10 mL or the 20 mL vial sizes of Etomidate Injection.;20 mL vial (NDC 00517-0781-10) Unavailable   American Regent is currently not releasing the 10 mL or the 20 mL vial size of Etomidate Injection.;2 mg/mL vial 10 mL vial (NDC 00517-0780-10) Unavailable   American Regent is currently not releasing the 10 mL or the 20 mL vial size of Etomidate Injection.;2 mg/mL; 20 mL vial (NDC 00517-0781-10) Unavailable   American Regent is currently not releasing the 10 mL or the 20 mL vial size of Etomidate Injection.,,,,,,,,,,,,,
Bedford,etoposide,1,4/28/11,7/12/12,demand increase,orange,,Bedford is releasing all etoposide solution for injection 20 mg/mL presentations as they become available.;Bedford anticipates release of 500 mg product in early May- 1g in the next 3-months- and 100 mg in the next 6-months.;Bedford estimates releasing the 5ml vials (NDC 55390-0291-01) at the end of June and the 25ml vials (NDC 55390-0292-01) mid-June- 2011.  No estimated date of availability for the 50ml vials (NDC 55390-0293-01).;Bedford Laboratories has all presentations on back order. The company estimates a release date by end of July for the 5 mL vials and there is not yet an estimated release date for the other presentations.;Bedford has allocated quantities available of etoposide 100 mg/5 mL vials (NDC 55390-0291-01). All other etoposide 20 mg/mL presentations are on back order and the company cannot estimate a release date.;Bedford has short supplies of 500 mg/25 mL (NDC 55390-0292-01) and 1 gram/50 mL (NDC 55390-0293-01). All other etoposide 20 mg/mL presentations are on back order and the company cannot estimate a release date.;Bedford has short supplies of 500 mg/25 mL (NDC 55390-0292-01) and 1 gram/50 mL (NDC 55390-0293-01)contact your local Bedford Account Executive. All other etoposide 20 mg/mL presentations are on back order and the company cannot estimate a release date.;Bedford has all  etoposide presentations  on back order and the company cannot estimate a release date.;Bedford Laboratories has 100mg/5ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown.  All other presentations are out os stock and the company cannot estimate a release date. Production is pending as capacity permits.  Availability of products is updated on the Bedford  Laboratories website.;Increased demand Bedford Laboratories has 100mg/5ml available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown.  All other presentations are out os stock and the company cannot estimate a release date. Production is pending as capacity permits.  Availability of products is updated on the Bedford  Laboratories website.;,,,,,,,,,,,,,
Accord,etoposide,1,6/22/11,7/12/12,demand increase; available,orange,,Accord healthcare has product available.;Accord will have limited products available beginning February.;Accord anticipates product will be avialable in early March and will be releasing product as it becomes available.;Etoposide Injection 20 mg/mL; 5 mL; 53776 vials in stock; approximately 45000 vials will be in warehouse by the 3rd week of this month.;Increase in demand Etoposide Injection 20 mg/mL; 5 mL; 53776 vials in stock; approximately 45000 vials will be in warehouse by the 3rd week of this month.;,,,,,,,,,,,,,
BMS,etoposide,1,4/28/11,7/12/12,demand increase; available,orange,,BMS has available Etopophos 100 mg powder for injection (NDC 00015-3404-20).;Increased demand BMS has available Etopophos 100 mg powder for injection (NDC 00015-3404-20).;,,,,,,,,,,,,,
APP,etoposide,1,9/14/10,4/7/11,demand increase; manufacturing delays,blue,,Increased demand     Manufacturing delays   Manufacturing delays   Increased demand  ,,,,,,,,,,,,,
APP,etoposide,2,4/22/11,4/22/11,demand increase; manufacturing delays,blue,,Increased demand     Manufacturing delays   Manufacturing delays   Increased demand,,,,,,,,,,,,,
Bedford,etoposide,1,9/14/10,4/22/11,demand increase; manufacturing delays,blue,,Increased demand     Manufacturing delays   Manufacturing delays   Increased demand  ;Increased demand     Manufacturing delays   Manufacturing delays   Increased demand;Increased demand     Manufacturing delays   Manufacturing delays   Increased demand,,,,,,,,,,,,,
BMS,etoposide,1,9/14/10,4/7/11,demand increase; manufacturing delays,blue,,Increased demand     Manufacturing delays   Manufacturing delays   Increased demand  ,,,,,,,,,,,,,
Teva,etoposide,1,9/14/10,4/7/11,demand increase; manufacturing delays,blue,,Increased demand     Manufacturing delays   Manufacturing delays   Increased demand  ,,,,,,,,,,,,,
Teva,etoposide,2,4/22/11,4/22/11,demand increase; manufacturing delays,blue,,Increased demand     Manufacturing delays   Manufacturing delays   Increased demand,,,,,,,,,,,,,
Teva,etoposide,1,4/28/11,7/12/12,manufacturing delays; available,blue,,Teva has Toposar 20 mg/mL solution for injection 5 mL vials (NDC 00703-5653-01) vials availalbe. The 25 mL and 50 mL vials are on back order.;Teva has Toposar 20 mg/mL solution for injection 5 mL (NDC 00703-5653-01)   25 mL and 50 mL vials on back order - Teva is working on having additional supplies as soon as possible.;Teva has limited inventory of Toposar 20 mg/mL solution for injection 5 mL (NDC 00703-5653-01) available on allocation.  Teva's 25 mL(NDC 00703-5656-01)  and 50 mL vials (NDC 00703-5657-01) are on back order. Teva is working on having additional supplies available by April 2012.;Teva has all Etoposide solution for injection available.;Manufacturing delays Teva has all Etoposide solution for injection available.;,,,,,,,,,,,,,
APP,etoposide,1,4/28/11,7/12/12,manufacturing delays; demand increase; available,blue,,APP is releasing all etoposide solution for injection 20 mg/mL presentations as they become available.;APP is allocating all etoposide 20 mg/mL 5 mL and 25 mL vials. 50 mL vials are on back order with an estimated release date of late-February- 2012.;APP is allocating all etoposide 20 mg/mL 5 mL and 25 mL vials & 50 mL vials.;APP has 20 mg/mL; 5 mL vial (NDC 63323-0104-05) & 20 mg/mL; 25 mL vial (NDC 63323-0104-25) available - check wholesalers for inventory.  APP is allocating 20 mg/mL; 50 mL vial (NDC 63323-0104-50).;Increased demand APP has 20 mg/mL; 5 mL vial (NDC 63323-0104-05) & 20 mg/mL; 25 mL vial (NDC 63323-0104-25) available - check wholesalers for inventory.  APP is allocating 20 mg/mL; 50 mL vial (NDC 63323-0104-50).;APP has all presentations of Etoposide available.  Check wholesalers for inventory.;,,,,,,,,,,,,,
Genzyme,fabrazyme,1,8/26/09,4/22/11,demand increase; manufacturing delays,blue,,Manufacturing delays  ;Manufacturing delays  ;Manufacturing delays  ;Manufacturing delays  ,,,,,,,,,,,,,
Genzyme,fabrazyme,1,4/28/11,3/16/12,manufacturing delays,blue,,"Please see Dear Doctor Letter (PDF - 395KB) for additional information. Visit Web site: Genzyme supply update;Please see Dear Doctor Letter (PDF - 395KB) for additional information. 
 
 Visit Web site: Genzyme supply update;Please see Dear Healthcare Provider Letter (PDF - 100KB) and Dear Member of the Fabry Community Letter (PDF - 94KB) for additional information. Visit Web site: Genzyme supply update;Please see Dear Healthcare Provider Letter (PDF - 100KB) and Dear Member of the Fabry Community Letter (PDF - 94KB) for additional information. 
 
 Visit Web site: Genzyme supply update;Please see Dear Healthcare Provider Letter (PDF - 148KB) and Dear Member of the Fabry Community Letter (PDF - 146KB) for additional information. Visit Web site: Genzyme supply update;Please see Dear Healthcare Provider Letter (PDF - 148KB) and Dear Member of the Fabry Community Letter (PDF - 146KB) for additional information. 
 
 Visit Web site: Genzyme supply update;Visit Web site: Genzyme supply update",,,,,,,,,,,,,
AstraZeneca,faslodex,1,8/6/09,10/30/09,supply constraints,green,,Supply constraints,,,,,,,,,,,,,
Actavis,fentanyl,1,4/28/11,6/22/11,available,,,All product available.,,,,,,,,,,,,,
Akorn,fentanyl,1,4/18/12,10/19/12,available,,,N/A 2 mL and 5 mL releasing in March. 20 mL releasing early April. Increased production available- contingent on market demand.;2 mL and 5 mL releasing in March. 20 mL releasing early April. Increased production available- contingent on market demand.;;2 mL ampule (NDC 17478-0030-02) Readily available;5 mL ample (NDC 17478-0030-05) Readily available;2 mL ampule; 25 pack (NDC 17478-0030-25) Readily available;20 mL ample (NDC 17478-0030-20) Readily available,,,,,,,,,,,,,
Apotex,fentanyl,1,4/28/11,6/22/11,available,,,All product available.,,,,,,,,,,,,,
Watson,fentanyl,1,4/28/11,6/22/11,available,,,All product available.,,,,,,,,,,,,,
WestWard,fentanyl,2,11/2/12,3/25/14,demand increase,orange,,50 mcg/mL  50 mL vial (NDC 0641-6030-01) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the October - November 2012 timeframe.    West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 5 mL ampul (NDC 0641-6025-10) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the October - November 2012 timeframe.    West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 20 mL ampul (NDC 0641-6026-05) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the October - November 2012 timeframe.    West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL2 mL ampul (NDC 0641-6024-10) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the October - November 2012 timeframe.    West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 2 mL vial (NDC 0641-6027-25) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the October - November 2012 timeframe.    West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 20 mL vial(NDC 0641-6029-25) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the October - November 2012 timeframe.    West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 5 mL vial (NDC 0641-6028-25) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the October - November 2012 timeframe.    West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 20 mL vial(NDC 0641-6029-25) West-Ward has limited quantities available for the majority Fentanyl presentations.   There is currently a slight backorder on the 20 mL and 50 mL vials.   Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the January - February 2013 timeframe.   West-Ward has continued to accelerate production on all codes      West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.   Product will be made available as it is released.;50 mcg/mL2 mL ampul (NDC 0641-6024-10) West-Ward has limited quantities available for the majority Fentanyl presentations.   There is currently a slight backorder on the 20 mL and 50 mL vials.   Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the January - February 2013 timeframe.   West-Ward has continued to accelerate production on all codes      West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.   Product will be made available as it is released.;50 mcg/mL  50 mL vial (NDC 0641-6030-01) West-Ward has limited quantities available for the majority Fentanyl presentations.   There is currently a slight backorder on the 20 mL and 50 mL vials.   Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the January - February 2013 timeframe.   West-Ward has continued to accelerate production on all codes      West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.   Product will be made available as it is released.;50 mcg/mL 5 mL ampul (NDC 0641-6025-10) West-Ward has limited quantities available for the majority Fentanyl presentations.   There is currently a slight backorder on the 20 mL and 50 mL vials.   Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the January - February 2013 timeframe.   West-Ward has continued to accelerate production on all codes      West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.   Product will be made available as it is released.;50 mcg/mL 2 mL vial (NDC 0641-6027-25) West-Ward has limited quantities available for the majority Fentanyl presentations.   There is currently a slight backorder on the 20 mL and 50 mL vials.   Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the January - February 2013 timeframe.   West-Ward has continued to accelerate production on all codes      West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.   Product will be made available as it is released.;50 mcg/mL 20 mL ampul (NDC 0641-6026-05) West-Ward has limited quantities available for the majority Fentanyl presentations.   There is currently a slight backorder on the 20 mL and 50 mL vials.   Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the January - February 2013 timeframe.   West-Ward has continued to accelerate production on all codes      West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.   Product will be made available as it is released.;50 mcg/mL 5 mL vial (NDC 0641-6028-25) West-Ward has limited quantities available for the majority Fentanyl presentations.   There is currently a slight backorder on the 20 mL and 50 mL vials.   Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the January - February 2013 timeframe.   West-Ward has continued to accelerate production on all codes      West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.   Product will be made available as it is released.;50 mcg/mL 5 mL vial (NDC 0641-6028-25) West-Ward has limited quantities available for the majority Fentanyl presentations.   There is currently a backorder on the 2 mL- 20 ml and 50 mL vials.   Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the February-March 2013 timeframe.   West-Ward has continued to accelerate production on all codes      Shortage per Manufacturer: Increase in product demand due to market supply issues.   Product will be made available as it is released.;50 mcg/mL 20 mL vial(NDC 0641-6029-25) West-Ward has limited quantities available for the majority Fentanyl presentations.   There is currently a backorder on the 2 mL- 20 ml and 50 mL vials.   Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the February-March 2013 timeframe.   West-Ward has continued to accelerate production on all codes      Shortage per Manufacturer: Increase in product demand due to market supply issues.   Product will be made available as it is released.;50 mcg/mL 2 mL vial (NDC 0641-6027-25) West-Ward has limited quantities available for the majority Fentanyl presentations.   There is currently a backorder on the 2 mL- 20 ml and 50 mL vials.   Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the February-March 2013 timeframe.   West-Ward has continued to accelerate production on all codes      Shortage per Manufacturer: Increase in product demand due to market supply issues.   Product will be made available as it is released.;50 mcg/mL2 mL ampul (NDC 0641-6024-10) West-Ward has limited quantities available for the majority Fentanyl presentations.   There is currently a backorder on the 2 mL- 20 ml and 50 mL vials.   Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the February-March 2013 timeframe.   West-Ward has continued to accelerate production on all codes      Shortage per Manufacturer: Increase in product demand due to market supply issues.   Product will be made available as it is released.;50 mcg/mL 20 mL ampul (NDC 0641-6026-05) West-Ward has limited quantities available for the majority Fentanyl presentations.   There is currently a backorder on the 2 mL- 20 ml and 50 mL vials.   Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the February-March 2013 timeframe.   West-Ward has continued to accelerate production on all codes      Shortage per Manufacturer: Increase in product demand due to market supply issues.   Product will be made available as it is released.;50 mcg/mL  50 mL vial (NDC 0641-6030-01) West-Ward has limited quantities available for the majority Fentanyl presentations.   There is currently a backorder on the 2 mL- 20 ml and 50 mL vials.   Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the February-March 2013 timeframe.   West-Ward has continued to accelerate production on all codes      Shortage per Manufacturer: Increase in product demand due to market supply issues.   Product will be made available as it is released.;50 mcg/mL 5 mL ampul (NDC 0641-6025-10) West-Ward has limited quantities available for the majority Fentanyl presentations.   There is currently a backorder on the 2 mL- 20 ml and 50 mL vials.   Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the February-March 2013 timeframe.   West-Ward has continued to accelerate production on all codes      Shortage per Manufacturer: Increase in product demand due to market supply issues.   Product will be made available as it is released.;50 mcg/mL  50 mL vial (NDC 0641-6030-01) West-Ward is experiencing a backorder situation on the Fentanyl presentations.   There are very limited quantities available only for the 5 mL ampul.   West-Ward has continued to accelerate production on all codes.      Additional lots of all presentation are scheduled for manufacturing with anticipated release and availability in the July-August 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 20 mL vial(NDC 0641-6029-25) West-Ward is experiencing a backorder situation on the Fentanyl presentations.   There are very limited quantities available only for the 5 mL ampul.   West-Ward has continued to accelerate production on all codes.      Additional lots of all presentation are scheduled for manufacturing with anticipated release and availability in the July-August 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL2 mL ampul (NDC 0641-6024-10) West-Ward is experiencing a backorder situation on the Fentanyl presentations.   There are very limited quantities available only for the 5 mL ampul.   West-Ward has continued to accelerate production on all codes.      Additional lots of all presentation are scheduled for manufacturing with anticipated release and availability in the July-August 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 5 mL ampul (NDC 0641-6025-10) West-Ward is experiencing a backorder situation on the Fentanyl presentations.   There are very limited quantities available only for the 5 mL ampul.   West-Ward has continued to accelerate production on all codes.      Additional lots of all presentation are scheduled for manufacturing with anticipated release and availability in the July-August 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 2 mL vial (NDC 0641-6027-25) West-Ward is experiencing a backorder situation on the Fentanyl presentations.   There are very limited quantities available only for the 5 mL ampul.   West-Ward has continued to accelerate production on all codes.      Additional lots of all presentation are scheduled for manufacturing with anticipated release and availability in the July-August 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 5 mL vial (NDC 0641-6028-25) West-Ward is experiencing a backorder situation on the Fentanyl presentations.   There are very limited quantities available only for the 5 mL ampul.   West-Ward has continued to accelerate production on all codes.      Additional lots of all presentation are scheduled for manufacturing with anticipated release and availability in the July-August 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 20 mL ampul (NDC 0641-6026-05) West-Ward is experiencing a backorder situation on the Fentanyl presentations.   There are very limited quantities available only for the 5 mL ampul.   West-Ward has continued to accelerate production on all codes.      Additional lots of all presentation are scheduled for manufacturing with anticipated release and availability in the July-August 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL2 mL ampul (NDC 0641-6024-10) West-Ward is experiencing a backorder situation on most Fentanyl presentations.   There are very limited quantities available only for the 2 mL ampule.   West-Ward has continued to accelerate production on all codes.      Additional lots of all presentations are scheduled for manufacturing with anticipated release and availability in the August-September 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL  50 mL vial (NDC 0641-6030-01) West-Ward is experiencing a backorder situation on most Fentanyl presentations.   There are very limited quantities available only for the 2 mL ampule.   West-Ward has continued to accelerate production on all codes.      Additional lots of all presentations are scheduled for manufacturing with anticipated release and availability in the August-September 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 20 mL vial(NDC 0641-6029-25) West-Ward is experiencing a backorder situation on most Fentanyl presentations.   There are very limited quantities available only for the 2 mL ampule.   West-Ward has continued to accelerate production on all codes.      Additional lots of all presentations are scheduled for manufacturing with anticipated release and availability in the August-September 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 5 mL vial (NDC 0641-6028-25) West-Ward is experiencing a backorder situation on most Fentanyl presentations.   There are very limited quantities available only for the 2 mL ampule.   West-Ward has continued to accelerate production on all codes.      Additional lots of all presentations are scheduled for manufacturing with anticipated release and availability in the August-September 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 5 mL ampul (NDC 0641-6025-10) West-Ward is experiencing a backorder situation on most Fentanyl presentations.   There are very limited quantities available only for the 2 mL ampule.   West-Ward has continued to accelerate production on all codes.      Additional lots of all presentations are scheduled for manufacturing with anticipated release and availability in the August-September 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 20 mL ampul (NDC 0641-6026-05) West-Ward is experiencing a backorder situation on most Fentanyl presentations.   There are very limited quantities available only for the 2 mL ampule.   West-Ward has continued to accelerate production on all codes.      Additional lots of all presentations are scheduled for manufacturing with anticipated release and availability in the August-September 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 2 mL vial (NDC 0641-6027-25) West-Ward is experiencing a backorder situation on most Fentanyl presentations.   There are very limited quantities available only for the 2 mL ampule.   West-Ward has continued to accelerate production on all codes.      Additional lots of all presentations are scheduled for manufacturing with anticipated release and availability in the August-September 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 20 mL ampul (NDC 0641-6026-05) West-Ward has quantities available for most presentations.   There is currently a backorder situation on the 20 mL ampul only.      West-Ward has continued to accelerate production on all codes.   Additional lots of all presentations are scheduled for manufacturing with anticipated release and availability in the November 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL2 mL ampul (NDC 0641-6024-10) West-Ward has quantities available for most presentations.   There is currently a backorder situation on the 20 mL ampul only.      West-Ward has continued to accelerate production on all codes.   Additional lots of all presentations are scheduled for manufacturing with anticipated release and availability in the November 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 2 mL vial (NDC 0641-6027-25) West-Ward has quantities available for most presentations.   There is currently a backorder situation on the 20 mL ampul only.      West-Ward has continued to accelerate production on all codes.   Additional lots of all presentations are scheduled for manufacturing with anticipated release and availability in the November 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 20 mL vial(NDC 0641-6029-25) West-Ward has quantities available for most presentations.   There is currently a backorder situation on the 20 mL ampul only.      West-Ward has continued to accelerate production on all codes.   Additional lots of all presentations are scheduled for manufacturing with anticipated release and availability in the November 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL  50 mL vial (NDC 0641-6030-01) West-Ward has quantities available for most presentations.   There is currently a backorder situation on the 20 mL ampul only.      West-Ward has continued to accelerate production on all codes.   Additional lots of all presentations are scheduled for manufacturing with anticipated release and availability in the November 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 5 mL vial (NDC 0641-6028-25) West-Ward has quantities available for most presentations.   There is currently a backorder situation on the 20 mL ampul only.      West-Ward has continued to accelerate production on all codes.   Additional lots of all presentations are scheduled for manufacturing with anticipated release and availability in the November 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL 5 mL ampul (NDC 0641-6025-10) West-Ward has quantities available for most presentations.   There is currently a backorder situation on the 20 mL ampul only.      West-Ward has continued to accelerate production on all codes.   Additional lots of all presentations are scheduled for manufacturing with anticipated release and availability in the November 2013 timeframe.   Product will be made available as it is released.;50 mcg/mL  50 mL vial (NDC 0641-6030-01) West-Ward has quantities available for all presentations.        West-Ward has continued to accelerate production on all codes.   Additional lots of all presentations are scheduled for manufacturing with anticipated availability in the January ? February 2014 timeframe.   Product will be made available as it is released.;50 mcg/mL2 mL ampul (NDC 0641-6024-10) West-Ward has quantities available for all presentations.        West-Ward has continued to accelerate production on all codes.   Additional lots of all presentations are scheduled for manufacturing with anticipated availability in the January ? February 2014 timeframe.   Product will be made available as it is released.;50 mcg/mL 2 mL vial (NDC 0641-6027-25) West-Ward has quantities available for all presentations.        West-Ward has continued to accelerate production on all codes.   Additional lots of all presentations are scheduled for manufacturing with anticipated availability in the January ? February 2014 timeframe.   Product will be made available as it is released.;50 mcg/mL 20 mL ampul (NDC 0641-6026-05) West-Ward has quantities available for all presentations.        West-Ward has continued to accelerate production on all codes.   Additional lots of all presentations are scheduled for manufacturing with anticipated availability in the January ? February 2014 timeframe.   Product will be made available as it is released.;50 mcg/mL 20 mL vial(NDC 0641-6029-25) West-Ward has quantities available for all presentations.        West-Ward has continued to accelerate production on all codes.   Additional lots of all presentations are scheduled for manufacturing with anticipated availability in the January ? February 2014 timeframe.   Product will be made available as it is released.;50 mcg/mL 5 mL ampul (NDC 0641-6025-10) West-Ward has quantities available for all presentations.        West-Ward has continued to accelerate production on all codes.   Additional lots of all presentations are scheduled for manufacturing with anticipated availability in the January ? February 2014 timeframe.   Product will be made available as it is released.;50 mcg/mL 5 mL vial (NDC 0641-6028-25) West-Ward has quantities available for all presentations.        West-Ward has continued to accelerate production on all codes.   Additional lots of all presentations are scheduled for manufacturing with anticipated availability in the January ? February 2014 timeframe.   Product will be made available as it is released.,,,,,,,,,,,,,
WestWard,fentanyl,1,10/27/11,10/19/12,demand increase,orange,,"West-Ward is currently experiencing a backorder situation on all presentations due to unforeseen demand driven by competitor supply issues. West-Ward has accelerated production and will have the following products available. Lots of the 2 mL- 5 mL- and 20 mL ampul products will be released and available in November 2011. Additional lots of the 2 mL- 5 mL- 20 mL- and 50 mL vials are scheduled to be manufactured and available in the November ? December 2011 timeframe. Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on all presentations due to unforeseen demand driven by competitor supply issues. West-Ward has accelerated production and will have the following products available.
 Lots of the 2 mL- 5 mL- and 20 mL ampul products will be released and available in November 2011.
 Additional lots of the 2 mL- 5 mL- 20 mL- and 50 mL vials are scheduled to be manufactured and available in the November ? December 2011 timeframe.
 Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on all presentations due to unforeseen demand.  West-Ward has accelerated production on all codes and will have the following products available. Multiple lots of the 2 mL- 5 mL- and 20 mL ampuls are anticipated to be released and available in February and March 2012. Lots of the 2 mL- 5 mL- 20 mL- and 50 mL vials are scheduled to be manufactured and available for release in the February - March 2012 timeframe.  Additional lots are also scheduled for manufacturing in March. Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on most presentations due to market demand.  There are limited quantities currently available of the 5 mL and 20 mL vials.
  
 West-Ward has accelerated production on all codes and will have the following products available: 
 Multiple lots of the 2 mL- 5 mL- and 20 mL ampuls are anticipated to be released and available in the April - May 2012 timeframe.
  
 Lots of the 2 mL- 5 mL- 20 mL- and 50 mL vials are scheduled to be manufactured and available for release in the March - April 2012 timeframe.
  
 Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on most presentations due to market demand.  There are limited quantities currently available of the 5 mL and 20 mL vials.   West-Ward has accelerated production on all codes and will have the following products available: Multiple lots of the 2 mL- 5 mL- and 20 mL ampuls are anticipated to be released and available in the April - May 2012 timeframe.   Lots of the 2 mL- 5 mL- 20 mL- and 50 mL vials are scheduled to be manufactured and available for release in the March - April 2012 timeframe.   Product will be made available as it is released.;Increase in product demand due to market supply issues. West-Ward is currently experiencing a backorder situation on most presentations due to market demand.  There are limited quantities currently available of the 5 mL and 20 mL vials.   West-Ward has accelerated production on all codes and will have the following products available: Multiple lots of the 2 mL- 5 mL- and 20 mL ampuls are anticipated to be released and available in the April - May 2012 timeframe.   Lots of the 2 mL- 5 mL- 20 mL- and 50 mL vials are scheduled to be manufactured and available for release in the March - April 2012 timeframe.   Product will be made available as it is released.;;50 mcg/mL  50 mL vial (NDC 0641-6030-01) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots are scheduled for manufacturing with the following availability: Multiple lots of the 2 mL- 5 mL- and 20 mL ampuls are anticipated to be released and available in the July - August 2012 timeframe.Additional lots of the 2 mL- 5 mL- 20 mL- and 50 mL vials are also scheduled to be available in the July - August 2012 timeframe.   West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 2 mL ampul (NDC 0641-6024-10) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots are scheduled for manufacturing with the following availability: Multiple lots of the 2 mL- 5 mL- and 20 mL ampuls are anticipated to be released and available in the July - August 2012 timeframe.Additional lots of the 2 mL- 5 mL- 20 mL- and 50 mL vials are also scheduled to be available in the July - August 2012 timeframe.   West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 5 mL ampul (NDC 0641-6025-10) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots are scheduled for manufacturing with the following availability: Multiple lots of the 2 mL- 5 mL- and 20 mL ampuls are anticipated to be released and available in the July - August 2012 timeframe.Additional lots of the 2 mL- 5 mL- 20 mL- and 50 mL vials are also scheduled to be available in the July - August 2012 timeframe.   West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 20 mL ampul (NDC 0641-6026-05) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots are scheduled for manufacturing with the following availability: Multiple lots of the 2 mL- 5 mL- and 20 mL ampuls are anticipated to be released and available in the July - August 2012 timeframe.Additional lots of the 2 mL- 5 mL- 20 mL- and 50 mL vials are also scheduled to be available in the July - August 2012 timeframe.   West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 2 mL vial (NDC 0641-6027-25) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots are scheduled for manufacturing with the following availability: Multiple lots of the 2 mL- 5 mL- and 20 mL ampuls are anticipated to be released and available in the July - August 2012 timeframe.Additional lots of the 2 mL- 5 mL- 20 mL- and 50 mL vials are also scheduled to be available in the July - August 2012 timeframe.   West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 20 mL vial(NDC 0641-6029-25) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots are scheduled for manufacturing with the following availability: Multiple lots of the 2 mL- 5 mL- and 20 mL ampuls are anticipated to be released and available in the July - August 2012 timeframe.Additional lots of the 2 mL- 5 mL- 20 mL- and 50 mL vials are also scheduled to be available in the July - August 2012 timeframe.   West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 5 mL vial (NDC 0641-6028-25) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots are scheduled for manufacturing with the following availability: Multiple lots of the 2 mL- 5 mL- and 20 mL ampuls are anticipated to be released and available in the July - August 2012 timeframe.Additional lots of the 2 mL- 5 mL- 20 mL- and 50 mL vials are also scheduled to be available in the July - August 2012 timeframe.   West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL2 mL ampul (NDC 0641-6024-10) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots are scheduled for manufacturing with the following availability: Multiple lots of the 2 mL- 5 mL- and 20 mL ampuls are anticipated to be released and available in the July - August 2012 timeframe.Additional lots of the 2 mL- 5 mL- 20 mL- and 50 mL vials are also scheduled to be available in the July - August 2012 timeframe.   West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 2 mL vial (NDC 0641-6027-25) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the October - November 2012 timeframe.    West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL2 mL ampul (NDC 0641-6024-10) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the October - November 2012 timeframe.    West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 20 mL ampul (NDC 0641-6026-05) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the October - November 2012 timeframe.    West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL  50 mL vial (NDC 0641-6030-01) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the October - November 2012 timeframe.    West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 20 mL vial(NDC 0641-6029-25) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the October - November 2012 timeframe.    West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 5 mL vial (NDC 0641-6028-25) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the October - November 2012 timeframe.    West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;50 mcg/mL 5 mL ampul (NDC 0641-6025-10) West-Ward has limited quantities available for all Fentanyl presentations. Additional lots of all presentation are scheduled for manufacturing with anticipated released and available in the October - November 2012 timeframe.    West-Ward has continued to accelerate production on all codes.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.",,,,,,,,,,,,,
Akorn,fentanyl,2,11/2/12,3/25/14,demand increase; available,orange,,5 mL ample (NDC 17478-0030-05) Readily available;20 mL ample (NDC 17478-0030-20) Readily available;2 mL ampule; 25 pack (NDC 17478-0030-25) Readily available;2 mL ampule (NDC 17478-0030-02) Readily available;20 mL ample (NDC 17478-0030-20) Readily available  NA;2 mL ampule; 25 pack (NDC 17478-0030-25) Readily available  NA;5 mL ample (NDC 17478-0030-05) Readily available  NA;2 mL ampule (NDC 17478-0030-02) Readily available  NA;5 mL ample (NDC 17478-0030-05) Available in wholesalers. Releasing in July.  NA;2 mL ampule; 25 pack (NDC 17478-0030-25) Available in wholesalers. Releasing in July  NA;2 mL ampule (NDC 17478-0030-02) Available in wholesalers. Releasing in July.  NA;2 mL ampule; 25 pack (NDC 17478-0030-25) Available in wholesalers. Releasing additional lots in August.  NA;2 mL ampule (NDC 17478-0030-02) Available in wholesalers. Releasing additional lots in August.  NA;5 mL ampule (NDC 17478-0030-05) Available in wholesalers.  NA;20 mL ampule (NDC 17478-0030-20) Available in wholesalers  NA;5 mL ampule (NDC 17478-0030-05) Available in wholesalers.  Releasing additional lots in September.  NA;2 mL ampule (NDC 17478-0030-02) Available in wholesalers. Releasing additional lots in September.  NA;20 mL ampule (NDC 17478-0030-20) Available in wholesalers.  Releasing additional lots in September.  NA;2 mL ampule; 25 pack (NDC 17478-0030-25) Available in wholesalers. Releasing additional lots in September.  NA;5 mL ampule (NDC 17478-0030-05) Readily Available later this month;2 mL ampule (NDC 17478-0030-02) Readily Available;2 mL ampule; 25 pack (NDC 17478-0030-25) Readily Available;20 mL ampule (NDC 17478-0030-20) Readily Available;2 mL ampule; 10 pack (NDC 17478-0030-02) Readily Available;5 mL ampule 25 pack (NDC 17478-0030-55) Readily Available;5 mL ampule 10pack (NDC 17478-0030-05) Readily Available,,,,,,,,,,,,,
ActavisTotowa,fentanyl,1,4/22/11,4/22/11,manufacturing issues,blue,,Manufacturing issues N/A Manufacturing issues Not Applicable; Capable of Supplying 100 % of Market Demand N/A N/A N/A,,,,,,,,,,,,,
Apotex,fentanyl,1,4/22/11,4/22/11,manufacturing issues,blue,,Manufacturing issues N/A Manufacturing issues Not Applicable; Capable of Supplying 100 % of Market Demand N/A N/A N/A,,,,,,,,,,,,,
Covidien,fentanyl,1,4/22/11,4/22/11,manufacturing issues,blue,,Manufacturing issues N/A Manufacturing issues Not Applicable; Capable of Supplying 100 % of Market Demand N/A N/A N/A,,,,,,,,,,,,,
Mylan,fentanyl,1,4/22/11,4/22/11,manufacturing issues,blue,,Manufacturing issues N/A Manufacturing issues Not Applicable; Capable of Supplying 100 % of Market Demand N/A N/A N/A,,,,,,,,,,,,,
Novaplus,fentanyl,1,4/22/11,4/22/11,manufacturing issues,blue,,Manufacturing issues N/A Manufacturing issues Not Applicable; Capable of Supplying 100 % of Market Demand N/A N/A N/A,,,,,,,,,,,,,
OrthoMcNeilJanssen,fentanyl,1,4/22/11,4/22/11,manufacturing issues,blue,,Manufacturing issues N/A Manufacturing issues Not Applicable; Capable of Supplying 100 % of Market Demand N/A N/A N/A,,,,,,,,,,,,,
Sandoz,fentanyl,1,4/22/11,4/22/11,manufacturing issues,blue,,Manufacturing issues N/A Manufacturing issues Not Applicable; Capable of Supplying 100 % of Market Demand N/A N/A N/A,,,,,,,,,,,,,
APP,fluorouracil,1,8/25/11,7/12/12,demand increase; available,orange,,APP has fluorouracil injection 50mg/mL 20mL vials on intermittent back order and the company is releasing product as it becomes available.;APP has Fluorouracil injection 50 mg/mL- 10 mL vials on allocation (NDC63323-117-10)- 50 mg/mL- 50 mL vials are available (NDC 63323-117-51)- 50 mg/mL- 20 mL (NDC 63323-117-20) & 100 mL (63323-117-61) vials on intermittent back-order and the company is releasing product as it becomes available.;APP has Fluorouracil injection on allocation but product is readily available. Check with wholesalers for inventory.;APP has all presentations of Fluorouracil available. Check with wholesalers for inventory.;Increased demand APP has all presentations of Fluorouracil available. Check with wholesalers for inventory.;,,,,,,,,,,,,,
Teva,fluorouracil,1,8/25/11,7/12/12,manufacturing delays; available,blue,,Teva has all fluorouracil injection presentations on back order and the company estimates a release date of 4th quarter- 2011.;Teva has fluorouracil injection 50 mg/mL in 10 mL- 50 mL and 100 mL vials available with ample inventory.;Manufacturing delays Teva has fluorouracil injection 50 mg/mL in 10 mL- 50 mL and 100 mL vials available with ample inventory.;,,,,,,,,,,,,,
APP,fluphenazine,1,4/30/13,11/8/13,material shortage,green,,125 mg- 5mL- multi-dose vial (NDC 63323-272-05) Currently back-ordered. Check wholesalers for inventory.  Next release anticipated Q3-2013.   Shortage per Manufacturer:  Manufacturing delay due to raw material delays;125 mg- 5mL- multi-dose vial (NDC 63323-272-05) Currently back-ordered.  Next release  expected August 2013.   Shortage per Manufacturer:  Manufacturing delay due to raw material delays;125 mg- 5mL- multi-dose vial (NDC 63323-272-05) Available.  Check wholesalers for inventory.  Shortage per Manufacturer:  Manufacturing delay due to raw material delays,,,,,,,,,,,,,
Fresenius,fluphenazine,1,12/28/13,3/2/14,material shortage,green,,125 mg- 5mL- multi-dose vial (NDC 63323-272-05) Available.  Check wholesalers for inventory.  Shortage per Manufacturer:  Manufacturing delay due to raw material delays,,,,,,,,,,,,,
APP,fluphenazineh,1,4/30/13,11/8/13,material shortage,green,,25 mg- 10 mL- multi-dose vial (NDC 633323-281-10) 7 months dating available through manufacturer (expiry 11/30/2013) for direct or drop shipment.  Next release anticipated late May.  7 months dating available   Shortage per Manufacturer:  Manufacturing delay due to raw material delays;25 mg- 10 mL- multi-dose vial (NDC 633323-281-10) Available  Check wholesalers for inventory.  7 months dating available   Shortage per Manufacturer:  Manufacturing delay due to raw material delays;25 mg- 10 mL- multi-dose vial (NDC 633323-281-10) Available  Check wholesalers for inventory.  Available   Shortage per Manufacturer:  Manufacturing delay due to raw material delays,,,,,,,,,,,,,
GlaxoSmithKline,fluticasone,1,10/14/12,10/19/12,manufacturing delays,blue,,ADVAIR HFA 45/21mcg   (NDC# 0173-0715-20 & 0173-0715-22)   Out-of-Stock Resupply expected 1Q 2013   All other strengths remain available.,,,,,,,,,,,,,
GlaxoSmithKline,fluticasone,2,11/2/12,11/8/13,manufacturing delays,blue,,ADVAIR HFA 45/21mcg   (NDC# 0173-0715-20 & 0173-0715-22)   Out-of-Stock Resupply expected 1Q 2013   All other strengths remain available.;ADVAIR HFA 45/21mcg (NDC# 0173-0715-20 & 0173-0715-22)   Out-of-Stock Resupply expected 4Q 2013   All other strengths remain available.,,,,,,,,,,,,,
Clinigen,foscarnet,1,6/22/11,10/19/12,available,,,Please see letter for information about availability from Clinigen in the UK (PDF - 1.8MB);Please see attached Dear Healthcare Professional Letter (PDF - 519KB) for updated information regarding distribution.;;24 mg/mL; 250 mL bottle (NDC 76310-024-25)  Effective July 11- 2012 Foscavir is available in the US. Clinigen?s distributor is Hospira Inc.  To order product- please contact Hospira- requesting list no.  #1182-02. Shortage per Manufacturer: Clinigen?s Foscavir is now FDA approved and available. No further supply issues are anticipated.;24 mg/mL; 250 mL bottle (NDC 76310-024-25) Effective July 11- 2012 Foscavir is available in the US. Clinigen?s distributor is Hospira Inc.  To order product- please contact Hospira- requesting list no.  #1182-02. Shortage per Manufacturer: Clinigen?s Foscavir is now FDA approved and available. No further supply issues are anticipated.,,,,,,,,,,,,,
Clinigen,foscarnet,2,11/2/12,3/1/13,available,,,24 mg/mL; 250 mL bottle (NDC 76310-024-25) Effective July 11- 2012 Foscavir is available in the US. Clinigen?s distributor is Hospira Inc.  To order product- please contact Hospira- requesting list no.  #1182-02. Shortage per Manufacturer: Clinigen?s Foscavir is now FDA approved and available. No further supply issues are anticipated.,,,,,,,,,,,,,
Amphastar,foscarnet,1,8/20/10,8/28/10,demand increase,orange,,Unanticipated Increased Demand,,,,,,,,,,,,,
Hospira,foscarnet,1,8/7/10,4/22/11,demand increase; manufacturing delays,blue,,Manufacturing delays;Unanticipated Increased Demand,,,,,,,,,,,,,
WestWard,fosphenytoin,2,4/26/12,10/19/12,manufacturing delays; demand increase,blue,,Information pending;;2 mL vial (NDC 0143-9788-25) Both presentations on backorder. At this time- West-Ward does not have a projected availability date. Shortage per Manufacturer: Manufacturing delays;10 mL vial (NDC 0143-9782-10) Both presentations on backorder. At this time- West-Ward does not have a projected availability date. Shortage per Manufacturer: Manufacturing delays,,,,,,,,,,,,,
AmericanRegent,fosphenytoin,1,4/28/11,3/16/12,available; discontinued,black,,American Regent has available fosphenytoin 75 mg/mL in 2 ml vials (NDC 00517-6902-25).;American Regent reports availability of fosphenytoin 75 mg/mL in 2 ml vials (NDC 00517-6902-25).;No longer manufacturing.,,,,,,,,,,,,,
APP,fosphenytoin,2,11/2/12,11/8/13,demand increase,orange,,NDC # 63323-403-02 (100 mg PE/2 mL- 2 mL vial) Next delivery expected late October 2012 All presentations currently back-ordered.  Check wholesalers for available inventory. Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-10 (500 mg PE/10 mL- 10 mL vial) Check wholesaler inventory All presentations currently back-ordered.  Check wholesalers for available inventory. Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-02 (100 mg PE/2 mL- 2 mL vial) Next delivery expected January 2013 All presentations currently back-ordered.  Check wholesalers for available inventory.   Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-10 (500 mg PE/10 mL- 10 mL vial) Next delivery expected January 2013 All presentations currently back-ordered.  Check wholesalers for available inventory.   Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-10 (500 mg PE/10 mL- 10 mL vial) Next delivery expected March 2013 All presentations currently back-ordered.  Check wholesalers for available inventory.   Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-02 (100 mg PE/2 mL- 2 mL vial) Next delivery expected February 2013 All presentations currently back-ordered.  Check wholesalers for available inventory.   Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-10 (500 mg PE/10 mL- 10 mL vial) Next delivery expected mid March 2013 All presentations currently back-ordered.  Check wholesalers for available inventory.   Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-02 (100 mg PE/2 mL- 2 mL vial) Next delivery expected April 2013 All presentations currently back-ordered.  Check wholesalers for available inventory.   Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-02 (100 mg PE/2 mL- 2 mL vial) Next delivery expected May 2013 All presentations currently back-ordered.  Check wholesalers for available inventory.   Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-10 (500 mg PE/10 mL- 10 mL vial) Next delivery expected May 2013 All presentations currently back-ordered.  Check wholesalers for available inventory.   Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-02 (100 mg PE/2 mL- 2 mL vial) Next delivery expected June 2013 All presentations currently back-ordered.  Check wholesalers for available inventory.   Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-10 (500 mg PE/10 mL- 10 mL vial) Next delivery expected June 2013 All presentations currently back-ordered.  Check wholesalers for available inventory.   Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-10 (500 mg PE/10 mL- 10 mL vial) Available. Check wholesaler inventory. All presentations currently back-ordered.  Check wholesalers for available inventory.   Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-02 (100 mg PE/2 mL- 2 mL vial) Next delivery expected July 2013 All presentations currently back-ordered.  Check wholesalers for available inventory.   Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-02 (100 mg PE/2 mL- 2 mL vial) Next delivery expected late July 2013 All presentations currently back-ordered.  Check wholesalers for available inventory.   Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-10 (500 mg PE/10 mL- 10 mL vial) Available. Check wholesalers inventory. Check wholesalers for inventory on all presentations.   Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-02 (100 mg PE/2 mL- 2 mL vial) Available.  Check wholesalers for inventory. Check wholesalers for inventory on all presentations.   Shortage per Manufacturer: Increase in Demand,,,,,,,,,,,,,
WestWard,fosphenytoin,1,4/28/11,3/16/12,demand increase,orange,,West-Ward has available NDC# 0143-9788-25 fosphenytoin 150 mg/2ml and NDC# 0143-9782-10 fosphenytoin 750 mg/10 ml.,,,,,,,,,,,,,
APP,fosphenytoin,1,4/28/11,10/19/12,demand increase; available; ,orange,,APP continues to release product as it becomes available.;APP has all presentations available.;All presentations currently available.;Available All presentations currently available.;All presentations currently back-ordered - check wholesaler inventory.  Next releases expected early June.;;NDC # 63323-403-02 (100 mg PE/2 mL- 2 mL vial) Next releases expected early August All presentations currently back-ordered.  Check wholesalers for available inventory. Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-10 (500 mg PE/10 mL- 10 mL vial) Next releases expected early August All presentations currently back-ordered.  Check wholesalers for available inventory. Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-10 (500 mg PE/10 mL- 10 mL vial) Next releases expected late September All presentations currently back-ordered.  Check wholesalers for available inventory. Shortage per Manufacturer: Increase in Demand;NDC # 63323-403-02 (100 mg PE/2 mL- 2 mL vial) Next releases expected late September All presentations currently back-ordered.  Check wholesalers for available inventory. Shortage per Manufacturer: Increase in Demand,,,,,,,,,,,,,
Akorn,fosphenytoin,1,4/15/10,4/22/11,demand increase; manufacturing delays,blue,,Not currently marketed.   Manufacturing delays.     Not currently marketed.   Increase in demand.  ;Not currently marketed.       Manufacturing delays.     Not currently marketed.     Increase in demand.  ;Not currently marketed.     Manufacturing delays.   Not currently marketed.     Increase in demand.  ;Not currently marketed.             Manufacturing delays.   Not currently marketed.     Increase in demand.  ;Not currently marketed.   Manufacturing delays.   Not currently marketed.     Increase in demand.  ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand  ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ,,,,,,,,,,,,,
AmericanRegent,fosphenytoin,1,2/2/11,4/22/11,demand increase; manufacturing delays,blue,,Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ,,,,,,,,,,,,,
APP,fosphenytoin,1,4/15/10,4/22/11,demand increase; manufacturing delays,blue,,Not currently marketed.   Manufacturing delays.     Not currently marketed.   Increase in demand.  ;Not currently marketed.       Manufacturing delays.     Not currently marketed.     Increase in demand.  ;Not currently marketed.     Manufacturing delays.   Not currently marketed.     Increase in demand.  ;Not currently marketed.             Manufacturing delays.   Not currently marketed.     Increase in demand.  ;Not currently marketed.   Manufacturing delays.   Not currently marketed.     Increase in demand.  ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand  ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ,,,,,,,,,,,,,
Bedford,fosphenytoin,1,4/15/10,4/22/11,demand increase; manufacturing delays,blue,,Not currently marketed.   Manufacturing delays.     Not currently marketed.   Increase in demand.  ;Not currently marketed.       Manufacturing delays.     Not currently marketed.     Increase in demand.  ;Not currently marketed.     Manufacturing delays.   Not currently marketed.     Increase in demand.  ;Not currently marketed.             Manufacturing delays.   Not currently marketed.     Increase in demand.  ;Not currently marketed.   Manufacturing delays.   Not currently marketed.     Increase in demand.  ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand  ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ,,,,,,,,,,,,,
Hospira,fosphenytoin,1,4/15/10,4/22/11,demand increase; manufacturing delays,blue,,Not currently marketed.   Manufacturing delays.     Not currently marketed.   Increase in demand.  ;Not currently marketed.       Manufacturing delays.     Not currently marketed.     Increase in demand.  ;Not currently marketed.     Manufacturing delays.   Not currently marketed.     Increase in demand.  ;Not currently marketed.             Manufacturing delays.   Not currently marketed.     Increase in demand.  ;Not currently marketed.   Manufacturing delays.   Not currently marketed.     Increase in demand.  ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand  ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ,,,,,,,,,,,,,
WestWard,fosphenytoin,1,11/18/10,4/22/11,demand increase; manufacturing delays,blue,,Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand  ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ;Not currently marketed   Manufacturing delays   Not currently marketed   Increase in demand Increased demand Newly launched product ,,,,,,,,,,,,,
WestWard,fosphenytoin,3,11/2/12,11/8/13,demand increase; manufacturing delays,blue,,2 mL vial (NDC 0143-9788-25) Both presentations on backorder. At this time- West-Ward does not have a projected availability date. Shortage per Manufacturer: Manufacturing delays;10 mL vial (NDC 0143-9782-10) Both presentations on backorder. At this time- West-Ward does not have a projected availability date. Shortage per Manufacturer: Manufacturing delays;10 mL vial (NDC 0143-9782-10) West-Ward is currently experiencing a backorder situation on both presentations. At this time- West-Ward does not have a projected availability date.;2 mL vial (NDC 0143-9788-25) West-Ward is currently experiencing a backorder situation on both presentations. At this time- West-Ward does not have a projected availability date.;10 mL vial (NDC 0641-6137-10)   West-Ward will have limited quantities available of the 2 mL vial in the beginning of August and the 10 mL vial presentation by the end of August 2013. West-Ward has resumed production. Additional quantities  will be available in September 2013.  Product will be made available as it is released.;2 mL vial (NDC 0641-6136-25)   West-Ward will have limited quantities available of the 2 mL vial in the beginning of August and the 10 mL vial presentation by the end of August 2013. West-Ward has resumed production. Additional quantities  will be available in September 2013.  Product will be made available as it is released.;2 mL vial (NDC 0641-6136-25)  50 mg PE/ml (PE = phenytoin sodium equivalents)   West-Ward currently has quantities available for both presentations West-Ward has resumed production. Additional quantities of both the 2 mL and 10 mL will be available in September 2013.  Product will be made available as it is released.;10 mL vial (NDC 0641-6137-10) 50 mg PE/ml (PE = phenytoin sodium equivalents)   West-Ward currently has quantities available for both presentations West-Ward has resumed production. Additional quantities of both the 2 mL and 10 mL will be available in September 2013.  Product will be made available as it is released.,,,,,,,,,,,,,
Akorn,fosphenytoin,1,4/28/11,3/16/12,production suspended,,,Akorn will be off the market for an undefined period of time.;Akorn will be off the market for an period of time.,,,,,,,,,,,,,
Bedford,fosphenytoin,1,4/28/11,3/16/12,production suspended; discontinued,black,,Bedford will be off the market for an undefined period of time.;Bedford will be off the market for an;Bedford does not have any reported date of availability.;Product Discontinued: Bedford currently has all presentations discontinued.,,,,,,,,,,,,,
Eisai,fospropofol,2,11/2/12,4/11/13,production suspended,,,NULL Product is no longer available. Shortage per Manufacturer: Suspension of manufacturing/Market withdrawal requested;1050 mg/30 mL (35 mg/mL)- 30 mL vial (NDC 62856-350-08) Product is no longer available. Shortage per Manufacturer: Suspension of manufacturing/Market withdrawal requested,,,,,,,,,,,,,
Eisai,fospropofol,1,6/23/12,10/19/12,production suspended; available,,,;NULL Product is no longer available. Please check with your wholesaler for available inventory.   Shortage per Manufacturer: Suspension of manufacturing/Market withdrawal requested;1050 mg/30 mL (35 mg/mL)- 30 mL vial (NDC 62856-350-08) Product is no longer available. Please check with your wholesaler for available inventory.   Shortage per Manufacturer: Suspension of manufacturing/Market withdrawal requested;1050 mg/30 mL (35 mg/mL)- 30 mL vial (NDC 62856-350-08) Product is no longer available. Shortage per Manufacturer: Suspension of manufacturing/Market withdrawal requested;NULL Product is no longer available. Shortage per Manufacturer: Suspension of manufacturing/Market withdrawal requested,,,,,,,,,,,,,
AmericanRegent,furosemide,2,6/23/12,10/19/12,available; not releasing,,,;10 mg/mL 10 mL vial (NDC 00517-5710-25) Unavailable American Regent is currently not releasing Furosemide Injection- USP.;10 mg/mL 2 mL vial (NDC 00517-5702-25) Unavailable American Regent is currently not releasing Furosemide Injection- USP.;10 mg/mL 4 mL vial (NDC 00517-5704-25) Unavailable American Regent is currently not releasing Furosemide Injection- USP.,,,,,,,,,,,,,
APP,furosemide,2,6/23/12,10/19/12,; demand increase,orange,,;20 mg/2 mL- SDV (NDC 63323-028-002) Next delivery late July. All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;100 mg/10 mL- SDV (NDC 63323-028-010)  Next delivery late July. All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;40 mg/4 mL- SDV (NDC 63323-028-004) Next delivery late July. All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;100 mg/10 mL- SDV (NDC 63323-028-010)  Next delivery anticipated late September All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;40 mg/4 mL- SDV (NDC 63323-028-004) Next delivery anticipated mid-October All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;20 mg/2 mL- SDV (NDC 63323-028-002) Next delivery anticipated late September All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;100 mg/10 mL- SDV (NDC 63323-028-010)  Next delivery expected for October 2012 All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;20 mg/2 mL- SDV (NDC 63323-028-002) Next delivery expected for November 2012 All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.,,,,,,,,,,,,,
Amphastar,furosemide,1,8/20/10,8/28/10,demand increase,orange,,Unanticipated increased demand,,,,,,,,,,,,,
APP,furosemide,3,11/2/12,11/8/13,demand increase,orange,,100 mg/10 mL- SDV (NDC 63323-028-010)  Check wholesalers for inventory All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;20 mg/2 mL- SDV (NDC 63323-028-002) Next delivery expected for November 2012 All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;40 mg/4 mL- SDV (NDC 63323-028-004) Next delivery anticipated November All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;100 mg/10 mL- SDV (NDC 63323-028-010)  Back-ordered. No estimated delivery at this time. All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;20 mg/2 mL- SDV (NDC 63323-028-002) Next delivery expected for January 2013 All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;40 mg/4 mL- SDV (NDC 63323-028-004) Next delivery anticipated December All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;40 mg/4 mL- SDV (NDC 63323-028-004) Next delivery expected March 2013. Check wholesalers for inventory All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;20 mg/2 mL- SDV (NDC 63323-028-002) Next delivery expected March 2013. Check wholesalers for inventory All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;20 mg/2 mL- SDV (NDC 63323-028-002) Backordered.  Next release anticipated Q3 2013. All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;40 mg/4 mL- SDV (NDC 63323-028-004) Allocated.  Next release anticipated Q3 2013. All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;40 mg/4 mL- SDV (NDC 63323-028-004) Manufacturer allocating.  Next release anticipated Q3 2013. All presentations currently back-ordered. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.,,,,,,,,,,,,,
Fresenius,furosemide,1,12/28/13,3/2/14,demand increase,orange,,100 mg/10 mL- SDV (NDC 63323-028-010)  Available.  Check wholesalers for inventory. All presentations are available. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;20 mg/2 mL- SDV (NDC 63323-028-002) Available.  Check wholesalers for inventory. All presentations are available. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.;40 mg/4 mL- SDV (NDC 63323-028-004) Available.  Check wholesalers for inventory. All presentations are available. Check wholesalers for available inventory. Shortage per Manufacturer: Increased demand.,,,,,,,,,,,,,
AmericanRegent,furosemide,1,4/28/11,3/1/12,demand increase; available,orange,,American Regent- Inc.- the distributor of Furosemide Injection- USP 10 mg/mL manufactured by Luitpold Pharmaceuticals- Inc.- will continue to notify its wholesalers of the product release dates for all three presentations of Furosemide Injection- USP 10 mg/mL (2 mL vial- 4 mL in a 5 mL vial and 10 mL vial) so they can communicate product availability and appropriately allocate to the end use.;American Regent has all presentations available: 2 mL vial (NDC 00517-5702-25)- 4 mL vial (NDC 00517-5704-25)- and 10 mL vial (NDC 00517-5710-25).,,,,,,,,,,,,,
APP,furosemide,1,4/28/11,3/1/12,demand increase; available,orange,,APP has available furosemide 10 mg/mL injection 2 mL (NDC 63323-0280-02) and 4 mL (NDC 63323-0280-04) vials.;APP has furosemide 10mg/ml 2 mL vials (NDC 63323-0280-02)- 4 mL vials (NDC 63323-0280-04)- and 10 mL vials (NDC 63323-0280-10) available.,,,,,,,,,,,,,
AmericanRegent,furosemide,1,6/25/10,8/15/10,demand increase; manufacturing delays,blue,,Manufacturing delays             Increase in demand                                   Increase in demand;Manufacturing delays       Increase in demand                                 Increase in demand;Manufacturing delays       Increase in demand                                 Increase in demand,,,,,,,,,,,,,
AmericanRegent,furosemide,2,9/14/10,4/22/11,demand increase; manufacturing delays,blue,,Manufacturing delays       Increase in demand                                 Increase in demand;Manufacturing delays       Increase in demand                                 Increase in demand;Manufacturing delays       Increase in demand                                 Increase in demand,,,,,,,,,,,,,
APP,furosemide,1,6/25/10,8/15/10,demand increase; manufacturing delays,blue,,Manufacturing delays             Increase in demand                                   Increase in demand;Manufacturing delays       Increase in demand                                 Increase in demand;Manufacturing delays       Increase in demand                                 Increase in demand,,,,,,,,,,,,,
APP,furosemide,2,9/14/10,4/22/11,demand increase; manufacturing delays,blue,,Manufacturing delays       Increase in demand                                 Increase in demand;Manufacturing delays       Increase in demand                                 Increase in demand;Manufacturing delays       Increase in demand                                 Increase in demand,,,,,,,,,,,,,
Hospira,furosemide,1,6/25/10,4/22/11,manufacturing delays,blue,,Manufacturing delays             Increase in demand                                   Increase in demand;Manufacturing delays       Increase in demand                                 Increase in demand;Manufacturing delays       Increase in demand                                 Increase in demand;Unanticipated increased demand;Manufacturing delays       Increase in demand                                 Increase in demand;Manufacturing delays       Increase in demand                                 Increase in demand;Manufacturing delays       Increase in demand                                 Increase in demand,,,,,,,,,,,,,
AmericanRegent,furosemide,3,11/2/12,3/2/14,not releasing,,,10 mg/mL 4 mL vial (NDC 00517-5704-25) Unavailable American Regent is currently not releasing Furosemide Injection- USP.;10 mg/mL 10 mL vial (NDC 00517-5710-25) Unavailable American Regent is currently not releasing Furosemide Injection- USP.;10 mg/mL 2 mL vial (NDC 00517-5702-25) Unavailable American Regent is currently not releasing Furosemide Injection- USP.;10 mg/mL 4 mL vial (NDC 00517-5704-25) Available American Regent is currently releasing the 4 mL vial of Furosemide Injection- USP.   American Regent is currently not releasing the 2 mL vial or 10 mL vial of Furosemide Injection- USP.;10 mg/mL 10 mL vial (NDC 00517-5710-25) Unavailable American Regent is currently releasing the 4 mL vial of Furosemide Injection- USP.   American Regent is currently not releasing the 2 mL vial or 10 mL vial of Furosemide Injection- USP.;10 mg/mL 2 mL vial (NDC 00517-5702-25) Unavailable American Regent is currently releasing the 4 mL vial of Furosemide Injection- USP.   American Regent is currently not releasing the 2 mL vial or 10 mL vial of Furosemide Injection- USP.;10 mg/mL 2 mL vial (NDC 00517-5702-25) Unavailable American Regent is currently not releasing the 2 mL- 4 mL or 10 mL vial of Furosemide Injection- USP.;10 mg/mL 10 mL vial (NDC 00517-5710-25) Unavailable American Regent is currently not releasing the 2 mL- 4 mL or 10 mL vial of Furosemide Injection- USP.;10 mg/mL 4 mL vial (NDC 00517-5704-25) Unavailable American Regent is currently not releasing the 2 mL- 4 mL or 10 mL vial of Furosemide Injection- USP.;10 mg/mL 2 mL vial (NDC 00517-5702-25) Unavailable American Regent is currently not releasing the 2 mL- 4 mL or 10 mL vial size of Furosemide Injection- USP.;10 mg/mL 4 mL vial (NDC 00517-5704-25) Unavailable American Regent is currently not releasing the 2 mL- 4 mL or 10 mL vial size of Furosemide Injection- USP.;10 mg/mL 10 mL vial (NDC 00517-5710-25) Unavailable American Regent is currently not releasing the 2 mL- 4 mL or 10 mL vial size of Furosemide Injection- USP.,,,,,,,,,,,,,
XenoPort,gabapentin,2,8/1/13,8/1/13,available,,,Horizant (gabapentin enacarbil) Extended- Release Tablets 600 mg  Available Please check with your wholesaler for available inventory.,,,,,,,,,,,,,
XenoPort,gabapentin,1,4/30/13,7/7/13,manufacturing delays; available,blue,,Horizant (gabapentin enacarbil) Extended- Release Tablets 600 mg  GlaxoSmithKline is currently experiencing a backorder situation for Horizant Tablets. XenoPort will assume responsibility for manufacturing and commercialization of Horizant on May 1- 2013. XenoPort anticipates lack of product availability to extend into June 2013. Manufacturing delays at contract manufacturer;Horizant (gabapentin enacarbil) Extended- Release Tablets 600 mg  Available Please check with your wholesaler for available inventory.,,,,,,,,,,,,,
Genta,gallium,1,6/5/13,8/15/13,discontinued,black,,No estimated date of availability. Business decision,,,,,,,,,,,,,
Genta,ganite,1,4/18/12,10/19/12,business decision; discontinued,black,,No estimated date of availability.;Business decision No estimated date of availability.;;No estimated date of availability. Business decision,,,,,,,,,,,,,
Genta,ganite,2,11/2/12,6/3/13,discontinued,black,,No estimated date of availability. Business decision,,,,,,,,,,,,,
Camber,gemfibrozil,1,5/27/10,6/20/10,demand increase,orange,,Increase in demand         Increase in demand         Change awaiting FDA approval,,,,,,,,,,,,,
Pfizer,gemfibrozil,1,5/27/10,6/20/10,demand increase,orange,,Increase in demand         Increase in demand         Change awaiting FDA approval,,,,,,,,,,,,,
Teva,gemfibrozil,1,5/27/10,6/20/10,demand increase,orange,,Increase in demand         Increase in demand         Change awaiting FDA approval,,,,,,,,,,,,,
Camber,gemifibrozil,1,3/12/10,5/21/10,demand increase,orange,,Increase in demand         Increase in demand         Change awaiting FDA approval,,,,,,,,,,,,,
Pfizer,gemifibrozil,1,3/12/10,5/21/10,demand increase,orange,,Increase in demand         Increase in demand         Change awaiting FDA approval,,,,,,,,,,,,,
Teva,gemifibrozil,1,3/12/10,5/21/10,demand increase,orange,,Increase in demand         Increase in demand         Change awaiting FDA approval,,,,,,,,,,,,,
Bedford,gluca,1,10/19/10,3/14/11,manufacturing delays,blue,, Manufacturing delays   Manufacturing delays  ; Manufacturing delays   Manufacturing delays  ,,,,,,,,,,,,,
EliLilly,gluca,1,10/19/10,3/14/11,manufacturing delays,blue,, Manufacturing delays   Manufacturing delays  ; Manufacturing delays   Manufacturing delays  ,,,,,,,,,,,,,
NovoNordisk,gluca,1,10/19/10,3/14/11,manufacturing delays,blue,, Manufacturing delays   Manufacturing delays  ; Manufacturing delays   Manufacturing delays  ,,,,,,,,,,,,,
APP,haloperidol,1,6/20/10,8/15/10,manufacturing delays,blue,,Manufacturing delays           See Related Information               See Related Information                             Manufacturing delays;Manufacturing delays           See Related Information               See Related Information                             Manufacturing delays;Manufacturing delays           See Related Information               See Related Information                   Manufacturing delays,,,,,,,,,,,,,
APP,haloperidol,2,9/14/10,4/22/11,manufacturing delays,blue,,Manufacturing delays           See Related Information               See Related Information                   Manufacturing delays;Manufacturing delays       See Related Information               See Related Information                 Manufacturing delays;Manufacturing delays     See Related Information       See Related Information             Manufacturing delays;Manufacturing delays     See Related Information       See Related Information             Manufacturing delays;Manufacturing delays     See Related Information       See Related Information             Manufacturing delays,,,,,,,,,,,,,
Bedford,haloperidol,1,6/20/10,8/15/10,manufacturing delays,blue,,Manufacturing delays           See Related Information               See Related Information                             Manufacturing delays;Manufacturing delays           See Related Information               See Related Information                             Manufacturing delays;Manufacturing delays           See Related Information               See Related Information                   Manufacturing delays,,,,,,,,,,,,,
Bedford,haloperidol,2,9/14/10,4/22/11,manufacturing delays,blue,,Manufacturing delays           See Related Information               See Related Information                   Manufacturing delays;Manufacturing delays       See Related Information               See Related Information                 Manufacturing delays;Manufacturing delays     See Related Information       See Related Information             Manufacturing delays;Manufacturing delays     See Related Information       See Related Information             Manufacturing delays;Manufacturing delays     See Related Information       See Related Information             Manufacturing delays,,,,,,,,,,,,,
Hospira,haloperidol,1,8/20/10,8/28/10,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
OrthoMcNeilJanssen,haloperidol,1,6/20/10,8/15/10,manufacturing delays,blue,,Manufacturing delays           See Related Information               See Related Information                             Manufacturing delays;Manufacturing delays           See Related Information               See Related Information                             Manufacturing delays;Manufacturing delays           See Related Information               See Related Information                   Manufacturing delays,,,,,,,,,,,,,
OrthoMcNeilJanssen,haloperidol,2,9/14/10,4/22/11,manufacturing delays,blue,,Manufacturing delays           See Related Information               See Related Information                   Manufacturing delays;Manufacturing delays       See Related Information               See Related Information                 Manufacturing delays;Manufacturing delays     See Related Information       See Related Information             Manufacturing delays;Manufacturing delays     See Related Information       See Related Information             Manufacturing delays;Manufacturing delays     See Related Information       See Related Information             Manufacturing delays,,,,,,,,,,,,,
Teva,haloperidol,1,6/20/10,8/15/10,manufacturing delays,blue,,Manufacturing delays           See Related Information               See Related Information                             Manufacturing delays;Manufacturing delays           See Related Information               See Related Information                             Manufacturing delays;Manufacturing delays           See Related Information               See Related Information                   Manufacturing delays,,,,,,,,,,,,,
Teva,haloperidol,2,9/14/10,4/22/11,manufacturing delays,blue,,Manufacturing delays           See Related Information               See Related Information                   Manufacturing delays;Manufacturing delays       See Related Information               See Related Information                 Manufacturing delays;Manufacturing delays     See Related Information       See Related Information             Manufacturing delays;Manufacturing delays     See Related Information       See Related Information             Manufacturing delays;Manufacturing delays     See Related Information       See Related Information             Manufacturing delays,,,,,,,,,,,,,
Teva,haloperidol,1,4/28/11,3/16/12,manufacturing delays,blue,,Teva has all presentations on back order.;Teva has all haloperidol decanoate presentations on long-term back order and the company cannot provide a release date.,,,,,,,,,,,,,
Bedford,haloperidol,1,4/28/11,3/16/12,manufacturing delays; discontinued,black,,Bedford has all haloperidol decanoate presentations on long term back order.;Bedford has all presentations of the Haloperidol Decanoate discontinued.,,,,,,,,,,,,,
APP,haloperidol,1,4/28/11,3/16/12,,,,APP has haloperidol decanoate available in 50 mg/mL 5 mL vials (NDC 63323-0469-05). 100 mg/mL 5 mL vials (NDC 63323-0471-05) and 100 mg/mL 1mL vials (NDC 63323-0471-01) and 50 mg/mL 1 mL vials (NDC 63323-0469-01) are being released as they become available.;APP has available Haloperidol Decanoate  50mg/mL- 5 mL vials (NDC 63323-0469-05)- and  and 100mg/mL- 5 mL (NDC 63323-0471-05) vials. The 100 mg/mL 1 mL (NDC 63323-0471-01) &  50 mg/mL 1 mL (NDC 63323-0469-01) presentations are on backorder and the company is releasing product as it becomes available.;APP has all presentations of Haloperidol Decanoate available - 50mg/mL- 5 mL vials (NDC 63323-0469-05)- 100mg/mL- 5 mL (NDC 63323-0471-05) vials- 100 mg/mL 1 mL (NDC 63323-0471-01) &  50 mg/mL 1 mL (NDC 63323-0469-01).,,,,,,,,,,,,,
Baxter,heparin,1,10/6/13,3/25/14,demand increase,orange,,2000 USP Heparin Units and 0.9% Sodium Chloride Injection in 1000 mL (NDC 0338-0433-04) Baxter continues to release product and anticipates supplies to recover by November 2013;1000 USP Heparin Units and 0.9% Sodium Chloride Injection in 500 mL (NDC 0338-0431-03)   Baxter continues to release product and anticipates supplies to recover by November 2013;2000 USP Heparin Units and 0.9% Sodium Chloride Injection in 1000 mL (NDC 0338-0433-04) Available;1000 USP Heparin Units and 0.9% Sodium Chloride Injection in 500 mL (NDC 0338-0431-03)   Baxter continues to release product and anticipates supplies to recover by March 2014;1000 USP Heparin Units and 0.9% Sodium Chloride Injection in 500 mL (NDC 0338-0431-03)   Baxter continues to release product and anticipates supplies to recover by May 2014,,,,,,,,,,,,,
Bbraun,heparin,1,8/19/13,3/25/14,demand increase,orange,,Heparin Sodium (100 U/mL)/5% Dextrose in 250 mL flexible plastic container P5872 (NDC 0264-9587-20) Not available.   Product availability in 2 months. N/A;Heparin Sodium (40 U/mL)/ 5% Dextrose in 500 mL flexible plastic container P5671 (NDC 0264-9567-10) Not available.   Product availability in 2 months. N/A;Heparin Sodium (50 U/mL)/5% Dextrose in 500 mL flexible plastic container P5771 (NDC 0264-9577-10) Not available.   Product availability in 2 months. N/A;Heparin Sodium (100 U/mL)/5% Dextrose in 250 mL flexible plastic container P5872 (NDC 0264-9587-20) Not available. Product availability in 2 months. N/A;Heparin Sodium (40 U/mL)/ 5% Dextrose in 500 mL flexible plastic container P5671 (NDC 0264-9567-10) Not available. Product availability in 2 months. N/A;Heparin Sodium (50 U/mL)/5% Dextrose in 500 mL flexible plastic container P5771 (NDC 0264-9577-10) Not available. Product availability in 2 months. N/A;Heparin Sodium (100 U/mL)/5% Dextrose in 250 mL flexible plastic container P5872 (NDC 0264-9587-20) Not available. Product availability in 2 months. Intermittent supply. Shortage per manufacturing disruption;Heparin Sodium (40 U/mL)/ 5% Dextrose in 500 mL flexible plastic container P5671 (NDC 0264-9567-10) Not available. Product availability in 2 months. Intermittent supply. Shortage per manufacturing disruption;Heparin Sodium (50 U/mL)/5% Dextrose in 500 mL flexible plastic container P5771 (NDC 0264-9577-10) Not available. Product availability in 2 months. Intermittent supply. Shortage per manufacturing disruption,,,,,,,,,,,,,
WestWard,heparin,1,10/6/13,3/25/14,demand increase,orange,,1-000 units/mL- 1 mL vial (NDC 0641-0391-12) West-Ward currently has inventory available for all presentations. West-Ward is anticipating having additional product available by the end of October 2013. Product will be made available as it is released.;1-000 units/mL- 30 mL vial (NDC 0641-2450-55) West-Ward currently has inventory available for all presentations. West-Ward is anticipating having additional product available by the end of October 2013. Product will be made available as it is released.;10-000 units/mL- 1 mL vial (NDC 0641-0410-12) West-Ward currently has inventory available for all presentations. West-Ward is anticipating having additional product available by the end of October 2013. Product will be made available as it is released.;5-000 units/mL- 1 mL vial (NDC 0641-0400-12) West-Ward currently has inventory available for all presentations. West-Ward is anticipating having additional product available by the end of October 2013. Product will be made available as it is released.;5-000 units/mL- 10 mL vial (NDC 0641-2460-55) West-Ward currently has inventory available for all presentations. West-Ward is anticipating having additional product available by the end of October 2013. Product will be made available as it is released.;1-000 units/mL- 1 mL vial (NDC 0641-0391-12) West-Ward currently has inventory available for all presentations. West-Ward has increased production and will have product available as it is released.;5-000 units/mL- 1 mL vial (NDC 0641-0400-12) West-Ward currently has inventory available for all presentations. West-Ward has increased production and will have product available as it is released.;1-000 units/mL- 30 mL vial (NDC 0641-2450-55) West-Ward currently has inventory available for all presentations. West-Ward has increased production and will have product available as it is released.;5-000 units/mL- 10 mL vial (NDC 0641-2460-55) West-Ward currently has inventory available for all presentations. West-Ward has increased production and will have product available as it is released.;10-000 units/mL- 1 mL vial (NDC 0641-0410-12) West-Ward currently has inventory available for all presentations. West-Ward has increased production and will have product available as it is released.,,,,,,,,,,,,,
Fresenius,heparin,1,12/28/13,3/25/14,manufacturing delays,blue,,10-000 USP/ 1 mL MDV (NDC 63323-542-01) Backordered.  Next release anticipated early January 2014. Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay;2-000 USP/ 2 mL SDV (NDC 63323-276-02) Available.  Check wholesalers for inventory. Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay;10-000 USP / 10 mL MDV (NDC 63323-540-11) Available.  Check wholesalers for inventory. Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay;50-000 USP/ 10 mL MDV (NDC 63323-047-10) Available.  Check wholesalers for inventory. Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay;30-000 USP/ 30 mL  MDV (NDC 63323-540-31) Available.  Check wholesalers for inventory. Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay;5-000 USP / 0.5 mL SDV PF (NDC 63323-543-02) Backordered.  Next release anticipated early January 2014. Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay;1-000 USP/ 1 mL MDV (NDC 63323-540-01) Backordered.  Next release anticipated December 2013. Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay;20-000 USP/ 1 mL  MDV (NDC 63323-915-01) Available.  Check wholesalers for inventory. Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay;5-000 USP/ 1 mL MDV (NDC 63323-262-01) Backordered. Next release anticipated December 2013. Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay;40-000 USP / 4 mL MDV (NDC 63323-459-09) Available.  Check wholesalers for inventory. Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay;50-000 USP/ 5 mL MDV (NDC 63323-542-07) Available.  Check wholesalers for inventory. Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay;1-000 USP/ 1 mL MDV (NDC 63323-540-01) Available.  Check wholesalers for inventory. Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay;5-000 USP/ 1 mL MDV (NDC 63323-262-01) Backordered.  Next release anticipated March 2014. Check wholesalers for inventory.   Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay;5-000 USP / 0.5 mL SDV PF (NDC 63323-543-02) Backordered.  Next release anticipated April 2014. Check wholesalers for inventory.   Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay;10-000 USP/ 1 mL MDV (NDC 63323-542-01) Backordered.  Next release anticipated March 2014.  Check wholesalers for inventory. Check wholesalers for inventory.   Shortage per Manufacturer: Manufacturing Delay,,,,,,,,,,,,,
APP,heparin,1,10/6/13,11/8/13,manufacturing delays; available,blue,,10-000 usp / 1 mL MDV (NDC #63323-542-01) Available.  Check wholesalers for inventory.;10-000 usp / 10 mL MDV (NDC #63323-540-11) Available.  Check wholesalers for inventory.;20-000 usp / 1 mL  MDV (NDC #63323-915-01) Available.  Check wholesalers for inventory.;30-000 usp / 30 mL  MDV (NDC # 63323-540-31) Available.  Check wholesalers for inventory.;40-000 usp / 4 mL MDV (NDC #63323-459-09) Available.  Check wholesalers for inventory.;5-000 usp / 1 mL MDV (NDC #63323-262-01) Available.  Check wholesalers for inventory.;50-000 usp / 10 mL MDV (NDC # 63323-047-10) Available.  Check wholesalers for inventory.;50-000 usp / 5 mL MDV (NDC #63323-542-07) Available.  Check wholesalers for inventory.;2-000 usp / 2 mL SDV (NDC #63323-276-02) Available.  Check wholesalers for inventory. Check wholesalers for inventory.;1-000 usp / 1 mL MDV (NDC #63323-540-01) Backordered.  Next release anticipated mid-October.;5-000 usp / 0.5 mL SDV PF (NDC #63323-543-02) Backordered.  Next release anticipated early October.,,,,,,,,,,,,,
Baxter,heparin,1,6/6/09,9/6/09,product recall,yellow,,Product recall,,,,,,,,,,,,,
Bbraun,heparin,1,6/6/09,9/6/09,product recall,yellow,,Product recall,,,,,,,,,,,,,
Baxter,heparin,2,2/20/10,9/23/10,,,,Shortage of Heparin Sodium drug substance that meets current qualification requirements                 Shortage of finished product that meets current specification.                 Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;Shortage of Heparin Sodium drug substance that meets current qualification requirements             Shortage of finished product that meets current specification.             Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;Shortage of Heparin Sodium drug substance that meets current qualification requirements                     Shortage of finished product that meets current specification.                         Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;Shortage of Heparin Sodium drug substance that meets current qualification requirements                     Shortage of finished product that meets current specification.                       Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;Shortage of Heparin Sodium drug substance that meets current qualification requirements           Shortage of finished product that meets current specification.                       Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;B. Braun now has heparin infusion solutions available                                           Shortage of finished product that meets current specification.                       Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;B. Braun now has heparin infusion solutions available                                           Shortage of finished product that meets current specification.                       Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;B. Braun now has heparin infusion solutions available                                   Shortage of finished product that meets current specification.         Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.,,,,,,,,,,,,,
Bbraun,heparin,2,2/20/10,9/23/10,,,,Shortage of Heparin Sodium drug substance that meets current qualification requirements                 Shortage of finished product that meets current specification.                 Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;Shortage of Heparin Sodium drug substance that meets current qualification requirements             Shortage of finished product that meets current specification.             Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;Shortage of Heparin Sodium drug substance that meets current qualification requirements                     Shortage of finished product that meets current specification.                         Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;Shortage of Heparin Sodium drug substance that meets current qualification requirements                     Shortage of finished product that meets current specification.                       Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;Shortage of Heparin Sodium drug substance that meets current qualification requirements           Shortage of finished product that meets current specification.                       Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;B. Braun now has heparin infusion solutions available                                           Shortage of finished product that meets current specification.                       Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;B. Braun now has heparin infusion solutions available                                           Shortage of finished product that meets current specification.                       Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;B. Braun now has heparin infusion solutions available                                   Shortage of finished product that meets current specification.         Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.,,,,,,,,,,,,,
Hospira,heparin,1,2/20/10,9/23/10,,,,Shortage of Heparin Sodium drug substance that meets current qualification requirements                 Shortage of finished product that meets current specification.                 Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;Shortage of Heparin Sodium drug substance that meets current qualification requirements             Shortage of finished product that meets current specification.             Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;Shortage of Heparin Sodium drug substance that meets current qualification requirements                     Shortage of finished product that meets current specification.                         Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;Shortage of Heparin Sodium drug substance that meets current qualification requirements                     Shortage of finished product that meets current specification.                       Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;Shortage of Heparin Sodium drug substance that meets current qualification requirements           Shortage of finished product that meets current specification.                       Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;B. Braun now has heparin infusion solutions available                                           Shortage of finished product that meets current specification.                       Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;B. Braun now has heparin infusion solutions available                                           Shortage of finished product that meets current specification.                       Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.;B. Braun now has heparin infusion solutions available                                   Shortage of finished product that meets current specification.         Short supply of drug substance and unanticipated issues to implement the new USP Heparin monograph.,,,,,,,,,,,,,
WestWard,hydromorphone,1,3/16/12,10/19/12,; demand increase,orange,,Information pending;Increase in product demand. West-Ward is currently experiencing a backorder situation on both presentations.   West-Ward has increased production and is anticipating having several lots of the 1 mL vial released and available by the end of March 2012.  Additional lots are scheduled for production in the April ? May 2012 timeframe.    Several lots of the 20 mL vial will also be available by the middle of April 2012.   Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on both presentations.   West-Ward has increased production and is anticipating having several lots of the 1 mL vial released and available by the end of March 2012.  Additional lots are scheduled for production in the April ? May 2012 timeframe.    Several lots of the 20 mL vial will also be available by the middle of April 2012.   Product will be made available as it is released.;;1 mL vial- 2 mg/mL (NDC 0641-0121-25)   West-Ward has limited quantities available for both the 1 mL and 20 mL vial presentations. West-Ward has increased production and is anticipating having additional lots of both presentations available in July - August 2012. Product will be made available as it is released Shortage per Manufacturer: Increase in product demand due to market supply issues;20 mL vial- 2 mg/mL (NDC 0641-2341-41)   West-Ward has limited quantities available for both the 1 mL and 20 mL vial presentations. West-Ward has increased production and is anticipating having additional lots of both presentations available in July - August 2012. Product will be made available as it is released Shortage per Manufacturer: Increase in product demand due to market supply issues,,,,,,,,,,,,,
Akorn,hydromorphone,2,11/2/12,3/2/14,available,,,10 mg/mL- 50 mL vials (NDC 17478-0540-50) Readily available;10 mg/mL- 1 mL ampules (NDC 17478-0540-01) Readily available;10 mg/mL- 5 mL ampules (NDC 17478-0540-05) Readily available;10 mg/mL- 1 mL ampules (NDC 17478-0540-01) Readily available  NA;10 mg/mL- 5 mL ampules (NDC 17478-0540-05) Readily available  NA;10 mg/mL- 50 mL vials (NDC 17478-0540-50) Readily available   NA;10 mg/mL- 50 mL vials (NDC 17478-0540-50) Readily available NA;10 mg/mL- 1 mL ampules (NDC 17478-0540-01) Readily available NA;10 mg/mL- 5 mL ampules (NDC 17478-0540-05) Readily available NA;10 mg/mL- 5 mL ampules (NDC 17478-0540-05) Readily available N/A;10 mg/mL- 1 mL ampules (NDC 17478-0540-01) Readily available N/A;10 mg/mL- 50 mL vials (NDC 17478-0540-50) Readily available N/A,,,,,,,,,,,,,
WestWard,hydromorphone,2,11/2/12,3/2/14,demand increase,orange,,1 mL vial- 2 mg/mL (NDC 0641-0121-25)   West-Ward has limited quantities available for both the 1 mL and 20 mL vial presentations. West-Ward has increased production and is anticipating having additional lots of both presentations available in July - August 2012. Product will be made available as it is released Shortage per Manufacturer: Increase in product demand due to market supply issues;20 mL vial- 2 mg/mL (NDC 0641-2341-41)   West-Ward has limited quantities available for both the 1 mL and 20 mL vial presentations. West-Ward has increased production and is anticipating having additional lots of both presentations available in July - August 2012. Product will be made available as it is released Shortage per Manufacturer: Increase in product demand due to market supply issues;1 mL vial- 2 mg/mL (NDC 0641-0121-25) West-Ward is currently experiencing a backorder situation on the 1 mL vial.  Limited quantities are available for the 20 mL vial presentation.   West-Ward has continued to accelerate production on both codes.   Additional lots of the 1 mL vial are scheduled for manufacturing with anticipated release and available in January 2013   Product will be made available as it is released Shortage per Manufacturer: Increase in product demand due to market supply issues;20 mL vial- 2 mg/mL (NDC 0641-2341-41) West-Ward is currently experiencing a backorder situation on the 1 mL vial.  Limited quantities are available for the 20 mL vial presentation.   West-Ward has continued to accelerate production on both codes.   Additional lots of the 1 mL vial are scheduled for manufacturing with anticipated release and available in January 2013   Product will be made available as it is released Shortage per Manufacturer: Increase in product demand due to market supply issues;20 mL vial- 2 mg/mL (NDC 0641-2341-41) West-Ward currently has limited quantities of both presentations available. West-Ward has continued to accelerate production on both codes. Additional lots are scheduled for manufacturing with anticipated released and available in March 2013.  Product will be made available as it is released Shortage per Manufacturer: Increase in product demand due to market supply issues;1 mL vial- 2 mg/mL (NDC 0641-0121-25) West-Ward currently has limited quantities of both presentations available. West-Ward has continued to accelerate production on both codes. Additional lots are scheduled for manufacturing with anticipated released and available in March 2013.  Product will be made available as it is released Shortage per Manufacturer: Increase in product demand due to market supply issues;1 mL vial- 2 mg/mL (NDC 0641-0121-25) West-Ward currently has quantities available for the 1 mL vial.  The 20 mL vial is currently on backorder.   West-Ward has continued to accelerate production on both codes.   Additional lots of both presentations are scheduled for manufacturing with anticipated release in July and August 2013.   Product will be made available as it is released   Shortage per Manufacturer: Increase in product demand due to market supply issues;20 mL vial- 2 mg/mL (NDC 0641-2341-41) West-Ward currently has quantities available for the 1 mL vial.  The 20 mL vial is currently on backorder.   West-Ward has continued to accelerate production on both codes.   Additional lots of both presentations are scheduled for manufacturing with anticipated release in July and August 2013.   Product will be made available as it is released   Shortage per Manufacturer: Increase in product demand due to market supply issues;20 mL vial- 2 mg/mL (NDC 0641-2341-41) West-Ward currently has quantities available for the 1 mL vial.  The 20 mL vial is currently on backorder.   West-Ward has continued to accelerate production on both codes.   Additional lots of both presentations are scheduled for manufacturing with anticipated release in September 2013.   Product will be made available as it is released   Shortage per Manufacturer: Increase in product demand due to market supply issues;1 mL vial- 2 mg/mL (NDC 0641-0121-25) West-Ward currently has quantities available for the 1 mL vial.  The 20 mL vial is currently on backorder.   West-Ward has continued to accelerate production on both codes.   Additional lots of both presentations are scheduled for manufacturing with anticipated release in September 2013.   Product will be made available as it is released   Shortage per Manufacturer: Increase in product demand due to market supply issues;20 mL vial- 2 mg/mL (NDC 0641-2341-41) West-Ward currently has quantities available for both the 1 mL and 20 vials.  West-Ward has continued to accelerate production on both codes to ensure sufficient quantities are available.   West-Ward has continued to accelerate production on both codes to ensure sufficient quantities are available.   Additional lots of both presentations are scheduled for manufacturing with anticipated availability in November 2013.   Product will be made available as it is released.   Shortage per Manufacturer: Increase in product demand due to market supply issues.;1 mL vial- 2 mg/mL (NDC 0641-0121-25) West-Ward currently has quantities available for both the 1 mL and 20 vials.  West-Ward has continued to accelerate production on both codes to ensure sufficient quantities are available.   West-Ward has continued to accelerate production on both codes to ensure sufficient quantities are available.   Additional lots of both presentations are scheduled for manufacturing with anticipated availability in November 2013.   Product will be made available as it is released.   Shortage per Manufacturer: Increase in product demand due to market supply issues.,,,,,,,,,,,,,
Akorn,hydromorphone,1,3/16/12,10/19/12,demand increase; available,orange,,Information pending;Information pending 1 mL ampoule (NDC 17478-0540-01)-Readily available 5 mL ampoule (NDC 17478-0540-05)-Releasing mid-April 50 mL vial (NDC 17478-0540-50)-Readily available;1 mL ampoule (NDC 17478-0540-01)-Readily available 5 mL ampoule (NDC 17478-0540-05)-Releasing mid-April 50 mL vial (NDC 17478-0540-50)-Readily available;;10 mg/mL- 5 mL ampules (NDC 17478-0540-05) Available in wholesalers- releasing late August;10 mg/mL- 1 mL ampules (NDC 17478-0540-01) Readily available;10 mg/mL- 50 mL vials (NDC 17478-0540-50) Available in wholesalers Quota request filed (Per manufacturer) Shortage per Manufacturer: Delayed DEA response (Per manufacturer);10 mg/mL- 50 mL vials (NDC 17478-0540-50) Readily available;10 mg/mL- 5 mL ampules (NDC 17478-0540-05) Readily available,,,,,,,,,,,,,
Teva,hydromorphone,1,3/16/12,10/19/12,demand increase; available,orange,,Product available;Teva has all presentations available.;Increased Demand Teva has all presentations available.;;10 mg/mL- 50 mL vials (NDC 00703-0118-01) Teva has all presentations available. Shortage per Manufacturer: Increased Demand;10 mg/mL- 1 mL vials (NDC 00703-0110-03) Teva has all presentations available. Shortage per Manufacturer: Increased Demand;10 mg/mL- 5 mL vials (NDC 00703-0113-03) Teva has all presentations available. Shortage per Manufacturer: Increased Demand,,,,,,,,,,,,,
Teva,hydromorphone,2,11/2/12,3/2/14,demand increase; available,orange,,10 mg/mL- 50 mL vials (NDC 00703-0118-01) Teva has all presentations available. Shortage per Manufacturer: Increased Demand;10 mg/mL- 1 mL vials (NDC 00703-0110-03) Teva has all presentations available. Shortage per Manufacturer: Increased Demand;10 mg/mL- 5 mL vials (NDC 00703-0113-03) Teva has all presentations available. Shortage per Manufacturer: Increased Demand;10 mg/mL- 5 mL vials (NDC 00703-0113-03) Teva has all presentations available.;10 mg/mL- 50 mL vials (NDC 00703-0118-01) Teva has all presentations available.;10 mg/mL- 1 mL vials (NDC 00703-0110-03) Teva has all presentations available.,,,,,,,,,,,,,
Genentech,ibandronate,1,9/1/12,8/15/13,manufacturing issues; demand increase,blue,,"3 mg/mL (single use syringe) Box of 1 (NDC 0004-0191-09 Current backlog at the US distribution center expected to continue until early-October 2012. Please check with your wholesaler for available inventory.   Shortage per Manufacturer: Compliance issue with i.v. infusion set that is enclosed in product kit and supplied by a third-party vendor;3 mg/mL (single use syringe) Box of 1 (NDC 0004-0191-09 Current backlog at the US distribution center expected to continue until end-October 2012. Please check with your wholesaler for available inventory.   Shortage per Manufacturer: Compliance issue with i.v. infusion set that is enclosed in product kit and supplied by a third-party vendor;3 mg/mL (single use syringe) 
 Box of 1 (NDC 0004-0191-09 Current backlog at the US distribution center expected to continue until end-October 2012.
 Please check with your wholesaler for available inventory. 
   Shortage per Manufacturer: 
 Compliance issue with i.v. infusion set that is enclosed in product kit and supplied by a third-party vendor;3 mg/mL (single use syringe) Box of 1 (NDC 0004-0191-09 Tight supply at the US distribution center is projected to continue through March 2013.   Please check with your wholesaler for available inventory.   Shortage per Manufacturer: Compliance issue with i.v. infusion set that is enclosed in product kit and supplied by a third-party vendor;3 mg/mL (single use syringe) Box of 1 (NDC 0004-0191-09 Current backlog at the US distribution center.  Date of next supply availability is to be determined.     Please check with an authorized Genentech distributor for product availability.   Shortage per Manufacturer: Compliance issue with i.v. infusion set that is enclosed in product kit and supplied by a third-party vendor;3 mg/3 mL (single use syringe) Box of 1 (NDC 0004-0191-09) Current backlog at the US distribution center.  Date of next supply availability is anticipated during the week of 7/22/2013.",,,,,,,,,,,,,
Akorn,indigo,1,12/15/11,3/16/12,demand increase,orange,,Akorn has indigo carmine available and releasing product as it becomes available.;Akorn has Indigo Carmine available.;Akorn has Indigo Carmine available on intermittent backorder with anticipated release in March.,,,,,,,,,,,,,
AmericanRegent,indigo,1,12/15/11,3/16/12,manufacturing delays; available,blue,,American Regent has indigo carmine on back order and the company cannot estimate a release date.;American Regent has indigo carmine available.,,,,,,,,,,,,,
Lundbeck,indocin,1,11/21/09,2/20/10,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
Watson,infed,1,6/6/09,8/14/09,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
SanofiAventis,insulin,1,10/20/11,5/15/12,manufacturing delays,blue,,"Product to be available 1st quarter 2012. Please note Apidra vials are not impacted by this shortage. Dear Healthcare Professional Letter (PDF - 33KB);Product to be available 1st quarter 2012. Please note Apidra vials are not impacted by this shortage. 
 
 Dear Healthcare Professional Letter (PDF - 33KB);Product to be available 2nd quarter 2012. Please note Apidra vials are not impacted by this shortage. 
 
 Dear Healthcare Professional Letter (PDF - 21KB);Product to be available 2nd quarter 2012. Please note Apidra vials are not impacted by this shortage. Dear Healthcare Professional Letter (PDF - 21KB);Manufacturing delays Product to be available 2nd quarter 2012. Please note Apidra vials are not impacted by this shortage. Dear Healthcare Professional Letter (PDF - 21KB);",,,,,,,,,,,,,
Baxter,intravenous,1,4/28/11,10/19/12,available,,,"Baxter has the following Intralipid emulsions available through normal distribution: 20% 100 mL (NDC 00338-0519-48) 20% 250 mL (NDC 00338-0519-02) 20% 500 mL (NDC 00338-0519-03) 20% 1000 mL (NDC 00338-0519-04) 30% 500 mL (NDC 00338-0520-03);Baxter has the following Intralipid emulsions available through normal distribution: 
 20% 100 mL (NDC 00338-0519-48) 20% 250 mL (NDC 00338-0519-02) 20% 500 mL (NDC 00338-0519-03) 20% 1000 mL (NDC 00338-0519-04) 30% 500 mL (NDC 00338-0520-03);Baxter now has adequate supply available to meet demand. Baxter has the following Intralipid emulsions available through normal distribution: 20% 100 mL (NDC 00338-0519-48) 20% 250 mL (NDC 00338-0519-02) 20% 500 mL (NDC 00338-0519-03) 20% 1000 mL (NDC 00338-0519-04) 30% 500 mL (NDC 00338-0520-03);;Intralipid 20% Emulsion- 500 mL (NDC 00338-0519-03) Baxter has Intralipid emulsions available through normal distribution. Available Shortage per Manufacturer: Available;Intralipid 20% Emulsion- 250 mL (NDC 00338-0519-02) Baxter has Intralipid emulsions available through normal distribution. Available Shortage per Manufacturer: Available;Intralipid 30% Emulsion- 500 mL (NDC 00338-0520-03) Baxter has Intralipid emulsions available through normal distribution. Available Shortage per Manufacturer: Available;Intralipid 20% Emulsion- 100 mL (NDC 00338-0519-48) 20% Baxter has Intralipid emulsions available through normal distribution. Available Shortage per Manufacturer: Available;Intralipid 20% Emulsion- 1000 mL (NDC 00338-0519-04) Baxter has Intralipid emulsions available through normal distribution. Available Shortage per Manufacturer: Available;Intralipid 20% Emulsion- 1000 mL (NDC 00338-0519-04) Available Available;Intralipid 20% Emulsion- 250 mL (NDC 00338-0519-02) Available Available;Intralipid 20% Emulsion- 100 mL (NDC 00338-0519-48) 20% Available Available;Intralipid 30% Emulsion- 500 mL (NDC 00338-0520-03) Available Available;Intralipid 20% Emulsion- 500 mL (NDC 00338-0519-03) Available Available",,,,,,,,,,,,,
Baxter,intravenous,3,10/1/13,1/8/14,demand increase,orange,,United Kingdom Intralipid 20% Emulsion in Biofine container: 100 mL (NDC 00338-0519-10) 250 mL (NDC 00338-0519-11) 500 mL (NDC 00338-0519-12) Baxter has the United Kingdom Intralipid 20% emulsions in Biofine container for temporary importation with product available in August. The 100 and 250 mL products are in limited quantities.  500 mL product is not available Baxter Healthcare Corporation and Fresenius Kabi AB in conjunction with FDA has initiated temporary importation of the United Kingdom Intralipid 20% Intravenous Fat Emulsion into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 2.3MB) for additional product and supply information. All orders must be made directly with Baxter's Center for Service by calling 1-888-229-0001;Intralipid 20% Emulsion- 250 mL (NDC 00338-0519-02)     Baxter has this product on allocation.   N/A;Intralipid 20% Emulsion- 500 mL (NDC 00338-0519-03) Baxter has this product on allocation.   N/A;Intralipid 30% Emulsion- 500 mL (NDC 00338-0520-03) Available;Intralipid 20% Emulsion- 1000 mL (NDC 00338-0519-04) Intermittent backorders through October. Baxter has this product on allocation. Baxter Healthcare Corporation and Fresenius Kabi AB in conjunction with FDA has initiated temporary importation of the United Kingdom Intralipid 20% Intravenous Fat Emulsion into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 2.3MB) for additional product and supply information. All orders must be made directly with Baxter's Center for Service by calling 1-888-229-0001;Intralipid 20% Emulsion- 100 mL (NDC 00338-0519-48)     Baxter has this product on allocation.   N/A;Intralipid 20% Emulsion- 1000 mL (NDC 00338-0519-04) Baxter has this product on allocation. Baxter Healthcare Corporation and Fresenius Kabi AB in conjunction with FDA has initiated temporary importation of the United Kingdom Intralipid 20% Intravenous Fat Emulsion into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 2.3MB) for additional product and supply information. All orders must be made directly with Baxter's Center for Service by calling 1-888-229-0001,,,,,,,,,,,,,
Baxter,intravenous,2,11/2/12,8/19/13,demand increase; available,orange,,Intralipid 30% Emulsion- 500 mL (NDC 00338-0520-03) Available Available;Intralipid 20% Emulsion- 1000 mL (NDC 00338-0519-04) Available Available;Intralipid 20% Emulsion- 500 mL (NDC 00338-0519-03) Available Available;Intralipid 20% Emulsion- 100 mL (NDC 00338-0519-48) 20% Available Available;Intralipid 20% Emulsion- 250 mL (NDC 00338-0519-02) Available Available;Intralipid 20% Emulsion- 1000 mL (NDC 00338-0519-04) Back-ordered. Baxter is currently experiencing an increase in demand. Please check with wholesalers for potential inventory.           n/a;Intralipid 20% Emulsion- 250 mL (NDC 00338-0519-02)     Back-ordered. Baxter is currently experiencing an increase in demand. Please check with wholesalers for potential inventory.           n/a;Intralipid 20% Emulsion- 100 mL (NDC 00338-0519-48)     Available       n/a;Intralipid 20% Emulsion- 500 mL (NDC 00338-0519-03) Back-ordered. Baxter is currently experiencing an increase in demand. Please check with wholesalers for potential inventory.           n/a;Intralipid 30% Emulsion- 500 mL (NDC 00338-0520-03) Available   n/a;Intralipid 20% Emulsion- 1000 mL (NDC 00338-0519-04) Back-ordered   Baxter has the following Intralipid 20% emulsions on allocation and is working to increase production to meet US market demand. All orders must be made directly with Baxter's Center for Service by calling 1-888-229-0001. N/A;Intralipid 30% Emulsion- 500 mL (NDC 00338-0520-03) Intralipid 30% Emulsion Available   N/A;Intralipid 20% Emulsion- 500 mL (NDC 00338-0519-03) Back-ordered   Baxter has the following Intralipid 20% emulsions on allocation and is working to increase production to meet US market demand. All orders must be made directly with Baxter's Center for Service by calling 1-888-229-0001. N/A;Intralipid 20% Emulsion- 100 mL (NDC 00338-0519-48)     Back-ordered   Baxter has the following Intralipid 20% emulsions on allocation and is working to increase production to meet US market demand. All orders must be made directly with Baxter's Center for Service by calling 1-888-229-0001. N/A;Intralipid 20% Emulsion- 250 mL (NDC 00338-0519-02)     Back-ordered   Baxter has the following Intralipid 20% emulsions on allocation and is working to increase production to meet US market demand. All orders must be made directly with Baxter's Center for Service by calling 1-888-229-0001. N/A;Intralipid 30% Emulsion- 500 mL (NDC 00338-0520-03) Available;Intralipid 20% Emulsion- 250 mL (NDC 00338-0519-02)     Baxter has this product on allocation.   N/A;Intralipid 20% Emulsion- 100 mL (NDC 00338-0519-48)     Baxter has this product on allocation.   N/A;United Kingdom Intralipid 20% Emulsion in Biofine container: 100 mL (NDC 00338-0519-10) 250 mL (NDC 00338-0519-11) 500 mL (NDC 00338-0519-12) Baxter has the United Kingdom Intralipid 20% emulsions in Biofine container for temporary importation with product available in August. The 100 and 250 mL products are in limited quantities.  500 mL product is not available Baxter Healthcare Corporation and Fresenius Kabi AB in conjunction with FDA has initiated temporary importation of the United Kingdom Intralipid 20% Intravenous Fat Emulsion into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 2.3MB) for additional product and supply information. All orders must be made directly with Baxter's Center for Service by calling 1-888-229-0001;Intralipid 20% Emulsion- 1000 mL (NDC 00338-0519-04) Intermittent backorders through October. Baxter has this product on allocation. Baxter Healthcare Corporation and Fresenius Kabi AB in conjunction with FDA has initiated temporary importation of the United Kingdom Intralipid 20% Intravenous Fat Emulsion into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 2.3MB) for additional product and supply information. All orders must be made directly with Baxter's Center for Service by calling 1-888-229-0001;Intralipid 20% Emulsion- 500 mL (NDC 00338-0519-03) Baxter has this product on allocation.   N/A,,,,,,,,,,,,,
Baxter,intravenous,1,7/3/10,4/22/11,manufacturing delays,blue,,Manufacturing issues                             Increase in demand;Manufacturing issues                             Increase in demand;Manufacturing issues                           Baxter now has adequate supply available to meet demand.;Manufacturing issues                           Baxter now has adequate supply available to meet demand.;Manufacturing issues                           Baxter now has adequate supply available to meet demand.,,,,,,,,,,,,,
Hospira,intravenous,1,7/3/10,4/22/11,manufacturing delays,blue,,Manufacturing issues                             Increase in demand;Manufacturing issues                             Increase in demand;Manufacturing issues                           Baxter now has adequate supply available to meet demand.;Manufacturing issues                           Baxter now has adequate supply available to meet demand.;Manufacturing issues                           Baxter now has adequate supply available to meet demand.,,,,,,,,,,,,,
ScheringPlough,intron,1,12/7/09,6/25/10,product recall,yellow,,Please see attached Recall Letter,,,,,,,,,,,,,
Sandoz,isoniazid,1,6/6/09,8/15/10,available,,,Product continues to be available with short expiration dating.,,,,,,,,,,,,,
Teva,isoniazid,1,9/22/11,10/19/12,delays; manufacturing delays; available; shipping delays; shipping delay,blue,,Releases planned for September for 300 mg product- 100 mg product continues to be in supply.;100mg 100's and 1000's - expected to have presentations available in May 2012. 30mg 30's and 1000's -  presentations are available.  30 mg 30's will remain in low inventory until 4Q12.;Manufacturing Delays 100mg 100's and 1000's - expected to have presentations available in May 2012. 30mg 30's and 1000's -  presentations are available.  30 mg 30's will remain in low inventory until 4Q12.;;300 mg- 1000 count (NDC 00555-0071-05) Available. Inventory will remain in low until end of year. As of July 18- low inventory levels- and will potentially go on/off backorder for balance of 2012;300 mg- 30 count (NDC 00555-0071-01) Available. Will remain in low inventory until 4Q12.;100 mg- 1000 count (NDC 00555-0066-05) Available. Teva supply adequate to meet demand.;300 mg- 100 count (NDC 00555-0071-02) Available. Inventory will remain in low until end of year.  As of July 18- low inventory levels- and will potentially go on/off backorder for balance of 2012.;100 mg- 100 count (NDC 00555-0066-02) Available. Teva supply adequate to meet demand.;300 mg- 30 count (NDC 00555-0071-01) Available. Inventory will remain low until end of year. As of August 16- low inventory levels of (NDC 00555-0071-02) and (NDC 00555-0071-05).  Will potentially go on/off backorder for balance of 2012. Shortage per Manufacturer:   Manufacturing delays;300 mg- 30 count (NDC 00555-0071-01) Available. Teva supply adequate to meet demand.;300 mg- 1000 count (NDC 00555-0071-05) Available. Inventory will remain in low until end of year.;300 mg- 100 count (NDC 00555-0071-02) Available. Inventory will remain in low until end of year.;300 mg- 100 count (NDC 00555-0071-02) Inventory will remain low until end of year.;300 mg- 1000 count (NDC 00555-0071-05) Inventory will remain low until end of year.;300 mg- 30 count (NDC 00555-0071-01) Available. Inventory will remain low until end of year.,,,,,,,,,,,,,
WestWard,isoniazid,1,9/22/11,2/9/12,demand increase,orange,,Releases planned for September and November,,,,,,,,,,,,,
AmericanRegent,isoniazid,1,8/20/10,8/28/10,demand increase; manufacturing delays,blue,,Manufacturing delays       Increase in demand                                 Increase in demand,,,,,,,,,,,,,
APP,isoniazid,1,8/20/10,8/28/10,demand increase; manufacturing delays,blue,,Manufacturing delays       Increase in demand                                 Increase in demand,,,,,,,,,,,,,
Hospira,isoniazid,1,8/20/10,8/28/10,demand increase; manufacturing delays,blue,,Manufacturing delays       Increase in demand                                 Increase in demand,,,,,,,,,,,,,
Teva,isoniazid,2,11/2/12,6/3/13,shipping delay; shipping delays; material shortage; demand increase,blue,,300 mg- 100 count (NDC 00555-0071-02) Inventory will remain low until end of year.;100 mg- 1000 count (NDC 00555-0066-05) Available. Teva supply adequate to meet demand.;100 mg- 100 count (NDC 00555-0066-02) Available. Teva supply adequate to meet demand.;300 mg- 1000 count (NDC 00555-0071-05) Inventory will remain low until end of year.;300 mg- 30 count (NDC 00555-0071-01) Available. Inventory will remain low until end of year.;300 mg- 1000 count (NDC 00555-0071-05) Low inventory possible backorders through December;300 mg- 100 count (NDC 00555-0071-02) Low inventory possible backorders through December;300 mg- 1000 count (NDC 00555-0071-05) Backorders into January;300 mg- 100 count (NDC 00555-0071-02) Backorders into January;300 mg- 30 count (NDC 00555-0071-01) Backorders into January;300 mg- 1000 count (NDC 00555-0071-05) Currently on backorder and will be on and off backorder through March 2013.   Additional stock will be available in late January however adequate supply to meet ongoing demand is not expected until April.;100 mg- 1000 count (NDC 00555-0066-05) Available. Teva supply adequate to meet forecasted demand.;300 mg- 30 count (NDC 00555-0071-01) Currently on backorder and will be on and off backorder through March 2013.  Additional stock will be available in late January however adequate supply to meet ongoing demand is not expected until April.;300 mg- 100 count (NDC 00555-0071-02) Currently on backorder and will be on and off backorder through March 2013.   Additional stock will be available in late January however adequate supply to meet ongoing demand is not expected until April.;100 mg- 100 count (NDC 00555-0066-02) Available. Teva supply adequate to meet forecasted demand.;300 mg- 30 count (NDC 00555-0071-01) Currently on backorder and will be on and off backorder through March 2013.  Teva- in cooperation with the FDA and the CDC- has established an emergency reserve to be disbursed in compliance with published CDC guidelines.  To access the emergency allocation from Teva- call their main number:  1-800-545-8800 and press 8 to speak with Bruce Cannelongo- Customer Service Manager.  In the event Bruce is unavailable- Andrew Pope- Customer Service Associate will be able to assist.;300 mg- 100 count (NDC 00555-0071-02) Available. Teva- in cooperation with the FDA and the CDC- has established an emergency reserve to be disbursed in compliance with published CDC guidelines.  To access the emergency allocation from Teva- call their main number:  1-800-545-8800 and press 8 to speak with Bruce Cannelongo- Customer Service Manager.  In the event Bruce is unavailable- Andrew Pope- Customer Service Associate will be able to assist.;100 mg- 1000 count (NDC 00555-0066-05) Available - limited supply through April. Teva supply adequate to meet forecasted demand.;100 mg- 100 count (NDC 00555-0066-02) Available - limited supply through April. Teva supply adequate to meet forecasted demand.;300 mg- 30 count (NDC 00555-0071-01) Available. Teva- in cooperation with the FDA and the CDC- has established an emergency reserve to be disbursed in compliance with published CDC guidelines.  To access the emergency allocation from Teva- call their main number:  1-800-545-8800 and press 8 to speak with Bruce Cannelongo- Customer Service Manager.  In the event Bruce is unavailable- Andrew Pope- Customer Service Associate will be able to assist.;300 mg- 1000 count (NDC 00555-0071-05) Available Teva- in cooperation with the FDA and the CDC- has established an emergency reserve to be disbursed in compliance with published CDC guidelines.  To access the emergency allocation from Teva- call their main number:  1-800-545-8800 and press 8 to speak with Bruce Cannelongo- Customer Service Manager.  In the event Bruce is unavailable- Andrew Pope- Customer Service Associate will be able to assist.,,,,,,,,,,,,,
VersaPharm,isoniazid,1,9/22/11,10/19/12,,,,Information pending;;100mg- 100s (NDC 61748-0016-01)   Information pending;300 mg- 1000s (NDC 61748-0013-10)   Information pending;300 mg- 30s (NDC 61748-0013-30)   Information pending;300 mg- 100s (NDC 61748-0013-01)   Information pending,,,,,,,,,,,,,
VersaPharm,isoniazid,2,11/2/12,6/3/13,,,,300 mg- 30s (NDC 61748-0013-30)   Information pending;300 mg- 100s (NDC 61748-0013-01)   Information pending;100mg- 100s (NDC 61748-0016-01)   Information pending;300 mg- 1000s (NDC 61748-0013-10)   Information pending;100mg- 100s (NDC 61748-0016-01)   100mg in stock   300mg may be available mid to late December 2012;300 mg- 100s (NDC 61748-0013-01)   100mg in stock   300mg may be available mid to late December 2012;300 mg- 1000s (NDC 61748-0013-10)   100mg in stock   300mg may be available mid to late December 2012;300 mg- 30s (NDC 61748-0013-30)   100mg in stock   300mg may be available mid to late December 2012;300 mg- 30s (NDC 61748-0013-30)   100mg very low in stock. Once supplies are depleted item will be out of stock for at least a year.   300mg may be available late January 2013- Still waiting on release.;300 mg- 100s (NDC 61748-0013-01)   100mg very low in stock. Once supplies are depleted item will be out of stock for at least a year.   300mg may be available late January 2013- Still waiting on release.;100mg- 100s (NDC 61748-0016-01)   100mg very low in stock. Once supplies are depleted item will be out of stock for at least a year.   300mg may be available late January 2013- Still waiting on release.;300 mg- 1000s (NDC 61748-0013-10)   100mg very low in stock. Once supplies are depleted item will be out of stock for at least a year.   300mg may be available late January 2013- Still waiting on release.;100mg- 100s (NDC 61748-0016-01)   100mg Long Term Out of Stock.  Expected back in market January 2014.   300mg Long Term Out of Stock. Expected back in market January 2014.;300 mg- 100s (NDC 61748-0013-01)   100mg Long Term Out of Stock.  Expected back in market January 2014.   300mg Long Term Out of Stock. Expected back in market January 2014.;300 mg- 1000s (NDC 61748-0013-10)   100mg Long Term Out of Stock.  Expected back in market January 2014.   300mg Long Term Out of Stock. Expected back in market January 2014.;300 mg- 30s (NDC 61748-0013-30)   100mg Long Term Out of Stock.  Expected back in market January 2014.   300mg Long Term Out of Stock. Expected back in market January 2014.,,,,,,,,,,,,,
SanofiAventis,isoniazidr,1,3/13/13,3/2/14,manufacturing delays; available,blue,,Rifamate capsules containing 300 mg rifampin and 150 mg isoniazid (NDC 0068-0509-60)   Next delivery June 2013   Estimated availability: July 2013   Shortage per Manufacturer: Manufacturing delays;Rifamate capsules containing 300 mg rifampin and 150 mg isoniazid (NDC 0068-0509-60)   Available  Available;Rifamate capsules containing 300 mg rifampin and 150 mg isoniazid (NDC 0068-0509-60)   Available  Shortage of supply expected to continue until September 16. No additional supply issues are anticipated thereafter for the next 6 months.;Rifamate capsules containing 300 mg rifampin and 150 mg isoniazid (NDC 0068-0509-60)   Available,,,,,,,,,,,,,
AmericanRegent,ketorolac,1,12/22/11,10/19/12,; not manufacturing,,,American Regent/Luitpold is currently not manufacturing Ketorolac Tromethamine Injection- USP;Unavailable American Regent/Luitpold is currently not manufacturing Ketorolac Tromethamine Injection- USP;;15 mg/mL 1 mL vial- 25 count (NDC 00517-0601-25) Unavailable American Regent/Luitpold is not manufacturing Ketorolac Tromethamine Injection- USP;30 mg/mL 2 mL vial for intramuscular use- 25 count (NDC 00517-0902-25) Unavailable American Regent/Luitpold is not manufacturing Ketorolac Tromethamine Injection- USP;30 mg/mL 1 mL vial- 25 count (NDC 00517-0801-25) Unavailable American Regent/Luitpold is not manufacturing Ketorolac Tromethamine Injection- USP,,,,,,,,,,,,,
Fresenius,ketorolac,1,12/28/13,3/25/14,demand increase,orange,,15 mg/mL 1 mL vial- 25 count (NDC 63323-0161-01) Available.  Check wholesaler inventory. Check wholesalers for inventory.;30 mg/mL 1 mL vial- 25 count (NDC 63323-0162-01) Available.  Check wholesaler inventory. Check wholesalers for inventory.;30 mg/mL 2 mL vial for intramuscular injection- 25 count (NDC 63323-0162-02) Available.  Check wholesaler inventory. Check wholesalers for inventory.,,,,,,,,,,,,,
Wockhardt,ketorolac,1,12/22/11,10/19/12,demand increase; available,orange,,Wockhardt has ketorolac 30 mg/mL 2 mL vials in 10 count and 25 count presentations on back order with an estimated release date of late-January- 2012. The 30 mg/mL 1 mL vial 10 count presentation is on back order and the company cannot estimate a release date.;Wockhardt has ketorolac 30 mg/mL 2 mL vials in 10 count and 25 count presentations on back order with an estimated release date of mid-late March- 2012. The 30 mg/mL 1 mL vial 10 count presentation is on back order and the company cannot estimate a release date.;Increase in demand Wockhardt has ketorolac 30 mg/mL 2 mL vials in 10 count and 25 count presentations on back order with an estimated release date of mid-late March- 2012. The 30 mg/mL 1 mL vial 10 count presentation is on back order and the company cannot estimate a release date.;;30 mg/mL 1 mL vial- 25 count (NDC 64679-0758-01) Wockhardt is presently  experiencing intermittent releases throughout the month;15 mg/mL 1 mL vial- 10 count (NDC 64679-0757-02) Presently on backorder.  An estimated release date is in the latter part of July.;30 mg/mL 2 mL vial- 10 count (NDC 64679-0758-06) Wockhardt is presently  experiencing intermittent releases throughout the month;30 mg/mL 1 mL vial- 10 count (NDC 64679-0758-04) Wockhardt is presently  experiencing intermittent releases throughout the month;30 mg/mL 2 mL vial- 25 count (NDC 64679-0758-02) Wockhardt is presently  experiencing intermittent releases throughout the month;15 mg/mL 1 mL vial- 25 count (NDC 64679-0757-01) Presently on backorder.  An estimated release date is in the latter part of July.;30 mg/mL 2 mL vial- 10 count (NDC 64679-0758-06) Wochkhardt has existing inventories and no backorder presently. Available;15 mg/mL 1 mL vial- 10 count (NDC 64679-0757-02) Wockhardt is presently  experiencing intermittent releases throughout the month;15 mg/mL 1 mL vial- 25 count (NDC 64679-0757-01) Wockhardt is presently  experiencing intermittent releases throughout the month,,,,,,,,,,,,,
Wockhardt,ketorolac,2,11/2/12,3/25/14,demand increase; available; manufacturing requirements; manufacturing practices requirements,yellow,,30 mg/mL 1 mL vial- 10 count (NDC 64679-0758-04) Wockhardt is presently  experiencing intermittent releases throughout the month;30 mg/mL 1 mL vial- 25 count (NDC 64679-0758-01) Wockhardt is presently  experiencing intermittent releases throughout the month;30 mg/mL 2 mL vial- 10 count (NDC 64679-0758-06) Wochkhardt has existing inventories and no backorder presently. Available;30 mg/mL 2 mL vial- 25 count (NDC 64679-0758-02) Wockhardt is presently  experiencing intermittent releases throughout the month;15 mg/mL 1 mL vial- 10 count (NDC 64679-0757-02) Wockhardt is presently  experiencing intermittent releases throughout the month;15 mg/mL 1 mL vial- 25 count (NDC 64679-0757-01) Wockhardt is presently  experiencing intermittent releases throughout the month;30 mg/mL 2 mL vial- 10 count (NDC 64679-0758-06) Wochkhardt has existing inventories and no backorder presently. Order via your wholesaler or distributor. Available;30 mg/mL 2 mL vial- 25 count (NDC 64679-0758-02) Wochkhardt has existing inventories and no backorder presently. Order via your wholesaler or distributor. Available;30 mg/mL 1 mL vial- 25 count (NDC 64679-0758-01) No estimated release date available.;15 mg/mL 1 mL vial- 25 count (NDC 64679-0757-01) No estimated release date available.;15 mg/mL 1 mL vial- 10 count (NDC 64679-0757-02) No estimated release date available.;30 mg/mL 2 mL vial- 10 count (NDC 64679-0758-06) No estimated release date available.;30 mg/mL 2 mL vial- 25 count (NDC 64679-0758-02) No estimated release date available.;30 mg/mL 1 mL vial- 10 count (NDC 64679-0758-04) No estimated release date available.,,,,,,,,,,,,,
Bedford,ketorolac,1,12/22/11,10/19/12,manufacturing delays,blue,,Bedford has all presentations of ketorolac injection on back order and the company cannot estimate a release date;Manufacturing delays Bedford has all presentations of ketorolac injection on back order and the company cannot estimate a release date;;15 mg/mL 1 mL vial- 10 count (NDC 55390-0480-01) Bedford has all presentations of ketorolac injection on back order and the company cannot estimate a release date Shortage per Manufacturer: Manufacturing delays;30 mg/mL 1 mL vial- 10 count (NDC 55390-0481-01) Bedford has all presentations of ketorolac injection on back order and the company cannot estimate a release date Shortage per Manufacturer: Manufacturing delays;30 mg/mL 10 mL vial- 10 count (NDC 55390-0481-10) Bedford has all presentations of ketorolac injection on back order and the company cannot estimate a release date Shortage per Manufacturer: Manufacturing delays,,,,,,,,,,,,,
Bedford,ketorolac,2,11/2/12,3/25/14,manufacturing delays; capacity constraints; pending manufacturing change,blue,,30 mg/mL 10 mL vial- 10 count (NDC 55390-0481-10) Bedford has all presentations of ketorolac injection on back order and the company cannot estimate a release date Shortage per Manufacturer: Manufacturing delays;30 mg/mL 1 mL vial- 10 count (NDC 55390-0481-01) Bedford has all presentations of ketorolac injection on back order and the company cannot estimate a release date Shortage per Manufacturer: Manufacturing delays;15 mg/mL 1 mL vial- 10 count (NDC 55390-0480-01) Bedford has all presentations of ketorolac injection on back order and the company cannot estimate a release date Shortage per Manufacturer: Manufacturing delays;15 mg/mL 1 mL vial- 10 count (NDC 55390-0480-01) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;30 mg/mL 10 mL vial- 10 count (NDC 55390-0481-10) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;30 mg/mL 1 mL vial- 10 count (NDC 55390-0481-01) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;60 mg Inj SDV 2 mL (NDC 55390-481-02) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;30 mg/mL 1 mL vial- 10 count (NDC 55390-0481-01) Unavailable Shortage per Manufacturer: Pending manufacturing change or addition. Availability of products is updated on the Bedford Laboratories website.;30 mg/mL 10 mL vial- 10 count (NDC 55390-0481-10) Unavailable Shortage per Manufacturer: Pending manufacturing change or addition. Availability of products is updated on the Bedford Laboratories website.;60 mg Inj SDV 2 mL (NDC 55390-481-02) Unavailable Shortage per Manufacturer: Pending manufacturing change or addition. Availability of products is updated on the Bedford Laboratories website.;15 mg/mL 1 mL vial- 10 count (NDC 55390-0480-01) Unavailable Shortage per Manufacturer: Pending manufacturing change or addition. Availability of products is updated on the Bedford Laboratories website.;30 mg/mL 1 mL vial- 10 count (NDC 55390-0481-01) Unavailable   Shortage per Manufacturer: Pending manufacturing change or addition. Availability of products is updated on the Bedford Laboratories website.;15 mg/mL 1 mL vial- 10 count (NDC 55390-0480-01) Unavailable   Shortage per Manufacturer: Pending manufacturing change or addition. Availability of products is updated on the Bedford Laboratories website.;60 mg Inj SDV 2 mL (NDC 55390-481-02) Unavailable   Shortage per Manufacturer: Pending manufacturing change or addition. Availability of products is updated on the Bedford Laboratories website.;30 mg/mL 10 mL vial- 10 count (NDC 55390-0481-10) Unavailable   Shortage per Manufacturer: Pending manufacturing change or addition. Availability of products is updated on the Bedford Laboratories website.,,,,,,,,,,,,,
APP,ketorolac,1,12/22/11,10/19/12,material shortage,green,,APP has all presentations of ketorolac injection on back order and the company cannot estimate a release date.;Raw material supply APP has all presentations of ketorolac injection on back order and the company cannot estimate a release date.;;15 mg/mL 1 mL vial- 25 count (NDC 63323-0161-01) APP has all presentations of ketorolac injection on back order and the company cannot estimate a release date. Shortage per Manufacturer: Raw material supply;30 mg/mL 1 mL vial- 25 count (NDC 63323-0162-01) APP has all presentations of ketorolac injection on back order and the company cannot estimate a release date. Shortage per Manufacturer: Raw material supply;30 mg/mL 2 mL vial for intramuscular injection- 25 count (NDC 63323-0162-02) APP has all presentations of ketorolac injection on back order and the company cannot estimate a release date. Shortage per Manufacturer: Raw material supply,,,,,,,,,,,,,
APP,ketorolac,2,11/2/12,11/8/13,material shortage; demand increase; available;,green,,30 mg/mL 1 mL vial- 25 count (NDC 63323-0162-01) APP has all presentations of ketorolac injection on back order and the company cannot estimate a release date. Shortage per Manufacturer: Raw material supply;15 mg/mL 1 mL vial- 25 count (NDC 63323-0161-01) APP has all presentations of ketorolac injection on back order and the company cannot estimate a release date. Shortage per Manufacturer: Raw material supply;30 mg/mL 2 mL vial for intramuscular injection- 25 count (NDC 63323-0162-02) APP has all presentations of ketorolac injection on back order and the company cannot estimate a release date. Shortage per Manufacturer: Raw material supply;15 mg/mL 1 mL vial- 25 count (NDC 63323-0161-01) APP has all presentations of ketorolac injection on back order and estimates a release in Q1 2013. Shortage per Manufacturer: Raw material supply;30 mg/mL 1 mL vial- 25 count (NDC 63323-0162-01) APP has all presentations of ketorolac injection on back order and estimates a release in Q1 2013. Shortage per Manufacturer: Raw material supply;30 mg/mL 2 mL vial for intramuscular injection- 25 count (NDC 63323-0162-02) APP has all presentations of ketorolac injection on back order and estimates a release in Q1 2013. Shortage per Manufacturer: Raw material supply;15 mg/mL 1 mL vial- 25 count (NDC 63323-0161-01) Next delivery expected January 2013.  Check wholesalers for inventory. Shortage per Manufacturer: Raw material supply;30 mg/mL 1 mL vial- 25 count (NDC 63323-0162-01) Next delivery expected January 2013.  Check wholesalers for inventory. Shortage per Manufacturer: Raw material supply;30 mg/mL 2 mL vial for intramuscular injection- 25 count (NDC 63323-0162-02) Next delivery expected January 2013.  Check wholesalers for inventory. Shortage per Manufacturer: Raw material supply;30 mg/mL 1 mL vial- 25 count (NDC 63323-0162-01) Available. Check wholesalers for inventory. Shortage per Manufacturer: Currently available;30 mg/mL 2 mL vial for intramuscular injection- 25 count (NDC 63323-0162-02) Available. Check wholesalers for inventory. Shortage per Manufacturer: Currently available;15 mg/mL 1 mL vial- 25 count (NDC 63323-0161-01) Available. Check wholesalers for inventory. Shortage per Manufacturer: Currently available;15 mg/mL 1 mL vial- 25 count (NDC 63323-0161-01) Backordered. Next release anticipated July 2013. Shortage per Manufacturer: Demand increase for the drug.;30 mg/mL 2 mL vial for intramuscular injection- 25 count (NDC 63323-0162-02) Available.  Check wholesaler inventory. Shortage per Manufacturer: Demand increase for the drug.;30 mg/mL 1 mL vial- 25 count (NDC 63323-0162-01) Available.  Check wholesaler inventory. Shortage per Manufacturer: Demand increase for the drug.;15 mg/mL 1 mL vial- 25 count (NDC 63323-0161-01) Backordered. Next release anticipated July 2013. Check wholesalers for inventory.;30 mg/mL 1 mL vial- 25 count (NDC 63323-0162-01) Backordered. Next release anticipated July 2013. Check wholesalers for inventory.;30 mg/mL 2 mL vial for intramuscular injection- 25 count (NDC 63323-0162-02) Available.  Check wholesaler inventory. Check wholesalers for inventory.;15 mg/mL 1 mL vial- 25 count (NDC 63323-0161-01) Available.  Check wholesaler inventory. Check wholesalers for inventory.;30 mg/mL 1 mL vial- 25 count (NDC 63323-0162-01) Available.  Check wholesaler inventory. Check wholesalers for inventory.,,,,,,,,,,,,,
AmericanRegent,ketorolac,2,11/2/12,3/25/14,not manufacturing; discontinued,black,,30 mg/mL 1 mL vial- 25 count (NDC 00517-0801-25) Unavailable American Regent/Luitpold is not manufacturing Ketorolac Tromethamine Injection- USP;15 mg/mL 1 mL vial- 25 count (NDC 00517-0601-25) Unavailable American Regent/Luitpold is not manufacturing Ketorolac Tromethamine Injection- USP;30 mg/mL 2 mL vial for intramuscular use- 25 count (NDC 00517-0902-25) Unavailable American Regent/Luitpold is not manufacturing Ketorolac Tromethamine Injection- USP;30 mg/mL 2 mL vial for intramuscular use- 25 count (NDC 00517-0902-25) Unavailable American Regent/Luitpold has discontinued manufacturing Ketorolac Tromethamine Injection- USP;30 mg/mL 1 mL vial- 25 count (NDC 00517-0801-25) Unavailable American Regent/Luitpold has discontinued manufacturing Ketorolac Tromethamine Injection- USP;15 mg/mL 1 mL vial- 25 count (NDC 00517-0601-25) Unavailable American Regent/Luitpold has discontinued manufacturing Ketorolac Tromethamine Injection- USP;15 mg/mL 1 mL vial- 25 count (NDC 00517-0601-25) Unavailable - No product available for release. No plan to manufacture. American Regent/Luitpold has discontinued manufacturing Ketorolac Tromethamine Injection- USP;30 mg/mL 2 mL vial for intramuscular use- 25 count (NDC 00517-0902-25) Unavailable - No product available for release. No plan to manufacture. American Regent/Luitpold has discontinued manufacturing Ketorolac Tromethamine Injection- USP;30 mg/mL 1 mL vial- 25 count (NDC 00517-0801-25) Unavailable - No product available for release. No plan to manufacture. American Regent/Luitpold has discontinued manufacturing Ketorolac Tromethamine Injection- USP,,,,,,,,,,,,,
Akorn,labetalol,1,10/18/11,3/1/12,demand increase,orange,,Akorn is releasing product as it becomes available and has increased production to meet current increased demand.;All product SKUs are readily available for market distribution.,,,,,,,,,,,,,
Bedford,labetalol,1,10/18/11,3/1/12,manufacturing delays,blue,,Bedford has short supplies of 100 mg/20 mL (NDC 55390-0130-20) and 200 mg/40 mL (55390-0130-40) available for drop shipment.;Bedford has short supplies of 100 mg/20 mL (NDC 55390-0130-20)contact your local Bedford Account Executive.  Bedford 200 mg/40 mL (55390-0130-40) is on backorder and the company cannot estimate a release date.;Bedford has 100 mg/20 mL (NDC 55390-0130-20)and 200 mg/40 mL (55390-0130-40)  on backorder and the company cannot estimate a release date.;Bedford has all labetalol presentations on backorder and the company cannot estimate a release date.,,,,,,,,,,,,,
AmericanRegent,lcysteine,1,10/18/11,3/1/12,manufacturing delays; available,blue,,American Regent has L-cysteine hydrochloride injection on back order and the company cannot estimate a release date.;American Regent has all presentations available.,,,,,,,,,,,,,
APP,leucovorin,1,4/28/11,11/8/13,; demand increase,orange,,"APP is currently back-ordered. Initial supplies are limited- however APP is continuing to produce and release leucovorin calcium lyophilized powder for injection (NDC# 63323-710-50 for the 200mg SDV and NDC# 63323-711-00 for the 500mg SDV).;APP is currently back-ordered due to increased demand. Intermittent releases expected Q1-2012. (NDC# 63323-710-50 for the 200mg SDV and NDC# 63323-711-00 for the 500mg SDV).;APP is currently back-ordered due to increased demand. Intermittent releases are being allocated. (NDC# 63323-710-50 for the 200mg SDV and NDC# 63323-711-00 for the 500mg SDV).;Increased demand APP is currently back-ordered due to increased demand. Intermittent releases are being allocated. (NDC# 63323-710-50 for the 200mg SDV and NDC# 63323-711-00 for the 500mg SDV).;;500 mg SDV (NDC 63323-711-00) APP is currently back-ordered due to increased demand. Intermittent releases are being allocated. Shortage per Manufacturer: Increased demand;200 mg SDV (NDC 63323-710-50) APP is currently back-ordered due to increased demand. Intermittent releases are being allocated. Shortage per Manufacturer: Increased demand;200 mg SDV (NDC 63323-710-50) APP is currently back-ordered due to increased demand. Intermittent releases are being allocated. Shortage per Manufacturer: 
 Increased demand;500 mg SDV (NDC 63323-711-00) APP is currently back-ordered due to increased demand. Intermittent releases are being allocated. Shortage per Manufacturer: 
 Increased demand;500 mg SDV (NDC 63323-711-00) Intermittent back-order.  APP is allocating product as it becomes available. Shortage per Manufacturer: Increased demand;200 mg SDV (NDC 63323-710-50) Intermittent back-order.  APP is allocating product as it becomes available. Shortage per Manufacturer: Increased demand;200 mg SDV (NDC 63323-710-50) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand;500 mg SDV (NDC 63323-711-00) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand;500 mg SDV (NDC 63323-711-00) Currently back-ordered.  Next release anticipated May 2013. Shortage per Manufacturer: Increased demand;500 mg SDV (NDC 63323-711-00) Currently back-ordered.  Next release anticipated June 2013. Shortage per Manufacturer: Increased demand;500 mg SDV (NDC 63323-711-00) Available. Check wholesaler inventory. Shortage per Manufacturer: Increased demand",,,,,,,,,,,,,
Fresenius,leucovorin,1,12/28/13,3/25/14,demand increase,orange,,500 mg SDV (NDC 63323-711-00) Backordered. Next release anticipated January 2014 Shortage per Manufacturer: Manufacturing delays;200 mg SDV (NDC 63323-710-50) Currently on allocation for direct orders. Shortage per Manufacturer: Manufacturing delays;500 mg SDV (NDC 63323-711-00) Currently on allocation for direct orders. Shortage per Manufacturer: Manufacturing delays,,,,,,,,,,,,,
APP,leucovorin,1,8/20/10,8/28/10,manufacturing delays,blue,,Manufacturing delays           See Related Information               See Related Information                   Manufacturing delays,,,,,,,,,,,,,
Bedford,leucovorin,1,6/20/10,6/25/10,manufacturing delays,blue,,Manufacturing delays                     Manufacturing delays,,,,,,,,,,,,,
Bedford,leucovorin,2,8/20/10,8/28/10,manufacturing delays,blue,,Manufacturing delays           See Related Information               See Related Information                   Manufacturing delays,,,,,,,,,,,,,
OrthoMcNeilJanssen,leucovorin,1,8/20/10,8/28/10,manufacturing delays,blue,,Manufacturing delays           See Related Information               See Related Information                   Manufacturing delays,,,,,,,,,,,,,
Teva,leucovorin,1,6/20/10,6/25/10,manufacturing delays,blue,,Manufacturing delays                     Manufacturing delays,,,,,,,,,,,,,
Teva,leucovorin,2,8/20/10,8/28/10,manufacturing delays,blue,,Manufacturing delays           See Related Information               See Related Information                   Manufacturing delays,,,,,,,,,,,,,
Teva,leucovorin,1,4/28/11,3/25/14,manufacturing delays; [temporary import]; demand increase; regulatory delay; available,yellow,,"Teva has leucovorin calcium lyophilized powder 100 mg and 350 mg vials on back order and the company does not anticipate release until April 2011.;Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information.;Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. 
 See Dear Healthcare Professional letter (PDF 692KB) for additional information.;Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information. Teva is currently on backorder and anticipates limited resupply by end of March 2012.;Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. 
 See Dear Healthcare Professional letter (PDF 692KB) for additional information. Teva is currently on backorder and anticipates limited resupply by end of April 2012.;Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information. Teva is currently on backorder and anticipates limited resupply by end of April 2012.;Manufacturing delays Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information. Teva is currently on backorder and anticipates limited resupply by end of April 2012.;Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information. Teva has limited inventory available for drop shipment only at this time.;;100mg/vial (NDC 0703-5140-01) 20mL  Teva has limited inventory available for drop shipment only at this time. Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information. Teva has limited inventory available for drop shipment only at this time. Shortage per Manufacturer: Manufacturing delays;350mg/vial (NDC 00703-5145-01) 30mL Teva has limited inventory available for drop shipment only at this time. Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information. Teva has limited inventory available for drop shipment only at this time. Shortage per Manufacturer: Manufacturing delays;100mg/vial (NDC 0703-5140-01) 20mL  Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information. Teva is currently on back order but expects additional inventory to be available by the end of September.;350mg/vial (NDC 00703-5145-01) 30mL Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information. Teva is currently on back order but expects additional inventory to be available by the end of September.;100mg/vial (NDC 0703-5140-01) 20mL  Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information.;350mg/vial (NDC 00703-5145-01) 30mL Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information.;100mg/vial (NDC 0703-5140-01) 20mL  Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva has limited inventory available of both presentations;350mg/vial (NDC 00703-5145-01) 30mL Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva has limited inventory available of both presentations;100mg/vial (NDC 0703-5140-01) 20mL  Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. We anticipate availability of 30 mL presentation by April. See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva has limited inventory available of both presentations.;350mg/vial (NDC 00703-5145-01) 30mL Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. We anticipate availability of 30 mL presentation by April. See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva has limited inventory available of both presentations.;350mg/vial (NDC 00703-5145-01) 30mL Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. Teva has  the 30ml  presentation available - ndc 00703-2797-01 See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva has limited inventory available of both presentations.;100mg/vial (NDC 0703-5140-01) 20mL  Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. Teva has  the 30ml  presentation available - ndc 00703-2797-01 See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva has limited inventory available of both presentations.;350mg/vial (NDC 00703-5145-01) 30mL Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. Teva only has the 30ml Calcium Folinate Solution available- NDC 00703-2797-01 See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva has limited inventory available of both presentations.;100mg/vial (NDC 0703-5140-01) 20mL  Teva- in conjunction with the FDA- is initiating a temporary importation of Leucovorin Calcium Folinate Solution for Injection- to the United States market to address the current shortage. Teva only has the 30ml Calcium Folinate Solution available- NDC 00703-2797-01 See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva has limited inventory available of both presentations.;100mg/vial (NDC 0703-5140-01) 20mL  Teva now has 00703-5145-01 Lyopholized Leucovorin available in addition to  a limited supply of the Calcium Folinate Solution for Injection (NDC 00703-2797-01)- which was imported into the United States market to address the shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva has limited inventory available of both presentations.;350mg/vial (NDC 00703-5145-01) 30mL Teva now has 00703-5145-01 Lyopholized Leucovorin available in addition to  a limited supply of the Calcium Folinate Solution for Injection (NDC 00703-2797-01)- which was imported into the United States market to address the shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva has limited inventory available of both presentations.;350mg/vial (NDC 00703-5145-01) 30mL Teva now has 00703-5145-01 Lyopholized Leucovorin available in addition to a limited supply of the Calcium Folinate Solution for Injection (NDC 00703-2797-01)- which was imported into the United States market to address the shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva has limited inventory available of both presentations.;100mg/vial (NDC 0703-5140-01) 20mL  Teva now has 00703-5145-01 Lyopholized Leucovorin available in addition to a limited supply of the Calcium Folinate Solution for Injection (NDC 00703-2797-01)- which was imported into the United States market to address the shortage. See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva has limited inventory available of both presentations.;100mg/vial (NDC 0703-5140-01) 20mL  Teva now has 00703-5145-01 Lyopholized Leucovorin available. See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva only has the 30ml presentation of Calcium Folinate Solution available- NDC 00703-2797-01.;350mg/vial (NDC 00703-5145-01) 30mL Teva now has 00703-5145-01 Lyopholized Leucovorin available. See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva only has the 30ml presentation of Calcium Folinate Solution available- NDC 00703-2797-01.;350mg/vial (NDC 00703-5145-01) 30mL Teva 00703-5145-01 Lyophilized Leucovorin is currently on backorder with resupply expected in January. See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva only has the 30ml presentation of Calcium Folinate Solution available- NDC 00703-2797-01.;100mg/vial (NDC 0703-5140-01) 20mL  The 100mg has been temporarily discontinued. See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva only has the 30ml presentation of Calcium Folinate Solution available- NDC 00703-2797-01.;350mg/vial (NDC 00703-5145-01) 30mL Teva 00703-5145-01 Lyophilized Leucovorin is currently on backorder and expected to last into March 2014. See Dear Healthcare Professional letter (PDF 692KB) for additional information.   Teva only has the 30ml presentation of Calcium Folinate Solution available- NDC 00703-2797-01.",,,,,,,,,,,,,
Bedford,leucovorin,1,4/28/11,3/25/14,manufacturing delays; demand increase; available; capacity constraints; pending manufacturing change,blue,,"Bedford is releasing product as it becomes available - the 50 mg vial (NDC 55390-0051-10) 100 mg vials (NDC 55390-0052-10) .200 mg vial (NDC 55390-0053-01) and 350 mg vial (NDC 55390-0054-10).;Bedford anticipates release of 200mg and 350mg lyophilized product in early May- 500mg liquid product in early May- and  100mg and 50mg lyophilized product in the next 3-months.;Bedford anticipates releasing the 50mg lyophilized product ((NDC 55390-0051-10)  at the end of July and the 100mg lyophilized product (NDC 55390-0052-10) ) mid-June- 2011.  The 200mg (NDC 55390-0053-01) and 350mg lyophilized product (NDC 55390-0054-10)  will be released mid June- 2011.  The 500mg solution (NDC 55390-0009-01) will be released at the end of July- 2011.;Bedford Laboratories has limited emergency quantities of 200mg lyophilized product (NDC 55390-0053-01). Late July is the anticipated release for the 50mg lyophilized product (NDC 55390-0051-10)- 100mg lyophilized product (NDC 55390-0052-10) 350mg lyophilized product (NDC 55390-0054-10) and 500mg solution (NDC 55390-0009-01).;Bedford  has limited allocated quantities available of powder for injection 50 mg (NDC 55390-0051-10)- 100 mg (NDC 55390-0052-10)- 200 mg (NDC 55390-0053-10)- and 350 mg vials(NDC 55390-0054-10).  Bedford  also has limited allocated quantities available of 10 mg/mL- 50 mL injection (NDC 55390-0009-01). Contact your local Bedford Account Executives.;Bedford  has all leucovirin presenations on backorder and the company cannot estimate a release date.;Manufacturing delays Bedford Laboratories has 50 mg- 100 mg- and 350 mg powder for injection available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. The 500 mg/50 mL solution and 200 mg powder for injection are pending release with release date yet to be determined. Availability of products is updated on the Bedford  Laboratories website.;Bedford Laboratories has 50 mg- 100 mg- and 350 mg powder for injection available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. The 500 mg/50 mL solution and 200 mg powder for injection are pending release with release date yet to be determined. Availability of products is updated on the Bedford  Laboratories website.;;50 mg (NDC 55390-0005-10) Bedford laboratories has 50mg- 100mg- and 350 mg powder for injection available in limited quantities. Once this supply is depleted the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website. The 50 mg/50 mL solution and 200 mg powder for injection are pending release with release date yet to be determines.  Shortage per Manufacturer: Manufacturing delays;100 mg (NDC 55390-0052-10) Bedford laboratories has 50mg- 100mg- and 350 mg powder for injection available in limited quantities. Once this supply is depleted the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website. The 50 mg/50 mL solution and 200 mg powder for injection are pending release with release date yet to be determines.  Shortage per Manufacturer: Manufacturing delays;350mg (NDC 55390-0054-01) Bedford laboratories has 50mg- 100mg- and 350 mg powder for injection available in limited quantities. Once this supply is depleted the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website. The 50 mg/50 mL solution and 200 mg powder for injection are pending release with release date yet to be determines.  Shortage per Manufacturer: Manufacturing delays;500mg 50mL solution (NDC 55390-0009-01) Bedford laboratories has 50mg- 100mg- and 350 mg powder for injection available in limited quantities. Once this supply is depleted the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website. The 50 mg/50 mL solution and 200 mg powder for injection are pending release with release date yet to be determines.  Shortage per Manufacturer: Manufacturing delays;200 mg (NDC 55390-0053-01) Bedford laboratories has 50mg- 100mg- and 350 mg powder for injection available in limited quantities. Once this supply is depleted the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website. The 50 mg/50 mL solution and 200 mg powder for injection are pending release with release date yet to be determines.  Shortage per Manufacturer: Manufacturing delays;200 mg (NDC 55390-0053-01) Bedford laboratories has 50mg- 100mg- and 350 mg powder for injection available in limited quantities. Once this supply is depleted the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website. The 50 mg/50 mL solution and 200 mg powder for injection are pending release with release date yet to be determines. 
 Shortage per Manufacturer: 
 Manufacturing delays;350mg (NDC 55390-0054-01) Bedford laboratories has 50mg- 100mg- and 350 mg powder for injection available in limited quantities. Once this supply is depleted the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website. The 50 mg/50 mL solution and 200 mg powder for injection are pending release with release date yet to be determines. 
 Shortage per Manufacturer: 
 Manufacturing delays;500mg 50mL solution (NDC 55390-0009-01) Bedford laboratories has 50mg- 100mg- and 350 mg powder for injection available in limited quantities. Once this supply is depleted the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website. The 50 mg/50 mL solution and 200 mg powder for injection are pending release with release date yet to be determines. 
 Shortage per Manufacturer: 
 Manufacturing delays;100 mg (NDC 55390-0052-10) Bedford laboratories has 50mg- 100mg- and 350 mg powder for injection available in limited quantities. Once this supply is depleted the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website. The 50 mg/50 mL solution and 200 mg powder for injection are pending release with release date yet to be determines. 
 Shortage per Manufacturer: 
 Manufacturing delays;50 mg (NDC 55390-0005-10) Bedford laboratories has 50mg- 100mg- and 350 mg powder for injection available in limited quantities. Once this supply is depleted the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website. The 50 mg/50 mL solution and 200 mg powder for injection are pending release with release date yet to be determines. 
 Shortage per Manufacturer: 
 Manufacturing delays;100 mg (NDC 55390-0052-10) Available;200 mg (NDC 55390-0053-01) Available;500mg 50mL solution (NDC 55390-0009-01) The 500 mg / 50 mL solution is currently backordered and release dates are to be determined.;50 mg (NDC 55390-0005-10) Available;350mg (NDC 55390-0054-01) Available;350mg (NDC 55390-0054-01) Unavailable Pending Release: Release Date Yet to be Determined;500mg 50mL solution (NDC 55390-0009-01) Unavailable Shortage per Manufacturer: Capacity constraint.  Availability of products is updated on the Bedford Laboratories website.;100 mg (NDC 55390-0052-10) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is undated on the Bedford Laboratories website;50 mg (NDC 55390-0005-10) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is undated on the Bedford Laboratories website.;200 mg (NDC 55390-0053-01) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;50 mg (NDC 55390-0005-10) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.;500mg 50mL solution (NDC 55390-0009-01) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.;100 mg (NDC 55390-0052-10) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.;200 mg (NDC 55390-0053-01) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.;350mg (NDC 55390-0054-01) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website.",,,,,,,,,,,,,
APP,leucovorinlevoleucovorin,1,4/14/11,4/14/11,manufacturing delays,blue,,Manufacturing delays               Manufacturing delays   APP has recently launched their leucovorin injection in response to the ongoing shortage.         Due to the shortage of both leucovorin and levoleucovorin products,,,,,,,,,,,,,
Bedford,leucovorinlevoleucovorin,1,7/3/10,8/15/10,manufacturing delays,blue,,Manufacturing delays                     Manufacturing delays             Supplies continue to be available.;Manufacturing delays                     Manufacturing delays       Supplies continue to be available.;Manufacturing delays                     Manufacturing delays       Supplies continue to be available.;Manufacturing delays                     Manufacturing delays       Supplies continue to be available.,,,,,,,,,,,,,
Bedford,leucovorinlevoleucovorin,2,9/14/10,12/25/10,manufacturing delays,blue,,Manufacturing delays               Manufacturing delays       Supplies continue to be available.;Manufacturing delays               Manufacturing delays       Supplies continue to be available.,,,,,,,,,,,,,
Bedford,leucovorinlevoleucovorin,3,1/6/11,4/22/11,manufacturing delays,blue,,Manufacturing delays               Manufacturing delays   APP has recently launched their leucovorin injection in response to the ongoing shortage.         Supplies continue to be available.  ;Manufacturing delays               Manufacturing delays   APP has recently launched their leucovorin injection in response to the ongoing shortage.         Spectrum is working with the FDA on additional supplies - new information will be posted soon about additional supplies to help address the shortage.  ;Manufacturing delays               Manufacturing delays   APP has recently launched their leucovorin injection in response to the ongoing shortage.         Due to the shortage of both leucovorin and levoleucovorin products, Inc. to temporarily import levoleucovorin 100 mg Powder for Injection manufactured by Pfizer Inc. Please see the Dear Healthcare Professional Letter (PDF - 159KB) for additional information.;Manufacturing delays               Manufacturing delays   APP has recently launched their leucovorin injection in response to the ongoing shortage.         Due to the shortage of both leucovorin and levoleucovorin products, the FDA has utilized regulatory enforcement discretion for Spectrum Pharmaceuticals, Inc. to temporarily import levoleucovorin 100 mg Powder for Injection manufactured by Pfizer Inc. Please see the Dear Healthcare Professional Letter (PDF - 159KB) for additional information.,,,,,,,,,,
Spectrum,leucovorinlevoleucovorin,1,7/3/10,8/15/10,manufacturing delays,blue,,Manufacturing delays                     Manufacturing delays             Supplies continue to be available.;Manufacturing delays                     Manufacturing delays       Supplies continue to be available.;Manufacturing delays                     Manufacturing delays       Supplies continue to be available.;Manufacturing delays                     Manufacturing delays       Supplies continue to be available.,,,,,,,,,,,,,
Spectrum,leucovorinlevoleucovorin,2,9/14/10,12/25/10,manufacturing delays,blue,,Manufacturing delays               Manufacturing delays       Supplies continue to be available.;Manufacturing delays               Manufacturing delays       Supplies continue to be available.,,,,,,,,,,,,,
Spectrum,leucovorinlevoleucovorin,3,1/6/11,4/22/11,manufacturing delays,blue,,Manufacturing delays               Manufacturing delays   APP has recently launched their leucovorin injection in response to the ongoing shortage.         Supplies continue to be available.  ;Manufacturing delays               Manufacturing delays   APP has recently launched their leucovorin injection in response to the ongoing shortage.         Spectrum is working with the FDA on additional supplies - new information will be posted soon about additional supplies to help address the shortage.  ;Manufacturing delays               Manufacturing delays   APP has recently launched their leucovorin injection in response to the ongoing shortage.         Due to the shortage of both leucovorin and levoleucovorin products, Inc. to temporarily import levoleucovorin 100 mg Powder for Injection manufactured by Pfizer Inc. Please see the Dear Healthcare Professional Letter (PDF - 159KB) for additional information.;Manufacturing delays               Manufacturing delays   APP has recently launched their leucovorin injection in response to the ongoing shortage.         Due to the shortage of both leucovorin and levoleucovorin products, the FDA has utilized regulatory enforcement discretion for Spectrum Pharmaceuticals, Inc. to temporarily import levoleucovorin 100 mg Powder for Injection manufactured by Pfizer Inc. Please see the Dear Healthcare Professional Letter (PDF - 159KB) for additional information.,,,,,,,,,,
Teva,leucovorinlevoleucovorin,1,7/3/10,8/15/10,manufacturing delays,blue,,Manufacturing delays                     Manufacturing delays             Supplies continue to be available.;Manufacturing delays                     Manufacturing delays       Supplies continue to be available.;Manufacturing delays                     Manufacturing delays       Supplies continue to be available.;Manufacturing delays                     Manufacturing delays       Supplies continue to be available.,,,,,,,,,,,,,
Teva,leucovorinlevoleucovorin,2,9/14/10,12/25/10,manufacturing delays,blue,,Manufacturing delays               Manufacturing delays       Supplies continue to be available.;Manufacturing delays               Manufacturing delays       Supplies continue to be available.,,,,,,,,,,,,,
Teva,leucovorinlevoleucovorin,3,1/6/11,4/22/11,manufacturing delays,blue,,Manufacturing delays               Manufacturing delays   APP has recently launched their leucovorin injection in response to the ongoing shortage.         Supplies continue to be available.  ;Manufacturing delays               Manufacturing delays   APP has recently launched their leucovorin injection in response to the ongoing shortage.         Spectrum is working with the FDA on additional supplies - new information will be posted soon about additional supplies to help address the shortage.  ;Manufacturing delays               Manufacturing delays   APP has recently launched their leucovorin injection in response to the ongoing shortage.         Due to the shortage of both leucovorin and levoleucovorin products, Inc. to temporarily import levoleucovorin 100 mg Powder for Injection manufactured by Pfizer Inc. Please see the Dear Healthcare Professional Letter (PDF - 159KB) for additional information.;Manufacturing delays               Manufacturing delays   APP has recently launched their leucovorin injection in response to the ongoing shortage.         Due to the shortage of both leucovorin and levoleucovorin products, the FDA has utilized regulatory enforcement discretion for Spectrum Pharmaceuticals, Inc. to temporarily import levoleucovorin 100 mg Powder for Injection manufactured by Pfizer Inc. Please see the Dear Healthcare Professional Letter (PDF - 159KB) for additional information.,,,,,,,,,,
Caraco,leuprolide,1,6/30/11,3/25/14,demand increase,orange,,"On intermittent backorder- anticipate release June.;On intermittent backorder.;Increase in demand On intermittent backorder.;;1 mg/0.2 ml (NDC 41616-0936-40) On intermittent backorder. Shortage per Manufacturer: Increase in demand;1 mg/0.2 ml (NDC 41616-0936-40) On intermittent backorder. Shortage per Manufacturer: 
 Increase in demand",,,,,,,,,,,,,
Teva,leuprolide,1,6/30/11,3/25/14,manufacturing delays; manufacturing practices requirements; regulatory delay,yellow,,Currently on backorder- anticipate release is Q411.;Manufacturing delays Currently on backorder- anticipate release is Q411.;;1 mg/0.2 ml (NDC 00703-4014-18) Teva has Leuprolide Injection on backorder.  Teva anticipates product availability in Q412 Shortage per Manufacturer: Manufacturing Delays;1 mg/0.2 ml (NDC 00703-4014-18) Teva has Leuprolide Injection on backorder.  Teva anticipates product availability in Q412;1 mg/0.2 ml (NDC 00703-4014-18) Teva has Leuprolide Injection on backorder.  Teva anticipates product availability in Q213;1 mg/0.2 ml (NDC 00703-4014-18) Teva has Leuprolide Injection on backorder.  Teva anticipates product availability in Q213.;1 mg/0.2 ml (NDC 00703-4014-18) Teva has Leuprolide Injection on backorder.  Teva anticipates product availability in Q2 2013.;1 mg/0.2 ml (NDC 00703-4014-18) Teva has Leuprolide Injection on backorder.  Teva anticipates product availability in Q4 2013.;1 mg/0.2 ml (NDC 00703-4014-18) Teva has Leuprolide Injection on backorder.  Teva anticipates product availability in Q1 2014.;1 mg/0.2 ml (NDC 00703-4014-18) Teva has Leuprolide Injection on backorder.  Teva anticipates product availability in Q3 2014.;1 mg/0.2 ml (NDC 00703-4014-18) Teva has Leuprolide Injection on backorder and has temporarily discontinued product.,,,,,,,,,,,,,
Akorn,levofloxacin,1,11/3/11,7/12/12,demand increase; available,orange,,Akorn has levofloxacin 25 mg/mL 20 mL and 30 mL vials on intermittent back order and the company is releasing product as it becomes available.;20 mL (NDC 17478-0107-20)-Readily available               30 mL (NDC 1748-0107-30)-Readily available;Increased Demand 20 mL (NDC 17478-0107-20)-Readily available               30 mL (NDC 1748-0107-30)-Readily available;,,,,,,,,,,,,,
Spectrum,levoleucovorin,1,4/28/11,7/12/12,[temporary import]; available,brown,,"Reminder: There is potential for dosing errors when interchanging leucovorin and levoleucovorin (Fusilev). The dose of levoleucovorin (Fusilev) is one-half the dose of racemic leucovorin injection (e.g.- levoleucovorin [Fusilev] 7.5 mg = racemic leucovorin 15 mg). For more information visit: Spectrum Pharmaceuticals web site.;Reminder: There is potential for dosing errors when interchanging leucovorin and levoleucovorin (Fusilev). The dose of levoleucovorin (Fusilev) is one-half the dose of racemic leucovorin injection (e.g.- levoleucovorin [Fusilev] 7.5 mg = racemic leucovorin 15 mg). 
 
 For more information visit: Spectrum Pharmaceuticals web site.;Spectrum Pharmaceuticals has increased production of Fusilev 50 mg vials (NDC 68152-101-00) and is continuing to release supplies as they become available. Reminder: There is potential for dosing errors when interchanging leucovorin and levoleucovorin (Fusilev). The dose of levoleucovorin (Fusilev) is one-half the dose of racemic leucovorin injection (e.g.- levoleucovorin [Fusilev] 7.5 mg = racemic leucovorin 15 mg). For more information visit: Spectrum Pharmaceuticals web site.;Fusilev (levoleucovorin) for Injection 50 mg vials (NDC 68152-101-00) are available from Spectrum Pharmaceuticals in ample quantities. Based upon the current and anticipated inventory- Spectrum Pharmaceuticals is able to meet all present and future demand. Please call the Company directly at 1-877-387-4538 to obtain Fusilev which is now approved for CRC. Reminder: There is potential for dosing errors when interchanging leucovorin and levoleucovorin (Fusilev). The dose of levoleucovorin (Fusilev) is one-half the dose of racemic leucovorin injection (e.g.- levoleucovorin [Fusilev] 7.5 mg = racemic leucovorin 15 mg). For more information visit: Spectrum Pharmaceuticals  web site.;Fusilev (levoleucovorin) for Injection 50 mg vials (NDC 68152-101-00) are available from Spectrum Pharmaceuticals in ample quantities. Based upon the current and anticipated inventory- Spectrum Pharmaceuticals is able to meet all present and future demand. Please call the Company directly at 1-877-387-4538 to obtain Fusilev which is now approved for CRC. 
 
 Reminder: There is potential for dosing errors when interchanging leucovorin and levoleucovorin (Fusilev). The dose of levoleucovorin (Fusilev) is one-half the dose of racemic leucovorin injection (e.g.- levoleucovorin [Fusilev] 7.5 mg = racemic leucovorin 15 mg). 
 
 For more information visit: Spectrum Pharmaceuticals  web site.;",,,,,,,,,,,,,
Roxane,levorphanol,1,4/15/10,4/22/11,manufacturing delays,blue,,Manufacturing delays.,,,,,,,,,,,,,
AmericanRegent,lidocaine,1,8/4/12,3/25/14,; discontinued; production suspended,black,,";1%- 50 mL vial package of 25 (NDC 00517-0625-25) Unavailable Shortage per Manufacturer: American Regent/Luitpold is not manufacturing Lidocaine HCl Injection- USP;2%- 50 mL vial package of 25 (NDC 00517-0626-25) Unavailable Shortage per Manufacturer: American Regent/Luitpold is not manufacturing Lidocaine HCl Injection- USP;2%- 50 mL vial package of 25 (NDC 00517-0626-25) Unavailable Shortage per Manufacturer: 
 American Regent/Luitpold is not manufacturing Lidocaine HCl Injection- USP;1%- 50 mL vial package of 25 (NDC 00517-0625-25) Unavailable Shortage per Manufacturer: 
 American Regent/Luitpold is not manufacturing Lidocaine HCl Injection- USP;2%- 50 mL vial package of 25 (NDC 00517-0626-25) Unavailable American Regent/Luitpold has discontinued manufacturing Lidocaine HCl Injection- USP;1%- 50 mL vial package of 25 (NDC 00517-0625-25) Unavailable American Regent/Luitpold has discontinued manufacturing Lidocaine HCl Injection- USP;1%- 50 mL vial package of 25 (NDC 00517-0625-25) Unavailable - No product available for release. No plan to manufacture. American Regent/Luitpold has discontinued manufacturing Lidocaine HCl Injection- USP;2%- 50 mL vial package of 25 (NDC 00517-0626-25) Unavailable - No product available for release. No plan to manufacture. American Regent/Luitpold has discontinued manufacturing Lidocaine HCl Injection- USP",,,,,,,,,,,,,
AuroMedics,lidocaine,1,12/28/13,3/25/14,available,,,1% 2 mL Ampoule (NDC 55150-158-72)   Available. All presentations are avaialble;1% 5 mL Ampoule (NDC 55150-159-74) Available. All presentations are avaialble;1% 2 mL Single Dose Vial (NDC 55150-161-02) Available. All presentations are avaialble;2% 5 mL Single Dose Vial (NDC 55150-165-05) Available. All presentations are avaialble;2% 2 mL Ampoule (NDC 55150-160-72) Available. All presentations are avaialble;2% 2 mL Single Dose Vial (NDC 55150-164-02) Available. All presentations are avaialble;1% 5 mL Single Dose Vial (NDC 55150-162-05) Available. All presentations are avaialble;1% 30 mL Single Dose Vial (NDC 55150-163-30) Available. All presentations are avaialble,,,,,,,,,,,,,
Fresenius,lidocaine,1,12/28/13,3/25/14,demand increase,orange,,Xylocaine 2% - MPF injection 20 mg/mL- 10 mL ampule (NDC 63323-0496-97) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 10 mL vial (NDC 63323-0486-10) discontinued   All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% injection 10 mg/mL- 20 mL vial (NDC 63323-0485-27) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1.5% - MPF injection 15 mg/mL- 20 mL ampule (NDC 63323-0493-91) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 2 mL vial (NDC 63323-0492-27) Backordered. Next release anticipated February 2014. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 20 mL vial (NDC 63323-0486-27) Available. Check Wholesalers for inventory.   All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% - MPF injection 20 mg/mL- 5 mL vial (NDC 63323-0495-07) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 2% injection 20 mg/mL- 2 mL vial (NDC 63323-0202-02) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 30 mL vial (NDC 63323-0492-37) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% injection 10 mg/mL- 50 mL vial (NDC 63323-0485-57) Currently back-ordered. Next release anticipated January 2014. Check wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 2 mL glass ampule (NDC 63323-0492-80) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 1% injection 10 mg/mL- 10 mL vial (NDC 63323-0201-10) Backordered. Next release anticipated January 2014. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 50 mL vial (NDC 63323-0486-50) ? NDC discontinued   All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1.5% - MPF injection 15 mg/mL- 10 mL ampule (NDC 63323-0493-97) Backordered.  Next release anticipated January 2014. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 0.5% injection 5 mg/mL- 50 mL vial (NDC 63323-0484-57) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 1% injection 10 mg/mL- 2 mL vial (NDC 63323-0201-02 Available. Check wholesalers for inventory.. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 30 mL vial- sterile pack (NDC 63323-0492-31) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 10 mL vial (NDC 63323-0486-17) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection NDC discontinued 20 mg/mL- 20 mL vial (NDC 63323-0486-20)-NDC discontinued   All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 5 mL vial (NDC 63323-0492-57) Available. Check wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 5 mL glass ampule (NDC 63323-0492-89) Available. Check Wholesalers for inventory.   All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% - MPF injection 20 mg/mL- 2 mL vial (NDC 63323-0495-27) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 2% injection 20 mg/mL- 5 mL SD Tear Top vial- preservative-free (NDC 63323-0208-05) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 0.5% - MPF injection- APP 5 mg/mL- 50 mL vial (NDC 63323-0491-57) Available. Check Wholesalers for inventory.  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 50 mL vial (NDC 63323-0486-57) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 2 mL glass ampule (NDC 63323-0492-80) 3-4-6 month expiry dating available direct by request. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 1% injection 10 mg/mL- 10 mL vial (NDC 63323-0201-10) Available. Check wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 1% injection 10 mg/mL- 2 mL vial (NDC 63323-0201-02 Available. Check wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% injection 10 mg/mL- 20 mL vial (NDC 63323-0485-27) Backordered. Next release anticipated April 2014. Check wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 5 mL vial (NDC 63323-0492-57) Backordered. Check wholesalers for inventory. Next anticipated release April 2014. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% - MPF injection 20 mg/mL- 5 mL vial (NDC 63323-0495-07) Backordered. Check wholesalers for inventory. Next release anticipated March 2014.   All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 20 mL vial (NDC 63323-0486-27) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% injection 10 mg/mL- 50 mL vial (NDC 63323-0485-57) Available. Check wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 5 mL glass ampule (NDC 63323-0492-89) 5 month expiry dating available by request. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 2% injection 20 mg/mL- 2 mL vial (NDC 63323-0202-02) Backordered.  Next release anticipated March 2014. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 2 mL vial (NDC 63323-0492-27) Available. Check wholesalers for inventory.. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1.5% - MPF injection 15 mg/mL- 10 mL ampule (NDC 63323-0493-97) Backordered.  Next release anticipated March 2014. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand,,,,,,,,,,,,,
Amphastar,lidocaine,1,5/11/12,3/25/14,demand increase; available,orange,,";2%- 5mL Luer-Jet Prefilled Syringe NDC 76329-3390-1(old NDC 0548-3390-00) Amphastar will regularly release products. Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues. Shortage per Manufacturer: Increased Demand;2%- 5mL Luer-Jet Prefilled Syringe
 NDC 76329-3390-1
 (old NDC 0548-3390-00) Amphastar will regularly release products. Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues.
 Shortage per Manufacturer: 
 Increased Demand;2%- 5mL Luer-Jet Prefilled Syringe NDC 76329-3390-1(old NDC 0548-3390-00) Amphastar will regularly release products. Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues.   Shortage per Manufacturer: Increased Demand;2%- 5mL Luer-Jet Prefilled Syringe NDC 76329-3390-1(old NDC 0548-3390-00) Available;2%- 5mL Luer-Jet Prefilled Syringe NDC 76329-3390-1 (old NDC 0548-3390-00) Available;Lidocaine HCl- 4% Topical Solution- USP- 4mL Laryng-O-Jet- NDC 0548-6300-00- new NDC 76329-6300-5 Amphastar will regularly release products.  Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues.;2%- 5mL Luer-Jet Prefilled Syringe new NDC 76329-3390-1 (old NDC 0548-3390-00) Amphastar will regularly release products.    Amphastar is  experiencing a product shortage due to an increase in product demand caused by market supply issues",,,,,,,,,,,,,
APP,lidocaine,1,2/23/12,11/8/13,manufacturing delays; discontinued; demand increase,black,,"APP has all lidocaine and Xylocaine presentations on intermittent back order and will be releasing product as it becomes available.;Manufacturing delay APP has all lidocaine and Xylocaine presentations on intermittent back order and will be releasing product as it becomes available.;;Xylocaine 0.5% - MPF injection- APP 5 mg/mL- 50 mL vial (NDC 63323-0491-57) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 5 mL glass ampule (NDC 63323-0492-89) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL- 20 mL ampule (NDC 63323-0493-91) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 50 mL vial (NDC 63323-0486-50) ? NDC discontinued Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 30 mL vial- sterile pack (NDC 63323-0492-31) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% - MPF injection 20 mg/mL- 2 mL vial (NDC 63323-0495-27) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 10 mL vial (NDC 63323-0486-17) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL- 10 mL ampule (NDC 63323-0493-97) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 1% Lidocaine 1% injection 10 mg/mL- 2 mL vial (NDC 63323-0201-02 Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 1% Lidocaine 1% injection 10 mg/mL- 10 mL vial (NDC 63323-0201-10) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% - MPF injection 20 mg/mL- 5 mL vial (NDC 63323-0495-07) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 5 mL vial (NDC 63323-0492-57) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 2% Lidocaine 2% injection 20 mg/mL- 5 mL SD Tear Top vial- preservative-free (NDC 63323-0208-05) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 2 mL glass ampule (NDC 63323-0492-80) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 2% Lidocaine 2% injection 20 mg/mL- 2 mL vial (NDC 63323-0202-02) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 30 mL vial (NDC 63323-0492-37) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 20 mL vial (NDC 63323-0486-27) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 10 mL vial (NDC 63323-0486-10) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 50 mL vial (NDC 63323-0486-57) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection NDC discontinued 20 mg/mL- 20 mL vial (NDC 63323-0486-20)-NDC discontinued Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% - MPF injection 20 mg/mL- 10 mL ampule (NDC 63323-0496-97) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% injection 10 mg/mL- 50 mL vial (NDC 63323-0485-57) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 0.5% Xylocaine 0.5% injection 5 mg/mL- 50 mL vial (NDC 63323-0484-57) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% injection 10 mg/mL- 20 mL vial (NDC 63323-0485-27) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 2 mL vial (NDC 63323-0492-27) Check Wholesalers for Inventory                  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 5 mL glass ampule (NDC 63323-0492-89) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 30 mL vial- sterile pack (NDC 63323-0492-31) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Lidocaine 1% Lidocaine 1% injection 10 mg/mL- 2 mL vial (NDC 63323-0201-02 Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 2% injection NDC discontinued 20 mg/mL- 20 mL vial (NDC 63323-0486-20)-NDC discontinued Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 2% - MPF injection 20 mg/mL- 10 mL ampule (NDC 63323-0496-97) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 1% injection 10 mg/mL- 20 mL vial (NDC 63323-0485-27) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 30 mL vial (NDC 63323-0492-37) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Lidocaine 1% Lidocaine 1% injection 10 mg/mL- 10 mL vial (NDC 63323-0201-10) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 2% injection 20 mg/mL- 10 mL vial (NDC 63323-0486-17) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Lidocaine 2% Lidocaine 2% injection 20 mg/mL- 2 mL vial (NDC 63323-0202-02) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Lidocaine 0.5% Xylocaine 0.5% injection 5 mg/mL- 50 mL vial (NDC 63323-0484-57) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Lidocaine 2% Lidocaine 2% injection 20 mg/mL- 5 mL SD Tear Top vial- preservative-free (NDC 63323-0208-05) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 2% injection 20 mg/mL- 20 mL vial (NDC 63323-0486-27) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 2% - MPF injection 20 mg/mL- 2 mL vial (NDC 63323-0495-27) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 2% - MPF injection 20 mg/mL- 5 mL vial (NDC 63323-0495-07) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 2% injection 20 mg/mL- 50 mL vial (NDC 63323-0486-57) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 2% injection 20 mg/mL- 10 mL vial (NDC 63323-0486-10) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 2% injection 20 mg/mL- 50 mL vial (NDC 63323-0486-50) ? NDC discontinued Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL- 20 mL ampule (NDC 63323-0493-91) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 5 mL vial (NDC 63323-0492-57) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 2 mL glass ampule (NDC 63323-0492-80) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 0.5% - MPF injection- APP 5 mg/mL- 50 mL vial (NDC 63323-0491-57) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL- 10 mL ampule (NDC 63323-0493-97) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 2 mL vial (NDC 63323-0492-27) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Xylocaine 1% injection 10 mg/mL- 50 mL vial (NDC 63323-0485-57) Check Wholesalers for Inventory   
          
      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available.
 Shortage per Manufacturer: 
 Increase in demand;Lidocaine 1% Lidocaine 1% injection 10 mg/mL- 10 mL vial (NDC 63323-0201-10) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 0.5% Xylocaine 0.5% injection 5 mg/mL- 50 mL vial (NDC 63323-0484-57) Available. Check Wholesalers for inventory.      All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 2% Lidocaine 2% injection 20 mg/mL- 2 mL vial (NDC 63323-0202-02) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 50 mL vial (NDC 63323-0486-57)   All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% - MPF injection 20 mg/mL- 2 mL vial (NDC 63323-0495-27) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 10 mL vial (NDC 63323-0486-10) discontinued   All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% injection 10 mg/mL- 50 mL vial (NDC 63323-0485-57) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 2 mL vial (NDC 63323-0492-27) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection NDC discontinued 20 mg/mL- 20 mL vial (NDC 63323-0486-20)-NDC discontinued   All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 5 mL glass ampule (NDC 63323-0492-89) Backordered. No estimated delivery at this time. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 0.5% - MPF injection- APP 5 mg/mL- 50 mL vial (NDC 63323-0491-57) Available. Check Wholesalers for inventory.  All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 30 mL vial (NDC 63323-0492-37) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 30 mL vial- sterile pack (NDC 63323-0492-31) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 2% Lidocaine 2% injection 20 mg/mL- 5 mL SD Tear Top vial- preservative-free (NDC 63323-0208-05) Backordered. Next release estimated February 2013. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL- 10 mL ampule (NDC 63323-0493-97) Backordered. No estimated delivery at this time. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 10 mL vial (NDC 63323-0486-17) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 50 mL vial (NDC 63323-0486-50) ? NDC discontinued   All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 1.5% Xylocaine 1.5% - MPF injection 15 mg/mL- 20 mL ampule (NDC 63323-0493-91) Backordered. No estimated delivery at this time. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 20 mL vial (NDC 63323-0486-27) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 2 mL glass ampule (NDC 63323-0492-80) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% - MPF injection 20 mg/mL- 5 mL vial (NDC 63323-0495-07) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 1% Lidocaine 1% injection 10 mg/mL- 2 mL vial (NDC 63323-0201-02 Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 5 mL vial (NDC 63323-0492-57) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% injection 10 mg/mL- 20 mL vial (NDC 63323-0485-27) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% - MPF injection 20 mg/mL- 10 mL ampule (NDC 63323-0496-97) Backordered. No Estimated delivery at this time.. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 2% Lidocaine 2% injection 20 mg/mL- 5 mL SD Tear Top vial- preservative-free (NDC 63323-0208-05) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 50 mL vial (NDC 63323-0486-57) Backordered.  Next release anticipated late March 2013. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 2% injection 20 mg/mL- 50 mL vial (NDC 63323-0486-57) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 2% injection 20 mg/mL- 5 mL SD Tear Top vial- preservative-free (NDC 63323-0208-05) Backordered.  Next release anticipated June 2013. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 2% Lidocaine 2% injection 20 mg/mL- 2 mL vial (NDC 63323-0202-02) Backordered.  Next release anticipated All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% injection 10 mg/mL- 20 mL vial (NDC 63323-0485-27) Currently back-ordered.  Next release expected late July 2013. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 1% Lidocaine 1% injection 10 mg/mL- 2 mL vial (NDC 63323-0201-02 Currently back-ordered.  Next release expected September 2013. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 5 mL glass ampule (NDC 63323-0492-89) Available. Check Wholesalers for inventory.   All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 2% injection 20 mg/mL- 5 mL SD Tear Top vial- preservative-free (NDC 63323-0208-05) Backordered.  Next release anticipated August 2013. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% injection 10 mg/mL- 20 mL vial (NDC 63323-0485-27) Currently back-ordered.  Next release expected September 2013. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% - MPF injection 10 mg/mL- 30 mL vial (NDC 63323-0492-37) Currently back-ordered. Next release anticipated september 2013. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 2% Lidocaine 2% injection 20 mg/mL- 2 mL vial (NDC 63323-0202-02) Backordered.  Next release anticipated October 2013. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Xylocaine 1% injection 10 mg/mL- 50 mL vial (NDC 63323-0485-57) Currently back-ordered. Nest release anticipated september 2013. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 2% injection 20 mg/mL- 5 mL SD Tear Top vial- preservative-free (NDC 63323-0208-05) Available. Check Wholesalers for inventory. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand;Lidocaine 1% Lidocaine 1% injection 10 mg/mL- 2 mL vial (NDC 63323-0201-02 Currently back-ordered.  Next release expected October 2013. All lidocaine and Xylocaine presentations are on intermittent back order and will be released as the product becomes available. Shortage per Manufacturer: Increase in demand",,,,,,,,,,,,,
,lidocaine,1,6/29/12,7/1/12,,,,,,,,,,,,,,,,,
Amphastar,lidocainehcl,1,8/4/12,1/10/13,demand increase; available,orange,,;4mL Laryng-O-Jet- NDC 76329-6300-5 (old NDC 0548-6300-00) Amphastar will regularly release products. Shortage per manufacturer:  Increase in product demand caused by market supply issues.;4mL Laryng-O-Jet- NDC 76329-6300-5 (old NDC 0548-6300-00) Available;4mL Laryng-O-Jet- NDC 76329-6300-5 (old NDC 0548-6300-00) Amphastar will regularly release products. Amphastar is  experiencing a product shortage due to an increase in product demand caused by market supply issues,,,,,,,,,,,,,
Amphastar,lidocainehcl,2,3/1/13,6/17/13,demand increase; available,orange,,4mL Laryng-O-Jet- NDC 76329-6300-5 (old NDC 0548-6300-00) Available;4mL Laryng-O-Jet NDC 76329-6300-5 (old NDC 0548-6300-00)  Amphastar will regularly release products.  Shortage per Manufacturer: Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues.;4mL Laryng-O-Jet NDC 76329-6300-5 (old NDC 0548-6300-00)  Available,,,,,,,,,,,,,
Forest,liotrix,1,6/5/13,3/25/14,manufacturing delays; material shortage,green,,Forest has not yet reported when Thyrolar will be available. Shortage per Manufacturer: Manufacturing delays;Thyrolar-1 (NDC 0456-0050-01) Product currently unavailable; estimated duration: 1 year Shortage per Manufacturer: Due to shortage of the T3 component of the formulation Forest cannot provide anticipated release date;Thyrolar-1/2 (NDC 0456-0045-01) Product currently unavailable; estimated duration: 1 year Shortage per Manufacturer: Due to shortage of the T3 component of the formulation Forest cannot provide anticipated release date;Thyrolar-3 (NDC 0456-0060-01)  Product currently unavailable; estimated duration: 1 year Shortage per Manufacturer: Due to shortage of the T3 component of the formulation Forest cannot provide anticipated release date;Thyrolar-1/4 (NDC 0456-0040-01) Product currently unavailable; estimated duration: 1 year Shortage per Manufacturer: Due to shortage of the T3 component of the formulation Forest cannot provide anticipated release date;Thyrolar-2 (NDC 0456-0055-01) Product currently unavailable; estimated duration: 1 year Shortage per Manufacturer: Due to shortage of the T3 component of the formulation Forest cannot provide anticipated release date,,,,,,,,,,,,,
Baxter,lorazepam,1,4/14/11,4/22/11,demand increase,orange,,Demand increase,,,,,,,,,,,,,
Baxter,lorazepam,1,4/28/11,12/9/11,demand increase,orange,,"Baxter has lorazepam 2 mg/mL- 10 mL vials (NDC 10019-0102-10) currently available for distribution. The 2 mg/mL- 1 mL vial presentation (NDC 10019-0102-01) will be on back order until the end of April.;Baxter has lorazepam 2 mg/mL- 10 mL vials (NDC 10019-0102-10) currently available for distribution. 
 
 The 2 mg/mL- 1 mL vial presentation (NDC 10019-0102-01) will be on back order until the end of April.;Baxter has available lorazepam 2 mg/mL 1 mL (NDC 10019-0102-01) and 10 mL (NDC 10019-0102-10) vials- 2 mg/mL 1 mL (NDC 10019-0105-01) and 10 mL (NDC 10019-0105-02) Novaplus vials- 4 mg/mL 10 mL (NDC 10019-0103-10) vials- and 4 mg/mL 1 mL (NDC 10019-0106-01) and 10 mL (NDC 10019-0106-02) Novaplus vials. The 4 mg/mL 1 mL vial is on back order with no estimated release date.",,,,,,,,,,,,,
Bedford,lorazepam,1,4/14/11,4/22/11,demand increase,orange,,Demand increase,,,,,,,,,,,,,
Hospira,lorazepam,1,4/22/11,4/22/11,demand increase,orange,,Demand increase,,,,,,,,,,,,,
WestWard,lorazepam,1,12/15/11,3/25/14,demand increase,orange,,"West-Ward is currently experiencing a backorder situation on the Ativan and Lorazepam 2 mg/mL- 1 mL vials and also the Lorazepam 4 mg/mL- 1 mL vial.    All other presentations of Ativan and Lorazepam are available in limited quantities.   West-Ward has accelerated production on Ativan and Lorazepam 2 mg/mL- 1 mL vial codes and will have additional lots availability in the November ? December 2011 timeframe. Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on the Ativan and Lorazepam 2 mg/mL- 1 mL vials and also the Lorazepam 4 mg/mL- 1 mL vial. 
  
 All other presentations of Ativan and Lorazepam are available in limited quantities.
  
 West-Ward has accelerated production on Ativan and Lorazepam 2 mg/mL- 1 mL vial codes and will have additional lots availability in the November ? December 2011 timeframe.
 Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on all Ativan and Lorazepam codes.  Manufacturing has been increased to meet product demand. Limited quantities of lorazepam 2 mg/mL- 1 mL vial and 4 mg/mL- 10 mL vial will be available in February 2012. Multiple lots of all codes are projected to be released and available in the March ? April 2012 timeframe. Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on all Ativan and Lorazepam codes.  Manufacturing has been increased to meet product demand. 
 
 Limited quantities of lorazepam 2 mg/mL- 1 mL vial and 4 mg/mL- 10 mL vial will be available in February 2012. 
 
 Multiple lots of all codes are projected to be released and available in the March ? April 2012 timeframe. 
 Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on all Ativan and Lorazepam codes.  Manufacturing has been increased to meet product demand. Multiple lots of all codes are projected to be released and available in the late March ? April 2012 timeframe. Product will be made available as it is released.;Increase in product demand due to market supply issues. West-Ward is currently experiencing a backorder situation on all Ativan and Lorazepam codes.  Manufacturing has been increased to meet product demand. Multiple lots of all codes are projected to be released and available in the late March ? April 2012 timeframe. Product will be made available as it is released.;;4 mg/mL- 1 mL vial (NDC 0641-6045-25) Available in very limited quantities Shortage per Manufacturer: Increase in product demand;4 mg/mL- 1 mL vial (NDC 0641-6003-25) Backordered Shortage per Manufacturer: Increase in product demand;2 mg/mL- 10 mL vial (NDC 0641-6000-10) Available in very limited quantities Shortage per Manufacturer: Increase in product demand;2 mg/mL- 1 mL vial (NDC 0641-6044-25) Backordered Shortage per Manufacturer: Increase in product demand;4 mg/mL- 10 mL vial -(NDC 0641-6047-10) Available in very limited quantities Shortage per Manufacturer: Increase in product demand;2 mg/mL- 10 mL vial -(NDC 0641-6046-10) Available in very limited quantities Shortage per Manufacturer: Increase in product demand;2 mg/mL- 1 mL vial (NDC 0641-6001-25) West-Ward has accelerated production on all codes and is projecting to have additional inventory available for release in the July - August 2012 timeframe. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand;4 mg/mL- 10 mL vial -(NDC 0641-6002-10) Available in very limited quantities Shortage per Manufacturer: Increase in product demand;2 mg/mL- 10 mL vial 
 (NDC 0641-6000-10) Available in very limited quantities Shortage per Manufacturer: 
 Increase in product demand;2 mg/mL- 10 mL vial -
 (NDC 0641-6046-10) Available in very limited quantities Shortage per Manufacturer: 
 Increase in product demand;4 mg/mL- 1 mL vial 
 (NDC 0641-6045-25) Available in very limited quantities Shortage per Manufacturer: 
 Increase in product demand;4 mg/mL- 10 mL vial -
 (NDC 0641-6002-10) Available in very limited quantities Shortage per Manufacturer: 
 Increase in product demand;4 mg/mL- 10 mL vial -
 (NDC 0641-6047-10) Available in very limited quantities Shortage per Manufacturer: 
 Increase in product demand;2 mg/mL- 1 mL vial 
 (NDC 0641-6001-25) West-Ward has accelerated production on all codes and is projecting to have additional inventory available for release in the July - August 2012 timeframe.
 Product will be made available as it is released. Shortage per Manufacturer: 
 Increase in product demand;4 mg/mL- 1 mL vial 
 (NDC 0641-6003-25) Backordered Shortage per Manufacturer: 
 Increase in product demand;2 mg/mL- 1 mL vial 
 (NDC 0641-6044-25) Backordered Shortage per Manufacturer: 
 Increase in product demand;2 mg/mL- 1 mL vial (NDC 0641-6001-25) West-Ward currently has available inventory of Lorazepam Injection- USP. There is a backorder situation on all Ativan codes. West-Ward has accelerated production on all Ativan/Lorazepam Injection product codes West-Ward is anticipating having additional lots of inventory available in the January - February 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 10 mL vial -(NDC 0641-6046-10) Available West-Ward is anticipating having additional lots of inventory available in the January - February 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 1 mL vial (NDC 0641-6045-25) Available West-Ward is anticipating having additional lots of inventory available in the January - February 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 1 mL vial (NDC 0641-6003-25) On backorder West-Ward is anticipating having additional lots of inventory available in the January - February 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 10 mL vial -(NDC 0641-6002-10) On backorder West-Ward is anticipating having additional lots of inventory available in the January - February 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 10 mL vial (NDC 0641-6000-10) On backorder West-Ward is anticipating having additional lots of inventory available in the January - February 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 1 mL vial (NDC 0641-6044-25) Available West-Ward is anticipating having additional lots of inventory available in the January - February 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 10 mL vial -(NDC 0641-6047-10) Available West-Ward is anticipating having additional lots of inventory available in the January - February 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 10 mL vial (NDC 0641-6000-10) On backorder West-Ward is anticipating having additional lots of inventory available in the March 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 1 mL vial (NDC 0641-6045-25) Available West-Ward is anticipating having additional lots of inventory available in the March 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 10 mL vial -(NDC 0641-6046-10) Available West-Ward is anticipating having additional lots of inventory available in the March 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 1 mL vial (NDC 0641-6044-25) Available West-Ward is anticipating having additional lots of inventory available in the March 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 1 mL vial (NDC 0641-6003-25) On backorder West-Ward is anticipating having additional lots of inventory available in the March 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 10 mL vial -(NDC 0641-6047-10) Available West-Ward is anticipating having additional lots of inventory available in the March 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 1 mL vial (NDC 0641-6001-25) West-Ward currently has limited inventory of Lorazepam Injection- USP. West-Ward has accelerated production on all Ativan/Lorazepam Injection product codes West-Ward is anticipating having additional lots of inventory available in the March 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 10 mL vial -(NDC 0641-6002-10) On backorder West-Ward is anticipating having additional lots of inventory available in the March 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 10 mL vial (NDC 0641-6000-10)   West-Ward is anticipating having additional lots of inventory available in the July-August 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 1 mL vial (NDC 0641-6001-25) West-Ward currently has limited inventory of Ativan/Lorazepam Injection- USP.      Only Lorazepam Injection- USP 2 mg/mL- 10 mL vial (NDC 0641-6046-10) is experiencing a backorder situation.   West-Ward has accelerated production on all Ativan/Lorazepam Injection product codes.   West-Ward is anticipating having additional lots of inventory available in the July-August 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 1 mL vial (NDC 0641-6045-25)     West-Ward is anticipating having additional lots of inventory available in the July-August 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 10 mL vial -(NDC 0641-6002-10)     West-Ward is anticipating having additional lots of inventory available in the July-August 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 10 mL vial -(NDC 0641-6047-10)     West-Ward is anticipating having additional lots of inventory available in the July-August 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 1 mL vial (NDC 0641-6044-25)     West-Ward is anticipating having additional lots of inventory available in the July-August 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 10 mL vial -(NDC 0641-6046-10)     West-Ward is anticipating having additional lots of inventory available in the July-August 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 1 mL vial (NDC 0641-6003-25)     West-Ward is anticipating having additional lots of inventory available in the July-August 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 10 mL vial -(NDC 0641-6047-10)     West-Ward is anticipating having additional lots of inventory available in the September -October 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 10 mL vial -(NDC 0641-6046-10)     West-Ward is anticipating having additional lots of inventory available in the September -October 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 10 mL vial -(NDC 0641-6002-10)     West-Ward is anticipating having additional lots of inventory available in the September -October 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 1 mL vial (NDC 0641-6044-25)     West-Ward is anticipating having additional lots of inventory available in the September -October 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 1 mL vial (NDC 0641-6045-25)     West-Ward is anticipating having additional lots of inventory available in the September -October 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 1 mL vial (NDC 0641-6001-25) West-Ward currently has inventory for most Ativan/Lorazepam Injection- USP presentations.    The Ativan 4 mg/mL- 1 mL and 10 mL vials are experiencing a temporary backorder situation.   West-Ward has accelerated production on all Ativan/Lorazepam Injection product codes.   West-Ward is anticipating having additional lots of inventory available in the September -October 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 10 mL vial (NDC 0641-6000-10)   West-Ward is anticipating having additional lots of inventory available in the September -October 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 1 mL vial (NDC 0641-6003-25)     West-Ward is anticipating having additional lots of inventory available in the September -October 2013 timeframe. Product will be made available as it is released.;4 mg/mL- 1 mL vial (NDC 0641-6045-25)     West-Ward is anticipating manufacturing additional lots with releases expected in February 2013. Product will be made available as it is released.;4 mg/mL- 1 mL vial (NDC 0641-6003-25)     West-Ward is anticipating manufacturing additional lots with releases expected in February 2013. Product will be made available as it is released.;2 mg/mL- 1 mL vial (NDC 0641-6044-25)     West-Ward is anticipating manufacturing additional lots with releases expected in February 2013. Product will be made available as it is released.;2 mg/mL- 1 mL vial (NDC 0641-6001-25) West-Ward currently has inventory for most Ativan/Lorazepam Injection- USP presentations. The Lorazepam 2 mg/mL- 10 mL vial- 4 mg/mL 1 mL and 10 mL vials are experiencing a temporary backorder situation. West-Ward has accelerated production on all Ativan/Lorazepam Injection codes.  West-Ward is anticipating manufacturing additional lots with releases expected in February 2013. Product will be made available as it is released.;4 mg/mL- 10 mL vial -(NDC 0641-6002-10)     West-Ward is anticipating manufacturing additional lots with releases expected in February 2013. Product will be made available as it is released.;4 mg/mL- 10 mL vial -(NDC 0641-6047-10)     West-Ward is anticipating manufacturing additional lots with releases expected in February 2013. Product will be made available as it is released.;2 mg/mL- 10 mL vial (NDC 0641-6000-10)   West-Ward is anticipating manufacturing additional lots with releases expected in February 2013. Product will be made available as it is released.;2 mg/mL- 10 mL vial -(NDC 0641-6046-10)     West-Ward is anticipating manufacturing additional lots with releases expected in February 2013. Product will be made available as it is released.",,,,,,,,,,,,,
Akorn,lorazepam,1,5/11/11,3/25/14,demand increase; available,orange,,"Akorn has Lorazepam injection available.;Akorn has Lorazepam injection 2 mg/mL- 1 mL vials on intermittent back order and are filling direct orders and shipping to wholesalers as product becomes available. .;Akorn has Lorazepam injection 2 mg/mL- 1 mL vials on intermittent back order and are filling direct orders and shipping to wholesalers as product becomes available.
 .;Akorn has Lorazepam injection 2 mg/mL- 1 mL vials on intermittent back order and are filling direct orders and shipping to wholesalers as product becomes available.;N/A Akorn has Lorazepam injection 2 mg/mL- 1 mL vials on intermittent back order and are filling direct orders and shipping to wholesalers as product becomes available.;;2 mg/mL- 1 mL vial (NDC 17478-0040-01) Readily available  Shortage per Manufacturer: Increased demand;2 mg/mL- 1 mL vial (NDC 17478-0040-01) Readily available;2 mg/mL- 1 mL vial 
 (NDC 17478-0040-01) Readily available  Shortage per Manufacturer: Increased demand;2 mg/mL- 1 mL vial (NDC 17478-0040-01) Readily available   NA;2 mg/mL- 1 mL vial (NDC 17478-0040-01) Available  NA;2 mg/mL- 1 mL vial (NDC 17478-0040-01) Not Available due to lack of market demand (Available in March)    NA;2 mg/mL- 1 mL vial (NDC 17478-0040-01) Not Available due to lack of market demand (Available in April)    NA",,,,,,,,,,,,,
Amphastar,lorazepam,1,11/13/12,3/25/14,demand increase; available,orange,,2mg/mL- 10 mL Vial (NDC 76329-8261-1) Available;2mg/mL- 10 mL Vial (NDC 76329-8261-1) Available Amphastar announces the availability of Lorazepam Injection USP- 2 mg/mL- 10 mL vial;2mg/mL- 10 mL Vial (NDC 76329-8261-1) Amphastar will regularly release products.  Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues.,,,,,,,,,,,,,
Bedford,lorazepam,1,4/28/11,8/15/13,production suspended; discontinued,black,,"Bedford has all lorazepam injection presentations on long-term back order and the company cannot estimate a release date.;Product Discontinued: Bedford currently has all presentations discontinued.;Not currrently marketed. Product Discontinued: Bedford currently has all presentations discontinued.;;2 mg/mL- 1 mL vial (NDC 55390-0168-10)- 10 mL vial (NDC 55390-0170-10) Product Discontinued: Bedford currently has all presentations discontinued.  Shortage per Manufacturer: Not currently marketed.;2 mg/mL- 1 mL vial (NDC 55390-0168-10)- 10 mL vial (NDC 55390-0170-10) Product Discontinued: Bedford currently has all presentations discontinued.  Shortage per Manufacturer: 
 Not currently marketed.",,,,,,,,,,,,,
Fresenius,magnesium,1,12/28/13,3/25/14,demand increase,orange,,500 mg/mL- 20 mL vial (NDC 63323-0064-20) Available. Check wholesalers for inventory. Check wholesalers for inventory.  All presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Available. Check wholesalers for inventory. Check wholesalers for inventory.  All presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 2 mL vial (NDC 63323-0064-02) Backordered. Next delivery anticipated January 2014. Check wholesalers for inventory. Check wholesalers for inventory.  All presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 10 mL vial (NDC 63323-0064-10) Backordered. Next delivery anticipated February 2014. Check wholesalers for inventory. Check wholesalers for inventory.  All presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 20 mL vial (NDC 63323-0064-20) Available. Check wholesalers for inventory. Check wholesalers for inventory.  Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Available. Check wholesalers for inventory. Check wholesalers for inventory.  Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 10 mL vial (NDC 63323-0064-10) Available. Check wholesalers for inventory. Check wholesalers for inventory.  Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 2 mL vial (NDC 63323-0064-02) Available. Check wholesalers for inventory. Check wholesalers for inventory.  Shortage per Manufacturer: Increased demand for the product.,,,,,,,,,,,,,
APP,magnesium,1,6/8/11,11/8/13,demand increase; available,orange,,"APP has all magnesium sulfate 500 mg/mL presentations on intermittent back order and the company is releasing the product as it becomes available.;APP has magnesium sulfate injection on shortage due to increased demand for the product. APP has all magnesium sulfate 500 mg/mL presentations on intermittent back order and the company is releasing the product as it becomes available.;;500 mg/mL- 2 mL vial (NDC 63323-0064-02) Available Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Currently back-ordered. Next delivery expected late August. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 20 mL vial (NDC 63323-0064-20) Available Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 10 mL vial (NDC 63323-0064-10) Currently back-ordered. Next delivery expected mid September. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Currently back-ordered. Next delivery expected early September. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 20 mL vial (NDC 63323-0064-20) Currenly backordered. Next delivery expected mid September Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 2 mL vial (NDC 63323-0064-02) Available Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available.
 Shortage per Manufacturer: 
 Increased demand for the product.;500 mg/mL- 10 mL vial (NDC 63323-0064-10) Currently back-ordered. Next delivery expected mid September. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available.
 Shortage per Manufacturer: 
 Increased demand for the product.;500 mg/mL- 20 mL vial (NDC 63323-0064-20) Currently back-ordered. Next delivery expected late September Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available.
 Shortage per Manufacturer: 
 Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Currently back-ordered. Next delivery expected late September. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available.
 Shortage per Manufacturer: 
 Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Currently back-ordered. Next delivery expected late September. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 20 mL vial (NDC 63323-0064-20) Currently back-ordered. Next delivery expected late September Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 20 mL vial (NDC 63323-0064-20) Back-ordered. Next delivery late October Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Currently back-ordered. Next delivery expected late October. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 10 mL vial (NDC 63323-0064-10) Currently back-ordered. Next delivery expected December 2012 Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Currently back-ordered. Next delivery expected December. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 10 mL vial (NDC 63323-0064-10) Currently back-ordered. Next release anticipated February 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Currently back-ordered. Next delivery expected April 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 2 mL vial (NDC 63323-0064-02) Currently back-ordered. Next delivery expected January 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 20 mL vial (NDC 63323-0064-20) Currently back-ordered. Next delivery expected February 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 10 mL vial (NDC 63323-0064-10) Currently back-ordered. Next release anticipated March 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 2 mL vial (NDC 63323-0064-02) Currently back-ordered. Next delivery expected March 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 20 mL vial (NDC 63323-0064-20) Currently available. Next delivery expected February 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 20 mL vial (NDC 63323-0064-20) Currently available. Next delivery expected April 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 2 mL vial (NDC 63323-0064-02) Currently back-ordered. Next delivery expected April 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 10 mL vial (NDC 63323-0064-10) Currently back-ordered. Next release anticipated May 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Currently back-ordered. Next delivery expected May 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 20 mL vial (NDC 63323-0064-20) Currently back-ordered. Next delivery expected May 2013. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 2 mL vial (NDC 63323-0064-02) Currently back-ordered. Next delivery expected May 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Currently back-ordered. Next delivery expected June 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 20 mL vial (NDC 63323-0064-20) Currently back-ordered. Next delivery expected June 2013. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 2 mL vial (NDC 63323-0064-02) Currently back-ordered. Next delivery expected June 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 10 mL vial (NDC 63323-0064-10) Currently back-ordered. Next release anticipated July 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Currently back-ordered. Next delivery expected July 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 20 mL vial (NDC 63323-0064-20) Currently back-ordered. Check wholesalers for inventory. Next delivery expected July 2013. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 2 mL vial (NDC 63323-0064-02) Currently back-ordered. Next delivery expected July 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 10 mL vial (NDC 63323-0064-10) Currently back-ordered. Next release anticipated September 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Currently back-ordered. Next delivery expected August 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 20 mL vial (NDC 63323-0064-20) Currently back-ordered. Check wholesalers for inventory. Next delivery expected september 2013. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 2 mL vial (NDC 63323-0064-02) Currently back-ordered. Next delivery expected September 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Currently back-ordered. Next delivery expected September 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All other presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 10 mL vial (NDC 63323-0064-10) Currently back-ordered. Next release anticipated September 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 2 mL vial (NDC 63323-0064-02) Currently back-ordered. Next delivery expected September 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 20 mL vial (NDC 63323-0064-20) Currently back-ordered. Check wholesalers for inventory. Next delivery expected september 2013. Check wholesalers for inventory.  All presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.;500 mg/mL- 50 mL vial (NDC 63323-0064-50) Currently back-ordered. Next delivery expected September 2013. Check wholesalers for inventory. Check wholesalers for inventory.  All presentations are on intermittent back-order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand for the product.",,,,,,,,,,,,,
AmericanRegent,magnesium,1,6/8/11,3/25/14,manufacturing delays; not releasing,blue,,American Regent has all magnesium sulfate 500 mg/mL presentations on back order and the company cannot estimate a release date.;Manufacturing delays American Regent has all magnesium sulfate 500 mg/mL presentations on back order and the company cannot estimate a release date.;;500 mg/mL- 10 mL vial (NDC 00517-2610-25) Unavailable Currently not releasing.;500 mg/mL- 50 mL vial (NDC 00517-2650-25) Unavailable Currently not releasing.;500 mg/mL- 2 mL vial (NDC 00517-2602-25) Unavailable Currently not releasing.;500 mg/mL- 10 mL vial (NDC 00517-2610-25) Unavailable Shortage per Manufacturer: American Regent is currently not releasing Magnesium Sulfate Injection.;500 mg/mL- 2 mL vial (NDC 00517-2602-25) Unavailable Shortage per Manufacturer: American Regent is currently not releasing Magnesium Sulfate Injection.;500 mg/mL- 50 mL vial (NDC 00517-2650-25) Unavailable Shortage per Manufacturer: American Regent is currently not releasing Magnesium Sulfate Injection.;500 mg/mL- 10 mL vial (NDC 00517-2610-25) Unavailable American Regent is currently not releasing Magnesium Sulfate Injection.;500 mg/mL- 50 mL vial (NDC 00517-2650-25) Unavailable American Regent is currently not releasing Magnesium Sulfate Injection.;500 mg/mL- 2 mL vial (NDC 00517-2602-25) Unavailable American Regent is currently not releasing Magnesium Sulfate Injection.;500 mg/mL- 10 mL vial (NDC 00517-2610-25) Unavailable. No product available for release. No plan to manufacture American Regent is currently not releasing Magnesium Sulfate Injection.;500 mg/mL- 2 mL vial (NDC 00517-2602-25) Unavailable. No product available for release. No plan to manufacture American Regent is currently not releasing Magnesium Sulfate Injection.;500 mg/mL- 50 mL vial (NDC 00517-2650-25) Unavailable. No product available for release. No plan to manufacture American Regent is currently not releasing Magnesium Sulfate Injection.;500 mg/mL- 10 mL vial pkg of 25(NDC 00517-2610-25) Unavailable. No product available for release. No plan to manufacture American Regent is currently not releasing Magnesium Sulfate Injection.;500 mg/mL- 2 mL vial pkg of 25(NDC 00517-2602-25) Unavailable. No product available for release. No plan to manufacture American Regent is currently not releasing Magnesium Sulfate Injection.;500 mg/mL- 50 mL vial pkg of 25(NDC 00517-2650-25) Unavailable. No product available for release. No plan to manufacture American Regent is currently not releasing Magnesium Sulfate Injection.,,,,,,,,,,,,,
Baxter,mannitol,1,2/23/12,3/25/14,available,,,";Product Available;20% OSMITROL Injection (20% Mannitol Injection- USP). NDC: 0338-0357-02   Shortage per Manufacturer: Product Available;20% OSMITROL Injection (20% Mannitol Injection- USP). NDC: 0338-0357-03   Shortage per Manufacturer: Product Available;20% OSMITROL Injection (20% Mannitol Injection- USP). NDC: 0338-0357-02 Available Shortage per Manufacturer: Product Available;20% OSMITROL Injection (20% Mannitol Injection- USP). NDC: 0338-0357-03 Available Shortage per Manufacturer: Product Available;20% OSMITROL Injection (20% Mannitol Injection- USP). NDC: 0338-0357-02 Available Shortage per Manufacturer: 
 Product Available;20% OSMITROL Injection (20% Mannitol Injection- USP). NDC: 0338-0357-03 Available Shortage per Manufacturer: 
 Product Available;20% OSMITROL Injection (20% Mannitol Injection- USP). NDC: 0338-0357-02 All presentations available.;20% OSMITROL Injection (20% Mannitol Injection- USP). NDC: 0338-0357-03 All presentations available.",,,,,,,,,,,,,
APP,mannitol,1,12/25/11,11/8/13,demand increase,orange,,"APP has increased production and will have intermittent releases of product.;Increase in product demand. APP has increased production and will have intermittent releases of product.;;250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Check wholesalers for Inventory APP has increased production and will have intermittent releases of product. Shortage per Manufacturer: Increase demand;250 mg/mL- 50 mL vial- 25 count 
 (NDC 63323-0024-25) Check wholesalers for Inventory. Next delivery anticipated late October. APP has increased production and will have intermittent releases of product.
 Shortage per Manufacturer: 
 Increase demand;250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Check wholesalers for Inventory. Next delivery anticipated late October. APP has increased production and will have intermittent releases of product. Shortage per Manufacturer: Increase demand;250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Check wholesalers for Inventory. Next delivery anticipated late November 2012. APP has increased production and will have intermittent releases of product. Shortage per Manufacturer: Increase demand;250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Check wholesalers for Inventory. Next delivery anticipated January 2013. APP has increased production and will have intermittent releases of product. Shortage per Manufacturer: Increase demand;250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Check wholesalers for Inventory. Next delivery anticipated March 2013. APP has increased production and will have intermittent releases of product. Shortage per Manufacturer: Increase demand;250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Check wholesalers for Inventory. Next delivery anticipated May 2013. APP has increased production and will have intermittent releases of product. Shortage per Manufacturer: Increase demand;250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Backordered. Check wholesalers for Inventory. Next delivery anticipated May 2013. APP has increased production and will have intermittent releases of product. Shortage per Manufacturer: Increase demand;250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Backordered. Check wholesalers for Inventory. Next delivery anticipated late May 2013. APP has increased production and will have intermittent releases of product. Shortage per Manufacturer: Increase demand;250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Backordered.  Next delivery anticipated late July 2013. APP has increased production and will have intermittent releases of product. Shortage per Manufacturer: Increase demand;250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Backordered.  Next delivery anticipated July 2013. APP has increased production and will have intermittent releases of product. Shortage per Manufacturer: Increase demand;250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Backordered.  Next delivery anticipated September 2013.  Check wholesaler inventory. APP has increased production and will have intermittent releases of product. Shortage per Manufacturer: Increase demand;250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Backordered.  Next delivery anticipated October 2013.  Check wholesaler inventory. APP has increased production and will have intermittent releases of product. Shortage per Manufacturer: Increase demand;250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Backordered.  Next delivery anticipated November 2013.  APP has increased production and will have intermittent releases of product. Shortage per Manufacturer: Increase demand",,,,,,,,,,,,,
Bbraun,mannitol,1,12/25/11,3/25/14,demand increase; available,orange,,"B. Braun has increased manufacturing forecast due to an anticipated increase in demand. B. Braun has inventory of the 500 mL product and a limited inventory of the 250 mL product. B. Braun is scheduled to manufacture additional units of the 250 mL product this week with anticipated availability the second week of January 2012.;B. Braun has increased manufacturing forecast due to an increase in demand. B. Braun has inventory of the 500 mL and  250 mL product  available and is scheduled to have additional product available mid February 2012.;No shortage B. Braun has increased manufacturing forecast due to an increase in demand. B. Braun has inventory of the 500 mL and  250 mL product  available and is scheduled to have additional product available mid February 2012.;;20% Mannitol Injection USP L5781 500 mL flexible plastic container NDC 0264-7578-10    B. Braun has increased manufacturing forecast due to an increase in demand. B. Braun has inventory of the 500 mL and  250 mL product available and is scheduled to have additional product available mid February 2012. Shortage per Manufacturer: No shortage;L5782 250 mL flexible plastic container NDC 0264-7578-20   B. Braun has increased manufacturing forecast due to an increase in demand. B. Braun has inventory of the 500 mL and  250 mL product available and is scheduled to have additional product available mid February 2012. Shortage per Manufacturer: No shortage;20% Mannitol Injection USP 
 L5781 500 mL flexible plastic container NDC 0264-7578-10    B. Braun has increased manufacturing forecast due to an increase in demand. B. Braun has inventory of the 500 mL and  250 mL product available and is scheduled to have additional product available mid February 2012.
 Shortage per Manufacturer: 
 No shortage;L5782 250 mL flexible plastic container NDC 0264-7578-20   B. Braun has increased manufacturing forecast due to an increase in demand. B. Braun has inventory of the 500 mL and  250 mL product available and is scheduled to have additional product available mid February 2012.
 Shortage per Manufacturer: 
 No shortage;20% Mannitol Injection USP 500 mL flexible plastic container NDC 0264-7578-10  All presentations available.;250 mL flexible plastic container NDC 0264-7578-20 All presentations available.",,,,,,,,,,,,,
Fresenius,mannitol,1,12/28/13,3/25/14,demand increase; available,orange,,250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Available. Check wholesalers for inventory. APP has increased production and will have intermittent releases of product. Shortage per Manufacturer: Increase demand;250 mg/mL- 50 mL vial- 25 count (NDC 63323-0024-25) Available.  Check wholesalers for inventory. Available Shortage per Manufacturer: Increase demand,,,,,,,,,,,,,
AmericanRegent,mannitol,1,12/25/11,3/25/14,demand increase; available; not releasing; material shortage,green,,"Mannitol Injection- USP 25%- 50 mL vial on back order and the company estimates a release date of January 2012.;American Regent is releasing Mannitol injection as it becomes available.;Available American Regent is releasing Mannitol injection as it becomes available.;;25%-  50 mL vial NDC 0517-4050-25 Unavailable Currently not releasing.;25%-  50 mL vial 
 NDC 0517-4050-25 Unavailable Currently not releasing.;25%-  50 mL vial NDC 0517-4050-25 Unavailable Shortage per Manufacturer: American Regent is currently not releasing Mannitol Injection.;25%-  50 mL vial NDC 0517-4050-25 Unavailable American Regent is currently not releasing Mannitol Injection.;25%-  50 mL vial (NDC 0517-4050-25) Unavailable - No product available for release. No plan to manufacture American Regent is currently not releasing Mannitol Injection.;25%-  50 mL vial package of 25 (NDC 0517-4050-25) Unavailable - No product available for release. No plan to manufacture American Regent is currently not releasing Mannitol Injection.",,,,,,,,,,,,,
APP,mesna,1,11/3/11,7/12/12,demand increase; available,orange,,NDC 63323-0773-10 - On allocation until Mid-November and NDC 63323-0773-11 - Available for shipping.;APP has available both 10 mL vials in the 1 count and 10 count.;Available APP has available both 10 mL vials in the 1 count and 10 count.;,,,,,,,,,,,,,
Baxter,mesna,1,11/3/11,7/12/12,demand increase; available,orange,,"Several releases planned for November and December.;Baxter has the following products available:   Product: Mesna 10 mL vial- 1 count (NDC 10019-0953-01) and 10 mL vial- 10 count (NDC 10019-0953-02).   Product: Mesnex 100 mg/mL Injection- 10 mL vial- 1 count (NDC 00338-1305-01) and 10 mL vial- 10 count (NDC 00338-1305-03.;Baxter has the following products available: 
   
 Product: Mesna 10 mL vial- 1 count (NDC 10019-0953-01) and 10 mL vial- 10 count (NDC 10019-0953-02). 
   
 Product: Mesnex 100 mg/mL Injection- 
 10 mL vial- 1 count (NDC 00338-1305-01) and 10 mL vial- 10 count (NDC 00338-1305-03.;Available Baxter has the following products available:   Product: Mesna 10 mL vial- 1 count (NDC 10019-0953-01) and 10 mL vial- 10 count (NDC 10019-0953-02).   Product: Mesnex 100 mg/mL Injection- 10 mL vial- 1 count (NDC 00338-1305-01) and 10 mL vial- 10 count (NDC 00338-1305-03.;",,,,,,,,,,,,,
Bedford,mesna,1,11/3/11,7/12/12,manufacturing delays,blue,,Bedford has mesna injection (NDC 55390-0045-01) on back order and the company cannot estimate a release date.;Bedford has mesna injection on back order and the company cannot estimate a release date.;Manufacturing delays Bedford has mesna injection on back order and the company cannot estimate a release date.;,,,,,,,,,,,,,
Teva,mesna,1,11/3/11,7/12/12,manufacturing delays,blue,,Anticipating release of product Q212/Q312.;Teva has limited inventory available on allocation.;Manufacturing delays Teva has limited inventory available on allocation.;,,,,,,,,,,,,,
Fera,methazolamide,1,7/12/12,3/2/14,available,,,";25 mg- 100s (NDC 48102-0100-01) Ample supply to meet the national market demand.  Shortage per Manufacturer: Available;50 mg- 100s (NDC 48102-0101-01) Ample supply to meet the national market demand.  Shortage per Manufacturer: Available;Neptazane- 25 mg- 90s (NDC 48102-0014-90) Ample supply to meet the national market demand.  Shortage per Manufacturer: Available;Neptazane- 50 mg- 90s (NDC 48102-0015-90) Ample supply to meet the national market demand.  Shortage per Manufacturer: Available;25 mg- 100s (NDC 48102-0100-01) Ample supply to meet the national market demand.  Shortage per Manufacturer: 
 Available;50 mg- 100s (NDC 48102-0101-01) Ample supply to meet the national market demand.  Shortage per Manufacturer: 
 Available;Neptazane- 25 mg- 90s (NDC 48102-0014-90) Ample supply to meet the national market demand.  Shortage per Manufacturer: 
 Available;Neptazane- 50 mg- 90s (NDC 48102-0015-90) Ample supply to meet the national market demand.  Shortage per Manufacturer: 
 Available;Neptazane- 50 mg- 90s (NDC 48102-0015-90) Available Shortage per Manufacturer: Available;50 mg- 100s (NDC 48102-0101-01) Available Shortage per Manufacturer: Available;Neptazane- 25 mg- 90s (NDC 48102-0014-90) Available Shortage per Manufacturer: Available;25 mg- 100s (NDC 48102-0100-01) Available Shortage per Manufacturer: Available;50 mg- 100s (NDC 48102-0101-01) Available Shortage per Manufacturer: Available.  No shortage anticipated in the next 6 months.;Neptazane- 25 mg- 90s (NDC 48102-0014-90) Available Shortage per Manufacturer: Available.  No shortage anticipated in the next 6 months.;25 mg- 100s (NDC 48102-0100-01) Available Shortage per Manufacturer: Available.  No shortage anticipated in the next 6 months.;Neptazane- 50 mg- 90s (NDC 48102-0015-90) Available Shortage per Manufacturer: Available.  No shortage anticipated in the next 6 months.",,,,,,,,,,,,,
Teva,methotrexate,2,3/1/13,3/1/13,available,,,25mg/mL; 40mL vial Preservative Free (NDC 00703-3678-01) All presentation are available with ample inventory. Teva launched this product on July 31- 2012.;25mg/ml; 10mL vial Preservative Free (NDC 00703-3675-01) All presentation are available with ample inventory. Teva launched this product on July 31- 2012.;25mg/ml; 2mL vial Preservative Free (NDC 00703-3671-03) All presentation are available with ample inventory. Teva launched this product on July 31- 2012.;25mg/ml; 4mL vial Preservative Free (NDC 00703-3673-01) All presentation are available with ample inventory. Teva launched this product on July 31- 2012.,,,,,,,,,,,,,
APP,methotrexate,1,6/6/09,3/12/10,demand increase,orange,,Bedford Laboratories- manufacturing delays               Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.       Hospira- unable to meet demand               GeneraMedix- increase in demand           APP has product available;Bedford Laboratories- manufacturing delays                       Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.           Hospira- unable to meet demand             GeneraMedix- increase in demand               APP has product available;Bedford Laboratories- manufacturing delays                 Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.         Hospira- unable to meet demand           GeneraMedix- increase in demand         APP has product available,,,,,,,,,,
APP,methotrexate,2,3/1/13,3/1/13,demand increase,orange,,1 g- SDV- Lyo (NDC 63323-0122-50) Available Please check wholesalers for inventory Shortage per Manufacturer: increased demand;25 mg/mL; 10 mL vial (NDC 63323-0123-10) Available Please check wholesalers for inventory Shortage per Manufacturer: increased demand,,,,,,,,,,,,,
Bedford,methotrexate,1,6/6/09,3/12/10,demand increase,orange,,Bedford Laboratories- manufacturing delays               Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.       Hospira- unable to meet demand               GeneraMedix- increase in demand           APP has product available;Bedford Laboratories- manufacturing delays                       Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.           Hospira- unable to meet demand             GeneraMedix- increase in demand               APP has product available;Bedford Laboratories- manufacturing delays                 Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.         Hospira- unable to meet demand           GeneraMedix- increase in demand         APP has product available,,,,,,,,,,
Ebewe,methotrexate,1,6/6/09,3/12/10,demand increase,orange,,Bedford Laboratories- manufacturing delays               Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.       Hospira- unable to meet demand               GeneraMedix- increase in demand           APP has product available;Bedford Laboratories- manufacturing delays                       Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.           Hospira- unable to meet demand             GeneraMedix- increase in demand               APP has product available;Bedford Laboratories- manufacturing delays                 Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.         Hospira- unable to meet demand           GeneraMedix- increase in demand         APP has product available,,,,,,,,,,
GeneraMedix,methotrexate,1,6/6/09,3/12/10,demand increase,orange,,Bedford Laboratories- manufacturing delays               Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.       Hospira- unable to meet demand               GeneraMedix- increase in demand           APP has product available;Bedford Laboratories- manufacturing delays                       Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.           Hospira- unable to meet demand             GeneraMedix- increase in demand               APP has product available;Bedford Laboratories- manufacturing delays                 Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.         Hospira- unable to meet demand           GeneraMedix- increase in demand         APP has product available,,,,,,,,,,
Hospira,methotrexate,1,6/6/09,3/12/10,demand increase,orange,,Bedford Laboratories- manufacturing delays               Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.       Hospira- unable to meet demand               GeneraMedix- increase in demand           APP has product available;Bedford Laboratories- manufacturing delays                       Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.           Hospira- unable to meet demand             GeneraMedix- increase in demand               APP has product available;Bedford Laboratories- manufacturing delays                 Ebewe Parenta Pharmaceuticals, Inc. has all presentations available.         Hospira- unable to meet demand           GeneraMedix- increase in demand         APP has product available,,,,,,,,,,
Teva,methotrexate,1,9/1/12,1/10/13,demand increase; available,orange,,25mg/ml; 10mL vial Preservative Free (NDC 00703-3675-01) All presentation are available with ample inventory Teva will launch this product the beginning of August.   Shortage per Manufacturer: Increased demand;25mg/ml; 2mL vial Preservative Free (NDC 00703-3671-03) All presentation are available with ample inventory Teva will launch this product the beginning of August.   Shortage per Manufacturer: Increased demand;25mg/mL; 40mL vial Preservative Free (NDC 00703-3678-01) All presentation are available with ample inventory Teva will launch this product the beginning of August.   Shortage per Manufacturer: Increased demand;25mg/ml; 4mL vial Preservative Free (NDC 00703-3673-01) All presentation are available with ample inventory Teva will launch this product the beginning of August.   Shortage per Manufacturer: Increased demand;25mg/ml; 10mL vial Preservative Free (NDC 00703-3675-01) All presentation are available with ample inventory. Teva will launch this product the beginning of August.   Shortage per Manufacturer: Increased demand;25mg/ml; 4mL vial Preservative Free (NDC 00703-3673-01) All presentation are available with ample inventory. Teva will launch this product the beginning of August.   Shortage per Manufacturer: Increased demand;25mg/ml; 2mL vial Preservative Free (NDC 00703-3671-03) All presentation are available with ample inventory. Teva will launch this product the beginning of August.   Shortage per Manufacturer: Increased demand;25mg/mL; 40mL vial Preservative Free (NDC 00703-3678-01) All presentation are available with ample inventory. Teva will launch this product the beginning of August.   Shortage per Manufacturer: Increased demand;25mg/ml; 4mL vial Preservative Free (NDC 00703-3673-01) All presentation are available with ample inventory. Teva launched this product on July 31- 2012.;25mg/ml; 10mL vial Preservative Free (NDC 00703-3675-01) All presentation are available with ample inventory. Teva launched this product on July 31- 2012.;25mg/ml; 2mL vial Preservative Free (NDC 00703-3671-03) All presentation are available with ample inventory. Teva launched this product on July 31- 2012.;25mg/mL; 40mL vial Preservative Free (NDC 00703-3678-01) All presentation are available with ample inventory. Teva launched this product on July 31- 2012.,,,,,,,,,,,,,
Bedford,methotrexate,2,3/1/13,3/1/13,discontinued,black,,Methotrexate lyophilized powder for injection 1 gram vial; (NDC 55390-0143-01   Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;25 mg/mL; 4 mL vial; Preservative Free (NDC 55390-0032-10)   Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;25 mg/mL; 2 mL vial; Preservative Free (NDC 55390-0031-10)   Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;25 mg/mL; 10 mL vial; Preservative Free (NDC 55390-0034-10)    Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;25 mg/mL; 8 mL vial; Preservative Free (NDC 55390-0033-10)   Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays,,,,,,,,,,,,,
APP,methotrexate,1,1/26/12,1/10/13,discontinued; demand increase; available,black,,"Product 25 mg/mL; 2 mL vial (NDC 63323-0123-02) discontinued.   Product 25 mg/mL; 10 mL vial (NDC 63323-0123-10) available.;Product 25 mg/mL; 2 mL vial (NDC 63323-0123-02) discontinued. 
   
 Product 25 mg/mL; 10 mL vial (NDC 63323-0123-10) available.;Product 25 mg/mL; 2 mL vial (NDC 63323-0123-02) discontinued   Product 25 mg/mL; 10 mL vial (NDC 63323-0123-10) is being allocated. Check wholesalers for inventory   Product  1 g- SDV (NDC 63323-0122-50) is available.;Increased demand. Product 25 mg/mL; 2 mL vial (NDC 63323-0123-02) discontinued   Product 25 mg/mL; 10 mL vial (NDC 63323-0123-10) is being allocated. Check wholesalers for inventory   Product  1 g- SDV (NDC 63323-0122-50) is available.;;1 g- SDV- Lyo (NDC 63323-0122-50) Available Please check wholesalers for inventory Shortage per Manufacturer: increased demand;25 mg/mL; 10 mL vial (NDC 63323-0123-10) Available Please check wholesalers for inventory Shortage per Manufacturer: increased demand;1 g- SDV- Lyo (NDC 63323-0122-50) Available Please check wholesalers for inventory
 Shortage per Manufacturer: 
 increased demand;25 mg/mL; 10 mL vial (NDC 63323-0123-10) Available Please check wholesalers for inventory
 Shortage per Manufacturer: 
 increased demand",,,,,,,,,,,,,
Bedford,methotrexate,1,1/26/12,1/10/13,production suspended; manufacturing delays; discontinued,blue,,"Bedford has all methotrexate injections on back order and the company cannot estimate a release date. The 10 mL preservative-free vials and 1 gram lyophilized powder for injection are pending release once manufacturing and distribution resumes while the other presentations will not be produced until capacity permits.;Bedford Laboratories has limited quantities available of methotrexate preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) and 250 mg/10 ml (NDC 55390-0034-10) with short expiry. Other presentations will not be available until capacity permits.;Bedford Laboratories has limited quantities available of methotrexate preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01). Other presentations will not be available until capacity permits.;Manufacturing delays Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website.;Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website.;;25 mg/mL; 2 mL vial; Preservative Free (NDC 55390-0031-10)   Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;Methotrexate lyophilized powder for injection 1 gram vial; (NDC 55390-0143-01   Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;25 mg/mL; 8 mL vial; Preservative Free (NDC 55390-0033-10)   Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;25 mg/mL; 4 mL vial; Preservative Free (NDC 55390-0032-10)   Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;25 mg/mL; 10 mL vial; Preservative Free (NDC 55390-0034-10)    Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;25 mg/mL; 10 mL vial; Preservative Free 
 (NDC 55390-0034-10)    Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;Methotrexate lyophilized powder for injection 
 1 gram vial; (NDC 55390-0143-01   Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;25 mg/mL; 8 mL vial; Preservative Free 
 (NDC 55390-0033-10)   Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;25 mg/mL; 4 mL vial; Preservative Free 
 (NDC 55390-0032-10)   Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;25 mg/mL; 2 mL vial; Preservative Free 
 (NDC 55390-0031-10)   Bedford Laboratories has preservative-free 1 gram lyophilized powder for injection (NDC 55390-0143-01) available in limited quantities.. Once this supply is depleted- the next estimated release dates are unknown. Other presentations are out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays",,,,,,,,,,,,,
Valeant,methoxsalen,1,11/13/12,8/15/13,manufacturing delays; available,blue,,There is not yet an estimated release date. Shortage per Manufacturer: Manufacturing delays;Oxoralen Lotion 1%  Currently available Product released to market April 2013,,,,,,,,,,,,,
AmericanRegent,methyldopate,1,2/9/12,3/25/14,manufacturing delays; not releasing; material shortage,green,,American Regent has methyldopate injection on back order and cannot estimate a release date;Manufacturing delays American Regent has methyldopate injection on back order and cannot estimate a release date;;50 mg/mL- 5 mL vial (NDC 00517-8905-10) Unavailable Currently not releasing.;50 mg/mL- 5 mL vial- 10s (NDC 00517-8905-10) Unavailable Shortage per Manufacturer: American Regent is currently not releasing Methyldopate HCl Injection- USP.;50 mg/mL- 5 mL vial- 10s (NDC 00517-8905-10) Unavailable - No product available for release. No plan to manufacture American Regent is currently not releasing Methyldopate HCl Injection- USP.,,,,,,,,,,,,,
Shionogi,methylin,1,3/6/13,3/25/14,manufacturing issues,blue,,10 mg tablets (NDC 59630-762-10)  Product temporairily unavailable. Shortage per Manufacturer: Manufacturing issues.;5 mg tablets (NDC 59630-761-10)  Product temporairily unavailable. Shortage per Manufacturer: Manufacturing issues.;2.5 mg tablets (NDC 59630-760-10) Product temporairily unavailable. Shortage per Manufacturer: Manufacturing issues.;10 mg tablets (NDC 59630-762-10)  Product temporarily unavailable. Shortage per Manufacturer: Manufacturing issues.;2.5 mg tablets (NDC 59630-760-10) Product temporarily unavailable. Shortage per Manufacturer: Manufacturing issues.;5 mg tablets (NDC 59630-761-10)  Product temporarily unavailable. Shortage per Manufacturer: Manufacturing issues.;2.5 mg tablets (NDC 59630-760-10) 100 package size Product temporarily unavailable. Shortage per Manufacturer: Manufacturing issues.;5 mg tablets (NDC 59630-761-10)  100 package size Product temporarily unavailable. Shortage per Manufacturer: Manufacturing issues.;10 mg tablets (NDC 59630-762-10)  100 package size Product temporarily unavailable. Shortage per Manufacturer: Manufacturing issues.,,,,,,,,,,,,,
Actavis,methylphenidate,1,7/24/13,7/24/13,available,,,Methylphenidate Hydrochloride Tablets- USP- 10 mg- NDC: 0591-5883-01 We are shipping our customers at their historical volume to fill their needs in the market.;Methylphenidate Hydrochloride Tablets- USP- 5 mg -NDC: 0591-5882-01 We are shipping our customers at their historical volume to fill their needs in the market.;Methylphenidate Hydrochloride Tablets- USP- 20 mg- NDC: 0591-5882-01 We are shipping our customers at their historical volume to fill their needs in the market.,,,,,,,,,,,,,
Actavis,methylphenidate,2,8/7/13,3/25/14,available,,,Methylphenidate Hydrochloride Tablets- USP- 10 mg- NDC: 0591-5883-01 We are shipping our customers at their historical volume to fill their needs in the market.;Methylphenidate Hydrochloride Tablets- USP- 20 mg- NDC: 0591-5882-01 We are shipping our customers at their historical volume to fill their needs in the market.;Methylphenidate Hydrochloride Tablets- USP- 5 mg -NDC: 0591-5882-01 We are shipping our customers at their historical volume to fill their needs in the market.;Methylphenidate Hydrochloride Tablets- USP- 10 mg- NDC: 0591-5883-01 We are shipping our customers at their historical volume to fill their needs in the market;Methylphenidate Hydrochloride Tablets- USP- 5 mg -NDC: 0591-5882-01 We are shipping our customers at their historical volume to fill their needs in the market;Methylphenidate Hydrochloride Tablets- USP- 20 mg- NDC: 0591-5882-01 We are shipping our customers at their historical volume to fill their needs in the market;Methylphenidate Hydrochloride Tablets- USP- 10 mg- NDC: 0591-5883-01 Available  No supply issues anticipated;Methylphenidate Hydrochloride Tablets- USP- 20 mg- NDC: 0591-5882-01 Available  No supply issues anticipated;Methylphenidate Hydrochloride Tablets- USP- 5 mg -NDC: 0591-5882-01 Available  No supply issues anticipated,,,,,,,,,,,,,
Watson,methylphenidate,1,4/28/11,7/12/12,available,,,Continues to have product available.;Watson has all 3 strengths available for contracted customers only.;n/a Watson has all 3 strengths available for contracted customers only.;,,,,,,,,,,,,,
UCB,methylphenidate,2,6/17/13,3/25/14,demand increase,orange,,10 mg Methylphenidate Hydrochloride Tablets USP - 100 Tabs (NDC 53014-530-07) Availability: 25th June 2013 Estimated Shortage Duration: 2 May thru 24 Jun 2013;NULL NULL NULL;20 mg Methylphenidate Hydrochloride Tablets- USP - 100 Tabs (NDC 53014-532-07)   Availability: 2nd July 2013 Estimated Shortage Duration: 7 May thru 1 Jul 2013;10 mg Methylphenidate Hydrochloride IR tablets- 100s (NDC 53014-532-07 Availability July 5- 2013 Estimated Shortage Duration: May 2 through July 5- 2013;20 mg Methylphenidate Hydrochloride IR tablets- 100s (NDC 53014-532-07 Availability October 2013 Currently in back ordered;5 mg Mehtylphenidate IR tablets- 100 tabs (NDC 53014-0531-07) Availability October 18th 2013 Currently in back order OOS from Sept 19th until Oct 17th.;20 mg Methylphenidate Hydrochloride IR tablets- 100s (NDC 53014-532-07 Availability December 2013 Limited availability during September;10 mg Methylphenidate IR Tablets - 100 tabs (NDC 53014-530-07) Available;20 mg Methylphenidate Hydrochloride IR tablets- 100 tabs (NDC 53014-532-07) Available;5 mg Methylphenidate IR tablets- 100 tabs (NDC 53014-0531-07) Available,,,,,,,,,,,,,
Covidien,methylphenidate,1,4/7/11,4/22/11,demand increase; API limitations,blue,,Capacity constraints and receiving API orders  API constraints Increase in demand n/a;Capacity constraints and receiving API orders   API constraints Increase in demand n/a;Capacity constraints and receiving API orders   API constraints Increase in demand n/a,,,,,,,,,,,,,
Sandoz,methylphenidate,1,4/7/11,4/22/11,demand increase; API limitations,blue,,Capacity constraints and receiving API orders  API constraints Increase in demand n/a;Capacity constraints and receiving API orders   API constraints Increase in demand n/a;Capacity constraints and receiving API orders   API constraints Increase in demand n/a,,,,,,,,,,,,,
UCB,methylphenidate,1,4/7/11,4/22/11,demand increase; API limitations,blue,,Capacity constraints and receiving API orders  API constraints Increase in demand n/a;Capacity constraints and receiving API orders   API constraints Increase in demand n/a;Capacity constraints and receiving API orders   API constraints Increase in demand n/a,,,,,,,,,,,,,
Watson,methylphenidate,1,4/7/11,4/22/11,demand increase; API limitations,blue,,Capacity constraints and receiving API orders  API constraints Increase in demand n/a;Capacity constraints and receiving API orders   API constraints Increase in demand n/a;Capacity constraints and receiving API orders   API constraints Increase in demand n/a,,,,,,,,,,,,,
UCB,methylphenidate,1,4/28/11,7/12/12,demand increase; available,orange,,"Minus the 5 mg IR presentation- UCB continues to have remaining presentations and strengths available. 5 mg tablets are expected to be on intermittent backorder until mid-May.;UCB has all presentations of 5 mg IR available.  All UCB presentations of 10 mg IR- 20 mg IR- and 20 mg ER- are out of stock.  The out of stock tablets are expected to be on intermittent backorder until approximately May 20.;UCB is currently in stock in all strengths of our methylphenidate products (IR- ER- and CD) and presentations.;UCB is currently in stock in all strengths and presentations of our methylphenidate IR and CD product.   UCB is currently out of stock of our 20 mg ER product and expect resupply by October 2011.;UCB is currently in stock in all strengths and presentations of our methylphenidate  CD- ER- and IR product.;UCB is currently in stock in all strengths and presentations of our methylphenidate ER and CD products.   
 
 UCB is currently out of stock of our  5 mg and 20 mg  I R product and expect resupply by  February 2012.;UCB is currently in stock in all strengths and presentations of our methylphenidate ER and CD products.   UCB is currently out of stock of our  5 mg and 20 mg  I R product and expect resupply by  February 2012.;UCB is currently in stock on all strengths and presentations of our methylphenidate ER and CD products- except for Methylphenidate ER 20 mg.   UCB is currently out of stock of our  5 mg and 20 mg.  UCB expects resupply by  February 2012.;UCB is currently out of stock of our 5 mg IR- 10 mg IR and 20 mg IR and our 20 mg ER products.  UCB expects resupply by February.;UCB has availability of 5 mg IR tablets- 10 mg IR tablets and 20 mg ER tablets.  UCB anticipates release of  the 20 mg IR Tablets shortly.;Increased demand UCB has availability of 5 mg IR tablets- 10 mg IR tablets and 20 mg ER tablets.  UCB anticipates release of  the 20 mg IR Tablets shortly.;",,,,,,,,,,,,,
Covidien,methylphenidate,1,4/28/11,5/9/11,material availability,green,,Currently experiencing a shortage and expect to have product available again in April 2011.,,,,,,,,,,,,,
Sandoz,methylphenidater,2,8/7/13,3/25/14,capacity constraints; material shortage,green,,20 mg Sustained-Release- 100s (NDC 00781-5754-01) Temporarily unavailable and Sandoz cannot estimate a release date. Shortage per Manufacturer: Manufacturing site capacity;20 mg Sustained-Release- 100s (NDC 00781-5754-01) Product is currently available.  No projected back order at this time. Shortage per Manufacturer: Manufacturing site capacity;20 mg Sustained-Release- 100s (NDC 00781-5754-01) Due to an API shortage- we will continue to see back orders until end of February. Manufacturing site capacity/API Shortage;20 mg Sustained-Release- 100s (NDC 00781-5754-01) Due to an API shortage- we will continue to see back orders until end of March. Manufacturing site capacity/ API supply delay. API has been received but a capacity constraint has pushed delivery until March,,,,,,,,,,,,,
UCB,methylphenidater,1,7/5/13,7/24/13,demand increase,orange,,20 mg Methylphenidate ER- 100s (NDC 53014-594-07) Availability: July 12- 2013 Estimated Shortage Duration: May 7 through August 15- 2013,,,,,,,,,,,,,
UCB,methylphenidater,2,8/7/13,3/25/14,demand increase,orange,,20 mg Methylphenidate ER- 100s (NDC 53014-594-07) Availability: July 12- 2013 Estimated Shortage Duration: May 7 through August 15- 2013;20 mg Methylphenidate ER- 100s (NDC 53014-594-07) Availability: October 2013 Currently in back ordered;20 mg Methylphenidate ER- 100s (NDC 53014-594-07) Available,,,,,,,,,,,,,
Actavis,methylphenidater,1,7/24/13,7/24/13,manufacturing delays; available,blue,,Methylphenidate Hydrochloride- ER Tablets- 18 MG 100s NDC: 00591-2715-01 Available;Methylphenidate Hydrochloride- ER Tablets- 36 MG 100s NDC: 00591-2717-01 Available;Methylphenidate Hydrochloride- ER Capsules-  20 mg- 100s NDC: 67767-0200-01 Currently back ordered due to manufacturing delays- non API related.;Methylphenidate Hydrochloride- ER Tablets- 54 MG 100s NDC: 00591-2718-01 Available;Methylphenidate Hydrochloride- ER Capsules- 30 mg- 100s NDC: 67767-0201-01 Currently back ordered due to manufacturing delays- non API related.;Methylphenidate Hydrochloride- ER Capsules- 40 mg- 100s NDC: 67767-0202-01  Currently back ordered due to manufacturing delays- non API related.;Methylphenidate Hydrochloride- ER Tablets- 27 MG 100s NDC: 00591-2716-01 Available,,,,,,,,,,,,,
Actavis,methylphenidater,2,8/7/13,3/25/14,manufacturing delays; available,blue,,Methylphenidate Hydrochloride- ER Tablets- 18 MG 100s NDC: 00591-2715-01 Available;Methylphenidate Hydrochloride- ER Tablets- 54 MG 100s NDC: 00591-2718-01 Available;Methylphenidate Hydrochloride- ER Capsules- 30 mg- 100s NDC: 67767-0201-01 Currently back ordered due to manufacturing delays- non API related.;Methylphenidate Hydrochloride- ER Tablets- 36 MG 100s NDC: 00591-2717-01 Available;Methylphenidate Hydrochloride- ER Capsules-  20 mg- 100s NDC: 67767-0200-01 Currently back ordered due to manufacturing delays- non API related.;Methylphenidate Hydrochloride- ER Tablets- 27 MG 100s NDC: 00591-2716-01 Available;Methylphenidate Hydrochloride- ER Capsules- 40 mg- 100s NDC: 67767-0202-01  Currently back ordered due to manufacturing delays- non API related.;Methylphenidate Hydrochloride- ER Capsules-  20 mg- 100s (NDC: 67767-0200-01) Available No supply issues anticipated;Methylphenidate Hydrochloride- ER Capsules- 30 mg- 100s (NDC: 67767-0201-01) Available No supply issues anticipated;Methylphenidate Hydrochloride- ER Tablets- 54 MG 100s (NDC: 00591-2718-01) Available No supply issues anticipated;Methylphenidate Hydrochloride- ER Tablets- 18 MG 100s (NDC: 00591-2715-01) Available No supply issues anticipated;Methylphenidate Hydrochloride- ER Tablets- 27 MG 100s (NDC: 00591-2716-01) Available No supply issues anticipated;Methylphenidate Hydrochloride- ER Tablets- 36 MG 100s (NDC: 00591-2717-01) Available No supply issues anticipated;Methylphenidate Hydrochloride- ER Capsules- 40 mg- 100s (NDC: 67767-0202-01) Available No supply issues anticipated,,,,,,,,,,,,,
Teva,methylphenidater,1,7/24/13,7/24/13,product recall,yellow,,20mg- 100 count (NDC 0093-5346-01) Teva has Methylphenidate Hydrochloride ER Capsules on back order and the company cannot estimate a release date. Shortage per Manufacturer: Recall initiated due to a routine stability failure;30mg- 100 count (NDC 0093-5347-01) Teva has Methylphenidate Hydrochloride ER Capsules on back order and the company cannot estimate a release date. Shortage per Manufacturer: Recall initiated due to a routine stability failure;40mg- 100 count (NDC 0093-5348-01) Teva has Methylphenidate Hydrochloride ER Capsules on back order and the company cannot estimate a release date. Shortage per Manufacturer: Recall initiated due to a routine stability failure,,,,,,,,,,,,,
Teva,methylphenidater,2,8/7/13,3/25/14,product recall,yellow,,20mg- 100 count (NDC 0093-5346-01) Teva has Methylphenidate Hydrochloride ER Capsules on back order and the company cannot estimate a release date. Shortage per Manufacturer: Recall initiated due to a routine stability failure;30mg- 100 count (NDC 0093-5347-01) Teva has Methylphenidate Hydrochloride ER Capsules on back order and the company cannot estimate a release date. Shortage per Manufacturer: Recall initiated due to a routine stability failure;40mg- 100 count (NDC 0093-5348-01) Teva has Methylphenidate Hydrochloride ER Capsules on back order and the company cannot estimate a release date. Shortage per Manufacturer: Recall initiated due to a routine stability failure,,,,,,,,,,,,,
BD,metoclopramide,1,6/5/13,11/8/13,available,,,10 mg/2 ml (5 mg/mL) in a pre-filled single-use glass syringe (NDC 76045-101-20) Available Please check with you wholesaler for available inventory.,,,,,,,,,,,,,
Baxter,metoclopramide,1,2/9/11,4/22/11,demand increase,orange,,Increased Demand   Hospira discontinued metoclopramide ampules in February,2010, and Carpuject syringes in May, 2009.;Increased Demand   Hospira discontinued metoclopramide ampules in February,2010, and Carpuject syringes in May,2009,,,,,,,
Baxter,metoclopramide,1,4/28/11,12/16/11,demand increase,orange,,Baxter is currently experiencing an increase in demand for metoclopramide injection 5 mg/mL- 2 mL vials (NDC 10019-0450-02). Lots are currently being manufactured and will be release for distribution as product becomes available.,,,,,,,,,,,,,
Hospira,metoclopramide,1,2/9/11,4/22/11,demand increase,orange,,Increased Demand   Hospira discontinued metoclopramide ampules in February,2010, and Carpuject syringes in May, 2009.;Increased Demand   Hospira discontinued metoclopramide ampules in February,2010, and Carpuject syringes in May,2009,,,,,,,
Teva,metoclopramide,1,2/9/11,4/22/11,demand increase,orange,,Increased Demand   Hospira discontinued metoclopramide ampules in February,2010, and Carpuject syringes in May, 2009.;Increased Demand   Hospira discontinued metoclopramide ampules in February,2010, and Carpuject syringes in May,2009,,,,,,,
WestWard,metoclopramide,1,12/22/11,2/6/12,demand increase,orange,,West-Ward is currently experiencing an increase in demand for metoclopramide injection 5 mg/mL- 2 mL vials (NDC 10019-0450-02). Lots are currently being manufactured and will be release for distribution as product becomes available.,,,,,,,,,,,,,
Teva,metoclopramide,1,4/28/11,11/8/13,discontinued; demand increase,black,,Teva has made a business decision to discontinue this product. See the Dear Valued Customer Letter (PDF - 32KB);;5 mg/mL- 2 mL vial- 25 count (NDC 00703-4502-04)   Teva has made a business decision to discontinue this product. See the Dear Valued Customer Letter (PDF - 32KB);5 mg/mL- 2 mL vial- 25 count (NDC 00703-4502-04) Not available  Teva has made a business decision to discontinue this product. See the Dear Valued Customer Letter (PDF - 32KB);5 mg/mL- 2 mL vial- 25 count (NDC 00703-4502-04) Teva has made the decision to re-introduce Metoclopramide to the market.  We expect availability by Q3 2013.;5 mg/mL- 2 mL vial- 25 count (NDC 00703-4502-04) Teva has made the decision to re-introduce Metoclopramide to the market.  We expect availability by late Q3 2013.,,,,,,,,,,,,,
Sandoz,mexiletine,1,8/20/10,8/28/10,available,,,Product continues to be available with short expiration dating.,,,,,,,,,,,,,
Teva,mexiletine,1,2/14/10,4/22/11,manufacturing delays,blue,,Manufacturing Delays,,,,,,,,,,,,,
Teva,mexiletine,1,4/28/11,3/1/12,manufacturing delays,blue,,Teva has mexiletine 150 mg capsules (NDC 00093-8793-01) and 250 mg capsules (NDC 00093-8741-01). There is not yet an availability date for the 200 mg capsules.,,,,,,,,,,,,,
WestWard,midazolam,1,1/5/12,9/1/13,; demand increase,orange,,"Pending information;West-Ward is currently experiencing a backorder situation on all 1 mg/mL and 5 mg/mL vials. West-Ward has accelerated production on all codes and will have the following products available. Lots of the1 mg/mL- 2 mL vials will be released and available at the end of January 2012. Additional lots of the other codes are scheduled to be manufactured and estimated availability in the February - March 2012 timeframe. Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on all 1 mg/mL and 5 mg/mL vials.
 
 West-Ward has accelerated production on all codes and will have the following products available.
 
 Lots of the1 mg/mL- 2 mL vials will be released and available at the end of January 2012.
 
 Additional lots of the other codes are scheduled to be manufactured and estimated availability in the February - March 2012 timeframe. 
 Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on the majority or Midazolam codes.  Limited quantities are available of the 1 mg/mL and 5 mg/mL- 2 mL vials.   West-Ward has accelerated production and will have units of all presentations available for release in the March ? April 2012 timeframe.   Additional lots are also projected to be manufactured in May 2012. Product will be made available as it is released.;Increase in product demand West-Ward is currently experiencing a backorder situation on the majority or Midazolam codes.  Limited quantities are available of the 1 mg/mL and 5 mg/mL- 2 mL vials.   West-Ward has accelerated production and will have units of all presentations available for release in the March ? April 2012 timeframe.   Additional lots are also projected to be manufactured in May 2012. Product will be made available as it is released.;;10 mL vial- 5 mg/mL (NDC 0641-6060-10)   West-Ward has accelerated production and will have units of all presentations available for release in the June ? July 2012 timeframe. West-Ward is currently experiencing a backorder situation on all of the Midazolam codes. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand;1 mL vial- 5 mg/mL(NDC  0641-6061-25)25 pack(NDC  0641-6061-10)10 pack West-Ward has accelerated production and will have units of all presentations available for release in the June ? July 2012 timeframe. West-Ward is currently experiencing a backorder situation on all of the Midazolam codes. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand;2 mL vial- 5 mg/mL (NDC  0641-6063-25)25 pack(NDC  0641-6063-10)10 pack West-Ward has accelerated production and will have units of all presentations available for release in the June ? July 2012 timeframe. West-Ward is currently experiencing a backorder situation on all of the Midazolam codes. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand;5 mL vial- 1 mg/mL (NDC 0641-6059-10) West-Ward has accelerated production and will have units of all presentations available for release in the June ? July 2012 timeframe. West-Ward is currently experiencing a backorder situation on all of the Midazolam codes. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand;10 mL vial- 1 mg/mL (NDC 0641-6056-10) West-Ward has accelerated production and will have units of all presentations available for release in the June ? July 2012 timeframe. West-Ward is currently experiencing a backorder situation on all of the Midazolam codes. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand;2 mL vial- 1 mg/mL (NDC 0641-6057-25)25 pack(NDC 0641-6057-10)10 pack West-Ward has accelerated production and will have units of all presentations available for release in the June ? July 2012 timeframe. West-Ward is currently experiencing a backorder situation on all of the Midazolam codes. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand;2 mL vial- 1 mg/mL
 (NDC 0641-6057-25)25 pack
 (NDC 0641-6057-10)10 pack West-Ward has accelerated production and will have units of all presentations available for release in the June ? July 2012 timeframe. West-Ward is currently experiencing a backorder situation on all of the Midazolam codes.
 Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand;10 mL vial- 5 mg/mL
 (NDC 0641-6060-10)
 
 
   West-Ward has accelerated production and will have units of all presentations available for release in the June ? July 2012 timeframe. West-Ward is currently experiencing a backorder situation on all of the Midazolam codes.
 Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand;2 mL vial- 5 mg/mL
 (NDC  0641-6063-25)25 pack
 (NDC  0641-6063-10)10 pack West-Ward has accelerated production and will have units of all presentations available for release in the June ? July 2012 timeframe. West-Ward is currently experiencing a backorder situation on all of the Midazolam codes.
 Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand;5 mL vial- 1 mg/mL
 (NDC 0641-6059-10) West-Ward has accelerated production and will have units of all presentations available for release in the June ? July 2012 timeframe. West-Ward is currently experiencing a backorder situation on all of the Midazolam codes.
 Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand;10 mL vial- 1 mg/mL 
 (NDC 0641-6056-10) West-Ward has accelerated production and will have units of all presentations available for release in the June ? July 2012 timeframe. West-Ward is currently experiencing a backorder situation on all of the Midazolam codes.
 Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand;1 mL vial- 5 mg/mL
 (NDC  0641-6061-25)25 pack(NDC  0641-6061-10)10 pack West-Ward has accelerated production and will have units of all presentations available for release in the June ? July 2012 timeframe. West-Ward is currently experiencing a backorder situation on all of the Midazolam codes.
 Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand;1 mL vial- 5 mg/mL(NDC  0641-6061-25)25 pack(NDC  0641-6061-10)10 pack West-Ward currently has limited quantities available.   There is a backorder situation on the 1 mg/mL- 2 mL vail (25 pack).   West-Ward has accelerated production on all Midazolam product codes.   Multiple lots are scheduled to be manufactured and released by the end of January 2013. West-Ward is anticipating having additional lots of inventory available by the end of February 2013. Product will be made available as it is released.;10 mL vial- 1 mg/mL (NDC 0641-6056-10) West-Ward currently has limited quantities available.   There is a backorder situation on the 1 mg/mL- 2 mL vail (25 pack).   West-Ward has accelerated production on all Midazolam product codes.   Multiple lots are scheduled to be manufactured and released by the end of January 2013. West-Ward is anticipating having additional lots of inventory available by the end of February 2013. Product will be made available as it is released.;10 mL vial- 5 mg/mL (NDC 0641-6060-10)   West-Ward currently has limited quantities available.   There is a backorder situation on the 1 mg/mL- 2 mL vail (25 pack).   West-Ward has accelerated production on all Midazolam product codes.   Multiple lots are scheduled to be manufactured and released by the end of January 2013. West-Ward is anticipating having additional lots of inventory available by the end of February 2013. Product will be made available as it is released.;2 mL vial- 1 mg/mL (NDC 0641-6057-25)25 pack(NDC 0641-6057-10)10 pack West-Ward currently has limited quantities available.   There is a backorder situation on the 1 mg/mL- 2 mL vail (25 pack).   West-Ward has accelerated production on all Midazolam product codes.   Multiple lots are scheduled to be manufactured and released by the end of January 2013. West-Ward is anticipating having additional lots of inventory available by the end of February 2013. Product will be made available as it is released.;2 mL vial- 5 mg/mL (NDC  0641-6063-25)25 pack(NDC  0641-6063-10)10 pack West-Ward currently has limited quantities available.   There is a backorder situation on the 1 mg/mL- 2 mL vail (25 pack).   West-Ward has accelerated production on all Midazolam product codes.   Multiple lots are scheduled to be manufactured and released by the end of January 2013. West-Ward is anticipating having additional lots of inventory available by the end of February 2013. Product will be made available as it is released.;5 mL vial- 1 mg/mL (NDC 0641-6059-10) West-Ward currently has limited quantities available.   There is a backorder situation on the 1 mg/mL- 2 mL vail (25 pack).   West-Ward has accelerated production on all Midazolam product codes.   Multiple lots are scheduled to be manufactured and released by the end of January 2013. West-Ward is anticipating having additional lots of inventory available by the end of February 2013. Product will be made available as it is released.;2 mL vial- 5 mg/mL (NDC  0641-6063-25)25 pack(NDC  0641-6063-10)10 pack West-Ward currently has limited quantities available.   There is a backorder situation on the 1 mg/mL- 2 mL vail (25 pack).   West-Ward has accelerated production on all Midazolam product codes.   West-Ward is anticipating having additional lots of inventory available by the end of March 2013. Product will be made available as it is released.;10 mL vial- 1 mg/mL (NDC 0641-6056-10) West-Ward currently has limited quantities available.   There is a backorder situation on the 1 mg/mL- 2 mL vail (25 pack).   West-Ward has accelerated production on all Midazolam product codes.   West-Ward is anticipating having additional lots of inventory available by the end of March 2013. Product will be made available as it is released.;5 mL vial- 1 mg/mL (NDC 0641-6059-10) West-Ward currently has limited quantities available.   There is a backorder situation on the 1 mg/mL- 2 mL vail (25 pack).   West-Ward has accelerated production on all Midazolam product codes.   West-Ward is anticipating having additional lots of inventory available by the end of March 2013. Product will be made available as it is released.;10 mL vial- 5 mg/mL (NDC 0641-6060-10)   West-Ward currently has limited quantities available.   There is a backorder situation on the 1 mg/mL- 2 mL vail (25 pack).   West-Ward has accelerated production on all Midazolam product codes.   West-Ward is anticipating having additional lots of inventory available by the end of March 2013. Product will be made available as it is released.;1 mL vial- 5 mg/mL(NDC  0641-6061-25)25 pack(NDC  0641-6061-10)10 pack West-Ward currently has limited quantities available.   There is a backorder situation on the 1 mg/mL- 2 mL vail (25 pack).   West-Ward has accelerated production on all Midazolam product codes.   West-Ward is anticipating having additional lots of inventory available by the end of March 2013. Product will be made available as it is released.;2 mL vial- 1 mg/mL (NDC 0641-6057-25)25 pack(NDC 0641-6057-10)10 pack West-Ward currently has limited quantities available.   There is a backorder situation on the 1 mg/mL- 2 mL vail (25 pack).   West-Ward has accelerated production on all Midazolam product codes.   West-Ward is anticipating having additional lots of inventory available by the end of March 2013. Product will be made available as it is released.;1 mL vial- 5 mg/mL(NDC  0641-6061-25)25 pack(NDC  0641-6061-10)10 pack West-Ward currently has limited quantities available for all presentations. West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the end of August 2013. Product will be made available as it is released.;2 mL vial- 1 mg/mL (NDC 0641-6057-25)25 pack(NDC 0641-6057-10)10 pack West-Ward currently has limited quantities available for all presentations. West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the end of August 2013. Product will be made available as it is released.;10 mL vial- 1 mg/mL (NDC 0641-6056-10) West-Ward currently has limited quantities available for all presentations. West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the end of August 2013. Product will be made available as it is released.;2 mL vial- 5 mg/mL (NDC  0641-6063-25)25 pack(NDC  0641-6063-10)10 pack West-Ward currently has limited quantities available for all presentations. West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the end of August 2013. Product will be made available as it is released.;5 mL vial- 1 mg/mL (NDC 0641-6059-10) West-Ward currently has limited quantities available for all presentations. West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the end of August 2013. Product will be made available as it is released.;10 mL vial- 5 mg/mL (NDC 0641-6060-10)   West-Ward currently has limited quantities available for all presentations. West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the end of August 2013. Product will be made available as it is released.;5 mL vial- 1 mg/mL (NDC 0641-6059-10) West-Ward currently has quantities available for most presentations. The 2 mL vial- 1 mg/mL 10 pack and 5 mL vial- 1 mg/mL are currently on backorder.   West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the middle of September 2013. Product will be made available as it is released.;10 mL vial- 5 mg/mL (NDC 0641-6060-10)   West-Ward currently has quantities available for most presentations. The 2 mL vial- 1 mg/mL 10 pack and 5 mL vial- 1 mg/mL are currently on backorder.   West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the middle of September 2013. Product will be made available as it is released.;10 mL vial- 1 mg/mL (NDC 0641-6056-10) West-Ward currently has quantities available for most presentations. The 2 mL vial- 1 mg/mL 10 pack and 5 mL vial- 1 mg/mL are currently on backorder.   West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the middle of September 2013. Product will be made available as it is released.;1 mL vial- 5 mg/mL(NDC  0641-6061-25)25 pack(NDC  0641-6061-10)10 pack West-Ward currently has quantities available for most presentations. The 2 mL vial- 1 mg/mL 10 pack and 5 mL vial- 1 mg/mL are currently on backorder.   West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the middle of September 2013. Product will be made available as it is released.;2 mL vial- 5 mg/mL (NDC  0641-6063-25)25 pack(NDC  0641-6063-10)10 pack West-Ward currently has quantities available for most presentations. The 2 mL vial- 1 mg/mL 10 pack and 5 mL vial- 1 mg/mL are currently on backorder.   West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the middle of September 2013. Product will be made available as it is released.;2 mL vial- 1 mg/mL (NDC 0641-6057-25)25 pack(NDC 0641-6057-10)10 pack West-Ward currently has quantities available for most presentations. The 2 mL vial- 1 mg/mL 10 pack and 5 mL vial- 1 mg/mL are currently on backorder.   West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the middle of September 2013. Product will be made available as it is released.",,,,,,,,,,,,,
Akorn,midazolam,2,10/1/13,10/1/13,available,,,5 mg / mL; (2 mL x 10 pack) (NDC 17478-0524-02) Readily available  NA;5 mg / mL; (10 mL x 10 pack) (NDC 17478-0524-10) Readily available  NA;5 mg / mL; (5 mL x 10 pack) (NDC 17478-0524-05) Readily available  NA;5 mg / mL; (1 mL x 10 pack) (NDC 17478-0524-01) Readily available  NA;1 mg / mL;  (5 mL x 25 pack) (NDC 17478-0523-55) Readily available  NA;1 mg / mL; (2 mL x 10 pack) (NDC 17478-0523-02) Readily available   NA;1 mg / mL; (10 mL x 10 pack) (NDC 17478-0523-10) Readily available  NA,,,,,,,,,,,,,
Sun,midazolam,1,9/22/12,9/1/13,available,,,"25mg/5mL (5mg/mL) NDC: 57664-0634-44- 10 pack Readily Available 
   Product Available;2mg/2mL (1mg/mL)  NDC: 57664-0633-43- 10 pack Readily Available 
   Product Available;50mg/10mL (5mg/mL) NDC: 57664-0634-45- 10 pack Readily Available 
   Product Available;25mg/5mL (5mg/mL) NDC: 57664-0634-44- 10 pack Readily Available   Product Available;2mg/2mL (1mg/mL)  NDC: 57664-0633-43- 10 pack Readily Available   Product Available;50mg/10mL (5mg/mL) NDC: 57664-0634-45- 10 pack Readily Available   Product Available",,,,,,,,,,,,,
Sun,midazolam,2,10/1/13,10/1/13,available,,,2mg/2mL (1mg/mL)  NDC: 57664-0633-43- 10 pack Readily Available   Product Available;50mg/10mL (5mg/mL) NDC: 57664-0634-45- 10 pack Readily Available   Product Available;25mg/5mL (5mg/mL) NDC: 57664-0634-44- 10 pack Readily Available   Product Available,,,,,,,,,,,,,
Wockhardt,midazolam,3,10/1/13,10/1/13,available,,,1mg/mL- 5mL x 10 (NDC # 64679-0762-02) Inventory is readily available;5mg/mL- 10mL x 10 (NDC # 64679-0763-04)   Inventory is readily available;NULL NULL,,,,,,,,,,,,,
Bedford,midazolam,2,10/1/13,10/1/13,capacity constraints,blue,,5 mg/mL- 10 mL vial- 10 count (NDC 55390-0126-10) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;1 mg/mL- 2 mL preservative-free vial- 10 count (NDC 55390-0137-02) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;5 mg/mL- 2 mL preservative-free vial- 10 count (NDC 55390-0138-02) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;1 mg/mL- 5 mL preservative-free vial- 10 count (NDC 55390-0137-05) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;5 mg/mL- 5 mL vial- 10 count (NDC 55390-0126-05) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;5 mg/mL- 1 mL preservative-free- in 2 mL vial- 10 count (NDC 55390-0138-01) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;1 mg/mL- 10 mL vial- 10 count (NDC 55390-0125-10) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;NULL Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.,,,,,,,,,,,,,
APP,midazolam,2,10/1/13,10/1/13,demand increase,orange,,5 mg/mL- 5 mL vial- 10 count (NDC 63323-0412-05) Available.  Check wholesalers for inventory. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;1 mg/mL- 2 mL vial- 25 count (NDC 63323-0411-12) Available.  Check wholesalers for inventory. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;1 mg/mL- 10 mL vial- 10 count (NDC 63323-0411-10) Available.  Check wholesalers for inventory. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 10 mL vial- 10 count (NDC 63323-0412-10) Available. Check wholesalers for inventory. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 1 mL fill in 2 mL vial- 25 count (NDC 63323-0412-25) Available.  Check wholesalers for inventory. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;1 mg/mL- 5 mL vial- 25 count (NDC 63323-0411-25) Backordered. Next release expected September 2013. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 2 mL vial- 25 count (NDC 63323-0412-02) Available.  Check wholesalers for inventory. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand,,,,,,,,,,,,,
WestWard,midazolam,2,10/1/13,10/1/13,demand increase,orange,,10 mL vial- 1 mg/mL (NDC 0641-6056-10) West-Ward currently has quantities available for most presentations. The 2 mL vial- 1 mg/mL 10 pack and 5 mL vial- 1 mg/mL are currently on backorder.   West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the middle of September 2013. Product will be made available as it is released.;10 mL vial- 5 mg/mL (NDC 0641-6060-10)   West-Ward currently has quantities available for most presentations. The 2 mL vial- 1 mg/mL 10 pack and 5 mL vial- 1 mg/mL are currently on backorder.   West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the middle of September 2013. Product will be made available as it is released.;1 mL vial- 5 mg/mL(NDC  0641-6061-25)25 pack(NDC  0641-6061-10)10 pack West-Ward currently has quantities available for most presentations. The 2 mL vial- 1 mg/mL 10 pack and 5 mL vial- 1 mg/mL are currently on backorder.   West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the middle of September 2013. Product will be made available as it is released.;2 mL vial- 1 mg/mL (NDC 0641-6057-25)25 pack(NDC 0641-6057-10)10 pack West-Ward currently has quantities available for most presentations. The 2 mL vial- 1 mg/mL 10 pack and 5 mL vial- 1 mg/mL are currently on backorder.   West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the middle of September 2013. Product will be made available as it is released.;2 mL vial- 5 mg/mL (NDC  0641-6063-25)25 pack(NDC  0641-6063-10)10 pack West-Ward currently has quantities available for most presentations. The 2 mL vial- 1 mg/mL 10 pack and 5 mL vial- 1 mg/mL are currently on backorder.   West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the middle of September 2013. Product will be made available as it is released.;5 mL vial- 1 mg/mL (NDC 0641-6059-10) West-Ward currently has quantities available for most presentations. The 2 mL vial- 1 mg/mL 10 pack and 5 mL vial- 1 mg/mL are currently on backorder.   West-Ward has accelerated production on all Midazolam product codes.            West-Ward is anticipating having additional lots of inventory available by the middle of September 2013. Product will be made available as it is released.,,,,,,,,,,,,,
APP,midazolam,1,1/5/12,9/1/13,demand increase,orange,,"APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory.;Increased demand APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory.;;1 mg/mL- 5 mL vial- 25 count (NDC 63323-0411-25) APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 2 mL vial- 25 count (NDC 63323-0412-02) APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 10 mL vial- 10 count (NDC 63323-0412-10) APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;1 mg/mL- 2 mL vial- 25 count (NDC 63323-0411-12) APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;1 mg/mL- 10 mL vial- 10 count (NDC 63323-0411-10) APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 1 mL fill in 2 mL vial- 25 count (NDC 63323-0412-25) APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 5 mL vial- 10 count (NDC 63323-0412-05) APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 1 mL fill in 2 mL vial- 25 count (NDC 63323-0412-25) APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory.
 Shortage per Manufacturer: 
 Increased demand;1 mg/mL- 5 mL vial- 25 count (NDC 63323-0411-25) APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory.
 Shortage per Manufacturer: 
 Increased demand;1 mg/mL- 10 mL vial- 10 count (NDC 63323-0411-10) APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory.
 Shortage per Manufacturer: 
 Increased demand;5 mg/mL- 5 mL vial- 10 count (NDC 63323-0412-05) APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory.
 Shortage per Manufacturer: 
 Increased demand;1 mg/mL- 2 mL vial- 25 count (NDC 63323-0411-12) APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory.
 Shortage per Manufacturer: 
 Increased demand;5 mg/mL- 2 mL vial- 25 count (NDC 63323-0412-02) APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory.
 Shortage per Manufacturer: 
 Increased demand;5 mg/mL- 10 mL vial- 10 count (NDC 63323-0412-10) APP has midazolam injection on intermittent back order and the company is releasing product on a regular basis. Check with wholesalers for inventory.
 Shortage per Manufacturer: 
 Increased demand;5 mg/mL- 2 mL vial- 25 count (NDC 63323-0412-02) Available.  Check wholesalers for inventory. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;1 mg/mL- 10 mL vial- 10 count (NDC 63323-0411-10) Available.  Check wholesalers for inventory. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;1 mg/mL- 5 mL vial- 25 count (NDC 63323-0411-25) Available.  Check wholesalers for inventory. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 5 mL vial- 10 count (NDC 63323-0412-05) Available.  Check wholesalers for inventory. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 1 mL fill in 2 mL vial- 25 count (NDC 63323-0412-25) Available.  Check wholesalers for inventory. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;1 mg/mL- 2 mL vial- 25 count (NDC 63323-0411-12) Available.  Check wholesalers for inventory. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 10 mL vial- 10 count (NDC 63323-0412-10) Available.  Check wholesalers for inventory. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 10 mL vial- 10 count (NDC 63323-0412-10) Backordered.  Next release expected April 2013. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 10 mL vial- 10 count (NDC 63323-0412-10) Backordered.  Next release expected June 2013. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;1 mg/mL- 2 mL vial- 25 count (NDC 63323-0411-12) Backordered. Next release expected June. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;1 mg/mL- 5 mL vial- 25 count (NDC 63323-0411-25) Backordered. Next release expected June. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 10 mL vial- 10 count (NDC 63323-0412-10) Backordered.  Next release expected July 2013. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;1 mg/mL- 2 mL vial- 25 count (NDC 63323-0411-12) Backordered. Next release expected July 2013. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 5 mL vial- 10 count (NDC 63323-0412-05) Backordered. Next release expected July 2013 Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 1 mL fill in 2 mL vial- 25 count (NDC 63323-0412-25) Backordered. Next release expected July 2013 Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;1 mg/mL- 5 mL vial- 25 count (NDC 63323-0411-25) Backordered. Next release expected August 2013. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;5 mg/mL- 10 mL vial- 10 count (NDC 63323-0412-10) Available. Check wholesalers for inventory. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand;1 mg/mL- 5 mL vial- 25 count (NDC 63323-0411-25) Backordered. Next release expected September 2013. Check with wholesalers for inventory. Shortage per Manufacturer: Increased demand",,,,,,,,,,,,,
Akorn,midazolam,1,4/18/12,9/1/13,demand increase; available,orange,,"All presentations- Re-launching late June.;N/A All presentations- Re-launching late June.;;5 mg / mL; (5 mL x 10 pack) (NDC 17478-0524-05) Readily available Shortage per Manufacturer: Market Demand;1 mg / mL;  (5 mL x 25 pack) (NDC 17478-0523-55) Available in wholesalers Shortage per Manufacturer: Market Demand;5 mg / mL; (10 mL x 10 pack) (NDC 17478-0524-10) Readily available Shortage per Manufacturer: Market Demand;5 mg / mL; (1 mL x 10 pack) (NDC 17478-0524-01) Readily available Shortage per Manufacturer: Market Demand;1 mg / mL; (10 mL x 10 pack) (NDC 17478-0523-10) Readily available Shortage per Manufacturer: Market Demand;5 mg / mL; (2 mL x 10 pack) (NDC 17478-0524-02) Readily available Shortage per Manufacturer: Market Demand;1 mg / mL; (2 mL x 10 pack) (NDC 17478-0523-02) Readily available  Shortage per Manufacturer: Market Demand;1 mg / mL; (10 mL x 10 pack) 
 (NDC 17478-0523-10) Readily available Shortage per Manufacturer: 
 Market Demand;5 mg / mL; (10 mL x 10 pack) 
 (NDC 17478-0524-10) Readily available Shortage per Manufacturer: 
 Market Demand;5 mg / mL; (5 mL x 10 pack) 
 (NDC 17478-0524-05) Readily available Shortage per Manufacturer: 
 Market Demand;5 mg / mL; (1 mL x 10 pack) 
 (NDC 17478-0524-01) Readily available Shortage per Manufacturer: 
 Market Demand;5 mg / mL; (2 mL x 10 pack) 
 (NDC 17478-0524-02) Readily available Shortage per Manufacturer: 
 Market Demand;1 mg / mL; (2 mL x 10 pack) 
 (NDC 17478-0523-02) Readily available
   Shortage per Manufacturer: 
 Market Demand;1 mg / mL;  (5 mL x 25 pack) 
 (NDC 17478-0523-55) Available in wholesalers Shortage per Manufacturer: 
 Market Demand;1 mg / mL; (10 mL x 10 pack) (NDC 17478-0523-10) Readily available;1 mg / mL; (2 mL x 10 pack) (NDC 17478-0523-02) Readily available;5 mg / mL; (1 mL x 10 pack) (NDC 17478-0524-01) Readily available;5 mg / mL; (2 mL x 10 pack) (NDC 17478-0524-02) Readily available;5 mg / mL; (10 mL x 10 pack) (NDC 17478-0524-10) Readily available;1 mg / mL;  (5 mL x 25 pack) (NDC 17478-0523-55) Readily available;5 mg / mL; (5 mL x 10 pack) (NDC 17478-0524-05) Readily available;1 mg / mL; (2 mL x 10 pack) (NDC 17478-0523-02) Readily available   NA;1 mg / mL; (10 mL x 10 pack) (NDC 17478-0523-10) Readily available  NA;1 mg / mL;  (5 mL x 25 pack) (NDC 17478-0523-55) Readily available  NA;5 mg / mL; (1 mL x 10 pack) (NDC 17478-0524-01) Readily available  NA;5 mg / mL; (5 mL x 10 pack) (NDC 17478-0524-05) Readily available  NA;5 mg / mL; (2 mL x 10 pack) (NDC 17478-0524-02) Readily available  NA;5 mg / mL; (10 mL x 10 pack) (NDC 17478-0524-10) Readily available  NA",,,,,,,,,,,,,
Wockhardt,midazolam,1,7/24/13,7/24/13,manufacturing practices requirements,yellow,,1mg/mL- 5mL x 10 (NDC # 64679-0762-02) No estimated release date available;NULL NULL;5mg/mL- 10mL x 10 (NDC # 64679-0763-04)   No estimated release date available,,,,,,,,,,,,,
Wockhardt,midazolam,2,8/7/13,9/1/13,manufacturing practices requirements; available,yellow,,1mg/mL- 5mL x 10 (NDC # 64679-0762-02) No estimated release date available;NULL NULL;5mg/mL- 10mL x 10 (NDC # 64679-0763-04)   No estimated release date available;1mg/mL- 5mL x 10 (NDC # 64679-0762-02) Inventory is readily available;5mg/mL- 10mL x 10 (NDC # 64679-0763-04)   Inventory is readily available,,,,,,,,,,,,,
Bedford,midazolam,1,1/5/12,9/1/13,production suspended; capacity constraints,blue,,"Bedford has all midazolam presentations on back order and the company cannot estimate a release date.   The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website;Bedford has all midazolam presentations on back order and the company cannot estimate a release date.
  
 The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.
  
 Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website;Temporary suspension of manufacturing. Bedford has all midazolam presentations on back order and the company cannot estimate a release date.   The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website;;1 mg/mL- 10 mL vial- 10 count (NDC 55390-0125-10) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;5 mg/mL- 2 mL preservative-free vial- 10 count (NDC 55390-0138-02) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;5 mg/mL- 5 mL vial- 10 count (NDC 55390-0126-05) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;1 mg/mL- 2 mL preservative-free vial- 10 count (NDC 55390-0137-02) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;5 mg/mL- 10 mL vial- 10 count (NDC 55390-0126-10)5 mg/mL- 10 mL vial- 10 count (NDC 55390-0126-10) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;NULL Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;5 mg/mL- 1 mL preservative-free- in 2 mL vial- 10 count (NDC 55390-0138-01) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;1 mg/mL- 5 mL preservative-free vial- 10 count (NDC 55390-0137-05) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;5 mg/mL- 1 mL preservative-free- in 2 mL vial- 10 count (NDC 55390-0138-01) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.
  
 Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website 
 Shortage per Manufacturer: 
 Temporary suspension of manufacturing.;5 mg/mL- 10 mL vial- 10 count (NDC 55390-0126-10)5 mg/mL- 10 mL vial- 10 count (NDC 55390-0126-10) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.
  
 Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website 
 Shortage per Manufacturer: 
 Temporary suspension of manufacturing.;5 mg/mL- 5 mL vial- 10 count (NDC 55390-0126-05) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.
  
 Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website 
 Shortage per Manufacturer: 
 Temporary suspension of manufacturing.;1 mg/mL- 5 mL preservative-free vial- 10 count (NDC 55390-0137-05) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.
  
 Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website 
 Shortage per Manufacturer: 
 Temporary suspension of manufacturing.;1 mg/mL- 2 mL preservative-free vial- 10 count (NDC 55390-0137-02) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.
  
 Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website 
 Shortage per Manufacturer: 
 Temporary suspension of manufacturing.;NULL Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.
  
 Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website 
 Shortage per Manufacturer: 
 Temporary suspension of manufacturing.;5 mg/mL- 2 mL preservative-free vial- 10 count (NDC 55390-0138-02) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.
  
 Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website 
 Shortage per Manufacturer: 
 Temporary suspension of manufacturing.;1 mg/mL- 10 mL vial- 10 count (NDC 55390-0125-10) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials vials are pending release while the other presentations will not be manufactured until capacity permits.
  
 Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website 
 Shortage per Manufacturer: 
 Temporary suspension of manufacturing.;5 mg/mL- 1 mL preservative-free- in 2 mL vial- 10 count (NDC 55390-0138-01) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;1 mg/mL- 2 mL preservative-free vial- 10 count (NDC 55390-0137-02) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;1 mg/mL- 10 mL vial- 10 count (NDC 55390-0125-10) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;5 mg/mL- 5 mL vial- 10 count (NDC 55390-0126-05) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;NULL Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;5 mg/mL- 10 mL vial- 10 count (NDC 55390-0126-10)5 mg/mL- 10 mL vial- 10 count (NDC 55390-0126-10) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;5 mg/mL- 2 mL preservative-free vial- 10 count (NDC 55390-0138-02) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;1 mg/mL- 5 mL preservative-free vial- 10 count (NDC 55390-0137-05) Bedford has all midazolam presentations on back order and the company cannot estimate a release date. The 1 mg/mL 2 mL and 10 mL vials and the 5 mg/mL 2 mL (1 mL fill)- 5 mL and 10 mL vials are pending release while the other presentations will not be manufactured until capacity permits.   Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products.  Availability of products is updated on the Bedford Laboratories website Shortage per Manufacturer: Temporary suspension of manufacturing.;1 mg/mL- 10 mL vial- 10 count (NDC 55390-0125-10) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;NULL Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;5 mg/mL- 10 mL vial- 10 count (NDC 55390-0126-10) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;1 mg/mL- 2 mL preservative-free vial- 10 count (NDC 55390-0137-02) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;5 mg/mL- 2 mL preservative-free vial- 10 count (NDC 55390-0138-02) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;1 mg/mL- 5 mL preservative-free vial- 10 count (NDC 55390-0137-05) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;5 mg/mL- 5 mL vial- 10 count (NDC 55390-0126-05) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;5 mg/mL- 1 mL preservative-free- in 2 mL vial- 10 count (NDC 55390-0138-01) Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.",,,,,,,,,,,,,
Accord,mitomycin,2,3/1/13,3/1/13,demand increase,orange,,20 mg (NDC 16729-0108-11) Available at this time; Orders are being shipped out.;5 mg (NDC 16729-0115-05) Available at this time; Orders are being shipped out.;40 mg (NDC 16729-0116-38) Available at this time; Orders are being shipped out.,,,,,,,,,,,,,
Accord,mitomycin,1,6/30/11,1/10/13,demand increase; available,orange,,Accord is releasing batches as they become available and is ramping up production to meet the increase in demand.;Accord is releasing products as they become available.;Accord currently has all presentations available and will continue releasing products as they become available.;Mitomycin Injection 5 mg; 5090 vials were received and shipments have been allocated for this quantity.   Mitomycin Injection 20 mg; Product is in stock. In addition- approximately 9000 vials will be coming into the warehouse by the 3rd week of this month.   Mitomycin Injection 40 mg; 1000 vials were received and shipments have been allocated for this quantity.;Increase in demand Mitomycin Injection 5 mg; 5090 vials were received and shipments have been allocated for this quantity.   Mitomycin Injection 20 mg; Product is in stock. In addition- approximately 9000 vials will be coming into the warehouse by the 3rd week of this month.   Mitomycin Injection 40 mg; 1000 vials were received and shipments have been allocated for this quantity.;;5 mg (NDC 16729-0115-05) Available at this time. Orders are being shipped out;20 mg (NDC 16729-0108-11) Stock arriving at warehouse 6/15/2012 and will be available for shipping. Orders are being shipped out;40 mg (NDC 16729-0116-38) Product shipped out the week of 6/11/2012. Additional coming in- mid of July 2012 Orders are being shipped out;40 mg (NDC 16729-0116-38) Available at this time; Orders are being shipped out.;20 mg (NDC 16729-0108-11) Available at this time; Orders are being shipped out.;5 mg (NDC 16729-0115-05) Available at this time; Orders are being shipped out.,,,,,,,,,,,,,
Accord,mitomycin,1,7/5/09,11/12/10,manufacturing delays,blue,,Manufacturing delays   Accord has the 5 mg vials (NDC number: 16729-0115-05) in limited quantities. The 20mg vials (NDC 16729-0108-11) will be available by mid-July.;Manufacturing delays    ;Manufacturing delays    ,,,,,,,,,,,,,
Bedford,mitomycin,1,8/20/10,8/28/10,manufacturing delays,blue,,Manufacturing delays                     Manufacturing delays       Supplies continue to be available.,,,,,,,,,,,,,
Bedford,mitomycin,1,6/30/11,1/10/13,manufacturing delays,blue,,"Bedford anticipates release within the next six months.;Bedford has limited allocated quantities of 5 mg (NDC 55390-0251-01) and 20 mg (NDC 55390-0252-01)- contact your local Bedford Account Executive.  Short supplies of 40 mg (NDC 55390-0235-01) are available for drop shipment.;Bedford has limited allocated quantities of 5 mg (NDC 55390-0251-01) and 20 mg (NDC 55390-0252-01) along with a short supply of 40 mg (NDC 55390-0253-01) are available for drop shipment- contact your local Bedford Account Executive.;Bedford has all mitomycin presentations on backorder and the company cannot estimate a release date.;Bedford Laboratories has 5 mg and 20 mg available in limited quantities. Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website.;Manufacturing delays Bedford Laboratories has 5 mg and 20 mg available in limited quantities. Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website.;;20 mg (NDC 55390-0252-01) Bedford Laboratories has 5 mg and 20 mg available in limited quantities. Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;5 mg (NDC 55390-0251-01) Bedford Laboratories has 5 mg and 20 mg available in limited quantities. Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;40 mg (NDC 55390-0253-01) Bedford Laboratories has 5 mg and 20 mg available in limited quantities. Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;20 mg (NDC 55390-0252-01) Bedford Laboratories has 5 mg and 20 mg available in limited quantities. Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;40 mg (NDC 55390-0253-01) Bedford Laboratories has 5 mg and 20 mg available in limited quantities. Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays;5 mg (NDC 55390-0251-01) Bedford Laboratories has 5 mg and 20 mg available in limited quantities. Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website.
 Shortage per Manufacturer: 
 Manufacturing delays",,,,,,,,,,,,,
Bedford,mitomycin,2,3/1/13,3/1/13,manufacturing delays,blue,,5 mg (NDC 55390-0251-01) Bedford Laboratories has 5 mg and 20 mg available in limited quantities. Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;40 mg (NDC 55390-0253-01) Bedford Laboratories has 5 mg and 20 mg available in limited quantities. Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;20 mg (NDC 55390-0252-01) Bedford Laboratories has 5 mg and 20 mg available in limited quantities. Bedford Laboratories is out of stock and the company cannot estimate a release date. Production is pending as capacity permits. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays,,,,,,,,,,,,,
BenVenue,mitomycin,1,6/6/09,11/12/10,manufacturing delays,blue,,Manufacturing delays;Manufacturing delays   Accord has the 5 mg vials (NDC number: 16729-0115-05) in limited quantities. The 20mg vials (NDC 16729-0108-11) will be available by mid-July.;Manufacturing delays    ;Manufacturing delays    ,,,,,,,,,,,,,
Spectrum,mitomycin,1,8/20/10,8/28/10,manufacturing delays,blue,,Manufacturing delays                     Manufacturing delays       Supplies continue to be available.,,,,,,,,,,,,,
Teva,mitomycin,1,8/20/10,8/28/10,manufacturing delays,blue,,Manufacturing delays                     Manufacturing delays       Supplies continue to be available.,,,,,,,,,,,,,
Amphastar,morphine,1,8/20/10,4/14/11,manufacturing delays,blue,,Manufacturing delays Increased demand Manufacturing delays ;Manufacturing delays Increased demand Manufacturing delays  ;Manufacturing delays Increased demand Manufacturing delays  ,,,,,,,,,,,,,
Baxter,morphine,1,8/20/10,4/14/11,manufacturing delays,blue,,Manufacturing delays Increased demand Manufacturing delays ;Manufacturing delays Increased demand Manufacturing delays  ;Manufacturing delays Increased demand Manufacturing delays  ,,,,,,,,,,,,,
Hospira,morphine,1,8/20/10,4/14/11,manufacturing delays,blue,,Manufacturing delays Increased demand Manufacturing delays ;Manufacturing delays Increased demand Manufacturing delays  ;Manufacturing delays Increased demand Manufacturing delays  ,,,,,,,,,,,,,
WestWard,morphines,1,3/16/12,9/1/13,; demand increase,orange,,"Information Pending;Increase in product demand West-Ward has limited availability of the 15 mg/mL- 1 mL vial and 10 mg/mL in both 1 mL and 10 mL vials.  All other presentations are on backorder. West-Ward has accelerated production on all morphine codes and is projecting to have multiple lots available by the end of March with additional units released in April 2012. Additional lots are also scheduled to be manufactured with an estimated availability in the May - June 2012 timeframe. Product will be made available as it is released.;West-Ward has limited availability of the 15 mg/mL- 1 mL vial and 10 mg/mL in both 1 mL and 10 mL vials.  All other presentations are on backorder. West-Ward has accelerated production on all morphine codes and is projecting to have multiple lots available by the end of March with additional units released in April 2012. Additional lots are also scheduled to be manufactured with an estimated availability in the May - June 2012 timeframe. Product will be made available as it is released.;;1 mL vial- 8 mg/mL (NDC 0641-6075-25) Available in limited quantities West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July ? August 2012 timeframe. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;20 mL vial- 15 mg/mL (NDC 0641-6072-01) Available in limited quantities West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July ? August 2012 timeframe. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;10mL vial- 10 mg/mL (NDC 0641-6068-01) Available in limited quantities West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July ? August 2012 timeframe. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;1 mL vial- 10 mg/mL) (NDC 0641-6070-25) Available in limited quantities West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July ? August 2012 timeframe. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;1 mL vial- 15 mg/mL (NDC 0641-6071-25) Backordered West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July ? August 2012 timeframe. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;1 mL vial- 5 mg/mL (NDC 0641-6073-25) Available in limited quantities West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July ? August 2012 timeframe. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand due to market supply issues.;1 mL vial- 15 mg/mL 
 (NDC 0641-6071-25) Backordered West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July ? August 2012 timeframe.
 Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand due to market supply issues.;1 mL vial- 10 mg/mL) 
 (NDC 0641-6070-25) Available in limited quantities West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July ? August 2012 timeframe.
 Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand due to market supply issues.;10mL vial- 10 mg/mL 
 (NDC 0641-6068-01) Available in limited quantities West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July ? August 2012 timeframe.
 Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand due to market supply issues.;20 mL vial- 15 mg/mL 
 (NDC 0641-6072-01) Available in limited quantities West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July ? August 2012 timeframe.
 Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand due to market supply issues.;1 mL vial- 5 mg/mL 
 (NDC 0641-6073-25) Available in limited quantities West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July ? August 2012 timeframe.
 Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand due to market supply issues.;1 mL vial- 8 mg/mL 
 (NDC 0641-6075-25) Available in limited quantities West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July ? August 2012 timeframe.
 Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand due to market supply issues.;1 mL vial- 15 mg/mL (NDC 0641-6071-25) Available in limited quantities West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the January ? February 2013 timeframe. Product will be made available as it is released;10mL vial- 10 mg/mL (NDC 0641-6068-01) Backordered   West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the January ? February 2013 timeframe. Product will be made available as it is released;20 mL vial- 15 mg/mL (NDC 0641-6072-01) Backordered   West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the January ? February 2013 timeframe. Product will be made available as it is released;1 mL vial- 8 mg/mL (NDC 0641-6075-25) Available in limited quantities West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the January ? February 2013 timeframe. Product will be made available as it is released;1 mL vial- 10 mg/mL) (NDC 0641-6070-25) Backordered   West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the January ? February 2013 timeframe. Product will be made available as it is released;1 mL vial- 5 mg/mL (NDC 0641-6073-25) Backordered   West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the January ? February 2013 timeframe. Product will be made available as it is released;1 mL vial- 15 mg/mL (NDC 0641-6071-25) Backordered   West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the February-March 2013 timeframe. Product will be made available as it is released;10mL vial- 10 mg/mL (NDC 0641-6068-01) Backordered   West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the February-March 2013 timeframe. Product will be made available as it is released;1 mL vial- 8 mg/mL (NDC 0641-6075-25) Backordered   West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the February-March 2013 timeframe. Product will be made available as it is released;1 mL vial- 5 mg/mL (NDC 0641-6073-25) Available in limited quantities  West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the February-March 2013 timeframe. Product will be made available as it is released;20 mL vial- 15 mg/mL (NDC 0641-6072-01) Backordered   West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the February-March 2013 timeframe. Product will be made available as it is released;1 mL vial- 10 mg/mL) (NDC 0641-6070-25) Backordered   West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the February-March 2013 timeframe. Product will be made available as it is released;20 mL vial- 15 mg/mL (NDC 0641-6072-01) Available in limited quantities  West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the February-March 2013 timeframe. Product will be made available as it is released;1 mL vial- 8 mg/mL (NDC 0641-6075-25) Available in limited quantities   West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the February-March 2013 timeframe. Product will be made available as it is released;10mL vial- 10 mg/mL (NDC 0641-6068-01) Available in limited quantities  West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the February-March 2013 timeframe. Product will be made available as it is released;1 mL vial- 15 mg/mL (NDC 0641-6071-25) Available in limited quantities  West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the February-March 2013 timeframe. Product will be made available as it is released;1 mL vial- 10 mg/mL) (NDC 0641-6070-25) Available in limited quantities  West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the February-March 2013 timeframe. Product will be made available as it is released;20 mL vial- 15 mg/mL (NDC 0641-6072-01) Available in limited quantities  West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July-August 2013 timeframe. Product will be made available as it is released;1 mL vial- 5 mg/mL (NDC 0641-6073-25) Available in limited quantities  West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July-August 2013 timeframe. Product will be made available as it is released;1 mL vial- 15 mg/mL (NDC 0641-6071-25) Available in limited quantities  West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July-August 2013 timeframe. Product will be made available as it is released;10mL vial- 10 mg/mL (NDC 0641-6068-01) Available in limited quantities  West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July-August 2013 timeframe. Product will be made available as it is released;1 mL vial- 10 mg/mL) (NDC 0641-6070-25) Available in limited quantities  West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July-August 2013 timeframe. Product will be made available as it is released;1 mL vial- 8 mg/mL (NDC 0641-6075-25) Available in limited quantities   West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in the July-August 2013 timeframe. Product will be made available as it is released;1 mL vial- 10 mg/mL) (NDC 0641-6070-25) Available West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;1 mL vial- 8 mg/mL (NDC 0641-6075-25) Available  West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;1 mL vial- 5 mg/mL (NDC 0641-6073-25) Available West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;1 mL vial- 15 mg/mL (NDC 0641-6071-25) Currently experiencing a backorder situation West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;20 mL vial- 15 mg/mL (NDC 0641-6072-01) Currently experiencing a backorder situation West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;10mL vial- 10 mg/mL (NDC 0641-6068-01) Available West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released",,,,,,,,,,,,,
Amphastar,morphines,2,10/1/13,11/8/13,available,,,1mg/mL- 30mL PCA Vial (NDC 0548-1911-25)   Available,,,,,,,,,,,,,
WestWard,morphines,2,10/1/13,11/8/13,demand increase,orange,,1 mL vial- 5 mg/mL (NDC 0641-6073-25) Available West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;1 mL vial- 10 mg/mL) (NDC 0641-6070-25) Available West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;1 mL vial- 8 mg/mL (NDC 0641-6075-25) Available  West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;1 mL vial- 15 mg/mL (NDC 0641-6071-25) Currently experiencing a backorder situation West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;10mL vial- 10 mg/mL (NDC 0641-6068-01) Available West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;20 mL vial- 15 mg/mL (NDC 0641-6072-01) Currently experiencing a backorder situation West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released,,,,,,,,,,,,,
Amphastar,morphines,1,3/1/12,9/1/13,demand increase; available,orange,,Amphastar has the following available: 1 mg/mL- 10 mL Luer-lock syringes (NDC 00548-3391-00);No current shortage Amphastar has the following available: 1 mg/mL- 10 mL Luer-lock syringes (NDC 00548-3391-00);;1mg/mL- 30mL PCA Vial (NDC 0548-1911-25) Available;1mg/mL- 30mL PCA Vial (NDC 0548-1911-25) Amphastar will regularly release products. Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues;1mg/mL- 30mL PCA Vial (NDC 0548-1911-25)   Amphastar will regularly release products.   Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues;1mg/mL- 30mL PCA Vial (NDC 0548-1911-25)   Available;1mg/mL- 30mL PCA Vial (NDC 0548-1911-25)   Amphastar will regularly release products. Shortage per Manufacturer: Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues.;1mg/mL- 30mL PCA Vial (NDC 0548-1911-25)   Amphastar will regularly release products. Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues.,,,,,,,,,,,,,
APP,morphines,1,3/16/12,3/16/12,manufacturing site change,blue,,APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012.,,,,,,,,,,,,,
Amphastar,morphinesulfate,1,9/14/13,9/14/13,available,,,1mg/mL- 30mL PCA Vial (NDC 0548-1911-25)   Available,,,,,,,,,,,,,
Roxane,morphinesulfate,1,6/6/09,10/6/09,available,,,Roxane- has product available. See information in Related Information section. Mallinckrodt- Increased demand due to another manufacturer leaving the market.                   Lannett-Increased demand due to another manufacturer leaving the market. Glenmark- Increased demand due to another manufacturer leaving the market.,,,,,,,,,,,,,
Glennmark,morphinesulfate,1,6/6/09,10/6/09,demand increase,orange,,Roxane- has product available. See information in Related Information section. Mallinckrodt- Increased demand due to another manufacturer leaving the market.                   Lannett-Increased demand due to another manufacturer leaving the market. Glenmark- Increased demand due to another manufacturer leaving the market.,,,,,,,,,,,,,
Lannett,morphinesulfate,1,6/6/09,10/6/09,demand increase,orange,,Roxane- has product available. See information in Related Information section. Mallinckrodt- Increased demand due to another manufacturer leaving the market.                   Lannett-Increased demand due to another manufacturer leaving the market. Glenmark- Increased demand due to another manufacturer leaving the market.,,,,,,,,,,,,,
Mallinckrodt,morphinesulfate,1,6/6/09,10/6/09,demand increase,orange,,Roxane- has product available. See information in Related Information section. Mallinckrodt- Increased demand due to another manufacturer leaving the market.                   Lannett-Increased demand due to another manufacturer leaving the market. Glenmark- Increased demand due to another manufacturer leaving the market.,,,,,,,,,,,,,
WestWard,morphinesulfate,1,4/18/12,3/25/14,demand increase,orange,,"West-Ward is currently experiencing a backorder situation on the Infumorph 25 mg/mL- 20 mL ampul and Duramorph 1 mg/mL- 10 mL ampul.  Limited quantities of the other Infumorph and Duramorph codes are available. West-Ward has accelerated production on all preservative-free morphine codes and will have the following products available. Lots of both Infumorph codes are scheduled for production and will be available for release by the middle of May 2012. Several lots of Duramorph are scheduled for manufacturing at the end of March.  Additional lots are projected to be manufactured and available in April 2012 Product will be made available as it is released.;Increase in product demand West-Ward is currently experiencing a backorder situation on the Infumorph 25 mg/mL- 20 mL ampul and Duramorph 1 mg/mL- 10 mL ampul.  Limited quantities of the other Infumorph and Duramorph codes are available. West-Ward has accelerated production on all preservative-free morphine codes and will have the following products available. Lots of both Infumorph codes are scheduled for production and will be available for release by the middle of May 2012. Several lots of Duramorph are scheduled for manufacturing at the end of March.  Additional lots are projected to be manufactured and available in April 2012 Product will be made available as it is released.;;Infumorph 20 mL ampul- 25 mg/mL (NDC 0641-6040-01) West-Ward currently has limited quantities available in all presentations. West-Ward has accelerated production on all Preservative-free Morphine codes and is projecting to have additional inventory available for release at the end of July 2012. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand;Duramorph 10 mL ampul- 1 mg/mL) (NDC  0641-6019-10) West-Ward currently has limited quantities available in all presentations. West-Ward has accelerated production on all Preservative-free Morphine codes and is projecting to have additional inventory available for release at the end of July 2012. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand;Infumorph 20 mL ampul- 10 mg/mL (NDC 0641-6039-01) West-Ward currently has limited quantities available in all presentations. West-Ward has accelerated production on all Preservative-free Morphine codes and is projecting to have additional inventory available for release at the end of July 2012. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand;Duramorph 10mL ampul- 0.5 mg/mL (NDC 0641-6020-10) West-Ward currently has limited quantities available in all presentations. West-Ward has accelerated production on all Preservative-free Morphine codes and is projecting to have additional inventory available for release at the end of July 2012. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand;Duramorph 10 mL ampul- 1 mg/mL) (NDC 0641-6019-10) West-Ward currently has limited quantities available in all presentations. West-Ward has accelerated production on all Preservative-free Morphine codes and is projecting to have additional inventory available for release at the end of July 2012. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand;Infumorph 
 20 mL ampul- 25 mg/mL 
 (NDC 0641-6040-01) West-Ward currently has limited quantities available in all presentations.
 West-Ward has accelerated production on all Preservative-free Morphine codes and is projecting to have additional inventory available for release at the end of July 2012. Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand;Duramorph 
 10mL ampul- 0.5 mg/mL 
 (NDC 0641-6020-10) West-Ward currently has limited quantities available in all presentations.
 West-Ward has accelerated production on all Preservative-free Morphine codes and is projecting to have additional inventory available for release at the end of July 2012. Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand;Infumorph 
 20 mL ampul- 10 mg/mL 
 (NDC 0641-6039-01) West-Ward currently has limited quantities available in all presentations.
 West-Ward has accelerated production on all Preservative-free Morphine codes and is projecting to have additional inventory available for release at the end of July 2012. Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand;Duramorph 
 10 mL ampul- 1 mg/mL) 
 (NDC 0641-6019-10) West-Ward currently has limited quantities available in all presentations.
 West-Ward has accelerated production on all Preservative-free Morphine codes and is projecting to have additional inventory available for release at the end of July 2012. Product will be made available as it is released.
 Shortage per Manufacturer: 
 Increase in product demand;Infumorph 20 mL ampul- 10 mg/mL (NDC 0641-6039-01) West-Ward is currently experiencing a backorder situation on all presentations. West-Ward has accelerated production on this product.   West-Ward is anticipating having product available by the end of February 2013. Product will be made available as it is released.;Duramorph 10mL ampul- 0.5 mg/mL (NDC 0641-6020-10) West-Ward is currently experiencing a backorder situation on all presentations. West-Ward has accelerated production on this product.   West-Ward is anticipating having product available by the end of February 2013. Product will be made available as it is released.;Duramorph 10 mL ampul- 1 mg/mL) (NDC 0641-6019-10) West-Ward is currently experiencing a backorder situation on all presentations. West-Ward has accelerated production on this product.   West-Ward is anticipating having product available by the end of February 2013. Product will be made available as it is released.;Infumorph 20 mL ampul- 25 mg/mL (NDC 0641-6040-01) West-Ward is currently experiencing a backorder situation on all presentations. West-Ward has accelerated production on this product.   West-Ward is anticipating having product available by the end of February 2013. Product will be made available as it is released.;Duramorph 10mL ampul- 0.5 mg/mL (NDC 0641-6020-10) West-Ward is currently experiencing a backorder situation on all presentations. West-Ward has accelerated production on this product.   West-Ward is anticipating having product available by the end of March 2013. Product will be made available as it is released.;Infumorph 20 mL ampul- 10 mg/mL (NDC 0641-6039-01) West-Ward is currently experiencing a backorder situation on all presentations. West-Ward has accelerated production on this product.   West-Ward is anticipating having product available by the end of March 2013. Product will be made available as it is released.;Infumorph 20 mL ampul- 25 mg/mL (NDC 0641-6040-01) West-Ward is currently experiencing a backorder situation on all presentations. West-Ward has accelerated production on this product.   West-Ward is anticipating having product available by the end of March 2013. Product will be made available as it is released.;Duramorph 10 mL ampul- 1 mg/mL) (NDC 0641-6019-10) West-Ward is currently experiencing a backorder situation on all presentations. West-Ward has accelerated production on this product.   West-Ward is anticipating having product available by the end of March 2013. Product will be made available as it is released.;Infumorph 20 mL ampul- 10 mg/mL (NDC 0641-6039-01) West-Ward is currently experiencing a small backorder situation on all presentations. West-Ward has accelerated production on this product.   West-Ward is anticipating having lots of each code available by the end of August 2013. Product will be made available as it is released.;Infumorph 20 mL ampul- 25 mg/mL (NDC 0641-6040-01) West-Ward is currently experiencing a small backorder situation on all presentations. West-Ward has accelerated production on this product.   West-Ward is anticipating having lots of each code available by the end of August 2013. Product will be made available as it is released.;Duramorph 10 mL ampul- 1 mg/mL) (NDC 0641-6019-10) West-Ward is currently experiencing a small backorder situation on all presentations. West-Ward has accelerated production on this product.   West-Ward is anticipating having lots of each code available by the end of August 2013. Product will be made available as it is released.;Duramorph 10mL ampul- 0.5 mg/mL (NDC 0641-6020-10) West-Ward is currently experiencing a small backorder situation on all presentations. West-Ward has accelerated production on this product.   West-Ward is anticipating having lots of each code available by the end of August 2013. Product will be made available as it is released.;Duramorph 10mL ampul- 0.5 mg/mL (NDC 0641-6020-10) West-Ward is currently experiencing backorder situation on both Duramorph presentations.  There are limited quantities of Infumorph available.    West-Ward has accelerated production on this product.   West-Ward is anticipating having lots of each product available by the middle of September 2013. Product will be made available as it is released.;Infumorph 20 mL ampul- 10 mg/mL (NDC 0641-6039-01) West-Ward is currently experiencing backorder situation on both Duramorph presentations.  There are limited quantities of Infumorph available.    West-Ward has accelerated production on this product.   West-Ward is anticipating having lots of each product available by the middle of September 2013. Product will be made available as it is released.;Duramorph 10 mL ampul- 1 mg/mL) (NDC 0641-6019-10) West-Ward is currently experiencing backorder situation on both Duramorph presentations.  There are limited quantities of Infumorph available.    West-Ward has accelerated production on this product.   West-Ward is anticipating having lots of each product available by the middle of September 2013. Product will be made available as it is released.;Infumorph 20 mL ampul- 25 mg/mL (NDC 0641-6040-01) West-Ward is currently experiencing backorder situation on both Duramorph presentations.  There are limited quantities of Infumorph available.    West-Ward has accelerated production on this product.   West-Ward is anticipating having lots of each product available by the middle of September 2013. Product will be made available as it is released.;1 mL vial- 10 mg/mL) (NDC 0641-6070-25) Available West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;1 mL vial- 5 mg/mL (NDC 0641-6073-25) Available West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;10mL vial- 10 mg/mL (NDC 0641-6068-01) Available West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;20 mL vial- 15 mg/mL (NDC 0641-6072-01) Currently experiencing a backorder situation West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;1 mL vial- 8 mg/mL (NDC 0641-6075-25) Available  West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;1 mL vial- 15 mg/mL (NDC 0641-6071-25) Currently experiencing a backorder situation West-Ward has accelerated production on all Morphine codes and is projecting to have additional inventory available for release in September 2013. Product will be made available as it is released;Infumorph 20 mL ampul- 25 mg/mL (NDC 0641-6040-01) Available West-Ward has accelerated production on this product.   West-Ward is anticipating having additional lots of each product code available in the January ? February 2014 timeframe. Product will be made available as it is released.;Duramorph 10mL ampul- 0.5 mg/mL (NDC 0641-6020-10) Available West-Ward has accelerated production on this product.  West-Ward is anticipating having additional lots of each product code available in the January ? February 2014 timeframe. Product will be made available as it is released.;Duramorph 10 mL ampul- 1 mg/mL) (NDC 0641-6019-10) Available West-Ward has accelerated production on this product.  West-Ward is anticipating having additional lots of each product code available in the January ? February 2014 timeframe. Product will be made available as it is released.;Infumorph 20 mL ampul- 10 mg/mL (NDC 0641-6039-01) Available West-Ward has accelerated production on this product.   West-Ward is anticipating having additional lots of each product code available in the January ? February 2014 timeframe. Product will be made available as it is released.",,,,,,,,,,,,,
Fresenius,morphinesulfate,1,12/28/13,3/25/14,manufacturing delays,blue,,Astramorph PF 0.5 mg/mL 10 mL vial- 5 count (NDC 63323-0291-10) Fresenius Kabi has PF Astramorph on back order Shortage per Manufacturer: Manufacturing delay;Astramorph PF 0.5 mg/mL 2 mL ampule- 10 count (NDC 63323-0291-80)   Fresenius Kabi has PF Astramorph on back order Shortage per Manufacturer: Manufacturing delay;Astramorph PF 1 mg/mL- 10 mL vial (NDC 63323-0292-10) Fresenius Kabi has PF Astramorph on back order Shortage per Manufacturer: Manufacturing delay;Astramorph PF 1 mg/mL 2 mL ampule- 10 count (NDC 63323-0292-80) Fresenius Kabi has PF Astramorph on back order Shortage per Manufacturer: Manufacturing delay,,,,,,,,,,,,,
APP,morphinesulfate,2,10/1/13,11/8/13,manufacturing delays; manufacturing site change,blue,,0.5 mg/mL 10 mL vial- 5 count (NDC 63323-0291-10) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release timing TBD. Shortage per Manufacturer: Manufacturing delay;1 mg/mL 2 mL ampule- 10 count (NDC 63323-0292-80) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release timing TBD. Shortage per Manufacturer: Manufacturing delay;1 mg/mL- 10 mL vial (NDC 63323-0292-10) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release timing TBD. Shortage per Manufacturer: Manufacturing delay;0.5 mg/mL 2 mL ampule- 10 count (NDC 63323-0291-80)   APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release timing TBD. Shortage per Manufacturer: Manufacturing delay,,,,,,,,,,,,,
APP,morphinesulfate,1,4/18/12,9/1/13,manufacturing site change; manufacturing delays,blue,,"Change in manufacturing sites APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012;APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012;;1 mg/mL- 10 mL vial (NDC 63323-0292-10)   APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: Change in manufacturing sites;1 mg/mL 2 mL ampule- 10 count (NDC 63323-0292-80)   APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: Change in manufacturing sites;0.5 mg/mL 2 mL ampule- 10 count (NDC 63323-0291-80)     APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: Change in manufacturing sites;0.5 mg/mL 10 mL vial- 5 count (NDC 63323-0291-10)   APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: Change in manufacturing sites;0.5 mg/mL 10 mL vial- 5 count (NDC 63323-0291-10) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: Change in manufacturing sites;1 mg/mL- 10 mL vial (NDC 63323-0292-10) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: Change in manufacturing sites;1 mg/mL 2 mL ampule- 10 count (NDC 63323-0292-80) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: Change in manufacturing sites;0.5 mg/mL 2 mL ampule- 10 count (NDC 63323-0291-80)   APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: Change in manufacturing sites;1 mg/mL 2 mL ampule- 10 count (NDC 63323-0292-80) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: 
 Change in manufacturing sites;0.5 mg/mL 2 mL ampule- 10 count (NDC 63323-0291-80) 
   APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: 
 Change in manufacturing sites;1 mg/mL- 10 mL vial (NDC 63323-0292-10) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: 
 Change in manufacturing sites;0.5 mg/mL 10 mL vial- 5 count (NDC 63323-0291-10) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: 
 Change in manufacturing sites;0.5 mg/mL 10 mL vial- 5 count (NDC 63323-0291-10) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: Manufacturing delay;1 mg/mL 2 mL ampule- 10 count (NDC 63323-0292-80) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: Manufacturing delay;1 mg/mL- 10 mL vial (NDC 63323-0292-10) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: Manufacturing delay;0.5 mg/mL 2 mL ampule- 10 count (NDC 63323-0291-80)   APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date in fourth quarter of 2012 Shortage per Manufacturer: Manufacturing delay;1 mg/mL 2 mL ampule- 10 count (NDC 63323-0292-80) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date of Q1 2013. Shortage per Manufacturer: Manufacturing delay;0.5 mg/mL 2 mL ampule- 10 count (NDC 63323-0291-80)   APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date of Q1 2013. Shortage per Manufacturer: Manufacturing delay;1 mg/mL- 10 mL vial (NDC 63323-0292-10) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date of Q1 2013. Shortage per Manufacturer: Manufacturing delay;0.5 mg/mL 10 mL vial- 5 count (NDC 63323-0291-10) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release date of Q1 2013. Shortage per Manufacturer: Manufacturing delay;0.5 mg/mL 10 mL vial- 5 count (NDC 63323-0291-10) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release timing TBD. Shortage per Manufacturer: Manufacturing delay;1 mg/mL 2 mL ampule- 10 count (NDC 63323-0292-80) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release timing TBD. Shortage per Manufacturer: Manufacturing delay;1 mg/mL- 10 mL vial (NDC 63323-0292-10) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release timing TBD. Shortage per Manufacturer: Manufacturing delay;0.5 mg/mL 2 mL ampule- 10 count (NDC 63323-0291-80)   APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release timing TBD. Shortage per Manufacturer: Manufacturing delay",,,,,,,,,,,,,
Amphastar,morphinesulfate,2,3/25/14,3/25/14,,,,Morphine sulfate inj. USP 1mg/mL- 30 mL PCA Vial- NDC 0548-1911-25- new NDC 767329-1911-1 Available;NULL NULL NULL,,,,,,,,,,,,,
BD,morphinesulfate,1,12/28/13,3/25/14,,,,10 mg/mL single-use Pre-filled syringe (Preservative-Free) (NDC 76045-008-10)  Estimate availability Early 2014   Scaling up for launch;8 mg/mL single-use Pre-filled syringe (Preservative-Free) (NDC 76045-007-10)  Estimate availability Early 2014 Scaling up for launch;5 mg/mL single-use Pre-filled syringe (Preservative-Free) (NDC 76045-006-10)  Estimate availability Early 2014   Scaling up for launch;2 mg/mL single-use Pre-filled syringe (Preservative-Free) (NDC 76045-004-10)  Estimate availability Early 2014   Scaling up for launch;4 mg/mL single-use Pre-filled syringe (Preservative-Free) (NDC 76045-005-10)  Estimate availability Early 2014    Scaling up for launch,,,,,,,,,,,,,
Lundbeck,mustargen,1,12/20/09,1/17/10,manufacturing delays,blue,,Manufacturing Delays,,,,,,,,,,,,,
Lundbeck,mustargen,2,3/16/10,4/22/11,,,,See Related Information.;See Related Information,,,,,,,,,,,,,
WestWard,mvi,1,9/14/13,9/14/13,demand increase,orange,,Duramorph 10 mL ampul- 1 mg/mL) (NDC 0641-6019-10) West-Ward is currently experiencing backorder situation on both Duramorph presentations.  There are limited quantities of Infumorph available.    West-Ward has accelerated production on this product.   West-Ward is anticipating having lots of each product available by the middle of September 2013. Product will be made available as it is released.;Duramorph 10mL ampul- 0.5 mg/mL (NDC 0641-6020-10) West-Ward is currently experiencing backorder situation on both Duramorph presentations.  There are limited quantities of Infumorph available.    West-Ward has accelerated production on this product.   West-Ward is anticipating having lots of each product available by the middle of September 2013. Product will be made available as it is released.;Infumorph 20 mL ampul- 10 mg/mL (NDC 0641-6039-01) West-Ward is currently experiencing backorder situation on both Duramorph presentations.  There are limited quantities of Infumorph available.    West-Ward has accelerated production on this product.   West-Ward is anticipating having lots of each product available by the middle of September 2013. Product will be made available as it is released.;Infumorph 20 mL ampul- 25 mg/mL (NDC 0641-6040-01) West-Ward is currently experiencing backorder situation on both Duramorph presentations.  There are limited quantities of Infumorph available.    West-Ward has accelerated production on this product.   West-Ward is anticipating having lots of each product available by the middle of September 2013. Product will be made available as it is released.,,,,,,,,,,,,,
Baxter,mvi,1,3/26/10,4/22/11,demand increase; manufacturing delays,blue,,Manufacturing delays                                       Increase in demand;Manufacturing delays                                                     Increase in demand;Manufacturing delays relative to all adult formulations; Hospira is working to restore adequate supply, no timing is available.     Increase in demand;Manufacturing delays relative to all adult formulations; Hospira is working to restore adequate supply, however, no timing is available.   Manufacturing delays;Manufacturing delays relative to all adult formulations; Hospira is working to restore adequate supply, however, no timing is available.   Manufacturing delays;Manufacturing delays relative to all adult formulations; Hospira is working to restore adequate supply, however, no timing is available.   Manufacturing delays,,,,,,
Hospira,mvi,1,3/26/10,4/22/11,demand increase; manufacturing delays,blue,,Manufacturing delays                                       Increase in demand;Manufacturing delays                                                     Increase in demand;Manufacturing delays relative to all adult formulations; Hospira is working to restore adequate supply, no timing is available.     Increase in demand;Manufacturing delays relative to all adult formulations; Hospira is working to restore adequate supply, however, no timing is available.   Manufacturing delays;Manufacturing delays relative to all adult formulations; Hospira is working to restore adequate supply, however, no timing is available.   Manufacturing delays;Manufacturing delays relative to all adult formulations; Hospira is working to restore adequate supply, however, no timing is available.   Manufacturing delays,,,,,,
Baxter,mvi,1,4/28/11,9/1/13,manufacturing delays; demand increase; manufacturing practices requirements,blue,,"Infuvite is now available for Baxter.;Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.
 
 For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;Manufacturing delays Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;;INFUVITE Adult- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5649-2) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition   Shortage per Manufacturer: Manufacturing delays;INFUVITE Adult- Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition   Shortage per Manufacturer: Manufacturing delays;INFUVITE Pediatric- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition   Shortage per Manufacturer: Manufacturing delays;INFUVITE Pediatric- Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition   Shortage per Manufacturer: Manufacturing delays;INFUVITE Adult- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5649-2) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.   Allocated availability through Sept. 2013. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition   Shortage per Manufacturer: Manufacturing delays;INFUVITE Adult- Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.   Allocated availability through Sept. 2013. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition   Shortage per Manufacturer: Manufacturing delays;INFUVITE Pediatric- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.   Allocated availability through Sept. 2013. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition   Shortage per Manufacturer: Manufacturing delays;INFUVITE Pediatric- Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.   Allocated availability through Sept. 2013. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition   Shortage per Manufacturer: Manufacturing delays;INFUVITE Adult- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5649-2) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.
  
 Allocated availability through Sept. 2013. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition  
 Shortage per Manufacturer: 
 Manufacturing delays;INFUVITE Adult- Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.
  
 Allocated availability through Sept. 2013. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition  
 Shortage per Manufacturer: 
 Manufacturing delays;INFUVITE Pediatric- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.
  
 Allocated availability through Sept. 2013. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition  
 Shortage per Manufacturer: 
 Manufacturing delays;INFUVITE Pediatric- Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.
  
 Allocated availability through Sept. 2013. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition  
 Shortage per Manufacturer: 
 Manufacturing delays;INFUVITE Adult- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5649-2) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.   Allocated availability through Sept. 2013. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Adult- Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.   Allocated availability through Sept. 2013. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Pediatric- Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.   Allocated availability through Sept. 2013. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Pediatric- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0) Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.   Allocated availability through Sept. 2013. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Adult- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5649-2) Next delivery is for late July. Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Adult- Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1) Next delivery is for late July. Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Pediatric- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0) Next delivery is for late July. Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Pediatric- Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1) Next delivery is for late July. Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Adult- Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1) Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Pediatric- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0) Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Adult- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5649-2) Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Pediatric- Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1) Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition",,,,,,,,,,,,,
APP,mvi,1,9/14/13,9/14/13,manufacturing delays; manufacturing site change,blue,,0.5 mg/mL 10 mL vial- 5 count (NDC 63323-0291-10) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release timing TBD. Shortage per Manufacturer: Manufacturing delay;1 mg/mL 2 mL ampule- 10 count (NDC 63323-0292-80) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release timing TBD. Shortage per Manufacturer: Manufacturing delay;0.5 mg/mL 2 mL ampule- 10 count (NDC 63323-0291-80)   APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release timing TBD. Shortage per Manufacturer: Manufacturing delay;1 mg/mL- 10 mL vial (NDC 63323-0292-10) APP has preservative-free Astramorph 0.5 mg/mL 2 mL ampules- 1 mg/mL 2 mL ampules and 10 mL ampules- and 0.5 mg/mL 10 mL vials on back order with an estimated release timing TBD. Shortage per Manufacturer: Manufacturing delay,,,,,,,,,,,,,
Baxter,mvi,2,10/1/13,3/25/14,manufacturing practices requirements,yellow,,INFUVITE Adult- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5649-2) Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Pediatric- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0) Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Pediatric- Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1) Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Adult- Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1) Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Pediatric- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0) Baxter has this product on allocation. Baxter is the distributor of INFUVITE Multiple Vitamins for Injection. Baxter has these products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.     For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Adult- Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1) Baxter has this product on allocation. Baxter is the distributor of INFUVITE Multiple Vitamins for Injection. Baxter has these products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.     For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Pediatric- Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1) Pediatric Single Dose is not available. Baxter is the distributor of INFUVITE Multiple Vitamins for Injection. Baxter has these products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.     For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Adult- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5649-2) Baxter has this product on allocation. Baxter is the distributor of INFUVITE Multiple Vitamins for Injection. Baxter has these products on allocation and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins.     For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition,,,,,,,,,,,,,
Hospira,nalbuphine,1,10/9/10,4/22/11,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
Baxter,nalbuphine,1,9/14/13,9/14/13,manufacturing practices requirements,yellow,,INFUVITE Adult- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5649-2) Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Adult- Multiple Vitamins for Injection. Single dose package. (NDC 54643-5649-1) Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Pediatric- Multiple Vitamins for Injection. Bulk package. (NDC 54643-5647-0) Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition;INFUVITE Pediatric- Multiple Vitamins for Injection. Single Dose package. (NDC 54643-5646-1) Allocated availability through Sept 2013.   Baxter is the distributor of INFUVITE Multi Vitamins. Baxter has these multi-vitamin products on allocation backorder and is working with the manufacturer to maximize the availability of INFUVITE Multi Vitamins. For detailed clinical recommendations to use during this shortage- please see information posted by the American Society of Parenteral and Enteral Nutrition,,,,,,,,,,,,,
Amphastar,naloxone,2,8/1/13,8/1/13,available,,,1mg/mL- 2mL Prefilled Syringe without needles (NDC 76329-3369-1) Available;1mg/mL- 2mL Prefilled Syringe with needles (NDC 76329-1469-5) Available,,,,,,,,,,,,,
Amphastar,naloxone,1,4/18/12,7/7/13,demand increase; available,orange,,Please check with your wholesaler for available inventory.;Amphastar is not experiencing a shortage. This shortage is due to increased demand. Please check with your wholesaler for available inventory.;;1mg/mL- 2mL Prefilled Syringe with needles (NDC 76329-1469-5) Available;1mg/mL- 2mL Prefilled Syringe without needles (NDC 76329-3369-1) Available,,,,,,,,,,,,,
Amphastar,naloxone,1,6/25/10,12/25/10,manufacturing delays,blue,,See related information section                         Manufacturing delays;See related information section                       Manufacturing delays;See related information section               Manufacturing delays,,,,,,,,,,,,,
Hospira,naloxone,1,6/25/10,12/25/10,manufacturing delays,blue,,See related information section                         Manufacturing delays;See related information section                       Manufacturing delays;See related information section               Manufacturing delays,,,,,,,,,,,,,
Teva,naltrexone,2,3/1/13,3/1/13,available,,,Naltrexone HCl Tablets- 50 mg 30 count (NDC 00555-0902-01) Both presentations have inventory available.;Naltrexone HCl Tablets- 50 mg- 100 count (NDC 00555-0902-02) Both presentations have inventory available.,,,,,,,,,,,,,
Sandoz,naltrexone,1,3/16/12,5/15/12,discontinued,black,,Product is discontinued at this time.;Supply issue Product is discontinued at this time.;,,,,,,,,,,,,,
Teva,naltrexone,1,4/18/12,1/10/13,manufacturing delays; demand increase; available,blue,,Both presentations have inventory available;Manufacturing Capacity Both presentations have inventory available;;Naltrexone HCl Tablets- 50 mg- 100 count (NDC 00555-0902-02) Both presentations have inventory available. Shortage per Manufacturer: Manufacturing Capacity;Naltrexone HCl Tablets- 50 mg 30 count (NDC 00555-0902-01) Both presentations have inventory available. Shortage per Manufacturer: Manufacturing Capacity;Naltrexone HCl Tablets- 50 mg- 100 count (NDC 00555-0902-02) Both presentations have inventory available.;Naltrexone HCl Tablets- 50 mg 30 count (NDC 00555-0902-01) Both presentations have inventory available.,,,,,,,,,,,,,
Covidien,naltrexone,1,2/9/12,2/23/12,material issues,green,,Covidien has all presentations on back order with an estimated release date of February- 2012.,,,,,,,,,,,,,
Teva,nefazodone,1,4/18/12,1/10/13,material availability; material shortage; available,green,,"Teva Nefazodone 50 mg- 100 mg- and 150 mg tablets are on back order. The company estimates a release date in mid-to-late May- 2012.;Availability of API Teva Nefazodone 50 mg- 100 mg- and 150 mg tablets are on back order. The company estimates a release date in mid-to-late May- 2012.;;50 mg- 100 count (NDC 00093-7178-01) Available. Inventory will remain low until 4Q12.    As of July 18- low inventory levels- however- no backorder or future projections of backorder. Improved inventory position expected by Q412.   Shortage per Manufacturer: Availability of API;150 mg- 60 count (NDC 00093-7113-06) Available. Inventory will remain low until 4Q12.  As of July 18- low inventory levels- however- no backorder or future projections of backorder. Improved inventory position expected by Q412.   Shortage per Manufacturer: Availability of API;100 mg- 60 count (NDC 00093-1024-06) Available.  Teva supply adequate to meet demand.  As of July 18- low inventory levels- however- no backorder or future projections of backorder. Improved inventory position expected by Q412.   Shortage per Manufacturer: Availability of API;150 mg- 60 count (NDC 00093-7113-06) Available. Inventory will remain low until 4Q12. No backorder or future projections of backorder. Improved inventory position expected by Q412.;50 mg- 100 count (NDC 00093-7178-01) Available. Inventory will remain low until 4Q12. 
   No backorder or future projections of backorder. Improved inventory position expected by Q412.;100 mg- 60 count (NDC 00093-1024-06) Available.  Teva supply adequate to meet demand. No backorder or future projections of backorder. Improved inventory position expected by Q412.;50 mg- 100 count (NDC 00093-7178-01) Available. Inventory will remain low until 4Q12.   No backorder or future projections of backorder. Improved inventory position expected by Q412.;150 mg- 60 count (NDC 00093-7113-06) Available.  Teva supply adequate to meet demand. No backorder or future projections of backorder. Improved inventory position expected by Q412.;50 mg- 100 count (NDC 00093-7178-01) Available.  Teva supply adequate to meet demand.  No backorder or future projections of backorder. Improved inventory position expected by Q412.",,,,,,,,,,,,,
Teva,nefazodone,2,3/1/13,3/1/13,material shortage,green,,150 mg- 60 count (NDC 00093-7113-06) Available.  Teva supply adequate to meet demand. No backorder or future projections of backorder. Improved inventory position expected by Q412.;100 mg- 60 count (NDC 00093-1024-06) Available.  Teva supply adequate to meet demand. No backorder or future projections of backorder. Improved inventory position expected by Q412.;50 mg- 100 count (NDC 00093-7178-01) Available.  Teva supply adequate to meet demand.  No backorder or future projections of backorder. Improved inventory position expected by Q412.,,,,,,,,,,,,,
Lundbeck,neoprofen,1,7/30/10,4/22/11,Quality issues,yellow,,Failure to meet a visible particulate quality specification.,,,,,,,,,,,,,
Eclat,neostigmine,1,8/19/13,9/1/13,available,,,Bloxiverz (neostigmine methylsulfate injection- USP)- 0.5 mg/mL- (NDC 76014-002-33) Available Please contact wholesaler to order inventory   Bloxiverz is the first & only FDA-Approved neostigmine methylsulfate injection product available;Bloxiverz (neostigmine methylsulfate injection- USP)- 1 mg/mL- (NDC  76014-003-33)  Available Please contact wholesaler to order inventory   Bloxiverz is the first & only FDA-Approved neostigmine methylsulfate injection product available,,,,,,,,,,,,,
Eclat,neostigmine,2,10/1/13,3/25/14,available,,,Bloxiverz (neostigmine methylsulfate injection- USP)- 0.5 mg/mL- (NDC 76014-002-33) Available Please contact wholesaler to order inventory   Bloxiverz is the first & only FDA-Approved neostigmine methylsulfate injection product available;Bloxiverz (neostigmine methylsulfate injection- USP)- 1 mg/mL- (NDC  76014-003-33)  Available Please contact wholesaler to order inventory   Bloxiverz is the first & only FDA-Approved neostigmine methylsulfate injection product available;Bloxiverz (neostigmine methylsulfate injection- USP)- 1 mg/mL- (NDC  76014-003-33) and (NDC 76014-003-10) Available Please contact wholesaler to order inventory   Bloxiverz is the first & only FDA-Approved neostigmine methylsulfate injection product available;Bloxiverz (neostigmine methylsulfate injection- USP)- 0.5 mg/mL- (NDC 76014-002-33) and (NDC 76014-002-10) Available Please contact wholesaler to order inventory   Bloxiverz is the first & only FDA-Approved neostigmine methylsulfate injection product available,,,,,,,,,,,,,
AmericanRegent,neostigmine,2,1/16/13,1/16/13,available; not releasing,,,1 mg/mL- 10 mL vial- package of 25 (NDC 00517-0033-25)  Available American Regent is currently releasing Neostigmine Methylsulfate Injection 1 mg/mL;0.5 mg/mL- 10 mL vial- package of 25 (NDC 00517-0034-25) Unavailable American Regent is currently not releasing Neostigmine Methylsulfate Injection 0.5 mg/mL,,,,,,,,,,,,,
AmericanRegent,neostigmine,1,4/28/11,2/6/12,demand increase,orange,,Additional information regarding supplies of 0.5 mg/mL 10 mL vials (NDC 00517-0034-25)- 1 mg/mL 10 mL vials (NDC 00517-0033-25) will be posted as soon as it's available.,,,,,,,,,,,,,
AmericanRegent(Luitpold),neostigmine,1,3/11/11,4/22/11,demand increase,orange,,Increased demand Increased demand Increased demand  ;Increased demand Increased demand Increased demand;Increased demand Increased demand Increased demand,,,,,,,,,,,,,
APP,neostigmine,1,4/14/11,4/14/11,demand increase,orange,,Increased demand Increased demand Increased demand,,,,,,,,,,,,,
APP,neostigmine,1,4/28/11,2/6/12,demand increase,orange,,APP is currently allocating Neostigmine 1 mg/mL 10 mL vials due to increased demand. The 0.5 mg/mL 10 mL vials are on back order and the company estimates a release date early-May- 2011.;APP has all Neostigmine Injection 0.5mg/mL and 1mg/mL presentations on allocation due to increased demand.;APP has all Neostigmine Injection 0.5 mg/mL & 1 mg/mL presentations available.,,,,,,,,,,,,,
APP,neostigmine,2,1/16/13,1/16/13,demand increase,orange,,0.5 mg/mL-  5 mg/10 mL MDV (NDC # 63323-382-10) Available. Check wholesaler.;1 mg/mL- 10 mg/10 mL MDV (NDC # 63323-383-10)   Back-ordered. Check wholesaler inventory.       Next release anticipated early March 2013,,,,,,,,,,,,,
APP,neostigmine,3,3/6/13,9/1/13,demand increase,orange,,1 mg/mL- 10 mg/10 mL MDV (NDC # 63323-383-10)   Back-ordered. Check wholesaler inventory.       Next release anticipated early March 2013;0.5 mg/mL-  5 mg/10 mL MDV (NDC # 63323-382-10) Backordered. Next release anticipated April 2013;1 mg/mL- 10 mg/10 mL MDV (NDC # 63323-383-10)   Back-ordered. Check wholesaler inventory.       Next release anticipated March 2013;1 mg/mL- 10 mg/10 mL MDV (NDC # 63323-383-10)   Back-ordered. Check wholesaler inventory.       Next release anticipated May 2013;0.5 mg/mL-  5 mg/10 mL MDV (NDC # 63323-382-10) Backordered. Next release anticipated May 2013. Check wholesaler for inventory.;0.5 mg/mL-  5 mg/10 mL MDV (NDC # 63323-382-10) Backordered. Next release anticipated late May 2013. Check wholesaler for inventory.;1 mg/mL- 10 mg/10 mL MDV (NDC # 63323-383-10)   Available. Check wholesaler for inventory.;0.5 mg/mL-  5 mg/10 mL MDV (NDC # 63323-382-10) Backordered. Next release anticipated June 2013. Check wholesaler for inventory.;0.5 mg/mL-  5 mg/10 mL MDV (NDC # 63323-382-10) Available. Check wholesaler for inventory.,,,,,,,,,,,,,
APP,neostigmine,4,10/1/13,11/8/13,demand increase,orange,,0.5 mg/mL-  5 mg/10 mL MDV (NDC # 63323-382-10) Available. Check wholesaler for inventory.;1 mg/mL- 10 mg/10 mL MDV (NDC # 63323-383-10)   Available. Check wholesaler for inventory.,,,,,,,,,,,,,
Baxter,neostigmine,1,3/11/11,4/22/11,demand increase,orange,,Increased demand Increased demand Increased demand  ;Increased demand Increased demand Increased demand;Increased demand Increased demand Increased demand,,,,,,,,,,,,,
Baxter,neostigmine,1,4/28/11,12/16/11,demand increase,orange,,Both strengths are on backorder with anticipation to have additional supply available in the March-April timeframe.;Baxter has available neostigmine 1 mg/mL- 10 mL vials (NDC 10019-0270-10). The 0.5 mg/mL 10 mL vials are on back order and there is not yet a reported release date.,,,,,,,,,,,,,
Fresenius,neostigmine,1,12/28/13,3/25/14,demand increase,orange,,0.5 mg/mL-  5 mg/10 mL MDV (NDC # 63323-382-10) Available. Check wholesaler for inventory.;1 mg/mL- 10 mg/10 mL MDV (NDC # 63323-383-10)   Backordered. Next release anticipated February 2014.;1 mg/mL- 10 mg/10 mL MDV (NDC # 63323-383-10)   Backordered. Check wholesaler for inventory. Next release anticipated April 2014,,,,,,,,,,,,,
WestWard,neostigmine,1,12/22/11,2/6/12,demand increase,orange,,West-Ward has available neostigmine 1 mg/mL- 10 mL vials (NDC 10019-0270-10). The 0.5 mg/mL 10 mL vials are on back order and there is not yet a reported release date.,,,,,,,,,,,,,
WestWard,neostigmine,2,1/16/13,1/16/13,demand increase,orange,,Neostigmine Methylsulfate Injection- USP 0.5 mg/mL- 10 mL vial (NDC 0641-6076-10) 1  mg/mL- 10 mL vial (NDC 0641-6077-10) West-Ward is currently experiencing a backorder situation on both presentations.  West-Ward has accelerated production on this product.  West-Ward is anticipating having product available by the end of January 2013. Additional lots are scheduled and expected to be available by the end of February 2013  Product will be made available as it is released.,,,,,,,,,,,,,
WestWard,neostigmine,3,3/6/13,9/1/13,demand increase,orange,,Neostigmine Methylsulfate Injection- USP 0.5 mg/mL- 10 mL vial (NDC 0641-6076-10) 1  mg/mL- 10 mL vial (NDC 0641-6077-10) West-Ward currently has limited quantities available of both presentations West-Ward has accelerated production on this product.  West-Ward is anticipating having product available by the end of February 2013. Product will be made available as it is released.;0.5 mg/mL- 10 mL vial (NDC 0641-6076-10)   1  mg/mL- 10 mL vial (NDC 0641-6077-10) West-Ward currently has limited quantities available of both presentations West-Ward has accelerated production on this product.  West-Ward is anticipating having product available by the end of July 2013. Product will be made available as it is released.;0.5 mg/mL- 10 mL vial (NDC 0641-6076-10)   1  mg/mL- 10 mL vial (NDC 0641-6077-10) West-Ward currently has quantities available for both presentations West-Ward has accelerated production on this product.  West-Ward is anticipating having additional product available by the end of September 2013. Product will be made available as it is released.,,,,,,,,,,,,,
WestWard,neostigmine,4,10/1/13,3/25/14,demand increase,orange,,0.5 mg/mL- 10 mL vial (NDC 0641-6076-10)   1  mg/mL- 10 mL vial (NDC 0641-6077-10) West-Ward currently has quantities available for both presentations West-Ward has accelerated production on this product.  West-Ward is anticipating having additional product available by the end of September 2013. Product will be made available as it is released.;0.5 mg/mL- 10 mL vial (NDC 0641-6076-10)   1  mg/mL- 10 mL vial (NDC 0641-6077-10) West-Ward is currently experiencing a backorder situation for both presentations.  West-Ward has accelerated production on this product.    West-Ward is manufacturing additional lots and anticipates having product available in the February - March 2014 timeframe. Product will be made available as it is released.,,,,,,,,,,,,,
AmericanRegent,neostigmine,3,3/6/13,9/1/13,not releasing; available,,,0.5 mg/mL- 10 mL vial- package of 25 (NDC 00517-0034-25) Unavailable American Regent is currently not releasing Neostigmine Methylsulfate Injection 0.5 mg/mL;1 mg/mL- 10 mL vial- package of 25 (NDC 00517-0033-25)  Available American Regent is currently releasing Neostigmine Methylsulfate Injection 1 mg/mL,,,,,,,,,,,,,
AmericanRegent,neostigmine,4,10/1/13,3/25/14,not releasing; available,,,0.5 mg/mL- 10 mL vial- package of 25 (NDC 00517-0034-25) Unavailable American Regent is currently not releasing Neostigmine Methylsulfate Injection 0.5 mg/mL;1 mg/mL- 10 mL vial- package of 25 (NDC 00517-0033-25)  Available American Regent is currently releasing Neostigmine Methylsulfate Injection 1 mg/mL;1 mg/mL- 10 mL vial- package of 25 (NDC 00517-0033-25)  Unavailable American Regent is currently not releasing Neostigmine Methylsulfate Injection 0.5 mg/mL or 1 mg/mL;0.5 mg/mL- 10 mL vial- package of 25 (NDC 00517-0034-25) Unavailable American Regent is currently not releasing Neostigmine Methylsulfate Injection 0.5 mg/mL or 1 mg/mL,,,,,,,,,,,,,
UCB,neupro,1,4/28/11,7/12/12,product recall; fda request,yellow,,"FDA has requested that UCB reformulate Neupro (rotigotine transdermal system) patches. UCB is committed to bringing Neupro to U.S. patients and has already made significant progress in the development of the new formulation. If you have additional questions about the status of Neupro- or about UCB?s Patient Access program for Neupro- please contact UCB Medical Information at 1-866-822-0068 (option 9).;FDA has requested that UCB reformulate Neupro (rotigotine transdermal system) patches. UCB is committed to bringing Neupro to U.S. patients and has already made significant progress in the development of the new formulation. 
 
 If you have additional questions about the status of Neupro- or about UCB?s Patient Access program for Neupro- please contact UCB Medical Information at 1-866-822-0068 (option 9).;UCB has recalled all domestic lots FDA has requested that UCB reformulate Neupro (rotigotine transdermal system) patches. UCB is committed to bringing Neupro to U.S. patients and has already made significant progress in the development of the new formulation. If you have additional questions about the status of Neupro- or about UCB?s Patient Access program for Neupro- please contact UCB Medical Information at 1-866-822-0068 (option 9).;",,,,,,,,,,,,,
UCB,neupro,1,6/6/09,4/22/11,product recall,yellow,,UCB has recalled all domestic lots,,,,,,,,,,,,,
Warner,neurolite,1,7/12/12,7/12/12,,,,,,,,,,,,,,,,,
Abbott,nimbex,1,4/30/10,7/3/10,demand increase,orange,,Unexpected Increased Demand and Manufacturing Delays,,,,,,,,,,,,,
Eclat,nitroglycerin,1,9/14/13,9/14/13,available,,,Bloxiverz (neostigmine methylsulfate injection- USP)- 0.5 mg/mL- (NDC 76014-002-33) Available Please contact wholesaler to order inventory   Bloxiverz is the first & only FDA-Approved neostigmine methylsulfate injection product available;Bloxiverz (neostigmine methylsulfate injection- USP)- 1 mg/mL- (NDC  76014-003-33)  Available Please contact wholesaler to order inventory   Bloxiverz is the first & only FDA-Approved neostigmine methylsulfate injection product available,,,,,,,,,,,,,
AmericanRegent,nitroglycerin,1,9/14/13,9/14/13,available; not releasing,,,1 mg/mL- 10 mL vial- package of 25 (NDC 00517-0033-25)  Available American Regent is currently releasing Neostigmine Methylsulfate Injection 1 mg/mL;0.5 mg/mL- 10 mL vial- package of 25 (NDC 00517-0034-25) Unavailable American Regent is currently not releasing Neostigmine Methylsulfate Injection 0.5 mg/mL,,,,,,,,,,,,,
Savage,nitroglycerin,2,10/1/13,11/8/13,component delay; demand increase,green,,Nitro-Bid (Nitroglycerin Ointment USP- 2%); 1 g foilpac (NDC 0281-0326-08) Backorder; next release in late August; company cannot estimate recovery date at this time. Shortage per manufacturer:  Manufacturing delays;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 30 g tube (NDC 0281-0326-30) Product now available;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 60 g tube (NDC 0281-0326-60) Product now available;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 1 g foilpac (NDC 0281-0326-08) Backorder; early October Estimated recovery 4Q 2013 Shortage per manufacturer:  Manufacturing delays,,,,,,,,,,,,,
APP,nitroglycerin,1,9/14/13,9/14/13,demand increase,orange,,0.5 mg/mL-  5 mg/10 mL MDV (NDC # 63323-382-10) Available. Check wholesaler for inventory.;1 mg/mL- 10 mg/10 mL MDV (NDC # 63323-383-10)   Available. Check wholesaler for inventory.,,,,,,,,,,,,,
Baxter,nitroglycerin,2,12/28/13,3/25/14,demand increase,orange,,100 mg Nitroglycerin in 5% Dextrose Injection; code 1A0696 (0338-1051-02) Baxter has this product on allocation through March 2014.;50 mg Nitroglycerin in 5% Dextrose Injection; code 1A0694 (0338-1049-02) Baxter has this product on allocation through March 2014.;25 mg Nitroglycerin in 5% Dextrose Injection; code 1A0692 (0338-1047-02) Baxter has this product on allocation through March 2014.,,,,,,,,,,,,,
WestWard,nitroglycerin,1,9/14/13,9/14/13,demand increase,orange,,0.5 mg/mL- 10 mL vial (NDC 0641-6076-10)   1  mg/mL- 10 mL vial (NDC 0641-6077-10) West-Ward currently has quantities available for both presentations West-Ward has accelerated production on this product.  West-Ward is anticipating having additional product available by the end of September 2013. Product will be made available as it is released.,,,,,,,,,,,,,
Savage,nitroglycerin,1,11/2/12,9/1/13,demand increase; component delay; manufacturing delays; available; ,green,,Nitro-Bid (Nitroglycerin Ointment USP- 2%); 30 g tube (NDC 0281-0326-30) Backorder; estimated release date November 2012 Backorder situation due to demand increase of 1 g foil package;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 1 g foilpac (NDC 0281-0326-08) Backorder; estimated release date December 2012 Shortage per manufacturer; delay in receiving acceptable printed foil;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 60 g tube (NDC 0281-0326-60) Available;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 1 g foilpac (NDC 0281-0326-08) Backorder; estimated recovery 1Q 2013 Shortage per manufacturer; Manufacturing delays;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 30 g tube (NDC 0281-0326-30) Backorder; estimated recovery 1Q 2013 Shortage per manufacturer; Manufacturing delays;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 60 g tube (NDC 0281-0326-60) Backorder; estimated recovery 1Q 2013 Shortage per manufacturer; Manufacturing delays;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 60 g tube (NDC 0281-0326-60) Backorder; next release mid to late March; estimated recovery 1Q 2013 Shortage per manufacturer; Manufacturing delays;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 1 g foilpac (NDC 0281-0326-08) Available;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 30 g tube (NDC 0281-0326-30) Backorder; next release mid to late March; estimated recovery 1Q 2013 Shortage per manufacturer; Manufacturing delays;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 1 g foilpac (NDC 0281-0326-08) Product now available; next release  late April- additional releases early June;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 60 g tube (NDC 0281-0326-60) Backorder; next release mid May;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 30 g tube (NDC 0281-0326-30) Product now available; next release early June;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 60 g tube (NDC 0281-0326-60) Product now available;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 1 g foilpac (NDC 0281-0326-08) Backorder Shortage per manufacturer:  Manufacturing delays;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 30 g tube (NDC 0281-0326-30) Product now available;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 1 g foilpac (NDC 0281-0326-08) Backorder; next release in late July; company cannot estimate recovery date at this time. Shortage per manufacturer:  Manufacturing delays;Nitro-Bid (Nitroglycerin Ointment USP- 2%); 1 g foilpac (NDC 0281-0326-08) Backorder; next release in late August; company cannot estimate recovery date at this time. Shortage per manufacturer:  Manufacturing delays,,,,,,,,,,,,,
Baxter,nitroglycerin,1,2/17/11,4/22/11,manufacturing delays,blue,,Manufacturing delays   Manufacturing delays  ;Manufacturing delays   Manufacturing delays;Manufacturing delays   Manufacturing delays,,,,,,,,,,,,,
Baxter,nitroglycerin,1,4/28/11,6/12/11,manufacturing delays,blue,,Baxter has premix nitroglycerin 10 mg/100 mL in dextrose 250 mL (NDC 00338-1047-02) and 20 mg/100 mL in dextrose 250 mL (NDC 00338-1049-02) available. The 40 mg/100 mL presentation is anticipated to be released by end of March- 2011.,,,,,,,,,,,,,
Hospira,nitroglycerin,1,2/17/11,4/22/11,manufacturing delays,blue,,Manufacturing delays   Manufacturing delays  ;Manufacturing delays   Manufacturing delays;Manufacturing delays   Manufacturing delays,,,,,,,,,,,,,
Luitpold,nitroglycerins,1,2/17/11,3/14/11,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
Pfizer,nitrostat,1,6/6/09,1/17/10,demand increase,orange,,Increase in demand,,,,,,,,,,,,,
Sandoz,norepinephrine,1,5/6/11,2/6/12,[temporary import],brown,,"??Sandoz- in conjunction with the FDA- is initiating a temporary importation of Norepinephrine Injection- to the United States market. Please see the Dear Healthcare Professional Letter (PDF - 296KB) for information about emergency supplies that are now available to help address the shortage.;ï»¿ï»¿Sandoz- in conjunction with the FDA- is initiating a temporary importation of Norepinephrine Injection- to the United States market. Please see the Dear Healthcare Professional Letter (PDF - 296KB) for information about emergency supplies that are now available to help address the shortage.;Sandoz- in conjunction with the FDA- is initiating a temporary importation of Norepinephrine Injection- to the United States market. Please see the Dear Healthcare Professional Letter (PDF - 296KB) for information about emergency supplies that are now available to help address the shortage.;Sandoz- in conjunction with the FDA- is initiating a temporary importation of Norepinephrine Injection- to the United States market. 
 
 Please see the Dear Healthcare Professional Letter (PDF - 296KB) for information about emergency supplies that are now available to help address the shortage.",,,,,,,,,,,,,
Bedford,norepinephrine,1,2/2/11,4/22/11,demand increase; manufacturing delays,blue,,Manufacturing delays   Increase in demand       Teva temporarily discontinued norepinephrine in June 2010.;Manufacturing delays   Increase in demand       Teva temporarily discontinued norepinephrine in June 2010.;Manufacturing delays   Increase in demand       Teva temporarily discontinued norepinephrine in June 2010.,,,,,,,,,,,,,
Hospira,norepinephrine,1,2/2/11,4/22/11,demand increase; manufacturing delays,blue,,Manufacturing delays   Increase in demand       Teva temporarily discontinued norepinephrine in June 2010.;Manufacturing delays   Increase in demand       Teva temporarily discontinued norepinephrine in June 2010.;Manufacturing delays   Increase in demand       Teva temporarily discontinued norepinephrine in June 2010.,,,,,,,,,,,,,
Teva,norepinephrine,1,2/2/11,4/22/11,demand increase; manufacturing delays,blue,,Manufacturing delays   Increase in demand       Teva temporarily discontinued norepinephrine in June 2010.;Manufacturing delays   Increase in demand       Teva temporarily discontinued norepinephrine in June 2010.;Manufacturing delays   Increase in demand       Teva temporarily discontinued norepinephrine in June 2010.,,,,,,,,,,,,,
Bedford,norepinephrine,1,4/28/11,2/6/12,manufacturing delays,blue,,Bedford has Norepinephrine Bitartrate Injection 1 mg/mL 4 mL vials on back order and the company cannot estimate a release date.;??Bedford has Norepinephrine Bitartrate Injection 1 mg/mL 4 mL vials on back order and the company cannot estimate a release date.;??Bedford anticipates release in the next 3-months.;ï»¿ï»¿Bedford anticipates release in the next 3-months.;Bedford anticipates release in the next 3-months.;Bedford has norepinephrine 1 mg/mL 4 mL (NDC 55390-0002-10) vials on back order and the company estimates a release date late 4th quarter- 2011.;Bedford has norepinephrine 1 mg/mL 4 mL (NDC 55390-0002-10) vials on back order and the company cannot estimate a release date.;Bedford has norepinephrine on back order and the company cannot estimate a release date.,,,,,,,,,,,,,
Teva,norepinephrine,1,4/28/11,2/6/12,production suspended,,,??Teva anticipates having product available again 4th quarter 2011.;ï»¿ï»¿Teva anticipates having product available again 4th quarter 2011.;Teva anticipates having product available again 4th quarter 2011.,,,,,,,,,,,,,
WestWard,norethindrone,1,7/12/12,8/4/12,available,,,,,,,,,,,,,,,,
APP,norethindrone,1,7/12/12,8/4/12,available,,,,,,,,,,,,,,,,
GlaxoSmithKline,norethindrone,1,7/12/12,8/4/12,discontinued,black,,,,,,,,,,,,,,,
Teva,norethindrone,1,7/12/12,8/4/12,discontinued,black,,,,,,,,,,,,,,,
Bedford,norethindrone,1,7/12/12,8/4/12,discontinued; production suspended,black,,,,,,,,,,,,,,,
Warner,norethindrone,1,4/29/12,7/1/12,manufacturing delays,blue,,,,,,,,,,,,,,,
WarnerChilcott,norethindrone,1,4/18/12,4/26/12,manufacturing delays,blue,,Manufacturing delays No estimated date of availability.;No estimated date of availability.,,,,,,,,,,,,,
WarnerChilcott,norethindrone,2,9/1/12,6/17/13,manufacturing delays,blue,,"28x6 (NDC 0430-0585-14) No estimated date of availability. Shortage per Manufacturer: Manufacturing delays;28x3 (NDC 0430-0585-45) No estimated date of availability. Shortage per Manufacturer: Manufacturing delays;28x3 (NDC 0430-0585-45) No estimated date of availability. Shortage per Manufacturer: 
 Manufacturing delays;28x6 (NDC 0430-0585-14) No estimated date of availability. Shortage per Manufacturer: 
 Manufacturing delays",,,,,,,,,,,,,
Caraco,norethindrone,1,7/12/12,8/4/12,production suspended,,,,,,,,,,,,,,,,
Warner,norethindrone,2,8/4/12,8/4/12,,,,,,,,,,,,,,,,,
Wockhardt,norethindrone,1,7/12/12,8/4/12,,,,,,,,,,,,,,,,,
Pfizer,norpace,1,11/15/09,1/11/10,demand increase,orange,,Increase in demand,,,,,,,,,,,,,
Covidien,octreoscan,1,1/25/10,2/10/10,product recall,yellow,,Product recall,,,,,,,,,,,,,
WestWard,ondansetron,1,1/5/12,7/1/12,; demand increase,orange,,"Pending information;West-Ward is currently experiencing a backorder situation on both the 2 mL and 20 mL vials.   West-Ward has accelerated production and is projecting to have additional lots available in the January - February 2012 timeframe.   Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on both the 2 mL and 20 mL vials.
  
 West-Ward has accelerated production and is projecting to have additional lots available in the January - February 2012 timeframe.
  
 Product will be made available as it is released;West-Ward is currently experiencing a backorder situation on both the 2 mL and 20 mL vials. West-Ward has accelerated production and is projecting to have additional units available.  Multiple lots are scheduled for manufacturing and release in May and June 2012. Product will be made available as it is released;Increase in product demand. West-Ward is currently experiencing a backorder situation on both the 2 mL and 20 mL vials. West-Ward has accelerated production and is projecting to have additional units available.  Multiple lots are scheduled for manufacturing and release in May and June 2012. Product will be made available as it is released;",,,,,,,,,,,,,
Apotex,ondansetron,1,1/5/12,5/15/12,; discontinued; manufacturing delays,black,,Pending information;Apotex has discontinued the manufacturing of Ondansetron Injection.;Manufacturing discontinued Apotex has discontinued the manufacturing of Ondansetron Injection.;,,,,,,,,,,,,,
AuroMedics,ondansetron,1,3/25/14,3/25/14,available,,,4 mg/ 2 mL SDV (NDC 55150-125-02) Available All presentations are available;40 mg/ 20 mL MDV (NDC 55150-126-20) Available All presentations are available,,,,,,,,,,,,,
Baxter,ondansetron,1,7/12/12,8/4/12,available,,,,,,,,,,,,,,,,
BD,ondansetron,1,8/22/13,9/1/13,available,,,4 mg/2 mL (2 mg/mL)- single-use Pre-filled syringe (Preservative-Free) NDC 76045-103-20 Available Please check with your wholesaler for available inventory.,,,,,,,,,,,,,
BD,ondansetron,2,10/1/13,3/25/14,available,,,4 mg/2 mL (2 mg/mL)- single-use Pre-filled syringe (Preservative-Free) NDC 76045-103-20 Available Please check with your wholesaler for available inventory.,,,,,,,,,,,,,
Bedford,ondansetron,3,10/1/13,3/25/14,capacity constraints,blue,,20 mL vial (NDC 55390-0121-01)  Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.;20 mL vial (NDC 55390-0121-01)  Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products are updated on the Bedford Laboratories website,,,,,,,,,,,,,
APP,ondansetron,2,9/1/12,9/1/13,demand increase,orange,,"4 mg; 2 mL (NDC 63323-0373-02) Check Wholesalers for Inventory APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;40 mg; 20 mL (NDC 63323-0374-20)   APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;4 mg; 2 mL (NDC 63323-0373-02) Check Wholesalers for Inventory. Next delivery expected late September. APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;40 mg; 20 mL (NDC 63323-0374-20)  Available APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;4 mg; 2 mL (NDC 63323-0373-02) Check Wholesalers for Inventory. Next delivery expected October 2012. APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;4 mg; 2 mL (NDC 63323-0373-02) Available Check wholesalers for inventory. APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory.   Shortage per Manufacturer: Increased demand;40 mg; 20 mL (NDC 63323-0374-20) Available Check wholesalers for inventory. APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory.   Shortage per Manufacturer: Increased demand;40 mg; 20 mL (NDC 63323-0374-20) Available Check wholesalers for inventory. APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory.
  
 Shortage per Manufacturer: 
 Increased demand;4 mg; 2 mL (NDC 63323-0373-02) Available Check wholesalers for inventory. APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory.
  
 Shortage per Manufacturer: 
 Increased demand",,,,,,,,,,,,,
APP,ondansetron,3,10/1/13,3/2/14,demand increase,orange,,4 mg; 2 mL (NDC 63323-0373-02) Available Check wholesalers for inventory. APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory.   Shortage per Manufacturer: Increased demand;40 mg; 20 mL (NDC 63323-0374-20) Available Check wholesalers for inventory. APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory.   Shortage per Manufacturer: Increased demand,,,,,,,,,,,,,
Fresenius,ondansetron,1,3/25/14,3/25/14,demand increase,orange,,4 mg; 2 mL (NDC 63323-0373-02) Available Check wholesalers for inventory. APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory.   Shortage per Manufacturer: Increased demand;40 mg; 20 mL (NDC 63323-0374-20) Available Check wholesalers for inventory. APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory.   Shortage per Manufacturer: Increased demand,,,,,,,,,,,,,
GlaxoSmithKline,ondansetron,2,9/1/12,9/1/13,demand increase,orange,,"20 mL vial (NDC 00173-0442-00)   GlaxoSmithKline has the following available: 20 mL vial (NDC 00173-0442-00) GlaxoSmithKline has discontinued Zofran 2 mL vials;Zofran injection- 2 mg/mL- 2 mL vials- packages of 5 (NDC 00173-00442-02)   GlaxoSmithKline has the following available: 20 mL vial (NDC 00173-0442-00) GlaxoSmithKline has discontinued Zofran 2 mL vials;Zofran injection- 2 mg/mL- 
 2 mL vials- packages of 5 
 (NDC 00173-00442-02)   GlaxoSmithKline has the following available: 
 
 20 mL vial (NDC 00173-0442-00) 
 
 GlaxoSmithKline has discontinued Zofran 2 mL vials;20 mL vial 
 (NDC 00173-0442-00)   GlaxoSmithKline has the following available: 
 
 20 mL vial (NDC 00173-0442-00) 
 
 GlaxoSmithKline has discontinued Zofran 2 mL vials",,,,,,,,,,,,,
GlaxoSmithKline,ondansetron,3,10/1/13,3/25/14,demand increase,orange,,20 mL vial (NDC 00173-0442-00)   GlaxoSmithKline has the following available: 20 mL vial (NDC 00173-0442-00) GlaxoSmithKline has discontinued Zofran 2 mL vials;Zofran injection- 2 mg/mL- 2 mL vials- packages of 5 (NDC 00173-00442-02)   GlaxoSmithKline has the following available: 20 mL vial (NDC 00173-0442-00) GlaxoSmithKline has discontinued Zofran 2 mL vials;Zofran 20 mL vial (NDC 00173-0442-00) Available GlaxoSmithKline has the following available: 20 mL vial (NDC 00173-0442-00) GlaxoSmithKline has discontinued Zofran 2 mL vials;Zofran injection- 2 mg/mL- 2 mL vials- packages of 5 (NDC 00173-00442-02)  Discontinued GlaxoSmithKline has the following available: 20 mL vial (NDC 00173-0442-00) GlaxoSmithKline has discontinued Zofran 2 mL vials,,,,,,,,,,,,,
WestWard,ondansetron,2,9/1/12,9/1/13,demand increase,orange,,"2 mg/mL- 2 mL vial (NDC 0641-6078-25) West-Ward currently has inventory available for both 2 mL and 20 mL vials.  Multiple lots are scheduled for manufacturing and release in July and August 2012. West-Ward has accelerated production and is projecting to have additional units available.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand.;2 mg/mL- 20 mL Vial (0641-6079-01) West-Ward currently has inventory available for both 2 mL and 20 mL vials.  Multiple lots are scheduled for manufacturing and release in July and August 2012. West-Ward has accelerated production and is projecting to have additional units available.  Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand.;2 mg/mL- 20 mL Vial (0641-6079-01) West-Ward has limited quantities available for both presentations.   West-Ward has accelerated production on this product.   West-Ward has increased production and is anticipating having additional product available in the January - February 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 2 mL vial (NDC 0641-6078-25) West-Ward has limited quantities available for both presentations.   West-Ward has accelerated production on this product.   West-Ward has increased production and is anticipating having additional product available in the January - February 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 2 mL vial (NDC 0641-6078-25) West-Ward has limited quantities available for both presentations.   West-Ward has accelerated production on this product.   West-Ward has increased production and is anticipating having additional product available in the March 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 20 mL Vial (0641-6079-01) West-Ward has limited quantities available for both presentations.   West-Ward has accelerated production on this product.   West-Ward has increased production and is anticipating having additional product available in the March 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 2 mL vial (NDC 0641-6078-25) West-Ward has limited quantities available for both presentations. 
  
 West-Ward has accelerated production on this product. 
   West-Ward has increased production and is anticipating having additional product available in the March 2013 timeframe. 
 Product will be made available as it is released.;2 mg/mL- 20 mL
 Vial (0641-6079-01) West-Ward has limited quantities available for both presentations. 
  
 West-Ward has accelerated production on this product. 
   West-Ward has increased production and is anticipating having additional product available in the March 2013 timeframe. 
 Product will be made available as it is released.;2 mg/mL- 2 mL vial (NDC 0641-6078-25) West-Ward has limited quantities available for both presentations.   West-Ward has accelerated production on this product.   West-Ward has increased production and is anticipating having additional product available in the July to August 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 20 mL Vial (0641-6079-01) West-Ward has limited quantities available for both presentations.   West-Ward has accelerated production on this product.   West-Ward has increased production and is anticipating having additional product available in the July to August 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 20 mL Vial (0641-6079-01) West-Ward has inventory available for both presentations.   West-Ward has accelerated production on this product.   West-Ward has increased production and is anticipating having additional product available for release in the August-September 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 2 mL vial (NDC 0641-6078-25) West-Ward has inventory available for both presentations.   West-Ward has accelerated production on this product.   West-Ward has increased production and is anticipating having additional product available for release in the August-September 2013 timeframe. Product will be made available as it is released.",,,,,,,,,,,,,
WestWard,ondansetron,3,10/1/13,3/25/14,demand increase,orange,,2 mg/mL- 20 mL Vial (0641-6079-01) West-Ward has inventory available for both presentations.   West-Ward has accelerated production on this product.   West-Ward has increased production and is anticipating having additional product available for release in the August-September 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 2 mL vial (NDC 0641-6078-25) West-Ward has inventory available for both presentations.   West-Ward has accelerated production on this product.   West-Ward has increased production and is anticipating having additional product available for release in the August-September 2013 timeframe. Product will be made available as it is released.;2 mg/mL- 2 mL vial (NDC 0641-6078-25) West-Ward has inventory available for both presentations. West-Ward has accelerated production on this product.     West-Ward has increased production and is anticipating having additional product available for release in the January - February 2014 timeframe.   Product will be made available as it is released.;2 mg/mL- 20 mL Vial (0641-6079-01) West-Ward has inventory available for both presentations. West-Ward has accelerated production on this product.     West-Ward has increased production and is anticipating having additional product available for release in the January - February 2014 timeframe.   Product will be made available as it is released.,,,,,,,,,,,,,
APP,ondansetron,1,1/5/12,7/1/12,demand increase; available,orange,,"APP has ondansetron 2 mg/mL 2 mL vials on back order with an estimated release date of early-January 2012. The 20 mL multiple dose vials (NDC 63323-0374-20) are Available;APP has ondansetron 2 mg/mL 2 mL vials on back order with an estimated release date of early-January 2012.
 The 20 mL multiple dose vials (NDC 63323-0374-20) are Available;APP has Ondansetron 2mg/mL 2 mL vials on back order with an estimated release date of late March 20 12.   The 20 mL multiple dose vials (NDC 63323-0374-20) are Available.;APP has Ondansetron 2 mg/mL 2 mL vials on back order with an estimated release date of late March 2012.   Limited quantities of the 20 mL multiple dose vials (NDC 63323-0374-20) are available.;APP has Ondansetron 2 mg/mL 2 mL vials on back order with an estimated release date of late March 2012.
  
 Limited quantities of the 20 mL multiple dose vials (NDC 63323-0374-20) are available.;APP has Ondansetron 2 mg/mL 2 mL vials on back order with an estimated release date of mid April 2012.  The 40 mg- 20mL vials are on back-order until late May.;Increased demand APP has Ondansetron 2 mg/mL 2 mL vials on back order with an estimated release date of mid April 2012.  The 40 mg- 20mL vials are on back-order until late May.;APP has Ondansetron 2 mg/mL 2 mL vials on back order with an estimated release date of early May 2012.  Check wholesalers for inventory. The 40 mg- 20mL vials are on back-order until late May.;",,,,,,,,,,,,,
Teva,ondansetron,2,10/1/13,3/25/14,demand increase; available,orange,,20 mL vials (NDC 00703-7226-01) Teva has inventory available.;2 mL vials (NDC 00703-7221-04) Teva has inventory available.;20 mL vials (NDC 00703-7226-03) Teva has inventory available.;2 mL vials (NDC 00703-7221-04) Teva is on backorder for this product and estimates resupply in 4Q 2013 for both SKUs.;20 mL vials (NDC 00703-7226-03) Teva is on backorder for this product and estimates resupply in 4Q 2013 for both SKUs.;20 mL vials (NDC 00703-7226-01) Teva is on backorder for this product and estimates resupply in 4Q 2013 for both SKUs.;2 mL vials (NDC 00703-7221-04) 20 mL cannot estimate a release date.   2 mL has returned to supply.;20 mL vials (NDC 00703-7226-03) 20 mL cannot estimate a release date.   2 mL has returned to supply.;20 mL vials (NDC 00703-7226-01) 20 mL cannot estimate a release date.   2 mL has returned to supply.,,,,,,,,,,,,,
Wockhardt,ondansetron,1,1/5/12,7/1/12,demand increase; available; ,orange,,"Wockhardt has the following products available: 2 mL vials- package of 5 (NDC 64679-0726-01) 20 mL vials- package of 1 (NDC 64679-0727-01);Wockhardt has the following products available: 
 2 mL vials- package of 5 (NDC 64679-0726-01) 
 20 mL vials- package of 1 (NDC 64679-0727-01);Wockhardt has all presentations of Ondansetron 2 mg/mL on back order with an estimated release date of February 2012.;Wockhardt has all presentations of Ondansetron 2 mg/mL on back order with an estimated release date of mid-late March 2012.;Increased demand Wockhardt has all presentations of Ondansetron 2 mg/mL on back order with an estimated release date of mid-late March 2012.;",,,,,,,,,,,,,
Wockhardt,ondansetron,2,9/1/12,9/1/13,demand increase; available; manufacturing practices requirements,yellow,,2 mg/mL- 2 mL vials- package of 5 (NDC 64679-0726-01)   Wockhardt is presently experiencing intermittent releases for the following strengths and sizes of Ondansetron for Injection throughout the month of May 2012. 2 mg/mL- 2 mL vials- package of 5 (NDC 64679-0726-01) 2 mg/mL- 20 mL vials- package of 1 (NDC 64679-0727-01;2 mg/mL- 20 mL vials- package of 1 (NDC 64679-0727-01)   Wockhardt is presently experiencing intermittent releases for the following strengths and sizes of Ondansetron for Injection throughout the month of May 2012. 2 mg/mL- 2 mL vials- package of 5 (NDC 64679-0726-01) 2 mg/mL- 20 mL vials- package of 1 (NDC 64679-0727-01;2 mg/mL- 20 mL vials- package of 1 (NDC 64679-0727-01)   Wockhardt is experiencing intermittent product releases throughout the month;2 mg/mL- 2 mL vials- package of 5 (NDC 64679-0726-01)   Wockhardt is experiencing intermittent product releases throughout the month;2 mg/mL- 2 mL vials- package of 5 (NDC 64679-0726-01) Wockhardt has existing inventories and no backorder presently  Available;2 mg/mL- 20 mL vials- package of 1 (NDC 64679-0727-01) Wockhardt has existing inventories and no backorder presently  Available;2 mg/mL- 20 mL vials- package of 1 (NDC 64679-0727-01) Wockhardt has existing inventories and no backorder presently. Order via your wholesaler or distributor. Available;2 mg/mL- 2 mL vials- package of 5 (NDC 64679-0726-01) Wockhardt has existing inventories and no backorder presently. Order via your wholesaler or distributor. Available;2 mg/mL- 2 mL vials- package of 5 (NDC 64679-0726-01) Inventory is readily available Available;2 mg/mL- 20 mL vials- package of 1 (NDC 64679-0727-01) No estimated release date available;2 mg/mL- 2 mL vials- package of 5 (NDC 64679-0726-01) No estimated release date available.,,,,,,,,,,,,,
Teva,ondansetron,1,1/5/12,9/1/13,discontinued; demand increase; available,black,,"Teva discontinued ondansetron 2 mL vials in 5 count packages. Teva has the following available: 2 mL vials- package of 25 (NDC 00703-7221-04) 20 mL vials- package of 10 (NDC 00703-7226-03) Teva has ondansetron 20 mL vials on allocation.;Teva discontinued ondansetron 2 mL vials in 5 count packages.
 Teva has the following available: 
 2 mL vials- package of 25 (NDC 00703-7221-04) 
 20 mL vials- package of 10 (NDC 00703-7226-03) 
 Teva has ondansetron 20 mL vials on allocation.;Teva discontinued ondansetron 2 mL vials in 5 count packages. 
 Teva has the following presentation on intermittent back-order. These skus will remain on allocation through Q212: 
 2 mL vials- package of 25 (NDC 00703-7221-04) 
 20 mL vials- package of 10 (NDC 00703-7226-03);Teva discontinued ondansetron 2 mL vials in 5 count packages. Teva has the following presentation on intermittent back-order. These skus will remain on allocation through Q212: 2 mL vials- package of 25 (NDC 00703-7221-04) 20 mL vials- package of 10 (NDC 00703-7226-03);;2 mL vials (NDC 00703-7221-04) Teva has limited inventory These skus will remain on allocation through the Q312.;20 mL vials (NDC 00703-7226-03) Teva has limited inventory These skus will remain on allocation through the Q312.;20 mL vials (NDC 00703-7226-01) Teva has limited inventory These skus will remain on allocation through the Q312.;2 mL vials- packages of 5 (NDC 00703-7221-02) - discontinued Teva has limited inventory These skus will remain on allocation through the Q312.;2 mL vials (NDC 00703-7221-04) Teva has limited inventory These skus will remain on allocation through the Q312.   Shortage per manufacturer:  Manufacturing delay;2 mL vials- packages of 5 (NDC 00703-7221-02) - discontinued Teva has limited inventory These skus will remain on allocation through the Q312.   Shortage per manufacturer:  Manufacturing delay;20 mL vials (NDC 00703-7226-03) Teva has limited inventory These skus will remain on allocation through the Q312.   Shortage per manufacturer:  Manufacturing delay;20 mL vials (NDC 00703-7226-01) Teva has limited inventory These skus will remain on allocation through the Q312.   Shortage per manufacturer:  Manufacturing delay;20 mL vials (NDC 00703-7226-01) Teva has limited inventory These skus will remain on allocation through the Q412.;20 mL vials (NDC 00703-7226-03) Teva has limited inventory These skus will remain on allocation through the Q412.;2 mL vials (NDC 00703-7221-04) Teva has limited inventory These skus will remain on allocation through the Q412.;2 mL vials (NDC 00703-7221-04) Teva has limited inventory;20 mL vials (NDC 00703-7226-01) Teva has limited inventory;20 mL vials (NDC 00703-7226-03) Teva has limited inventory;2 mL vials (NDC 00703-7221-04) Teva has inventory available.;20 mL vials (NDC 00703-7226-01) Teva has inventory available.;20 mL vials (NDC 00703-7226-03) Teva has inventory available.",,,,,,,,,,,,,
Wockhardt,ondansetron,3,10/1/13,3/25/14,manufacturing practices requirements,yellow,,2 mg/mL- 20 mL vials- package of 1 (NDC 64679-0727-01) No estimated release date available;2 mg/mL- 2 mL vials- package of 5 (NDC 64679-0726-01) No estimated release date available.,,,,,,,,,,,,,
Caraco,ondansetron,1,1/5/12,7/1/12,production suspended,,,Caraco temporarily discontinued ondansetron injection;,,,,,,,,,,,,,
Caraco,ondansetron,2,9/1/12,9/1/13,production suspended,,,2 mL ampules (NDC 62756-0181-01) Caraco temporarily discontinued ondansetron injection;20 mL vials (NDC 62756-0182-01) Caraco temporarily discontinued ondansetron injection,,,,,,,,,,,,,
Caraco,ondansetron,3,10/1/13,3/25/14,production suspended,,,2 mL ampules (NDC 62756-0181-01) Caraco temporarily discontinued ondansetron injection;20 mL vials (NDC 62756-0182-01) Caraco temporarily discontinued ondansetron injection,,,,,,,,,,,,,
Bedford,ondansetron,2,9/1/12,9/1/13,production suspended; capacity constraints,blue,,"2 mL Novaplus vials- packages of 10 (NDC 55390-0307-10) - discontinued   Bedford has ondansetron 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date. Bedford Laboratories has multiple products affected by this temporary suspension of manufacturing. Bedford will have the affected- as well as the available products- listed on their website and are updating this information as it changes. The company voluntarily suspended all manufacturing and distribution in mid-November- 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes. Bedford discontinued the following products: 2 mL vials- packages of 10 (NDC 55390-0121-10) 2 mL Novaplus vials- packages of 10 (NDC 55390-0307-10) 20 mL Novaplus vials- packages of 1 (NDC 55390-0307-01) Shortage per Manufacturer: Temporary suspension of manufacturing.;2 mL vials- packages of 10 (NDC 55390-0121-10) - discontinued   Bedford has ondansetron 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date. Bedford Laboratories has multiple products affected by this temporary suspension of manufacturing. Bedford will have the affected- as well as the available products- listed on their website and are updating this information as it changes. The company voluntarily suspended all manufacturing and distribution in mid-November- 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes. Bedford discontinued the following products: 2 mL vials- packages of 10 (NDC 55390-0121-10) 2 mL Novaplus vials- packages of 10 (NDC 55390-0307-10) 20 mL Novaplus vials- packages of 1 (NDC 55390-0307-01) Shortage per Manufacturer: Temporary suspension of manufacturing.;20 mL Novaplus vials- packages of 1 (NDC 55390-0307-01) - discontinued   Bedford has ondansetron 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date. Bedford Laboratories has multiple products affected by this temporary suspension of manufacturing. Bedford will have the affected- as well as the available products- listed on their website and are updating this information as it changes. The company voluntarily suspended all manufacturing and distribution in mid-November- 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes. Bedford discontinued the following products: 2 mL vials- packages of 10 (NDC 55390-0121-10) 2 mL Novaplus vials- packages of 10 (NDC 55390-0307-10) 20 mL Novaplus vials- packages of 1 (NDC 55390-0307-01) Shortage per Manufacturer: Temporary suspension of manufacturing.;2 mL Novaplus vials- packages of 10 (NDC 55390-0307-10) - discontinued   Bedford has ondansetron 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date. Bedford Laboratories has multiple products affected by this temporary suspension of manufacturing. Bedford will have the affected- as well as the available products- listed on their website and are updating this information as it changes. The company voluntarily suspended all manufacturing and distribution in mid-November- 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes.
 Bedford discontinued the following products: 
 2 mL vials- packages of 10 (NDC 55390-0121-10) 
 2 mL Novaplus vials- packages of 10 (NDC 55390-0307-10) 
 20 mL Novaplus vials- packages of 1 (NDC 55390-0307-01)
 Shortage per Manufacturer: 
 Temporary suspension of manufacturing.;20 mL Novaplus vials- packages of 1 (NDC 55390-0307-01) - discontinued   Bedford has ondansetron 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date. Bedford Laboratories has multiple products affected by this temporary suspension of manufacturing. Bedford will have the affected- as well as the available products- listed on their website and are updating this information as it changes. The company voluntarily suspended all manufacturing and distribution in mid-November- 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes.
 Bedford discontinued the following products: 
 2 mL vials- packages of 10 (NDC 55390-0121-10) 
 2 mL Novaplus vials- packages of 10 (NDC 55390-0307-10) 
 20 mL Novaplus vials- packages of 1 (NDC 55390-0307-01)
 Shortage per Manufacturer: 
 Temporary suspension of manufacturing.;2 mL vials- packages of 10 (NDC 55390-0121-10) - discontinued   Bedford has ondansetron 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date. Bedford Laboratories has multiple products affected by this temporary suspension of manufacturing. Bedford will have the affected- as well as the available products- listed on their website and are updating this information as it changes. The company voluntarily suspended all manufacturing and distribution in mid-November- 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes.
 Bedford discontinued the following products: 
 2 mL vials- packages of 10 (NDC 55390-0121-10) 
 2 mL Novaplus vials- packages of 10 (NDC 55390-0307-10) 
 20 mL Novaplus vials- packages of 1 (NDC 55390-0307-01)
 Shortage per Manufacturer: 
 Temporary suspension of manufacturing.;20 mL vial (NDC 55390-0121-01)  Unavailable Shortage per Manufacturer: Capacity constraint. Availability of products is updated on the Bedford Laboratories website.",,,,,,,,,,,,,
Bedford,ondansetron,1,1/5/12,7/1/12,production suspended; discontinued,black,,"Bedford has ondansetron 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date. Bedford Laboratories has multiple products affected by this temporary suspension of manufacturing. Bedford will have the affected- as well as the available products- listed on their website and are updating this information as it changes. The company voluntarily suspended all manufacturing and distribution in mid-November- 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes. Bedford discontinued the following products: 2 mL vials- packages of 10 (NDC 55390-0121-10) 2 mL Novaplus vials- packages of 10 (NDC 55390-0307-10) 20 mL Novaplus vials- packages of 1 (NDC 55390-0307-01);Bedford has ondansetron 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date. Bedford Laboratories has multiple products affected by this temporary suspension of manufacturing. Bedford will have the affected- as well as the available products- listed on their website and are updating this information as it changes. The company voluntarily suspended all manufacturing and distribution in mid-November- 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes.
 Bedford discontinued the following products: 
 2 mL vials- packages of 10 (NDC 55390-0121-10) 
 2 mL Novaplus vials- packages of 10 (NDC 55390-0307-10) 
 20 mL Novaplus vials- packages of 1 (NDC 55390-0307-01);Temporary suspension of manufacturing. Bedford has ondansetron 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date. Bedford Laboratories has multiple products affected by this temporary suspension of manufacturing. Bedford will have the affected- as well as the available products- listed on their website and are updating this information as it changes. The company voluntarily suspended all manufacturing and distribution in mid-November- 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes. Bedford discontinued the following products: 2 mL vials- packages of 10 (NDC 55390-0121-10) 2 mL Novaplus vials- packages of 10 (NDC 55390-0307-10) 20 mL Novaplus vials- packages of 1 (NDC 55390-0307-01);",,,,,,,,,,,,,
GlaxoSmithKline,ondansetron,1,1/5/12,7/1/12,some discontinued,black,,"Pending information;GlaxoSmithKline has the following available: 20 mL vial (NDC 00173-0442-00) GlaxoSmithKline has discontinued Zofran 2 mL vials;GlaxoSmithKline has the following available: 
 
 20 mL vial (NDC 00173-0442-00) 
 
 GlaxoSmithKline has discontinued Zofran 2 mL vials;",,,,,,,,,,,,,
Claris,ondansetron,1,7/12/12,8/4/12,,,,,,,,,,,,,,,,,
Cura,ondansetron,1,1/5/12,5/15/12,,,,Pending information;Pending information Pending information;,,,,,,,,,,,,,
Baxter,ondansetron32,1,1/5/12,7/1/12,demand increase; available,orange,,Baxter has the 32 mg/50 mL premixed bags available.;Baxter has 32 mg/50 mL premixed bags on back order with an estimated release date of late April 2012.;Increase in demand Baxter has 32 mg/50 mL premixed bags on back order with an estimated release date of late April 2012.;,,,,,,,,,,,,,
Teva,ondansetron32,1,1/5/12,7/1/12,manufacturing delays,blue,,Teva has ondansetron 32 mg/50 mL premixed bags on back order and the company cannot estimate a release date.;Manufacturing delay Teva has ondansetron 32 mg/50 mL premixed bags on back order and the company cannot estimate a release date.;,,,,,,,,,,,,,
Teva,ondansetron32,2,9/1/12,3/13/13,manufacturing delays; manufacturing practices requirements; discontinued,yellow,,32 mg/50 mL (NDC 00703-7239-39)   Teva has ondansetron 32 mg/50 mL premixed bags on back order and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delay;32 mg/50 mL (NDC 00703-7239-39) Teva has ondansetron 32 mg/50 mL premixed bags on back order and the company cannot estimate a release date.;32 mg/50 mL (NDC 00703-7239-39) Teva has voluntarily withdrawn their application for this product.,,,,,,,,,,,,,
Baxter,ondansetron32,2,9/1/12,3/13/13,product recall,yellow,,Ondansetron Injection 32 mg/50 mL premixed bags (NDC 00338-1762-41) Baxter has issued a voluntary recall and discontinued the manufacture and sale of this product.  N/A;Ondansetron Injection 32 mg/50 mL premixed bags (NDC 00338-1762-41) Baxter has issued a voluntary recall and discontinued the manufacture and sale of this product.  New safety information communicated in the  FDA Drug Safety Communication issued 06/29/2012,,,,,,,,,,,,,
Claris,ondansetron32,1,1/5/12,7/1/12,,,,Pending information;Pending information Pending information;,,,,,,,,,,,,,
Claris,ondansetron32,2,9/1/12,3/13/13,,,,32 mg/50 mL (NDC 36000-0014-06)   Pending information Shortage per Manufacturer: Pending information,,,,,,,,,,,,,
WestWard,ondansetron32,1,1/5/12,5/15/12,,,,Pending information;Pending information Pending information;,,,,,,,,,,,,,
Eisai,ontak,1,9/22/11,11/13/12,manufacturing issues; manufacturing delays,blue,,Eisai is working to have product available again. For information on Patient Access Program- please visit: http://www.ontak.com/;Manufacturing issue Eisai is working to have product available again. For information on Patient Access Program- please visit: http://www.ontak.com/;;150 mcg/mL- Eisai 2 mL vial (NDC 62856-0603-01) Eisai is working to have product available again. For information on Patient Access Program- please visit: http://www.ontak.com/ Shortage per Manufacturer: Manufacturing issue,,,,,,,,,,,,,
Endo,opana,1,2/9/12,3/1/12,manufacturing delays,blue,,10 mg tablets - anticipated availability mid-February 2012. (new formulation/new NDC). 20- 30 mg tablets -  anticipated availability mid-February 2012. 40 mg tablets - anticipated availability late February 2012.;10 mg tablets ? product available as of February 20- 2012 (new formulation/new NDC).   20- 30 mg tablets - anticipated availability mid-February 2012.   40 mg tablets - anticipated availability late February 2012.,,,,,,,,,,,,,
Gate,orap,1,7/31/09,8/14/09,manufacturing delays,blue,,Manufacturing Delays,,,,,,,,,,,,,
Humco,ora-sweet,1,9/27/09,10/6/09,,,,See information in Related Information section.            ,,,,,,,,,,,,,
Paddock,ora-sweet,1,9/27/09,10/6/09,,,,See information in Related Information section.            ,,,,,,,,,,,,,
Watson,orphenadrine,1,1/26/12,7/12/12,available,,,Information pending;Available;Available Available;,,,,,,,,,,,,,
Akorn,orphenadrine,1,1/26/12,7/12/12,demand increase; available,orange,,Akorn has all presentations of orphenadrine citrate injection on back order and with an estimated a release date of mid-February- 2012.;The 2 mL presentation continues to release monthly into the marketplace- with inventory reserves at wholesalers.;Readily available.;Increased demand Readily available.;,,,,,,,,,,,,,
Bedford,orphenadrine,1,1/26/12,7/12/12,not producing,,,;Bedford currently not producing.,,,,,,,,,,,,,
Genentech,oseltamivir,1,1/10/13,1/16/13,demand increase,orange,,Oral Suspension 6 mg/mL 60 mL (NDC 00004-0820-09) Genentech has Tamiflu for Oral Suspension on intermittent backorder- however supplies remain in distribution at wholesalers and pharmacies. Tamiflu 30 mg- 45 mg and 75 mg capsules remain available.   Pediatric patients over 1 year of age can be dosed correctly using the 30 mg and 45 mg capsules.   For those patients who cannot swallow capsules- the capsules can be opened and the contents may be mixed with chocolate syrup or some other thick- sweet liquid- as directed by a healthcare professional.   If there is difficulty locating commercial Tamiflu for Oral Suspension- FDA would like to remind healthcare professionals of the FDA-approved Instructions for the emergency compounding of an oral suspension from Tamiflu 75 mg capsules. These instructions provide for an alternative oral suspension when commercially manufactured oral suspension formulation is not readily available. Please see the information for healthcare professionals   regarding compounding an oral suspension from Tamiflu 75 mg capsules.   Alternatives to Tamiflu treatment for influenza are described on the CDC website.,,,,,,,,,,,,,
Genentech,oseltamivir,2,3/6/13,9/1/13,demand increase; shipping delay,orange,,"Oral Suspension 6 mg/mL 60 mL (NDC 00004-0820-09) Genentech has Tamiflu for Oral Suspension on intermittent backorder- however supplies remain in distribution at wholesalers and pharmacies. Tamiflu 30 mg- 45 mg and 75 mg capsules remain available.   Pediatric patients over 1 year of age can be dosed correctly using the 30 mg and 45 mg capsules.   For those patients who cannot swallow capsules- the capsules can be opened and the contents may be mixed with chocolate syrup or some other thick- sweet liquid- as directed by a healthcare professional.   If there is difficulty locating commercial Tamiflu for Oral Suspension- FDA would like to remind healthcare professionals of the FDA-approved Instructions for the emergency compounding of an oral suspension from Tamiflu 75 mg capsules. These instructions are in the current package insert and are also posted separately on the manufacturer's website as information for healthcare professionals   regarding compounding an oral suspension from Tamiflu 75 mg capsules.   Alternatives to Tamiflu treatment for influenza are described on the CDC website.;Oral Suspension 6 mg/mL 60 mL (NDC 00004-0820-09) Genentech has Tamiflu for Oral Suspension on intermittent backorder- however supplies remain in distribution at wholesalers and pharmacies. Tamiflu 30 mg- 45 mg and 75 mg capsules remain available.   Pediatric patients over 1 year of age can be dosed correctly using the 30 mg and 45 mg capsules.
  
 For those patients who cannot swallow capsules- the capsules can be opened and the contents may be mixed with chocolate syrup or some other thick- sweet liquid- as directed by a healthcare professional.
  
 If there is difficulty locating commercial Tamiflu for Oral Suspension- FDA would like to remind healthcare professionals of the FDA-approved Instructions for the emergency compounding of an oral suspension from Tamiflu 75 mg capsules. These instructions are in the current package insert and are also posted separately on the manufacturer's website as information for healthcare professionals   regarding compounding an oral suspension from Tamiflu 75 mg capsules.
  
 Alternatives to Tamiflu treatment for influenza are described on the CDC website.;Oral Suspension 6 mg/mL 60 mL (NDC 00004-0820-09) Tamiflu for Oral Suspension has been on backorder from Genentech since 4/25/13.  Very limited supplies remain in distribution at wholesalers and pharmacies.   Please check with authorized Genentech distributors and retailers for product availability.   Genentech expects to resume shipping Tamiflu for Oal Suspension during August 2013. Tamiflu 30 mg- 45 mg and 75 mg capsules remain available.   Pediatric patients over 1 year of age can be dosed correctly using the 30 mg and 45 mg capsules.   For those patients who cannot swallow capsules- the capsules can be opened and the contents may be mixed with chocolate syrup or some other thick- sweet liquid- as directed by a healthcare professional.   If there is difficulty locating commercial Tamiflu for Oral Suspension- FDA would like to remind healthcare professionals of the FDA-approved Instructions for the emergency compounding of an oral suspension from Tamiflu 75 mg capsules. These instructions are in the current package insert and are also posted separately on the manufacturer's website as information for healthcare professionals   regarding compounding an oral suspension from Tamiflu 75 mg capsules.   Alternatives to Tamiflu treatment for influenza are described on the CDC website.;Oral Suspension 6 mg/mL 60 mL (NDC 00004-0820-09)   New product NDC 0004-0822-05 Tamiflu for Oral Suspension has been on backorder from Genentech since 4/25/13.  Very limited supplies remain in distribution at wholesalers and pharmacies.   Please check with authorized Genentech distributors and retailers for product availability.   Genentech expects to ship new product (NDC 0004-0822-05) by October.   At this point in time manufacturer does not foresee a supply disruption for the upcoming flu season.   Tamiflu 30 mg- 45 mg and 75 mg capsules remain available.   Pediatric patients over 1 year of age can be dosed correctly using the 30 mg and 45 mg capsules.   For those patients who cannot swallow capsules- the capsules can be opened and the contents may be mixed with chocolate syrup or some other thick- sweet liquid- as directed by a healthcare professional.   If there is difficulty locating commercial Tamiflu for Oral Suspension- FDA would like to remind healthcare professionals of the FDA-approved Instructions for the emergency compounding of an oral suspension from Tamiflu 75 mg capsules. These instructions are in the current package insert and are also posted separately on the manufacturer's website as information for healthcare professionals   regarding compounding an oral suspension from Tamiflu 75 mg capsules.   Alternatives to Tamiflu treatment for influenza are described on the CDC website.",,,,,,,,,,,,,
Genentech,oseltamivir,3,10/1/13,3/2/14,shipping delay,,,Oral Suspension 6 mg/mL 60 mL (NDC 00004-0820-09)   New product NDC 0004-0822-05 Tamiflu for Oral Suspension has been on backorder from Genentech since 4/25/13.  Very limited supplies remain in distribution at wholesalers and pharmacies.   Please check with authorized Genentech distributors and retailers for product availability.   Genentech expects to ship new product (NDC 0004-0822-05) by October.   At this point in time manufacturer does not foresee a supply disruption for the upcoming flu season.   Tamiflu 30 mg- 45 mg and 75 mg capsules remain available.   Pediatric patients over 1 year of age can be dosed correctly using the 30 mg and 45 mg capsules.   For those patients who cannot swallow capsules- the capsules can be opened and the contents may be mixed with chocolate syrup or some other thick- sweet liquid- as directed by a healthcare professional.   If there is difficulty locating commercial Tamiflu for Oral Suspension- FDA would like to remind healthcare professionals of the FDA-approved Instructions for the emergency compounding of an oral suspension from Tamiflu 75 mg capsules. These instructions are in the current package insert and are also posted separately on the manufacturer's website as information for healthcare professionals   regarding compounding an oral suspension from Tamiflu 75 mg capsules.   Alternatives to Tamiflu treatment for influenza are described on the CDC website.,,,,,,,,,,,,,
Sandoz,oxcarbazepine,1,8/4/12,8/4/12,,,,,,,,,,,,,,,,,
Valeant,oxsoralen,1,3/19/10,4/22/11,manufacturing delays,blue,,Manufacturing delays  ;Manufacturing delays  ;Manufacturing delays ,,,,,,,,,,,,,
Valeant,oxsoralen,1,4/28/11,11/13/12,manufacturing delays,blue,,There is not yet an estimated release date.;Manufacturing delays There is not yet an estimated release date.;;There is not yet an estimated release date. Shortage per Manufacturer: Manufacturing delays,,,,,,,,,,,,,
Valeant,oxsoralen-ultra,1,3/19/10,4/22/11,manufacturing delays,blue,,Manufacturing delays  ;Manufacturing delays  ;Manufacturing delays  ;Manufacturing delays  ,,,,,,,,,,,,,
Valeant,oxsoralen-ultra,1,4/28/11,11/17/11,manufacturing delays,blue,,"Valeant has released limited quantity of Oxsoralen-Ultra 10mg capsules to the market and is committed to ensuring the product is allocated properly to patients in need. Please see the Dear Healthcare Professional Letter (PDF - 49KB) for additional information. You may also contact Valeant by e-mail at pharmcs@valeant.com for additional information.;Valeant has released limited quantity of Oxsoralen-Ultra 10mg capsules to the market and is committed to ensuring the product is allocated properly to patients in need. Please see the Dear Healthcare Professional Letter (PDF - 49KB) for additional information. 
 
 You may also contact Valeant by e-mail at pharmcs@valeant.com for additional information.",,,,,,,,,,,,,
ActavisTotowa,oxycodone,1,6/6/09,9/6/09,demand increase,orange,,Increase in demand related to product recalls by other manufacturers Visit: FDA News,,,,,,,,,,,,,
Mallinckrodt,oxycodone,1,6/6/09,9/6/09,demand increase,orange,,Increase in demand related to product recalls by other manufacturers Visit: FDA News,,,,,,,,,,,,,
Sun,oxycodone,1,6/6/09,9/6/09,demand increase,orange,,Increase in demand related to product recalls by other manufacturers Visit: FDA News,,,,,,,,,,,,,
Vintage,oxycodone,1,6/6/09,9/6/09,demand increase,orange,,Increase in demand related to product recalls by other manufacturers Visit: FDA News,,,,,,,,,,,,,
Xanodyne,oxycodone,1,6/6/09,9/6/09,demand increase,orange,,Increase in demand related to product recalls by other manufacturers Visit: FDA News,,,,,,,,,,,,,
Lannett,oxycodone,1,10/9/10,11/12/10,Raw material constraints,green,,Raw material constraints,,,,,,,,,,,,,
Endo,oxymorphone,1,4/18/12,3/1/13,material shortage; manufacturing practices requirements,yellow,,Temporarily unavailable and Endo cannot estimate a release date at this time. We will continue to provide updates as further information becomes available.;Material shortage (API) Temporarily unavailable and Endo cannot estimate a release date at this time. We will continue to provide updates as further information becomes available.;;Opana (oxymorphone hydrochloride): 10mg tablet- 100 count bottle (NDC 63481-0613-70) Temporarily unavailable and Endo cannot estimate a release date at this time. We will continue to provide updates as further information becomes available. Shortage per Manufacturer: Material shortage (API);Oxymorphone hydrochloride: 10mg tablet- 100 count bottle (NDC 60951-0795-70) Temporarily unavailable and Endo cannot estimate a release date at this time. We will continue to provide updates as further information becomes available. Shortage per Manufacturer: Material shortage (API);Opana (oxymorphone hydrochloride): 5mg tablet- 100 count bottle (NDC 63481-0612-70) Temporarily unavailable and Endo cannot estimate a release date at this time. We will continue to provide updates as further information becomes available. Shortage per Manufacturer: Material shortage (API);Oxymorphone hydrochloride: 5mg tablet- 100 count bottle (NDC 60951-0794-70) Temporarily unavailable and Endo cannot estimate a release date at this time. We will continue to provide updates as further information becomes available. Shortage per Manufacturer: Material shortage (API);Opana (oxymorphone hydrochloride): 10mg tablet- 100 count bottle (NDC 63481-0613-70) Temporarily unavailable and Endo cannot estimate a release date at this time. We will continue to provide updates as further information becomes available.;Oxymorphone hydrochloride: 10mg tablet- 100 count bottle (NDC 60951-0795-70) Temporarily unavailable and Endo cannot estimate a release date at this time. We will continue to provide updates as further information becomes available.;Opana (oxymorphone hydrochloride): 5mg tablet- 100 count bottle (NDC 63481-0612-70) Temporarily unavailable and Endo cannot estimate a release date at this time. We will continue to provide updates as further information becomes available.;Oxymorphone hydrochloride: 5mg tablet- 100 count bottle (NDC 60951-0794-70) Temporarily unavailable and Endo cannot estimate a release date at this time. We will continue to provide updates as further information becomes available.,,,,,,,,,,,,,
WestWard,oxytocin,1,12/25/11,7/12/12,; demand increase,orange,,"Information pending;West-Ward currently has limited quantities available of the 10 mL vial (10019-291-04). The 1 mL vial (10019-291-02 is currently on backorder. West-Ward has accelerated production and is expecting to have additional lots available for both presentations in the February - March 2012 timeframe. Product will be made available as it is released.;West-Ward currently has limited quantities available of the 10 mL vial (10019-291-04). The 1 mL vial (10019-291-02 is currently on backorder. 
 West-Ward has accelerated production and is expecting to have additional lots available for both presentations in the February - March 2012 timeframe. 
 Product will be made available as it is released.;Increase in product demand West-Ward currently has limited quantities available of the 10 mL vial (10019-291-04). The 1 mL vial (10019-291-02 is currently on backorder. West-Ward has accelerated production and is expecting to have additional lots available for both presentations in the February - March 2012 timeframe. Product will be made available as it is released.;",,,,,,,,,,,,,
APP,oxytocin,1,12/25/11,7/12/12,demand increase; available,orange,,"10 mL vial on back-order with an estimated release date of early to mid-February 2012.   1 mL vial available with an estimated release date of mid-January 2012   30 mL vial available. Estimated release date TBD.;10 mL vial on back-order with an estimated release date of early to mid-February 2012.
  
 1 mL vial available with an estimated release date of mid-January 2012
  
 30 mL vial available. Estimated release date TBD.;APP has all Oxytocin presentations available.  Check wholesaler for inventory.;Available APP has all Oxytocin presentations available.  Check wholesaler for inventory.;",,,,,,,,,,,,,
APP,paclitaxel,1,8/14/11,7/12/12,demand increase; available,orange,,APP is on intermittent back order and is releasing product as it becomes available.;Increase in demand APP is on intermittent back order and is releasing product as it becomes available.;APP is currently back-ordered on 100 mg/16.7 mL vial (NDC 63323-0763-16) and 300 mg/50 mL vial (NDC 63323-0763-50).  30 mg/5 mL vial (NDC 63323-0763-05) is currently available.;,,,,,,,,,,,,,
Bedford,paclitaxel,1,8/14/11,7/12/12,manufacturing delays,blue,,Bedford has paclitaxel 6 mg/mL injections in 30 mg/5 mL and 100 mg/16.7 mL vials allocated for drop shipment only. The other presentations are on back order and the company cannot estimate a release date.;Bedford Laboratories has limited emergency supplies of paclitaxel 6 mg/mL injections in 30 mg/5 mL- 100 mg/16.7 mL and 300 mg/50 mL allocated for drop shipment only.;Bedford has short supplies of 30 mg/5 mL (NDC 55390-0114-05)- 100 mg/16.7 mL (NDC55390-0114-20) and 300 mg/50 mL (NDC55390-0144-50)  available for drop shipment.;Bedford has short supplies of 30 mg/5 mL (NDC 55390-0114-05) and 100 mg/16.7 mL (NDC55390-0114-20) available for drop shipment. All other presentations are on backorder and the company cannot estimate a release date.;Bedford has short supplies of 30 mg/5 mL (NDC 55390-0114-05)  available for drop shipment contact your local Bedford Account Executive. All other presentations are on backorder and the company cannot estimate a release date.;Bedford has all paclitaxel presentations  on backorder and the company cannot estimate a release date.;Manufacturing delays Bedford has all paclitaxel presentations  on backorder and the company cannot estimate a release date.;,,,,,,,,,,,,,
Sandoz,paclitaxel,1,8/14/11,7/12/12,manufacturing delays,blue,,Sandoz is currently on backorder.;Manufacturing delays Sandoz is currently on backorder.;,,,,,,,,,,,,,
Teva,paclitaxel,1,8/14/11,7/12/12,manufacturing delays; demand increase; available,blue,,Teva currently has all paclitaxel 6 mg/mL presentations on back order.;Teva expecting releases of 16.7 mL- 25 mL- and 50 mL;Teva continues to release Paclitaxel 30mg/5mL vial (NDC 00703-4764-01)- Paclitaxel 100mg/16.7mL vial (NDC 00703-4766-01)- Paclitaxel 150mg/25mL (NDC 00703-4767-01) and Paclitaxel 300mg/50mL (NDC 00703-4768-01) as it becomes available;Teva has all presentation available with ample inventory.;Teva has 6mg/mL- 30mg on backorder until April 2012.  All other presentations are available with ample inventory.;Increased Demand Teva has 6mg/mL- 30mg on backorder until April 2012.  All other presentations are available with ample inventory.;Teva has all presentations available with ample inventory.;,,,,,,,,,,,,,
Hospira,pancuronium,1,5/27/10,8/15/10,demand increase,orange,,Teva initiated withdrawal of multiple lots of pancuronium injection from the market on 5/4/10.   Increased demand;Teva initiated withdrawal of multiple lots of pancuronium injection from the market on 5/4/10.     Increased demand;Teva initiated withdrawal of multiple lots of pancuronium injection from the market on 5/4/10.     Increased demand,,,,,,,,,,,,,
Hospira,pancuronium,2,10/9/10,1/26/11,demand increase,orange,,Teva initiated withdrawal of multiple lots of pancuronium injection from the market on 5/4/10.     Increased demand,,,,,,,,,,,,,
Teva,pancuronium,2,10/9/10,1/26/11,demand increase,orange,,Teva initiated withdrawal of multiple lots of pancuronium injection from the market on 5/4/10.     Increased demand,,,,,,,,,,,,,
Teva,pancuronium,1,5/27/10,8/15/10,product recall,yellow,,Teva initiated withdrawal of multiple lots of pancuronium injection from the market on 5/4/10.   Increased demand;Teva initiated withdrawal of multiple lots of pancuronium injection from the market on 5/4/10.     Increased demand;Teva initiated withdrawal of multiple lots of pancuronium injection from the market on 5/4/10.     Increased demand,,,,,,,,,,,,,
AmericanRegent,papaverine,1,12/24/12,9/1/13,manufacturing delays,blue,,30 mg/mL- 2 mL vial (NDC 0517-4002-25) Company estimates a manufacturing date of 1Q 2013 Shortage per Manufacturer: Manufacturing delay;30 mg/mL- 10 mL vial (NDC 00517-4010-01) Company estimates a manufacturing date of 1Q 2013 Shortage per Manufacturer: Manufacturing delay;30 mg/mL- 2 mL vial (NDC 0517-4002-25) Company estimates a manufacturing date of 2Q 2013 Shortage per Manufacturer: Manufacturing delay;30 mg/mL- 10 mL vial (NDC 00517-4010-01) Company estimates a manufacturing date of 2Q 2013 Shortage per Manufacturer: Manufacturing delay;30 mg/mL- 10 mL vial (NDC 00517-4010-01) Estimated release end of July 2013. Shortage per Manufacturer: Manufacturing delay;30 mg/mL- 2 mL vial (NDC 0517-4002-25) Estimated release end of July 2013. Shortage per Manufacturer: Manufacturing delay;30 mg/mL- 10 mL vial (NDC 00517-4010-01) Estimated release beginning of July 2013 Shortage per Manufacturer: Manufacturing delay;30 mg/mL- 2 mL vial (NDC 0517-4002-25) Estimated release beginning of July 2013 Shortage per Manufacturer: Manufacturing delay;30 mg/mL- 10 mL vial (NDC 00517-4010-01) Estimated release mid July 2013 Shortage per Manufacturer: Manufacturing delay;30 mg/mL- 2 mL vial (NDC 0517-4002-25) Estimated release mid July 2013 Shortage per Manufacturer: Manufacturing delay;30 mg/mL- 10 mL vial (NDC 00517-4010-01) Estimated release August 2013 Shortage per Manufacturer: Manufacturing delay;30 mg/mL- 2 mL vial (NDC 0517-4002-25) Estimated release August 2013 Shortage per Manufacturer: Manufacturing delay,,,,,,,,,,,,,
AmericanRegent,papaverine,2,10/1/13,3/25/14,manufacturing delays; shipping delay; demand increase,blue,,30 mg/mL- 10 mL vial (NDC 00517-4010-01) Estimated release August 2013 Shortage per Manufacturer: Manufacturing delay;30 mg/mL- 2 mL vial (NDC 0517-4002-25) Estimated release August 2013 Shortage per Manufacturer: Manufacturing delay;30 mg/mL- 2 mL vial (NDC 0517-4002-25) Estimated release TBD Shortage per Manufacturer: Manufacturing delay;NULL Estimated release TBD Shortage per Manufacturer: Manufacturing delay;30 mg/mL- 2 mL vial (NDC 0517-4002-25) Unavailable - Product on backorder and will be made available as it is released. Shortage per Manufacturer: Manufacturing delay;NULL Unavailable - Product on backorder and will be made available as it is released. Shortage per Manufacturer: Manufacturing delay,,,,,,,,,,,,,
APP,pchloride,1,6/13/12,9/1/13,demand increase; manufacturing delays,blue,,";2 mEq/mL- 10 mL vials- (NDC 63323-0965-10) The firm anticipates next delivery of the 5 mL- 10 mL & 30 mL presentations early August 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 5 mL vials- (NDC 63323-0965-05) The firm anticipates next delivery of the 5 mL- 10 mL & 30 mL presentations early August 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 15 mL vials- (NDC 63323-0965-15) The firm anticipates next delivery of the 5 mL- 10 mL & 30 mL presentations early August 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 20 mL vials- (NDC 63323-0965-20) The firm anticipates next delivery of the 5 mL- 10 mL & 30 mL presentations early August 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 30 mL vials- (NDC 63323-0967-30) The firm anticipates next delivery of the 5 mL- 10 mL & 30 mL presentations early August 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 20 mL vials- (NDC 63323-0965-20) The firm anticipates next delivery of the 5 mL- 10 mL- 20mL & 30 mL presentations early September 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 5 mL vials- (NDC 63323-0965-05) The firm anticipates next delivery of the 5 mL- 10 mL- 20mL & 30 mL presentations early September 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 10 mL vials- (NDC 63323-0965-10) The firm anticipates next delivery of the 5 mL- 10 mL- 20mL & 30 mL presentations early September 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 15 mL vials- (NDC 63323-0965-15) The firm anticipates next delivery of the 5 mL- 10 mL- 20mL & 30 mL presentations early September 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 30 mL vials- (NDC 63323-0967-30) The firm anticipates next delivery of the 5 mL- 10 mL- 20mL & 30 mL presentations early September 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 20 mL vials- (NDC 63323-0965-20) The firm anticipates next delivery of the 5 mL- 10 mL- 20mL & 30 mL presentations mid to late September 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 5 mL vials- (NDC 63323-0965-05) The firm anticipates next delivery of the 5 mL- 10 mL- 20mL & 30 mL presentations mid to late September 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 30 mL vials- (NDC 63323-0967-30) The firm anticipates next delivery of the 5 mL- 10 mL- 20mL & 30 mL presentations mid to late September 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 10 mL vials- (NDC 63323-0965-10) The firm anticipates next delivery of the 5 mL- 10 mL- 20mL & 30 mL presentations mid to late September 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 15 mL vials- (NDC 63323-0965-15) The firm anticipates next delivery of the 5 mL- 10 mL- 20mL & 30 mL presentations mid to late September 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 5 mL vials- (NDC 63323-0965-05) Back-ordered APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 15 mL vials- (NDC 63323-0965-15) Unavailable APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 20 mL vials- (NDC 63323-0965-20) Back-ordered. Next delivery December 2012. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 10 mL vials- (NDC 63323-0965-10) Back-ordered. Next delivery expected November 2012. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 30 mL vials- (NDC 63323-0967-30) Back-ordered. Next delivery November 2012. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: Increased demand;2 mEq/mL- 30 mL vials- (NDC 63323-0967-30) Available APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 15 mL vials- (NDC 63323-0965-15) Unavailable APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 5 mL vials- (NDC 63323-0965-05) Back-ordered APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 20 mL vials- (NDC 63323-0965-20) Back-ordered. Next delivery Late November 2012 APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 10 mL vials- (NDC 63323-0965-10) Back-ordered. Next delivery expected December 2012. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 10 mL vials- (NDC 63323-0965-10) Available.  Check wholesalers for inventory. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 5 mL vials- (NDC 63323-0965-05) Back-ordered. Next delivery anticipated January 2013. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 20 mL vials- (NDC 63323-0965-20) Back-ordered. Next delivery anticipated January 2013. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 5 mL vials- (NDC 63323-0965-05) Available. Check wholesalers for inventory. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 30 mL vials- (NDC 63323-0967-30) Backordered. No estimated release at this time. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 20 mL vials- (NDC 63323-0965-20) Available. Check wholesalers for inventory. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 10 mL vials- (NDC 63323-0965-10) Backordered. No estimated release at this time. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 20 mL vials- (NDC 63323-0965-20) Backordered. No estimated release at this time. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 5 mL vials- (NDC 63323-0965-05) Backordered. No estimated release at this time. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 10 mL vials- (NDC 63323-0965-10) Backordered. No estimated release at this time. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. 
  
 Shortage per Manufacturer: 
 Increased demand;2 mEq/mL- 30 mL vials- (NDC 63323-0967-30) Backordered. No estimated release at this time. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. 
  
 Shortage per Manufacturer: 
 Increased demand;2 mEq/mL- 5 mL vials- (NDC 63323-0965-05) Backordered. No estimated release at this time. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. 
  
 Shortage per Manufacturer: 
 Increased demand;2 mEq/mL- 15 mL vials- (NDC 63323-0965-15) Unavailable APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. 
  
 Shortage per Manufacturer: 
 Increased demand;2 mEq/mL- 20 mL vials- (NDC 63323-0965-20) Backordered. No estimated release at this time. APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. 
  
 Shortage per Manufacturer: 
 Increased demand;2 mEq/mL- 10 mL vials- (NDC 63323-0965-10) Backordered. Next release anticipated mid-late July 2013. Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 30 mL vials- (NDC 63323-0967-30) Backordered. Next release anticipated late July 2013. Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 20 mL vials- (NDC 63323-0965-20) Backordered. Next release anticipated mid July 2013 Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 5 mL vials- (NDC 63323-0965-05) Backordered. Next release anticipated August 2013. Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 15 mL vials- (NDC 63323-0965-15) Unavailable Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 30 mL vials- (NDC 63323-0967-30) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 20 mL vials- (NDC 63323-0965-20) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 10 mL vials- (NDC 63323-0965-10) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 5 mL vials- (NDC 63323-0965-05) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand Manufacturing Delay",,,,,,,,,,,,,
Bbraun,pchloride,2,10/1/13,3/25/14,available,,,2 mEq/mL- 250 mL bulk package (NDC 00264-1940-20) Available  Per manufacturer: No shortage;2 mEq/mL- 250 mL bulk package (NDC 00264-1940-20) Available Shortage Per manufacturer: No shortage,,,,,,,,,,,,,
Baxter,pchloride,2,10/1/13,3/25/14,demand increase; available,orange,,20 mEq/500 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0671-03) Available;20 mEq/1000 mL in 5% dextrose and 0.2% sodium chloride (NDC 00338-0663-04) Available;20 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0671-04) Available;40 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0807-04) Available;20 mEq/1000 mL in 5% dextrose (NDC 00338-0683-04) Available;20 mEq/500 mL in 5% dextrose and 0.2% sodium chloride (NDC 00338-0663-03) Available;10 mEq/100 mL in sterile water (NDC 00338-0709-48) Available;40 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0695-04) Available;40 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0675-04) Available;20 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0691-04) Available;20 mEq/1000 mL in 0.45% sodium chloride (NDC 00338-0704-34) Available;20 mEq/1000 mL in lactated ringers and dextrose 5% (NDC 00338-0811-04) Available;40 mEq/100 mL in sterile water (NDC 00338-0703-48) Available;10 mEq/50 mL in sterile water (NDC 00338-0705-41) Available;10 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0669-04) Available;20 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0803-04) Available;20 mEq/100 mL in sterile water (NDC 00338-0705-48) Available;20 mEq/50 mL in sterile water (NDC 00338-0703-41) Available;20 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0691-04) Baxter is experiencing limited supplies and anticipates supplies to recover by April 2014.;20 mEq/1000 mL in 0.45% sodium chloride (NDC 00338-0704-34) Baxter is experiencing limited supplies and anticipates supplies to recover by April 2014.;10 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0669-04) Baxter is experiencing limited supplies and anticipates supplies to recover by March 2014.;40 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0695-04) Baxter is experiencing limited supplies and anticipates supplies to recover by April 2014.;40 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0675-04) Baxter is experiencing limited supplies and anticipates supplies to recover by May 2014.;20 mEq/1000 mL in 5% dextrose (NDC 00338-0683-04) Baxter is experiencing limited supplies and anticipates supplies to recover by March 2014.;20 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0803-04) Baxter is experiencing limited supplies and anticipates supplies to recover by March 2014.,,,,,,,,,,,,,
Fresenius,pchloride,1,3/25/14,3/25/14,demand increase; manufacturing delays,blue,,2 mEq/mL- 20 mL vials- (NDC 63323-0965-20) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 30 mL vials- (NDC 63323-0967-30) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 5 mL vials- (NDC 63323-0965-05) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 10 mL vials- (NDC 63323-0965-10) Backordered. Next release anticipated March 2014 Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 15 mL vials- (NDC 63323-0965-15) Unavailable Shortage per Manufacturer: Increased demand Manufacturing Delay,,,,,,,,,,,,,
APP,pchloride,2,10/1/13,3/2/14,demand increase; manufacturing delays; demand increase,blue,,2 mEq/mL- 30 mL vials- (NDC 63323-0967-30) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 10 mL vials- (NDC 63323-0965-10) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 15 mL vials- (NDC 63323-0965-15) Unavailable Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 5 mL vials- (NDC 63323-0965-05) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand Manufacturing Delay;2 mEq/mL- 20 mL vials- (NDC 63323-0965-20) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand Manufacturing Delay,,,,,,,,,,,,,
Baxter,pchloride,1,8/4/12,9/1/13,manufacturing delays; demand increase; available,blue,,;40 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0807-04) Available Shortage per Manufacturer:   Manufacturing Delay;20 mEq/1000 mL in 5% dextrose (NDC 00338-0683-04) Available Shortage per Manufacturer:   Manufacturing Delay;20 mEq/50 mL in sterile water (NDC 00338-0703-41) Stocked out.  Supply recovery expected in August. Shortage per Manufacturer:   Manufacturing Delay;20 mEq/1000 mL in 0.45% sodium chloride (NDC 00338-0704-34) Available Shortage per Manufacturer:   Manufacturing Delay;40 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0695-04) Available Shortage per Manufacturer:   Manufacturing Delay;20 mEq/100 mL in sterile water (NDC 00338-0705-48) Available Shortage per Manufacturer:   Manufacturing Delay;20 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0691-04) Available Shortage per Manufacturer:   Manufacturing Delay;20 mEq/1000 mL in lactated ringers and dextrose 5% (NDC 00338-0811-04) Available Shortage per Manufacturer:   Manufacturing Delay;10 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0669-04) Available Shortage per Manufacturer:   Manufacturing Delay;40 mEq/100 mL in sterile water (NDC 00338-0703-48) Available Shortage per Manufacturer:   Manufacturing Delay;20 mEq/500 mL in 5% dextrose and 0.2% sodium chloride (NDC 00338-0663-03) Available Shortage per Manufacturer:   Manufacturing Delay;10 mEq/50 mL in sterile water (NDC 00338-0705-41) Available Shortage per Manufacturer:   Manufacturing Delay;20 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0671-04) Available Shortage per Manufacturer:   Manufacturing Delay;20 mEq/1000 mL in 5% dextrose and 0.2% sodium chloride (NDC 00338-0663-04) Available Shortage per Manufacturer:   Manufacturing Delay;20 mEq/500 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0671-03) Stocked out.  Supply recovery expected before 30 July 2012. Shortage per Manufacturer:   Manufacturing Delay;40 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0675-04) Available Shortage per Manufacturer:   Manufacturing Delay;20 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0803-04) Available Shortage per Manufacturer:   Manufacturing Delay;10 mEq/100 mL in sterile water (NDC 00338-0709-48) Available Shortage per Manufacturer:   Manufacturing Delay;10 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0669-04) Available;20 mEq/500 mL in 5% dextrose and 0.2% sodium chloride (NDC 00338-0663-03) Available;20 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0671-04) Available;20 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0803-04) Available;20 mEq/50 mL in sterile water (NDC 00338-0703-41) Available;20 mEq/500 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0671-03) Available;10 mEq/100 mL in sterile water (NDC 00338-0709-48) On backorder.  Supply recovery expected in October.;40 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0807-04) Available;20 mEq/1000 mL in 5% dextrose (NDC 00338-0683-04) Available;20 mEq/100 mL in sterile water (NDC 00338-0705-48) On backorder.  Supply recovery expected in October.;20 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0691-04) Available;10 mEq/50 mL in sterile water (NDC 00338-0705-41) On backorder.  Supply recovery expected in October.;40 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0675-04) Available;20 mEq/1000 mL in 5% dextrose and 0.2% sodium chloride (NDC 00338-0663-04) Available;40 mEq/100 mL in sterile water (NDC 00338-0703-48) On backorder.  Supply recovery expected in October.;40 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0695-04) Available;20 mEq/1000 mL in lactated ringers and dextrose 5% (NDC 00338-0811-04) Available;20 mEq/1000 mL in 0.45% sodium chloride (NDC 00338-0704-34) Available;20 mEq/100 mL in sterile water (NDC 00338-0705-48) Available;40 mEq/100 mL in sterile water (NDC 00338-0703-48) Available;10 mEq/100 mL in sterile water (NDC 00338-0709-48) Available;10 mEq/50 mL in sterile water (NDC 00338-0705-41) On backorder.  Supply recovery expected in early October.;10 mEq/50 mL in sterile water (NDC 00338-0705-41) Available,,,,,,,,,,,,,
Bbraun,pchloride,1,6/29/12,9/1/13,material shortage; available,green,,;2 mEq/mL- 250 mL bulk package (NDC 00264-1940-20) Product not available due to glass supply. Next scheduled manufacturing planned for end of August 2012. Shortage per Manufacturer: Glass supply;2 mEq/mL- 250 mL bulk package (NDC 00264-1940-20) Available;2 mEq/mL- 250 mL bulk package (NDC 00264-1940-20) Available  Per manufacturer: No shortage,,,,,,,,,,,,,
Genentech,pegasys,1,4/18/12,6/3/13,demand increase; manufacturing delays; available,blue,,Increased demand and Manufacturing delays of the Pre-filled Syringes Potential limited availability of the PFS form of 180 mcg/mL Pegasys in the next 6 months (NDC 0004-0352-39- NDC 0004-0357-30). The firm anticipates that the potential shortage of the PFS will resolve by September 2012.   Please see the Dear Health Care Provider Letter (PDF - 147KB) and the Dear Pharmacist Letter (PDF - 147KB)   The firm has adequate supplies of the following presentations of Pegasys: * 180 mcg/0.5 mL Autoinjector for single use (NDC 0004-0365-09) *135 mcg/0.5 mL Autoinjector for single use (NDC 0004-0360-09) * 180 mcg/mL Vial for single use   (NDC 0004-0350-09);Potential limited availability of the PFS form of 180 mcg/mL Pegasys in the next 6 months (NDC 0004-0352-39- NDC 0004-0357-30). The firm anticipates that the potential shortage of the PFS will resolve by September 2012.   Please see the Dear Health Care Provider Letter (PDF - 147KB) and the Dear Pharmacist Letter (PDF - 147KB)   The firm has adequate supplies of the following presentations of Pegasys: * 180 mcg/0.5 mL Autoinjector for single use (NDC 0004-0365-09) *135 mcg/0.5 mL Autoinjector for single use (NDC 0004-0360-09) * 180 mcg/mL Vial for single use   (NDC 0004-0350-09);;135 mcg/0.5 mL Autoinjector for single use (NDC 0004-0360-09) The firm has adequate supplies Please see the Dear Health Care Provider Letter (PDF - 147KB) and the Dear Pharmacist Letter (PDF - 147KB)  Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes;180 mcg/0.5 mL Autoinjector for single use (NDC 0004-0365-09) The firm has adequate supplies Please see the Dear Health Care Provider Letter (PDF - 147KB) and the Dear Pharmacist Letter (PDF - 147KB)  Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes;180 mcg/0.5 mL Pegasys Prefilled syringe (PFS) for single use (NDC 0004-0352-39) (NDC 0004-0357-30) Potential limited availability of the PFS form of 180 mcg/mL Pegasys in the next 6 months. The firm anticipates that the potential shortage of the PFS will resolve by September 2012. Please see the Dear Health Care Provider Letter (PDF - 147KB) and the Dear Pharmacist Letter (PDF - 147KB)  Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes;180 mcg/mL Vial for single use   (NDC 0004-0350-09) The firm has adequate supplies Please see the Dear Health Care Provider Letter (PDF - 147KB) and the Dear Pharmacist Letter (PDF - 147KB)  Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes;180 mcg/mL Vial for single use   (NDC 0004-0350-09) The firm has adequate supplies Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes;135 mcg/0.5 mL Autoinjector for single use (NDC 0004-0360-09) The firm has adequate supplies Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes;180 mcg/0.5 mL Autoinjector for single use (NDC 0004-0365-09) The firm has adequate supplies Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes;180 mcg/0.5 mL Pegasys Prefilled syringe (PFS) for single use (NDC 0004-0352-39) (NDC 0004-0357-30) Potential limited availability of the PFS form of 180 mcg/mL Pegasys. The firm anticipates that the potential shortage of the PFS will resolve by end of June 2013. Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes,,,,,,,,,,,,,
Genentech,peginterferon,1,6/5/13,7/7/13,demand increase; manufacturing delays,blue,,"180 mcg/0.5 mL Pegasys Prefilled syringe (PFS) for single use (NDC 0004-0352-39) 
 (NDC 0004-0357-30) Potential limited availability of the PFS form of 180 mcg/mL Pegasys. The firm anticipates that the potential shortage of the PFS will resolve by end of June 2013. Shortage per Manufacturer: 
 Increased demand and manufacturing delays of the Prefilled Syringes;180 mcg/mL Vial for single use   (NDC 0004-0350-09) The firm has adequate supplies Shortage per Manufacturer: 
 Increased demand and manufacturing delays of the Prefilled Syringes;180 mcg/0.5 mL Autoinjector for single use (NDC 0004-0365-09) The firm has adequate supplies Shortage per Manufacturer: 
 Increased demand and manufacturing delays of the Prefilled Syringes;135 mcg/0.5 mL Autoinjector for single use (NDC 0004-0360-09) The firm has adequate supplies Shortage per Manufacturer: 
 Increased demand and manufacturing delays of the Prefilled Syringes;180 mcg/0.5 mL Pegasys Prefilled syringe (PFS) for single use (NDC 0004-0352-39) (NDC 0004-0357-30) Potential limited availability of the PFS form of 180 mcg/mL Pegasys. The firm anticipates that the potential shortage of the PFS will resolve by end of June 2013. Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes;135 mcg/0.5 mL Autoinjector for single use (NDC 0004-0360-09) The firm has adequate supplies Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes;180 mcg/0.5 mL Autoinjector for single use (NDC 0004-0365-09) The firm has adequate supplies Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes;180 mcg/mL Vial for single use   (NDC 0004-0350-09) The firm has adequate supplies Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes",,,,,,,,,,,,,
Genentech,peginterferon,2,8/1/13,8/1/13,demand increase; manufacturing delays,blue,,180 mcg/0.5 mL Pegasys Prefilled syringe (PFS) for single use (NDC 0004-0352-39) (NDC 0004-0357-30) Potential limited availability of the PFS form of 180 mcg/mL Pegasys. The firm anticipates that the potential shortage of the PFS will resolve by end of June 2013. Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes;135 mcg/0.5 mL Autoinjector for single use (NDC 0004-0360-09) The firm has adequate supplies Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes;180 mcg/0.5 mL Autoinjector for single use (NDC 0004-0365-09) The firm has adequate supplies Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes;180 mcg/mL Vial for single use   (NDC 0004-0350-09) The firm has adequate supplies Shortage per Manufacturer: Increased demand and manufacturing delays of the Prefilled Syringes,,,,,,,,,,,,,
APP,pentam,1,9/4/12,8/19/13,material shortage,green,,"300mg- Lyophilized Powder for Injection (NDC #633230-113-10)   APP has placed this product on allocation Shortage per Manufacturer: API issues;300mg- Lyophilized Powder for Injection (NDC #633230-113-10)   Back-ordered Shortage per Manufacturer: API issues;300mg- Lyophilized Powder for Injection (NDC #633230-113-10)   APP is currently back-ordered.  Next release anticipated early December. Shortage per Manufacturer: API issues;300mg- Lyophilized Powder for Injection (NDC #633230-113-10)   Available.  Check wholesalers for inventory. Shortage per Manufacturer: API issues;300mg- Lyophilized Powder for Injection (NDC #633230-113-10) 
 
   Available.  Check wholesalers for inventory. Shortage per Manufacturer: 
 API issues",,,,,,,,,,,,,
APP,pentamidine,1,9/4/12,8/19/13,material shortage,green,,"300 mg- SDV (NDC 63323-0877-15)   APP is currently back-ordered and cannot estimate a release date at this time.   Shortage per Manufacturer: API issues;300 mg- SDV (NDC 63323-0877-15)   APP is currently back-ordered. Next release anticipated early December.   Shortage per Manufacturer: API issues;300 mg- SDV (NDC 63323-0877-15)   Available.  Check wholesalers for inventory.   Shortage per Manufacturer: API issues;300 mg- SDV (NDC 63323-0877-15) 
   Available.  Check wholesalers for inventory. 
   Shortage per Manufacturer: 
 API issues",,,,,,,,,,,,,
Bedford,pentostatin,1,4/18/12,3/1/13,manufacturing delays; discontinued,black,,Bedford Laboratories has 10 mg lyophilized powder for injection available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.;Manufacturing Delays Bedford Laboratories has 10 mg lyophilized powder for injection available in limited quantities. Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.;,,,,,,,,,,,,,
Hospira,pentothal,1,11/6/09,1/19/11,manufacturing issues,blue,,Manufacturing issue,,,,,,,,,,,,,
Sandoz,phentolamine,1,6/13/12,3/13/13,[temporary import],brown,,;Phentolamine Mesylate Injection 5mg/mL (boxes of 10-1 mL single dose vials) NDC 00781-3028-95 Please contact your wholesaler or Sandoz Customer Service at 800-525-8747 for ordering information. Sandoz in conjunction with FDA has initiated temporary importation of phentolamine mesylate injection into the US market to address this shortage.  The Sandoz phentolamine mesylate injection 5 mg/mL product contains the same active ingredient- phentolamine mesylate- as the phentolamine mesylate for injection 5 mg vial product approved in the United States. However- there are important differences between the US product and Canadian product that Healthcare providers should be aware of before prescribing and product preparation.  Please see the Dear Healthcare Professional Letter (PDF - 260KB) for additional product and supply information.,,,,,,,,,,,,,
Bedford,phentolamine,1,11/24/11,3/13/13,manufacturing delays,blue,,Bedford has no supply of Phentolamine mesylate for injection- 5 mg lyophilized vial (NDC 55390-0113-01). No estimated release date. For additional information please see: http://www.benvenue.com/pages/release.html;Bedford has phentolamine on backorder and the company cannot estimate a release date.;Manufacturing delay Bedford has phentolamine on backorder and the company cannot estimate a release date.;;Phentolamine mesylate for injection- 5 mg lyophilized vial (NDC 55390-0113-01) On backorder Bedford has phentolamine on backorder and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delay,,,,,,,,,,,,,
Baxter,phenylephrine,1,4/28/11,6/22/11,demand increase,orange,,Baxter is currently experiencing a back order situation on the 1 mL vial (NDC 10019-163-12) Baxter has accelerated production and will have product available in mid May. Additional lots are scheduled for manufacturing and will be available for distribution in the June ? July timeframe.,,,,,,,,,,,,,
WestWard,phenylephrine,1,6/30/11,2/6/12,demand increase,orange,,"West-Ward currently has available inventory.  West-Ward has accelerated production and will have additional lots available for release in July and August. .;West-Ward currently has available inventory.  West-Ward has accelerated production and will have additional lots available for release in July and August. 
 
 .",,,,,,,,,,,,,
AmericanRegent,phenylephrine,1,4/28/11,2/6/12,manufacturing delays,blue,,American Regent cannot estimate a release date at this time.;American Regent has available phenylephrine 10 mg/mL 1 mL (NDC 00517-0299-25) and 5 mL (NDC 00517-0405-25) vials.,,,,,,,,,,,,,
Sandoz,phenylephrine,1,4/28/11,2/6/12,,,,Sandoz anticipates increased product availability by the end of May.;Sandoz anticipates increased product availability by the end of July.,,,,,,,,,,,,,
Fresenius,phosphate,1,6/5/13,9/1/13,[temporary import],brown,,"Glycophos (sodium glycerophosphate) injection- 20 mL vial 
 (NDC 63323-241-20)   Importation began May 2013 and will continue until all patient needs are met with US product.  Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Glycophos (sodium glycerophosphate) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 458KB) for additional product and supply information.  FK USA is releasing Glycophos to its authorized distributors. 
  
 Shortage per Manufacturer: 
 Increase in demand;Glycophos (sodium glycerophosphate) injection- 20 mL vial (NDC 63323-241-20)   Importation began May 2013 and will continue until all patient needs are met with US product.  Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Glycophos (sodium glycerophosphate) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 458KB) for additional product and supply information.  FK USA is releasing Glycophos to its authorized distributors.   Shortage per Manufacturer: Increase in demand;Glycophos (sodium glycerophosphate) injection- 20 mL vial (NDC 63323-241-20)   Importation began May 2013 and will continue until all patient needs are met with US product. Please check wholesalers for inventory. Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Glycophos (sodium glycerophosphate) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 458KB) for additional product and supply information.  FK USA is releasing Glycophos to its authorized distributors.   Shortage per Manufacturer: Increase in demand;Glycophos (sodium glycerophosphate) injection- 20 mL vial (NDC 63323-241-20)   Importation began May 2013 and will continue until all patient needs are met with US product. Please check wholesalers for inventory. Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Glycophos (sodium glycerophosphate) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 443KB) for additional product and supply information.  FK USA is releasing Glycophos to its authorized distributors.   Shortage per Manufacturer: Increase in demand",,,,,,,,,,,,,
Fresenius,phosphate,2,10/1/13,3/25/14,[temporary import],brown,,Glycophos (sodium glycerophosphate) injection- 20 mL vial (NDC 63323-241-20)   Importation began May 2013 and will continue until all patient needs are met with US product. Please check wholesalers for inventory. Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Glycophos (sodium glycerophosphate) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 443KB) for additional product and supply information.  FK USA is releasing Glycophos to its authorized distributors.   Shortage per Manufacturer: Increase in demand;Glycophos (sodium glycerophosphate) injection- 20 mL vial (NDC 63323-241-20)     Importation began May 2013. Please check wholesalers for inventory and reference Glycophos.   Currently back-ordered. No release data at this time.   Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Glycophos (sodium glycerophosphate) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 443KB) for additional product and supply information.  FK USA is releasing Glycophos to its authorized distributors.   Shortage per Manufacturer: Increase in demand,,,,,,,,,,,,,
Axcan,photofrin,1,10/9/10,10/9/10,FDA Review,yellow,,Pending supplement under review with FDA,,,,,,,,,,,,,
Amphastar,phytonadione,1,11/10/11,11/13/12,demand increase; available,orange,,Amphastar reports availability. Please note that Vitamin K injection- contains polysorbate 80 and propylene glycol.;Amphastar is not experiencing a shortage. This shortage is due to increased demand and Amphastar has increased production to meet demand. Amphastar reports availability. Please note that Vitamin K injection- contains polysorbate 80 and propylene glycol.;;1 mg/0.5 mL- SAF-T-JET prefilled syringe contains polysorbate 80 and propylene glycol   NDC 76329-1240-5(old NDC 00548-1240-00) Available,,,,,,,,,,,,,
Alcon,pilocarpine,1,6/13/12,9/1/13,manufacturing delays,blue,,";NULL NULL Updates will be provided as further information becomes available. Shortage per Manufacturer: Manufacturing delay;PILOPINE HS (pilocarpine hydrochloride ophthalmic gel) 4% 4 gm tube: (NDC 0065-0215-35)   Unable to estimate a release date Updates will be provided as further information becomes available. Shortage per Manufacturer: Manufacturing delay;NULL NULL Updates will be provided as further information becomes available.
 Shortage per Manufacturer: 
 Manufacturing delay;PILOPINE HS (pilocarpine hydrochloride ophthalmic gel) 4% 
 
 4 gm tube: (NDC 0065-0215-35) 
   Unable to estimate a release date Updates will be provided as further information becomes available.
 Shortage per Manufacturer: 
 Manufacturing delay",,,,,,,,,,,,,
Alcon,pilocarpine,2,10/1/13,3/25/14,manufacturing delays,blue,,PILOPINE HS (pilocarpine hydrochloride ophthalmic gel) 4% 4 gm tube: (NDC 0065-0215-35)   Unable to estimate a release date Updates will be provided as further information becomes available. Shortage per Manufacturer: Manufacturing delay;NULL NULL Updates will be provided as further information becomes available. Shortage per Manufacturer: Manufacturing delay;4 gm tube: (NDC 0065-0215-35)   Unable to estimate a release date Updates will be provided as further information becomes available. Shortage per Manufacturer: Manufacturing delay,,,,,,,,,,,,,
AmericanRegent,potassium,1,6/30/11,9/1/13,manufacturing delays; available; discontinued; not manufacturing; production suspended,blue,,"American Regent anticipates releasing 3 mMol/mL- 50 mL vial (NDC 00517-2350-25) vials mid-July.;American Regent has the 50 mL vials available.  The 5 mL vials and 15 mL vials are currently not being manufactured.;Manufacturing delays     American Regent has the 50 mL vials available.  The 5 mL vials and 15 mL vials are currently not being manufactured.;;3 mMol/mL- 50 mL vial (NDC 00517-2350-25) Available American Regent//Luitpold is not manufacturing the 5 mL vials and 15 mL vials.     Please check with your wholesaler for available inventory.;3 mMol/mL- 5 mL vial (NDC 00517-2305-25) Unavailable American Regent//Luitpold is not manufacturing the 5 mL vials and 15 mL vials.     Please check with your wholesaler for available inventory.;3 mMol/mL- 15 mL vial (NDC 00517-2315-25) Unavailable American Regent//Luitpold is not manufacturing the 5 mL vials and 15 mL vials.     Please check with your wholesaler for available inventory.;3 mMol/mL- 5 mL vial (NDC 00517-2305-25) Unavailable Shortage per Manufacturer: American Regent//Luitpold is not manufacturing the 5 mL vials.   American Regent//Luitpold is not manufacturing the 15 mL vials.   American Regent//Luitpold is not releasing the 50 mL vials;3 mMol/mL- 15 mL vial (NDC 00517-2315-25) Unavailable Shortage per Manufacturer: American Regent//Luitpold is not manufacturing the 5 mL vials.   American Regent//Luitpold is not manufacturing the 15 mL vials.   American Regent//Luitpold is not releasing the 50 mL vials;3 mMol/mL- 50 mL vial (NDC 00517-2350-25) Unavailable Shortage per Manufacturer: American Regent//Luitpold is not manufacturing the 5 mL vials.   American Regent//Luitpold is not manufacturing the 15 mL vials.   American Regent//Luitpold is not releasing the 50 mL vials;3 mMol/mL- 15 mL vial (NDC 00517-2315-25) Unavailable Shortage per Manufacturer: American Regent//Luitpold is not manufacturing the 5 mL vials. 
  
 American Regent//Luitpold is not manufacturing the 15 mL vials. 
  
 American Regent//Luitpold is not releasing the 50 mL vials;3 mMol/mL- 5 mL vial (NDC 00517-2305-25) Unavailable Shortage per Manufacturer: American Regent//Luitpold is not manufacturing the 5 mL vials. 
  
 American Regent//Luitpold is not manufacturing the 15 mL vials. 
  
 American Regent//Luitpold is not releasing the 50 mL vials;3 mMol/mL- 50 mL vial (NDC 00517-2350-25) Unavailable Shortage per Manufacturer: American Regent//Luitpold is not manufacturing the 5 mL vials. 
  
 American Regent//Luitpold is not manufacturing the 15 mL vials. 
  
 American Regent//Luitpold is not releasing the 50 mL vials;3 mMol/mL- 50 mL vial (NDC 00517-2350-25) Unavailable American Regent//Luitpold is not manufacturing the 5 mL or 15 mL vials. American Regent//Luitpold is not releasing the 50 mL vials;3 mMol/mL- 5 mL vial (NDC 00517-2305-25) Unavailable American Regent//Luitpold is not manufacturing the 5 mL or 15 mL vials. American Regent//Luitpold is not releasing the 50 mL vials;3 mMol/mL- 15 mL vial (NDC 00517-2315-25) Unavailable American Regent//Luitpold is not manufacturing the 5 mL or 15 mL vials. American Regent//Luitpold is not releasing the 50 mL vials",,,,,,,,,,,,,
AmericanRegent,potassium,2,10/1/13,3/25/14,production suspended; material shortage,green,,3 mMol/mL- 5 mL vial (NDC 00517-2305-25) Unavailable American Regent//Luitpold is not manufacturing the 5 mL or 15 mL vials. American Regent//Luitpold is not releasing the 50 mL vials;3 mMol/mL- 15 mL vial (NDC 00517-2315-25) Unavailable American Regent//Luitpold is not manufacturing the 5 mL or 15 mL vials. American Regent//Luitpold is not releasing the 50 mL vials;3 mMol/mL- 50 mL vial (NDC 00517-2350-25) Unavailable American Regent//Luitpold is not manufacturing the 5 mL or 15 mL vials. American Regent//Luitpold is not releasing the 50 mL vials;3 mMol/mL- 50 mL vial- package of 25 (NDC 00517-2350-25) Unavailable - No product available for release. No plan to manufacture.  American Regent/Luitpold is not releasing the 5 mL- 15 mL or 50 mL vials.;3 mMol/mL- 5 mL vial- package of 25 (NDC 00517-2305-25) Unavailable - No product available for release. No plan to manufacture.  American Regent/Luitpold is not releasing the 5 mL- 15 mL or 50 mL vials.;3 mMol/mL- 15 mL vial- package of 25 (NDC 00517-2315-25) Unavailable - No product available for release. No plan to manufacture.  American Regent/Luitpold is not releasing the 5 mL- 15 mL or 50 mL vials.,,,,,,,,,,,,,
Fresenius,potassium,1,3/25/14,3/25/14,demand increase,orange,,45 mMol/mL- 15 mL SDV (NDC 63323-0086-15) Available.  Check wholesalers for inventory.  Check wholesalers for inventory.;15 mMol/mL- 5 mL SDV (NDC 63323-0086-05) Currently available.  Check wholesalers for inventory.  Check wholesalers for inventory.;150 mMol/mL- 50 mL SDV (NDC 63323-0086-50) Currently available.  Check wholesalers for inventory.  Check wholesalers for inventory.,,,,,,,,,,,,,
AmericanRegent,potassiuma,1,3/6/13,9/1/13,not releasing,,,100 mL Pharmacy Bulk Package- package of 25 (NDC 00517-2400-25) Unavailable American Regent is currently not releasing Potassium Acetate Injection- USP.;20 mL vial- package of 25 (NDC 00517-2053-25) Unavailable American Regent is currently not releasing Potassium Acetate Injection- USP.;Potassium Acetate Injection- USP 2 mEq/mL Unavailable American Regent is currently not releasing Potassium Acetate Injection- USP.;50 mL vial- package of 25 (NDC 00517-2450-25) Unavailable American Regent is currently not releasing Potassium Acetate Injection- USP.,,,,,,,,,,,,,
AmericanRegent,potassiuma,2,10/1/13,3/25/14,not releasing; material shortage,green,,20 mL vial- package of 25 (NDC 00517-2053-25) Unavailable American Regent is currently not releasing Potassium Acetate Injection- USP.;50 mL vial- package of 25 (NDC 00517-2450-25) Unavailable American Regent is currently not releasing Potassium Acetate Injection- USP.;100 mL Pharmacy Bulk Package- package of 25 (NDC 00517-2400-25) Unavailable American Regent is currently not releasing Potassium Acetate Injection- USP.;100 mL Pharmacy Bulk Package- package of 25 (NDC 00517-2400-25) Unavailable - No product available for release. No plan to manufacture American Regent is currently not releasing Potassium Acetate Injection- USP.;20 mL vial- package of 25 (NDC 00517-2053-25) Unavailable - No product available for release. No plan to manufacture American Regent is currently not releasing Potassium Acetate Injection- USP.;50 mL vial- package of 25 (NDC 00517-2450-25) Unavailable - No product available for release. No plan to manufacture American Regent is currently not releasing Potassium Acetate Injection- USP.,,,,,,,,,,,,,
SanofiAventis,primaquine,1,10/18/11,3/1/12,manufacturing issues; available,blue,,"Sanofi-aventis U.S. is working to restore supply as soon as possible.;Sanofi-aventis U.S. is working to restore supply as soon as possible. Expect product availability in January 2012.;Sanofi-aventis U.S. is working to restore supply as soon as possible. 
 
 Expect product availability in January 2012.;Sanofi-Aventis U.S. currently has limited quantity of primaquine phosphate available.  Expect shortage to be resolved end of March.",,,,,,,,,,,,,
Hospira,procainamide,1,11/18/10,4/22/11,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
Heritage,prochlorperazine,1,3/25/14,3/25/14,available,,,5 mg/mL: 2mL vial- package of 10 (NDC 23155-294-42) Available from January 2014 New launch,,,,,,,,,,,,,
Bedford,prochlorperazine,2,10/1/13,3/25/14,demand increase,orange,,5 mg/mL- 2mL vial- 10 count (NDC 55390-0077-10)   Available. 2 mL is released to wholesalers.;5 mg/mL- 2mL vial- 10 count (NDC 55390-0077-10)   2 mL is AVAILABLE in limited quantities.,,,,,,,,,,,,,
Bedford,prochlorperazine,1,2/2/12,9/1/13,manufacturing delays; demand increase,blue,,Bedford has both prochlorperazine 5 mg/mL injection presentations on back order and the company cannot estimate a release date. The 2 mL vials are pending release while the 10 mL vials will not be manufactured until capacity permits.;Manufacturing delays Bedford has both prochlorperazine 5 mg/mL injection presentations on back order and the company cannot estimate a release date. The 2 mL vials are pending release while the 10 mL vials will not be manufactured until capacity permits.;;5 mg/mL- 2mL vial- 10 count (NDC 55390-0077-10) Bedford has both prochlorperazine 5 mg/mL injection presentations on back order and the company cannot estimate a release date. The 2 mL vials are pending release while the 10 mL vials will not be manufactured until capacity permits. Shortage per Manufacturer: Manufacturing delays;5 mg/mL- 10 mL vial (NDC 55390-0077-01) Bedford has both prochlorperazine 5 mg/mL injection presentations on back order and the company cannot estimate a release date. The 2 mL vials are pending release while the 10 mL vials will not be manufactured until capacity permits. Shortage per Manufacturer: Manufacturing delays;5 mg/mL- 2mL vial- 10 count (NDC 55390-0077-10) Available. 2 mL is released to wholesalers.;5 mg/mL- 10 mL vial (NDC 55390-0077-01) Presentations on back order and the company cannot estimate a release date.;5 mg/mL- 2mL vial- 10 count (NDC 55390-0077-10)   Available. 2 mL is released to wholesalers.,,,,,,,,,,,,,
WestWard,promethazine,1,2/16/12,9/1/13,; demand increase,orange,,"Information pending;Increase in product demand. West-Ward is currently experiencing a backorder situation on Promethazine 25 mg/mL-1 mL vial- 50 mg/mL- 1 mL ampul and Phenergan 25 mg/mL- 1 mL vial.  All other codes are available in limited quantities. West-Ward has accelerated production and will have units of all presentations available for release in the March ? April 2012 timeframe. Product will be made available as it is released;West-Ward is currently experiencing a backorder situation on Promethazine 25 mg/mL-1 mL vial- 50 mg/mL- 1 mL ampul and Phenergan 25 mg/mL- 1 mL vial.  All other codes are available in limited quantities. West-Ward has accelerated production and will have units of all presentations available for release in the March ? April 2012 timeframe. Product will be made available as it is released;;Promethazine 1 mL vial- 25 mg/mL (NDC 0641-0928-25) 1 mL vial- 50 mg/mL (NDC 0641-0929-25)  1 mL ampul- 25mg/mL (NDC 0641-1495-35) 1 mL ampul- 50 mg/mL (NDC 0641-1496-35)   West-Ward is currently experiencing a backorder situation on Promethazine 25 mg/mL-1 mL vial- 50 mg/mL- 1 mL ampul and Phenergan 25 mg/mL- 1 mL vial.  All other codes are available in limited quantities. West-Ward has accelerated production and will have units of all presentations available for release in the March ? April 2012 timeframe. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand.;Phenergan 1 mL vial- 25 mg/mL (NDC 0641-6084-25) 1 mL vial- 50 mg/mL (NDC 0641-6085-25)  1 mL ampul- 25mg/mL (NDC 0641-6082-25) 1 mL ampul- 50 mg/mL (NDC 0641-6083-25)   West-Ward is currently experiencing a backorder situation on Promethazine 25 mg/mL-1 mL vial- 50 mg/mL- 1 mL ampul and Phenergan 25 mg/mL- 1 mL vial.  All other codes are available in limited quantities. West-Ward has accelerated production and will have units of all presentations available for release in the March ? April 2012 timeframe. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand.;Phenergan 1 mL vial- 25 mg/mL (NDC 0641-6084-25) 1 mL vial- 50 mg/mL (NDC 0641-6085-25)  1 mL ampul- 25mg/mL (NDC 0641-6082-25) 1 mL ampul- 50 mg/mL (NDC 0641-6083-25) West-Ward is currently experiencing a small backorder situation on the Phenergan 25 mg/mL- 1 mL vial.   All other Phenergan and Promethazine codes have available inventory.   West-Ward has accelerated production and will have additional units available for release by the end of January 2013. Product will be made available as it is released.;Promethazine 1 mL vial- 25 mg/mL (NDC 0641-0928-25) 1 mL vial- 50 mg/mL (NDC 0641-0929-25)  1 mL ampul- 25mg/mL (NDC 0641-1495-35) 1 mL ampul- 50 mg/mL (NDC 0641-1496-35) West-Ward is currently experiencing a small backorder situation on the Phenergan 25 mg/mL- 1 mL vial.   All other Phenergan and Promethazine codes have available inventory.   West-Ward has accelerated production and will have additional units available for release by the end of January 2013. Product will be made available as it is released.;Phenergan 
 1 mL vial- 25 mg/mL 
 (NDC 0641-6084-25) 
 1 mL vial- 50 mg/mL 
 (NDC 0641-6085-25)  
 1 mL ampul- 25mg/mL 
 (NDC 0641-6082-25) 
 1 mL ampul- 50 mg/mL 
 (NDC 0641-6083-25) West-Ward is currently experiencing a small backorder situation on the Phenergan 25 mg/mL- 1 mL vial. 
  
 All other Phenergan and Promethazine codes have available inventory. 
   West-Ward has accelerated production and will have additional units available for release by the end of January 2013. 
 Product will be made available as it is released.;Promethazine 
 1 mL vial- 25 mg/mL 
 (NDC 0641-0928-25) 
 1 mL vial- 50 mg/mL 
 (NDC 0641-0929-25)  
 1 mL ampul- 25mg/mL 
 (NDC 0641-1495-35) 
 1 mL ampul- 50 mg/mL 
 (NDC 0641-1496-35) West-Ward is currently experiencing a small backorder situation on the Phenergan 25 mg/mL- 1 mL vial. 
  
 All other Phenergan and Promethazine codes have available inventory. 
   West-Ward has accelerated production and will have additional units available for release by the end of January 2013. 
 Product will be made available as it is released.;Promethazine 1 mL vial- 25 mg/mL (NDC 0641-0928-25) 1 mL vial- 50 mg/mL (NDC 0641-0929-25)  1 mL ampul- 25mg/mL (NDC 0641-1495-35) 1 mL ampul- 50 mg/mL (NDC 0641-1496-35) West-Ward is currently experiencing a small backorder situation on the Phenergan 50 mg/mL- 1 mL vial.   All other Phenergan and Promethazine codes have available inventory.   West-Ward has accelerated production on all codes and will have additional units available for release by the end of July 2013.  Several lots of the 50 mg/mL- 1 mL ampul will also be available. Product will be made available as it is released.;Phenergan 1 mL vial- 25 mg/mL (NDC 0641-6084-25) 1 mL vial- 50 mg/mL (NDC 0641-6085-25)  1 mL ampul- 25mg/mL (NDC 0641-6082-25) 1 mL ampul- 50 mg/mL (NDC 0641-6083-25) West-Ward is currently experiencing a small backorder situation on the Phenergan 50 mg/mL- 1 mL vial.   All other Phenergan and Promethazine codes have available inventory.   West-Ward has accelerated production on all codes and will have additional units available for release by the end of July 2013.  Several lots of the 50 mg/mL- 1 mL ampul will also be available. Product will be made available as it is released.;Phenergan 1 mL vial- 25 mg/mL (NDC 0641-6084-25) 1 mL vial- 50 mg/mL (NDC 0641-6085-25)  1 mL ampul- 25mg/mL (NDC 0641-6082-25) 1 mL ampul- 50 mg/mL (NDC 0641-6083-25) West-Ward currently has inventory available for all Promethazine and Phenergan presentations.  West-Ward will have additional units available for release by the end of September 2013.     Product will be made available as it is released.;Promethazine 1 mL vial- 25 mg/mL (NDC 0641-0928-25) 1 mL vial- 50 mg/mL (NDC 0641-0929-25)  1 mL ampul- 25mg/mL (NDC 0641-1495-35) 1 mL ampul- 50 mg/mL (NDC 0641-1496-35) West-Ward currently has inventory available for all Promethazine and Phenergan presentations.  West-Ward will have additional units available for release by the end of September 2013.     Product will be made available as it is released.",,,,,,,,,,,,,
WestWard,promethazine,2,10/1/13,3/2/14,demand increase,orange,,Promethazine 1 mL vial- 25 mg/mL (NDC 0641-0928-25) 1 mL vial- 50 mg/mL (NDC 0641-0929-25)  1 mL ampul- 25mg/mL (NDC 0641-1495-35) 1 mL ampul- 50 mg/mL (NDC 0641-1496-35) West-Ward currently has inventory available for all Promethazine and Phenergan presentations.  West-Ward will have additional units available for release by the end of September 2013.     Product will be made available as it is released.;Phenergan 1 mL vial- 25 mg/mL (NDC 0641-6084-25) 1 mL vial- 50 mg/mL (NDC 0641-6085-25)  1 mL ampul- 25mg/mL (NDC 0641-6082-25) 1 mL ampul- 50 mg/mL (NDC 0641-6083-25) West-Ward currently has inventory available for all Promethazine and Phenergan presentations.  West-Ward will have additional units available for release by the end of September 2013.     Product will be made available as it is released.,,,,,,,,,,,,,
Teva,promethazine,1,2/16/12,9/1/13,manufacturing delays; date. manufacturing delays manufacturing estimate; manufacturing practices requirements; method remediation delays,blue,,Teva has all promethazine injection presentations on back order and the company cannot estimate a release date.;Manufacturing delay Teva has all promethazine injection presentations on back order and the company cannot estimate a release date.;;25 mg/mL; 1 mL vial (NDC 00703-2191-04)    Teva has all promethazine injection presentations on back order and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delay;50 mg/mL; 1 mL vial (NDC 00703-2201-04   Teva has all promethazine injection presentations on back order and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delay;25 mg/mL; 1 mL vial (NDC 00703-2191-04)  Teva has all promethazine injection presentations on back order and the company cannot estimate a release date.;50 mg/mL; 1 mL vial (NDC 00703-2201-04 Teva has all promethazine injection presentations on back order and the company cannot estimate a release date.;25 mg/mL; 1 mL vial (NDC 00703-2191-04)  Teva has all promethazine injection presentations on back order and the company cannot estimate a release date.  Shortage per Manufacturer: Method remediation delays;50 mg/mL; 1 mL vial (NDC 00703-2201-04 Teva has all promethazine injection presentations on back order and the company cannot estimate a release date.  Shortage per Manufacturer: Method remediation delays,,,,,,,,,,,,,
Teva,promethazine,2,10/1/13,3/2/14,method remediation delays,yellow,,25 mg/mL; 1 mL vial (NDC 00703-2191-04)  Teva has all promethazine injection presentations on back order and the company cannot estimate a release date.  Shortage per Manufacturer: Method remediation delays;50 mg/mL; 1 mL vial (NDC 00703-2201-04 Teva has all promethazine injection presentations on back order and the company cannot estimate a release date.  Shortage per Manufacturer: Method remediation delays,,,,,,,,,,,,,
APP,propofol,1,4/28/11,10/20/11,demand increase,orange,,";APP has available ALL generic Propofol 1% sizes (20mL- 50mL and 100mL) and generic Novaplus propofol (20 mL- 50mL and 100 mL) vials available through wholesalers and distributors.  Effective May 19- 2011 orders should be placed directly with wholesalers and distribution centers.  See  http://www.apppharma.com/our-products/product-updates.html  for more information. APP Diprivan (20mL- 50mL and 100mL) and Novaplus Diprivan (20mL- 50mL- and 100 mL) vials are on intermittent back order and the company is releasing product weekly.  These presentations can be ordered direct through APP- or wholesalers can place drop ship orders on the customer's behalf directly with APP.;ALL Diprivan and Propofol presentations are sufficiently stocked at wholesalers and distributors nationwide.   Diprivan 1% (20mL- 50mL- and 100mL) Generic Propofol 1% (20mL- 50mL- and 100mL) Novaplus Propofol 1% (20mL- 50mL- and 100mL) Please check with your wholesalers and distribution centers for available inventory.;ALL Diprivan and Propofol presentations are sufficiently stocked at wholesalers and distributors nationwide.  
 Diprivan 1% (20mL- 50mL- and 100mL)
 Generic Propofol 1% (20mL- 50mL- and 100mL)
 Novaplus Propofol 1% (20mL- 50mL- and 100mL)
 Please check with your wholesalers and distribution centers for available inventory.",,,,,,,,,,,,,
Teva,propofol,3,3/6/13,6/3/13,demand increase,orange,,10 mg/mL; 100 mL (NDC 0703-2859-03)   Teva expects to have limited quantities available April 2013. Product will be available on allocation through upon receipt;10 mg/mL; 20 mL (NDC 0703-2856-04) Teva expects to have limited quantities available April 2013. Product will be available on allocation through upon receipt;10 mg/mL; 100 mL (NDC 0703-2859-03)   Teva has limited units available of the 20 mL presentation. Teva has established a dedicated distribution network for propofol 20 mL - product can be ordered by calling 1-855-284-3896.;10 mg/mL; 20 mL (NDC 0703-2856-04) Teva has limited units available of the 20 mL presentation. Teva has established a dedicated distribution network for propofol 20 mL - product can be ordered by calling 1-855-284-3896.;10 mg/mL; 100 mL (NDC 0703-2859-03)   Teva has limited quantities of the 20 mL and 100 mL vials available. Product will be available on allocation through next several months.   Teva has established a dedicated distribution network for propofol 20 mL - product can be ordered by calling 1-855-284-3896.;10 mg/mL; 20 mL (NDC 0703-2856-04) Teva has limited quantities of the 20 mL and 100 mL vials available. Product will be available on allocation through next several months.   Teva has established a dedicated distribution network for propofol 20 mL - product can be ordered by calling 1-855-284-3896.,,,,,,,,,,,,,
APP,propofol,2,4/18/12,6/3/13,demand increase; [temporary import],brown,,APP is currently back-ordered on all presentations of Propofol.  Check wholesalers for available inventory.  APP has all presentations of Diprivan available- 20mL (NDC 63323-269-20)- 50 mL (NDC 63323-269-50) and 100 mL (NDC 63323-269-65) - Check wholesalers for inventory.;Increased demand APP is currently back-ordered on all presentations of Propofol.  Check wholesalers for available inventory.  APP has all presentations of Diprivan available- 20mL (NDC 63323-269-20)- 50 mL (NDC 63323-269-50) and 100 mL (NDC 63323-269-65) - Check wholesalers for inventory.;;Propofol 100 mL (NDC 63323-270-65) Check wholesalers for inventory APP is releasing Propofol ad Diprivan directly into the channel.  Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;Fresenius Propoven 1% 100 mL SD Vial (NDC 63323-297-66) Importation begins early July- with product available in the channel by mid July APP in conjunction with FDA has initiated temporary importation of Fresenius Propoven 1% (propofol) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 614KB)for additional product and supply information. APP is releasing Fresenius Propoven 1% (propofol) directly into the channel as it becomes available. Shortage per Manufacturer: Manufacturing delay .;Fresenius Propoven 1% 20 mL glass ampule (NDC 63323-297-30) Importation begins early July- with product available in the channel by mid July APP in conjunction with FDA has initiated temporary importation of Fresenius Propoven 1% (propofol) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 614KB)for additional product and supply information. APP is releasing Fresenius Propoven 1% (propofol) directly into the channel as it becomes available. Shortage per Manufacturer: Manufacturing delay .;Propofol  50 mL (NDC 63323-270-50) Check wholesalers for inventory APP is releasing Propofol ad Diprivan directly into the channel.  Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;Diprivan 100 mL (NDC 63323-269-65) Check wholesalers for inventory APP is releasing Propofol ad Diprivan directly into the channel.  Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;Propofol 20 mL (NDC 63323-270-25) Check wholesalers for inventory APP is releasing Propofol ad Diprivan directly into the channel.  Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;Diprivan 20 mL (NDC 63323-269-20) Check wholesalers for inventory APP is releasing Propofol ad Diprivan directly into the channel.  Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;Fresenius Propoven 1% 50 mL SD Vial (NDC 63323-297-50) Importation begins early July- with product available in the channel by mid July APP in conjunction with FDA has initiated temporary importation of Fresenius Propoven 1% (propofol) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 614KB)for additional product and supply information. APP is releasing Fresenius Propoven 1% (propofol) directly into the channel as it becomes available. Shortage per Manufacturer: Manufacturing delay .;Diprivan 50 mL (NDC 63323-269-50) Check wholesalers for inventory APP is releasing Propofol ad Diprivan directly into the channel.  Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;Diprivan 100 mL (NDC 63323-269-65) All propofol is on intermittent backorder.   APP is currently experiencing unavoidable delays on inbound shipments and product releases due to Hurricane Sandy.   Please continue to check wholesalers for inventory. APP is committed to resolving the distribution challenges as quickly as possible.;Diprivan 50 mL (NDC 63323-269-50) All propofol is on intermittent backorder.   APP is currently experiencing unavoidable delays on inbound shipments and product releases due to Hurricane Sandy.   Please continue to check wholesalers for inventory. APP is committed to resolving the distribution challenges as quickly as possible.;Diprivan 20 mL (NDC 63323-269-20) All propofol is on intermittent backorder.   APP is currently experiencing unavoidable delays on inbound shipments and product releases due to Hurricane Sandy.   Please continue to check wholesalers for inventory. APP is committed to resolving the distribution challenges as quickly as possible.;Propofol  50 mL (NDC 63323-270-50) All propofol is on intermittent backorder.   APP is currently experiencing unavoidable delays on inbound shipments and product releases due to Hurricane Sandy.   Please continue to check wholesalers for inventory. APP is committed to resolving the distribution challenges as quickly as possible.;Propofol 20 mL (NDC 63323-270-25) All propofol is on intermittent backorder.   APP is currently experiencing unavoidable delays on inbound shipments and product releases due to Hurricane Sandy.   Please continue to check wholesalers for inventory. APP is committed to resolving the distribution challenges as quickly as possible.;Propofol 100 mL (NDC 63323-270-65) All propofol is on intermittent backorder.   APP is currently experiencing unavoidable delays on inbound shipments and product releases due to Hurricane Sandy.   Please continue to check wholesalers for inventory. APP is committed to resolving the distribution challenges as quickly as possible.;Fresenius Propoven 1% 100 mL SD Vial (NDC 63323-297-66) Importation began July 2012 and will continue until all patient needs are met with approved propofol APP in conjunction with FDA has initiated temporary importation of Fresenius Propoven 1% (propofol) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 614KB)for additional product and supply information. APP is releasing Fresenius Propoven 1% (propofol) directly into the channel as it becomes available. Shortage per Manufacturer: Manufacturing delay .;Diprivan 50 mL (NDC 63323-269-50) All propofol is on intermittent backorder.   APP is releasing Propofol and Diprivan directly into the channel.  Please check wholesalers for inventory.;Diprivan 100 mL (NDC 63323-269-65) All propofol is on intermittent backorder.   APP is releasing Propofol and Diprivan directly into the channel.  Please check wholesalers for inventory.;Fresenius Propoven 1% 20 mL glass ampule (NDC 63323-297-30) Importation began July 2012 and will continue until all patient needs are met with approved propofol APP in conjunction with FDA has initiated temporary importation of Fresenius Propoven 1% (propofol) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 614KB)for additional product and supply information. APP is releasing Fresenius Propoven 1% (propofol) directly into the channel as it becomes available. Shortage per Manufacturer: Manufacturing delay .;Propofol 100 mL (NDC 63323-270-65) All propofol is on intermittent backorder.   APP is releasing Propofol and Diprivan directly into the channel.  Please check wholesalers for inventory.;Diprivan 20 mL (NDC 63323-269-20) All propofol is on intermittent backorder.   APP is releasing Propofol and Diprivan directly into the channel.  Please check wholesalers for inventory.;Propofol 20 mL (NDC 63323-270-25) All propofol is on intermittent backorder.   APP is releasing Propofol and Diprivan directly into the channel.  Please check wholesalers for inventory.;Fresenius Propoven 1% 50 mL SD Vial (NDC 63323-297-50) Importation began July 2012 and will continue until all patient needs are met with approved propofol APP in conjunction with FDA has initiated temporary importation of Fresenius Propoven 1% (propofol) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 614KB)for additional product and supply information. APP is releasing Fresenius Propoven 1% (propofol) directly into the channel as it becomes available. Shortage per Manufacturer: Manufacturing delay .;Propofol  50 mL (NDC 63323-270-50) All propofol is on intermittent backorder.   APP is releasing Propofol and Diprivan directly into the channel.  Please check wholesalers for inventory.;Diprivan 100 mL (NDC 63323-269-65) Weekly Releases  APP is releasing Propofol and Diprivan directly into the channel.  Please check wholesalers for inventory.   APP is introducing a new Diprivan 20mL in a 10/pk configuration (NDC# 63323-269-29) to replace the Diprivan 20mL in a 25/pk configuration (NDC# 63323-269-20).;Propofol  50 mL (NDC 63323-270-50) Weekly Releases  APP is releasing Propofol and Diprivan directly into the channel.  Please check wholesalers for inventory.   APP is introducing a new Diprivan 20mL in a 10/pk configuration (NDC# 63323-269-29) to replace the Diprivan 20mL in a 25/pk configuration (NDC# 63323-269-20).;Diprivan 50 mL (NDC 63323-269-50) Weekly Releases  APP is releasing Propofol and Diprivan directly into the channel.  Please check wholesalers for inventory.   APP is introducing a new Diprivan 20mL in a 10/pk configuration (NDC# 63323-269-29) to replace the Diprivan 20mL in a 25/pk configuration (NDC# 63323-269-20).;Diprivan 20 mL (NDC 63323-269-20) -discontinue 25/pk   Diprivan 20mL  (NDC 63323-269-29) - introducing new 10/pk   Weekly Releases  APP is releasing Propofol and Diprivan directly into the channel.  Please check wholesalers for inventory.   APP is introducing a new Diprivan 20mL in a 10/pk configuration (NDC# 63323-269-29) to replace the Diprivan 20mL in a 25/pk configuration (NDC# 63323-269-20).;Propofol 100 mL (NDC 63323-270-65) Weekly Releases  APP is releasing Propofol and Diprivan directly into the channel.  Please check wholesalers for inventory.   APP is introducing a new Diprivan 20mL in a 10/pk configuration (NDC# 63323-269-29) to replace the Diprivan 20mL in a 25/pk configuration (NDC# 63323-269-20).;Propofol 20 mL (NDC 63323-270-25) Weekly Releases  APP is releasing Propofol and Diprivan directly into the channel.  Please check wholesalers for inventory.   APP is introducing a new Diprivan 20mL in a 10/pk configuration (NDC# 63323-269-29) to replace the Diprivan 20mL in a 25/pk configuration (NDC# 63323-269-20).,,,,,,,,,,,,,
APP,propofol,1,10/30/09,4/22/11,demand increase; product recall,yellow,,Increase in demand     Recent recall of specific lots has led to increased demand.     Increase in demand.;Increase in demand             Recent recall of specific lots has led to increased demand.     Increase in demand.;Increase in demand             Recent recall of specific lots has led to increased demand.             Increase in demand.;Teva Pharmaceuticals does not currently have propofol available. Teva manufactures propofol injection 10 mg/mL in 20 mL vials (NDC 00703-2856-04), 50 mL vials (NDC 00409-4699-33), and 100 mL vials (NDC 00409-4699-24).   Please see information on availability in the Related Information section.;Teva Pharmaceuticals recalled specific lots in fall 2009 due to possible sterility issues. Teva has recently released some propofol 20ml, 50ml and 100ml vials and expects additional quantities over the coming months. Teva manufactures propofol injection 10 mg/mL in 20 mL vials (NDC 00703-2856-04), 50 mL vials (NDC 00703-2858-08), and 100 mL vials (NDC 00703-2859-03).   Hospira Pharmaceuticals recalled specific lots due to presence of particulate matter in vials. Hospira has released some propofol 20ml, 50ml and 100ml and expects additional quantities in the coming months. Hospira manufactures Propofol injection 10 mg/mL, in 20 mL vials (NDC 00409-4699-30), 50 mL vials (NDC 00409-4699-33), and 100 mL vials (NDC 00409-4699-24).   APP has increased production in response to the increased demand. Please see information on availability in the Related Information section.;Teva Pharmaceuticals recalled specific lots in fall 2009 due to possible sterility issues.   Hospira Pharmaceuticals recalled specific lots due to presence of particulate matter in vials. Hospira has released some propofol 20ml, 50ml and 100ml and expects additional quantities in the coming months. Hospira manufactures Propofol injection 10 mg/mL, in 20 mL vials (NDC 00409-4699-30), 50 mL vials (NDC 00409-4699-33), and 100 mL vials (NDC 00409-4699-24).   APP has increased production in response to the increased demand. Please see information on availability in the Related Information section.;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira Inc. recalled specific lots because some containers may contain particulate matter. Hospira has implemented improvements to its manufacturing process and is coordinating with the FDA to begin distribution of propofol manufactured under a new process as soon as possible.   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira Inc. recalled specific lots because some containers may contain particulate matter. Hospira has implemented improvements to its manufacturing process and is coordinating with the FDA to begin distribution of propofol manufactured under a new process as soon as possible.   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira is beginning to release a limited number of batches of propofol. Further delivery information will be forthcoming   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira is beginning to release a limited number of batches of propofol. Further delivery information will be forthcoming   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira is beginning to release a limited number of batches of propofol. Further delivery information will be forthcoming   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section
Hospira,propofol,1,10/30/09,4/22/11,demand increase; product recall,yellow,,Increase in demand     Recent recall of specific lots has led to increased demand.     Increase in demand.;Increase in demand             Recent recall of specific lots has led to increased demand.     Increase in demand.;Increase in demand             Recent recall of specific lots has led to increased demand.             Increase in demand.;Teva Pharmaceuticals does not currently have propofol available. Teva manufactures propofol injection 10 mg/mL in 20 mL vials (NDC 00703-2856-04), 50 mL vials (NDC 00409-4699-33), and 100 mL vials (NDC 00409-4699-24).   Please see information on availability in the Related Information section.;Teva Pharmaceuticals recalled specific lots in fall 2009 due to possible sterility issues. Teva has recently released some propofol 20ml, 50ml and 100ml vials and expects additional quantities over the coming months. Teva manufactures propofol injection 10 mg/mL in 20 mL vials (NDC 00703-2856-04), 50 mL vials (NDC 00703-2858-08), and 100 mL vials (NDC 00703-2859-03).   Hospira Pharmaceuticals recalled specific lots due to presence of particulate matter in vials. Hospira has released some propofol 20ml, 50ml and 100ml and expects additional quantities in the coming months. Hospira manufactures Propofol injection 10 mg/mL, in 20 mL vials (NDC 00409-4699-30), 50 mL vials (NDC 00409-4699-33), and 100 mL vials (NDC 00409-4699-24).   APP has increased production in response to the increased demand. Please see information on availability in the Related Information section.;Teva Pharmaceuticals recalled specific lots in fall 2009 due to possible sterility issues.   Hospira Pharmaceuticals recalled specific lots due to presence of particulate matter in vials. Hospira has released some propofol 20ml, 50ml and 100ml and expects additional quantities in the coming months. Hospira manufactures Propofol injection 10 mg/mL, in 20 mL vials (NDC 00409-4699-30), 50 mL vials (NDC 00409-4699-33), and 100 mL vials (NDC 00409-4699-24).   APP has increased production in response to the increased demand. Please see information on availability in the Related Information section.;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira Inc. recalled specific lots because some containers may contain particulate matter. Hospira has implemented improvements to its manufacturing process and is coordinating with the FDA to begin distribution of propofol manufactured under a new process as soon as possible.   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira Inc. recalled specific lots because some containers may contain particulate matter. Hospira has implemented improvements to its manufacturing process and is coordinating with the FDA to begin distribution of propofol manufactured under a new process as soon as possible.   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira is beginning to release a limited number of batches of propofol. Further delivery information will be forthcoming   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira is beginning to release a limited number of batches of propofol. Further delivery information will be forthcoming   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira is beginning to release a limited number of batches of propofol. Further delivery information will be forthcoming   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section
Teva,propofol,1,10/30/09,4/22/11,demand increase; product recall,yellow,,Increase in demand     Recent recall of specific lots has led to increased demand.     Increase in demand.;Increase in demand             Recent recall of specific lots has led to increased demand.     Increase in demand.;Increase in demand             Recent recall of specific lots has led to increased demand.             Increase in demand.;Teva Pharmaceuticals does not currently have propofol available. Teva manufactures propofol injection 10 mg/mL in 20 mL vials (NDC 00703-2856-04), 50 mL vials (NDC 00409-4699-33), and 100 mL vials (NDC 00409-4699-24).   Please see information on availability in the Related Information section.;Teva Pharmaceuticals recalled specific lots in fall 2009 due to possible sterility issues. Teva has recently released some propofol 20ml, 50ml and 100ml vials and expects additional quantities over the coming months. Teva manufactures propofol injection 10 mg/mL in 20 mL vials (NDC 00703-2856-04), 50 mL vials (NDC 00703-2858-08), and 100 mL vials (NDC 00703-2859-03).   Hospira Pharmaceuticals recalled specific lots due to presence of particulate matter in vials. Hospira has released some propofol 20ml, 50ml and 100ml and expects additional quantities in the coming months. Hospira manufactures Propofol injection 10 mg/mL, in 20 mL vials (NDC 00409-4699-30), 50 mL vials (NDC 00409-4699-33), and 100 mL vials (NDC 00409-4699-24).   APP has increased production in response to the increased demand. Please see information on availability in the Related Information section.;Teva Pharmaceuticals recalled specific lots in fall 2009 due to possible sterility issues.   Hospira Pharmaceuticals recalled specific lots due to presence of particulate matter in vials. Hospira has released some propofol 20ml, 50ml and 100ml and expects additional quantities in the coming months. Hospira manufactures Propofol injection 10 mg/mL, in 20 mL vials (NDC 00409-4699-30), 50 mL vials (NDC 00409-4699-33), and 100 mL vials (NDC 00409-4699-24).   APP has increased production in response to the increased demand. Please see information on availability in the Related Information section.;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira Inc. recalled specific lots because some containers may contain particulate matter. Hospira has implemented improvements to its manufacturing process and is coordinating with the FDA to begin distribution of propofol manufactured under a new process as soon as possible.   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira Inc. recalled specific lots because some containers may contain particulate matter. Hospira has implemented improvements to its manufacturing process and is coordinating with the FDA to begin distribution of propofol manufactured under a new process as soon as possible.   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira is beginning to release a limited number of batches of propofol. Further delivery information will be forthcoming   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira is beginning to release a limited number of batches of propofol. Further delivery information will be forthcoming   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section;Teva Pharmaceuticals has discontinued their propofol injection.   Hospira is beginning to release a limited number of batches of propofol. Further delivery information will be forthcoming   APP has increased production in response to the increased demand. Please see additional information on availability in the Related Information section
Teva,propofol,1,4/28/11,10/20/11,discontinued,black,,Questions and Answers on the Propofol Shortage;,,,,,,,,,,,,,
Teva,propofol,2,1/10/13,1/16/13,,,,10 mg/mL; 100 mL (NDC 0703-2859-03)   Expected availability late February 2013. Product will be available on allocation;10 mg/mL; 20 mL (NDC 0703-2856-04) Expected availability late February 2013. Product will be available on allocation,,,,,,,,,,,,,
Sandoz,regnol,1,3/6/13,6/3/13,demand increase; available,orange,,5 mg/mL (NDC 0781-3040-95) Available Shortage per Manufacturer: Manufacturing delays and increase in demand;5 mg/mL (NDC 0781-3040-95) Available,,,,,,,,,,,,,
Sandoz,regonol,1,2/9/11,3/19/11,manufacturing delays,blue,,Manufacturing delays  ,,,,,,,,,,,,,
Guardian,renacidin,1,2/2/11,4/22/11,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
Guardian,renacidin,1,4/28/11,5/18/11,manufacturing delays,blue,,Guardian Laboratories has less than a one week supply as of 1/27/11 and continues to allocate product with no back-orders. The planned date of release will be posted once available. Guardian Labs cannot estimate when product will be available.,,,,,,,,,,,,,
Sandoz,reserpine,2,10/1/13,3/25/14,component delay,green,,0.1 mg   1000s (NDC 0185-0032-10) Next available supply August 2014  Delay of active ingredient;0.25 mg  100s (NDC 0185-0134-01) Next available supply August 2014  Delay of active ingredient;0.25 mg   1000s (NDC 0185-0134-10) Next available supply August 2014  Delay of active ingredient;0.1 mg   100s (NDC 0185-0032-01) Next available supply August 2014  Delay of active ingredient;0.25 mg   1000s (NDC 0185-0134-10) Next available supply October 2014 Active Pharmaceutical Ingredient and Raw Material changes Required. Changes currently in process.;0.1 mg   1000s (NDC 0185-0032-10) Next available supply October 2014 Active Pharmaceutical Ingredient and Raw Material changes Required. Changes currently in process.;0.25 mg  100s (NDC 0185-0134-01) Next available supply October 2014 Active Pharmaceutical Ingredient and Raw Material changes Required. Changes currently in process.;0.1 mg   100s (NDC 0185-0032-01) Next available supply October 2014 Active Pharmaceutical Ingredient and Raw Material changes Required. Changes currently in process.,,,,,,,,,,,,,
Sandoz,reserpine,1,4/11/13,9/1/13,material shortage; component delay,green,,"0.1 mg   1000s (NDC 0185-0032-10) Next available supply August 2013;0.1 mg   100s (NDC 0185-0032-01) Next available supply August 2013;0.25 mg  100s (NDC 0185-0134-01) Next available supply August 2013;0.25 mg   1000s (NDC 0185-0134-10) Next available supply August 2013;0.1 mg   1000s 
 (NDC 0185-0032-10) Next available supply August 2013;0.25 mg   1000s 
 (NDC 0185-0134-10) Next available supply August 2013;0.25 mg  100s 
 (NDC 0185-0134-01) Next available supply August 2013;0.1 mg   1000s (NDC 0185-0032-10) Next available supply July 2014  Delay of active ingredeint;0.1 mg   100s (NDC 0185-0032-01) Next available supply July 2014  Delay of active ingredeint;0.25 mg  100s (NDC 0185-0134-01) Next available supply July 2014  Delay of active ingredeint;0.25 mg   1000s (NDC 0185-0134-10) Next available supply July 2014  Delay of active ingredeint;0.1 mg   1000s (NDC 0185-0032-10) Next available supply July 2014  Delay of active ingredient;0.1 mg   100s (NDC 0185-0032-01) Next available supply July 2014  Delay of active ingredient;0.25 mg  100s (NDC 0185-0134-01) Next available supply July 2014  Delay of active ingredient;0.25 mg   1000s (NDC 0185-0134-10) Next available supply July 2014  Delay of active ingredient;0.1 mg   1000s (NDC 0185-0032-10) Next available supply August 2014  Delay of active ingredient;0.1 mg   100s (NDC 0185-0032-01) Next available supply August 2014  Delay of active ingredient;0.25 mg  100s (NDC 0185-0134-01) Next available supply August 2014  Delay of active ingredient;0.25 mg   1000s (NDC 0185-0134-10) Next available supply August 2014  Delay of active ingredient",,,,,,,,,,,,,
Sanofi,rifampin,1,5/5/13,5/12/13,available,,,600 mg vial (NDC 00068-0597-01) Available N/A,,,,,,,,,,,,,
Akorn,rifampin,1,5/5/13,5/12/13,demand increase,orange,,600 mg vial (NDC 17478-0151-42) Unavailable Please check with your wholesaler for available inventory,,,,,,,,,,,,,
Akorn,rifampin,2,6/5/13,9/1/13,demand increase,orange,,600 mg vial (NDC 17478-0151-42) Unavailable Please check with your wholesaler for available inventory;600 mg vial (NDC 17478-0151-42) Unavailable   Seeking re-introduction during 4Q 2013 Please check with your wholesaler for available inventory Shortage per manufacturer: manufacturing delay,,,,,,,,,,,,,
Akorn,rifampin,3,10/1/13,3/25/14,demand increase,orange,,600 mg vial (NDC 17478-0151-42) Unavailable   Seeking re-introduction during 4Q 2013 Please check with your wholesaler for available inventory Shortage per manufacturer: manufacturing delay,,,,,,,,,,,,,
Sanofi,rifampin,2,6/5/13,9/1/13,demand increase; available,orange,,600 mg vial (NDC 00068-0597-01) Available Available;600 mg vial (NDC 00068-0597-01) Unavailable.  Expected recovery date 9/12/2013 Shortage per manufacturer.,,,,,,,,,,,,,
Sanofi,rifampin,3,10/1/13,3/25/14,demand increase; available,orange,,600 mg vial (NDC 00068-0597-01) Unavailable.  Expected recovery date 9/12/2013 Shortage per manufacturer.;600 mg vial (NDC 00068-0597-01) Drug product currently on allocation due to increased product demand;600 mg vial (NDC 00068-0597-01) Available,,,,,,,,,,,,,
Bedford,rifampin,1,4/11/13,9/1/13,demand increase; manufacturing delays,blue,,"600 mg vial (NDC 55390-0123-01) Currently on backorder.;600 mg vial (NDC 55390-0123-01) Currently on backorder. Availability of products is updated on the Bedford Laboratories website. Shortage per Manufacturer: Manufacturing delays;600 mg vial (NDC 55390-0123-01) Unavailable Shortage per Manufacturer: 
 Manufacturing delays 
 Availability of products is updated on the Bedford Laboratories website.;600 mg vial (NDC 55390-0123-01) Unavailable Shortage per Manufacturer: Manufacturing delays  Availability of products is updated on the Bedford Laboratories website.;600 mg vial (NDC 55390-0123-01) Unavailable Availability of products is updated on the Bedford Laboratories website. Shortage per Manufacturer: Manufacturing delays;600 mg vial (NDC 55390-0123-01) Unavailable Shortage per Manufacturer: Manufacturing delays availability of product is updated on the Bedford Laboratories website.",,,,,,,,,,,,,
Bedford,rifampin,2,10/1/13,3/25/14,manufacturing delays; pending manufacturing change,blue,,600 mg vial (NDC 55390-0123-01) Unavailable Shortage per Manufacturer: Manufacturing delays availability of product is updated on the Bedford Laboratories website.;600 mg vial (NDC 55390-0123-01) Unavailable Shortage: Pending Manufacturing Change or Addition. Availability of products is updated on the Bedford Laboratories website.,,,,,,,,,,,,,
ChiRhoClin,secretin,1,6/23/12,3/25/14,manufacturing site change,blue,,;16 mcg vial (NDC  67066-2225-01) No presentations are available. On back order and the company cannot estimate a release date. Shortage per Manufacturer: Cannot provide a reason for the shortage.;16 mcg vial (NDC  67066-005-01) Current supply is available until January 2013.  Expect new manufacturing facility to be qualified February 2013. Qualifying a new manufacturing site. See the Dear Health Care Provider Letter: Secretin Injection (ChiRhoStim) (PDF -110KB);16 mcg vial (NDC  67066-005-01) Current supply is available until January 2013. Qualifying a new manufacturing site. See the Dear Health Care Provider Letter: Secretin Injection (ChiRhoStim) (PDF -110KB);16 mcg vial (NDC  67066-005-01) Current supply's expiration date has been extended to July 2013. Qualifying a new manufacturing site. See the Dear Health Care Provider Letter: Secretin Injection (ChiRhoStim) (PDF -244KB);16 mcg vial (NDC  67066-005-01) Unavailable Qualifying a new manufacturing site.,,,,,,,,,,,,,
AmericanRegent,selenium,1,11/3/11,3/25/14,manufacturing delays; not releasing; available; shipping delay; demand increase,blue,,American Regent has selenium injection on back order and the company cannot estimate a release date.;American Regent has Selenium Injection on back order and the company cannot estimate a release date.;Manufacturing delays American Regent has Selenium Injection on back order and the company cannot estimate a release date.;;40 mcg/mL elemental selenium 10 mL vial- package of 25 (NDC 00157-6510-25)   Available Please check with your wholesaler for available inventory. Shortage per Manufacturer: American Regent is currently not releasing Selenium Injection.;40 mcg/mL elemental selenium 10 mL vial- package of 25 (NDC 00157-6510-25)   Unavailable Shortage per Manufacturer: American Regent is currently not releasing Selenium Injection.;40 mcg/mL elemental selenium 10 mL vial- package of 25 (NDC 00157-6510-25)   Unavailable Shortage per Manufacturer: American Regent is currently not releasing the 10 mL vial.;40 mcg/mL elemental selenium 10 mL vial- package of 25 (NDC 00157-6510-25)   Temporarily unavailable. Next delivery end January 2013;40 mcg/mL elemental selenium 10 mL vial- package of 25 (NDC 00157-6510-25)   Temporarily unavailable. Next delivery end of March 2013;40 mcg/mL elemental selenium 10 mL vial- package of 25 (NDC 00157-6510-25)   Temporarily unavailable. Next delivery end of April 2013;40 mcg/mL elemental selenium 10 mL vial- package of 25 (NDC 00157-6510-25)   Available American Regent is currently releasing the 10 mL vial size.;40 mcg/mL elemental selenium 10 mL vial- package of 25 (NDC 00157-6510-25)  Available American Regent is currently releasing the 10 mL vial size.;40 mcg/mL elemental selenium 10 mL vial- package of 25 (NDC 00157-6510-25)  Unavailable American Regent is currently not releasing the 10 mL vial size.;40 mcg/mL elemental selenium 10 mL vial- package of 25 (NDC 00157-6510-25)  Unavailable. Product on backorder and will be made available as it is released. Shortage per Manufacturer: Manufacturing delay,,,,,,,,,,,,,
Bracco,sincalide,1,7/2/13,3/25/14,manufacturing delays,blue,,5 ug/vial powder- lyophilized for solution NDC:  0270-0556-15  Product inventory will be completely depleted and ?out of stock? by July 1. We anticipate this ?out of stock? situation to continue for a 7 week period.   Manufacturing delay at contract manufacturer. Product manufacturing is due to resume on July 3 with an anticipated 6 week production schedule. Commercially saleable product is anticipated to be available after August 14. Please note timelines may change as product manufacturing commences and the process advances. Updates will be provided to customers- as they become available.;5 ug/vial powder- lyophilized for solution NDC:  0270-0556-15  Product inventory will be completely depleted and ?out of stock? by July 1. We anticipate this ?out of stock? situation to continue for a 7 week period.   Product manufacturing resumed in July with an anticipated 6 week production schedule. Commercially saleable product is anticipated to be available after August 14. Please note timelines may change as the product manufacturing process advances. Updates will be provided to customers- as they become available.;5 ug/vial powder- lyophilized for solution NDC:  0270-0556-15  Anticipate commercial availability during the week of September 9- 2013.;5 mcg/vial powder- lyophilized for solution NDC: 0270-0556-15 A limited supply of Kinevac will be available this week. All back orders will be partially filled. New orders that are placed with Bracco will remain on back order and may be partially fulfilled based on available Kinevac market units.,,,,,,,,,,,,,
Merck,sinemet,1,2/9/11,2/19/11,,,,See Related Information,,,,,,,,,,,,,
APP,sodiuma,1,2/2/12,3/2/14,demand increase,orange,,APP has sodium acetate on back order and estimates a release date in mid-March.;APP has sodium acetate on back order and estimates a release date in late-March.;APP has sodium acetate on back order and estimates a release date in mid-April.;Increased Demand APP has sodium acetate on back order and estimates a release date in mid-April.;APP has sodium acetate on back order and cannot estimate a release date at this time.;;2 mEq/mL- 100 mL vial (NDC 63323-0032-61) Currently back-ordered APP has sodium acetate on back order and expects a release mid August. Shortage per Manufacturer: Increased demand;2 mEq/mL- 100 mL vial (NDC 63323-0032-61) Currently back-ordered. Next release anticipated early September. APP has sodium acetate on back order and expects a release early September.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 100 mL vial (NDC 63323-0032-61) Available. Check Wholesalers for inventory. APP has sodium acetate on back order and expects a release early September.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 100 mL vial (NDC 63323-0032-61) Back-ordered. Next delivery November 2012 APP has sodium acetate on back order and expects a release November 2012.   Shortage per Manufacturer: Increased demand;2 mEq/mL- 100 mL vial (NDC 63323-0032-61) Available.  Check wholesalers for inventory. Check wholesalers for inventory   Shortage per Manufacturer: Increased demand;2 mEq/mL- 100 mL vial (NDC 63323-0032-61) Backordered.  Next release anticipated early April 2013. Check wholesalers for inventory   Shortage per Manufacturer: Increased demand;2 mEq/mL- 100 mL vial (NDC 63323-0032-61) Available. Check wholesalers for inventory. Check wholesalers for inventory   Shortage per Manufacturer: Increased demand;2 mEq/mL- 100 mL vial (NDC 63323-0032-61) Available Check wholesalers for inventory   Shortage per Manufacturer: Increased demand,,,,,,,,,,,,,
AmericanRegent,sodiuma,1,2/9/12,3/2/14,manufacturing delays; available; not releasing; discontinued; demand increase; not manufacturing,black,,American Regent has the 20 mL vials and 50 mL vials available.  The 100 mL vial has been discontinued.;American Regent has the 20 mL vials and 50 mL vials currently on back order. The 100 mL vial has been discontinued.;Manufacturing delays American Regent has the 20 mL vials currently on backorder. American Regent has the 50 mL vials currently on backorder. The 100 mL vial has been discontinued.;American Regent has the 20 mL vials currently on backorder. American Regent has the 50 mL vials currently on backorder. The 100 mL vial has been discontinued.;;4 mEq/mL- 50 mL vial (NDC 00517-5023-25) Unavailable Shortage per Manufacturer: Increased Demand American Regent is currently not releasing the 20 mL  or 50mL vials.;2 mEq/mL- 100 mL vial (NDC 00517-2500-25) Discontinued Shortage per Manufacturer: Increased Demand American Regent is currently not releasing the 20 mL  or 50mL vials.;2 mEq/mL- 20 mL vial (NDC 00517-2096-25) Unavailable Shortage per Manufacturer: Increased Demand American Regent is currently not releasing the 20 mL  or 50mL vials.;2 mEq/mL- 100 mL vial- 25s (NDC 00517-2500-25) Discontinued Shortage per Manufacturer: American Regent is currently not releasing the 20 mL vial.   American Regent/Luitpold has discontinued manufacturing the 100 mL vial.   American Regent is currently not releasing the 50 mL vial.;4 mEq/mL- 50 mL vial- 25s (NDC 00517-5023-25) Unavailable Shortage per Manufacturer: American Regent is currently not releasing the 20 mL vial.   American Regent/Luitpold has discontinued manufacturing the 100 mL vial.   American Regent is currently not releasing the 50 mL vial.;2 mEq/mL- 20 mL vial- 25s (NDC 00517-2096-25) Unavailable Shortage per Manufacturer: American Regent is currently not releasing the 20 mL vial.   American Regent/Luitpold has discontinued manufacturing the 100 mL vial.   American Regent is currently not releasing the 50 mL vial.;4 mEq/mL- 50 mL vial- 25s (NDC 00517-5023-25) Unavailable American Regent is currently not releasing the 20 mL vial.   American Regent/Luitpold has discontinued manufacturing the 100 mL vial.   American Regent is currently not releasing the 50 mL vial.;2 mEq/mL- 100 mL vial- 25s (NDC 00517-2500-25) Discontinued American Regent is currently not releasing the 20 mL vial.   American Regent/Luitpold has discontinued manufacturing the 100 mL vial.   American Regent is currently not releasing the 50 mL vial.;2 mEq/mL- 20 mL vial- 25s (NDC 00517-2096-25) Unavailable American Regent is currently not releasing the 20 mL vial.   American Regent/Luitpold has discontinued manufacturing the 100 mL vial.   American Regent is currently not releasing the 50 mL vial.,,,,,,,,,,,,,
Ucyclyd,sodiumammonul,1,11/13/12,8/19/13,,,,50mL vial (NDC 62592-720-50) Limited supplies continue to be available. Please see attached Dear Healthcare Professional Letter (PDF - 25KB) for important safety information.,,,,,,,,,,,,,
Amphastar,sodiumb,1,4/18/12,7/7/13,demand increase,orange,,Increased Demand due to competitor backorders Next release on March 26- 2011 Additional release anticipated on April 5- 2011.;Next release on March 26- 2011 Additional release anticipated on April 5- 2011.;;8.4%- 50mL Luer-Jet Prefilled Syringe   NDC 76329-3352-1(old NDC 0548-3352-00) Amphastar will regularly release products.   Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues. Shortage per Manufacturer: Increase demand,,,,,,,,,,,,,
Amphastar,sodiumb,2,8/1/13,8/1/13,demand increase,orange,,8.4%- 50mL Luer-Jet Prefilled Syringe   NDC 76329-3352-1(old NDC 0548-3352-00) Amphastar will regularly release products.   Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues. Shortage per Manufacturer: Increase demand,,,,,,,,,,,,,
APP,sodiumb,2,8/1/13,8/1/13,demand increase,orange,,4.2% 2.5 mEq- 5 mL (NDC 63323-0026-05) Currently available.  Check wholesalers for inventory. Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand,,,,,,,,,,,,,
APP,sodiumb,1,4/18/12,7/7/13,demand increase,orange,,APP is currently back-ordered and expects a release late May.  Please check wholesalers for inventory.;Increased demand APP is currently back-ordered and expects a release late May.  Please check wholesalers for inventory.;;4.2% 2.5 mEq- 5 mL (NDC 63323-0026-05) APP is currently back-ordered and expects a release early September. Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;4.2% 2.5 mEq- 5 mL (NDC 63323-0026-05) APP is currently back-ordered and expects a release early October. Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;4.2% 2.5 mEq- 5 mL (NDC 63323-0026-05) Available Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;4.2% 2.5 mEq- 5 mL (NDC 63323-0026-05) Next delivery expected late October. Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;4.2% 2.5 mEq- 5 mL (NDC 63323-0026-05) Next delivery expected mid December. Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;4.2% 2.5 mEq- 5 mL (NDC 63323-0026-05) Next delivery expected December 2012. Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand;4.2% 2.5 mEq- 5 mL (NDC 63323-0026-05) Currently available.  Check wholesalers for inventory. Please check wholesalers for inventory. Shortage per Manufacturer: Increased demand,,,,,,,,,,,,,
Fresenius,sodiumc,1,3/25/14,3/25/14,demand increase,orange,,200 mL vials (NDC 63323-0088-63) Backordered. Next estimated release April 2014. Shortage per Manufacturer: Increased demand;100 mL vials (NDC 63323-0088-61) Currently backordered. Next release anticipated April 2014. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand;30 mL vials (NDC 63323-0087-30) Currently backordered. Next release anticipated March 2014. Check wholesalers for inventory. Shortage per Manufacturer: Increased demand,,,,,,,,,,,,,
APP,sodiumc,1,4/28/11,3/2/14,demand increase,orange,,APP has sodium chloride 23.4% solution for injection 30 mL and 100 mL vials on allocation. The 200 mL vials are on back order and the company estimates a release date of early-April- 2011.;APP has sodium chloride 23.4% solution for injection on intermittent back order and the company is releasing product as it becomes available.;Increased demand APP has sodium chloride 23.4% solution for injection on intermittent back order and the company is releasing product as it becomes available.;;100 mL vials (NDC 63323-0088-61) Check Wholesalers for Inventory. APP has all presentations of sodium chloride 23.4% solution for injection on intermittent back order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand;200 mL vials (NDC 63323-0088-63) Check Wholesalers for Inventory. APP has all presentations of sodium chloride 23.4% solution for injection on intermittent back order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand;30 mL vials (NDC 63323-0087-30)  Check Wholesalers for Inventory. APP has all presentations of sodium chloride 23.4% solution for injection on intermittent back order and the company is releasing product as it becomes available. Shortage per Manufacturer: Increased demand;100 mL vials (NDC 63323-0088-61) Next release anticipated early December Shortage per Manufacturer: Increased demand;200 mL vials (NDC 63323-0088-63) Available. Check Wholesalers for Inventory. Shortage per Manufacturer: Increased demand;30 mL vials (NDC 63323-0087-30) Available. Check Wholesalers for Inventory. Shortage per Manufacturer: Increased demand;100 mL vials (NDC 63323-0088-61) Available. Check Wholesalers for Inventory.   Shortage per Manufacturer: Increased demand;200 mL vials (NDC 63323-0088-63) Backordered.  Next delivery expected January 2013. Shortage per Manufacturer: Increased demand;100 mL vials (NDC 63323-0088-61) Available. Check Wholesalers for Inventory. Shortage per Manufacturer: Increased demand;200 mL vials (NDC 63323-0088-63) Backordered. Next estimated release June 2013. Shortage per Manufacturer: Increased demand;100 mL vials (NDC 63323-0088-61) Backordered. Next estimated release May 2013. Shortage per Manufacturer: Increased demand;100 mL vials (NDC 63323-0088-61) Backordered. Next estimated release June 2013. Shortage per Manufacturer: Increased demand;100 mL vials (NDC 63323-0088-61) Backordered. Next estimated release August 2013. Shortage per Manufacturer: Increased demand;200 mL vials (NDC 63323-0088-63) Backordered. Next estimated release August 2013. Shortage per Manufacturer: Increased demand;100 mL vials (NDC 63323-0088-61) Backordered. Next estimated release September 2013. Shortage per Manufacturer: Increased demand;200 mL vials (NDC 63323-0088-63) Backordered. Next estimated release September 2013. Shortage per Manufacturer: Increased demand,,,,,,,,,,,,,
AmericanRegent,sodiumc,1,4/28/11,3/25/14,demand increase; discontinued; not manufacturing; ,black,,American Regent has sodium chloride 23.4% solution 30 mL vials on back order and expects release by end of March The 100 mL vials are on back order and the company cannot estimate a release date.;American Regent has sodium chloride 23.4% solution 30 mL vials and 100 mL vials are on back order and cannot estimate a release date.;No longer manufacturing.;Unavailable American Regent/Luitpold is no longer manufacturing Sodium Chloride Injection 23.4%. .;American Regent/Luitpold is no longer manufacturing Sodium Chloride Injection 23.4%. .;;100 mL vials (NDC 00517-2900-25) Unavailable American Regent/Luitpold is no longer manufacturing Sodium Chloride Injection 23.4%..;30 mL vials (NDC 00517-2930-25) Unavailable American Regent/Luitpold is no longer manufacturing Sodium Chloride Injection 23.4%..;30 mL vials- 25s (NDC 00517-2930-25) Unavailable Shortage per Manufacturer: American Regent/Luitpold has discontinued manufacturing Concentrated Sodium Chloride Injection 23.4%.;100 mL vials- 25s (NDC 00517-2900-25) Unavailable Shortage per Manufacturer: American Regent/Luitpold has discontinued manufacturing Concentrated Sodium Chloride Injection 23.4%.;30 mL vials- package of 25 (NDC 00517-2930-25) Unavailable - No product available for release. No plan to manufacture. Shortage per Manufacturer: American Regent/Luitpold has discontinued manufacturing Concentrated Sodium Chloride Injection 23.4%.;100 mL vials- package of 25 (NDC 00517-2900-25) Unavailable - No product available for release. No plan to manufacture. Shortage per Manufacturer: American Regent/Luitpold has discontinued manufacturing Concentrated Sodium Chloride Injection 23.4%.,,,,,,,,,,,,,
AmericanRegent,sodiumc,1,2/9/11,4/22/11,demand increase; manufacturing delays,blue,,Increased demand Increase in demand Manufacturing delays  ;Increased demand Increase in demand Manufacturing delays;Increased demand Increase in demand Manufacturing delays,,,,,,,,,,,,,
APP,sodiumc,1,2/9/11,4/22/11,demand increase; manufacturing delays,blue,,Increased demand Increase in demand Manufacturing delays  ;Increased demand Increase in demand Manufacturing delays;Increased demand Increase in demand Manufacturing delays,,,,,,,,,,,,,
Hospira,sodiumc,1,2/9/11,4/22/11,demand increase; manufacturing delays,blue,,Increased demand Increase in demand Manufacturing delays  ;Increased demand Increase in demand Manufacturing delays;Increased demand Increase in demand Manufacturing delays,,,,,,,,,,,,,
AmericanRegent,sodiumci,1,4/14/11,4/14/11,demand increase,orange,,Increase in demand   Increased demand ,,,,,,,,,,,,,
APP,sodiumci,1,2/9/11,4/22/11,demand increase,orange,,Increase in demand   Increased demand  ;Increase in demand   Increased demand ;Increase in demand   Increased demand ,,,,,,,,,,,,,
APP,sodiumci,1,4/28/11,2/9/12,demand increase,orange,,APP does not yet have a release date.;APP has sodium chloride 14.6% solution for injection 40 mL vials are available. The 20 mL vials are on long-term back order with no estimated release date.,,,,,,,,,,,,,
Hospira,sodiumci,1,2/9/11,4/22/11,demand increase,orange,,Increase in demand   Increased demand  ;Increase in demand   Increased demand ;Increase in demand   Increased demand ,,,,,,,,,,,,,
Baxter,sodiuml,1,6/13/12,10/7/12,discontinued,black,,;167 mEq/mL; 1000 mL (NDC 00338-0129-04) Baxter has discontinued manufacturing of the product. Shortage per Manufacturer: Product has been discontinued,,,,,,,,,,,,,
Hope,sodiumn,1,6/13/12,7/12/12,available,,,,,,,,,,,,,,,,
Hope,sodiumns,1,6/13/12,7/12/12,available,,,,,,,,,,,,,,,,
Akorn,sodiumns,1,6/13/12,8/4/12,discontinued,black,,,,,,,,,,,,,,,
AmericanRegent,sodiumphosphate,1,1/16/13,1/16/13,not releasing,,,3 mmol/ml- 15 ml vial (NDC 00517-3415-25) Unavailable American Regent is currently not releasing Sodium Phosphate Injection- USP.;3 mmol/mL- 5 mL vials (NDC 00517-3405-25) Unavailable American Regent is currently not releasing Sodium Phosphate Injection- USP.;3 mmol/mL- 50 mL via (NDC 00517-3450-25) Unavailable American Regent is currently not releasing Sodium Phosphate Injection- USP.,,,,,,,,,,,,,
AmericanRegent,sodiumphosphate,2,3/6/13,3/25/14,not releasing,,,3 mmol/mL- 50 mL via (NDC 00517-3450-25) Unavailable American Regent is currently not releasing Sodium Phosphate Injection- USP.;3 mmol/ml- 15 ml vial (NDC 00517-3415-25) Unavailable American Regent is currently not releasing Sodium Phosphate Injection- USP.;3 mmol/mL- 5 mL vials (NDC 00517-3405-25) Unavailable American Regent is currently not releasing Sodium Phosphate Injection- USP.;3 mmol/ml- 15 ml vial (NDC 00517-3415-25) Unavailable Please see Dear Healthcare Professional (DHCP) letter (PDF).;3 mmol/mL- 5 mL vials (NDC 00517-3405-25) Unavailable Please see Dear Healthcare Professional (DHCP) letter (PDF).;3 mmol/mL- 50 mL via (NDC 00517-3450-25) Next delivery mid April 2013 for the 50 mL vial. Dear Healthcare Professional Letter (PDF) Please see Dear Healthcare Professional (DHCP) letter (PDF).;3 mmol/ml- 15 ml vial (NDC 00517-3415-25) Unavailable American Regent is currently not releasing the 5 mL or the 15 mL vials.   Please see Dear Healthcare Professional (DHCP) letter (PDF).   American Regent is currently releasing the 50 mL vial size.;3 mmol/mL- 50 mL via (NDC 00517-3450-25) Available Dear Healthcare Professional Letter (PDF) American Regent is currently not releasing the 5 mL or the 15 mL vials.   Please see Dear Healthcare Professional (DHCP) letter (PDF).   American Regent is currently releasing the 50 mL vial size.;3 mmol/mL- 5 mL vials (NDC 00517-3405-25) Unavailable American Regent is currently not releasing the 5 mL or the 15 mL vials.   Please see Dear Healthcare Professional (DHCP) letter (PDF).   American Regent is currently releasing the 50 mL vial size.;3 mmol/mL- 50 mL via (NDC 00517-3450-25) Unavailable Dear Healthcare Professional Letter (PDF) American Regent is currently not releasing the 5 mL- 15 mL- or the 50 mL vials.   Please see Dear Healthcare Professional (DHCP) letter (PDF).;3 mmol/ml- 15 ml vial (NDC 00517-3415-25) Unavailable American Regent is currently not releasing the 5 mL- 15 mL- or the 50 mL vials.   Please see Dear Healthcare Professional (DHCP) letter (PDF).;3 mmol/mL- 5 mL vials (NDC 00517-3405-25) Unavailable American Regent is currently not releasing the 5 mL- 15 mL- or the 50 mL vials.   Please see Dear Healthcare Professional (DHCP) letter (PDF).;3 mmol/mL- 50 mL via (NDC 00517-3450-25) Unavailable American Regent is currently not releasing the 5 mL- 15 mL- or the 50 mL vials.;3 mmol/ml- 15 ml vial (NDC 00517-3415-25) Unavailable American Regent is currently not releasing the 5 mL- 15 mL- or the 50 mL vials.;3 mmol/mL- 5 mL vials (NDC 00517-3405-25) Unavailable American Regent is currently not releasing the 5 mL- 15 mL- or the 50 mL vials.;3 mmol/mL- 50 mL via (NDC 00517-3450-25) Unavailable - No product available for release. No plan to manufacture.     American Regent is currently not releasing the 5 mL- 15 mL- or the 50 mL vials.;3 mmol/mL- 5 mL vials (NDC 00517-3405-25) Unavailable - No product available for release. No plan to manufacture.     American Regent is currently not releasing the 5 mL- 15 mL- or the 50 mL vials.;3 mmol/ml- 15 ml vial (NDC 00517-3415-25) Unavailable - No product available for release. No plan to manufacture.     American Regent is currently not releasing the 5 mL- 15 mL- or the 50 mL vials.,,,,,,,,,,,,,
AmericanRegent,sodiumpi,1,4/29/11,3/16/12,manufacturing delays; available,blue,,American Regent has sodium phosphate injections on back order and the company cannot estimate a release date.;American Regent expects mid August release for  sodium phosphate 5 mmol/mL 5 mL (NDC 00517-3405-25)- 15 mL (NDC 00517-3415-25)- and 50 mL (NDC 00517-3450-25) vials.;American Regent has all presentations available.,,,,,,,,,,,,,
Hope,sodiumt,1,6/13/12,7/12/12,available,,,,,,,,,,,,,,,,
AmericanRegent,sodiumt,1,6/13/12,6/13/12,available,,,,,,,,,,,,,,,,
AmericanRegent,sodiumt,2,8/4/12,8/4/12,available,,,,,,,,,,,,,,,,
Xgen,strep,1,9/15/11,11/17/11,manufacturing delays,blue,,X-Gen plans to have streptomycin injection available by end of September 2011.;X-Gen plans to have streptomycin injection available by end of October 2011.,,,,,,,,,,,,,
Sandoz,succinylcholine,1,4/28/11,7/16/11,demand increase,orange,,Sandoz reports weekly releases are occurring for Anectine 20 mg/mL 10 mL vials (NDC 00781-3009-95),,,,,,,,,,,,,
Hospira,succinylcholine,1,8/28/10,4/22/11,demand increase; manufacturing delays,blue,,Increased demand Manufacturing delays ;Increased demand Manufacturing delays  ;Increased demand Manufacturing delays;Increased demand Manufacturing delays,,,,,,,,,,,,,
Sandoz,succinylcholine,1,8/28/10,4/22/11,demand increase; manufacturing delays,blue,,Increased demand Manufacturing delays ;Increased demand Manufacturing delays  ;Increased demand Manufacturing delays;Increased demand Manufacturing delays,,,,,,,,,,,,,
Sandoz,succinylcholine,2,9/4/12,3/25/14,discontinued,orange,,Anectine- 20 mg/mL- 10 mL vial (NDC 00781-3009-95 Currently on Backorder.  Estimate ongoing shortages into November. Releasing product on a lot by lot basis.;Anectine- 20 mg/mL- 10 mL vial (NDC 00781-3009-95 Currently on Backorder.  Estimate ongoing shortages through year end.. Releasing product on a lot by lot basis.;Anectine- 20 mg/mL- 10 mL vial (NDC 00781-3009-95 Product currently unavailable. Sandoz cannot estimate a release date.;Anectine- 20 mg/mL- 10 mL vial (NDC 00781-3009-95 Product currently unavailable. Shortage per Manufacturer Sandoz cannot estimate a release date.;Anectine- 20 mg/mL- 10 mL vial (NDC 00781-3009-95 Product temporarily unavailable. Sandoz will provide status information by October 15.;Anectine- 20 mg/mL- 10 mL vial (NDC 00781-3009-95 Product on short term backorder.,,,,,,,,,,,,,
WestWard,sufentanil,1,3/16/12,3/25/14,; demand increase,orange,,Pending Information;Increase in product demand due to market supply issues. West-Ward is currently experiencing a backorder situation on all presentations due to an increase in market demand.  Multiple lots of the 5 mL ampul are anticipated to be released and available in the April - May 2012 timeframe. No update is available at this time on the availability of the 1 mL and 2 mL ampuls - Product will be made available as it is released.;West-Ward is currently experiencing a backorder situation on all presentations due to an increase in market demand.  Multiple lots of the 5 mL ampul are anticipated to be released and available in the April - May 2012 timeframe. No update is available at this time on the availability of the 1 mL and 2 mL ampuls - Product will be made available as it is released.;;50 mcg/mL- 5 mL ampul (NDC 0641-6112-10) West-Ward is currently experiencing a backorder situation on all presentations.  Multiple lots of each code are scheduled for production and anticipated to be available at the end July or beginning of August 2012. West-Ward has accelerated production. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand.;50 mcg/mL- 1 mL ampul (NDC 0641-6110-10) West-Ward is currently experiencing a backorder situation on all presentations.  Multiple lots of each code are scheduled for production and anticipated to be available at the end July or beginning of August 2012. West-Ward has accelerated production. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand.;50 mcg/mL- 2 mL ampul (NDC 0641-6111-10) West-Ward is currently experiencing a backorder situation on all presentations.  Multiple lots of each code are scheduled for production and anticipated to be available at the end July or beginning of August 2012. West-Ward has accelerated production. Product will be made available as it is released. Shortage per Manufacturer: Increase in product demand.;50 mcg/mL- 5 mL ampul (NDC 0641-6112-10) West-Ward has very limited quantities currently available.   West-Ward has accelerated production on this product West-Ward has increased production and is anticipating having additional product available by the end of February 2013.   Product will be made available as it is released.;50 mcg/mL- 2 mL ampul (NDC 0641-6111-10) West-Ward has very limited quantities currently available.   West-Ward has accelerated production on this product West-Ward has increased production and is anticipating having additional product available by the end of February 2013.   Product will be made available as it is released.;50 mcg/mL- 1 mL ampul (NDC 0641-6110-10) West-Ward has very limited quantities currently available.   West-Ward has accelerated production on this product West-Ward has increased production and is anticipating having additional product available by the end of February 2013.   Product will be made available as it is released.;50 mcg/mL- 5 mL ampul (NDC 0641-6112-10) West-Ward has very limited quantities currently available.   West-Ward has accelerated production on this product West-Ward has increased production and is anticipating having additional product available by the end of March 2013.   Product will be made available as it is released.;50 mcg/mL- 1 mL ampul (NDC 0641-6110-10) West-Ward has very limited quantities currently available.   West-Ward has accelerated production on this product West-Ward has increased production and is anticipating having additional product available by the end of March 2013.   Product will be made available as it is released.;50 mcg/mL- 2 mL ampul (NDC 0641-6111-10) West-Ward has very limited quantities currently available.   West-Ward has accelerated production on this product West-Ward has increased production and is anticipating having additional product available by the end of March 2013.   Product will be made available as it is released.;50 mcg/mL- 5 mL ampul (NDC 0641-6112-10) West-Ward has very limited quantities currently available.   West-Ward has accelerated production on this product West-Ward has increased production and is anticipating having additional product available by the end of August 2013.   Product will be made available as it is released.;50 mcg/mL- 1 mL ampul (NDC 0641-6110-10) West-Ward has very limited quantities currently available.   West-Ward has accelerated production on this product West-Ward has increased production and is anticipating having additional product available by the end of August 2013.   Product will be made available as it is released.;50 mcg/mL- 2 mL ampul (NDC 0641-6111-10) West-Ward has very limited quantities currently available.   West-Ward has accelerated production on this product West-Ward has increased production and is anticipating having additional product available by the end of August 2013.   Product will be made available as it is released.;50 mcg/mL- 1 mL ampul (NDC 0641-6110-10) West-Ward has limited quantities currently available.   West-Ward has accelerated production on this product West-Ward has increased production and is anticipating having additional product available by the end of September 2013.   Product will be made available as it is released.;50 mcg/mL- 2 mL ampul (NDC 0641-6111-10) West-Ward has limited quantities currently available.   West-Ward has accelerated production on this product West-Ward has increased production and is anticipating having additional product available by the end of September 2013.   Product will be made available as it is released.;50 mcg/mL- 5 mL ampul (NDC 0641-6112-10) West-Ward has limited quantities currently available.   West-Ward has accelerated production on this product West-Ward has increased production and is anticipating having additional product available by the end of September 2013.   Product will be made available as it is released.;50 mcg/mL- 5 mL ampule (NDC 0641-6112-10) West-Ward has inventory currently available.   West-Ward has accelerated production on this product. West-Ward is anticipating having additional product available by February 2014.   Product will be made available as it is released.;50 mcg/mL- 1 mL ampule(NDC 0641-6110-10) West-Ward has inventory currently available.   West-Ward has accelerated production on this product. West-Ward is anticipating having additional product available by February 2014.   Product will be made available as it is released.;50 mcg/mL- 2 mL ampule (NDC 0641-6111-10) West-Ward has inventory currently available.   West-Ward has accelerated production on this product. West-Ward is anticipating having additional product available by February 2014.   Product will be made available as it is released.,,,,,,,,,,,,,
Akorn,sufentanil,1,3/16/12,3/25/14,material shortage; available,green,,"Akorn has the 5 mL ampule (NDC 17478-0050-05) available. 
 
 Akorn has the 1 mL and 2 mL ampules on back order and the company is now releasing the 1 mL ampules for distribution- and mid-March- 2012 for the 2 mL ampules);Material Shortage 1 mL ampoule  (NDC 17478-0050-01)-Releasing mid-April 2 mL  ampoule (NDC 17478-0050-02)-Releasing next week (week of March 19th) 5 mL ampoule (NDC 17478-0050-05)-Targeted release in May;1 mL ampoule  (NDC 17478-0050-01)-Releasing mid-April 2 mL  ampoule (NDC 17478-0050-02)-Releasing next week (week of March 19th) 5 mL ampoule (NDC 17478-0050-05)-Targeted release in May;;50 mcg/mL- 2 mL ampoule- 10 pack NDC 17478-0050-02 Available in wholesalers- releasing in September    Quota request filed. (Per manufacturer) Shortage per Manufacturer: Delayed DEA response. (Per manufacturer);50mcg/ml- 5ml ampule- 10 pack NDC 7478-0050-05 Available in wholesalers- releasing in August Quota request filed. (Per manufacturer) Shortage per Manufacturer: Delayed DEA response. (Per manufacturer);50 mcg/mL- 1 mL ampoule- 10 packNDC 17478-0050-01 Available in wholesalers- releasing in August Quota request filed. (Per manufacturer) Shortage per Manufacturer: Delayed DEA response. (Per manufacturer);50mcg/ml- 5ml ampule- 10 pack NDC 7478-0050-05 Readily available Quota request filed. (Per manufacturer) Shortage per Manufacturer: Delayed DEA response. (Per manufacturer);50 mcg/mL- 2 mL ampoule- 10 pack NDC 17478-0050-02 Available in wholesalers- releasing in November    Quota request filed. (Per manufacturer) Shortage per Manufacturer: Delayed DEA response. (Per manufacturer);50 mcg/mL- 1 mL ampoule- 10 packNDC 17478-0050-01 Available in wholesalers- releasing in October Quota request filed. (Per manufacturer) Shortage per Manufacturer: Delayed DEA response. (Per manufacturer);50 mcg/mL- 1 mL ampoule- 10 packNDC 17478-0050-01 Available in wholesalers- releasing in October NA;50 mcg/mL- 2 mL ampoule- 10 pack NDC 17478-0050-02 Available in wholesalers- releasing in November    NA;50mcg/ml- 5ml ampule- 10 pack NDC 7478-0050-05 Readily available NA;50 mcg/mL- 2 mL ampoule- 10 pack NDC 17478-0050-02 Readily available   NA;50mcg/ml- 5ml ampule- 10 pack NDC 7478-0050-05 Readily available   NA;50 mcg/mL- 1 mL ampoule- 10 packNDC 17478-0050-01 Readily available   NA;50 mcg/mL- 1 mL ampoule- 10 packNDC 17478-0050-01 Available in wholesalers.  Releasing in October.  N/A;50 mcg/mL- 2 mL ampoule- 10 pack NDC 17478-0050-02 Readily Available N/A;50 mcg/mL- 2 mL ampoule- 10 pack NDC 17478-0050-02 Available in wholesalers.  Releasing in October.  N/A;50mcg/ml- 5ml ampule- 10 pack NDC 7478-0050-05 Readily Available N/A;50mcg/ml- 5ml ampule- 10 pack (NDC 7478-0050-05) Available in wholesaler inventory (due for release in March).;50 mcg/mL- 1 mL ampoule- 10 pack(NDC 17478-0050-01) Readily Available;50 mcg/mL- 2 mL ampoule- 10 pack (NDC 17478-0050-02) Readily Available",,,,,,,,,,,,,
Hospira,sulfamethoxazole,1,8/20/10,9/23/10,demand increase,orange,,Teva initiated withdrawal of multiple lots of pancuronium injection from the market on 5/4/10.     Increased demand,,,,,,,,,,,,,
Teva,sulfamethoxazole,1,5/27/10,4/22/11,product recall,yellow,,Teva recalled Lot #31308526B/Exp. Date 9/12 of SMX/TMP Injection 10 ml vials to the retail level because some vials may have defective crimps. All sizes of vials are currently unavailable.;Teva recalled Lot #31308526B/Exp. Date 9/12 of SMX/TMP Injection 10 ml vials to the retail level because some vials may have defective crimps.;Teva initiated withdrawal of multiple lots of pancuronium injection from the market on 5/4/10.     Increased demand,,,,,,,,,,,,,
Teva,sulfamethoxazole,1,4/28/11,3/2/14,product recall; manufacturing delays; manufacturing practices requirements; available,yellow,,Teva manufactures 5 ml vials (NDC 00703-9503-03)- 10 ml vials (NDC 00703-9514-03) and 30 ml vials (NDC 00703-9526-01). Limited emergency supplies are available from Teva.;Teva is reviewing orders for sulfamethoxazole/trimethoprim injection in 5ml and 10 ml vials- and these are available for drop shipment only.  The 30ml vials are on back order and the company estimates a release date in third quarter of 2012.;Manufacturing delays Teva is reviewing orders for the 5mL and 10mL presentations- and are available for drop shipments only.  The 30mL is on back order and Teva estimates a release date in Q312.;Teva is reviewing orders for the 5mL and 10mL presentations- and are available for drop shipments only.  The 30mL is on back order and Teva estimates a release date in Q312.;;80 mg/16 mg/mL- 30 mL (NDC 00703-9526-01 The 30 mL is on back order and Teva estimates a release date of Jan 2013. Shortage per Manufacturer: Manufacturing Delays;80 mg/16 mg/mL- 10 mL (NDC 00703-9514-03) Teva is reviewing orders for the 5mL and 10mL presentations prior to distribution. Shortage per Manufacturer: Manufacturing Delays;80 mg/16 mg/mL- 5 mL (NDC 00703-9503-03)   Teva is reviewing orders for the 5mL and 10mL presentations prior to distribution. Shortage per Manufacturer: Manufacturing Delays;80 mg/16 mg/mL- 5 mL (NDC 00703-9503-03)   Teva is on backorder for the 5mL. The 10mL presentation is available- orders are reviewed prior to distribution.;80 mg/16 mg/mL- 30 mL (NDC 00703-9526-01 The 30 mL is on back order and Teva estimates a release date of Jan 2013.;80 mg/16 mg/mL- 10 mL (NDC 00703-9514-03) Teva is on backorder for the 5mL. The 10mL presentation is available- orders are reviewed prior to distribution.;80 mg/16 mg/mL- 30 mL (NDC 00703-9526-01 The 30 mL is on back order and Teva can not estimate a release date at this time.;80 mg/16 mg/mL- 10 mL (NDC 00703-9514-03) Teva is on backorder for the 5mL and can not estimate a release date. The 10mL presentation is available- orders are reviewed prior to distribution.;80 mg/16 mg/mL- 5 mL (NDC 00703-9503-03)   Teva is on backorder for the 5mL and can not estimate a release date. The 10mL presentation is available- orders are reviewed prior to distribution.;80 mg/16 mg/mL- 10 mL (NDC 00703-9514-03) Teva is on backorder for the 5mL and can not estimate a release date. The 10mL presentation is availableand shipping.;80 mg/16 mg/mL- 5 mL (NDC 00703-9503-03)   Teva is on backorder for the 5mL and can not estimate a release date. The 10mL presentation is availableand shipping.;80 mg/16 mg/mL- 30 mL (NDC 00703-9526-01 The 30 mL is on back order.  Teva anticipates product availability in Q313.;80 mg/16 mg/mL- 10 mL (NDC 00703-9514-03) Teva is on backorder for the 5mL and cannot estimate a release date at this time. The 10mL presentation is available and shipping.;80 mg/16 mg/mL- 5 mL (NDC 00703-9503-03)   Teva is on backorder for the 5mL and cannot estimate a release date at this time. The 10mL presentation is available and shipping.;80 mg/16 mg/mL- 30 mL (NDC 00703-9526-01 The 30 mL is on back order.  Teva anticipates product availability in Q3 2013.;80 mg/16 mg/mL- 30 mL (NDC 00703-9526-01 Teva has the 30 mL product available.,,,,,,,,,,,,,
Genentech,tamiflu,1,1/19/11,4/22/11,demand increase,orange,,Increased demand,,,,,,,,,,,,,
Genentech,tamiflu,1,4/28/11,6/22/11,demand increase,orange,,"Genentech has Tamiflu for Oral Suspension on backorder- however supplies remain in distribution at wholesalers and pharmacies. Tamiflu 75mg- 45 mg and 30 mg capsules remain available. For those patients who have difficulty swallowing capsules- the contents can be mixed into sweetened liquids- such as chocolate syrup- as directed by a healthcare professional. If there is difficulty locating commercial Tamiflu for Oral Suspension- FDA would like to remind healthcare professionals of the FDA-approved Instructions for the emergency compounding of an oral suspension from Tamiflu 75 mg capsules. These instructions provide for an alternative oral suspension when commercially manufactured oral suspension formulation is not readily available. Please refer to the Tamiflu package insert for information regarding compounding an oral suspension from Tamiflu 75mg capsules or see the following link for healthcare professionals: Tamiflu;Genentech has Tamiflu for Oral Suspension on backorder- however supplies remain in distribution at wholesalers and pharmacies. Tamiflu 75mg- 45 mg and 30 mg capsules remain available. For those patients who have difficulty swallowing capsules- the contents can be mixed into sweetened liquids- such as chocolate syrup- as directed by a healthcare professional. 
 
 If there is difficulty locating commercial Tamiflu for Oral Suspension- FDA would like to remind healthcare professionals of the FDA-approved Instructions for the emergency compounding of an oral suspension from Tamiflu 75 mg capsules. These instructions provide for an alternative oral suspension when commercially manufactured oral suspension formulation is not readily available. 
 
 Please refer to the Tamiflu package insert for information regarding compounding an oral suspension from Tamiflu 75mg capsules or see the following link for healthcare professionals: Tamiflu",,,,,,,,,,,,,
Genentech,tamiflu,2,7/6/11,8/18/11,demand increase,orange,,Genentech plans to begin releasing Tamiflu for Oral Suspension in mid July.,,,,,,,,,,,,,
Roche,tamiflu,1,10/10/09,2/5/10,,,,See Related Information Section,,,,,,,,,,,,,
Covidien,technetium,1,6/6/09,12/19/10,Source issues,green,,Reduced supply due to material sourcing issues.,,,,,,,,,,,,,
Lantheus,technetium,1,6/6/09,12/19/10,Source issues,green,,Reduced supply due to material sourcing issues.,,,,,,,,,,,,,
Theravance,telavancin,1,3/6/13,3/25/14,available,,,PDS 250 mg (NDC 52118-002-01) Mid-2013;PDS 750 mg (NDC 52118-001-01) Mid-2013;PDS 250 mg (NDC 52118-002-01) Unavailable   Estimated availability is September or October 2013;PDS 750 mg (NDC 52118-001-01) Unavailable   Estimated availability is September or October 2013;PDS 750 mg (NDC 52118-001-01) Available Theravance- Inc. has commenced shipments of VIBATIV (telavancin) into the U.S. wholesaler channel. Additional information on ordering VIBATIV can be obtained by calling Theravance at:  1-855-7-THRX-SALES  (855-784-7972).;PDS 250 mg (NDC 52118-002-01) VIBATIV 250mg will be re-introduced in the future Theravance- Inc. has commenced shipments of VIBATIV (telavancin) into the U.S. wholesaler channel. Additional information on ordering VIBATIV can be obtained by calling Theravance at:  1-855-7-THRX-SALES  (855-784-7972).,,,,,,,,,,,,,
Astellas,telavancin,1,12/22/11,3/1/13,manufacturing delays,blue,,"Astellas has no estimated date of availability.   See the Dear Health Care Provider Letter (PDF - 97KB);Astellas has no estimated date of availability.   See the Dear Health Care Provider Letter (PDF - 142KB);Astellas has no estimated date of availability.
  
 See the Dear Health Care Provider Letter (PDF - 142KB);Manufacturing delays Astellas has no estimated date of availability.   See the Dear Health Care Provider Letter (PDF - 142KB);;PDS 250 mg (NDC 00469-3525-30) Astellas has no estimated date of availability. See the Dear Health Care Provider Letter (PDF - 142KB)34 Shortage per Manufacturer: Manufacturing delays;PDS 750 mg (NDC 00469-3575-50) Astellas has no estimated date of availability. See the Dear Health Care Provider Letter (PDF - 142KB)34 Shortage per Manufacturer: Manufacturing delays",,,,,,,,,,,,,
Teva,tetracycline,1,11/10/11,3/2/14,manufacturing delays; material shortage,green,,Teva has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date.;Manufacturing delays Teva has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date.;;250 mg- 100 count (NDC 00172-2416-60) Temporarily unavailable Teva has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delays;500 mg- 100 count unit dose (00172-2407-10) Temporarily unavailable Teva has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delays;250 mg- 100 count unit dose (NDC 00172-2416-10) Temporarily unavailable Teva has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delays;500 mg- 1000 count (NDC 00172-2407-80) Temporarily unavailable Teva has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delays;250 mg- 1000 count (NDC 00172-2416-80) Temporarily unavailable Teva has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delays;500 mg- 100 count (NDC 00172-2407-60) Temporarily unavailable Teva has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delays;500 mg- 1000 count (NDC 00172-2407-80) Temporarily unavailable Teva has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date.;250 mg- 100 count unit dose (NDC 00172-2416-10) Temporarily unavailable Teva has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date.;250 mg- 1000 count (NDC 00172-2416-80) Temporarily unavailable Teva has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date.;500 mg- 100 count (NDC 00172-2407-60) Temporarily unavailable Teva has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date.;500 mg- 100 count unit dose (00172-2407-10) Temporarily unavailable Teva has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date.;250 mg- 100 count (NDC 00172-2416-60) Temporarily unavailable Teva has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date.,,,,,,,,,,,,,
Watson,tetracycline,1,11/10/11,3/2/14,manufacturing delays; material shortage,green,,Watson has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date.;Manufacturing delays Watson has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date.;;250 mg- 100 count (NDC 00591-2234-01)   Watson has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delays;500 mg- 1000 count (NDC 00591-2235-10)   Watson has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delays;500 mg- 100 count (NDC 00591-2235-01)   Watson has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delays;250 mg- 1000 count (NDC 00591-2234-10)   Watson has all tetracycline capsules temporarily unavailable and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delays;250 mg- 100 count (NDC 00591-2234-01) Watson has all tetracycline capsules temporarily unavailable.    Estimated release Q4 2013.;250 mg- 1000 count (NDC 00591-2234-10) Watson has all tetracycline capsules temporarily unavailable.    Estimated release Q4 2013.;500 mg- 100 count (NDC 00591-2235-01) Watson has all tetracycline capsules temporarily unavailable.    Estimated release Q4 2013.;500 mg- 1000 count (NDC 00591-2235-10) Watson has all tetracycline capsules temporarily unavailable.    Estimated release Q4 2013.,,,,,,,,,,,,,
Adienne,thiotepa,1,5/18/11,3/25/14,[temporary import],brown,,Adienne- in conjunction with the FDA- is initiating a temporary importation of Thiotepa for injection- to the United States market. Please see the Dear Healthcare Professional Letter (PDF - 1MB) for information about emergency supplies that are now available to help address the shortage.;;Please see the Dear Healthcare Professional Letter (PDF - 68KB)35 for information about emergency supplies that are now available to help address the shortage. Adienne- in conjunction with the FDA- is initiating a temporary importation of Thiotepa for injection- to the United States market.;Please see the Dear Healthcare Professional Letter (PDF - 68KB) for information about emergency supplies that are now available to help address the shortage. Adienne- in conjunction with the FDA- is initiating a temporary importation of Thiotepa for injection- to the United States market.;Please see the Dear Healthcare Professional Letter (PDF - 95KB) for information about emergency supplies that are now available to help address the shortage. Adienne- in conjunction with the FDA- is initiating a temporary importation of Thiotepa for injection- to the United States market.;100 mg vial Please see the Dear Healthcare Professional Letter (PDF - 95KB) for information about emergency supplies that are now available to help address the shortage. Adienne- in conjunction with the FDA- is initiating a temporary importation of Thiotepa for injection- to the United States market.;100 mg vial Please see the Dear Healthcare Professional Letter (PDF - 56KB) for information about emergency supplies that are now available to help address the shortage. Adverse Event Reporting Instructions (Urgent Thiotepa Update (PDF - 176KB) Adienne- in conjunction with the FDA- is initiating a temporary importation of Thiotepa for injection- to the United States market.;15 mg vial Please see the Dear Healthcare Professional Letter (PDF - 56KB) for information about emergency supplies that are now available to help address the shortage. Adverse Event Reporting Instructions (Urgent Thiotepa Update (PDF - 176KB) Adienne- in conjunction with the FDA- is initiating a temporary importation of Thiotepa for injection- to the United States market.,,,,,,,,,,,,,
Bedford,thiotepa,1,11/21/09,3/12/10,manufacturing delays,blue,,Manufacturing delays  ,,,,,,,,,,,,,
Bedford,thiotepa,1,4/28/11,3/25/14,manufacturing delays; capacity constraints,blue,,"FDA awaiting additional information and will post when available. Adienne- in conjunction with the FDA- is initiating a temporary importation of Thiotepa for injection- to the United States market. Please see Dear Healthcare Professional Letter (PDF - 1MB) for information about emergency supplies that are now available to help address the shortage.;FDA awaiting additional information and will post when available. 
 
 Adienne- in conjunction with the FDA- is initiating a temporary importation of Thiotepa for injection- to the United States market. Please see Dear Healthcare Professional Letter (PDF - 1MB) for information about emergency supplies that are now available to help address the shortage.;Bedford anticipates release mid-May.;Bedford anticipates release within the next three months.;Bedford has limited allocted quantiites of thiotepa (NDC 55390-0030-10) available for drop shipment- contact your local Bedford Account Executives.;Bedford has thiotepa (NDC 55390-0030-10) on backorder and the company cannot estimate a release date.;Bedford has thiotepa on backorder and the company cannot estimate a release date.;Bedford Laboratories has 15mg available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.;Manufacturing delays Bedford Laboratories has 15mg available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.;;15 mg/mL vial (NDC 55390-0030-10) Bedford Laboratories has 15mg available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;15 mg vial (NDC 53964-001) 100 mg vial (NDC 53964-002) Bedford Laboratories has 15mg available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website. Shortage per Manufacturer: Manufacturing delays;15 mg Inj VL 2 mL (NDC 5539003011) Unavailable Shortage per Manufacturer: Capacity constraints;15 mg Inj VL 2 mL (NDC 5539003011) Unavailable Shortage per Manufacturer: Capacity constraints   Availability of products is updated on the Bedford Laboratories website.;15 mg Inj VL 2 mL (NDC 5539-0030-10) Unavailable Shortage per Manufacturer: Capacity constraints   Availability of products is updated on the Bedford Laboratories website.;15 mg Inj VL 2 mL (NDC 5539-0030-10) Unavailable Shortage: Pending Manufacturing Change or Addition.   Availability of products are updated on the Bedford Laboratories website.",,,,,,,,,,,,,
Bedford,thiotepa,2,3/31/11,4/22/11,,,,unspecified;unspecified See related information section,,,,,,,,,,,,,
Genzyme,thyrogen,1,7/6/11,11/2/12,temporary delays,,,Thyrogen product supply has resumed shipment although temporary shipment delays remain.;A limited supply of Thyrogen was released to the U.S. market in June.  Due to unexpected delays in the release of three lots of Thyrogen- a stock-out is expected in July and will persist until these lots are released.  Temporary shipment delays will then continue to occur for the remainder of 2011 and throughout 2012.;Intermittent shipments of the product have resumed globally.  Genzyme continues to expect that Thyrogen supply constraints will occur through 2012.;Temporary Delays Intermittent shipments of the product have resumed globally.  Genzyme continues to expect that Thyrogen supply constraints will occur through 2012.;;1.1 mg vials- kit with 2 vials Thyrogen and 2 vials diluent (NDC 58468-1849-04) Intermittent shipments of the product have resumed globally.  Genzyme continues to expect that Thyrogen supply constraints will occur through 2012. Shortage per Manufacturer: Temporary Delays,,,,,,,,,,,,,
Genzyme,thyrogen,1,5/27/10,11/26/10,,,,Please see information in Related Information section.,,,,,,,,,,,,,
Forest,thyroid,1,4/28/11,6/22/11,manufacturing issues,blue,,FDA approved levothyroxine products continue to be available from multiple manufacturers.,,,,,,,,,,,,,
Forest,thyroid,1,2/14/10,4/22/11,manufacturing issues,blue,,Forest reports manufacturing issues involving the raw material and RLC reports increased demand. FDA has not ordered Forest or RLC to remove these thyroid (desiccated) tablets from the market.,,,,,,,,,,,,,
RLC,thyroid,1,2/14/10,4/22/11,manufacturing issues,blue,,Forest reports manufacturing issues involving the raw material and RLC reports increased demand. FDA has not ordered Forest or RLC to remove these thyroid (desiccated) tablets from the market.,,,,,,,,,,,,,
Forest,thyrolar,1,1/11/10,4/22/11,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
Forest,thyrolar,1,4/28/11,6/3/13,manufacturing delays,blue,,Forest has not yet reported when Thyrolar will be available.;Manufacturing delays Forest has not yet reported when Thyrolar will be available.;;Forest has not yet reported when Thyrolar will be available. Shortage per Manufacturer: Manufacturing delays,,,,,,,,,,,,,
Genzyme,thyrotropin,1,11/13/12,3/1/13,temporary delays,,,1.1 mg vials- kit with 2 vials Thyrogen and 2 vials diluent (NDC 58468-1849-04) Intermittent shipments of the product have resumed globally.  Genzyme continues to expect that Thyrogen supply constraints will occur through 2012. Shortage per Manufacturer: Temporary Delays,,,,,,,,,,,,,
GlaxoSmithKline,ticarcillin,1,9/1/12,3/25/14,manufacturing delays; discontinued; available,black,,31 gm/100 mL bulk package (NDC# 00029 -6579-21) Available Batches of the 3.1g/50mL vial are expected in mid November.       Shortage per Manufacturer: Manufacturing delay due to facility modifications.;3.1 gm ADDVantage vial (NDC# 00029 -6571-40) Discontinued with some supply still available. Batches of the 3.1g/50mL vial are expected in mid November.       Shortage per Manufacturer: Manufacturing delay due to facility modifications.;3.1 gm/50 mL vial (NDC# 00029-6571 -26) Out of stock Batches of the 3.1g/50mL vial are expected in mid November.       Shortage per Manufacturer: Manufacturing delay due to facility modifications.;31 gm/100 mL bulk package (NDC# 00029 -6579-21) Available 3.1g and 31g batches released in January 2013.  3.1g batches consumed with backorders.  Additional 3.1g supply is expected in February 2013.;3.1 gm ADDVantage vial (NDC# 00029 -6571-40) Discontinued with some supply still available. 3.1g and 31g batches released in January 2013.  3.1g batches consumed with backorders.  Additional 3.1g supply is expected in February 2013.;3.1 gm/50 mL vial (NDC# 00029-6571 -26) Out of stock 3.1g and 31g batches released in January 2013.  3.1g batches consumed with backorders.  Additional 3.1g supply is expected in February 2013.;3.1 gm ADDVantage vial (NDC# 00029 -6571-40) Discontinued   Additional supply is expected in July 2013.;3.1 gm/50 mL vial (NDC# 00029-6571 -26) Out of stock Additional supply is expected in July 2013.;31 gm/100 mL bulk package (NDC# 00029 -6579-21) Out of stock Additional supply is expected in July 2013.;31 gm/100 mL bulk package (NDC# 00029 -6579-21) Out of stock Additional supply is expected in January 2014.;3.1 gm ADDVantage vial (NDC# 00029 -6571-40) Discontinued;3.1 gm/50 mL vial (NDC# 00029-6571 -26) Out of stock Additional supply is expected in December 2013.,,,,,,,,,,,,,
Teva,ticlopidine,2,8/1/13,8/1/13,available,,,250 mg- 100 count (NDC 00093-0154-01) Available. Teva supply adequate to meet demand.,,,,,,,,,,,,,
Teva,ticlopidine,1,11/24/11,7/7/13,manufacturing delays; demand increase; available,blue,,Teva has ticlopidine tablets on back order and the company estimates a release date in first quarter- 2012.;Teva has ticlopidine tablets in stock.;Manufacturing delays Teva has ticlopidine tablets in stock.;;250 mg- 100 count (NDC 00093-0154-01) Available. Teva supply adequate to meet demand.,,,,,,,,,,,,,
Apotex,ticlopidine,1,11/24/11,7/7/13,manufacturing delays; production suspended,blue,,Apotex has ticlopidine tablets on back order and the company estimate a release date of February- 2012.;Apotex has ticlopidine tablets on back order and the company estimate a release date of May- 2012.;Manufacturing delays Apotex has Ticlopidine Tablets on back order and the company estimate a release date of May- 2012.;Apotex has Ticlopidine Tablets on back order and the company estimate a release date of May- 2012.;;Ticlopidine Tablets  250 mg- 500 count   (NDC 60505-0027-07) Temporarily unavailable.   Tenatative release revised to Nov-Dec 2012. Shortage per Manufacturer: This product is unavailable.;Ticlopidine Tablets 250 mg- 30 count (NDC 60505-0027-02) Temporarily unavailable.   Tenatative release revised to Nov-Dec 2012. Shortage per Manufacturer: This product is unavailable.;Ticlopidine Tablets  250 mg- 60 count (NDC 60505-0027-04) Temporarily unavailable.   Tenatative release revised to Nov-Dec 2012. Shortage per Manufacturer: This product is unavailable.;Ticlopidine Tablets  250 mg- 60 count (NDC 60505-0027-04) Temporarily unavailable.   Tenatative release revised to Feb-March 2013. Shortage per Manufacturer: This product is unavailable.;Ticlopidine Tablets  250 mg- 500 count   (NDC 60505-0027-07) Temporarily unavailable.   Tenatative release revised to Feb-March 2013. Shortage per Manufacturer: This product is unavailable.;Ticlopidine Tablets 250 mg- 30 count (NDC 60505-0027-02) Temporarily unavailable.   Tenatative release revised to Feb-March 2013. Shortage per Manufacturer: This product is unavailable.,,,,,,,,,,,,,
Apotex,ticlopidine,2,8/1/13,8/1/13,production suspended,,,Ticlopidine Tablets  250 mg- 60 count (NDC 60505-0027-04) Temporarily unavailable.   Tenatative release revised to Feb-March 2013. Shortage per Manufacturer: This product is unavailable.;Ticlopidine Tablets 250 mg- 30 count (NDC 60505-0027-02) Temporarily unavailable.   Tenatative release revised to Feb-March 2013. Shortage per Manufacturer: This product is unavailable.;Ticlopidine Tablets  250 mg- 500 count   (NDC 60505-0027-07) Temporarily unavailable.   Tenatative release revised to Feb-March 2013. Shortage per Manufacturer: This product is unavailable.,,,,,,,,,,,,,
Pfizer,tikosyn,1,11/27/09,1/11/10,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
APP,tobramycin,1,12/8/11,8/4/12,demand increase; available; ,orange,,"APP has tobramycin solution for injection 40 mg/mL 2 mL vials on back order and the company estimates a release date of early-December- 2011.   APP has all tobramycin 1.2 gram lyophilized powder for injection presentations on back order and the company estimates a release date of late-December- 2011.;APP has tobramycin solution for injection 40 mg/mL 2 mL vials on back order and the company estimates a release date of early-December- 2011.
  
 APP has all tobramycin 1.2 gram lyophilized powder for injection presentations on back order and the company estimates a release date of late-December- 2011.;The 40 mg/mL 2 mL vials are on back order with an estimated release date of mid-February- 2012.   APP has tobramycin solution for injection 40 mg/mL 2 mL vials on intermittent back order. Product may be available at wholesalers. The 40 mg/mL 50 mL vials are on back order with an estimated release date of  mid-February- 2012.  The NovaPlus vials are available.  Please check wholesaler inventory for both.   APP has available tobramycin 1.2 gram lyophilized powder for injection presentations. Please check wholesaler inventory.;APP has available tobramycin 1.2 gram lyophilized powder for injection presentations. Please check wholesaler inventory. 
 
 The 40 mg/mL 2 mL vials are available ? check wholesalers for inventory. 
 
 APP has tobramycin solution for injection 10 mg/mL 2 mL vials on intermittent back order. Product may be available at wholesalers. 
 
 The 40 mg/mL 50 mL vials are available.  Please check wholesaler inventory.;Increase in demand/manufacturing delays APP has available tobramycin 1.2 gram lyophilized powder for injection presentations. Please check wholesaler inventory. The 40 mg/mL 2 mL vials are available ? check wholesalers for inventory. APP has tobramycin solution for injection 10 mg/mL 2 mL vials on intermittent back order. Product may be available at wholesalers. The 40 mg/mL 50 mL vials are available.  Please check wholesaler inventory.;APP has available tobramycin 1.2 gram lyophilized powder for injection presentations. Please check wholesaler inventory. The 40 mg/mL 2 mL vials are available ? check wholesalers for inventory. APP has tobramycin solution for injection 10 mg/mL 2 mL vials on intermittent back order. Product may be available at wholesalers. The 40 mg/mL 50 mL vials are available.  Please check wholesaler inventory.;APP has all presentations of Tobramycin available - check wholesalers for inventory.;",,,,,,,,,,,,,
Teva,tobramycin,1,12/8/11,8/4/12,manufacturing delays,blue,,Teva has all tobramycin 40 mg/mL solution for injection on long term back order and the company cannot estimate a release date.;Manufacturing delays Teva has all tobramycin 40 mg/mL solution for injection on long term back order and the company cannot estimate a release date.;,,,,,,,,,,,,,
Teva,tobramycin_sulfate,1,9/1/12,3/25/14,manufacturing practices requirements; method remediation delays,yellow,,40 mg/mL- 2 mL vial (NDC 00703-9402-04) All tobramycin 40 mg/mL solution for injection on long term back order and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delays;40 mg/mL- 30 mL vial (NDC 00703-9416-01) All tobramycin 40 mg/mL solution for injection on long term back order and the company cannot estimate a release date. Shortage per Manufacturer: Manufacturing delays;40 mg/mL- 30 mL vial (NDC 00703-9416-01) All tobramycin 40 mg/mL solution for injection on long term back order and the company cannot estimate a release date.;40 mg/mL- 2 mL vial (NDC 00703-9402-04) All tobramycin 40 mg/mL solution for injection on long term back order and the company cannot estimate a release date.;40 mg/mL- 2 mL vial (NDC 00703-9402-04) All tobramycin 40 mg/mL solution for injection are on long term back order and the company cannot estimate a release date.;40 mg/mL- 30 mL vial (NDC 00703-9416-01) All tobramycin 40 mg/mL solution for injection are on long term back order and the company cannot estimate a release date.;40 mg/mL- 2 mL vial (NDC 00703-9402-04) All tobramycin 40 mg/mL solution for injection are on long term back order.  Estimated release date 3Q 2014. Shortage per manufacturer: Method remediation delays;40 mg/mL- 30 mL vial (NDC 00703-9416-01) All tobramycin 40 mg/mL solution for injection are on long term back order.  Estimated release date 3Q 2014. Shortage per manufacturer: Method remediation delays;40 mg/mL- 30 mL vial (NDC 00703-9416-01) All tobramycin 40 mg/mL solution for injection are on long term back order.  Estimated release date 1Q 2015.   Shortage per manufacturer: Method remediation delays;40 mg/mL- 2 mL vial (NDC 00703-9402-04) All tobramycin 40 mg/mL solution for injection are on long term back order.  Estimated release date 1Q 2015.   Shortage per manufacturer: Method remediation delays;40 mg/mL- 2 mL vial (NDC 00703-9402-04) All tobramycin 40 mg/mL solution for injection are on long term back order.  Estimated release date 2Q 2015.   Shortage per manufacturer: Method remediation delays.;40 mg/mL- 30 mL vial (NDC 00703-9416-01) All tobramycin 40 mg/mL solution for injection are on long term back order.  Estimated release date 2Q 2015.   Shortage per manufacturer: Method remediation delays.,,,,,,,,,,,,,
Fresenius,tobramycin_sulfate,1,3/25/14,3/25/14,demand increase; manufacturing delays,blue,,1.2 gram 50 mL Novaplus vial- preservative-free- 6 count (NDC 63323-0303-55) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 50 mL vial (NDC 63323-0307-51) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;1.2 gram 50 mL vial- preservative-free- 6 count (NDC 63323-0303-51) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL vial (NDC 63323-0306-30) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;10 mg/ml; 2ml vial (NDC 63323-0305-02) Available Check wholesaler inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL vial (NDC 63323-0306-02) Available Check wholesaler inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL Novaplus vial (NDC 63323-0306-56)   Backordered.  No estimated delivery at this time. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL  Novaplus vial (NDC 63323-0306-55) Backordered.  No estimated delivery at this time. Shortage per Manufacturer: Increase in demand/manufacturing delays,,,,,,,,,,,,,
APP,tobramycin_sulfate,1,9/1/12,3/2/14,demand increase; manufacturing delays; demand increase,blue,,40 mg/mL- 50 mL vial (NDC 63323-0307-51) Available All  presentations currently available.  Please check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;10 mg/ml; 2ml vial (NDC 63323-0305-02) Available All  presentations currently available.  Please check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;Tobramycin Lyophilized Powder for Injection Available All  presentations currently available.  Please check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL vial (NDC 63323-0306-02) Available All  presentations currently available.  Please check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL vial (NDC 63323-0306-30) Available All  presentations currently available.  Please check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;1.2 gram 50 mL vial- preservative-free- 6 count (NDC 63323-0303-51) Available All  presentations currently available.  Please check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL Novaplus vial (NDC 63323-0306-56) Available All  presentations currently available.  Please check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;1.2 gram 50 mL Novaplus vial- preservative-free- 6 count (NDC 63323-0303-55) Available All  presentations currently available.  Please check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL  Novaplus vial (NDC 63323-0306-55) Available All  presentations currently available.  Please check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 50 mL vial (NDC 63323-0307-51) Back-ordered. Next delivery expected mid October All  presentations currently available.  Please check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 50 mL vial (NDC 63323-0307-51) Back-ordered. Next delivery expected November 2012 All  presentations currently available.  Please check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;1.2 gram 50 mL Novaplus vial- preservative-free- 6 count (NDC 63323-0303-55) Available All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 50 mL vial (NDC 63323-0307-51) Back-ordered. Next delivery expected December 2012 All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL Novaplus vial (NDC 63323-0306-56) Available All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL vial (NDC 63323-0306-30) Back-ordered. Next delivery anticipated December 2012.   All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL  Novaplus vial (NDC 63323-0306-55) Available All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;10 mg/ml; 2ml vial (NDC 63323-0305-02) Available All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL vial (NDC 63323-0306-02) Available All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;Tobramycin Lyophilized Powder for Injection Available All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;1.2 gram 50 mL vial- preservative-free- 6 count (NDC 63323-0303-51) Available All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL vial (NDC 63323-0306-02) Available.  Check wholesalers for inventory. All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL vial (NDC 63323-0306-30) Back-ordered. Next delivery anticipated January 2013.   All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;1.2 gram 50 mL Novaplus vial- preservative-free- 6 count (NDC 63323-0303-55) Available.  Check wholesalers for inventory. All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;1.2 gram 50 mL vial- preservative-free- 6 count (NDC 63323-0303-51) Available.  Check wholesalers for inventory. All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL  Novaplus vial (NDC 63323-0306-55) Available.  Check wholesalers for inventory. All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;10 mg/ml; 2ml vial (NDC 63323-0305-02) Available.  Check wholesalers for inventory. All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 50 mL vial (NDC 63323-0307-51) Available.  Check wholesalers for inventory. All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL Novaplus vial (NDC 63323-0306-56) Available.  Check wholesalers for inventory. All  presentations currently available.  Please check wholesalers for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL Novaplus vial (NDC 63323-0306-56) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;Tobramycin Lyophilized Powder for Injection Available Shortage per Manufacturer: Increase in demand/manufacturing delays;1.2 gram 50 mL Novaplus vial- preservative-free- 6 count (NDC 63323-0303-55) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL vial (NDC 63323-0306-02) Back-ordered. Next delivery anticipated February 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL  Novaplus vial (NDC 63323-0306-55) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;10 mg/ml; 2ml vial (NDC 63323-0305-02) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 50 mL vial (NDC 63323-0307-51) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;1.2 gram 50 mL vial- preservative-free- 6 count (NDC 63323-0303-51) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL vial (NDC 63323-0306-30) Back-ordered. Next delivery anticipated February 2013.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL vial (NDC 63323-0306-02) Back-ordered. Next delivery anticipated February 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 50 mL vial (NDC 63323-0307-51) Back-ordered. No estimated delivery at this time. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL vial (NDC 63323-0306-30) Back-ordered. Next delivery anticipated March 2013.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL vial (NDC 63323-0306-02) Back-ordered. Next delivery anticipated late March 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;10 mg/ml; 2ml vial (NDC 63323-0305-02) Backordered.  Next release anticipated mid-April 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL Novaplus vial (NDC 63323-0306-56) Backordered.  No estimated delivery at this time. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL  Novaplus vial (NDC 63323-0306-55) Backordered.  No estimated delivery at this time. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL vial (NDC 63323-0306-30) Back-ordered. Next delivery anticipated late April 2013.  Check Wholesaler inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 50 mL vial (NDC 63323-0307-51) Back-ordered. Next delivery anticipated April 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL vial (NDC 63323-0306-02) Back-ordered. Next delivery anticipated April 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;10 mg/ml; 2ml vial (NDC 63323-0305-02) Backordered.  Next release anticipated April 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;1.2 gram 50 mL Novaplus vial- preservative-free- 6 count (NDC 63323-0303-55) Backordered. Next release anticipated April 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;1.2 gram 50 mL Novaplus vial- preservative-free- 6 count (NDC 63323-0303-55) Backordered. Next release anticipated May 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL vial (NDC 63323-0306-02) Backordered. Next delivery anticipated May 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL vial (NDC 63323-0306-30) Backordered. Next delivery anticipated late May 2013.  Check Wholesaler for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;10 mg/ml; 2ml vial (NDC 63323-0305-02) Backordered.  Next release anticipated May 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 50 mL vial (NDC 63323-0307-51) Backordered. Next delivery anticipated May 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL vial (NDC 63323-0306-02) Backordered. Next delivery anticipated late May 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 50 mL vial (NDC 63323-0307-51) Backordered. Next delivery anticipated July 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;1.2 gram 50 mL Novaplus vial- preservative-free- 6 count (NDC 63323-0303-55) Available.  Check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL vial (NDC 63323-0306-02) Backordered. Next delivery anticipated late June 2013. Check wholesaler inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;10 mg/ml; 2ml vial (NDC 63323-0305-02) Backordered.  Next release anticipated July 2013. Check wholesaler inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL vial (NDC 63323-0306-30) Available.  Check Wholesaler for inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL vial (NDC 63323-0306-30) Backordered. Next delivery anticipated September 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL vial (NDC 63323-0306-02) Backordered. Next delivery anticipated late July 2013. Check wholesaler inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;1.2 gram 50 mL vial- preservative-free- 6 count (NDC 63323-0303-51) Backordered. Next delivery anticipated July 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 50 mL vial (NDC 63323-0307-51) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL Novaplus vial (NDC 63323-0306-56)   Backordered.  No estimated delivery at this time. Shortage per Manufacturer: Increase in demand/manufacturing delays;1.2 gram 50 mL vial- preservative-free- 6 count (NDC 63323-0303-51) Available. Check wholesalers for inventory Shortage per Manufacturer: Increase in demand/manufacturing delays;10 mg/ml; 2ml vial (NDC 63323-0305-02) Available Check wholesaler inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 2 mL vial (NDC 63323-0306-02) Available Check wholesaler inventory.   Shortage per Manufacturer: Increase in demand/manufacturing delays;40 mg/mL- 30 mL vial (NDC 63323-0306-30) Backordered. Next delivery anticipated late September 2013. Shortage per Manufacturer: Increase in demand/manufacturing delays,,,,,,,,,,,,,
Fresenius,trace,1,6/5/13,3/2/14,[temporary import],brown,,Peditrace injection- 10 mL vial (NDC 63323-147-10 ) Importation began May 2013 and will continue until all patient needs are met with US product. Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Addamel N (adult trace elements) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 458KB) for additional product and supply information.  FK USA is releasing Addamel N by direct order.     Shortage per Manufacturer: Increase in demand;Addamel N injection- 10 mL ampule (NDC 63323-143-97) Importation began May 2013 and will continue until all patient needs are met with US product. Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Addamel N (adult trace elements) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 458KB) for additional product and supply information.  FK USA is releasing Addamel N by direct order.     Shortage per Manufacturer: Increase in demand;Peditrace injection- 10 mL vial (NDC 63323-147-10 ) Importation began May 2013 and will continue until all patient needs are met with US product. Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Peditrace (pediatric trace elements) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 391KB) for additional product and supply information.  FK USA is releasing Peditrace to its authorized distributors.     Shortage per Manufacturer: Increase in demand;Peditrace injection- 10 mL vial (NDC 63323-147-10 ) Importation began May 2013 and will continue until all patient needs are met with US product. Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Peditrace (pediatric trace elements) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 1.47MB) for additional product and supply information.  FK USA is releasing Peditrace to its authorized distributors.     Shortage per Manufacturer: Increase in demand;Peditrace injection- 10 mL vial (NDC 63323-147-10 ) Importation began May 2013 and will continue until all patient needs are met with US product. Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Addamel N (adult trace elements) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 458KB) for additional product and supply information.  FK USA is releasing Addamel N to its authorized distributors.   Shortage per Manufacturer: Increase in demand;Addamel N injection- 10 mL ampule (NDC 63323-143-97) Importation began May 2013 and will continue until all patient needs are met with US product. Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Addamel N (adult trace elements) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 458KB) for additional product and supply information.  FK USA is releasing Addamel N to its authorized distributors.   Shortage per Manufacturer: Increase in demand;Addamel N injection- 10 mL ampule (NDC 63323-143-97) Importation began May 2013 and will continue until all patient needs are met with US product. Please check wholesalers for inventory. Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Addamel N (adult trace elements) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 444KB) for additional product and supply information.  FK USA is releasing Addamel N to its authorized distributors.   Shortage per Manufacturer: Increase in demand;Peditrace injection- 10 mL vial (NDC 63323-147-10 ) Importation began May 2013 and will continue until all patient needs are met with US product. Please check wholesalers for inventory. Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Peditrace (pediatric trace elements) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 377KB) for additional product and supply information.  FK USA is releasing Peditrace to its authorized distributors.     Shortage per Manufacturer: Increase in demand;Peditrace injection- 10 mL vial (NDC 63323-147-10 ) Importation began May 2013 and will continue until all patient needs are met with US product. Please check wholesalers for inventory. Fresenius Kabi USA- LLC (FK USA) in conjunction with FDA has initiated temporary importation of Addamel N (adult trace elements) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 444KB) for additional product and supply information.  FK USA is releasing Addamel N to its authorized distributors.   Shortage per Manufacturer: Increase in demand,,,,,,,,,,,,,
AmericanRegent,trace,1,1/16/13,1/16/13,not releasing,,,Multitrace-4 Concentrate- 10 mL vial (NDC 00517-7210-25) Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-4 Neonatal- 2 mL vial (NDC 00517-6202-25) Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-4 Pediatric- 3 mL vial (NDC 00517-9203-25)   Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-4 Concentrate- 1 mL vial (NDC 00517-7201-25) Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-5 Concentrate 1 mL vial (NDC 00517-8201-25) Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-5 Concentrate 10 mL vial (NDC 00517-8210-25) Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-5 Regular- 10 mL vial (NDC 00517-8510-25) Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-4 Regular- 10 mL vial (NDC 00517-7410-25) Unavailable American Regent is currently not releasing any Trace Element products.;Trace elements-4 pediatric injection- 10 mL vial (NDC 00517-9310-25) Unavailable American Regent is currently not releasing any Trace Element products.,,,,,,,,,,,,,
AmericanRegent,trace,2,3/6/13,3/2/14,not releasing,,,Multitrace-4 Concentrate- 1 mL vial (NDC 00517-7201-25) Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-4 Concentrate- 10 mL vial (NDC 00517-7210-25) Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-4 Neonatal- 2 mL vial (NDC 00517-6202-25) Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-4 Regular- 10 mL vial (NDC 00517-7410-25) Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-5 Concentrate 1 mL vial (NDC 00517-8201-25) Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-5 Concentrate 10 mL vial (NDC 00517-8210-25) Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-4 Pediatric- 3 mL vial (NDC 00517-9203-25)   Unavailable American Regent is currently not releasing any Trace Element products.;Trace elements-4 pediatric injection- 10 mL vial (NDC 00517-9310-25) Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-5 Regular- 10 mL vial (NDC 00517-8510-25) Unavailable American Regent is currently not releasing any Trace Element products.;Multitrace-4 Concentrate- 1 mL vial (NDC 00517-7201-25) Unavailable. Estimated release of Multitrace - 4 Pediatric 3 mL vial end of September 2013. American Regent is currently not releasing any Trace Element products.;Multitrace-5 Concentrate 10 mL vial (NDC 00517-8210-25) Unavailable. Estimated release of Multitrace - 4 Pediatric 3 mL vial end of September 2013. American Regent is currently not releasing any Trace Element products.;Trace elements-4 pediatric injection- 10 mL vial (NDC 00517-9310-25) Unavailable. Estimated release of Multitrace - 4 Pediatric 3 mL vial end of September 2013. American Regent is currently not releasing any Trace Element products.;Multitrace-4 Neonatal- 2 mL vial (NDC 00517-6202-25) Unavailable. Estimated release of Multitrace - 4 Pediatric 3 mL vial end of September 2013. American Regent is currently not releasing any Trace Element products.;Multitrace-5 Concentrate 1 mL vial (NDC 00517-8201-25) Unavailable. Estimated release of Multitrace - 4 Pediatric 3 mL vial end of September 2013. American Regent is currently not releasing any Trace Element products.;Multitrace-4 Regular- 10 mL vial (NDC 00517-7410-25) Unavailable. Estimated release of Multitrace - 4 Pediatric 3 mL vial end of September 2013. American Regent is currently not releasing any Trace Element products.;Multitrace-5 Regular- 10 mL vial (NDC 00517-8510-25) Unavailable. Estimated release of Multitrace - 4 Pediatric 3 mL vial end of September 2013. American Regent is currently not releasing any Trace Element products.;Multitrace-4 Pediatric- 3 mL vial (NDC 00517-9203-25)   Unavailable. Estimated release of Multitrace - 4 Pediatric 3 mL vial end of September 2013. American Regent is currently not releasing any Trace Element products.;Multitrace-4 Concentrate- 10 mL vial (NDC 00517-7210-25) Unavailable. Estimated release of Multitrace - 4 Pediatric 3 mL vial end of September 2013. American Regent is currently not releasing any Trace Element products.,,,,,,,,,,,,,
Sandoz,triamcinolone,1,6/6/09,7/5/09,manufacturing delays,blue,,Manufacturing Delays,,,,,,,,,,,,,
Hospira,tromethamine,1,10/26/10,4/22/11,manufacturing delays,blue,,Manufacturing delays,,,,,,,,,,,,,
Indevus,valstar,1,6/6/09,9/6/09,discontinued,black,,Product was previously discontinued,,,,,,,,,,,,,
AmericanRegent,vasopressin,1,6/8/11,1/19/12,available,,,American Regent has all strengths of vasopressin 20 units/mL injection 1 mL multi-dose vials (NDC 00517-1020-25)- 10 mL multi-dose vials (NDC 00517-0410-10)- 0.5 mL multi-dose vials available for ordering.,,,,,,,,,,,,,
AmericanRegent,vasopressin,2,2/9/12,7/12/12,available,,,"American Regent has Vasopressin 20 units/mL Injection- American Regent 0.5 mL multi-dose vial- 25 count (NDC 00517-0510-25) and 1 mL multi-dose vial- 25 count (NDC 00517-1020-25) available. 20 units/ml 10ml vials on back order and the company estimates a release date of March 2012;American Regent has Vasopressin 20 units/mL Injection- American Regent 0.5 mL multi-dose vial- 25 count (NDC 00517-0510-25) and 1 mL multi-dose vial- 25 count (NDC 00517-1020-25) available. 
 
 20 units/ml 10ml vials on back order and the company estimates a release date of March 2012;American Regent has 0.5 mL multi-dose vial is currently on backorder and will be available mid-May. 1 mL multi-dose vial on back order and will be available mid-May 2012. 10 mL multi-dose vial on back order and will be available end of April 2012.;American Regent has 0.5 mL multi-dose vial is currently on backorder and will be available end of May. 1 mL multi-dose vial on back order and will be available end of May 2012. 10 mL multi-dose vial on back order and will be available end of May 2012.;",,,,,,,,,,,,,
APP,vasopressin,1,6/8/11,1/19/12,manufacturing delays; demand increase,blue,,APP has vasopressin 20 units/mL injection on back order and the company estimates an August release date.;APP has vasopressin 20 units/mL injection available for shipping. Additional releases expected mid-late October 2011.;APP has Vasopressin 20 units/mL injection available.,,,,,,,,,,,,,
Sun,vecuronium,1,4/28/11,7/12/12,demand increase,orange,,"Sun Pharmaceutical Industries (Distributor: Caraco Pharmaceutical Labs- Ltd.) is continuing to release product as it becomes available. Vecuronium Bromide for Injection 10 mg 10 vials NDC 41616-0931-44 Vecuronium Bromide for Injection 20 mg 10 vials NDC 41616-0932-44;Sun Pharmaceutical Industries (Distributor: Caraco Pharmaceutical Labs- Ltd.) is continuing to release product as it becomes available. 
 
 Vecuronium Bromide for Injection 10 mg 10 vials NDC 41616-0931-44 
 
 Vecuronium Bromide for Injection 20 mg 10 vials NDC 41616-0932-44;Increase in demand Sun Pharmaceutical Industries (Distributor: Caraco Pharmaceutical Labs- Ltd.) is continuing to release product as it becomes available. Vecuronium Bromide for Injection 10 mg 10 vials NDC 41616-0931-44 Vecuronium Bromide for Injection 20 mg 10 vials NDC 41616-0932-44;",,,,,,,,,,,,,
Bedford,vecuronium,1,11/21/09,4/22/11,demand increase; manufacturing delays,blue,,Increase in demand     Increase in demand         Increase in demand         Manufacturing Delays;Increase in demand     Increase in demand           Increase in demand         Manufacturing Delays;Increase in demand         Increase in demand                 Increase in demand             Manufacturing Delays;Increase in demand       Increase in demand             Increase in demand               Manufacturing Delays;Increase in demand       Increase in demand               Increase in demand               Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold                   Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold                 Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold                 Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold             Manufacturing Delays;Increase in demand       Increase in demand                   On manufacturing hold           Manufacturing Delays;Increase in demand         Increase in demand                   On manufacturing hold           Manufacturing Delays;Increase in demand         Increase in demand                   On manufacturing hold           Manufacturing Delays;Increase in demand     Increase in demand         On manufacturing hold       Manufacturing Delays;Increase in demand     Increase in demand         On manufacturing hold       Manufacturing Delays;Increase in demand     Increase in demand         On manufacturing hold       Manufacturing Delays,,,,,,,,,,,,,
Bedford,vecuronium,1,4/28/11,7/12/12,demand increase; manufacturing delays,blue,,Bedford has vecuronium 20 mg vials (NDC 55390-0039-10) available.;Bedford anticipates release of the 10mg product in early May and the 20mg product in the next 3-months.;Bedford is allocating vecuronium 20 mg vials and these are available for drop-shipment. Vecuronium 10 mg vials are on back order and no release date is reported.;Bedford has limited allocated quantities 10 mg (NDC 55390-0037-10) and 20 mg (NDC 55390-0039-10) available for dropship- contact your local Bedford Account Executives.;Bedford has limited allocated quantities 10 mg (NDC 55390-0037-10)  and 20 mg (NDC 55390-0039-10) available for dropship- contact your local Bedford Account Executive. Next anticipated release Late October.;Bedford has limited allocated quantities 10 mg (NDC 55390-0037-10)  and 20 mg (NDC 55390-0039-10) available for dropship- contact your local Bedford Account Executive.;Bedford has all vecurionium presentations on backorder and the company cannot estimate a release date.;Bedford Laboratories has 10 mg and 20mg available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.;Manufacturing Delays Bedford Laboratories has 10 mg and 20mg available in limited quantities.  Once this supply is depleted- the next estimated release dates are unknown. Availability of products is updated on the Bedford  Laboratories website.;,,,,,,,,,,,,,
Hospira,vecuronium,1,11/21/09,4/22/11,demand increase; manufacturing delays,blue,,Increase in demand     Increase in demand         Increase in demand         Manufacturing Delays;Increase in demand     Increase in demand           Increase in demand         Manufacturing Delays;Increase in demand         Increase in demand                 Increase in demand             Manufacturing Delays;Increase in demand       Increase in demand             Increase in demand               Manufacturing Delays;Increase in demand       Increase in demand               Increase in demand               Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold                   Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold                 Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold                 Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold             Manufacturing Delays;Increase in demand       Increase in demand                   On manufacturing hold           Manufacturing Delays;Increase in demand         Increase in demand                   On manufacturing hold           Manufacturing Delays;Increase in demand         Increase in demand                   On manufacturing hold           Manufacturing Delays;Increase in demand     Increase in demand         On manufacturing hold       Manufacturing Delays;Increase in demand     Increase in demand         On manufacturing hold       Manufacturing Delays;Increase in demand     Increase in demand         On manufacturing hold       Manufacturing Delays,,,,,,,,,,,,,
Sun,vecuronium,1,11/21/09,4/22/11,demand increase; manufacturing delays,blue,,Increase in demand     Increase in demand         Increase in demand         Manufacturing Delays;Increase in demand     Increase in demand           Increase in demand         Manufacturing Delays;Increase in demand         Increase in demand                 Increase in demand             Manufacturing Delays;Increase in demand       Increase in demand             Increase in demand               Manufacturing Delays;Increase in demand       Increase in demand               Increase in demand               Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold                   Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold                 Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold                 Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold             Manufacturing Delays;Increase in demand       Increase in demand                   On manufacturing hold           Manufacturing Delays;Increase in demand         Increase in demand                   On manufacturing hold           Manufacturing Delays;Increase in demand         Increase in demand                   On manufacturing hold           Manufacturing Delays;Increase in demand     Increase in demand         On manufacturing hold       Manufacturing Delays;Increase in demand     Increase in demand         On manufacturing hold       Manufacturing Delays;Increase in demand     Increase in demand         On manufacturing hold       Manufacturing Delays,,,,,,,,,,,,,
Teva,vecuronium,1,11/21/09,4/22/11,demand increase; manufacturing delays,blue,,Increase in demand     Increase in demand         Increase in demand         Manufacturing Delays;Increase in demand     Increase in demand           Increase in demand         Manufacturing Delays;Increase in demand         Increase in demand                 Increase in demand             Manufacturing Delays;Increase in demand       Increase in demand             Increase in demand               Manufacturing Delays;Increase in demand       Increase in demand               Increase in demand               Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold                   Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold                 Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold                 Manufacturing Delays;Increase in demand           Increase in demand                         On manufacturing hold             Manufacturing Delays;Increase in demand       Increase in demand                   On manufacturing hold           Manufacturing Delays;Increase in demand         Increase in demand                   On manufacturing hold           Manufacturing Delays;Increase in demand         Increase in demand                   On manufacturing hold           Manufacturing Delays;Increase in demand     Increase in demand         On manufacturing hold       Manufacturing Delays;Increase in demand     Increase in demand         On manufacturing hold       Manufacturing Delays;Increase in demand     Increase in demand         On manufacturing hold       Manufacturing Delays,,,,,,,,,,,,,
Teva,vecuronium,1,4/28/11,7/12/12,production suspended; manufacturing delays,blue,,Teva has the 10mg/vial (NDC 00703-2914-03) and 20 mg/vial (NDC 00703-2925-03) on backorder.;Teva has the 10mg/vial (NDC 00703-2914-03) and 20 mg/vial (NDC 00703-2925-03) on long term backorder and the company cannot estimate a release date.;Manufacturing delay Teva has the 10mg/vial (NDC 00703-2914-03) and 20 mg/vial (NDC 00703-2925-03) on long term backorder and the company cannot estimate a release date.;,,,,,,,,,,,,,
Barr/Duramed(Teva),viaspan,3,3/1/13,3/1/13,available,,,1000 mL bag Teva supply is adequate to meet demand. Comments: FDA regulates this product as a device and it is handled by Center for Devices and Radiological Health (CDRH) in FDA. Contact information for this issue: FDA/CDRH Office of Compliance: 301-796-5770,,,,,,,,,,,,,
Barr/Duramed(Teva),viaspan,2,9/1/12,1/10/13,available; recall,yellow,,1000 mL bag Available with ample inventory. Shortage per manufacturer: Product Recall of two (2) batches Comments: FDA regulates this product as a device and it is handled by Center for Devices and Radiological Health (CDRH) in FDA. Contact information for this issue: FDA/CDRH Office of Compliance: 301-796-5770;1000 mL bag Available with ample inventory. Comments: FDA regulates this product as a device and it is handled by Center for Devices and Radiological Health (CDRH) in FDA. Contact information for this issue: FDA/CDRH Office of Compliance: 301-796-5770   Shortage per manufacturer: Product Recall of two (2) batches;1000 mL bag Teva supply is adequate to meet demand. Comments: FDA regulates this product as a device and it is handled by Center for Devices and Radiological Health (CDRH) in FDA. Contact information for this issue: FDA/CDRH Office of Compliance: 301-796-5770,,,,,,,,,,,,,
Barr/Duramed(Teva),viaspan,1,4/18/12,4/26/12,product recall,yellow,,Product Recall of two (2) batches ViaSpan is currently unavailable and will continue to be unavailable until early to mid June at the earliest. Comments: FDA regulates this product as a device and it is handled by Center for Devices and Radiological Health (CDRH) in FDA. Contact information for this issue: FDA/CDRH Office of Compliance: 301-796-5770;ViaSpan is currently unavailable and will continue to be unavailable until early to mid June at the earliest. Comments: FDA regulates this product as a device and it is handled by Center for Devices and Radiological Health (CDRH) in FDA. Contact information for this issue: FDA/CDRH Office of Compliance: 301-796-5770,,,,,,,,,,,,,
Barr/Duramed,viaspan,1,4/29/12,8/4/12,product recall,yellow,,,,,,,,,,,,,,,
Bedford,vinblastine,1,8/7/13,3/2/14,capacity constraints,blue,,10 mg Inj vial 10 mL (NDC 5539-0091-10 Unavailable Shortage per Manufacturer: Capacity constraint   Availability of products is updated on the Bedford Laboratories website.,,,,,,,,,,,,,
APP,vinblastine,1,2/2/12,3/2/14,demand increase; available,orange,,APP has vinblastine sulfate injection on back order with an estimated release date of mid-February- 2012.;APP has vinblastine sulfate injection on back order with an estimated release date of late-March 2012.;APP is currently allocating 1 mg/mL- 10 mL.;Increased Demand APP is currently allocating 1 mg/mL- 10 mL.;;1 mg/mL; 10 mL vial (NDC 63323-0278-10) Available Check wholesalers for inventory. Shortage per Manufacturer: Increased Demand;1 mg/mL; 10 mL vial (NDC 63323-0278-10) Backordered. Check wholesaler inventory. Next release anticipated early June 2013. Check wholesalers for inventory. Shortage per Manufacturer: Increased Demand;1 mg/mL; 10 mL vial (NDC 63323-0278-10) Backordered. Check wholesaler inventory. Next release anticipated late June 2013. Check wholesalers for inventory. Shortage per Manufacturer: Increased Demand;1 mg/mL; 10 mL vial (NDC 63323-0278-10) Available.  Check wholesalers for inventory. Check wholesalers for inventory. Shortage per Manufacturer: Increased Demand;1 mg/mL; 10 mL vial (NDC 63323-0278-10) Available. Check wholesalers for inventory. Shortage per Manufacturer: Increased Demand,,,,,,,,,,,,,
Teva,vincristine,1,5/25/11,2/9/12,available,,,Teva has 1 mg/mL 1 mL vial (NDC 00703-4402-11) and 2 mL vial (NDC 00703-4412-11) now available and is shipping to wholesalers.,,,,,,,,,,,,,
Amphastar,vitamink,1,3/6/13,6/17/13,demand increase; available,orange,,1 mg/0.5 mL- SAF-T-JET prefilled syringe- contains polysorbate 80 and propylene glycol   NDC 76329-1240-5   (old NDC 00548-1240-00) Amphastar will regularly release products. Shortage per Manufacturer: Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues;NULL Amphastar will regularly release products. Shortage per Manufacturer: Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues;1 mg/0.5 mL- SAF-T-JET prefilled syringe- contains polysorbate 80 and propylene glycol   NDC 76329-1240-5   (old NDC 00548-1240-00) Amphastar will regularly release products. Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues;NULL Amphastar will regularly release products. Amphastar is experiencing a product shortage due to an increase in product demand caused by market supply issues;1 mg/0.5 mL- SAF-T-JET prefilled syringe- contains polysorbate 80 and propylene glycol   NDC 76329-1240-5   (old NDC 00548-1240-00) Available;NULL Available,,,,,,,,,,,,,
Amphastar,vphytonadione,2,3/1/13,3/1/13,demand increase,orange,,1 mg/0.5 mL- SAF-T-JET prefilled syringe contains polysorbate 80 and propylene glycol   NDC 76329-1240-5(old NDC 00548-1240-00) Amphastar will regularly release products. Amphastar is  experiencing a product shortage due to an increase in product demand caused by market supply issues,,,,,,,,,,,,,
Amphastar,vphytonadione,1,11/13/12,1/10/13,demand increase; available,orange,,1 mg/0.5 mL- SAF-T-JET prefilled syringe contains polysorbate 80 and propylene glycol   NDC 76329-1240-5(old NDC 00548-1240-00) Available;1 mg/0.5 mL- SAF-T-JET prefilled syringe contains polysorbate 80 and propylene glycol   NDC 76329-1240-5(old NDC 00548-1240-00) Amphastar will regularly release products. Amphastar is  experiencing a product shortage due to an increase in product demand caused by market supply issues,,,,,,,,,,,,,
Genentech,xeloda,1,3/31/11,4/22/11,product recall,yellow,,Recall of 13 manufacturing lots of the customary 120 count bottles currently approved for use in the US.  Genentech is working closely with FDA to ensure that US supply of Xeloda 500mg tablets remains  unchanged.,,,,,,,,,,,,,
Genentech,xeloda,1,4/28/11,7/16/11,product recall,yellow,,Please see the Dear Healthcare Professional Letter (PDF - 95KB).,,,,,,,,,,,,,
Aguettant(Baxter),zinc,1,3/25/14,3/25/14,[temporary import],brown,,Zinc Injectable (zinc gluconate trihydrate) solution for infusion 1 mg/mL; 10 mL glass vial; 10 vials/box (NDC 60710-2320-1) Available Laboratoire Aguettant- and its authorized distributor- Baxter Healthcare- in conjunction with the FDA- are initiating a temporary importation of a Zinc Injectable (zinc gluconate trihydrate) solution for infusion into the United States market to address this shortage.   Please see the Dear Heathcare Professional Letter (PDF - 12MB) for information about supplies that are now available to help address the shortage. All orders must be made directly with Baxter's Center for Service by calling 1-888-229-0001- or email: CFS_Customer_Service@baxter.com.,,,,,,,,,,,,,
AmericanRegent,zinc,1,2/16/12,3/25/14,manufacturing delays; available; not releasing; discontinued,black,,American Regent has all presentations of zinc sulfate on back order with no estimated release date.;American Regent has Concentrated Zinc Sulfate 5 mL vial available.  All other  presentations of zinc sulfate are on backorder with no estimated release date.;Manufacturing delay American Regent has Concentrated Zinc Sulfate 5 mL vial available.  All other  presentations of zinc sulfate are on backorder with no estimated release date.;;5 mg/mL Concentrate- 5 mL vial- package of 25 (NDC 00517-8105-25)  Unavailable American Regent is currently not releasing the 5 mL (concentrate) or the 10 mL vial sizes. Shortage per Manufacturer: Discontinuation of the manufacture of the drug.;1 mg/mL- 10 mL vial- package of 25 (NDC 00517-6110-25) Unavailable American Regent is currently not releasing the 5 mL (concentrate) or the 10 mL vial sizes. Shortage per Manufacturer: Discontinuation of the manufacture of the drug.;1 mg/mL- 10 mL vial- package of 25 (NDC 00517-6110-25) Unavailable American Regent is currently not releasing the 5 mL (concentrate) or the 10 mL vial sizes.;5 mg/mL Concentrate- 5 mL vial- package of 25 (NDC 00517-8105-25)  Unavailable American Regent is currently not releasing the 5 mL (concentrate) or the 10 mL vial sizes.;1 mg/mL- 10 mL vial- package of 25 (NDC 00517-6110-25) Unavailable American Regent is currently not releasing the 10 mL vial sizes.;5 mg/mL Concentrate- 5 mL vial- package of 25 (NDC 00517-8105-25)  Unavailable American Regent is currently not releasing the 10 mL vial sizes.;5 mg/mL Concentrate- 5 mL vial- package of 25 (NDC 00517-8105-25)  Available American Regent is currently not releasing the 10 mL vial sizes.;1 mg/mL- 10 mL vial- package of 25 (NDC 00517-6110-25) Unavailable American Regent is currently not releasing the 10 mL vial sizes.   American Regent is currently releasing the 5 mL vial size.;5 mg/mL Concentrate- 5 mL vial- package of 25 (NDC 00517-8105-25)  Available American Regent is currently not releasing the 10 mL vial sizes.   American Regent is currently releasing the 5 mL vial size.;5 mg/mL Concentrate- 5 mL vial- package of 25 (NDC 00517-8105-25)  Unavailable American Regent is currently not releasing the 10 mL vial sizes.   American Regent is currently releasing the 5 mL vial size.;5 mg/mL Concentrate- 5 mL vial- package of 25 (NDC 00517-8105-25)  Unavailable American Regent is currently not releasing the 10 mL vial sizes.     Shortage per Manufacturer: Manufacturing delay.;5 mg/mL Concentrate- 5 mL vial- package of 25 (NDC 00517-8105-25)  Company estimates a manufacturing date of 2Q 2013. American Regent is currently not releasing the 10 mL vial sizes.     Shortage per Manufacturer: Manufacturing delay.;1 mg/mL- 10 mL vial- package of 25 (NDC 00517-6110-25) Unavailable American Regent is currently not releasing the 10 mL vial sizes.     Shortage per Manufacturer: Manufacturing delay.;5 mg/mL Concentrate- 5 mL vial- package of 25 (NDC 00517-8105-25)  Company estimates a manufacturing date of 2Q 2013. American Regent is currently releasing the 10 mL vial sizes.     Shortage per Manufacturer: Manufacturing delay.;5 mg/mL Concentrate- 5 mL vial- package of 25 (NDC 00517-8105-25)  Available American Regent is currently releasing the 10 mL vial sizes.     Shortage per Manufacturer: Manufacturing delay.;1 mg/mL- 10 mL vial- package of 25 (NDC 00517-6110-25) Available American Regent is currently releasing the 10 mL vial sizes.     Shortage per Manufacturer: Manufacturing delay.;5 mg/mL Concentrate- 5 mL vial- package of 25 (NDC 00517-8105-25)  Estimate release end of July. American Regent is currently releasing the 10 mL vial sizes.     Shortage per Manufacturer: Manufacturing delay.;5 mg/mL Concentrate- 5 mL vial- package of 25 (NDC 00517-8105-25)  Estimate release August-September 2013 American Regent is currently releasing the 10 mL vial sizes.     Shortage per Manufacturer: Manufacturing delay.;5 mg/mL Concentrate- 5 mL vial- package of 25 (NDC 00517-8105-25)  Estimated release end of September 2013 American Regent is currently releasing the 10 mL vial sizes.     Shortage per Manufacturer: Manufacturing delay.;Zinc Sulfate 5 mg/mL Concentrate- 5 mL vial- package of 25 (NDC 00517-8105-25)  Available American Regent is currently releasing the 5 mL vials (code 00517-8105-25);Zinc Sulfate 1 mg/mL- 10 mL vial- package of 25 (NDC 00517-6110-25) Unavailable - No product available for release.  No plan to manufacture. American Regent is currently not releasing the 10 mL vial sizes.,,,,,,,,,,,,,
